NZ628800B2 - Factor viii compositions and methods of making and using same - Google Patents

Abstract

Disclosed is a recombinant factor VIII fusion protein comprising a factor VIII polypeptide fused to an extended recombinant polypeptide (XTEN), wherein the factor VIII polypeptide comprises A1 domain, A2 domain, A3 domain, a3 domain, C1 domain, C2 domain, and optionally a B domain or a portion thereof, wherein the XTEN is inserted within the factor VIII polypeptide. of, wherein the XTEN is inserted within the factor VIII polypeptide.

Description

FACTOR VIII COMPOSITIONS AND METHODS OF MAKING AND USING SAME CROSS-REFERENCE TO RELATED APPLICATION This application claims priority benefit to US. Provisional Application Serial No. ,400 filed February 15, 2012, which application is orated herein by reference.

SEQUENCE LISTING The instant ation contains a Sequence Listing which has been submitted in ASCII format Via EFS-Web, and is hereby incorporated by reference in its entirety. Said ASCII copy, created on July 11, 2012, is named 32887346.txt and is 13,344,768 Bytes in size.

BACKGROUND OF THE INVENTION Factor VIII is an important component of the intrinsic pathway of the blood coagulation cascade. In the circulation, factor VIII is mainly complexed to von Willebrand factor. Upon activation by thrombin, (Factor Ila), it dissociates from the complex to interact with factor IXa in the intrinsic coagulation cascade, which, in turn, tes factor X. Once removed from the von Willebrand factor complex, activated factor VIII is lytically inactivated by activated Protein C (APC), factor Xa, and factor IXa, and is quickly cleared from the blood . When complexed with normal von Willebrand factor protein, the half-life of factor VIII is approximately 12 hours, whereas in the absence of von Willebrand factor, the ife of factor VIII is d to 2 hours (Tuddenham EG, et al., Br J Haematol. (1982) 52(2):259-267).

In hemophilia, the clotting of blood is disturbed by a lack of certain plasma blood clotting factors. ilia A is a deficiency of factor VIII, and is a recessive sex-linked, X chromosome disorder that represents 80% of hemophilia cases. The standard of care for the management of hemophilia A is replacement therapy with inant factor VIII concentrates. ts with severe hemophilia A have circulating procoagulant factor VIII levels below 1-2% of normal and are generally on prophylactic therapy with the aim of keeping factor VIII above 1% between doses, which can usually be achieved by giving factor VIII two to three times a week. Persons with moderately severe hemophilia (factor VIII levels of 2-5% of normal) constitute 25-30% hemophilia incidents and manifest bleeding after minor trauma. Persons with mild hemophilia A (factor VIII levels of 5-40% of normal) comprise -20% of all hemophilia incidents, and p bleeding only after significant trauma or surgery.

The in vivo activity of exogenously supplied factor VIII is limited both by a short protein half- life and inhibitors that bind to the factor VIII and diminish or destroy atic function.

Up to 30% of hemophilia A patients receiving exogenously-supplied factor VIII mount an IgG immune se towards factor VIII (Towfighi, F., et al. Comparative measurement of anti-factor VIII 2012/046326 antibody by Bethesda assay and ELISA reveals restricted isotype profile and epitope specificity. Acta Haematol (2005) 114:84-90), which can result in the te inhibition of its procoagulant activity and/or promote more rapid clearance of the factor VIII (Briet E et al. High titer inhibitors in severe haemophilia A. A meta-analysis based on eight long-term follow-up studies concerning inhibitors associated with crude or intermediate purity factor VIII products. Throm. Haemost. (1994) 72: 162-164).

The IgG antibodies, called FVIII inhibitors, are primarily directed towards the A2, A3 and C2 domains (Scandella D et al. zation of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization. Blood (1989) 74:1618-1626), but can arise against the A1, B and C1 domains, as well. As such, treatment s for patients with FVIII inhibitors are limited.

Large proteins such as factor VIII are normally given enously so that the medicament is directly available in the blood stream. It has been preViously demonstrated that an unmodified factor VIII injected intramuscularly yielded a maximum ating level of only 1.4% of the normal plasma level (Pool et al, Ineffectiveness of Intramuscularly Injected Factor VIII Concentrate in Two Hemophilic ts. New d I. Medicine (1966) 275(10):547-548). Formulations that could be administered other than by the intravenous route would y simplify their use, increase safety, and result in substantial cost savings.

Chemical modifications to a therapeutic protein can modify its in Vivo clearance rate and subsequent serum half-life. One e of a common modification is the addition of a polyethylene glycol (PEG) moiety, typically coupled to the n Via an aldehyde or N-hydroxysuccinimide (NHS) group on the PEG reacting with an amine group (e.g. lysine side chain or the inus). However, the conjugation step can result in the formation of heterogeneous product es that require extraction, purification and/or other further processes, all of which ineVitably affect product yield and quality control.

Also, the pharmacologic on of coagulation factors may be hampered if amino acid side chains in the Vicinity of its binding site become modified by the PEGylation process. Other ches include the genetic fusion of an EC domain to the therapeutic protein, which increases the size of the therapeutic protein, hence reducing the rate of clearance through the kidney. In some cases, the Fc domain confers the ability to bind to, and be recycled from lysosomes by the FcRn receptor, resulting in increased pharmacokinetic half-life. unately, the Fc domain does not fold efficiently during recombinant expression, and tends to form insoluble precipitates known as inclusion bodies. These inclusion bodies must be solubilized and functional protein must be renatured from the misfolded aggregate, which is a time-consuming, inefficient, and expensive process.

SUMMARY OF THE INVENTION The present invention relates to novel coagulation factor VIII fusion protein compositions and the uses f. Specifically, the compositions provided herein are ularly used for the treatment or improvement of a ion associated with hemophilia A, deficiencies of factor VIII, bleeding disorders and coagulopathies. In one aspect, the present invention provides compositions of isolated fusion proteins comprising a factor VIII ) and one or more extended recombinant polypeptides (XTEN) 2012/046326 wherein the fusion protein exhibits procoagulant activity. A subject XTEN useful for constructing such fusion proteins is typically a polypeptide with a non-repetitive ce and unstructured conformation.

In one embodiment, one or more XTEN is linked to a coagulation factor FVIII (“CF”) selected from native human factor VIII, factor VIII in d sequences (“FVIII BDD”), and sequence variants thereof (all the foregoing collectively “FVIII” or “CF”), resulting in a recombinant factor TEN fusion protein (“CFXTEN”). The factor VIII polypeptide component of the CFXTEN comprises an Al domain, an A2 domain, a Cl domain, a C2 domain, and optionally a B domain or a portion f In some embodiments, the FVIII is further characterized by delineation of the aforementioned domains to se an acidic a1, a2 and a3 spacer. In another embodiment, the present disclosure is directed to pharmaceutical compositions comprising the fusion proteins and the uses thereof in methods and regimens for treating factor VIII-related conditions. The CFXTEN compositions have enhanced pharmacokinetic and pharmacologic properties ed to FVIII not linked to XTEN, which may permit more convenient dosing and improved efflcacy.

In a first aspect, the invention relates to recombinant factor VIII fusion proteins comprising a factor VIII polypeptide and one or more extended recombinant polypeptide (XTEN) linked to the factor VIII. In some embodiments, the invention provides recombinant factor VIII fusion proteins comprising a factor VIII polypeptide and at least one extended recombinant polypeptide (XTEN), wherein said factor VIII polypeptide comprises an Al domain including an al acidic spacer region, an A2 domain ing an a2 acidic spacer region, an A3 domain including an a3 acidic spacer region, Cl domain, C2 domain and optionally all or a portion of B domain, and wherein said at least one XTEN is linked to said factor VIII polypeptide at (i) the C-terminus of said factor VIII polypeptide; (ii) within B domain of said factor VIII polypeptide if all or a portion of B domain is present; (iii) within the Al domain of said factor VIII polypeptide; (iV) within the A2 domain of said factor VIII polypeptide; (V) within the A3 domain of said factor VIII polypeptide; (Vi) within the Cl domain of said factor VIII polypeptide; (Vii) within the C2 domain of said factor VIII polypeptide; (Viii) at the N—terminus of said factor VIII polypeptide, or (ix) between two domains of said factor VIII polypeptide, wherein the fusion protein retains at least about %, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, or 500% of the procoagulant ty, when measured by an in Vitro coagulation assay, compared to a corresponding factor VIII not linked to XTEN. In one embodiment, in the ing recombinant factor VIII fusion n the at least one XTEN is linked to said factor VIII polypeptide at a site at or within 1 to 6 amino acids of a site selected from Table 5, Table 6, Table 7, Table 8, and Table 9. In other embodiments, the invention provides recombinant factor VIII fusion ns comprising a factor VIII polypeptide and at least a first extended recombinant polypeptide (XTEN), wherein said factor VIII polypeptide comprises an Al domain including an al acidic spacer , an A2 domain including an a2 acidic spacer region, an A3 domain including an a3 acidic spacer region, a Cl domain, a C2 domain and optionally all or a n of a B domain, and wherein said first XTEN is linked to said factor VIII polypeptide at (i) the C- terminus of said factor VIII polypeptide; (ii) within the B domain of said factor VIII ptide if all or a portion of the B domain is present; (iii) within the Al domain of said factor VIII polypeptide; (iV) within the A2 domain of said factor VIII polypeptide; (V) within the A3 domain of said factor VIII ptide; (Vi) within the C1 domain of said factor VIII polypeptide; or (Vii) within the C2 domain of said factor VIII polypeptide; and when ed to a corresponding factor VIII protein not linked to XTEN, the fusion protein (a) retains at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% 100%, 200%, 300%, 400%, or 500% of the procoagulant actiVity in an in Vitro coagulation assay described herein or other such assays known in the art, and/or (b) exhibits reduced binding to an anti- factor VIII antibody in an in vitro binding assay described herein or other such assays known in the art. I n one embodiment, in the ing recombinant factor VIII fusion protein the at least one XTEN is linked to said factor VIII polypeptide at a site at or within 1 to 6 amino acids of a site ed from Table , Table 6, Table 7, Table 8, and Table 9. In other ments, the invention provides recombinant factor VIII fusion proteins comprising a factor VIII polypeptide and at least a first extended recombinant polypeptide (XTEN), wherein said factor VIII polypeptide comprises an A1 domain including an al acidic spacer region, an A2 domain including an a2 acidic spacer region, an A3 domain including an a3 acidic spacer region, a C1 domain, a C2 domain and optionally all or a portion of a B domain, and wherein said first XTEN is linked to said factor VIII polypeptide at an insertion site selected from Table 6 and Table 7 and n the fusion protein retains at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%,100%, 200%, 300%, 400%, or 500% of the procoagulant activity, when ed by an in vitro coagulation assay described herein or other such assays known in the art, compared to a corresponding factor VIII protein not linked to XTEN. Non-limiting examples of the factor VIII protein not linked to XTEN includes native FVIII, BDD FVIII, pBC100 and ces from Table 1. In another embodiment of the recombinant factor VIII fusion protein, the factor VIII polypeptide has at least about 80% sequence identity, or about 90%, or about 91%, or about 92%, or about 93%, or about 94%, or about 95%, or about 96%, or about 97%, or about 98%, or about 99%, to about 100% ce identity to a sequence selected from the group consisting of the sequences of Table 1, the ce depicted in and the sequence depicted in when optimally d. In yet another embodiment, the fusion protein comprises at least another XTEN linked to said factor VIII polypeptide at the C-terminus of said factor VIII polypeptideor within or optionally replacing the B domain of said factor VIII polypeptide. In a specific embodiment, the fusion protein comprises at least one XTEN sequence located within or optionally replacing the B domain of said factor VIII polypeptide. In another specific embodiment, the fusion n comprises at least one XTEN sequence linked to said factor VIII polypeptide at the C- terminus of said factor VIII polypeptide. In one ment, the recombinant factor VIII fusion protein comprises a B-domain deleted variant of human factor VIII, wherein the B-domain deletion starts from a first position at about amino acid residue number 741 to about 750 and ending at a second position at amino acid e number 1635 to about 1648 with reference to full-length human factor VIII sequence as set forth in In another embodiment, the recombinant factor VIII fusion protein comprises a first XTEN sequence linked to said factor VIII polypeptide at the C-terminus of said factor VIII polypeptide, and at least a second XTEN within or replacing the B domain of said factor VIII polypeptide, wherein the second XTEN is linked to the C-terminal end of about amino acid residue number 741 to about 750 and to the N—terminal end of amino acid residue numbers 1635 to about 1648 with reference to full-length human factor VIII sequence as set forth in wherein the cumulative length of the XTEN is at least about 100 amino acid residues. In one ment, in the ing fusion protein, the second XTEN links the factor VIII amino acids between N745 to P1640 or between S743 to Q1638 or between P747 to V1642 or between N745 and Q1656 or between N745 and S1657 or between N745 and T1667 or n N745 and Q1686 or between R747 and V1642 or between T751 and T1667.

In one embodiment, the recombinant factor VIII fusion protein comprises a sequence haVing at least about 80% sequence identity, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99%, to about 100% sequence identity compared to a sequence of comparable length selected from Table 21, when optimally d. In another embodiment, the recombinant factor VIII fusion protein ses at least a second XTEN, optionally a third XTEN, optionally a fourth XTEN, optionally a fifth XTEN and optionally a sixth XTEN, wherein each of the second, third, fourth, fifth, or sixth XTEN is linked to said factor VIII polypeptide at a second, third, fourth, fifth, or sixth site selected from the group ting of an insertion site from Table 5, Table 6, Table 7 Table 8, and Table 9; a location within 6 amino acids of amino acid residue 32, 220, 224, 336, 339, 390, 399, 416, 603, 1656, 1711, 1725, 1905 and 1910 ofmature factor VIII; a location between any two adjacent domains of said factor VIII polypeptide, wherein said two nt domains are selected from the group consisting ofA1 and A2 domains, A2 and B domains, B and A3 s, A3 and C1 domains, and C1 and C2 domains; a location within the B domain of said factor VIII ptide, wherein the second XTEN is linked to the C-terminal end of about amino acid residue number 741 to about 750 and to the N—terminal end of amino acid residue numbers 1635 to about 1648 of a native factor VIII sequence; and the C-terminus of said factor VIII polypeptide. In one embodiment, the first XTEN is separated from the second XTEN by at least 10 amino acids, at least 50 amino acids, at least 100 amino acids, at least 200 amino acids, at least 300 amino acids, or at least 400 amino acids. In one embodiment of the recombinant factor VIII fusion protein that comprises at least a second XTEN, ally a third XTEN, optionally a fourth XTEN, optionally a fifth XTEN and optionally a sixth XTEN, each XTEN has at least about 80% sequence identity, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99%, or about 100% sequence identity compared to an XTEN of comparable length selected from the group consisting of the sequences in Table 4, Table 13, Table 14, Table 15, Table 16, and Table 17, when optimally aligned. In yet another embodiment of the recombinant factor VIII fusion protein that comprises at least a second XTEN, optionally a third XTEN, optionally a fourth XTEN, optionally a fifth XTEN and optionally a sixth XTEN, In preferred embodiments, the recombinant factor VIII fusion protein exhibits a terminal half-life at least about 3 hours, or 4 hours, or 6 hours, or 12 hours, or 13 hours, or 14 hours, or 16 hours, or 24 hours, or 48 hours, or 72 hours, or 96 hours, or 120 hours, or 144 hours, or 7 days, or 14 days, or 21 days when administered to a subject, wherein said subject is selected from human and factor on Willebrand factor double knock-out mouse. Further, in the embodiments of this paragraph, the fusion protein exhibits reduced binding to anti-factor VIII dy or r ed procoagulant activity, or both as compared to a corresponding factor VIII not linked to XTEN. In one embodiment, the procoagulant ty of the recombinant factor VIII fusion protein is at least 30%, or 40%, 50%, 80%, 100%, 200%, 300%, 400%, or 500% greater procoagulant actiVity in the presence of the anti-FVIII antibody compared to a corresponding factor VIII not linked to XTEN when each are d by an in Vitro coagulation assay. In one embodiment, the reduced g of the fusion n to anti-factor VIII antibody is determined using a Bethesda assay using anti-factor VIII antibody selected from the group ting of the antibodies of Table 10 and polyclonal antibody from a hemophilia A patient with factor VIII inhibitors, n the d binding and retained procoagulant actiVity of the fusion protein is eVidenced by a lower da titer of at least about 2, 4, 6, 8, 10, 12, 15, 20, 30, 40, 50, 60, 70, 80, 100, or 200 Bethesda units for the fusion protein ed to that for the factor VIII not linked to XTEN.

In one embodiment, the recombinant factor VIII fusion protein can, for example, comprise one or more XTEN wherein the XTEN has at least about 80% sequence identity, or about 90%, or about 91%, or about 92%, or about 93%, or about 94%, or about 95%, or about 96%, or about 97%, or about 98%, or about 99%, to about 100% sequence identity compared to one or more XTEN of comparable length selected from Table 4, Table 13, Table 14, Table 15, Table 16, and Table 17, when optimally aligned.

In another aspect, the invention relates to recombinant factor VIII fusion ns comprising FVIII and one or more XTEN in specific N— to C-terminus configurations. In one embodiment of the CFXTEN composition, the invention provides a recombinant factor VIII fusion protein of formula I: (XTEN)X-CF-(XTEN)y I wherein independently for each occurrence, CF is a factor VIII as defined herein, including sequences having at least about 80%, or at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% or 100% sequence identity with sequenced from Table 1; X is either 0 or 1 and y is either 0 or 1 wherein x+y 31; and XTEN is an extended recombinant polypeptide as described herein, including, but not limited to sequences having at least about 80%, or at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% or 100% sequence identity to sequences set forth in Table 4. Accordingly, the CFXTEN fusion composition can have XTEN-CF, XTEN-CF-XTEN, or CF-XTEN configurations.

In r embodiment of the CFXTEN composition, the invention provides a recombinant factor VIII fusion protein of formula II: (XTEN)X-(S)X-(CF)-(XTEN) y II wherein independently for each ence, CF is a factor VIII as defined herein, including sequences having at least about 80%, or at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% or 100% sequence identity to sequences set forth in Table 1; S is a spacer sequence having between 1 to about 50 amino acid residues that can optionally include a cleavage sequence or amino acids compatible with restrictions sites; x is either 0 or 1 and y is either 0 or 1 n x+y 21; and XTEN is an extended recombinant polypeptide as described herein including, but not limited to sequences having at least about 80%, or at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% or 100% sequence identity to sequences set forth in Table 4.

In another embodiment of the CFXTEN composition, the ion provides a recombinant factor VIII fusion protein, wherein the fusion protein is of formula III: (XTEN)X-(S)X-(CF)-(S)y-(XTEN)y 111 wherein independently for each occurrence, CF is a factor VIII as defined herein, including sequences having at least about 80%, or at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% or 100% sequence identity to sequence set for in Table 1; S is a spacer sequence having between 1 to about 50 amino acid residues that can ally include a cleavage sequence or amino acids compatible with restrictions sites; x is either 0 or 1 and y is either 0 or 1 wherein x+y 21; and XTEN is an extended recombinant polypeptide as described herein ing, but not limited to sequences having at least about 80%, or at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% or 100% sequence identity to sequences set forth in Table 4.

In another embodiment of the CFXTEN composition, the invention provides a inant factor VIII fusion protein of formula IV: XTEN)u-(A2)-(XTEN)V-(B)-(XTEN)W-(A3)-(XTEN)x-(C1)-(XTEN)y-(C2)-(XTEN)Z wherein ndently for each occurrence, A1 is an A1 domain of FVIII; A2 is an A2 domain of FVIII; A3 is an A3 domain of FVIII; B is a B domain of FVIII which can be a fragment or a splice variant of the B domain; C1 is a C1 domain of FVIII; C2 is a C2 domain of FVIII; v is either 0 or 1; w is either 0 or 1; X is either 0 or 1; y is either 0 or 1; y is either 0 or 1 with the proviso that u + v + X + y+z 31; and XTEN is an extended recombinant polypeptide as described herein including, but not d to sequences having at least about 80%, or at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% or 100% sequence identity to sequences set forth in Table 4.

In another embodiment of the CFXTEN composition, the invention provides a recombinant factor VIII fusion protein of a V: (XTEN)t-(S)a -(A1)-(S)b-(XTEN)u-(S)b-(A2)-(S)c-(XTEN)V-(S)c-(B)-(S)d-(XTEN)w-(S)d-(A3)—(S)e- (XTEN)x-(S)e-(C1)-(s)r(XTEN)y-(S)r(cz)-(S)g-(XTEN)Z V wherein independently for each occurrence, A1 is an A1 domain of FVIII; A2 is an A2 domain of FVIII; A3 is an A3 domain of FVIII; B is a B domain of FVIII which can be a fragment or a splice variant of the B domain; C1 is a C1 domain of FVIII; C2 is a C2 domain of FVIII; S is a spacer sequence having between 1 to about 50 amino acid residues that can optionally include a cleavage ce or amino acids compatible with restrictions sites; a is either 0 or 1; b is either 0 or 1; c is either 0 or 1; d is either 0 or 1; e is either 0 or 1; f is either 0 or 1; g is either 0 or 1; t is either 0 or 1; u is either 0 or 1; v is either 0 WO 22617 or 1; W is 0 or 1, X is either 0 or 1; y is either 0 or 1; z is either 0 or 1 with the proviso that t + u + V + w+ X + y + z 31; and XTEN is an extended recombinant polypeptide as described herein including, but not limited to sequences having at least about 80%, or at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% or 100% sequence identity to sequences set forth in Table 4. In another embodiment of formula V, the spacer sequence is glycine or a sequence selected from Tables 11 and 12.

In another embodiment of the CFXTEN composition, the invention provides a recombinant factor VIII fusion protein of formula VI: (XTEN)u-(S)a-(A1)-(S)b-(XTEN)v-(S)b-(A2)-(S)c-(XTEN)w-(S)c-(A3)-(S)d-(XTEN)x-(S)d-(C1)- (s)e-(XTEN)y-(8)6-(C2)—(S)r(XTEN)Z VI wherein independently for each occurrence, A1 is an A1 domain of FVIII; A2 is an A2 domain of FVIII; A3 is an A3 domain of FVIII; C1 is a C1 domain of FVIII; C2 is a C2 domain of FVIII; S is a spacer ce having between 1 to about 50 amino acid residues that can ally include a cleavage sequence or amino acids compatible with restrictions sites; a is either 0 or 1; b is either 0 or 1; c is either 0 or 1; dis either 0 or 1; e is either 0 or 1; fis either 0 or 1; uis either 0 or 1; Vis either 0 or 1; Wis 0 or 1, X is either 0 or 1; y is either 0 or 1; z is either 0 or 1 with the proviso that u + V + w+ X + y + z 31; and XTEN is an ed recombinant ptide as described herein including, but not limited to sequences having at least about 80%, or at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% or 100% sequence identity to sequences set forth in Table 4. In r embodiment of formula V, the spacer sequence is glycine or a sequence selected from Tables 11 and 12.

In another embodiment of the CFXTEN composition, the invention provides a recombinant factor VIII fusion protein of formula VII: (SP)-(XTEN)x-(CS)X-(S)x-(FVIII_1-745)-(S)y-(XTEN)y-(S)y-(FVIII_1640-2332)-(S)Z-(CS)Z- (XTEN)Z VII wherein independently for each occurrence, SP is a signal peptide, ably with sequence MQIELSTCFFLCLLRFCFS (SEQ ID NO: 1611), CS is a cleavage ce listed in Table 12, S is a spacer sequence having between 1 to about 50 amino acid residues that can ally include amino acids compatible with restrictions sites, “FVIII_1-745” is residues 1-745 of Factor FVIII and “FVIII_1640-2332” is residues 1640-2332 of FVIII, X is either 0 or 1, y is either 0 or 1, and z is either 0 or 1, wherein x+y+z >2; and XTEN is an eXtended inant polypeptide as described herein ing, but not limited to sequences having at least about 80%, or at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% or 100% sequence identity sequences set forth in Table 4. In one embodiment of formula VII, the spacer sequence is GPEGPS (SEQ ID NO: 1612). In another embodiment of formula V, the spacer sequence is glycine or a sequence selected from Tables 11 and 12.

In r embodiment of the CFXTEN composition, the invention provides a recombinant factor VIII fusion protein of formula VIII: (A1)—(S)a-(XTEN)V-(S)a-(A2)-(B1)—(S)b-(XTEN)w-(S)b-(B2)-(A3)—(S)c-(XTEN)x-(S)c-(C1)—(S)d- (XTEN)y-(S)d-(C2)-(S)e-(XTEN)Z VIII wherein independently for each occurrence, A1 is an A1 domain of FVIII; A2 is an A2 domain of FVIII; B1 is a fragment of the B domain that can have from residue 741 to 743-750 of FVIII or alternatively from about residue 741 to about residues 745 of FVIII; B2 is a fragment of the B domain that can have from residues 1635-1686 to 1689 of FVIII or alternatively from about e 1640 to about residues 1689 of FVIII; A3 is an A3 domain of FVIII; C1 is a C1 domain of FVIII; C2 is a C2 domain of FVIII; S is a spacer sequence having between 1 to about 50 amino acid residues that can optionally include a cleavage sequence or amino acids compatible with ctions sites; a is either 0 or 1; b is either 0 or 1; c is either 0 or 1; d is either 0 or 1; e is either 0 or 1; f is either 0 or 1; u is either 0 or 1; V is either 0 or 1; W is 0 or 1, X is either 0 or 1; y is either 0 or 1; z is either 0 or 1 With the proviso that u + V + w+ X + y + z 21; and XTEN is an extended recombinant polypeptide as bed herein including, but not limited to sequences having at least about 80%, or at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% or 100% sequence identity to sequences set forth in Table 4. In one embodiment of formula VIII, the spacer sequence is GPEGPS (SEQ ID NO: 1612). In another embodiment of a V, the spacer sequence is e or a sequence ed from Tables 11 and 12.

In another embodiment of the CFXTEN composition, the invention provides a recombinant factor VIII fusion protein of formula IX: (A1N)'(S)a'(XTEN)I'(S)b'(A1C)'(A2 N)-(S)c-(XTEN)u-(S)d-(A2c)-(BN)-(S)e-(XTEN)v-(S)r(Bc)-(A3N)- (S)g'(XTEN)W'(S)h'(A3C)'(C1N)'(S)i'(XTEN)X'(S)j'(C1C)'(C2N)'(S)k'(XTEN)y'(S)1'(C2C)'(S)m'(XTEN)z Wherein independently for each occurrence, AlN is a fragment of the A1 domain from at least residue number 1 (numbered relative to , mature FVIII) to no more than residue number 371, A1C is a fragment of the A1 domain from at least residue number 2 to no more than residue number 372, With the priViso that no sequence of the A1N fragment is duplicated in the A1C is a fragment; A2N is a fragment of the A2 domain from at least residue number 373 to no more than residue number 739, Me is a fragment of the A2 domain from at least residue number 374 to no more than residue number 740, With the priViso that no sequence of the A2N fragment is duplicated in the Me is a fragment; BN is a nt of the B domain from at least residue number 741 to no more than residue number 1647, BC is a fragment of the B domain from at least residue number 742 to no more than residue number 1648, With the priViso that no sequence of the BN fragment is duplicated in the BC is a fragment; A3N is a fragment of the A3 domain from at least residue number 1649 to no more than residue number 2019, A3C is a nt of the A3 domain from at least residue number 1650 to no more than e number 2019, With the priViso that no sequence of the A3N fragment is duplicated in the A3C is a fragment; ClN is a fragment of the C1 domain from at least residue number 2020 to no more than residue number 2171, C1C is a nt of the C1 domain from at least residue number 2021 to no more than residue number 2172, With the o that no sequence of the ClN fragment is duplicated in the C1C is a fragment; C2N is a fragment of the C2 domain from at least residue number 2173 to no more than residue number 2331, C2C is a fragment of the C2 domain from at least e number 2174 to no more than residue number 2332, with the priviso that no sequence of the C2N fragment is duplicated in the C2C is a fragment; S is a spacer sequence having between 1 to about 50 amino acid residues that can optionally include a cleavage sequence or amino acids compatible with restrictions sites; a is either 0 or 1; b is either 0 or 1; c is either 0 or 1; d is either 0 or 1; e is either 0 or 1; f is either 0 or 1; g is either 0 or 1; h is either 0 or 1; i is either 0 or 1; j is either 0 or 1; k is either 0 or 1; l is either 0 or 1; m is either 0 or 1; t is either 0 or 1; u is either 0 or 1; V is either 0 or 1; W is 0 or 1, X is either 0 or 1; y is either 0 or 1; z is either 0 or 1 with the proviso that t + u + V + w+ X + y + z 31; and XTEN is an ed recombinant polypeptide as bed herein including, but not limited to sequences having at least about 80% sequence identity, or about 90%, or about 91%, or about 92%, or about 93%, or about 94%, or about 95%, or about 96%, or about 97%, or about 98%, or about 99%, to about 100% sequence identity compared to one or more XTEN of comparable length selected from Table 4. In one embodiment of formula IX, the spacer sequence is GPEGPS (SEQ ID NO: 1612).

In another embodiment of formula V, the spacer sequence is glycine or a ce selected from Tables 11 and 12. In another embodiment of a IX, Z is 1. In another embodiment of the fusion protein of formula IX V is 1 and the XTEN is linked to the C-terminal end of about amino acid residue number 741 to about 750 and to the N—terminal end of amino acid residue numbers 1635 to about 1648 with reference to full-length human factor VIII sequence as set forth in In another embodiment of the fusion protein of formula IX, the sum of t, u, v, W, X, y, and 2 equals 2, 3, 4, 5, or 6. In another embodiment of formula IX, the sum of t, u, v, W, X, y, and 2 equals 2, and v is 1 and z is 1. In another embodiment of the fusion protein of formula IX, the sum of t, u, v, W, X, y, and 2 equals 3, v and 2 each equal 1, and either t, u, W, X or y is 1. In another embodiment of a IX, the sum of t, u, v, W, X, y, and 2 equals 4, v and W and 2 each equal 1, and two of t, u, X or y is 1. In another ment of the fusion protein of a IX, the cumulative length of the XTENs is between about 84 to about 3000 amino acid es. In another embodiment of formula IX, at least one XTEN is ed immediately downstream of an amino acid which corresponds to an amino acid in mature native human factor VIII selected from the group consisting of amino acid residue number 32, 220, 224, 336, 339, 399, 416, 603, 1656, 1711, 1725, 1905 and 1910. In another embodiment of the fusion protein a IX, each XTEN is linked to said fusion protein at sites selected from Table 5, Table 6, Table 7, Table 8, and Table 9. In another embodiment of the fusion protein formula IX, each XTEN has at least about 80%, or about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99%, or about 100% sequence identity compared to an XTEN of comparable length selected from the group consisting of the sequences in Table 4, Table 13, Table 14, Table 15, Table 16, and Table 17, when lly aligned.

In another embodiment of the CFXTEN composition, the invention provides a first recombinant factor VIII polypeptide of formula X: (A1)—a1—(A2)—a2—[B] X and a second polypeptide comprising Formula XI: a3 — (A3) — (Cl) - (C2) XI wherein the first polypeptide and the second polypeptide are fused or exist as a heterodimer; wherein, Al is an Al domain of factor VIII; A2 is an A2 domain of factor VIII; [B] is a B domain of factor VIII, a fragment thereof, or is deleted; A3 is an A3 domain of factor VIII; Cl is a Cl domain of factor VIII; C2 is a C2 domain of factor VIII; al, a2, and a3 are acidic spacer regions; wherein the Al domain comprises an XTEN permissive loop-l (Al -1) region and an XTEN permissive loop-2 (Al -2) region; wherein the A2 domain comprises an XTEN permissive loop-l (A2-l) region and an XTEN permissive loop-2 (A2- 2) ; n the A3 domain comprises an XTEN permissive loop-l (A3-l) region and an XTEN permissive loop-2 (A3 -2) region; wherein an XTEN sequence is inserted into at least one of the regions Al -1, Al -2, A2-l, A2-2, A3-l, or A3 -2; and wherein the recombinant factor VIII protein exhibits procoagulant activity. In one embodiment of the heterodimer, the first polypeptide and the second polypeptide form a single polypeptide chain comprising the formula (Al) al (A2) a2 [B] [a3] (A3) — (C1) — (C2). In one embodiment of the foregoing, “fused” means a peptidic bond.

In another ment of the CFXTEN composition, the invention provides a first recombinant factor VIII polypeptide of formula X: (Al)—al—(A2)—a2—[B] X and a second polypeptide comprising Formula XI: a3 — (A3) — (Cl) - (C2) XI wherein the first polypeptide and the second polypeptide are fused or exist as a heterodimer; wherein, Al is an Al domain of factor VIII; A2 is an A2 domain of factor VIII; [B] is a B domain of factor VIII, a nt thereof, or is deleted; A3 is an A3 domain of factor VIII; Cl is a Cl domain of factor VIII; C2 is a C2 domain of factor VIII; al, a2, and a3 are acidic spacer regions; wherein an XTEN sequence is ed into a3; and wherein the recombinant factor VIII protein exhibits procoagulant actiVity. In one embodiment of the heterodimer, the first polypeptide and the second polypeptide form a single polypeptide chain comprising the formula (Al) al (A2) a2 [B] [a3] (A3) (C1) (C2). In one embodiment of the foregoing, “fused” means a peptidic bond. in embodiments of the foregoing ae X and XI polypeptides, the XTEN permissive loops are contained within surface-exposed, flexible loop structures, and wherein Al-l is located n beta strand 1 and beta strand 2, Al -2 is located between beta strand 11 and beta strand l2, A2-l is located n beta strand 22 and beta strand 23, A2-2 is located between beta strand 32 and beta strand 33, A3-l is located between beta strand 38 and beta strand 39 and A3-2 is located between beta strand 45 and beta strand 46, according to the secondary structure of mature factor VIII stored as Accession Number 2R7E of the DSSP database. In other embodiments of the foregoing formulae X and \I ptides, the surface-exposed, flexible loop structure sing Al-l corresponds to a region in native mature human factor VIII from about amino acid 15 to about amino acid 45. In other embodiments ofthe foregoing formulae X and Xi polypeptides the Al -1 corresponds to a region in native mature human factor VIII from about amino acid 18 to about amino acid 41. In other ments of the foregoing formulae X and XI polypeptides, the surface-exposed, flexible loop structure sing A1-2 corresponds to a region in native mature human factor VIII from about amino acid 201 to about amino acid 232. In other embodiments of the foregoing formulae X and XI polypeptides the A1-2 corresponds to a region in native mature human factor VIII from about amino acid 218 to about amino acid 229. In other embodiments of the foregoing formulae X and XI polypeptides, the surface-exposed, flexible loop structure comprising A2-1 corresponds to a region in native mature human factor VIII from about amino acid 395 to about amino acid 421. In other embodiments of the foregoing formulae X and XI polypeptides, the A2-1 ponds to a region in native mature human factor VIII from about amino acid 397 to about amino acid 418. In other embodiments of the foregoing formulae X and XI polypeptides, the surface-exposed, flexible loop structure comprising A2-2 corresponds to a region in native mature human factor VIII from about amino acid 577 to about amino acid 635. In other embodiments of the foregoing formulae X and XI polypeptides, the A2-2 corresponds to a region in native mature human factor VIII from about amino acid 595 to about amino acid 607. In other embodiments of the foregoing formulae X and XI polypeptides, the e-exposed, flexible loop structure comprising A3-1 ponds to a region in native mature human factor VIII from about amino acid 1705 to about amino acid 1732. In other embodiments of the foregoing formulae X and XI polypeptides, the A3-1 corresponds to a region in native mature human factor VIII from about amino acid 1711 to about amino acid 1725. In other embodiments of the foregoing formulae X and XI polypeptides, the the surface-exposed, flexible loop structure sing A3-2 corresponds to a region in native mature human factor VIII from about amino acid 1884 to about amino acid 1917. In other embodiments of the foregoing formulae X and XI polypeptides, the A3-2 corresponds to a region in native mature human factor VIII from about amino acid 1899 to about amino acid 1911. in other embodiments of the foregoing formulae X and XI polypeptides, an XTEN sequence is inserted into at least two of the regions A1-1, A1-2, A2-1, A2-2, A3-1, or A3-2. In other embodiments of the ‘oregoin0'0. formulae X and XI polypeptides, an XTEN sequence is inserted immediately downstream of an amino acid which corresponds to an amino acid in mature native human factor VIII selected from the group consisting of amino acid residue number 32, 220, 224, 336, 339, 399, 416, 603, 1656, 1711, 1725, 1905 and 1910. In other embodiments of the foregoing ae X and Xl polypeptides, an additional XTEN ce is inserted into the a3 acidic spacer region. In other embodiments of the foregoing ae X and XI polypeptides, an additional XTEN ce is inserted into the a3 acide spacer ately downstream of an amino acid which corresponds to amino acid 1656. In other embodiments of the foregoing formulae X and XI polypeptides, the A1 domain comprises an XTEN permissive loop-1 (A1- 1) region and an XTEN permissive loop-2 (A1-2) region wherein the A2 domain comprises an XTEN permissive loop-1 (A2-1) region and an XTEN permissive loop-2 (A2-2) region, and wherein the A3 domain comprises an XTEN permissive loop-1 (A3-1) region and an XTEN permissive loop-2 (A3 -2) region, and wherein an additional XTEN sequence is inserted into at least one of the regions A1-1, A1-2, A2-1, A2-2, A3-1, or A3 -2. In other embodiments of the foregoing formulae X and XI polypeptides, an onal XTEN sequence is inserted immediately downstream of an amino acid which ponds to an amino acid in mature native human factor VIII ed from the group consisting of amino acid residue number 32, 220, 224, 336, 339, 390, 399, 416, 603, 1656, 1711, 1725, 1905 and 1910. In the foregoing embodiments of ae X and Xi polypeptides, the fusion protein ts at least about %, 40%, 50%, 60%, 70%, or 80%, or 90% of the procoagulant activity of the corresponding factor VIII not linked to XTEN, wherein the procoagulant activity is assayed by an in vitro coagulation assay.

In all ments, the polypeptide can, for example, exhibit an in vitro procoagulant activity exceeding 0.5 IU/ml, or 1.0, or 1.5, or 2.0 IU/ml When expressed in cell-culture medium and assayed by an in vitro coagulation assay. The procoagulant activity can be measured by a chromogenic assay, a one stage clotting assay (e. g., a aPTT) or both.

In some ments, Wherein the inant factor VIII fusion protein comprises a factor VIII and at least a first and a second XTEN, the at least first XTEN is separated from the at least second XTEN by at least 10 amino acids, at least 50 amino acids, at least 100 amino acids, at least 200 amino acids, at least 300 amino acids, or at least 400 amino acids. $026} In preferred embodiments, the recombinant factor VIII fusion protein comprising a factor VIII and at least a first XTEN and, optionally, at least a second, or optionally at least a third, or ally at least a fourth XTEN, the fusion protein exhibits reduced binding to an actor VIII antibody as compared to the corresponding factor VIII not linked to XTEN. The reduced binding can be assessed either in vivo or by an in vitro assay. In one embodiment, the in vitro assay is an ELISA assay, Wherein the binding of an anti-FVIII antibody to the fusion n is reduced at least about 5%, 10%, 15%, 20%, %, 30%, 35% or at least about 40% or more compared to a FVIII not linked to XTEN. In another embodiment, the in vitro assay is a Bethesda assay Wherein the reduced binding of the fusion protein is evidenced by a lower Bethesda titer of at least about 2, 4, 6, 8, 10, 12, 15, 20, 30, 40, 50, 60, 70, 80, 100, or 200 Bethesda units for the fusion n compared to that for a factor VIII not linked to XTEN. In the in vitro assays, the anti-factor VIII antibody is selected from an antibody of Table 10 and polyclonal antibody from a hemophilia A patient With factor VIII inhibitors. In particular ments of a recombinant factor VIII fusion protein sing a factor VIII and at least a first and a second XTEN ting reduced binding to a factor VIII inhibitor antibody, the first XTEN is linked to said factor VIII polypeptide Within a C2 domain of said factor VIII polypeptide, and the second XTEN is linked to said factor VIII polypeptide Within an A1 or A2 domain of said factor VIII polypeptide, Wherein said fusion protein ts reduced binding to a factor VIII inhibitor antibody as compared to the corresponding factor VIII not linked to XTEN, Wherein the factor VIII inhibitor antibody is capable of binding to an epitope located Within the A1, A2 or C2 domain, and further n the fusion protein exhibits procoagulant activity. In one embodiment of the foregoing fusion protein, the second XTEN is linked to said factor VIII polypeptide with in the A2. domain of the factor VIII polypeptide and the factor VIII inhibitor antibody binds to the A2 domain of the factor VIII polypeptide. In another ment of the foregoing fusion protein, the second XTEN is linked to said factor VIII polypeptide Within the (.2 domain of the factor VIII polypeptide and the factor VIII inhibitor antibody binds to the C2 domain of the factor VIII polypeptide. The binding of an anti—factor VIII antibody to the fusion protein is reduced by at least about 5%, I094), I596, 20%, 25%, 30%, 35% or 40% compared to the eorreoponding factor 2012/046326 VIII not ed to XTEN when assayed by an ELISA assay, wherein the anti~factor \HII antibody is selected from the group consisting of the antibodies in Table l0 and a polyclonal antibody from a hemophilia A subject with factor Vlll inhibitors. The foregoing fusion proteins can further comprise at least three XTEN s, wherein the at least third XTEN is linked to the factor VIII at a site ed from within or replacing the B domain, at the {TL-terminus, and at or Within 1, 2, 3, 4, 5, or 6 amino acids of an insertion site selected from Table 7 or Table 9. in the ments with d binding to anti-factor Vlll antibodies, the fusion protein has greater procoagulant activity in the presence of the anti—FVlll antibody of at least l0%, 20%, 30%, 40%., 50%, 80%, l00%, 200%, 300%, 400%, or 500%. or more compared to a corresponding factor VIII not linked to XTEN when assayed by an in Vll't’O ation assay (eg, a chromogenic or one—stage clotting assay). {0027} in all embodiments, the XTEN of the fusion protein can, for example, be characterized in that the XTEN comprise at least 36, or at least 42, or at least 72, or at least 96, or at least 144, or at least 288, or at least 400, or at least 500, or at least 576, or at least 600, or at least 700, or at least 800, or at least 864, or at least 900, or at least 1000, or at least 2000, to about 3000 amino acid es or even more residues; the sum of glycine (G), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P) residues constitutes at least about 80%, or at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% of the total amino acid residues of the XTEN; the XTEN is substantially non-repetitive such that (i) the XTEN contains no three uous amino acids that are identical unless the amino acids are serine; (ii) at least about 80% of the XTEN sequence consists of erlapping sequence motifs, each of the ce motifs comprising about 9 to about 14, or about 12 amino acid residues consisting of four to six amino acids selected from glycine (G), alanine (A), serine (S), threonine (T), ate (E) and proline (P), wherein any two contiguous amino acid residues do not occur more than twice in each of the non-overlapping sequence motifs; or (iii) the XTEN ce has a subsequence score of less than 10; the XTEN has greater than 90%, or greater than 95%, or greater than 99% random coil formation as determined by GOR algorithm; the XTEN has less than 2% alpha helices and 2% beta-sheets as determined by Chou-Fasman algorithm; the XTEN lacks a predicted T-cell epitope When analyzed by TEPITOPE algorithm, wherein the PE threshold score for said prediction by said algorithm has a threshold of —9, and wherein said fusion protein exhibits a terminal half-life that is longer than at least about 12 h, or at least about 24 h, or at least about 48 h, or at least about 72 h, or at least about 96 h, or at least about 120 h, or at least about 144 h, or at least about 21 days or greater. In one embodiment, the recombinant factor VIII fusion protein comprises at least a second, or at least a third, or at least a fourth XTEN, Which can be identical or different to the other XTEN. According to a different approach, the at least one, at least a second, or at least a third, or at least a fourth XTEN of the CFXTEN fusion protein each have at least about 80% ce identity, or about 90%, or about 91%, or about 92%, or about 93%, or about 94%, or about 95%, or about 96%, or about 97%, or about 98%, or about 99%, to about 100% sequence identity compared to one or more XTEN of comparable length selected from Table 4, Table 13, Table 14, Table , Table 16, and Table 17, When optimally aligned. In yet another different approach, the at least one, at least a second, or at least a third, or at least a fourth XTEN of the CFXTEN fusion protein each have at least 90%, or about 91%, or about 92%, or about 93%, or about 94%, or about 95%, or about 96%, or about 97%, or about 98%, or about 99%, to about 100% sequence identity compared to a sequence selected from AE42_1, AE42_2, AE42_3, AG42_1, AG42_2, AG42_3, AG42_4, AE144_1A, AE144_2A, AE144_2B, AE144_3A, 3B, AE144_4A, AE144_4B, 5A, AE144_6B, AG144_1, AG144_2, AG144_A, AG144_B, AG144_C, F, AG144_3, AG144_4, AE288_1, AE288_2, AG288_1, and AG288_2. {0028} In one embodiment, the factor ‘v’lll component of the CFXTEN recombinant factor Vlll fusion protein eon’iprisies one, two or three amino acid substitutions selected from es R1648, Yl680, and R1689, numbered relative to mature human factor VIII, wherein the substitutions are selected from alanine, glycine, and phenylalanine. Non-limiting es ofsaid substitutions e Rl648A, YléSQE, and R1689A. {002,9} ln another embodiment, the CFXTEN fusion protein exhibits an apparent molecular weight lactor of at least about L3, or at least about two, or at least about three, or at least about four, or at least about five, or at least about six, or at least about seven, or at least about eight, or at least about nine, or at least about 10, when measured by size exclusion tography or comparable method.

In some embodiments of the CFXTEN fusion proteins, one or more of the XTEN is to the FVIII Via one or two cleavage sequences that each is cleavable by a mammalian protease selected from the group consisting of factor XIa, factor XIIa, kallikrein, factor VIIa, factor IXa, factor Xa, factor Ila (thrombin), se-2, MMP-12, MMP13, MMP-17 and MMP-20, wherein cleavage at the cleavage sequence by the mammalian protease es the factor VIII ce from the XTEN sequence, and wherein the released factor VIII sequence exhibits an increase in procoagulant activity compared to the ved fusion protein. In one embodiment, the cleavage sequence(s) are cleavable by factor XIa.

According to a different approach, the CFXTEN fusion proteins comprise at least three XTENs located at different locations of the factor VIII polypeptide, wherein said different locations are selected from: an insertion location at or Within 1 to 6 amino acids from a site selected from Table 5, Table 6, Table 7 Table 8, and Table 9; a location at or Within 1 to 6 amino acids of amino acid residue 32, 220, 224, 336, 339, 390, 399, 416, 603, 1656, 1711, 1725, 1905 and 1910 ofmature factor VIII; a location between any two adjacent domains in the factor VIII ce, n said two adjacent domains are selected from the group consisting of A1 and A2, A2 and B, B and A3, A3 and C1, and C1 and C2; a location Within an internal B domain deletion starting from a first position at about amino acid residue number 741 to about 750 and ending at a second position at amino acid residue number 1635 to about 1648 With reference to full-length human factor VIII sequence as set forth in and the C-terminus of the factor VIII sequence, n the cumulative length of the multiple XTENs is at least about 100 to about 3000 amino acid residues and wherein the fusion protein retains at least about 30%, or about 40%, or about 50%, or about 60%, or about 70%, or about 80%, or about 90% of the procoagulant activity compared to the corresponding factor VIII not linked to XTEN, wherein the procoagulant activity is assayed by an in Vitro coagulation assay. In one embodiment of the foregoing, the fusion protein exhibits a prolonged terminal half-life when administered to a subject as compared to a corresponding factor VIII polypeptide lacking said XTEN, wherein said fusion protein ts a terminal half-life at least about 3 hours, or 4 hours, or 6 hours, or 12 hours, or 13 hours, or 14 hours, or 16 hours, or 24 hours, or 48 hours, or 72 hours, or 96 hours, or 120 hours, or 144 hours, or 7 days, or 14 days, or 21 days when administered to a subject. In one embodiment, the subject is selected from the group consisting of human and a factor VIII/von Willebrand factor double knock-out mouse. In one embodiment of the foregoing, the fusion protein does not se a sequence selected from TASSSP (SEQ ID NO: 31), GSSTPSGATGSP (SEQ ID NO: 32), GSSPSASTGTGP (SEQ ID NO: 33), GASPGTSSTGSP (SEQ ID NO: 34), and GSEPATSGSETPGTSESATPESGPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGSEPATSG SETPGSEPATSGSETPGSEPATSGSETPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTST EPSEGSAP (SEQ ID NO: 59). In another embodiment of the foregoing, the fusion n does not contain an XTEN ce consisting of GSEPATSGSETPGTSESATPESGPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGSEPATSG SETPGSEPATSGSETPGSEPATSGSETPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTST EPSEGSAP (SEQ ID NO: 59), PGSSPSASTGTGPGSSPSASTGTGPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGASPGTS TPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGTP GSGTASSS (SEQ ID NO: 71), or PGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSG ATGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGA SPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTG SPGASPGTSSTGSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTGSPGSSPSASTGTGPGTPGSG TASSSPGSSTPSGATGS (SEQ ID NO: 80).

In a timber aspect, the invention concerns CFXTEN fusion proteins with enhanced pharmacokinetic properties, including enhanced parameters compared to FVIII not linked to XTEN, wherein the enhanced properties e but are not limited to longer terminal half-life, larger area under the curve, increased time in which the blood concentration remains within the therapeutic window, increased time between consecutive doses results in blood concentrations within the therapeutic window, and decreased dose in IU over time that can be administered compared to a FVIII not linked to XTEN, yet still result in a blood concentration above a threshold concentration needed for a procoagulant effect.

In some embodiments, a CFXTEN fusion proteins exhibit a prolonged al half-life when stered to a subject as compared to a corresponding factor VIII polypeptide lacking said XTEN.

The subject can be a human or a mouse, such as a factor VIII/von Willebrand factor double out mouse. In one embodiment of the foregoing, the CFXTEN exhibits a terminal half-life that is at least about two-fold, or about three fold, or about four-fold, or about five-fold, or about 10-fold, or about 20- fold longer when administered to a subject compared to the corresponding factor VIII not linked to XTEN. In one embodiment, the CFXTEN fusion protein exhibits a al half-life at least about 3 hours, or 4 hours, or 6 hours, or 12 hours, or 13 hours, or 14 hours, or 16 hours, or 24 hours, or 48 hours, or 72 hours, or 96 hours, or 120 hours, or 144 hours, or 7 days, or 14 days, or 21 days when stered to the subject. In other embodiments, the ed pharmacokinetic property of the fiJsion proteins of the embodiments is the property of maintaining a circulating blood concentration of procoagulant fusion protein in a subject in need thereof above a threshold concentration of 0.01 IU/ml, or 0.05 IU/ml, or 0.1 IU/ml, or 0.2 IU/ml, or 0.3 IU/ml, or 0.4 IU/ml or 0.5 IU/ml for a period that is at least about two fold, or at least about three-fold, or at least about old, or at least about five-fold, or at least about six-fold, or at least about eight-fold, or at least about ten-fold, or at least about 20-fold, or at least about 40-fold, or at least about d longer compared to the corresponding FVIII not linked to XTEN and administered to a subject at a comparable dose. The increase in half-life and time spent above the threshold concentration permits less frequent dosing and decreased amounts of the fusion protein (in moles equivalent) that are stered to a subject, compared to the corresponding FVIII not linked to XTEN.

In one embodiment, stration of a subject fusion protein to a subject using a therapeutically- effective dose regimen results in a gain in time of at least two-fold, or at least three-fold, or at least four- fold, or at least five-fold, or at least six-fold, or at least eight-fold, or at least 10-fold, or at least about 20- fold, or at least about 40-fold, or at least about 60-fold or higher between at least two consecutive CmaX peaks and/or Cmin troughs for blood levels of the fusion protein compared to the corresponding FVIII not linked to the XTEN and administered using a comparable dose regimen to a t.

In preferred embodiments, the CFXTEN fusion proteins retain at least about 30%, or about 40%, or about 50%, or about 60%, or about 70%, or about 80%, or about 90% of the procoagulant activity compared to the ponding factor VIII not linked to XTEN, wherein the procoagulant activity is assayed by an in vitro coagulation assay such as, but not limited to a chromogenic assay or a one- or two-stage clotting assay.

According to a different approach, the invention provides recombinant factor VIII fusion proteins comprising a factor VIII polypeptide and at least one extended recombinant polypeptide (XTEN), n said factor VIII polypeptide comprises A1 , A2 domain, A3 domain, C1 domain, C2 domain and ally all or a portion of B domain, and wherein said at least one XTEN is linked to said factor VIII polypeptide at an insertion site selected form residue numbers 18-32, or 40, or 211-224, or 3, or 599, or 745-1640, or 1656-1728, or 1796-1804, or 1900-1912, or 2171-2332; and n the fusion protein retains at least about 30%, or about 40%, or about 50%, or about 60%, or about 70%, or about 80%, or about 90% of the gulant activity compared to the corresponding factor VIII not linked to XTEN. In one embodiment of the foregoing, the fusion protein comprises at least a second XTEN, or at least a third, or at least a fourth XTEN n the XTEN are linked to the factor VIII at a site at or within 1 to 6 amino acids of a site selected from Table 5, Table 6, Table 7, Table 8, and Table 9. In another embodiment, the invention provides an recombinant factor VIII fusion protein further comprising at least a second XTEN, or at least a third, or at least a fourth XTEN linked to said FVIII polypeptide at an insertion site selected from Table 5, Table 6, Table 7, Table 8, Table 9, at or within 6 amino acids to the N— or C-terminus side of an insertion location at one or more insertion locations from Figure 8 and within one or more insertion ranges from Figure 9 wherein at least two XTEN are separated by an amino acid sequence of at least 100 to about 400 amino acids.

The invention provides CFXTEN wherein the XTEN have a Ratio XTEN Radii of at least 2.3 or at least 2.5, and are separated by an amino acid sequence of at least about 20 amino acid residues, or at least about 50, or at least about 100, or at least about 200, or at least about 300, or at least about 400 amino acid residues. In other embodiments, the CFXTEN comprise at least four XTEN wherein the XTEN have a Ratio XTEN Radii of at least 2.3, or at least 2.5, or at least 2.8, and n at least three of the four of the XTEN linked to the fusion protein are separated by an amino acid sequence of at least about 20 amino acid es, or at least about 50, or at least about 100, or at least about 200, or at least about 300, or at least about 400 amino acid residues, and the fourth XTEN is linked within the B domain (or a fragment thereof) or within the C domain (or the terminus thereof).

In some ments, the subject compositions are configured to have reduced binding affinity for a nce receptor in a t as compared to the corresponding FVIII not linked to the XTEN. In one embodiment, the CFXTEN fusion protein exhibits g affinity for a clearance receptor of the FVIII in the range of about 0.01%-30%, or about 0.1% to about 20%, or about 1% to about 15%, or about 2% to about 10% of the binding affinity of the corresponding FVIII not linked to the XTEN. In r embodiment, a fusion protein with reduced affinity for a clearance receptor has reduced active clearance and a corresponding increase in half-life of at least about 2-fold, or 3-fold, or at least 4-fold, or at least about 5-fold, or at least about 6-fold, or at least about 7-fold, or at least about 8-fold,or at least about 9- fold, or at least about 10-fold, or at least about 12-fold, or at least about 15 -fold, or at least about 17-fold, or at least about 20-fold longer compared to the corresponding FVIII that is not linked to the XTEN.

In an embodiment, the invention provides a recombinant factor VIII fusion protein sing FVIII and one or more XTEN wherein the fusion protein exhibits increased solubility of at least three- fold, or at least about four-fold, or at least about five-fold, or at least about six-fold, or at least about fold, or at least about eight-fold, or at least about nine-fold, or at least about ld, or at least about 15-fold, or at least a 20-fold, or at least 40-fold, or at least 60-fold at physiologic conditions compared to the FVIII not linked to XTEN.

In a further aspect, the invention provides a pharmaceutical composition comprising the fusion protein of any of the embodiments described herein and a pharmaceutically acceptable carrier.

In another embodiment, the invention es a method of treating a coagulopathy in a subject, comprising administering to said subject a composition comprising a clotting effective amount of the pharmaceutical ition. In one ment of the method, after said administration, a blood concentration of procoagulant factor VIII is maintained at about 0.05, or 1, or 1.5 IU/ml or more for at least 48 hours after said administration. In another embodiment, the invention provides a method of clotting blood in a subject, comprising contacting a clotting effective amount of the pharmaceutical composition with the blood.

In another embodiment, the invention provides a method of treating a opathy in a subject with circulating inhibitors of factor VIII, comprising administering to said subject a composition comprising a therapeutically effective amount of the pharmaceutical ition of , wherein the composition ts greater procoagulant activity in said subject compared to a composition comprising the corresponding factor VIII not linked to XTEN and administered using a able amount. In one ment of the method, the coagulopathy is hemophilia A. In another embodiment, the coagulopathy is the result of trauma or surgery or infection.

The invention provides a method of treating a bleeding episode in a subject, comprising administering to said t a composition comprising a clotting effective amount of the CFXTEN pharmaceutical composition, wherein the clotting effective amount of the fusion protein arrests a bleeding episode for a period that is at least three-fold, or at least four-fold, or at least five-fold longer compared to a corresponding factor VIII not linked to XTEN and administered using a comparable amount to said subject. miting es of a ponsing factor VIII not linked to XTEN include native FVIII, the sequences of Table l, BDD-FVIII, and the pCB0114 FVIII.

In another embodiment, the invention provides a CFXTEN recombinant factor VIII fusion protein for use in a pharmaceutical regimen for treating a hemophilia A patient, said regimen comprising a pharmaceutical composition sing a CFXTEN fusion n. In one embodiment of the pharmaceutical regimen, the regimen further comprises the step of determining the amount of ceutical composition comprising the CFXTEN needed to achieve hemostasis in the hemophilia A patient. In another embodiment, the pharmaceutical n for treating a hemophilia A subject comprises administering the pharmaceutical composition in two or more successive doses to the subject at an effective amount, wherein the administration results in at least a 10%, or 20%, or 30%, or 40%, or 50%, or 60%, or 70%, or 80%, or 90% r improvement of at least one, two, or three parameters associated with the hemophilia A disease compared to the factor VIII not linked to XTEN and administered using a comparable dose. Non-limited examples of parameters improved include blood concentration of procoagulant FVIII, a reduced activated partial prothrombin (aPTT) assay time, a reduced one-stage or two-stage clotting assay time, delayed onset of a bleeding episode, a reduced chromogenic assay time, a reduced bleeding assay time, resolution of a bleeding event, or a d da titer to native FVIII.

In another aspect, the invention provides isolated nucleic acid ces encoding the fusion proteins of any one of the embodiments of the CFXTEN fusion protein. In one ment, the ed nucleic acid is the complement of a ce encoding a CFXTEN fusion protein of the embodiments.

In one ment, the isolated nucleic acid further comprises a sequence encoding a signal peptide, wherein said sequence is ATGCAAATAGAGCTCTCCACCTGCTTCTTTCTGTGCCTTTTGCGATTCTGCTTTAGT (SEQ ID NO: 1613), or the complement thereof In another embodiment, the invention provides an expression vector comprising the nucleic acid encoding the fusion protein, or the complement thereof. In another embodiment, the invention provides an isolated host cell comprising the foregoing expression vector. In another embodiment, the invention provides a method of producing the fusion protein of any of the embodiments, comprising providing a host cell comprising the expression vector; culturing the host cell to effect production of the fiision protein; and recovering the fusion protein.

In one embodiment, the invention provides an isolated fusion protein comprising a polypeptide having at least about 80% sequence identity, or about 90%, or about 91%, or about 92%, or about 93%, or about 94%, or about 95%, or about 96%, or about 97%, or about 98%, or about 99%, to about 100% sequence identity compared to a sequence of comparable length selected from Table 21, when optimally aligned.

In another ment, the invention provides an isolated nucleic acid comprising a cleotide sequence selected from (a) a ce having at least about 80% sequence identity, or about 90%, or about 91%, or about 92%, or about 93%, or about 94%, or about 95%, or about 96%, or about 97%, or about 98%, or about 99%, to about 100% sequence identity compared to a sequence of comparable length selected from Table 21, when optimally aligned, or (b) the complement of the polynucleotide of (a). In another embodiment, the isolated c acid comprises the sequence ATGCAAATAGAGCTCTCCACCTGCTTCTTTCTGTGCCTTTTGCGATTCTGCTTTAGT (SEQ ID NO: 1613) linked to the 5’ end of the c acid of (a) or the complement of the sequence linked to the 3 ’ end of (b).

It is specifically contemplated that the recombinant factor VIII fusion proteins can exhibit one or more or any combination of the properties disclosed . [0046A] In one aspect, the invention provides a recombinant factor VIII fusion protein comprising a factor VIII polypeptide fused to an extended recombinant polypeptide (XTEN), wherein the factor VIII polypeptide comprises A1 domain, A2 domain, A3 domain, a3 domain, C1 domain, C2 domain, and optionally a B domain or a portion thereof, n the XTEN is inserted within the factor VIII polypeptide. [0046B] In one embodiment, the XTEN is ed into the B domain or the portion thereof. [0046C] In r embodiment, the XTEN is inserted into the A1 domain, the A2 , the A3 , the 33 , or any combination thereof. [0046B] In a further embodiment, the A1 domain comprises a permissive loop-1 (Al-l) region and a sive loop-2 (Al-2) region wherein the XTEN is inserted into Al-l, A1-2, or both. [0046E] In another embodiment, the A2 domain comprises a permissive loop-l (AZ-l) region and a permissive loop-2 (A2—2) region wherein the at least one XTEN is inserted into A2-1, A2-2, or both. [0046F] In a further embodiment, the A3 domain comprises a permissive loop-1 (A3-l) region and a permissive loop—2 (A3 -2) region wherein the at least one XTEN is inserted into A3-1, A3—2, or both. [0046G] In another embodiment, the permissive loop-l (Al-1) region corresponds to a region in native mature human factor VIII from amino acid 15 to amino acid 45 or from amino acid 18 to amino acid 32 of SEQ ID N012, and wherein the XTEN is inserted into Al-l. [0046H] In a further embodiment, the permissive loop-2 (Al—2) region corresponds to a region in native mature human factor VIII from amino acid 201 to amino acid 232 or from amino acid 211 to amino acid 224 of SEQ ID NO: 2, and wherein the XTEN is inserted into Al—2.

In another embodiment, the permissive loop-1 (AZ-1) region corresponds to a region in native mature human factor VIII from amino acid 395 to amino acid 421 or from amino acid 397 to amino acid 418 of SEQ ID NO: 2, and wherein the XTEN is inserted into A2-1. [0046.)] In a further embodiment, the permissive loop-2 (A2—2) region ponds to a region in native mature human factor VIII from amino acid 577 to amino acid 635 or from amino acid 595 to amino acid 607 of SEQ ID NO: 2, and wherein the XTEN is inserted into A2-2. [0046K] In another embodiment, the permissive loop-1 (A3-1) region corresponds to a region in native mature human factor VIII from amino acid 1705 to amino acid 1732 or from amino acid 1711 to amino acid 1725 of SEQ ID NO: 2, and wherein the XTEN is inserted into A3-1. [0046L] In a r embodiment, the permissive loop-2 (A3 -2) region corresponds to a region in native mature human factor VIII from amino acid 1884 to amino acid 1917 or from amino acid 1900 to amino acid 1912 of SEQ ID NO: 2, and wherein the XTEN is inserted into A3-2. [0046M] In another embodiment, the XTEN is inserted within Al-l immediately downstream of an amino acid ponding to amino acid 17 of SEQ ID NO: 2, amino acid 18 of SEQ ID NO: 2, amino acid 22 of SEQ ID NO: 2, amino acid 24 of SEQ ID NO: 2, amino acid 26 of SEQ ID NO: 2, amino acid 28 of SEQ ID NO: 2, amino acid 32 of SEQ ID NO: 2, amino acid 38 of SEQ ID NO: 2, amino acid 40 of SEQ ID NO: 2, or amino acid 41 of SEQ ID NO: 2. [0046N] In a r embodiment, the XTEN is inserted within A1-2 immediately downstream of an amino acid corresponding toamino acid 205 of SEQ ID NO: 2, amino acid 210 of SEQ ID NO: 2, amino acid 211 of SEQ ID NO: 2, amino acid 216 of SEQ ID NO: 2, amino acid 220 of SEQ ID NO: 2, amino acid 222 of SEQ ID NO: 2, amino acid 223 of SEQ ID NO: 2, amino acid 224 of SEQ ID NO: 2, or amino acid 230 of SEQ ID NO: 2.

In another embodiment, the XTEN is inserted within A2-1 immediately downstream of an amino acid corresponding to amino acid 399 of SEQ ID NO: 2, amino acid 403 of SEQ ID NO: 2, amino acid 405 of SEQ ID NO: 2, amino acid 409 of SEQ ID NO: 2, or amino acid 416 of SEQ ID NO: 2.

] In a further embodiment, the XTEN is inserted within A2-2 ately downstream of an amino acid corresponding to amino acid 598 of SEQ ID NO: 2, amino acid 599 of SEQ ID NO: 2, amino acid 603 of SEQ ID NO: 2, or amino acid 616 of SEQ ID NO: 2.

] In another embodiment, the XTEN is inserted within A3-1 immediately downstream of an amino acid corresponding to amino acid 1711 of SEQ ID NO: 2, amino acid 1713 of SEQ ID NO: 2, amino acid 1720 of SEQ ID NO: 2, amino acid 1724 of SEQ ID NO: 2, amino acid 1725 of SEQ ID NO: 2, or amino acid 1726 of SEQ ID NO: 2. [0046R] In a further embodiment, the XTEN is inserted Within A3 -2 immediately downstream of an amino acid corresponding to amino acid 1896 of SEQ ID NO: 2, amino acid 1900 of SEQ ID NO: 2, amino acid 1904 of SEQ ID NO: 2, amino acid 1905 of SEQ ID NO: 2, or amino acid 1910 of SEQ ID NO: 2.

] In another embodiment, the XTEN is inserted within a3 ately downstream of an amino acid corresponding to amino acid 1656 of SEQ ID NO: 2. [0046T] In a further embodiment, the at the least one XTEN is inserted immediately downstream of an amino acid corresponding to amino acid 740 or 745 of SEQ ID NO: 2. [0046U] In another embodiment, the XTEN is inserted within the C1 or the C2 domain. [0046V] In a further embodiment, the XTEN is inserted immediately downstream of an amino acid corresponding to an amino acid selected from the group consisting of amino acid 2020 of SEQ ID NO: 2, amino acid 2044 of SEQ ID NO: 2, amino acid 2068 of SEQ ID NO: 2, amino acid 2073 of SEQ ID NO: 2, amino acid 2090 of SEQ ID NO: 2, amino acid 2092 of SEQ ID NO: 2, amino acid 2093 of SEQ ID NO: 2, amino acid 2111 of SEQ ID NO: 2, amino acid 2115 of SEQ ID NO: 2, amino acid 2120 of.

SEQ ID NO: 2, amino acid 2125 of SEQ ID NO: 2, amino acid 2171 of SEQ ID NO: 2, amino acid 2173 of SEQ ID NO: 2, amino acid 2188 of SEQ ID NO: 2, amino acid 2223 of SEQ ID NO: 2, amino acid 2224 of SEQ ID NO: 2, amino acid 2227 of SEQ ID NO: 2, amino acid 2268 of SEQ ID NO: 2, amino acid 2277 of SEQ ID NO: 2, amino acid 2278 of SEQ ID NO: 2, or amino acid 2290 of SEQ ID NO: 2. [0046W] In r ment, the XTEN is inserted immediately downstream of an amino acid corresponding to an amino acid selected from the group consisting of amino acid 18 of SEQ ID NO: 2, amino acid 22 of SEQ ID NO: 2, amino acid 26 of SEQ ID NO: 2, amino acid 28 of SEQ ID NO: 2, amino acid 32 of SEQ ID NO: 2, amino acid 40 of SEQ ID NO: 2, amino acid 211 of SEQ ID NO: 2, amino acid 216 of SEQ ID NO: 2, amino acid 220 of SEQ ID NO: 2, amino acid 224 of SEQ ID NO: 2, amino acid 333 of SEQ ID NO: 2, amino acid 336 of SEQ ID NO: 2, amino acid 339 of SEQ H3 NO: 2, amino acid 399 of SEQ ID NO: 2, amino acid 403 of SEQ ID NO: 2, amino acid 409 of SEQ ID NO: 2, amino acid 416 of SEQ ID NO: 2, amino acid 599 of SEQ ID NO: 2, amino acid 603 of SEQ ID NO: 2, amino acid 740 of SEQ ID NO: 2, amino acid 745 of SEQ ID NO: 2, amino acid 1656 of SEQ ID NO: 2, amino acid 1711 of SEQ ID NO: 2, amino acid 1720 of SEQ ID NO: 2, amino acid 1796 of SEQ ID NO: 2, amino acid 1802 of SEQ ID NO: 2, amino acid 1900 of SEQ ID NO: 2, amino acid 1904 of SEQ ID NO: 2, amino acid 1905 of SEQ ID NO: 2, amino acid 1910 of SEQ ID NO: 2, amino acid 1656 of SEQ ID NO: 2 amino acid 2068 of SEQ ID NO: 2, amino acid 2171 of SEQ ID NO: 2, amino acid 2227 of SEQ ID NO: 2, or amino acid 2277 of SEQ ID NO: 2. [0046X] In a further embodiment, the recombinant factor VIII fusion protein comprises two XTENs. [0046Y] In another ment, the two XTENs are inserted or fused immediately downstream of one or two amino acids corresponding to amino acid 18 of SEQ ID NO: 2, amino acid 26 of SEQ ID NO: 2, amino acid 40 of SEQ ID NO: 2, amino acid 399 of SEQ ID NO: 2, amino acid 403 of SEQ ID NO: 2, amino acid 599 of SEQ ID NO: 2, amino acid 745 of SEQ ID NO: 2, amino acid 1656 of SEQ ID NO: 2, amino acid 1711 of SEQ ID NO: 2, amino acid 1720 of SEQ ID NO: 2, amino acid 1725 of SEQ ID NO: 2, amino acid 1900 of SEQ ID NO: 2, amino acid 1905 of SEQ ID NO: 2, or amino acid 2332 of SEQ ID NO: 2.

] In a further embodiment, the two XTENs are inserted or fused immediately downstream of the amino acids corresponding to: i. amino acids 745 and 2332 of SEQ ID NO: 2; ii. amino acids 1656 and 2332 of SEQ ID NO: 2; iii. amino acids 26 and 403 of SEQ ID NO: 2; iv. amino acids 40 and 403 of SEQ ID NO: 2; V. amino acids 18 and 403 of SEQ ID NO: 2; vi. amino acids 26 and 599 of SEQ ID NO: 2; vii. amino acids 40 and 599 of SEQ ID NO: 2; viii. amino acids 18 and 599 of SEQ ID NO: 2; ix. amino acids 18 and 1656 of SEQ ID NO: 2; x. amino acids 26 and 1656 of SEQ ID NO: 2; xi. amino acids 40 and 1656 of SEQ ID NO: 2; xii. amino acids 403 and 1656 of SEQ ID NO: 2; xiii. amino acids 1656 and 1720 of SEQ ID NO: 2; xiv. amino acids 40 and 399 of SEQ ID NO: 2; xv. amino acids 26 and 1900 of SEQ ID NO: 2; xvi. amino acids 18 and 399 of SEQ ID NO: 2; xvii. amino acids 40 and 399 of SEQ ID NO: 2; or xviii. amino acids 1656 and 1900 of SEQ ID NO: 2. [0046AA] In another embodiment, the recombinant factor VIII fusion protein comprises three XTENS, four XTENs, five XTENs, or six XTENs. [0046AB] In a further embodiment: i. the three XTENs are inserted or fused immediately ream of one or more amino acids corresponding to amino acid 18 of SEQ ID NO: 2, amino acid 26 of SEQ ID NO: 2, amino acid 40 of SEQ ID NO: 2, amino acid 399 of SEQ ID NO: 2, amino acid 403 of SEQ ID NO: 2, amino acid 599 of SEQ ID NO: 2, amino acid 745 of SEQ ID NO: 2, amino acid 1656 of SEQ ID NO: 2, amino acid 1711 of SEQ ID NO: 2, amino acid 1720 of SEQ ID NO: 2, amino acid 1725 of SEQ ID NO: 2, amino acid 1900 of SEQ ID NO: 2, amino acid 1905 of SEQ ID NO: 2, amino acid 1910 of SEQ ID NO: 2, or amino acid 2332 of SEQ ID NO: 2; ii. the four XTENs are inserted or fused immediately downstream of one or more amino acids corresponding to amino acid 18 of SEQ ID NO: 2, amino acid 26 of SEQ ID NO: 2, amino acid 40 of SEQ ID NO: 2, amino acid 403 of SEQ ID NO: 2, amino acid 409 of SEQ ID NO: 2, amino acid 745 of SEQ ID NO: 2, amino acid 1656 of SEQ ID NO: 2, amino acid 1720 of SEQ ID NO: 2, amino acid 1900 of SEQ ID NO: 2, amino acid 1905 of SEQ ID NO: 2, amino acid 1910 of SEQ ID NO: 2, or amino acid 2332 of SEQ ID NO: 2; or iii. the five XTENs are inserted or fused immediately downstream of one or more amino acids corresponding to amino acid 18 of SEQ ID NO: 2, amino acid 403 of SEQ ID NO: 2, amino acid 745 of SEQ ID NO: 2, amino acid 1656 of SEQ ID NO: 2, amino acid 1720 of SEQ ID NO: 2, amino acid 1900 of SEQ ID NO: 2, or amino acid 2332 of SEQ ID NO: 2. [0046AC] In another embodiment, the XTEN comprises 36 amino acids, 42 amino acids, 72 amino acids, 96 amino acids, 144 amino acids, or 288 amino acids. [0046AD] In a further embodiment, the XTEN comprises 72 amino acids, 144 amino acids, or 288 amino acids. [0046AE] In another embodiment, the XTEN comprises one or more XTEN ce motifs, which are selected from the group consisting of SEQ ID N05: 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, and 48. [0046AF] In a further embodiment, the one or more XTEN sequence motifs are selected from the group consisting of SEQ ID NOS: 23, 24, 25, and 26. [0046AG] In another ment, the XTEN comprises an amino acid sequence having 90%, 96%, 97%, 98%, 99%, or 100% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID N03: 49, 50, 51, 52, 57, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 78, and 79. [0046AH] In a further ment, the XTEN comprises an amino acid sequence having 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 279, 281, 283, 285, 287, 289, 291, 293, 295, 297, 299, 301, 303, 305, 307, 309, 311, 313, 315, 317, 319, 321, 323, 325, 327, 329, 331, 333, 335, 337, 339, 341, 343, 345, 347, 349, and 351. [0046AI] In another embodiment, the factor VIII polypeptide comprises a native factor VIII polypeptide. [0046AJ] In a further embodiment, the factor VIII polypeptide comprises a partially deleted B domain or a fully deleted B domain. [0046AK] In another embodiment, the factor VIII polypeptide comprises a single chain factor VIII polypeptide. [0046AL] In a further embodiment, a heterologous polypeptide is fused to the factor VIII polypeptide. [0046AM] In another embodiment, the heterologous polypeptide is an Fc fragment of globulin or an FcRn binding domain. [0046AN] In a further embodiment, the heterologous polypeptide is selected from the group consisting of n or a fragment thereof, a [3 subunit of C-terminal e of human chorionic tropin, a HAP ce, a transferrin, a PAS polypeptide, a polyglycine linker, a polyserine linker, and a combination f. [0046AC] In another aspect, the present invention provides an isolated c acid encoding the recombinant factor VIII fusion protein of the present invention. [0046AP] In a r aspect, the present invention provides a vector comprising the isolated c acid of the present invention. [0046AQ] In one embodiment, the vector is a plasmid, a cosmid, a viral particle, or phage. [0046AR] In another aspect, the present invention provides a host cell sing the vector of the present invention. [0046AS] In a further aspect, the present invention provides a pharmaceutical composition comprising the recombinant factor VIII fusion protein of the present invention and a pharmaceutically acceptable carrier. [0046AT] In another , the present invention provides a pharmaceutical composition comprising the isolated c acid of the present invention, the vector of the t invention, or the host cell of the present invention, and a pharmaceutically able carrier. [0046AU] In a further aspect, the present ion provides a method of making a recombinant factor VIII fusion protein comprising culturing the host cell of the present invention in media under suitable conditions.

V] In another aspect, the present ion provides a use of the pharmaceutical composition of the present invention in the manufacture of a medicament for the treatment of a coagulopathy in a t in need thereof. [0046AW] In a further aspect, the present invention provides a use of the recombinant factor VIII fusion protein of the t ion in the manufacture of a medicament for the treatment of a coagulopathy.

INCORPORATION BY REFERENCE All publications, s, and patent applications mentioned in this specification are herein incorporated by nce to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

BRIEF DESCRIPTION OF THE DRAWINGS The features and advantages of the invention may be further explained by reference to the following detailed description and accompanying drawings that sets forth illustrative embodiments. shows a schematic representation of the FVIII architecture and spatial arrangement of the s during processing and ng, and is intended to represent both native FVIII and B domain deleted variants. The Al domain ranges from residue 1 to 372 (numbering relative to the mature form of FVIII sequence NCBI Protein RefSeq NP_000123 and encompassing a1 residues), A2 domain ranges from residue 373 to 740, B domain ranges from residue 741 to 1648, A3 domain ranges from residue 1649 to 2019 (encompassing a3 acidic region), C1 domain ranges from 2020 to 2172, and the C2 domain ranges from residue 2173 to 2332. BDD variants include deletions between the range 741 to '1648, leaving some or no remnant residues, with a non- limiting BDD remnant sequence being SFSQNPPVLKRHQR (SEQ ID NO: 1614). shows the domain ecture of a single chain FVIII prior to processing. Arrows indicate the sites at residues R3 72, R740, R1648, and R1689 that are cleaved in the processing and conversion of FVIII to FVIIIa. shows the FVIII molecule that has been processed into the heterodimer by the cleavage at the R1648 e, with the a3 acidic region of [Text continues on page 21] the A3 domain indicated on the N—terminus of the A3. shows the FVIII molecule processed into the FVIIIa heterotrimer by the cleavage at the R372, R740, and R1689 residues. is a schematic of the coagulation e, showing the intrinsic and extrinsic arms leading to the common pathway. depicts the amino acid sequence of mature human factor VIII (SEQ ID NO: 1592). depicts a factor VIII sequence with a deletion of a portion of the B domain (SEQ ID NO: 1593). illustrates several examples of CFXTEN configurations of FVIII linked to XTEN (the latter shown as thick, wavy lines). In all cases, the FVIII can be either native or a BDD form of FVIII, or a single chain form in which the entire B domain, including the native cleavage sites are removed. shows, left to right, three variations of single chain factor VIII with XTEN linked to the N—terminus, the C-terminus, and two XTEN linked to the N— and C-terminus. shows six variations of mature dimer FVIII with, left to right, an XTEN linked to the inus of the A1 domain; an XTEN linked to the C-terminus of the C2 domain; an XTEN linked to the N—terminus of the A1 domain and the C-terminus of the C2 domain; an XTEN linked to the N-terminus of the A1 domain and to the N- us of the A3 domain; an XTEN linked to the C-terminus of the C2 domain and to the N-terminus of the A3 domain via residual B domain amino acids; and an XTEN linked to the N-terminus of the A1 domain, the C-terminus of the A2 domain via residual B domain amino acids, and to the C-terminus of the C2 domain. shows, left to right, three variations of single chain factor VIII: an XTEN linked to the N—terminus of the A1 , an XTEN linked within a surface loop of the A1 domain and an XTEN linked within a surface loop of the A3 domain; an XTEN linked within a surface loop of the A2 domain, an XTEN linked within a surface loop of the C2 domain and an XTEN linked to the C terminus of the C2 domain; an XTEN linked to the N—terminus of the A1 domain and within a surface loop of the C1 domain and to the C-terminus of the C . shows six variations of mature heterodimer FVIII with, left to right, an XTEN linked to the N-terminus of the A1 domain, an XTEN linked within a surface loop of the A1 domain, and an XTEN linked within a surface loop of the A3 domain; an XTEN linked within a surface loop of the A2 domain, and an XTEN linked within a surface loop of the C1 domain, and an XTEN linked to the C-terminus of the C2 domain; an XTEN linked to the N—terminus of the A1 domain, an XTEN linked within a surface loop of the A1 domain, an XTEN linked within a surface loop of the A3 domain, and an XTEN linked to the C-terminus of the C2 ; an XTEN linked to the N—terminus of the A1 domain, an XTEN linked to the N—terminus of the A3 domain via residual amino acids of the B domain, and an XTEN linked within a surface loop of the C2 domain; an XTEN linked within a surface loop of the A2 , an XTEN linked to the N—terminus of the A3 domain via al amino acids of the B domain, an XTEN linked within a surface loop of the C1 domain, and an XTEN linked to the C-terminus of the C2 domain; and an XTEN linked within the B domain or between the residual B domain residues of the BDD variant (and the invention also contemplates a ion in which the XTEN replaces the entirety of the B , including all native cleavage sites, linking the A2 and A3 domains, resulting in a single chain form of factor VIII). This figure also embodies all variations in which one or more XTEN sequences are inserted within the B domain and the resulting fusions are cleaved at one or more sites (e.g., at R1648 site) during intracellular processing. is a graphic portrayal of a CFXTEN construct with an XTEN inserted within the B domain and linked to the C-terminus of the C2 domain rating the unstructured characteristic of the XTEN leading to random coil formation that can cover portions of the factor VIII proximal to the XTEN.

In the lower panel, the drawing s that when XTEN is in random coil, it can adopt a conformation resulting in steric hindrance that blocks binding of factor VIII inhibitor antibodies that would otherwise have affinity for epitopes proximal to the XTEN site of insertion. is a graphic portrayal of the various analyses performed on a FVIII B-domain deleted ce to identify insertion sites for XTEN within the FVIII sequence. Each of lines A—H are on an arbitrary scale of Y axis values across the FVIII BDD sequence such that low values represent areas with a high predicted tolerance for XTEN insertion, with the residue numbers on the X axis. Line A shows the domain boundaries; all discontinuities in this line represent boundaries that are likely to accept XTEN.

Line B shows exon boundaries; i.e., each step in the line represents a new exon. Line C shown regions that were not visible in the X-ray structure due to a lack of order in the crystal. Lines labeled D represents le predictions of order that were calculated using the respective programs dex found on the Wide web site bip.weizmann.ac.il/fidbin/findex (last accessed February 23, 2011) (see Jaime Prilusky, Clifford E. Felder, Tzviya en-Mordehai, Edwin Rydberg, Oma Man, Jacques S. nn, Israel Silman, and Joel L. n, 2005, Bioinformatics based on the Kyte & lle algorithm, as well as RONN found on the Wide web site strubi.ox.ac.uk/RONN (last accessed ry 23, 2011) (see Yang,Z.R., Thomson, R., McMeil, P. and Esnouf, R.M. (2005) RONN: the bio- basis function neural network technique applied to the ion of natively disordered regions in proteins Bioinformatics 21: 3369-3376. Lines E and F were calculated based on multiple ce alignments of FVIII genes from 11 s available in GenBank. Line E represents the conservation of individual residues. Line F represent the conservation of 3 amino acid segments of FVIII. Lines G and H represent gaps and insertions observed in the le ce alignment of 11 mammalian FVIII genes. Line J lists the XTEN insertion points by amino acid number that were obtained based by combining the multiple measurements above. depicts the sites in a FVIII B-domain deleted sequence (SEQ ID NO: 1594) identified as active insertion points for XTEN using the information depicted in and as confirmed in the assays of Example 34. depicts the range of sites in a FVIII B-domain deleted sequence (SEQ ID NO: 1595) identified for insertion ofXTEN using the information depicted in and or Example 34 plus a span of amino acids around each insertion point that are considered suitable for insertion of XTEN. is a schematic of the assembly of a CFXTEN library created by identifying insertion points as described for FIGS. 7 followed by insertion of single XTEN (black bars) at the various insertion points using molecular biology techniques. The constructs are expressed and recovered, then evaluated for FVIII activity and pharmacokinetic properties to identify those CFXTEN configurations that result in enhanced ties. is a schematic of the assembly of a CFXTEN component library in which segments of FVIII BDD domains, either singly or linked to various s ofXTEN (black bars) are assembled in a combinatorial fashion into libraries of genes encoding the CFXTEN, which can then be evaluated for FVIII actiVity and pharmacokinetic properties to identify those CFXTEN configurations that result in enhanced properties. illustrates several examples of CFXTEN configurations with XTEN (shown as thick, wavy lines), with certain XTEN releasable by inserting cleavage sequences (indicated by black triangles) that are cleavable by procoagulant ses. A illustrates a scFVIII with two terminal releasable XTENS. B illustrates the same configuration as A but with an onal non-releasable XTEN linking the A3 and C1 domains. C illustrates a mature heterodimer FVIII with two terminal releasable XTEN. D illustrates the same configuration as 10C but with an additional non-releasable XTEN linking the A3 and C1 domains. is a tic rt of representative steps in the assembly, production and the tion of an XTEN. is a schematic flowchart of representative steps in the assembly of a CFXTEN polynucleotide construct encoding a fusion protein. Individual oligonucleotides 501 are annealed into sequence motifs 502 such as a 12 amino acid motif (“12-mer”), which is ligated to additional sequence motifs from a library to create a pool that encompasses the desired length of the XTEN 504, as well as ligated to a smaller concentration of an oligo containing BbsI, and KpnI restriction sites 503. The resulting pool of ligation products is gel-purified and the band with the desired length ofXTEN is cut, resulting in an isolated XTEN gene with a stopper ce 505. The XTEN gene is cloned into a stuffer vector. In this case, the vector encodes an optional CBD sequence 506 and a GFP gene 508. Digestion is then performed with BbsI/HindIII to remove 507 and 508 and place the stop codon. The resulting product is then cloned into a BsaI/HindIII digested vector containing a gene encoding the FVIII, ing in the gene 500 encoding an FVIII-XTEN fusion n. is a tic flowchart of representative steps in the assembly of a gene encoding fusion protein comprising a CF and XTEN, its expression and ry as a fusion protein, and its evaluation as a candidate CFXTEN product. illustrates the use of donor XTEN sequences to produce ted XTENs. A provides the sequence of AG864 (SEQ ID NO: 1596), with the underlined sequence used to generate a sequence length of 576 (SEQ ID NO: 1597). B provides the sequence of AG864 (SEQ ID NO: 1598), with the ined sequence used to generate a ce length of 288 (SEQ ID NO: 1599).

C provides the sequence of AG864 (SEQ ID NO: 1600), with the underlined sequence used to generate a sequence length of 144 (SEQ ID NO: 1601). D provides the sequence of AE864 (SEQ ID NO: 1602), with the underlined sequence used to generate a sequence length of 576 (SEQ ID NO: 1603). E provides the sequence of AE864 (SEQ ID NO: 1604), with the underlined sequence WO 22617 used to generate a sequence length of 288 (SEQ ID NO: 1605). F provides the sequence of AE864 (SEQ ID NO: 1606) used to generate four sequences of 144 length (SEQ ID NOS 1607-1610, respectively, in order of ance) (the double underline indicates the first amino acid in the 144 sequence with the single underline representing the balance of that sequence). is a schematic representation of the design of Factor VIII-XTEN expression vectors with different strategies introducing XTEN elements into the FVIII coding sequence. A shows an expression vector ng XTEN fused to the 3’ end of the sequence encoding FVIII. B depicts an sion vector encoding an XTEN element inserted into the middle of the coding sequence encoding a single FVIII. C depicts an expression vector encoding two XTEN elements: one inserted internal to the FVIII coding sequence, and the other fused to the 3’ end of the FVIII coding sequence. rates the process of combinatorial gene assembly of genes encoding XTEN. In this case, the genes are assembled from 6 base fragments and each fragment is available in 4 different codon versions (A, B, C and D). This allows for a theoretical diversity of 4096 in the assembly of a 12 amino acid motif. shows the pharmacokinetic profile (plasma concentrations) in cynomolgus monkeys after single doses of different compositions of GFP linked to unstructured polypeptides of varying length, administered either subcutaneously or intravenously, as described in Example 41. The compositions were GFP-L288, 76, GFP-XTEN_AF576, GFP-Y576 and D836-GFP. Blood samples were analyzed at various times after injection and the tration of GFP in plasma was measured by ELISA using a polyclonal antibody t GFP for capture and a biotinylated preparation of the same polyclonal antibody for detection. Results are presented as the plasma concentration versus time (h) after dosing and show, in particular, a considerable increase in half-life for the D836-GFP, the composition with the longest sequence length of XTEN. The construct with the shortest sequence length, the GFP-L288 had the shortest half-life. shows an SDS-PAGE gel of samples from a stability study of the fusion protein of XTEN_AE864 fused to the inus of GFP (see Example 42). The GFP-XTEN was ted in cynomolgus plasma and rat kidney lysate for up to 7 days at 37°C. In addition, GFP-XTEN administered to cynomolgus monkeys was also assessed. Samples were withdrawn at O, 1 and 7 days and analyzed by SDS PAGE ed by detection using Western analysis with dies against GFP. shows results of a size exclusion chromatography analysis of glucagon-XTEN construct samples measured against protein standards of known molecular weight, with the graph output as absorbance versus retention volume, as described in Example 40. The on-XTEN constructs are 1) glucagon-Y288; 2) glucagonY-144; 3) glucagon-Y72; and 4) on-Y36. The s indicate an increase in apparent molecular weight with increasing length ofXTEN moiety (see Example 40 for data). shows results of a Western blot of proteins expressed by cell culture of cells transformed with constructs as designated (Example 25). The samples in lanes 1-12 were: MW Standards, FVIII (42.5 ng), pBCOIOOB, pBC0114A, pBC0100, pBC0114, pBC0135, pBC0136, pBC0137, pBC0145, 9, and pBC0146, respectively. Lanes 8, 9 and 12 show bands consistent with a FVIII with a C-terminal XTEN288, with an estimated MW of 95 kDa. Lanes 7 and 11 show bands consistent with a FVIII with a C-terminal XTEN42, with an estimated MW of 175 kDa. Lanes 2-6 show bands consistent with FVIII and heavy chain. Lanes 10 and 23 show bands consistent with heavy chain. Lane 7 shows a band consistent with heavy chain and an attached XTEN42. shows the results of FVIII assay on samples obtained from FVIII and von Willebrand factor double knock-out mice with hydrodynamic plasmid DNA injection, as detailed in e 36. is a graphic and tabular portrayal of the pharmacokinetic properties of rBDD-FVIII and the purified CFXTEN fusion proteins pBC0145 and pBC0146 (with C-terminal XTEN) stered to either HemA or FVIII/VWF double knock-out mice as bed in Example 30, showing the enhanced half-life of the CFXTEN in both strains of mice. is a graphic and tabular portrayal of the pharmacokinetic properties of rBDD-FVIII and the CFXTEN fusion proteins pSD0050 and pSDOO62 (with internal inserted XTEN) administered to either HemA (A) or FVIII/VWF double knock-out mice (B) using a cell culture PK assay in HemA mice. Dose, 5-minute recovery, and half-life (Tl/2) are shown, as described in Example 32, underscoring the enhanced recovery and half-life of the CFXTEN ed to the positive l FVIII in both strains of mice. is a graphic depiction of a titration of GMA8021 FVIII inhibitor using the pBC0114 BDD-FVIII AND CFXTEN construct 9.002 with three 144 amino acid XTEN insertions at es 18, 745 and 2332. The data indicate a right-shift of imately 0.7 order of magnitude in the amount of antibody in [Lg/ml required to inhibit the CFXTEN to the 50% level, compared to FVIII positive control. is a schematic of the logic flow chart of the algorithm SegScore. In the figure the following legend applies: i, j - counters used in the control loops that run through the entire sequence; HitCount- this variable is a counter that keeps track of how many times a subsequence encounters an identical subsequence in a block; SubSeqX - this variable holds the subsequence that is being checked for redundancy; SubSeqY - this variable holds the subsequence that the SubSeqX is checked against; en - this variable holds the user determined length of the block; SegLen - this variable holds the length of a t. The program is hardcoded to generate scores for subsequences of s 3, 4, 5, 6, 7, 8, 9, and 10; Block - this le holds a string of length en. The string is composed of letters from an input XTEN sequence and is ined by the position of the i counter; SubSeqList - this is a list that holds all of the generated subsequence scores. depicts the application of the algorithm SegScore to a hypothetical XTEN of 11 amino acids (SEQ ID NO: 1591) in order to determine the repetitiveness. An XTEN sequence consisting ofN amino acids is divided into N—S+1 subsequences of length S (S=3 in this case). A pair-wise comparison of all subsequences is performed and the average number of identical subsequences is calculated to result in the subsequence score of 1.89. is a graph of the individual construct values of the ratio of FVIII activity in the assayed CFXTEN to that of the pBC114 FVIII ve control after exposure to the GMA8021 antibody to FVIII, grouped ing to the number ofXTEN in the construct fusion protein (see Example 28). The s show an essentially linear relationship in the ability of the CFXTEN to retain FVIII actiVity with increasing number of incorporated XTEN. depicts the primary sequence and domain structure of mature B-domain deleted (BDD) human FVIII construct (Example 46). The location of the introduced NheI and Clal restriction sites is shown. Note that the amino acid numbering corresponds to the amino acid positions in the primary sequence of mature FVIII (). Individual domains are bounded by gray lines/boxes with domain identification in gray text. Acidic regions (a1, a2, a3) are indicated with dashed boxes. Solid wedges/triangles indicate sites of thrombin ge in the activation of FVIII to . Unfilled /triangle indicates the site of intracellular proteolytic processing to the ained form of FVIII.

Hexagons indicate sites of N—linked glycosylation. Circles indicate sites of Tyr sulfation. Unique non- native restriction sites (Nhel, GCTAG; Clal, ATCGAT) introduced into cDNA to facilitate XTEN insertion/recombination are highlighted in gray with double ine. provides graphical representation of the FVIII construct described in , indicating the domain organization and the location of native and non-native restriction sites. shows the graphical ASAView outputs for structural datasets 2R7E, 3CDZ, and PMOO76106. Accessible Solvent Areas (ASA) for the amino acids in domains A1, A2, A3, C1 and C2 are shown. Analyses were performed on X-ray crystallographic coordinates 3CDZ (Ngo et al., Structure 16: 597-606 (2008)) and 2R7E (Shen et al., Blood 111:1240-1247 ) deposited in the Protein Data Bank maintained by the Research oratory for Structural Bioinformatics (RCSB; /www.rcsb.org/pdb), as well as on atomic coordinates PMOO76106 for the predicted refined FVIII structure derived from a molecular dynamics simulation study (Venkateswarlu, BMC Struct. Biol. 10:7 (2010)) deposited in the n Model Database (http://mi.caspur.it/PMDB/main.php) maintained by Consorzio Interuniversitario per le Applicazioni di Supercalcolo per Universita e Riserca (CASPUR) and the Department of Biochemical Sciences of the University of Rome. shows a structural representation of the on ofXTEN insertion sites. The central drawing corresponding to the crystal structure of FVIII (PDB: 2R7E) is surrounded by detailed View of domains A1, A2, A3, C1 and C2. Beta strands and alpha helices are shown as ribbon representation.

Loops are shown as alpha carbon pipes. The amino acids at XTEN ion sites are shown as CPK sphere representation. The number in each graph indicate the location of the XTEN insertion sites according to the numbering in . shows a structural entation of the location ofXTEN insertion sites shown in wherein the resulting recombinant FVIII protein displays FVIII ty. shows a structural representation of the location ofXTEN insertion sites shown in wherein the resulting recombinant FVIII protein displays FVIII actiVity. shows a structural representation of the location ofXTEN insertion sites shown in wherein the resulting recombinant FVIII n displays FVIII activity. shows a ClustalW multiple sequence ent of domains A], A2, A3, C1 and C2 of FVIII showing the on ofXTEN insertions resulting in recombinant FVIII proteins displaying FVIII actiVity (black box, white text) or displaying no FVIII actiVity (grey box, bold text). shows a DSSP graphical representation of the ary structure of the two polypeptide chains in a native active human FVIII crystal ure deposited under the identifier 2R7E at the Protein Data Bank (see Example 47). Amino acid sequence numbering is the same as in the protein sequence in . The beta sheet regions are shown as filled arrows and are designated B1 to B66.

The location of the XTEN permissive loops is denoted by crosshatched boxes. Domain Al XTEN permissive loops are designated Loop Al-l and Loop Al -2. Domain A2 XTEN permissive loops are designated Loop A2-l and Loop A2-2. Domain A3 XTEN permissive loops are designated Loop A3-l and Loop A3-2. shows a DSSP graphical representation of the secondary ure of the two polypeptide chains in a native active human FVIII crystal structure deposited under the identifier 2R7E at the Protein Data Bank (see Example 47). Amino acid sequence numbering is the same as in the protein sequence in . The beta sheet regions are shown as filled arrows and are designated B1 to B66.

The location of the XTEN permissive loops is denoted by crosshatched boxes. Domain Al XTEN permissive loops are designated Loop Al-l and Loop Al -2. Domain A2 XTEN permissive loops are designated Loop A2-l and Loop A2-2. Domain A3 XTEN permissive loops are designated Loop A3-l and Loop A3-2. shows a ClustalW multiple sequence alignment of domains A], A2, A3, C1 and C2 of FVIII showing the location ofXTEN insertions resulting in recombinant FVIII proteins displaying FVIII actiVity (black box, white text) or displaying no FVIII actiVity (grey box, bold text). The locations of the XTEN permissive loops are indicated by dashed rectangles (see Example 47).

. A presents a front View ural representation of human FVIII R7E) showing the location of domains Al, A2, A3, C1 and C2 (circled in dashed lined) and the locations of XTEN permissive loops Al -1, Al -2, A2-l, A2-2, A3-l and A3-2 highlighted as CPK sphere representations. B presents a side View structural representation of human FVIII (PDB:2R7E) g the location of domains Al, A2, A3, C1 and C2 (circled in dashed lined) and the locations of XTEN sive loops Al -1, Al -2, A2-l, A2-2, A3-l and A3-2 highlighted as CPK sphere entations. shows the top View structural representations of ed human FVIII (PDB:2R7E) A domains showing the location ofXTEN sive loops highlighted as CPK sphere representations.

B, 42D and 42F show side View structural representations of isolated human FVIII (PDB:2R7E) A domains showing the location ofXTEN permissive loops highlighted as CPK sphere representations. shows sequences of various factor VIII in deletions and individual mutations.

Lines 4-10 show various B-domain deletions with indicated XTEN linking the flanking B-domain residual or A3 domain residues. The R1648A on is indicated by arrow in line 5 and 8, while the Y] 68OF mutation is ted by arrow in lines 8-10. is a bar graph of chromogenic and aPTT assay activity of various CFXTEN with single XTEN insertions (Example 49). is a bar graph of chromogenic and aPTT assay actiVity of various CFXTEN with 2 XTEN insertions (Example 49).

FIG 46 is a bar graph of chromogenic and aPTT assay actiVity of various CFXTEN with 3 XTEN insertions (Example 49). is a graph of plasma levels in DKO mice of various stered CFXTEN with single XTEN insertions compared to a BDD-FVIII l, demonstrating the 10- to d longer half-life achieved by the XTEN insertions at various locations (Example 50). is a graph of plasma levels in DKO mice of various administered CFXTEN with one, two, and three XTEN insertions ed to a BDD-FVIII control, demonstrating the increases in half- life achieved by the inclusion of additional XTEN insertions compared to single or two insertions (Example 51). are graphs of the plotted inhbition curves for remaining factor VIII procoagulant actiVity in samples assayed in the Bethesda assay with three hemophilia patient sera (FIGS. 49A—C) or sheep anti-FVII (D) described in Example 52, demonstrating a clear left-shift of the inhibition curve for the two CFXTEN molecules compared to the FVIII not linked to XTEN.

DETAILED PTION OF THE INVENTION Before the ments of the ion are described, it is to be understood that such embodiments are ed by way of example only, and that various alternatives to the embodiments of the invention described herein may be employed in practicing the ion. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention.

Unless ise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting. Numerous variations, changes, and substitutions will now occur to those skilled in the art t departing from the ion.

DEFINITIONS ] In the context of the present application, the following terms have the meanings ascribed to them unless specified otherwise: ] As used in the specification and claims, the singular forms 66 39 66 a an” and “the” include plural references unless the context clearly dictates ise. For example, the term “a cell” includes a plurality of cells, including mixtures thereof.

The terms “polypeptide”, “peptide”, and “protein” are used interchangeably herein to refer to polymers of amino acids of any length. The polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non-amino acids. The terms also encompass an amino acid polymer that has been d, for example, by disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation With a labeling component.

As used herein, the term “amino acid” refers to either natural and/or ral or synthetic amino acids, including but not limited to both the D or L optical isomers, and amino acid analogs and peptidomimetics. Standard single or three letter codes are used to designate amino acids.

The term "domain," When used in reference to a factor VIII polypeptide refers to either a full length domain or a functional fragment thereof, for example, full length or onal fragments of the A1 domain, A2 domain, A3 domain, B domain, C1 domain, and/or C2 domain of factor VIII.

] The term “natural L-amino acid” means the L optical isomer forms of glycine (G), proline (P), alanine (A), valine (V), leucine (L), isoleucine (I), methionine (M), cysteine (C), phenylalanine (F), tyrosine (Y), tryptophan (W), ine (H), lysine (K), arginine (R), glutamine (Q), asparagine (N), glutamic acid (E), ic acid (D), serine (S), and threonine (T).

The term “non-naturally occurring,” as applied to sequences and as used herein, means polypeptide or polynucleotide sequences that do not have a counterpart to, are not complementary to, or do not have a high degree of homology With a Wild-type or naturally-occurring sequence found in a mammal. For example, a non-naturally occurring polypeptide or fragment may share no more than 99%, 98%, 95%, 90%, 80%, 70%, 60%, 50% or even less amino acid sequence identity as compared to a natural sequence When suitably d.

The terms “hydrophilic” and “hydrophobic” refer to the degree of affinity that a substance has With water. A hydrophilic substance has a strong y for water, tending to dissolve in, mix With, or be wetted by water, While a hydrophobic substance substantially lacks affinity for water, tending to repel and not absorb water and tending not to dissolve in or mix With or be wetted by water. Amino acids can be characterized based on their hydrophobicity. A number of scales have been developed. An example is a scale developed by Levitt, M, et al., J Mol Biol (1976) 104:59, which is listed in Hopp, TP, et al., Proc Natl Acad Sci U S A (1981) 78:3 824. Examples of “hydrophilic amino acids” are ne, , threonine, alanine, asparagine, and glutamine. Of particular interest are the hydrophilic amino acids aspartate, glutamate, and serine, and glycine. Examples of “hydrophobic amino acids” are tryptophan, tyrosine, phenylalanine, methionine, e, cine, and valine.

A ent” When applied to a protein, is a truncated form of a native biologically active n that retains at least a portion of the therapeutic and/or biological activity. A “variant”. When applied to a protein is a protein With ce homology to the native biologically active protein that 2012/046326 retains at least a portion of the therapeutic and/or biological activity of the biologically active protein. For example, a variant protein may share at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% amino acid sequence identity compared with the reference ically active protein. As used herein, the term “biologically active protein moiety” includes proteins modified deliberately, as for example, by site directed nesis, synthesis of the encoding gene, insertions, or accidentally through mutations.

The term “sequence variant” means polypeptides that have been modified compared to their native or original sequence by one or more amino acid insertions, deletions, or substitutions. Insertions may be located at either or botlt termini of the n, and/or may be positioned within internal regions of the amino acid sequence. A non—limiting example is insertion of an XTEN sequence within the sequence ot‘the biologically—active payload protein. In deletion variants, one or more amino acid residues in a polypeptide as described herein are removed. Deletion variants, therefore, include all fragments of a payload polypeptide sequence. in substitution ts, one or more amino acid residues of a polypeptide are d and replaced with alternative residues. in one aspect, the substitutions are conservative in nature and conservative substitutions of this type are well known in the art.

] As used herein, “internal XTEN” refers to XTEN sequences that have been inserted into the sequence of the coagulation factor. Internal XTENs can be constructed by insertion of an XTEN ce into the sequence of a ation factor such as FVIII, either by insertion between two nt amino acids within a domain (“intradomain”) or between two domains (“interdomain”) of the coagulation factor or wherein XTEN replaces a partial, internal sequence of the coagulation factor.

As used herein, “terminal XTE ” refers to XTEN sequences that have been fused to or in the N— or C-terminus of the coagulation factor or to a proteolytic cleavage sequence or linker at the N— or C- terminus of the coagulation factor. Terminal XTENs can be fused to the native termini of the coagulation factor. Alternatively, terminal XTENs can replace a portion of a terminal sequence of the coagulation factor.

] The term “XTEN release site” refers to a cleavage ce in CFXTEN fusion proteins that can be recognized and cleaved by a mammalian protease, effecting release of an XTEN or a portion of an XTEN from the CFXTEN fusion protein. As used herein, lian protease” means a protease that normally exists in the body fluids, cells or tissues of a mammal. XTEN release sites can be engineered to be cleaved by various mammalian proteases (a.k.a. “XTEN e proteases”) such as FXIa, FXIIa, rein, FVIIIa, FVIIIa, FXa, FIIa (thrombin), Elastase-2, MMP-12, MMP13, MMP-l7, MMP-20, or any protease that is present during a clotting event. Other equivalent proteases enous or exogenous) that are capable of recognizing a defined cleavage site can be utilized. The cleavage sites can be adjusted and tailored to the protease utilized.

] The term “within”, when referring to a first polypeptide being linked to a second polypeptide, encompasses linking that connects the N—terminus of the first or second polypeptide to the inus of the second or first polypeptide, respectively, as well as insertion of the first polypeptide into the ce of the second polypeptide. For example, when an XTEN is linked “within” a domain of a factor VIII polypeptide, the XTEN may be linked to the N—terminus, the C-terminus, or may be inserted in said domain.

As used , the term “site,” when used to refer to an insertion site of an XTEN within or to a biological polypeptide such as a factor VIII, represents the amino acid position at which the XTEN is linked. When numbered sites are described, such as a first, second, third, fourth, fifth, or sixth site for the insertion of an XTEN within or to the factor VIII, each site will be understood to ent a ct site in the factor VIII; e.g., the second site is a different factor VIII location from the first site, the third site is ent from the second and the first, etc.

“Activity” or agulant activity” as applied to ) of a CFXTEN polypeptide provided herein, refers to the ability to bind to a target coagulation protein substrate or cofactor and promote a clotting event, r measured by an in vitro, ex vivo or in vivo assay. Such assays include, but are not limited to, one-stage clotting assays, two-stage clotting assays, chromogenic assays, and ELISA assays.

“Biological actiVity” refers to an in vitro or in vivo biological function or effect, including but not limited to either or or ligand binding, or an effect on ation lly known in the art for the FVIII coagulation factor, or a cellular, physiologic, or clinical response, including arrest of a bleeding episode.

As used herein, the term "ELISA" refers to an enzyme-linked immunosorbent assay as described herein or as otherwise known in the art.

A “host cell” includes an individual cell or cell culture which can be or has been a recipient for the subject vectors. Host cells include progeny of a single host cell. The progeny may not necessarily be completely identical (in morphology or in genomic of total DNA complement) to the al parent cell due to natural, accidental, or deliberate on. A host cell includes cells transfected in Vivo with a vector of this invention.

“Isolated” when used to describe the various polypeptides disclosed herein, means ptide that has been identified and separated and/or recovered from a component of its natural environment.

Contaminant components of its natural environment are materials that would typically interfere with diagnostic or therapeutic uses for the polypeptide, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. As is apparent to those of skill in the art, a non-naturally occurring polynucleotide, peptide, polypeptide, protein, antibody, or fragments thereof, does not e “isolation” to distinguish it from its naturally occurring counterpart. In addition, a “concentrated”, “separated” or “diluted” polynucleotide, peptide, polypeptide, protein, antibody, or fragments f, is distinguishable from its naturally occurring counterpart in that the concentration or number of molecules per volume is generally greater than that of its naturally occurring counterpart. In general, a polypeptide made by recombinant means and expressed in a host cell is considered to be “isolated.” ] An “isolated” polynucleotide or polypeptide-encoding nucleic acid or other polypeptide- encoding c acid is a nucleic acid molecule that is identified and separated from at least one contaminant nucleic acid molecule with which it is ordinarily associated in the natural source of the polypeptide-encoding c acid. An isolated polypeptide-encoding nucleic acid le is other than in the form or setting in which it is found in nature. Isolated polypeptide-encoding nucleic acid molecules therefore are distinguished from the c polypeptide-encoding nucleic acid molecule as it exists in natural cells. However, an isolated polypeptide-encoding nucleic acid molecule includes polypeptide-encoding nucleic acid molecules contained in cells that ordinarily express the polypeptide where, for example, the nucleic acid molecule is in a chromosomal or extra-chromosomal on different from that of natural cells.

A ric” protein contains at least one fusion polypeptide comprising at least one region in a different position in the sequence than that which occurs in . The regions may normally exist in separate proteins and are brought together in the fusion polypeptide; or they may normally exist in the same protein but are placed in a new arrangement in the fusion polypeptide. A chimeric protein may be d, for example, by chemical synthesis, or by creating and translating a polynucleotide in which the peptide regions are encoded in the desired relationship.

“Conjugated”, “linked,” “fused,” and “fusion” are used interchangeably herein. These terms refer to the joining together of two or more chemical elements, sequences or components, by whatever means ing chemical ation or recombinant means. For example, a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence. Generally, bly linked” means that the DNA sequences being linked are contiguous, and in reading phase or in-frame.

An “in-frame fusion” refers to the joining of two or more open reading frames (ORFs) to form a continuous longer ORF, in a manner that maintains the correct reading frame of the original ORFs.

Thus, the ing recombinant fusion protein is a single protein containing two or more segments that pond to polypeptides encoded by the original ORFs (which segments are not normally so joined in nature).

] In the context of polypeptides, a “linear sequence” or a nce” is an order of amino acids in a polypeptide in an amino to carboxyl terminus direction in which residues that neighbor each other in the sequence are contiguous in the y structure of the polypeptide. A “partial sequence” is a linear sequence of part of a polypeptide that is known to comprise additional residues in one or both directions.

“Heterologous” means derived from a genotypically distinct entity from the rest of the entity to which it is being compared. For example, a glycine rich sequence d from its native coding sequence and operatively linked to a coding sequence other than the native sequence is a heterologous e rich sequence. The term “heterologous” as applied to a cleotide, a polypeptide, means that the polynucleotide or polypeptide is derived from a genotypically distinct entity from that of the rest of the entity to which it is being compared.

The terms “polynucleotides”, “nucleic acids”, “nucleotides” and “oligonucleotides” are used interchangeably. They refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof Polynucleotides may have any three- dimensional structure, and may perform any function, known or unknown. The following are non- limiting es of polynucleotides: coding or ding regions of a gene or gene fragment, loci (locus) defined from linkage analysis, exons, introns, messenger RNA , transfer RNA, ribosomal RNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, 2012/046326 isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. A polynucleotide may comprise modified tides, such as methylated nucleotides and tide analogs. If t, modifications to the nucleotide structure may be imparted before or after assembly of the polymer. The ce of nucleotides may be interrupted by non-nucleotide components. A polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component.

The term “complement of a polynucleotide” denotes a polynucleotide molecule having a mentary base sequence and reverse ation as compared to a reference sequence, such that it could hybridize with a reference sequence with complete y.

“Recombinant” as applied to a polynucleotide means that the polynucleotide is the product of various combinations of in vitro cloning, restriction and/or ligation steps, and other procedures that result in a construct that can potentially be expressed as a inant protein in a host cell.

The terms “gene” and “gene fragment” are used interchangeably herein. They refer to a polynucleotide ning at least one open reading frame that is capable of encoding a particular protein after being ribed and translated. A gene or gene fragment may be genomic or cDNA, as long as the polynucleotide contains at least one open g frame, which may cover the entire coding region or a segment thereof A “fusion gene” is a gene composed of at least two heterologous polynucleotides that are linked together.

“Homology” or “homologous” or “sequence identity” refers to sequence similarity or interchangeability between two or more cleotide sequences or between two or more polypeptide sequences. When using a program such as BestFit to determine sequence identity, rity or homology between two different amino acid sequences, the default settings may be used, or an appropriate scoring matrix, such as blosum45 or blosum80, may be selected to optimize identity, similarity or homology scores. Preferably, polynucleotides that are homologous are those which hybridize under ent conditions as defined herein and have at least 70%, preferably at least 80%, more ably at least 90%, more preferably 95%, more preferably 97%, more preferably 98%, and even more ably 99% sequence identity compared to those sequences. Polypeptides that are homologous preferably have sequence identities that are at least 70%, ably at least 80%, even more preferably at least 90%, even more preferably at least 95-99%, and most preferably 100% identical.

”Ligation” refers to the process of forming phosphodiester bonds between two nucleic acid fragments or genes, linking them together. To ligate the DNA fragments or genes together, the ends of the DNA must be compatible with each other. In some cases, the ends will be directly compatible after endonuclease digestion. However, it may be necessary to first convert the staggered ends commonly produced after endonuclease digestion to blunt ends to make them compatible for ligation.

The terms “stringent conditions” or gent hybridization conditions” includes reference to conditions under which a polynucleotide will hybridize to its target sequence, to a detectably r degree than other sequences (e.g., at least 2-fold over background). Generally, stringency of hybridization is expressed, in part, with reference to the temperature and salt concentration under which the wash step is carried out. lly, stringent conditions will be those in which the salt tration is less than about 1.5 M Na ion, typically about 0.01 to 1.0 M Na ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short polynucleotides (e. g., 10 to 50 nucleotides) and at least about 60°C for long polynucleotides (e. g., greater than 50 nucleotides)—for example, “stringent conditions” can include hybridization in 50% formamide, 1 M NaCl, 1% SDS at 37°C, and three washes for 15 min each in SC/1% SDS at 60°C to 65°C. atively, temperatures of about 65°C, 60°C, 55°C, or 42°C may be used. SSC concentration may be varied from about 0.1 to 2><SSC, with SDS being present at about 0.1%. Such wash temperatures are typically selected to be about 5°C to °C lower than the thermal melting point for the specific sequence at a defined ionic strength and pH.

The Tm is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. An equation for calculating Tm and conditions for nucleic acid hybridization are well known and can be found in Sambrook, J. et a]. “Molecular Cloning: A Laboratory Manual,” 3ml edition, Cold Spring Harbor Laboratory Press, 2001. Typically, blocking reagents are used to block non-specific hybridization. Such blocking reagents include, for instance, sheared and denatured salmon sperm DNA at about 0 ug/ml. Organic solvent, such as formamide at a concentration of about 35-50% v/v, may also be used under particular circumstances, such as for RNA:DNA hybridizations. Useful variations on these wash conditions will be readily apparent to those of ordinary skill in the art.

The terms “percent identity,” tage of sequence identity,” and “% identity,” as applied to polynucleotide ces, refer to the percentage of residue matches between at least two polynucleotide sequences aligned using a standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences. Percent identity may be measured over the length of an entire defined cleotide sequence, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polynucleotide sequence, for ce, a fragment of at least 45, at least 60, at least 90, at least 120, at least 150, at least 210 or at least 450 contiguous es. Such lengths are exemplary only, and it is understood that any fragment length supported by the ces shown herein, in the tables, figures or Sequence Listing, may be used to describe a length over which percentage identity may be ed. The percentage of sequence identity is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of matched ons (at which identical residues occur in both polypeptide sequences), dividing the number of matched positions by the total number of positions in the window of comparison (i.e., the window size), and lying the result by 100 to yield the percentage of sequence identity. When sequences of different length are to be compared, the st sequence defines the length of the window of comparison. Conservative substitutions are not ered when calculating ce identity.

“Percent (%) sequence identity,” with t to the polypeptide sequences identified herein, is defined as the percentage of amino acid residues in a query sequence that are identical with the amino acid es of a second, nce polypeptide sequence or a portion thereof, after aligning the ces and introducing gaps, if necessary, to achieve the maximum percent ce identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence ty can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) re. Those skilled in the art can ine appropriate parameters for measuring alignment, including any thms needed to achieve maximal alignment over the full length of the sequences being compared. Percent ty may be measured over the length of an entire defined polypeptide sequence, or may be measured over a r length, for example, over the length of a nt taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues.

Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures or Sequence Listing, may be used to describe a length over which percentage identity may be ed.

The term “non-repetitiveness” as used herein in the t of a polypeptide refers to a lack or limited degree of internal homology in a peptide or polypeptide sequence. The term “substantially non- repetitive” can mean, for example, that there are few or no instances of four contiguous amino acids in the sequence that are identical amino acid types or that the polypeptide has a subsequence score (defined infra) of 10 or less or that there is no a pattern in the order, from N- to C-terminus, of the sequence motifs that constitute the polypeptide sequence. The term “repetitiveness” as used herein in the context of a polypeptide refers to the degree of internal homology in a peptide or polypeptide sequence. In contrast, a itive” sequence may contain le identical copies of short amino acid sequences. For instance, a polypeptide sequence of interest may be divided into n-mer sequences and the number of identical sequences can be counted. Highly tive sequences contain a large fraction of identical sequences while non-repetitive sequences contain few identical sequences. In the context of a ptide, a sequence can contain multiple copies of shorter sequences of defined or variable length, or motifs, in which the motifs themselves have non-repetitive sequences, rendering the full-length polypeptide substantially non-repetitive. The length of polypeptide within which the non-repetitiveness is measured can vary from 3 amino acids to about 200 amino acids, about from 6 to about 50 amino acids, or from about 9 to about 14 amino acids. “Repetitiveness” used in the context of polynucleotide sequences refers to the degree of internal homology in the sequence such as, for example, the frequency of identical nucleotide sequences of a given length. Repetitiveness can, for example, be measured by analyzing the frequency of identical sequences.

A “vector” is a c acid le, preferably self-replicating in an appropriate host, which transfers an inserted nucleic acid molecule into and/or between host cells. The term includes vectors that function ily for insertion of DNA or RNA into a cell, replication of vectors that function primarily for the ation of DNA or RNA, and expression vectors that function for transcription and/or translation of the DNA or RNA. Also included are vectors that provide more than one of the above functions. An “expression vector” is a polynucleotide which, when introduced into an appropriate host cell, can be ribed and translated into a polypeptide(s). An “expression system” y connotes a le host cell comprised of an expression vector that can function to yield a desired expression product.

“Serum degradation resistance,” as applied to a polypeptide, refers to the ability of the polypeptides to withstand degradation in blood or components thereof, which typically involves proteases in the serum or plasma. The serum ation resistance can be measured by combining the protein with human (or mouse, rat, monkey, as appropriate) serum or plasma, typically for a range of days (e.g. 0.25, 0.5, l, 2, 4, 8, 16 days), typically at about 37°C. The samples for these time points can be run on a Western blot assay and the protein is detected with an antibody. The antibody can be to a tag in the protein. If the protein shows a single band on the western, where the protein’s size is identical to that of the injected protein, then no ation has occurred. In this exemplary method, the time point where 50% of the protein is degraded, as judged by Western blots or equivalent techniques, is the serum degradation half-life or “serum half-life” of the protein.

The term “t1/2 ” as used herein means the terminal half-life calculated as ln(2)/Kel. K61 is the terminal elimination rate constant calculated by linear regression of the terminal linear portion of the log concentration vs. time curve. ife typically refers to the time required for half the quantity of an administered substance ted in a living organism to be metabolized or eliminated by normal biological processes. The terms “t1/239 ccterminal half-life39 cc elimination half-life” and “circulating half- , , life” are used interchangeably herein.

“Active clearance” means the mechanisms by which a protein is removed from the circulation other than by filtration or coagulation, and which includes removal from the circulation mediated by cells, receptors, lism, or ation of the protein.

“Apparent molecular weight factor” and ent molecular weight” are related terms referring to a measure of the relative increase or se in apparent lar weight exhibited by a particular amino acid sequence. The apparent molecular weight is ined using size exclusion chromatography (SEC) or similar methods by comparing to globular protein standards, and is measured in “apparent kD” units. The apparent molecular weight factor is the ratio between the apparent molecular weight and the actual molecular weight; the latter predicted by adding, based on amino acid composition, the ated molecular weight of each type of amino acid in the composition or by estimation from ison to molecular weight standards in an SDS electrophoresis gel.

The terms “hydrodynamic radius” or “Stokes ” is the effective radius (R}1 in nm) of a molecule in a solution measured by assuming that it is a body moving through the solution and resisted by the solution’s viscosity. In the embodiments of the invention, the hydrodynamic radius measurements of the XTEN fusion ns correlate with the ‘apparent lar weight factor’, which is a more intuitive measure. The “hydrodynamic radius” of a n affects its rate of diffusion in aqueous solution as well as its ability to migrate in gels of olecules. The hydrodynamic radius of a protein is determined by its molecular weight as well as by its structure, including shape and tness. s for determining the hydrodynamic radius are well known in the art, such as by the use of size exclusion chromatography (SEC), as described in US. Patent Nos. 6,406,632 and 7,294,513. Most proteins have ar ure, which is the most compact three-dimensional structure a protein can have with the smallest hydrodynamic radius. Some proteins adopt a random and open, unstructured, or ‘linear’ conformation and as a result have a much larger hydrodynamic radius compared to typical globular proteins of similar molecular weight.

“Physiological conditions” refers to a set of conditions in a living host as well as in vitro conditions, including temperature, salt tration, pH, that mimic those conditions of a living subject.

A host of physiologically nt conditions for use in in vitro assays have been established. Generally, a physiological buffer contains a logical concentration of salt and is adjusted to a neutral pH ranging from about 6.5 to about 7.8, and preferably from about 7.0 to about 7.5. A variety of physiological s are listed in Sambrook et al. (2001). Physiologically relevant temperature ranges from about 250C to about 380C, and preferably from about 350C to about 370C.

A “reactive group” is a chemical structure that can be coupled to a second reactive group.

Examples for reactive groups are amino groups, carboxyl groups, sulfhydryl , hydroxyl groups, aldehyde groups, azide groups. Some reactive groups can be activated to facilitate coupling with a second reactive group. miting examples for activation are the reaction of a carboxyl group with carbodiimide, the conversion of a carboxyl group into an activated ester, or the conversion of a carboxyl group into an azide function.

“Controlled release agent”, “slow release agent”, “depot formulation” and “sustained release agent” are used interchangeably to refer to an agent capable of extending the duration of release of a polypeptide of the invention ve to the duration of release when the polypeptide is administered in the absence of agent. Different embodiments of the present invention may have different release rates, resulting in different therapeutic amounts.

The terms “antigen”, t antigen” and “immunogen” are used interchangeably herein to refer to the structure or g determinant that an antibody fragment or an antibody fragment-based eutic binds to or has specificity against.

] The term “payload” as used herein refers to a protein or peptide sequence that has biological or eutic activity; the counterpart to the pharmacophore of small molecules. Examples of payloads e, but are not limited to, coagulation factors, cytokines, enzymes, hormones, and blood and grth factors.

The term “antagonist”, as used herein, includes any molecule that partially or fully blocks, inhibits, or neutralizes a biological activity of a native ptide disclosed herein. Methods for identifying antagonists of a polypeptide may comprise ting a native polypeptide with a candidate antagonist molecule and measuring a able change in one or more biological activities normally associated with the native polypeptide. In the context of the present invention, antagonists may include proteins, nucleic acids, carbohydrates, antibodies or any other molecules that decrease the effect of a biologically active protein.

] The term “agonist” is used in the broadest sense and includes any molecule that mimics a biological activity of a native polypeptide disclosed . Suitable t molecules specifically include agonist antibodies or antibody fragments, nts or amino acid sequence variants of native polypeptides, peptides, small organic molecules, etc. Methods for identifying agonists of a native polypeptide may se contacting a native polypeptide with a candidate agonist le and measuring a detectable change in one or more biological activities normally associated with the native polypeptide.

As used herein, “treat” or “treating,” or “palliating” or “ameliorating” are used interchangeably and mean stering a drug or a biologic to achieve a therapeutic benefit, to cure or reduce the severity of an ng condition, or to achieve a prophylactic benefit, prevent or reduce the likelihood of onset or severity the occurrence of a condition. By therapeutic benefit is meant eradication or amelioration of the underlying condition being treated or one or more of the logical symptoms associated with the ying condition such that an improvement is observed in the subject, notwithstanding that the subject may still be afflicted with the underlying condition.

A “therapeutic effect” or “therapeutic benefit,” as used herein, refers to a logic effect, including but not limited to the mitigation, amelioration, or prevention of disease in humans or other s, or to otherwise enhance physical or mental wellbeing of humans or animals, resulting from administration of a fusion protein of the ion other than the ability to induce the production of an antibody against an antigenic epitope possessed by the biologically active protein. For prophylactic , the compositions may be administered to a subject at risk of developing a ular e, condition or symptom of the disease (e. g., a bleed in a diagnosed hemophilia A subject), or to a subject reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease may not have been made.

The terms “therapeutically effective amount” and “therapeutically effective dose”, as used herein, refer to an amount of a drug or a biologically active protein, either alone or as a part of a fusion protein composition, that is capable of having any detectable, beneficial effect on any symptom, aspect, measured ter or teristics of a disease state or condition when administered in one or repeated doses to a subject. Such effect need not be absolute to be beneficial. Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.

] The term “therapeutically effective dose regimen”, as used herein, refers to a schedule for consecutively administered multiple doses (i.e., at least two or more) of a biologically active protein, either alone or as a part of a fusion protein composition, n the doses are given in therapeutically ive amounts to result in sustained ial effect on any symptom, aspect, measured parameter or characteristics of a disease state or condition.

I). GENERAL TECHNIQUES The practice of the present invention employs, unless otherwise indicated, conventional techniques of immunology, biochemistry, chemistry, molecular biology, microbiology, cell biology, genomics and recombinant DNA, which are within the skill of the art. See Sambrook, J. et al., “Molecular Cloning: A Laboratory Manual,” 3ml edition, Cold Spring Harbor Laboratory Press, 2001; “Current protocols in molecular biology”, F. M. Ausubel, et al. eds.,1987; the series “Methods in Enzymology,” Academic Press, San Diego, CA.; “PCR 2: a practical approach”, M.J. MacPherson, B.D.

Hames and GR. Taylor eds., Oxford University Press, 1995; “Antibodies, a laboratory manual” Harlow, E. and Lane, D. eds., Cold Spring Harbor Laboratory,1988; “Goodman & Gilman’s The Pharmacological Basis of Therapeutics,” 11th Edition, McGraw—Hill, 2005; and Freshney, R.I., “Culture of Animal Cells: A Manual of Basic Technique,” 4th edition, John Wiley & Sons, Somerset, NJ, 2000, the contents of which are incorporated in their ty herein by reference.

II). COAGULATION FACTOR VIII The present invention s, in part, to compositions comprising factor VIII coagulation factor (CF) linked to one or more extended recombinant proteins (XTEN), resulting in a CFXTEN fusion protein composition. As used herein, “CF” refers to factor VIII ) or mimetics, sequence ts and truncated versions of FVIII, as described below.

“Factor VIII” or “FVIII” or “FVIII protein” means a blood coagulation factor protein and species (including human, porcine, canine, rat or murine FVIII proteins) and sequence variants thereof that includes, but is not limited to the 2351 amino acid single-chain sor protein (with a 19-amino acid hobic signal peptide), the mature 2332 amino acid factor VIII cofactor protein of approximately 270-330 kDa with the domain structure B-A3-C1-C2, as well as the nonenzymatic “active” or or form of FVIII (FVIIIa) that is a circulating heterodimer of two chains that form as a result of proteolytic ge after R1648 of a heavy chain form composed of A1 -A2-B (in the range of 90-220 kD) of amino acids 1-1648 (numbered ve to the mature FVIII form) and a light chain A3- C1-C2 of 80 kDa of amino acids 1649-2232, each of which is depicted schematically in Further, and as used herein, each of A1, A2 and the A3 domain encompasses acidic spacer regions; a1, a2, and a3 acidic regions, respectively. Thus, it will be tood that CFXTEN constructs described as having A1, A2, A3, B, C1 and C2 domains include the al, a2 and a3 acidic regions. As used herein, “Factor VIII” or “FVIII” or “FVIII polypeptide” also includes variant forms, including proteins with tutions, additions and/or deletions so long as the variant s a desired biological activity such as procoagulant activity. Myriad onal FVIII variants have been ucted and can be used as recombinant FVIII proteins as described herein. See PCT Publication Nos. A2, A2, A2, or A2, all of which are incorporated herein by reference in their entireties. A great many functional FVIII variants are known. In addition, hundreds of nonfunctional mutations in FVIII have been identified in hemophilia patients. See, e.g., Cutler et al., Hum. Mutat. 19:274-8 (2002), incorporated herein by reference in its entirety. In addition, comparisons between FVIII from humans and other species have identified conserved residues that are likely to be required for function. See, e. g., Cameron et al., Thromb. Haemost. 79:317-22 (1998) and US 632, incorporated herein by reference in their entireties.

] In one embodiment, the human factor VIII domains are defined by the following amino acid residues: A1, residues Ala1-Arg372; A2, residues Ser373-Arg740; B, residues Ser741-Arg1648; A3, residues Ser1649-Asn2019; C1, residues Lys2020-Asn2172; C2, es Ser2l73-Tyr2332. The A3-C1- C2 sequence includes residues Ser1649-Tyr2332. In another embodiment, residues Arg336-Arg372 is usually referred to as the al , and the Arg3 72 is cleaved by in. In certain embodiments, the a2 region is part of the A1 domain. In another embodiment, residues Glul649-Arg1689, is referred to as the a3 acidic region. In n embodiments, the a3 acidic region is a part of the A3 domain. In another embodiment, a native FVIII protein has the following formula: A1-a1-A2-a2-B-a3-A3-C1-C2, where A1, A2, and A3 are the structurally-related ”A domains," B is the ”B domain,” C1 and C2 are the structurally- related ”C domains," and a1, a2 and a3 are acidic spacer s. In the foregoing formula and referring to the primary amino acid sequence position in , the A1 domain of human FVIII s from Alal to about Arg336, the al spacer region s from about Met337 to about Arg372, the A2 domain extends from about Ser3 73 to about Tyr7l9, the a2 spacer region extends from about Glu720 to about Arg740, the B domain extends from about Ser741 to about Arg 1648, the a3 spacer region extends from about Glul649 to about Arg1689, the A3 domain extends from about Ser1690 to about Asn2019, the C1 domain extends from about Lys2020 to about Asn2172, and the C2 domain extends from about Ser2l73 to Tyr2332 (Saenko et al., 2005, J Thromb Hemostasis, 1, 922-930). Other than specific proteolytic cleavage sites, designation of the locations of the boundaries between the domains and s of FVIII can vary in different literature nces. The boundaries noted herein are therefore designated as approximate by use of the term “about.” Such factor VIII e truncated sequences such as B-domain deleted “BDD” sequences in which a portion or the majority of the B domain sequence is deleted (such as BDD sequences disclosed or referenced in US Pat Nos. 6,818,439 and 7,632,921). An example of a BDD FVIII is REFACTO® or XYNTHA® binant BDD FVIII), which comprises a first polypeptide corresponding to amino acids 1 to 743 of , fused to a second polypeptide ponding to amino acids 1638 to 2332 of . Exemplary BDD FVIII constructs which can be used to produce recombinant proteins of the invention include, but are not limited to FVIII with a deletion of amino acids corresponding to amino acids 747-1638 of mature human FVIII () (Hoeben R.C., et al. J. Biol. Chem. 265 (13): 7318- 7323 (1990), incorporated herein by nce in its entirety), and FVIII with a on of amino acids corresponding to amino acids 771—1666 or amino acids 868-1562 of mature human FVIII () (Meulien P., et al. Protein Eng. 2(4): 301-6 (1988), incorporated herein by reference in its entirety).

In addition, sequences that e heterologous amino acid insertions or substitutions (such as aspartic acid substituted for valine at on 75), or single chain FVIII (scFVIII) in which the heavy and light chains are covalently connected by a linker. As used herein, “FVIII” shall be any functional form of factor VIII molecule with the typical characteristics of blood coagulation factor VIII capable of correcting human factor VIII deficiencies when administered to such a subject, e.g., a t with hemophilia A. FVIII or sequence variants have been isolated, characterized, and cloned, as described in US. Patent or Application Nos. 4,757,006; 4,965,199; 5,004,804; 5,198,349, 5,250,421; 5,919,766; 6,228,620; 6,818,439; 7,138,505; 7,632,921; and 20100081615.

Human factor VIII is encoded by a single-copy gene residing at the tip of the long arm of the X chromosome (q28). It comprises nearly 186,000 base pairs (bp) and tutes approximately 0.1% of the X-chromosome (White, G.C. and Shoemaker, C.B., Blood (1989) 73:1-12). The human FVIII amino acid sequence was d from cDNA as shown in US. Pat. No. 4,965,199, which is incorporated herein by reference in its entirety. Native mature human FVIII derived from the cDNA sequence (i.e., t the secretory signal peptide but prior to other post-translational sing) is presented as FIG.

The DNA encoding the mature factor VIII mRNA is found in 26 separate exons ranging in size from 69 to 3,106 bp. The 25 intervening intron regions that separate the exons range in size from 207 to 32,400 bp. The complete gene consists of approximately 9 kb of exon and 177 kb of intron. The three repeat A domains have approximately 30% sequence homology. The B domain contains 19 of the approximately 25 predicted glycosylation sites, and the A3 domain is believed to contain a g site for the von Willebrand factor. The tandem C domains follow the A3 domain and have approximately 37% homology to each other (White, G.C. and Shoemaker, C.B., Blood (1989) 73:1-12).

The B domain separates the A2 and A3 domains of native factor FVIII in the newly synthesized precursor -chain molecule. The precise boundaries of the B domain have been variously reported as extending from amino acids 712 to 1648 of the sor sequence (Wood et al., Nature (1984) 312:330-337) or amino acids 741—1648 (Pipe, SW, Haemophilia (2009) 7—1196 and US Pat. No. 7,560,107) or amino acids 740-1689 (Toole, JJ. Proc. Natl. Acad. Sci. USA (1986) 9-5942). As used herein, ”B domain” means amino acids 741-1648 of mature factor VIII. As used herein, “FVIII B domain deletion” or “FVIII BDD” means a FVIII ce with any, a nt of, or all of amino acids 741 to 1648 deleted. In one embodiment, FVIII BDD variants retain remnant amino acids of the B domain from the N-terminal end (“B1” as used herein) and C-terminal end (“B2” as used herein). In one FVIII BDD variant, the B domain remnant amino acids are SFSQNPPVLKRHQR (SEQ ID NO: 1614). In one FVIII BDD variant, the B1 remnant is SFS and the B2 remnant is QNPPVLKRHQR (SEQ ID NO: 1615). In another FVIII BDD variant, the B1 t is SFSQN (SEQ ID NO: 1616) and the B2 remnant is HQR (SEQ ID NO: 1617). A ain—deleted factor VIII,” ”FVIII BDD,” or ”BDD FVIII” may have the full or partial deletions disclosed in US. Pat. Nos. 6,316,226, 6,346,513, 7,041,635, 5,789,203, 6,060,447, 5,595,886, 6,228,620, 5,972,885, 720, ,543,502, 278, 5,171,844, 5,112,950, 4,868,112, and 6,458,563, each ofwhich is incorporated herein by reference in its entirety. In some embodiments, a B-domain—deleted factor VIII sequence of the present invention comprises any one of the deletions disclosed at col. 4, line 4 to col. 5, line 28 and examples 1-5 of US. Pat. No. 6,316,226 (also in US 6,346,513). In another embodiment, a B-domain deleted factor VIII is the S743/Q1638 B-domain deleted factor VIII (SQ version factor VIII) (e. g., factor VIII having a deletion from amino acid 744 to amino acid 1637, e. g., factor VIII having amino acids 1- 743 and amino acids 163 8-2332 of full-length factor VIII). In some embodiments, a B-domain-deleted factor VIII of the present invention has a deletion sed at col. 2, lines 26-51 and examples 5-8 of US. Patent No. 5,789,203 (also US 447, US 886, and US 6,228,620). In some embodiments, a B-domain-deleted factor VIII has a deletion described in col. 1, lines 25 to col. 2, line 40 of US Patent No. 5,972,885; col. 6, lines 1-22 and example 1 of US. Patent no. 6,048,720; col. 2, lines 17-46 of US.

Patent No. 5,543,502; col. 4, line 22 to col. 5, line 36 of US. Patent no. 5,171,844; col. 2, lines 55-68, figure 2, and example 1 ofU.S. Patent No. 5,112,950; col. 2, line 2 to col. 19, line 21 and table 2 ofU.S.

Patent No. 112; col. 2, line 1 to col. 3, line 19, col. 3, line 40 to col. 4, line 67, col. 7, line 43 to col. 8, line 26, and col. 11, line 5 to col. 13, line 39 ofU.S. Patent no. 7,041,635; or col. 4, lines 25-53, of US. Patent No. 6,458,563. In some ments, a B-domain-deleted factor VIII has a deletion of most of the B domain, but still contains amino-terminal sequences of the B domain that are essential for in vivo proteolytic processing of the primary translation product into two polypeptide chain, as disclosed in W0 91/09122, which is incorporated herein by reference in its entirety. In some embodiments, a B-domain- deleted factor VIII is constructed with a deletion of amino acids 747-163 8, i. e., lly a complete deletion of the B domain. Hoeben R.C., et al. J. Biol. Chem. 265 (13): 7318-7323 (1990), incorporated herein by reference in its ty. A B-domain-deleted factor VIII may also contain a deletion of amino acids 771—1666 or amino acids 868-1562 of factor VIII. Meulien P., et al. Protein Eng. 2(4): 301-6 , incorporated herein by reference in its entirety. Additional B domain deletions that are part of the invention include: deletion of amino acids 982 through 1562 or 760 through 1639 (Toole et al., Proc.

Natl. Acad. Sci. U.S.A. (1986) 83, 5939-5942)), 797 through 1562 (Eaton, et al. Biochemistry (1986) :8343-8347)), 741 through 1646 (Kaufman (PCT hed application No. WO 87/04187)), 747-1560 (Sarver, et al., DNA (1987) 6:553-564)), 741 though 1648 (Pasek (PCT ation No.88/00831)), or 816 through 1598 or 741 through 1648 (Lagner (Behring Inst. Mitt. (1988) No 25, EP 295597)), each of which is incorporated herein by reference in its entirety. Each of the foregoing deletions may be made in any factor VIII sequence utilized in the embodiments of the present invention. ns involved in ng e factor I, factor II, factor III, factor IV, factor V, factor VI, factor VII, factor VIII, factor IX, factor X, factor XI, factor XII, factor XIII, Protein C, and tissue factor ctively or individually “clotting protein(s)”). The interaction of the major clotting proteins in the intrinsic and extrinsic ng pathways is showed in The majority of the clotting proteins are present in zymogen form, but when activated, exhibit a procoagulant protease actiVity in which they activate another of the clotting proteins, contributing to the intrinsic or extrinsic coagulation pathway and clot formation. In the intrinsic pathway of the coagulation cascade, FVIII associates with a complex of activated factor IX, factor X, calcium, and phospholipid. The factor VIII heterodimer has no enzymatic activity, but the heterodimer becomes active as a cofactor of the enzyme factor IXa after proteolytic activation by thrombin or factor Xa, with the actiVity of factor VIIIa characterized by its ability to form a ne binding site for factors IXa and X in a conformation suitable for activation of the factor X by factor IXa. Upon cleavage by thrombin, activated FVIII (FVIIIa) dissociates from von Willebrand factor and binds to negatively charged phospholipid PL, and the resulting complex participates as a cofactor to factor IXa in the factor X activating (tenase) complex. Within the C2 domain and amino acid residues WO 22617 1649 through 1689 in the A3 domain are von Willebrand factor (VWF) binding sites that act to complex with von Willebrand factor, the resulting ating complex protects FVIII from rapid degradation in the blood (Weiss HJ, et al. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease. J Clin Invest (1977) 60390).

Activated factor VIII is a heterotrimer comprised of the A1 domain and the A2 domain and the light chain including domains A3-C1-C2. The activation of factor IX is achieved by a two-step removal of the activation peptide (Ala 146-Arg 180) from the molecule (Bajaj et al., Human factor IX and factor IXa, in METHODS IN ENZYMOLOGY. 1993). The first ge is made at the Arg 145-Ala 146 site by either factor XIa or factor VIIa/tissue . The second, and rate limiting cleavage is made at Arg 180-Val 181. The activation removes 35 residues. Activated human factor IX exists as a heterodimer of the C-terminal heavy chain (28 kDa) and an N—terminal light chain (18 kDa), which are held together by one disulfide bridge attaching the enzyme to the Gla domain. Factor IXa in turn activates factor X in concert with activated factor VIII. Alternatively, s IX and X can both be activated by factor VIIa complexed with lipidated tissue factor, generated Via the extrinsic pathway. Factor Xa then participates in the final common pathway whereby ombin is converted to thrombin, and in, in turn converts fibrinogen to fibrin to form the clot.

Defects in the coagulation process can lead to bleeding disorders (coagulopathies) in which the time taken for clot formation is prolonged. Such s can be congenital or acquired. For example, hemophilia A and B are inherited diseases characterized by deficiencies in FVIII and FIX, respectively.

Stated differently, ically active factor VIII corrects the coagulation defect in plasma derived from individuals afflicted with hemophilia A. Recombinant FVIII has been shown to be effective and has been approved for the ent of hemophilia A in adult and pediatric patients, and also is used to stop bleeding episodes or t bleeding associated with trauma and/or surgery. Current therapeutic uses of factor VIII can be problematic in the treatment of indiViduals exhibiting a deficiency in factor VIII, as well as those indiViduals with Von rand's disease. In addition, individuals receiving factor VIII in ement therapy ntly develop antibodies to these proteins that often reduce or eliminate the procoagulant actiVity of the bound FVIII. Continuing treatment is exceedingly difficult because of the presence of these antibodies that reduce or negate the efficacy of the treatment.

In one aspect, the invention plates inclusion of FVIII sequences in the CFXTEN fusion protein compositions that are identical to human FVIII, sequences that have homology to FVIII sequences, sequences that are natural, such as from humans, non-human primates, mammals (including domestic animals), or truncated version of FVIII; all of which retain at least a portion of the procoagulant actiVity of native FVIII and that are useful for preventing, treating, mediating, or ameliorating hemophilia A or bleeding es d to trauma, surgery, or deficiency of ation factor VIII. Sequences with homology to FVIII may be found by standard homology searching techniques, such as NCBI BLAST, or in public databases such as Chemical Abstracts es Databases (e. g., the CAS Registry), GenBank, The Universal Protein Resource (UniProt) and subscription ed databases such as GenSeq (e. g., Derwent).

In one embodiment, the FVIII incorporated into the subject CFXTEN compositions is a recombinant ptide with a sequence corresponding to a FVIII protein found in nature. In another embodiment, the FVIII is a tural FVIII sequence variant, fragment, g, or a mimetic of a l sequence that retains at least a portion of the procoagulant activity of the corresponding native FVIII. In another embodiment, the FVIII is a truncated variant with all or a portion of the B domain deleted I BDD”), which can be in either heterodimeric form or can remain as a single chain (“scFVIII”), the latter described in Meulien et al., Protein Eng. (1988) 2(4):301-306. Non-limiting examples of FVIII BDD are factor VIII sequences in which the amino acids are deleted between residue number 741 and residue number 1640 (numbered relative to native, mature FVIII), or n residue number 745 and residue number 1640, or between e number 745 and residue number 1640, or n residue number 741 and residue number 1690, or between residue number 745 and residue number 1667, or between residue number 745 and residue number 1657, or between residue number 747 and residue number 1642, or between residue number 751 and residue number 1667.

In another embodiment, heterologous sequences are incorporated into the FVIII, which may e XTEN, as described more fully below. Table 1 provides a non-limiting list of amino acid sequences of FVIII that are encompassed by the CFXTEN fusion proteins of the invention. In some embodiments, FVIII incorporated into CFXTEN fusion proteins e proteins that have at least about 70% sequence identity, or alternatively 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity compared to an amino acid sequence of able length selected from Table 1.

Table 1: FVIII amino acid seguences Name Amino Acid Sequence ID (source) FVIII MQIELSTCFFLCLLRFCFSATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPK 1 precursor SFPFNTSVVYKKTLFVEFTDHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNM polypeptide ASHPVSLHAVGVSYWKASEGAEYDDQTSQREKEDDKVFPGGSHTYVWQVLKEN (human) GPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCREGSLAKEKTQTLHKFILLF AVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNRSLPGLIGCHRKS VYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLMDLGQFLL FCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFD DDNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNG PQRIGRKYKKVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASR PYNIYPHGITDVRPLYSRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPR SSFVNMERDLASGLIGPLLICYKESVDQRGNQIMSDKRNVILFSVFDENR SWYLTENIQRFLPNPAGVQLEDPEFQASNIMHSINGYVFDSLQLSVCLHEVAYWY ILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGETVFMSMENPGLWILGCHN SDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNAIEPRSFSQNSRHPS TRQKQFNATTIPENDIEKTDPWFAHRTPMPKIQNVSSSDLLMLLRQSPTPHGLSLS DLQEAKYETFSDDPSPGAIDSNNSLSEMTHFRPQLHHSGDMVFTPESGLQLRLNE KLGTTAATELKKLDFKVSSTSNNLISTIPSDNLAAGTDNTSSLGPPSMPVHYDSQL DTTLFGKKSSPLTESGGPLSLSEENNDSKLLESGLMNSQESSWGKNVSSTESGRLF KGKRAHGPALLTKDNALFKVSISLLKTNKTSNNSATNRKTHIDGPSLLIENSPSVW QNILESDTEFKKVTPLIHDRMLMDKNATALRLNHMSNKTTSSKNMEMVQQKKE WO 22617 Name Amino Acid Sequence ID (source) GPIPPDAQNPDMSFFKMLFLPESARWIQRTHGKNSLNSGQGPSPKQLVSLGPEKSV EGQNFLSEKNKVVVGKGEFTKDVGLKEMVFPSSRNLFLTNLDNLHENNTHNQEK KIQEEIEKKETLIQENVVLPQIHTVTGTKNFMKNLFLLSTRQNVEGSYDGAYAPVL QDFRSLNDSTNRTKKHTAHFSKKGEEENLEGLGNQTKQIVEKYACTTRISPNTSQ QNFVTQRSKRALKQFRLPLEETELEKRIIVDDTSTQWSKNMKHLTPSTLTQIDYNE KEKGAITQSPLSDCLTRSHSIPQANRSPLPIAKVSSFPSIRPIYLTRVLFQDNSSHLPA ASYRKKDSGVQESSHFLQGAKKNNLSLAILTLEMTGDQREVGSLGTSATNSVTY VLPKPDLPKTSGKVELLPKVHIYQKDLFPTETSNGSPGHLDLVEGSLLQ GTEGAIKWNEANRPGKVPFLRVATESSAKTPSKLLDPLAWDNHYGTQIPKEEWK EKTAFKKKDTILSLNACESNHAIAAINEGQNKPEIEVTWAKQGRTERLCS QNPPVLKRHQREITRTTLQSDQEEIDYDDTISVEMKKEDFDIYDEDENQSPRSFQK IAAVERLWDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPL YRGELNEHLGLLGPYIRAEVEDNIMVTFRNQASRPYSFYSSLISYEEDQRQGAEPR KNFVKPNETKTYFWKVQHHMAPTKDEFDCKAWAYFSDVDLEKDVHSGLIGPLL VCHTNTLNPAHGRQVTVQEFALFFTIFDETKSWYFTENMERNCRAPCNIQMEDPT FKENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIHSIHFSGHVFTVR KKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLVYSNK MASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDL LAPMIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVD SSGIKHNIFNPPIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDA QITASSYFTNMFATWSPSKARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVT GVTTQGVKSLLTSMYVKEFLISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVN SLDPPLLTRYLRIHPQSWVHQIALRMEVLGCEAQDLY FVIII ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFT 2 mature DHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKAS (human) EGAEYDDQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHV NSGLIGALLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLM QDRDAASARAWPKMHTVNGYVNRSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFL EGHTFLVRNHRQASLEISPITFLTAQTLLMDLGQFLLFCHISSHQHDGMEAYVKV DSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDDDNSPSFIQIRSVAKKHPKT WVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKYKKVRFMAYTDE TFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPLYSRRLP KGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGL IGPLLICYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQL EDPEFQASNIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFK HKMVYEDTLTLFPFSGETVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDK NTGDYYEDSYEDISAYLLSKNNAIEPRSFSQNSRHPSTRQKQFNATTIPENDIEKTD PWFAHRTPMPKIQNVSSSDLLMLLRQSPTPHGLSLSDLQEAKYETFSDDPSPGAID SNNSLSEMTHFRPQLHHSGDMVFTPESGLQLRLNEKLGTTAATELKKLDFKVSST SNNLISTIPSDNLAAGTDNTSSLGPPSMPVHYDSQLDTTLFGKKSSPLTESGGPLSL SEENNDSKLLESGLMNSQESSWGKNVSSTESGRLFKGKRAHGPALLTKDNALFK VSISLLKTNKTSNNSATNRKTHIDGPSLLIENSPSVWQNILESDTEFKKVTPLIHDR MLMDKNATALRLNHMSNKTTSSKNMEMVQQKKEGPIPPDAQNPDMSFFKMLFL PESARWIQRTHGKNSLNSGQGPSPKQLVSLGPEKSVEGQNFLSEKNKVVVGKGEF TKDVGLKEMVFPSSRNLFLTNLDNLHENNTHNQEKKIQEEIEKKETLIQENVVLP QIHTVTGTKNFMKNLFLLSTRQNVEGSYDGAYAPVLQDFRSLNDSTNRTKKHTA HFSKKGEEENLEGLGNQTKQIVEKYACTTRISPNTSQQNFVTQRSKRALKQFRLPL EETELEKRIIVDDTSTQWSKNMKHLTPSTLTQIDYNEKEKGAITQSPLSDCLTRSHS IPQANRSPLPIAKVSSFPSIRPIYLTRVLFQDNSSHLPAASYRKKDSGVQESSHFLQG AKKNNLSLAILTLEMTGDQREVGSLGTSATNSVTYKKVENTVLPKPDLPKTSGKV ELLPKV RVATESSAKTPSKLLDPLAWDNHYGTQIPKEEWKSQEKSPEKTAFKKKDTILSLN ACESNHAIAAINEGQNKPEIEVTWAKQGRTERLCSQNPPVLKRHQREITRTTLQSD QEEIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERLWDYGMSS SPHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVE DNIMVTFRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHH MAPTKDEFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEF ALFFTIFDETKSWYFTENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGL VMAQDQRIRWYLLSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYPGVFETV EMLPSKAGIWRVECLIGEHLHAGMSTLFLVYSNKCQTPLGMASGHIRDFQITASG Name Amino Acid Sequence ID (source) QYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAPMIIHGIKTQGARQKFSSL YISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARYIRLHP THYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSKA RLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEF LISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVH QIALRMEVLGCEAQDLY FVIII MQVELYTCCFLCLLPFSLSATRKYYLGAVELSWDYMQSDLLSALHADTSFSSRVP 3 (Canine) GSLPLTTSVTYRKTVFVEFTDDLFNIAKPRPPWMGLLGPTIQAEVYDTVVIVLKN MASHPVSLHAVGVSYWKASEGAEYEDQTSQKEKEDDNVIPGESHTYVWQVLKE NGPMASDPPCLTYSYFSHVDLVKDLNSGLIGALLVCKEGSLAKERTQTLQEFVLL GKSWHSETNASLTQAEAQHELHTINGYVNRSLPGLTVCHKRSVYWHVI GMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTFLMDLGQFLLFCHIPSH QHDGMEAYVKVDSCPEEPQLRMKNNEDKDYDDGLYDSDMDVVSFDDDSSSPFI QIRSVAKKHPKTWVHYIAAEEEDWDYAPSGPTPNDRSHKNLYLNNGPQRIGKKY KKVRFVAYTDETFKTREAIQYESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGI NYVTPLHTGRLPKGVKHLKDMPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSS FINLERDLASGLIGPLLICYKESVDQRGNQMMSDKRNVILFSVFDENRSWYLTEN MQRFLPNADVVQPHDPEFQLSNIMHSINGYVFDNLQLSVCLHEVAYWYILSVGA QTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGETVFMSMENPGLWVLGCHNSDFR NRGMTALLKVSSCNRNIDDYYEDTYEDIPTPLLNENNVIKPRSFSQNSRHPSTKEK QLKATTTPENDIEKIDLQSGERTQLIKAQSVSSSDLLMLLGQNPTPRGLFLSDLREA HSRGAIERNKGPPEVASLRPELRHSEDREFTPEPELQLRLNENLGTNTTV ELKKLDLKISSSSDSLMTSPTIPSDKLAAATEKTGSLGPPNMSVHFNSHLGTIVFGN NSSHLIQSGVPLELSEEDNDSKLLEAPLMNIQESSLRENVLSMESNRLFKEERIRGP ASLIKDNALFKVNISSVKTNRAPVNLTTNRKTRVAIPTLLIENSTSVWQDIMLERN TEFKEVTSLIHNETFMDRNTTALGLNHVSNKTTLSKNVEMAHQKKEDPVPLRAE SKIPFLPDWIKTHGKNSLSSEQRPSPKQLTSLGSEKSVKDQNFLSEEKVVV GEDEFTKDTELQEIFPNNKSIFFANLANVQENDTYNQEKKSPEEIERKEKLTQENV ALPQAHTMIGTKNFLKNLFLLSTKQNVAGLEEQPYTPILQDTRSLNDSPHSEGIHM ANFSKIREEANLEGLGNQTNQMVERFPSTTRMSSNASQHVITQRGKRSLKQPRLS QGEIKFERKVIANDTSTQWSKNMNYLAQGTLTQIEYNEKEKRAITQSPLSDCSMR NHVTIQMNDSALPVAKESASPSVRHTDLTKIPSQHNSSHLPASACNYTFRERTSGV QEGSHFLQEAKRNNLSLAFVTLGITEGQGKFSSLGKSATNQPMYKKLENTVLLQP GLSETSDKVELLSQVHVDQEDSFPTKTSNDSPGHLDLMGKIFLQKTQGPVKMNK TNSPGKVPFLKWATESSEKIPSKLLGVLAWDNHYDTQIPSEEWKSQKKSQTNTAF KRKDTILPLGPCENNDSTAAINEGQDKPQREAMWAKQGEPGRLCSQNPPVSKHH QREITVTTLQPEEDKFEYDDTFSIEMKREDFDIYGDYENQGLRSFQKKTRHYFIAA VERLWDYGMSRSPHILRNRAQSGDVQQFKKVVFQEFTDGSFTQPLYRGELNEHL IRAEVEDNIVVTFKNQASRPYSFYSSLISYDEDEGQGAEPRRKFVNPNET VQHHMAPTKDEFDCKAWAYFSDVDLEKDVHSGLIGPLLICRSNTLNPA HGRQVTVQEFALVFTIFDETKSWYFTENLERNCRAPCNVQKEDPTLKENFRFHAI NGYVKDTLPGLVMAQDQKVRWYLLSMGSNENIHSIHFSGHVFTVRKKEEYKMA VYNLYPGVFETVEMLPSQVGIWRIECLIGEHLQAGMSTLFLVYSKKCQTPLGMAS GHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKDPFSWIKVDLLAPMIIHGI MTQGARQKFSSLYVSQFIIMYSLDGNKWHSYRGNSTGTLMVFFGNVDSSGIKHNI FNPPIIAQYIRLHPTHYSIRSTLRMELLGCDFNSCSMPLGMESKAISDAQITASSYLS SMLATWSPSQARLHLQGRTNAWRPQANNPKEWLQVDFRKTMKVTGITTQGVKS LLISMYVKEFLISSSQDGHNWTLFLQNGKVKVFQGNRDSSTPVRNRLEPPLVARY VR LHPQSWAHHIALRLEVLGCDTQQPA FVIII (Pig) ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFT 4 DHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKAS EGAEYDDQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHV DLVKDLNSGLIGALLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLM QDRDAASARAWPKMHTVNGYVNRSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFL EGHTFLVRNHRQASLEISPITFLTAQTLLMDLGQFLLFCHISSHQHDGMEAYVKV DSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDDDNSPSFIQIRSVAKKHPKT WVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKYKKVRFMAYTDE TFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPLYSRRLP KGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGL Name Amino Acid Sequence ID (source) IGPLLICYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQL EDPEFQASNIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFK HKMVYEDTLTLFPFSGETVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDK EDSYEDISAYLLSKNNAIEPRSFSQNSRHPSTRQKQFNATTIPENDIEKTD PWFAHRTPMPKIQNVSSSDLLMLLRQSPTPHGLSLSDLQEAKYETFSDDPSPGAID EMTHFRPQLHHSGDMVFTPESGLQLRLNEKLGTTAATELKKLDFKVSST SNNLISTIPSDNLAAGTDNTSSLGPPSMPVHYDSQLDTTLFGKKSSPLTESGGPLSL SEENNDSKLLESGLMNSQESSWGKNVSSTESGRLFKGKRAHGPALLTKDNALFK VSISLLKTNKTSNNSATNRKTHIDGPSLLIENSPSVWQNILESDTEFKKVTPLIHDR MLMDKNATALRLNHMSNKTTSSKNMEMVQQKKEGPIPPDAQNPDMSFFKMLFL PESARWIQRTHGKNSLNSGQGPSPKQLVSLGPEKSVEGQNFLSEKNKVVVGKGEF TKDVGLKEMVFPSSRNLFLTNLDNLHENNTHNQEKKIQEEIEKKETLIQENVVLP QIHTVTGTKNFMKNLFLLSTRQNVEGSYDGAYAPVLQDFRSLNDSTNRTKKHTA EEENLEGLGNQTKQIVEKYACTTRISPNTSQQNFVTQRSKRALKQFRLPL EETELEKRIIVDDTSTQWSKNMKHLTPSTLTQIDYNEKEKGAITQSPLSDCLTRSHS SPLPIAKVSSFPSIRPIYLTRVLFQDNSSHLPAASYRKKDSGVQESSHFLQG AKKNNLSLAILTLEMTGDQREVGSLGTSATNSVTYKKVENTVLPKPDLPKTSGKV ELLPKV RVATESSAKTPSKLLDPLAWDNHYGTQIPKEEWKSQEKSPEKTAFKKKDTILSLN ACESNHAIAAINEGQNKPEIEVTWAKQGRTERLCSQNPPVLKRHQREITRTTLQSD QEEIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERLWDYGMSS SPHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVE FRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHH MAPTKDEFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEF ALFFTIFDETKSWYFTENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGL VMAQDQRIRWYLLSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYPGVFETV EMLPSKAGIWRVECLIGEHLHAGMSTLFLVYSNKCQTPLGMASGHIRDFQITASG QYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAPMIIHGIKTQGARQKFSSL YISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARYIRLHP THYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSKA RLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEF LISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVH QIALRMEVLGCEAQDLY FVIII AIRRYYLGAVELSWNYIQSDLLSVLHTDSRFLPRMSTSFPFNTSIMYKKTVFVEYK 5 (Mouse) DQLFNIAKPRPPWMGLLGPTIWTEVHDTVVITLKNMASHPVSLHAVGVSYWKAS EGDEYEDQTSQMEKEDDKVFPGESHTYVWQVLKENGPMASDPPCLTYSYMSHV DLVKDLNSGLIGALLVCKEGSLSKERTQMLYQFVLLFAVFDEGKSWHSETNDSY TQSMDSASARDWPKMHTVNGYVNRSLPGLIGCHRKSVYWHVIGMGTTPEIHSIF LEGHTFFVRNHRQASLEISPITFLTAQTLLIDLGQFLLFCHISSHKHDGMEAYVKV DSCPEESQWQKKNNNEEMEDYDDDLYSEMDMFTLDYDSSPFIQIRSVAKKYPKT WIHYISAEEEDWDYAPSVPTSDNGSYKSQYLSNGPHRIGRKYKKVRFIAYTDETF KTRETIQHESGLLGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVSPLHARRLPR GIKHVKDLPIHPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFINPERDLASGLIGP LLICYKESVDQRGNQMMSDKRNVILFSIFDENQSWYITENMQRFLPNAAKTQPQD NIMHSINGYVFDSLELTVCLHEVAYWHILSVGAQTDFLSIFFSGYTFKHK MVYEDTLTLFPFSGETVFMSMENPGLWVLGCHNSDFRKRGMTALLKVSSCDKST SDYYEEIYEDIPTQLVNENNVIDPRSFFQNTNHPNTRKKKFKDSTIPKNDMEKIEPQ FEEIAEMLKVQSVSVSDMLMLLGQSHPTPHGLFLSDGQEAIYEAIHDDHSPNAIDS NEGPSKVTQLRPESHHSEKIVFTPQPGLQLRSNKSLETTIEVKWKKLGLQVSSLPS NLMTTTILSDNLKATFEKTDSSGFPDMPVHSSSKLSTTAFGKKAYSLVGSHVPLN ASEENSDSNILDSTLMYSQESLPRDNILSIENDRLLREKRFHGIALLTKDNTLFKDN VSLMKTNKTYNHSTTNEKLHTESPTSIENSTTDLQDAILKVNSEIQEVTALIHDGT LLGKNSTYLRLNHMLNRTTSTKNKDIFHRKDEDPIPQDEENTIMPFSKMLFLSESS NWFKKTNGNNSLNSEQEHSPKQLVYLMFKKYVKNQSFLSEKNKVTVEQDGFTK NIGLKDMAFPHNMSIFLTTLSNVHENGRHNQEKNIQEEIEKEALIEEKVVLPQVHE ATGSKNFLKDILILGTRQNISLYEVHVPVLQNITSINNSTNTVQIHMEHFFKRRKDK ETNSEGLVNKTREMVKNYPSQKNITTQRSKRALGQFRLSTQWLKTINCSTQCIIKQ IDHSKEMKKFITKSSLSDSSVIKSTTQTNSSDSHIVKTSAFPPIDLKRSPFQNKFSHV QASSYIYDFKTKSSRIQESNNFLKETKINNPSLAILPWNMFIDQGKFTSPGKSNTNS VTYKKRENIIFLKPTLPEESGKIELLPQVSIQEEEILPTETSHGSPGHLNLMKEVFLQ Name Amino Acid Sequence ID (source) KIQGPTKWNKAKRHGESIKGKTESSKNTRSKLLNHHAWDYHYAAQIPKDMWKS KEKSPEIISIKQEDTILSLRPHGNSHSIGANEKQNWPQRETTWVKQGQTQRTCSQIP PVLKRHQRELSAFQSEQEATDYDDAITIETIEDFDIYSEDIKQGPRSFQQKTRHYFI AAVERLWDYGMSTSHVLRNRYQSDNVPQFKKVVFQEFTDGSFSQPLYRGELNEH LGLLGPYIRAEVEDNIMVTFKNQASRPYSFYSSLISYKEDQRGEEPRRNFVKPNET KIYFWKVQHHMAPTEDEFDCKAWAYFSDVDLERDMHSGLIGPLLICHANTLNPA VQEFALLFTIFDETKSWYFTENVKRNCKTPCNFQMEDPTLKENYRFHA1 NGYVMDTLPGLVMAQDQRIRWYLLSMGNNENIQSIHFSGHVFTVRKKEEYKMA VYNLYPGVFETLEMIPSRAGIWRVECLIGEHLQAGMSTLFLVYSKQCQIPLGMAS GSIRDFQITASGHYGQWAPNLARLHYSGSINAWSTKEPFSWIKVDLLAPMIVHGIK TQGARQKFSSLYISQFIIMYSLDGKKWLSYQGNSTGTLMVFFGNVDSSGIKHNSF NPPIIARYIRLHPTHSSIRSTLRMELMGCDLNSCSIPLGMESKVISDTQITASSYFTN MFATWSPSQARLHLQGRTNAWRPQVNDPKQWLQVDLQKTMKVTGIITQGVKSL FTSMFVKEFLISSSQDGHHWTQILYNGKVKVFQGNQDSSTPMMNSLDPPLLTRYL RIHPQIWEHQIALRLEILGCEAQQQY FVIII BDD MQIELSTCFFLCLLRFCFSATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPK variant SFPFNTSVVYKKTLFVEFTVHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNM (US Pat ASHPVSLHAVGVSYWKASEGAEYDDQTSQREKEDDKVFPGGSHTYVWQVLKEN No. GPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCREGSLAKEKTQTLHKFILLF 763292 1 , AVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNRSLPGLIGCHRKS SEQ ID VYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLMDLGQFLL NO: 3) FCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFD DDNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNG PQRIGRKYKKVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASR PYNIYPHGITDVRPLYSRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPR CLTRYYSSFVNMERDLASGLIGPLLICYKESVDQRGNQIMSDKRNVILFSVFDENR SWYLTENIQRFLPNPAGVQLEDPEFQASNIMHSINGYVFDSLQLSVCLHEVAYWY ILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGETVFMSMENPGLWILGCHN SDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNAIEPRSFSQNPPVL KRHQREITRTTLQSDQEEIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYF IAAVERLWDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNE HLGLLGPYIRAEVEDNIMVTFRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPN ETKTYFWKVQHHMAPTKDEFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTL QVTVQEFALFFTIFDETKSWYFTENMERNCRAPCNIQMEDPTFKENYRF HAINGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIHSIHFSGHVFTVRKKEEYK MALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLVYSNKCQTPLG MASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAPMII HGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIK HNIFNPPIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASS YFTNMFATWSPSKARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQ GVKSLLTSMYVKEFLISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPL LTRYLRIHPQSWVHQIALRMEVLGCEAQDLY FVIII ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFT BDD-Z AKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKAS DQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHV DLVKDLNSGLIGALLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLM QDRDAASARAWPKMHTVNGYVNRSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFL EGHTFLVRNHRQASLEISPITFLTAQTLLMDLGQFLLFCHISSHQHDGMEAYVKV DSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDDDNSPSFIQIRSVAKKHPKT WVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKYKKVRFMAYTDE TFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPLYSRRLP KGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGL IGPLLICYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQL EDPEFQASNIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFK HKMVYEDTLTLFPFSGETVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDK EDSYEDISAYLLSKNNAIEPRSFSQNPPVLKRHQREITRTTLQSDQEEIDY DDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLR NRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVT FRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKD WO 22617 Name Amino Acid Sequence ID (source) EFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIF DETKSWYFTENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQD QRIRWYLLSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPSK AGIWRVECLIGEHLHAGMSTLFLVYSNKCQTPLGMASGHIRDFQITASGQYGQW APKLARLHYSGSINAWSTKEPFSWIKVDLLAPMIIHGIKTQGARQKFSSLYISQFII MYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARYIRLHPTHYSIR STLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSKARLHLQ GRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQ DGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALR MEVLGCEAQDLY FVIII ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFT 8 BDD-3 VHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKAS (G1 648) EGAEYDDQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHV DLVKDLNSGLIGALLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLM QDRDAASARAWPKMHTVNGYVNRSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFL EGHTFLVRNHRQASLEISPITFLTAQTLLMDLGQFLLFCHISSHQHDGMEAYVKV DSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDDDNSPSFIQIRSVAKKHPKT WVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKYKKVRFMAYTDE TFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPLYSRRLP KGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGL IGPLLICYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQL EDPEFQASNIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFK HKMVYEDTLTLFPFSGETVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDK NTGDYYEDSYEDISAYLLSKNNAIEPRSFSQNPPVLKRHQGEITRTTLQSDQEEIDY DDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLR NRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVT FRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKD WAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIF DETKSWYFTENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQD QRIRWYLLSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPSK AGIWRVECLIGEHLHAGMSTLFLVYSNKCQTPLGMASGHIRDFQITASGQYGQW APKLARLHYSGSINAWSTKEPFSWIKVDLLAPMIIHGIKTQGARQKFSSLYISQFII MYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARYIRLHPTHYSIR STLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSKARLHLQ GRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQ DGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALR EAQDLY FVIII ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFT 9 BDD-4 VHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKAS EGAEYDDQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHV DLVKDLNSGLIGALLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLM QDRDAASARAWPKMHTVNGYVNRSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFL EGHTFLVRNHRQASLEISPITFLTAQTLLMDLGQFLLFCHISSHQHDGMEAYVKV DSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDDDNSPSFIQIRSVAKKHPKT WVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKYKKVRFMAYTDE AIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPLYSRRLP KGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGL CYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQL ASNIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFK HKMVYEDTLTLFPFSGETVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDK NTGDYYEDSYEDISAYLLSKNNAIEPRSFSQQSPRSFQKKTRHYFIAAVERLWDY GMSSSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIR AEVEDNIMVTFRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKV QHHMAPTKDEFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVT VQEFALFFTIFDETKSWYFTENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMD TLPGLVMAQDQRIRWYLLSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYPG VFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLVYSNKCQTPLGMASGHIRDFQ ITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAPMIIHGIKTQGARQ KFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARYI Name Amino Acid Sequence ID (source) RLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWS PSKARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMY SSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQS WVHQIALRMEVLGCEAQDLY FVIII ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFT 10 BDD-5 VHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKAS EGAEYDDQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHV NSGLIGALLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLM QDRDAASARAWPKMHTVNGYVNRSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFL VRNHRQASLEISPITFLTAQTLLMDLGQFLLFCHISSHQHDGMEAYVKV DSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDDDNSPSFIQIRSVAKKHPKT WVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKYKKVRFMAYTDE TFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPLYSRRLP KGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGL CYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQL EDPEFQASNIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFK HKMVYEDTLTLFPFSGETVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDK QSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFT DGSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVTFRNQASRPYSFYSSLISYEED QRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKDEFDCKAWAYFSDVDLEKDV HSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFDETKSWYFTENMERNCRAP CNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIHSIH FSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHAGMS TLFLVYSNKCQTPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKE PFSWIKVDLLAPMIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGT LMVFFGNVDSSGIKHNIFNPPIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLG MESKAISDAQITASSYFTNMFATWSPSKARLHLQGRSNAWRPQVNNPKEWLQVD FQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQDGHQWTLFFQNGKVKVFQGN VVNSLDPPLLTRYLRIHPQSWVHQIALRMEVLGCEAQDLY FVIII ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFT 11 BDD-6 DHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKAS EGAEYDDQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHV DLVKDLNSGLIGALLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLM QDRDAASARAWPKMHTVNGYVNRSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFL EGHTFLVRNHRQASLEISPITFLTAQTLLMDLGQFLLFCHISSHQHDGMEAYVKV DSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDDDNSPSFIQIRSVAKKHPKT WVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKYKKVRFMAYTDE TFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPLYSRRLP KGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGL IGPLLICYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQL EDPEFQASNIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFK HKMVYEDTLTLFPFSGETVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDK NTGDYYEDSYEDISAYLLSKNNAIEPRSFSQNSRHPSTRQKQFNATTIPENDIEKTD TISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLRNR PQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVTFR NQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKDEF DCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFDE TKSWYFTENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQR IRWYLLSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPSKAG IWRVECLIGEHLHAGMSTLFLVYSNKCQTPLGMASGHIRDFQITASGQYGQWAP KLARLHYSGSINAWSTKEPFSWIKVDLLAPMIIHGIKTQGARQKFSSLYISQFIIMY SLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARYIRLHPTHYSIRSTL RMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSKARLHLQGRS NAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQDGH QWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRMEV LGCEAQDLY FVIII ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFT 12 BDD-7 VHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKAS EGAEYDDQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHV Name Amino Acid Sequence ID (source) DLVKDLNSGLIGALLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLM QDRDAASARAWPKMHTVNGYVNRSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFL EGHTFLVRNHRQASLEISPITFLTAQTLLMDLGQFLLFCHISSHQHDGMEAYVKV DSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDDDNSPSFIQIRSVAKKHPKT AEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKYKKVRFMAYTDE TFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPLYSRRLP KGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGL IGPLLICYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQL EDPEFQASNIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFK HKMVYEDTLTLFPFSGETVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDK NTGDYYEDSYEDISAYLLSKNNAIEPRSFSQSPRSFQKKTRHYFIAAVERLWDYG MSSSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRA EVEDNIMVTFRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQ HHMAPTKDEFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTV FTIFDETKSWYFTENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTL PGLVMAQDQRIRWYLLSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYPGVF ETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLVYSNKCQTPLGMASGHIRDFQIT ASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAPMIIHGIKTQGARQKF SSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARYIRL HPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPS KARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVK EFLISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSW VHQIALRMEVLGCEAQDLY FVIII MQIELSTCFFLCLLRFCFSATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPK 1 3 BDD-8 SFPFNTSVVYKKTLFVEFTDHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNM precursor LHAVGVSYWKASEGAEYDDQTSQREKEDDKVFPGGSHTYVWQVLKEN (US Pat. PLCLTYSYLSHVDLVKDLNSGLIGALLVCREGSLAKEKTQTLHKFILLF N0. AVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNRSLPGLIGCHRKS 681 8439 VYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLMDLGQFLL SEQ ID FCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFD NO: 47) DDNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNG KYKKVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASR PYNIYPHGITDVRPLYSRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPR CLTRYYSSFVNMERDLASGLIGPLLICYKESVDQRGNQIMSDKRNVILFSVFDENR SWYLTENIQRFLPNPAGVQLEDPEFQASNIMHSINGYVFDSLQLSVCLHEVAYWY ILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGETVFMSMENPGLWILGCHN SDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNAIEPRSFSQNPPVL KRHQREITRTTLQSDQEEIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYF IAAVERLWDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNE HLGLLGPYIRAEVEDNIMVTFRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPN ETKTYFWKVQHHMAPTKDEFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTL NPAHGRQVTVQEFALFFTIFDETKSWYFTENMERNCRAPCNIQMEDPTFKENYRF HAINGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIHSIHFSGHVFTVRKKEEYK MALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLVYSNKCQTPLG MASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAPMII HGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIK HNIFNPPIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASS YFTNMFATWSPSKARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQ GVKSLLTSMYVKEFLISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPL LTRYLRIHPQSWVHQIALRMEVLGCEAQDLY FVIII ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFT 14 BDD-9 DHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKAS mature EGAEYDDQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHV (US Pat. DLVKDLNSGLIGALLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLM N0. QDRDAASARAWPKMHTVNGYVNRSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFL 681 8439) EGHTFLVRNHRQASLEISPITFLTAQTLLMDLGQFLLFCHISSHQHDGMEAYVKV DSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDDDNSPSFIQIRSVAKKHPKT WVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKYKKVRFMAYTDE TFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPLYSRRLP Name Amino Acid Sequence ID (source) KGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGL IGPLLICYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQL EDPEFQASNIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFK HKMVYEDTLTLFPFSGETVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDK EDSYEDISAYLLSKNNAIEPRSFSQNPPVLKRHQREITRTTLQSDQEEIDY EMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLR NRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVT FRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKD EFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIF YFTENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQD QRIRWYLLSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPSK AGIWRVECLIGEHLHAGMSTLFLVYSNKCQTPLGMASGHIRDFQITASGQYGQW APKLARLHYSGSINAWSTKEPFSWIKVDLLAPMIIHGIKTQGARQKFSSLYISQFII MYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARYIRLHPTHYSIR STLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSKARLHLQ GRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQ DGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALR MEVLGCEAQDLY FVIII LGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFT 1 5 BDD- 1 0 DHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKAS EGAEYDDQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHV NSGLIGALLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLM QDRDAASARAWPKMHTVNGYVNRSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFL EGHTFLVRNHRQASLEISPITFLTAQTLLMDLGQFLLFCHISSHQHDGMEAYVKV DSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDDDNSPSFIQIRSVAKKHPKT WVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKYKKVRFMAYTDE TFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPLYSRRLP KGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGL IGPLLICYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQL EDPEFQASNIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFK HKMVYEDTLTLFPFSGETVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDK NTGDYYEDSYEDISAYLLSKNNAIEPRSFSQNPPVLKRHQAEITRTTLQSDQEEIDY DDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLR NRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVT FRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKD EFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIF YFTENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQD QRIRWYLLSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPSK AGIWRVECLIGEHLHAGMSTLFLVYSNKCQTPLGMASGHIRDFQITASGQYGQW APKLARLHYSGSINAWSTKEPFSWIKVDLLAPMIIHGIKTQGARQKFSSLYISQFII MYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARYIRLHPTHYSIR STLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSKARLHLQ GRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQ DGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALR MEVLGCEAQDLY FVIII ATRATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTS V V Y KKTLF 16 BDD-1 1 VEFTDHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSY WKASEGAEYDDQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSY LSHVDLVKDLNSGLIGALLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETK NSLMQDRDAASARAWPKMHTVNGYVNRSLPGLIGCHRKSVYWHVIGMGTTPEV HSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLMDLGQFLLFCHISSHQHDGMEAY VKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDDDNSPSFIQIRSVAKK HPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKYKKVRFMA YTDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPLYS RRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDL ASGLIGPLLICYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPA GVQLEDPEFQASNIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSG YTFKHKMVYEDTLTLFPFSGETVFMSMENPGLWILGCHNSDFRNRGMTALLKVS SCDKNTGDYYEDSYEDISAYLLSKNNAIEPRSFSQNPPVLKRHQAEITRTTLQSDQ Name Amino Acid Sequence ID (source) EEIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERLWDYGMSSS PHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVED NIMVTFRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHM APTKDEFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFA LFFTIFDETKSWYFTENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLV MAQDQRIRWYLLSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYPGVFETVE MLPSKAGIWRVECLIGEHLHAGMSTLFLVYSNKCQTPLGMASGHIRDFQITASGQ YGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAPMIIHGIKTQGARQKFSSLYI SQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARYIRLHPTH YSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSKARL HLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLIS SSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIA LRMEVLGCEAQDLY FVIII LGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFT 1 7 BDD- 12 AKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKAS EGAEYDDQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHV NSGLIGALLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLM QDRDAASARAWPKMHTVNGYVNRSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFL EGHTFLVRNHRQASLEISPITFLTAQTLLMDLGQFLLFCHISSHQHDGMEAYVKV DSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDDDNSPSFIQIRSVAKKHPKT WVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKYKKVRFMAYTDE TFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPLYSRRLP KGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGL IGPLLICYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQL EDPEFQASNIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFK HKMVYEDTLTLFPFSGETVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDK NTGDYYEDSYEDISAYLLSKNNAIEPRSFSQNPPVLKRHQAEITRTTLQSDQEEIDY DDTISVEMKKEDFDIFDEDENQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLR NRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVT FRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKD EFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIF DETKSWYFTENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQD QRIRWYLLSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPSK ECLIGEHLHAGMSTLFLVYSNKCQTPLGMASGHIRDFQITASGQYGQW APKLARLHYSGSINAWSTKEPFSWIKVDLLAPMIIHGIKTQGARQKFSSLYISQFII KKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARYIRLHPTHYSIR STLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSKARLHLQ GRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQ DGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALR MEVLGCEAQDLY FVIII ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFT 1 8 BDD- 1 3 DHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKAS EGAEYDDQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHV DLVKDLNSGLIGALLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLM QDRDAASARAWPKMHTVNGYVNRSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFL EGHTFLVRNHRQASLEISPITFLTAQTLLMDLGQFLLFCHISSHQHDGMEAYVKV DSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDDDNSPSFIQIRSVAKKHPKT WVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKYKKVRFMAYTDE TFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPLYSRRLP KGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGL IGPLLICYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQL EDPEFQASNIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFK HKMVYEDTLTLFPFSGETVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDK NTGDYYEDSYEDISAYLLSKNNAIEPRSFSQNPPVLKRHQREITRTTLQSDQEEIDY DDTISVEMKKEDFDIFDEDENQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLR NRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVT FRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKD EFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIF DETKSWYFTENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQD (31:32:) Amino Acid Sequence ID QRIRWYLLSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPSK AGIWRVECLIGEHLHAGMSTLFLVYSNKCQTPLGMASGHIRDFQITASGQYGQW LHYSGSINAWSTKEPFSWIKVDLLAPMIIHGIKTQGARQKFSSLYISQFII MYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARYIRLHPTHYSIR STLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSKARLHLQ GRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQ DGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALR MEVLGCEAQDLY The present invention also contemplates CFXTEN sing FVIII with various amino acid deletions, insertions and substitutions made in the FVIII sequences of Table 1 that retain procoagulant activity. Examples of conservative tutions for amino acids in polypeptide sequences are shown in Table 2. In embodiments of the CFXTEN in which the sequence identity of the FVIII is less than 100% compared to a specific sequence disclosed herein, the invention contemplates substitution of any of the other 19 natural L-amino acids for a given amino acid residue of the given FVIII, which may be at any position within the sequence of the FVIII, including adjacent amino acid residues. If any one substitution results in an undesirable change in procoagulant activity, then one of the ative amino acids can be employed and the construct protein evaluated by the methods described herein (e. g., the assays of Table 49), or using any of the techniques and guidelines for conservative and non-conservative mutations set forth, for instance, in US. Pat. No. 5,364,934, the content of which is incorporated by reference in its entirety, or using methods generally known in the art. In a preferred substitution, the FVIII ent of the CFXTEN embodiments is modified by replacing the R1648 residue (numbered relative to the native mature form of FVIII) with glycine or alanine to prevent proteolytic processing to the heterodimer form. In another substitution, the FVIII component of the CFXTEN embodiments is modified by replacing the Y1680 residue (numbered relative to the native mature form of FVIII) with phenylalanine.

In r embodiment, the FVIII ent of the CFXTEN embodiments is modified by replacing the Y1680 residue (numbered ve to the native mature form of FVIII) with phenylalanine and the R1648 residue (numbered ve to the native mature form of FVIII) with glycine or alanine.

In one embodiment, the FVIII of the fusion protein composition has one or more amino acid substitutions designed to reduce the g of FVIII tors at epitopes recognized by the antibodies of Table 9, including but not limited to substitutions at Lys(377), Lys(466), Lys(3 80), Ser(488), Arg(489), Arg(490), Leu(491), Lys(493), Lys(496), His(497), Lys(499), Lys(512), Lys(523), Lys(556), Met (2199), Phe(2200), Leu(2252), Val(2223), and Lys(2227). In addition, variants can include, for instance, polypeptides wherein one or more amino acid residues are added or d at or near the N— or C-terminus of the full-length native amino acid sequence or of a domain of a FVIII so long as the t s some if not all of the procoagulant actiVity of the native peptide. The resulting FVIII sequences that retain at least a portion (e. g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or at least 95% or more) of the procoagulant actiVity in comparison to native circulating FVIII are ered useful for the fusion n compositions of this invention. Examples of FVIII variants are known in the art, including those described in US Patent and Application Nos. 6,316,226; 6,818,439; 7,632,921; 20080227691, which are incorporated herein by reference. In one embodiment, a PV111 sequence variant has an aspartic acid substituted for valine at amino acid position 75 (numbered relative to the native mature form of FVIII).

Table 2: Exemplary conservative amino acid substitutions Original e Exemplary Substitutions Ala (A) val; leu; ile Arg (R) lys; gln; asn Asn (N) gin; his; lys; arg Asp (D) Glu Cys (C) Ser Gln (Q) Asn Glu (E) Asp Gly (G) Pro His (H) asn: gin: lys; arg lle (l) leu; val; met; ala; phe: norleucine Leu (L) norleucine: ile: val; met; ala: phe Lys (K) arg: gin: asn Met (M) leu; phe; ile Phe (F) leu: val: ile; ala Pro (P) Gly Ser (S) Thr Thr (T) Ser Trp (W) Tyr Tyr(Y) Trp: phe: thr: ser Val (V) lle; leu; met; phe; ala; cine III). EXTENDED RECOMBINANT POLYPEPTIDES In one aspect, the invention provides XTEN polypeptide compositions that are useful as fusion protein partner(s) to link to and/or incorporate Within a FVIII polypeptide, resulting in a CFXTEN fusion protein. XTEN are generally polypeptides With turally occurring, substantially non-repetitive sequences having a low degree of or no secondary or tertiary structure under physiologic conditions.

XTEN typically have from about 36 to about 3000 amino acids of Which the majority or the entirety are small hydrophilic amino acids. As used , “XTEN” specifically excludes Whole antibodies or dy fragments (e. g. single-chain antibodies and PC fragments). XTEN polypeptides have utility as a fusion protein partners in that they serve various roles, conferring certain desirable pharmacokinetic, physicochemical, pharmacologic, and pharmaceutical properties When linked to a FVlll protein to a create a CFXTEN fusion protein. Such CFXTEN fusion protein itions have ed properties compared to the corresponding FVIH not linked to XTEN, making them useful in the treatment of certain conditions d to FVHI encies or bleeding disorders, as more fully described below.

The ion ia for the XTEN to be fused to the FVIII proteins used to create the inventive fusion proteins compositions generally relate to attributes of physical/chemical properties and conformational structure of the XTEN that is, in turn, used to confer enhanced pharmaceutical, pharmacologic, and pharmacokinetic properties to the FVIII fusion proteins compositions. The unstructured characteristic and al/chemical properties of the XTEN result, in part, from the overall amino acid composition portionately limited to 4-6 hydrophilic amino acids, the linking of the amino acids in a quantifiable non-repetitive design, and the length of the XTEN polypeptide. In an advantageous feature common to XTEN but uncommon to polypeptides, the ties ofXTEN disclosed herein are not tied to absolute primary amino acid ces, as evidenced by the diversity of the exemplary sequences of Table 4 that, within varying ranges of length, s similar properties, many of which are documented in the Examples. The XTEN of the present invention may exhibit one or more, or all of the following advantageous properties: unstructured conformation, conformational flexibility, enhanced aqueous solubility, high degree of protease resistance, low immunogenicity, low binding to mammalian ors, a defined degree of , and increased hydrodynamic (or Stokes) radii; properties that can make them particularly useful as fusion protein partners. Non-limiting examples of the enhanced properties that XTEN confer on the fusion proteins comprising FVIII fused to XTEN, compared to FVIH not linked to XTEN, include increases in the overall solubility and/or metabolic stability, reduced susceptibility to proteolysis, reduced immunogenicity, reduced rate of absorption when administered subcutaneously or intramuscularly, d binding to FVIII clearance receptors, reduced reactivity to anti-payload antibodies, enhanced interactions with substrate, and/or enhanced pharmacokinetic properties when administered to a subject. The enhanced pharmacokinetic properties of the CFXTEN compositions compared to FVIII not linked to XTEN include longer terminal half-life (e. g., two-fold, three-fold, four-fold or more), increased area under the curve (AUC) (e. g., 25%, 50%, 100% or more), lower volume of distribution, and enhanced absorption after subcutaneous or intramuscular injection (an advantage compared to commercially-available forms of FVIII that must be administered intravenously). In addition, it is believed that the CFXTEN compositions comprising cleavage sequences (described more fully, below) permit sustained release of biologically active FVIH, such that the administered CFXTEN acts as a depot. It is specifically contemplated that the inventive CFXTEN fusion proteins can exhibit one or more or any combination of the improved properties disclosed herein. As a result of these enhanced properties, it is believed that CFXTEN compositions permit less frequent dosing compared to FVIH not linked to XTEN when administered at comparable s. Such CFXTEN fusion protein itions have utility to treat certain factor VIII-related conditions, as described herein.

] A variety of methods and assays are known in the art for determining the physical/chemical ties of proteins such as the CFXTEN compositions comprising XTEN. Such properties include but are not limited to ary or ry ure, solubility, protein aggregation, stability, absolute and apparent molecular , purity and uniformity, melting properties, contamination and water t.

Methods to assay these properties include analytical centrifugation, EPR, HPLC-ion exchange, HPLC- size exclusion, HPLC-reverse phase, light scattering, capillary electrophoresis, circular dichroism, differential ng metry, fluorescence, HPLC-ion exchange, HPLC-size exclusion, IR, NMR, Raman spectroscopy, refractometry, and UV/Visible spectroscopy. Additional methods are disclosed in Arnau, er al., Prot Expr and Purif (2006) 48, 1-13.

The XTEN component(s) of the CFXTEN are designed to behave like denatured peptide sequences under physiological conditions, e the extended length of the polymer. “Denatured” describes the state of a peptide in solution that is characterized by a large conformational freedom of the e backbone. Most peptides and proteins adopt a denatured mation in the presence of high concentrations of denaturants or at elevated temperature. es in denatured conformation have, for example, characteristic circular ism (CD) spectra and are characterized by a lack of long-range ctions as determined by NMR. “Denatured conformation” and “unstructured conformation” are used synonymously herein. In some embodiments, the invention provides XTEN sequences that, under physiologic conditions, are largely devoid of secondary structure. In other cases, the XTEN sequences are substantially devoid of secondary structure under physiologic conditions such that the XTEN can adopt random coil conformation. “Largely devoid,” as used in this context, means that at least 50% of the XTEN amino acid residues of the XTEN sequence do not contribute to ary structure as measured or determined by the means described herein. “Substantially devoid,” as used in this context, means that at least about 60%, or about 70%, or about 80%, or about 90%, or about 95%, or at least about 99% of the XTEN amino acid residues of the XTEN sequence do not bute to secondary structure, as measured or determined by the methods described herein.

A variety of methods have been ished in the art to discern the presence or absence of secondary and tertiary structures in a given ptide. In particular, secondary structure can be measured spectrophotometrically, e. g., by circular dichroism spectroscopy in the “far-UV” al region (190-250 nm). Secondary structure elements, such as alpha-helix and beta-sheet, each give rise to a characteristic shape and ude of CD spectra, as does the lack of these structure elements.

Secondary structure can also be predicted for a polypeptide sequence via certain computer programs or algorithms, such as the well-known Chou-Fasman algorithm (Chou, P. Y., et al. (1974) Biochemistry, 13: 222-45) and the -Osguthorpe-Robson (“GOR”) algorithm (Gamier J, Gibrat JF, Robson B.

, GOR method for predicting protein secondary structure from amino acid ce. s Enzym01266:540-553), as described in US Patent Application Publication No. 20030228309A1. For a given sequence, the algorithms can predict Whether there exists some or no secondary structure at all, expressed as the total and/or percentage of residues of the sequence that form, for example, alpha-helices or heets or the percentage of residues of the sequence predicted to result in random coil formation (which lacks secondary structure).

In one embodiment, the XTEN ces used in the subject fusion protein compositions have an alpha-helix percentage ranging from 0% to less than about 5% as determined by the Chou-Fasman algorithm. In another embodiment, the XTEN sequences of the fusion protein compositions have a beta- sheet percentage ranging from 0% to less than about 5% as determined by the Chou-Fasman algorithm.

In some embodiments, the XTEN sequences of the fusion protein compositions have an alpha-helix percentage ranging from 0% to less than about 5% and a beta-sheet tage ranging from 0% to less than about 5% as determined by the Chou-Fasman algorithm. In some embodiments, the XTEN sequences of the fusion protein compositions have an alpha-helix tage less than about 2% and a beta-sheet percentage less than about 2%. The XTEN sequences of the fusion n compositions have a high degree of random coil percentage, as determined by the GOR algorithm. In some embodiments, an XTEN sequence have at least about 80%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, and most preferably at least about 99% random coil, as determined by the GOR algorithm. In some embodiments, the XTEN sequences of the fusion protein compositions have an alpha- heliX percentage ranging from 0% to less than about 5% and a beta-sheet tage ranging from 0% to less than about 5% as determined by the Chou-Fasman algorithm and at least about 90% random coil, as determined by the GOR algorithm. In other embodiments, the XTEN sequences of the fiJsion n compositions have an alpha-helix percentage less than about 2% and a beta-sheet percentage less than about 2% at least about 90% random coil, as determined by the GOR algorithm. 1. Non-repetitive Sequences It is contemplated that the XTEN sequences of the CFXTEN embodiments are substantially non-repetitive. In l, repetitive amino acid sequences have a tendency to aggregate or form higher order structures, as exemplified by natural repetitive sequences such as collagens and leucine zippers.

These repetitive amino acids may also tend to form contacts resulting in crystalline or pseudocrystaline structures. In contrast, the low tendency of non-repetitive sequences to aggregate enables the design of long-sequence XTENs with a relatively low frequency of charged amino acids that would otherwise be likely to aggregate if the sequences were repetitive. The non-repetitiveness of a subject XTEN can be ed by assessing one or more of the ing features. In one embodiment, a “substantially non- repetitive” XTEN ce has about 36, or at least 72, or at least 96, or at least 144, or at least 288, or at least 400, or at least 500, or at least 600, or at least 700, or at least 800, or at least 864, or at least 900, or at least 1000, or at least 2000, to about 3000 or more amino acid residues, or has a length ranging from about 36 to about 3000, about 100 to about 500, about 500 to about 1000, about 1000 to about 3000 amino acids and residues, in which no three contiguous amino acids in the sequence are identical amino acid types unless the amino acid is serine, in which case no more than three contiguous amino acids are serine residues. In r embodiment, as described more fully below, a “substantially non-repetitive” XTEN sequence comprises motifs of 9 to 14 amino acid es wherein the motifs consist of 4 to 6 types of amino acids ed from glycine (G), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P), and wherein the sequence of any two contiguous amino acid residues in any one motif is not repeated more than twice in the sequence motif.

The degree of repetitiveness of a ptide or a gene can be measured by computer ms or algorithms or by other means known in the art. According to the current invention, algorithms to be used in calculating the degree of repetitiveness of a particular polypeptide, such as an XTEN, are WO 22617 disclosed herein, and examples of sequences analyzed by algorithms are provided (see Examples, below).

In one , the repetitiveness of a polypeptide of a predetermined length can be calculated (hereinafter quence score”) according to the a given by Equation 1: Subsequence score Em}. C $33.31: g‘ , . I wherein: m = (amino acid length of polypeptide) — (amino acid length of uence) + 1; and Count,- = cumulative number of occurrences of each unique subsequence within sequence,- An algorithm termed “SegScore” was developed to apply the foregoing equation to quantitate repetitiveness of polypeptides, such as an XTEN, providing the subsequence score wherein sequences of a predetermined amino acid length “n” are analyzed for repetitiveness by determining the number of times (a “count”) a unique subsequence of length “s” appears in the set length, d by the absolute number of subsequences within the predetermined length of the sequence. depicts a logic flowchart of the SegScore algorithm, while portrays a schematic of how a subsequence score is derived for a fictitious XTEN with 11 amino acids and a subsequence length of 3 amino acid residues.

For example, a ermined polypeptide length of 200 amino acid residues has 192 overlapping 9- amino acid subsequences and 198 3-mer uences, but the subsequence score of any given polypeptide will depend on the absolute number of unique subsequences and how frequently each unique subsequence (meaning a different amino acid sequence) appears in the predetermined length of the sequence.

In the t of the t invention, “subsequence score” means the sum of ences of each unique 3-mer frame across 200 consecutive amino acids of the cumulative XTEN polypeptide divided by the absolute number of unique 3-mer subsequences within the 200 amino acid sequence.

Examples of such subsequence scores derived from 200 consecutive amino acids of tive and nonrepetitive polypeptides are presented in e 45. In one embodiment, the invention es a CFXTEN comprising one XTEN in which the XTEN has a subsequence score less than 12, more preferably less than 10, more preferably less than 9, more preferably less than 8, more preferably less than 7, more preferably less than 6, and most preferably less than 5. In another embodiment, the invention provides CFXTEN comprising at least two to about six XTEN in which 200 amino acids of the XTEN have a subsequence score of less than 10, more preferably less than 9, more preferably less than 8, more preferably less than 7, more preferably less than 6, and most preferably less than 5. In the embodiments of the CFXTEN fusion protein compositions described herein, an XTEN component of a fusion protein with a subsequence score of 10 or less (i.e., 9, 8, 7, etc.) is also substantially non- repetitive.

It is believed that the non-repetitive characteristic ofXTEN of the present invention er with the particular types of amino acids that predominate in the XTEN, rather than the absolute primary sequence, confers many of the enhanced physicochemical and biological properties of the CFXTEN fusion proteins. These enhanced properties include a higher degree of expression of the fusion protein in the host cell, greater genetic stability of the gene encoding XTEN, a r degree of solubility, less cy to aggregate, and enhanced pharmacokinetics of the resulting CFXTEN compared to fusion proteins comprising polypeptides having repetitive sequences. These enhanced properties permit more efficient manufacturing, lower cost of goods, and facilitate the formulation of XTEN-comprising pharmaceutical preparations containing extremely high protein concentrations, in some cases ing 100 mg/ml. Furthermore, the XTEN polypeptide sequences of the embodiments are designed to have a low degree of internal repetitiveness in order to reduce or substantially eliminate immunogenicity when administered to a mammal. Polypeptide sequences composed of short, repeated motifs largely limited to only three amino acids, such as glycine, serine and glutamate, may result in relatively high antibody titers when administered to a mammal despite the absence of predicted T-cell epitopes in these sequences.

This may be caused by the repetitive nature of polypeptides, as it has been shown that immunogens with repeated epitopes, including protein aggregates, cross-linked immunogens, and repetitive carbohydrates are highly genic and can, for example, result in the cross-linking of B-cell receptors g B- cell activation. sson, J., et al. (2007) e, 25 82 ; Yankai, Z., et al. (2006) Biochem s Res Commun, 345 :1365-71 ; Hsu, C. T., et al. (2000) Cancer Res, 1-5); Bachmann MF, et al. Eur J Immunol. (1995) 25(12):3445-3451). 2. Exemplary Sequence Motifs The t invention encompasses XTEN used as fusion partners that comprise multiple units of shorter sequences, or motifs, in which the amino acid sequences of the motifs are petitive. The non-repetitive property is met despite the use of a “building block” approach using a library of sequence motifs that are multimerized to create the XTEN sequences. Thus, while an XTEN sequence may consist of multiple units of as few as four ent types of sequence motifs, e the motifs themselves generally consist of non-repetitive amino acid sequences, the overall XTEN sequence is designed to render the sequence substantially non-repetitive.

In one embodiment, an XTEN has a substantially non-repetitive sequence of greater than about 36 to about 3000, or about 100 to about 2000, or about 144 to about 1000 amino acid residues, or even longer wherein at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 97%, or about 100% of the XTEN sequence consists of erlapping ce motifs, and wherein each of the motifs has about 9 to 36 amino acid residues. In other ments, at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 97%, or about 100% of the XTEN sequence consists of non-overlapping sequence motifs wherein each of the motifs has 9 to 14 amino acid residues. In still other embodiments, at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 97%, or about 100% of the XTEN sequence consists of non-overlapping sequence motifs wherein each of the motifs has 12 amino acid residues. In these embodiments, it is preferred that the sequence motifs are composed of substantially (e. g., 90% or more) or exclusively small hydrophilic amino acids, such that the overall sequence has an unstructured, e characteristic. Examples of amino acids that are included in XTEN are, e. g., arginine, lysine, threonine, alanine, asparagine, glutamine, aspartate, glutamate, serine, and glycine. As a result of testing variables such as codon optimization, assembly polynucleotides encoding sequence motifs, expression of n, charge distribution and solubility of expressed protein, and secondary and ry structure, it was discovered that XTEN compositions with the ed characteristics disclosed herein mainly or exclusively include glycine (G), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P) residues wherein the sequences are designed to be substantially non-repetitive. In one embodiment, XTEN sequences have predominately four to six types of amino acids selected from glycine (G), e (A), serine (S), threonine (T), glutamate (E) or proline (P) that are arranged in a substantially non-repetitive sequence that is greater than about 36 to about 3000, or about 100 to about 2000, or about 144 to about 1000 amino acid residues in length. In some embodiment, an XTEN sequence is made of 4, 5, or 6 types of amino acids selected from the group consisting of glycine (G), alanine (A), serine (S), threonine (T), glutamate (E) or proline (P). In some embodiments, XTEN have sequences of greater than about 36 to about 1000, or about 100 to about 2000, or about 400 to about 3000 amino acid residues n at least about 80% of the sequence ts of non-overlapping sequence motifs wherein each of the motifs has 9 to 36 amino acid es and wherein at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or 100% of each of the motifs consists of 4 to 6 types of amino acids selected from glycine (G), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P), and wherein the content of any one amino acid type in the full-length XTEN does not exceed 30%. In other embodiments, at least about 90% of the XTEN sequence consists of non-overlapping sequence motifs wherein each of the motifs has 9 to 36 amino acid residues wherein the motifs consist of 4 to 6 types of amino acids selected from glycine (G), e (A), serine (S), threonine (T), glutamate (E) and proline (P), and wherein the content of any one amino acid type in the full-length XTEN does not exceed 40%, or about 30%, or 25%, or about 17%. In other embodiments, at least about 90% of the XTEN sequence consists of non-overlapping sequence motifs wherein each of the motifs has 12 amino acid residues consisting of 4 to 6 types of amino acids selected from glycine (G), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P), and wherein the content of any one amino acid type in the ength XTEN does not exceed 40%, or 30%, or about 25%. In yet other embodiments, at least about 90%, or about 91%, or about 92%, or about 93%, or about 94%, or about 95%, or about 96%, or about 97%, or about 98%, or about 99%, to about 100% of the XTEN sequence consists of non-overlapping ce motifs wherein each of the motifs has 12 amino acid residues consisting of glycine (G), alanine (A), serine (S), threonine (T), ate (E) and e (P).

In still other embodiments, XTENs comprise substantially non-repetitive sequences of greater than about 36 to about 3000 amino acid residues wherein at least about 80%, or at least about 90%, or about 91%, or about 92%, or about 93%, or about 94%, or about 95%, or about 96%, or about 97%, or about 98%, or about 99% of the sequence consists of erlapping ce motifs of 9 to 14 amino acid residues wherein the motifs t of 4 to 6 types of amino acids selected from glycine (G), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P), and wherein the sequence of any two contiguous amino acid residues in any one motif is not repeated more than twice in the sequence motif.

In other embodiments, at least about 90%, or about 91%, or about 92%, or about 93%, or about 94%, or about 95%, or about 96%, or about 97%, or about 98%, or about 99% of an XTEN sequence consists of non-overlapping sequence motifs of 12 amino acid residues n the motifs consist of four to six types of amino acids selected from glycine (G), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P), and wherein the sequence of any two contiguous amino acid residues in any one sequence motif is not repeated more than twice in the sequence motif. In other embodiments, at least about 90%, or about 91%, or about 92%, or about 93%, or about 94%, or about 95%, or about 96%, or about 97%, or about 98%, or about 99% of an XTEN sequence ts of non-overlapping sequence motifs of 12 amino acid es wherein the motifs consist of glycine (G), alanine (A), serine (S), ine (T), glutamate (E) and e (P), and wherein the sequence of any two contiguous amino acid residues in any one sequence motif is not repeated more than twice in the ce motif In yet other embodiments, XTENs consist of 12 amino acid ce motifs wherein the amino acids are selected from glycine (G), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P), and wherein the sequence of any two contiguous amino acid residues in any one sequence motif is not repeated more than twice in the sequence motif, and wherein the content of any one amino acid type in the ength XTEN does not exceed 30%. The foregoing ments are examples of substantially non-repetitive XTEN sequences. onal examples are detailed below.

] In some embodiments, the invention provides CFXTEN compositions comprising one, or two, or three, or four, five, six or more non-repetitive XTEN sequence(s) of about 36 to about 1000 amino acid es, or cumulatively about 100 to about 3000 amino acid residues wherein at least about 80%, or at least about 90%, or about 91%, or about 92%, or about 93%, or about 94%, or about 95%, or about 96%, or about 97%, or about 98%, or about 99% to about 100% of the sequence consists of multiple units of four or more non-overlapping sequence motifs selected from the amino acid sequences of Table 3, wherein the overall sequence remains substantially non-repetitive. In some embodiments, the XTEN comprises non-overlapping sequence motifs in which about 80%, or at least about 85%, or at least about 90%, or about 91%, or about 92%, or about 93%, or about 94%, or about 95%, or about 96%, or about 97%, or about 98%, or about 99% or about 100% of the sequence consists of multiple units of non- overlapping sequences selected from a single motif family selected from Table 3, resulting in a family sequence. As used herein, y” means that the XTEN has motifs selected only from a single motif category from Table 3; i.e., AD, AE, AF, AG, AM, AQ, BC, or BD XTEN, and that any other amino acids in the XTEN not from a family motif are selected to achieve a needed property, such as to permit incorporation of a restriction site by the encoding nucleotides, incorporation of a cleavage sequence, or to achieve a better linkage to a FVIII coagulation factor component of the CFXTEN. In some embodiments ofXTEN families, an XTEN sequence comprises multiple units of non-overlapping sequence motifs of the AD motif family, or of the AE motif family, or of the AF motif family, or of the AG motif family, or of the AM motif family, or of the AQ motif family, or of the BC family, or of the BD family, with the ing XTEN exhibiting the range of homology described above. In other embodiments, the XTEN comprises multiple units of motif sequences from two or more of the motif families of Table 3. These sequences can be selected to achieve desired physical/chemical characteristics, including such properties as net charge, hydrophilicity, lack of secondary structure, or lack of repetitiveness that are conferred by the amino acid composition of the motifs, described more fully below. In the embodiments hereinabove described in this paragraph, the motifs incorporated into the XTEN can be selected and assembled using the s described herein to e an XTEN of about 36 to about 3000 amino acid residues.

Table 3: XTEN Seguence Motifs of 12 Amino Acids and Motif Families AD GESPGGSSGSES 19 AD GSEGSSGPGESS 20 AD GSSESGSSEGGP 21 AD GSGGEPSESGSS 22 AE, AM GSPAGSPTSTEE 23 AE, AM, AQ GSEPATSGSETP 24 AE, AM, AQ GTSESATPESGP 25 AE, AM, AQ GTSTEPSEGSAP 26 AF, AM GSTSESPSGTAP 27 AF, AM GTSTPESGSASP 28 AF, AM ESSTAP 29 AF, AM GSTSSTAESPGP 30 AG, AM GTPGSGTASSSP 31 AG, AM GSSTPSGATGSP 32 AG, AM GSSPSASTGTGP 33 AG, AM GASPGTSSTGSP 34 AQ GEPAGSPTSTSE 35 AQ GTGEPSSTPASE 36 AQ GSGPSTESAPTE 37 AQ GSETPSGPSETA 38 AQ GPSETSTSEPGA 39 AQ GSPSEPTEGTSA 40 BC GSGASEPTSTEP 41 BC GSEPATSGTEPS 42 BC GTSEPSTSEPGA 43 BC SEPGSA 44 BD GSTAGSETSTEA 45 BD GSETATSGSETA 46 BD GTSESATSESGA 47 BD GTSTEASEGSAS 48 permutations, results in a “family sequence” ] In some embodiments ofXTEN families, an XTEN sequence comprises multiple units of non- overlapping sequence motifs of the AD motif family, the AE motif family, or the AF motif family, or the AG motif family, or the AM motif family, or the AQ motif , or the BC , or the BD family, with the resulting XTEN ting the range of homology bed above. In other embodiments, the XTEN comprises multiple units of motif sequences from two or more of the motif families of Table 3, selected to achieve desired physicochemical characteristics, including such properties as net charge, lack of secondary structure, or lack of repetitiveness that may be conferred by the amino acid composition of the motifs, described more fully below. In the embodiments hereinabove described in this paragraph, the motifs or portions of the motifs incorporated into the XTEN can be selected and assembled using the methods described herein to achieve an XTEN of about 36, about 42, about 72, about 144, about 288, about 576, about 864, about 1000, about 2000 to about 3000 amino acid residues, or any intermediate length. Non-limiting examples ofXTEN family sequences useful for incorporation into the subject CFXTEN are presented in Table 4. It is intended that a specified ce mentioned relative to Table 4 has that sequence set forth in Table 4, While a generalized reference to an AEl44 sequence, for example, is intended to encompass any AE sequence having 144 amino acid residues; e. g., 1A, AEl44_2A, etc., or a generalized reference to an AG144 sequence, for example, is intended to encompass any AG sequence having 144 amino acid residues, e. g., AG144_1, AG144_2, AG144_A, AG144_B, AG144_C, etc.

Table 4: XTEN Polypeptides XTEN Amino Acid Sequence IDQ Name AE42 GAPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPASS 49 AE42_1 TEPSEGSAPGSPAGSPTSTEEGTSESATPESGPGSEPATSGS 50 AE42_2 PAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGSEPATSG 51 AE42_3 SEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGSPAGSP 52 AG42_1 GAPSPSASTGTGPGTPGSGTASSSPGSSTPSGATGSPGPSGP 53 AG42_2 GPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGASP 54 AG42_3 SPSASTGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGA 55 AG42_4 SASTGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATG 56 AE48 SPTSTEEGTPGSGTASSSPGSSTPSGATGSPGASPGTSSTGS 57 AM48 MAEPAGSPTSTEEGASPGTSSTGSPGSSTPSGATGSPGSSTPSGATGS 58 AE 1 44 SGSETPGTSESATPESGPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGS 59 SETPGSEPATSGSETPGSEPATSGSETPGTSTEPSEGSAPGTSESATPESGPGSEP ATSGSETPGTSTEPSEGSAP AEl44_ SPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTS 60 1A TEPSEGSAPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSES ATPESGPGTSTEPSEGSAPG AEl44_ TSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTS 61 2A TEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSTEPSEGSAPGTSTEPSEGSAPGTSES PGTSESATPESGPG AEl44_ TSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTS 62 2B TEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSTEPSEGSAPGTSTEPSEGSAPGTSES PGTSESATPESGPG AEl44_ SPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTS 63 3A TEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGSPAG EGTSTEPSEGSAPG AE 1 44_ SPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTS 64 3B TEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGSPAG SPTSTEEGTSTEPSEGSAPG AEl44_ TSESATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTS 65 4A TEPSEGSAPGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGSPAGSPTSTEEGTSES ATPESGPGTSTEPSEGSAPG AEl44_ TSESATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTS 66 4B TEPSEGSAPGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGSPAGSPTSTEEGTSES ATPESGPGTSTEPSEGSAPG WO 22617 XTEN Amino Acid Sequence ID Name AE144_ TSESATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTS 67 5A TEPSEGSAPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSPAG SPTSTEEGSPAGSPTSTEEG AE144_ TSTEPSEGSAPGTSESATPESGPGTSESATPESGPGTSESATPESGPGSEPATSGSETPGSE 68 6B PATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGSEPATSGSETPGTSES ATPESGPGTSTEPSEGSAPG AF144 GTSTPESGSASPGTSPSGESSTAPGTSPSGESSTAPGSTSSTAESPGPGSTSESPSGTAPGS 69 TSSTAESPGPGTSPSGESSTAPGTSTPESGSASPGSTSSTAESPGPGTSPSGESSTAPGTSPS GESSTAPGTSPSGESSTAP AG144_ SGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSPSA 70 1 STGTGPGSSPSASTGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSAST GTGPGSSPSASTGTGPGASP AG144_ PGSSPSASTGTGPGSSPSASTGTGPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGP 71 2 GASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGASPGTSSTGSPG ASPGTSSTGSPGTPGSGTASSS AG144_ GASPGTSSTGSPGSSPSASTGTGPGSSPSASTGTGPGTPGSGTASSSPGSSTPSGATGSPG 72 A SSPSASTGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGA SPGTSSTGSPGASPGTSSTGSP AG144_ GTPGSGTASSSPGSSTPSGATGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPG 73 B SSPSASTGTGPGSSPSASTGTGPGSSTPSGATGSPGSSTPSGATGSPGASPGTSSTGSPGA SPGTSSTGSPGASPGTSSTGSP AG144_ TASSSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGSSPSASTGTGPG 74 C TPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPGSS TPSGATGSPGASPGTSSTGSP AG144_ GSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPG 75 F TGTGPGASPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGSSTPSGATGSPGSS TPSGATGSPGASPGTSSTGSP AG144_ GTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPG 76 3 ASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGA SPGTSSTGSPGASPGTSSTGSP AG144_ GTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPG 77 4 ASPGTSSTGSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTGSPGSSPSASTGTGPGTP GSGTASSSPGSSTPSGATGSP AE288_ GTSESATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGT 78 1 STEPSEGSAPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSPA GSPTSTEEGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGTSESA TPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSE GSAPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAP AE288_ GSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGT 79 STEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGSPA EEGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSEPAT SGSETPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSPAGSPTSTEEGSPAGSPT PAGSPTSTEEGTSESATPESGPGTSTEPSEGSAP AG288_ PGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSP 80 GSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPG SSPSASTGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSS PSASTGTGPGASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPGSSPSASTGTGPGASP GTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGSSTPSGATGS AG288_ GSSPSASTGTGPGSSPSASTGTGPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPG 81 ASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGASPGTSSTGSPGA SPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGASPGTSSTGSPGTPGSGTASSSPGSST PSGATGSPGSSPSASTGTGPGSSPSASTGTGPGSSTPSGATGSPGSSTPSGATGSPGASPG TSSTGSPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSP AF504 GASPGTSSTGSPGSSPSASTGTGPGSSPSASTGTGPGTPGSGTASSSPGSSTPSGATGSPG 82 SXPSASTGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGA SPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGASPGTSSTGSPGTPG SGTASSSPGSSTPSGATGSPGSXPSASTGTGPGSSPSASTGTGPGSSTPSGATGSPGSSTPS GATGSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGASPGTS STGSPGASPGTSSTGSPGASPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGASPGTSST XTEN Amino Acid Sequence ID Name PGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPGSSTPSGATGSPGASPGTSSTG SPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGP GASPGTSSTGSP AF54O GSTSSTAESPGPGSTSSTAESPGPGSTSESPSGTAPGSTSSTAESPGPGSTSSTAESPGPGT 83 SASPGSTSESPSGTAPGTSPSGESSTAPGSTSESPSGTAPGSTSESPSGTAPGTSPS GESSTAPGSTSESPSGTAPGSTSESPSGTAPGTSPSGESSTAPGSTSESPSGTAPGSTSESPS GTAPGSTSESPSGTAPGTSTPESGSASPGSTSESPSGTAPGTSTPESGSASPGSTSSTAESP GPGSTSSTAESPGPGTSTPESGSASPGTSTPESGSASPGSTSESPSGTAPGTSTPESGSASP GTSTPESGSASPGSTSESPSGTAPGSTSESPSGTAPGSTSESPSGTAPGSTSSTAESPGPGT STPESGSASPGTSTPESGSASPGSTSESPSGTAPGSTSESPSGTAPGTSTPESGSASPGSTSE PGSTSESPSGTAPGTSTPESGSASPGTSPSGESSTAPGSTSSTAESPGPGTSPSGE SSTAPGSTSSTAESPGPGTSTPESGSASPGSTSESPSGTAP AD576 GSSESGSSEGGPGSGGEPSESGSSGSSESGSSEGGPGSSESGSSEGGPGSSESGSSEGGPG 84 SSESGSSEGGPGSSESGSSEGGPGESPGGSSGSESGSEGSSGPGESSGSSESGSSEGGPGSS GGPGSSESGSSEGGPGSGGEPSESGSSGESPGGSSGSESGESPGGSSGSESGSGG EPSESGSSGSSESGSSEGGPGSGGEPSESGSSGSGGEPSESGSSGSEGSSGPGESSGESPGG SSGSESGSGGEPSESGSSGSGGEPSESGSSGSGGEPSESGSSGSSESGSSEGGPGESPGGSS GSESGESPGGSSGSESGESPGGSSGSESGESPGGSSGSESGESPGGSSGSESGSSESGSSEG GPGSGGEPSESGSSGSEGSSGPGESSGSSESGSSEGGPGSGGEPSESGSSGSSESGSSEGG PGSGGEPSESGSSGESPGGSSGSESGESPGGSSGSESGSSESGSSEGGPGSGGEPSESGSS SSEGGPGSGGEPSESGSSGSGGEPSESGSSGESPGGSSGSESGSEGSSGPGESSG SSESGSSEGGPGSEGSSGPGESS AE576 GSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGT 85 STEPSEGSAPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSE SATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEP SEGSAPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSTEPSE GSAPGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGSPAGSPTSTEEGTSESATPES GPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAP GTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGT SESATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTST EPSEGSAPGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGSPAGSPTSTEEGTSESA TPESGPGTSTEPSEGSAP AF576 GSTSSTAESPGPGSTSSTAESPGPGSTSESPSGTAPGSTSSTAESPGPGSTSSTAESPGPGT 86 STPESGSASPGSTSESPSGTAPGTSPSGESSTAPGSTSESPSGTAPGSTSESPSGTAPGTSPS GESSTAPGSTSESPSGTAPGSTSESPSGTAPGTSPSGESSTAPGSTSESPSGTAPGSTSESPS GTAPGSTSESPSGTAPGTSTPESGSASPGSTSESPSGTAPGTSTPESGSASPGSTSSTAESP GPGSTSSTAESPGPGTSTPESGSASPGTSTPESGSASPGSTSESPSGTAPGTSTPESGSASP GTSTPESGSASPGSTSESPSGTAPGSTSESPSGTAPGSTSESPSGTAPGSTSSTAESPGPGT STPESGSASPGTSTPESGSASPGSTSESPSGTAPGSTSESPSGTAPGTSTPESGSASPGSTSE SPSGTAPGSTSESPSGTAPGTSTPESGSASPGTSPSGESSTAPGSTSSTAESPGPGTSPSGE STSSTAESPGPGTSTPESGSASPGSTSESPSGTAPGSTSSTAESPGPGTSTPESGS ASPGTSTPESGSASP AGS76 PGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGSSTPSGATGSP 87 GSSTPSGATGSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPG ASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGA SPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPGSSTPSGATGSPGASP GTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSTPSGATGSPGSSPSA STGTGPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGASPGTSSTGSPGASPGTS STGSPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTA SSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGT GPGSSPSASTGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTG PGSSPSASTGTGPGASPGTSSTGS AE624 MAEPAGSPTSTEEGTPGSGTASSSPGSSTPSGATGSPGASPGTSSTGSPGSPAGSPTSTEE 88 GTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGT SESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSESATPESGPGTST EPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGTSESA TPESGPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSTEPSEGSAPGTSTEPSE GSAPGTSESATPESGPGTSESATPESGPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSE TPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAP XTEN Amino Acid Sequence ID Name GTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGS EPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSE SATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGTSTEP SEGSAP AD836 GSSESGSSEGGPGSSESGSSEGGPGESPGGSSGSESGSGGEPSESGSSGESPGGSSGSESG 89 ESPGGSSGSESGSSESGSSEGGPGSSESGSSEGGPGSSESGSSEGGPGESPGGSSGSESGES PGGSSGSESGESPGGSSGSESGSSESGSSEGGPGSSESGSSEGGPGSSESGSSEGGPGSSES GSSEGGPGSSESGSSEGGPGSSESGSSEGGPGSGGEPSESGSSGESPGGSSGSESGESPGG SSGSESGSGGEPSESGSSGSEGSSGPGESSGSSESGSSEGGPGSGGEPSESGSSGSEGSSGP GESSGSSESGSSEGGPGSGGEPSESGSSGESPGGSSGSESGSGGEPSESGSSGSGGEPSES GSSGSSESGSSEGGPGSGGEPSESGSSGSGGEPSESGSSGSEGSSGPGESSGESPGGSSGS ESGSEGSSGPGESSGSEGSSGPGESSGSGGEPSESGSSGSSESGSSEGGPGSSESGSSEGGP GESPGGSSGSESGSGGEPSESGSSGSEGSSGPGESSGESPGGSSGSESGSEGSSGPGSSES GSSEGGPGSGGEPSESGSSGSEGSSGPGESSGSEGSSGPGESSGSEGSSGPGESSGSGGEP SESGSSGSGGEPSESGSSGESPGGSSGSESGESPGGSSGSESGSGGEPSESGSSGSEGSSGP GESSGESPGGSSGSESGSSESGSSEGGPGSSESGSSEGGPGSSESGSSEGGPGSGGEPSES GSSGSSESGSSEGGPGESPGGSSGSESGSGGEPSESGSSGSSESGSSEGGPGESPGGSSGS EPSESGSSGESPGGSSGSESGSGGEPSESGSS AE864 GSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGT 90 STEPSEGSAPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSE SATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEP SEGSAPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSTEPSE GSAPGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGSPAGSPTSTEEGTSESATPES GPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAP GTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGT SESATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTST EPSEGSAPGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGSPAGSPTSTEEGTSESA GTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSG SETPGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSE TPGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGP GTSESATPESGPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGT STEPSEGSAPGTSTEPSEGSAPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAP AF864 GSTSESPSGTAPGTSPSGESSTAPGSTSESPSGTAPGSTSESPSGTAPGTSTPESGSASPGT 91 STPESGSASPGSTSESPSGTAPGSTSESPSGTAPGTSPSGESSTAPGSTSESPSGTAPGTSPS GESSTAPGTSPSGESSTAPGSTSSTAESPGPGTSPSGESSTAPGTSPSGESSTAPGSTSSTA ESPGPGTSTPESGSASPGTSTPESGSASPGSTSESPSGTAPGSTSESPSGTAPGTSTPESGS ASPGSTSSTAESPGPGTSTPESGSASPGSTSESPSGTAPGTSPSGESSTAPGSTSSTAESPG PGTSPSGESSTAPGTSTPESGSASPGSTSSTAESPGPGSTSSTAESPGPGSTSSTAESPGPG STSSTAESPGPGTSPSGESSTAPGSTSESPSGTAPGSTSESPSGTAPGTSTPESGPXXXGAS TXXXXSESPSGTAPGSTSESPSGTAPGSTSESPSGTAPGSTSESPSGTAPGSTSES PSGTAPGSTSESPSGTAPGTSTPESGSASPGTSPSGESSTAPGTSPSGESSTAPGSTSSTAE SPGPGTSPSGESSTAPGTSTPESGSASPGSTSESPSGTAPGSTSESPSGTAPGTSPSGESST APGSTSESPSGTAPGTSTPESGSASPGTSTPESGSASPGSTSESPSGTAPGTSTPESGSASP GSTSSTAESPGPGSTSESPSGTAPGSTSESPSGTAPGTSPSGESSTAPGSTSSTAESPGPGT SPSGESSTAPGTSTPESGSASPGTSPSGESSTAPGTSPSGESSTAPGTSPSGESSTAPGSTSS PGSTSSTAESPGPGTSPSGESSTAPGSSPSASTGTGPGSSTPSGATGSPGSSTPSG ATGSP AG864_ GASPGTSSTGSPGSSPSASTGTGPGSSPSASTGTGPGTPGSGTASSSPGSSTPSGATGSPG 92 TGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGA SPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGASPGTSSTGSPGTPG SGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGSSTPSGATGSPGSSTPS GASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGASPGTS STGSPGASPGTSSTGSPGASPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGASPGTSST GSPGASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPGSSTPSGATGSPGASPGTSSTG SPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGP GASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPG ASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSS TPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGSSPS ASTGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSA XTEN Amino Acid Sequence ID Name STGTGPGASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPGSSPSASTGTGPGASPGTS STGSPGSSPSASTGTGPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGASPGTSST AM875 SEGSAPGSEPATSGSETPGSPAGSPTSTEEGSTSSTAESPGPGTSTPESGSASPGS 93 TSESPSGTAPGSTSESPSGTAPGTSTPESGSASPGTSTPESGSASPGSEPATSGSETPGTSE SATPESGPGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSTEPSEGSAPGTSTEP SEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTSESATP ESGPGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTSTEPSEGSAPGSEPATSGSE TPGSPAGSPTSTEEGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGTSTEPSEGSAP GTSTEPSEGSAPGSEPATSGSETPGSPAGSPTSTEEGSPAGSPTSTEEGTSTEPSEGSAPGA SASGAPSTGGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGSTSSTAESPGPGSTSE SPSGTAPGTSPSGESSTAPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSEPATS GSETPGTSESATPESGPGSEPATSGSETPGSTSSTAESPGPGSTSSTAESPGPGTSPSGESS TAPGSEPATSGSETPGSEPATSGSETPGTSTEPSEGSAPGSTSSTAESPGPGTSTPESGSAS PGSTSESPSGTAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGSSTPSGATGSPG TGTGPGASPGTSSTGSPGSEPATSGSETPGTSESATPESGPGSPAGSPTSTEEGSS TPSGATGSPGSSPSASTGTGPGASPGTSSTGSPGTSESATPESGPGTSTEPSEGSAPGTSTE PSEGSAP AE912 MAEPAGSPTSTEEGTPGSGTASSSPGSSTPSGATGSPGASPGTSSTGSPGSPAGSPTSTEE 94 GTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGT ESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSESATPESGPGTST EPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGTSESA TPESGPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSTEPSEGSAPGTSTEPSE GSAPGTSESATPESGPGTSESATPESGPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSE TPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAP SEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGS EPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSE SATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGTSTEP SEGSAPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATP ESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPES GSPTSTEEGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSESATPESGP GTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGT STEPSEGSAPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAP AM923 SPTSTEEGASPGTSSTGSPGSSTPSGATGSPGSSTPSGATGSPGTSTEPSEGSAP 95 GSEPATSGSETPGSPAGSPTSTEEGSTSSTAESPGPGTSTPESGSASPGSTSESPSGTAPGS TSESPSGTAPGTSTPESGSASPGTSTPESGSASPGSEPATSGSETPGTSESATPESGPGSPA GSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGS PTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGTSTEPSE GSAPGTSTEPSEGSAPGTSESATPESGPGTSTEPSEGSAPGSEPATSGSETPGSPAGSPTST EEGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGTSTEPSEGSAPGTSTEPSEGSAP GSEPATSGSETPGSPAGSPTSTEEGSPAGSPTSTEEGTSTEPSEGSAPGASASGAPSTGGT SESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGSTSSTAESPGPGSTSESPSGTAPGTSP SGESSTAPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSEPATSGSETPGTSESA TPESGPGSEPATSGSETPGSTSSTAESPGPGSTSSTAESPGPGTSPSGESSTAPGSEPATSG SETPGSEPATSGSETPGTSTEPSEGSAPGSTSSTAESPGPGTSTPESGSASPGSTSESPSGT APGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGSSTPSGATGSPGSSPSASTGTGP GASPGTSSTGSPGSEPATSGSETPGTSESATPESGPGSPAGSPTSTEEGSSTPSGATGSPGS SPSASTGTGPGASPGTSSTGSPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAP AM1318 GTSTEPSEGSAPGSEPATSGSETPGSPAGSPTSTEEGSTSSTAESPGPGTSTPESGSASPGS 96 TSESPSGTAPGSTSESPSGTAPGTSTPESGSASPGTSTPESGSASPGSEPATSGSETPGTSE SATPESGPGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSTEPSEGSAPGTSTEP SEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTSESATP ESGPGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTSTEPSEGSAPGSEPATSGSE TPGSPAGSPTSTEEGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGTSTEPSEGSAP GTSTEPSEGSAPGSEPATSGSETPGSPAGSPTSTEEGSPAGSPTSTEEGTSTEPSEGSAPGP EPTGPAPSGGSEPATSGSETPGTSESATPESGPGSPAGSPTSTEEGTSESATPESGPGSPA GSPTSTEEGSPAGSPTSTEEGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGSTSST AESPGPGSTSESPSGTAPGTSPSGESSTAPGSTSESPSGTAPGSTSESPSGTAPGTSPSGES STAPGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGSEPATSGSETPGTSESATPES XTEN Amino Acid Sequence ID Name GPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGTSTEPSEGSAPGTSPSGESSTAP GTSPSGESSTAPGTSPSGESSTAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGS SPSASTGTGPGSSTPSGATGSPGSSTPSGATGSPGSSTPSGATGSPGSSTPSGATGSPGAS PGTSSTGSPGASASGAPSTGGTSPSGESSTAPGSTSSTAESPGPGTSPSGESSTAPGTSESA TPESGPGTSTEPSEGSAPGTSTEPSEGSAPGSSPSASTGTGPGSSTPSGATGSPGASPGTSS TGSPGTSTPESGSASPGTSPSGESSTAPGTSPSGESSTAPGTSESATPESGPGSEPATSGSE TPGTSTEPSEGSAPGSTSESPSGTAPGSTSESPSGTAPGTSTPESGSASPGSPAGSPTSTEE GTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGS STPSGATGSPGASPGTSSTGSPGSSTPSGATGSPGSTSESPSGTAPGTSPSGESSTAPGSTS STAESPGPGSSTPSGATGSPGASPGTSSTGSPGTPGSGTASSSPGSPAGSPTSTEEGSPAG SPTSTEEGTSTEPSEGSAP BC 864 GTSTEPSEPGSAGTSTEPSEPGSAGSEPATSGTEPSGSGASEPTSTEPGSEPATSGTEPSGS 97 EPATSGTEPSGSEPATSGTEPSGSGASEPTSTEPGTSTEPSEPGSAGSEPATSGTEPSGTST EPSEPGSAGSEPATSGTEPSGSEPATSGTEPSGTSTEPSEPGSAGTSTEPSEPGSAGSEPAT SGTEPSGSEPATSGTEPSGTSEPSTSEPGAGSGASEPTSTEPGTSEPSTSEPGAGSEPATSG TEPSGSEPATSGTEPSGTSTEPSEPGSAGTSTEPSEPGSAGSGASEPTSTEPGSEPATSGTE PSGSEPATSGTEPSGSEPATSGTEPSGSEPATSGTEPSGTSTEPSEPGSAGSEPATSGTEPS GSGASEPTSTEPGTSTEPSEPGSAGSEPATSGTEPSGSGASEPTSTEPGTSTEPSEPGSAGS GASEPTSTEPGSEPATSGTEPSGSGASEPTSTEPGSEPATSGTEPSGSGASEPTSTEPGTST EPSEPGSAGSEPATSGTEPSGSGASEPTSTEPGTSTEPSEPGSAGSEPATSGTEPSGTSTEP SEPGSAGSEPATSGTEPSGTSTEPSEPGSAGTSTEPSEPGSAGTSTEPSEPGSAGTSTEPSE PGSAGTSTEPSEPGSAGTSTEPSEPGSAGTSEPSTSEPGAGSGASEPTSTEPGTSTEPSEPG SAGTSTEPSEPGSAGTSTEPSEPGSAGSEPATSGTEPSGSGASEPTSTEPGSEPATSGTEPS GSEPATSGTEPSGSEPATSGTEPSGSEPATSGTEPSGTSEPSTSEPGAGSEPATSGTEPSGS GASEPTSTEPGTSTEPSEPGSAGSEPATSGTEPSGSGASEPTSTEPGTSTEPSEPGSA BD864 GSETATSGSETAGTSESATSESGAGSTAGSETSTEAGTSESATSESGAGSETATSGSETA 98 SGSETAGTSTEASEGSASGTSTEASEGSASGTSESATSESGAGSETATSGSETA GTSTEASEGSASGSTAGSETSTEAGTSESATSESGAGTSESATSESGAGSETATSGSETA GTSESATSESGAGTSTEASEGSASGSETATSGSETAGSETATSGSETAGTSTEASEGSAS ETSTEAGTSESATSESGAGTSTEASEGSASGSETATSGSETAGSTAGSETSTEA GSTAGSETSTEAGSETATSGSETAGTSESATSESGAGTSESATSESGAGSETATSGSETA GTSESATSESGAGTSESATSESGAGSETATSGSETAGSETATSGSETAGTSTEASEGSAS GSTAGSETSTEAGSETATSGSETAGTSESATSESGAGSTAGSETSTEAGSTAGSETSTEA GSTAGSETSTEAGTSTEASEGSASGSTAGSETSTEAGSTAGSETSTEAGTSTEASEGSAS GSTAGSETSTEAGSETATSGSETAGTSTEASEGSASGTSESATSESGAGSETATSGSETA GTSESATSESGAGTSESATSESGAGSETATSGSETAGTSESATSESGAGSETATSGSETA GTSTEASEGSASGTSTEASEGSASGSTAGSETSTEAGSTAGSETSTEAGSETATSGSETA GTSESATSESGAGTSESATSESGAGSETATSGSETAGSETATSGSETAGSETATSGSETA GTSTEASEGSASGTSESATSESGAGSETATSGSETAGSETATSGSETAGTSESATSESGA TSESGAGSETATSGSETA AE948 GTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGS 99 PAGSPTSTEEGTSTEPSEGSAPGSEPATSGSETPGTSESATPESGPGTSESATPESGPGSEP ATSGSETPGTSTEPSEGSAPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGSEPAT SGSETPGTSTEPSEGSAPGSEPATSGSETPGSEPATSGSETPGTSTEPSEGSAPGSEPATSG SETPGSEPATSGSETPGTSTEPSEGSAPGSEPATSGSETPGSPAGSPTSTEEGTSESATPES EPSEGSAPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGSEPATSGSETP GTSESATPESGPGSPAGSPTSTEEGTSESATPESGPGSPAGSPTSTEEGTSTEPSEGSAPGT SESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSE SATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGTSESATPESGPGTSTEP SEGSAPGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGSEPATSGSETPGSPAGSPT STEEGTSESATPESGPGTSTEPSEGSAPGSEPATSGSETPGSEPATSGSETPGSEPATSGSE TPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEE GSPAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSTEPSEGSAPGT STEPSEGSAPGSPAGSPTSTEEGSPAGSPTSTEEGSPAGSPTSTEEGTSTEPSEGSAPGTSE SATPESGPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSESA TPESGPGTSESATPESGP AE1044 SGSETPGSEPATSGSETPGTSTEPSEGSAPGTSESATPESGPGSPAGSPTSTEEGT 100 STEPSEGSAPGTSESATPESGPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGTSE SATPESGPGTSESATPESGPGSPAGSPTSTEEGTSTEPSEGSAPGSEPATSGSETPGTSTEP PCT/U82012/046326 {EITEN Amino Acid Sequence ID GSPAGSPTSTEEGSPAGSPTSTEEGSPAGSPTSTEEGTSTEPSEGSAPGTSESATP ESGPGSEPATSGSETPGTSESATPESGPGTSESATPESGPGSPAGSPTSTEEGTSTEPSEGS APGSEPATSGSETPGTSTEPSEGSAPGTSESATPESGPGSPAGSPTSTEEGTSTEPSEGSAP GTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGSPAGSPTSTEEGT ESGPGSEPATSGSETPGTSTEPSEGSAPGSEPATSGSETPGTSESATPESGPGTST EPSEGSAPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGSEPATSGSETPGSPAGS PTSTEEGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSESATP ESGPGTSTEPSEGSAPGSEPATSGSETPGSEPATSGSETPGTSESATPESGPGTSESATPES GPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGSPAGSPTSTEE GTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGT STEPSEGSAPGSEPATSGSETPGSPAGSPTSTEEGTSESATPESGPGTSESATPESGPGSEP ATSGSETPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEP SEGSAPGSEPATSGSETPGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGSPAGSPT STEEGTSESATPESGPGTSESATPESGPGTST AE1140 GSEPATSGSETPGSEPATSGSETPGTSTEPSEGSAPGSEPATSGSETPGTSESATPESGPGS 101 EPATSGSETPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSTEPSEGSAPGTSE SATPESGPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGSEPATSGSETPGSPAGS PTSTEEGTSTEPSEGSAPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGTSESATP PAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSESATPES GPGSEPATSGSETPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEE GSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGS STEEGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSPA GSPTSTEEGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGSPAGSPTSTEEGTSTEP GTSESATPESGPGTSESATPESGPGSPAGSPTSTEEGTSTEPSEGSAPGSPAGSPT STEEGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSTEPSEGSAPGSEPATSGSE TPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGTSTEPSEGSAP GTSTEPSEGSAPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGSEPATSGSETPGS PAGSPTSTEEGTSESATPESGPGSPAGSPTSTEEGTSTEPSEGSAPGSEPATSGSETPGSEP ATSGSETPGSEPATSGSETPGTSESATPESGPGTSESATPESGPGTSTEPSEGSAPGTSTEP SEGSAPGSEPATSGSETPGTSTEPSEGSAPGTSESATPESGPGSPAGSPTSTEEGSPAGSPT STEEGTSTEPSEGSAPGSPAGSPTSTEEGSPA AE1236 GSPAGSPTSTEEGTSTEPSEGSAPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGT 102 GSAPGTSTEPSEGSAPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGSEP ATSGSETPGSPAGSPTSTEEGTSESATPESGPGSPAGSPTSTEEGTSTEPSEGSAPGSPAGS PTSTEEGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGSPAGSPTSTEEGSPAGSPT STEEGTSTEPSEGSAPGSEPATSGSETPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSE TPGSEPATSGSETPGTSESATPESGPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETP GSEPATSGSETPGTSESATPESGPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGT SESATPESGPGSPAGSPTSTEEGTSTEPSEGSAPGSEPATSGSETPGSPAGSPTSTEEGTST EPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGSPAGSPTSTEEGSPAGSPTSTEEGTSESA TPESGPGSEPATSGSETPGTSESATPESGPGTSESATPESGPGTSTEPSEGSAPGTSESATP ESGPGSPAGSPTSTEEGTSESATPESGPGTSESATPESGPGTSTEPSEGSAPGSEPATSGSE TPGTSTEPSEGSAPGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAP GSEPATSGSETPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGSPAGSPTSTEEGT SESATPESGPGSEPATSGSETPGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGTST EPSEGSAPGSEPATSGSETPGTSTEPSEGSAPGSPAGSPTSTEEGSPAGSPTSTEEGTSESA TPESGPGSEPATSGSETPGSPAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGSEPATSG SETPGTSTEPSEGSAPGTSTEPSEGSAPGSEP AE1332 GSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGSEPATSGSETPGT 103 STEPSEGSAPGTSESATPESGPGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGSPA GSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSTEPSEGSAPGSEPATSGSETPGSEPAT SGSETPGSEPATSGSETPGTSESATPESGPGSPAGSPTSTEEGTSESATPESGPGSEPATSG SETPGTSESATPESGPGTSESATPESGPGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPES GPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGSEPATSGSETPGTSTEPSEGSAP GTSESATPESGPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGS EPATSGSETPGTSTEPSEGSAPGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGTST EPSEGSAPGSEPATSGSETPGSEPATSGSETPGTSTEPSEGSAPGSEPATSGSETPGSPAGS PTSTEEGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGTSESATPESGPGTSESATP ESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGSEPATSGSE XTEN Amino Acid Sequence ID Name TPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGSEPATSGSETPGTSESATPESGP GTSTEPSEGSAPGSPAGSPTSTEEGTSESATPESGPGTSESATPESGPGTSTEPSEGSAPGS EPATSGSETPGSEPATSGSETPGTSTEPSEGSAPGTSESATPESGPGSPAGSPTSTEEGTST APGTSTEPSEGSAPGSPAGSPTSTEEGSPAGSPTSTEEGTSTEPSEGSAPGSEPAT SGSETPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGTSESATP ESGPGTSESATPESGPGTSTEPSEGSAPGTST AE1428 GSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGSEPATSGSETPGTSESATPESGPGT 104 STEPSEGSAPGTSESATPESGPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGSPA GSPTSTEEGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSEPAT SGSETPGTSTEPSEGSAPGTSTEPSEGSAPGSEPATSGSETPGTSTEPSEGSAPGTSTEPSE GSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGTSTEPSEGS APGTSTEPSEGSAPGSPAGSPTSTEEGSPAGSPTSTEEGTSTEPSEGSAPGSEPATSGSETP GSPAGSPTSTEEGTSTEPSEGSAPGSPAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGS EPATSGSETPGSEPATSGSETPGTSTEPSEGSAPGSPAGSPTSTEEGSPAGSPTSTEEGTSE SATPESGPGSEPATSGSETPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGSEPAT SGSETPGTSESATPESGPGTSESATPESGPGTSESATPESGPGTSESATPESGPGSPAGSPT STEPSEGSAPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPES GPGTSTEPSEGSAPGTSESATPESGPGSPAGSPTSTEEGTSTEPSEGSAPGSEPATSGSETP SEGSAPGSEPATSGSETPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGT SESATPESGPGTSTEPSEGSAPGSEPATSGSETPGTSESATPESGPGTSESATPESGPGTSE SATPESGPGTSTEPSEGSAPGSEPATSGSETPGSPAGSPTSTEEGTSESATPESGPGTSTEP SEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGTSTEPSE GSAPGSPAGSPTSTEEGTSESATPESGPGSPA AE1524 GTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGS 105 PAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSTEPSEGSAPGTSESATPESGPGTST EPSEGSAPGTSESATPESGPGTSESATPESGPGSPAGSPTSTEEGTSTEPSEGSAPGSEPAT SGSETPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGSPAGSPTSTEEGSPAGSPT STEEGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSESATPES GPGSPAGSPTSTEEGTSTEPSEGSAPGSEPATSGSETPGTSTEPSEGSAPGSPAGSPTSTEE GSPAGSPTSTEEGTSTEPSEGSAPGSEPATSGSETPGSPAGSPTSTEEGTSESATPESGPGS EPATSGSETPGSPAGSPTSTEEGTSESATPESGPGTSESATPESGPGTSTEPSEGSAPGSEP ATSGSETPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSTEPSEGSAPGSPAGS PTSTEEGTSTEPSEGSAPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSESATP ESGPGTSTEPSEGSAPGSPAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGSPAGSPTST EEGTSTEPSEGSAPGSEPATSGSETPGSEPATSGSETPGSEPATSGSETPGTSESATPESGP GTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGSEPATSGSETPGTSTEPSEGSAPGT SESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGSPA GSPTSTEEGTSTEPSEGSAPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESA TPESGPGSEPATSGSETPGSEPATSGSETPGTSTEPSEGSAPGTSESATPESGPGTSTEPSE GSAPGTSTEPSEGSAPGTSESATPESGPGSPA AE1620 SGSETPGTSTEPSEGSAPGSEPATSGSETPGTSTEPSEGSAPGTSESATPESGPGT 106 SESATPESGPGSEPATSGSETPGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTST EPSEGSAPGTSTEPSEGSAPGSEPATSGSETPGSPAGSPTSTEEGTSESATPESGPGTSESA TPESGPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSESATP ESGPGTSTEPSEGSAPGTSTEPSEGSAPGSEPATSGSETPGSPAGSPTSTEEGTSESATPES GPGSEPATSGSETPGSEPATSGSETPGTSESATPESGPGTSESATPESGPGSPAGSPTSTEE GTSTEPSEGSAPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGT STEPSEGSAPGSPAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGSEP ATSGSETPGTSTEPSEGSAPGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGTSTEP GSPAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSTEPSE GSAPGTSTEPSEGSAPGSEPATSGSETPGSPAGSPTSTEEGTSESATPESGPGSPAGSPTST EEGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSESATPESGP GSPAGSPTSTEEGTSTEPSEGSAPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGS EPATSGSETPGSEPATSGSETPGTSESATPESGPGTSESATPESGPGTSTEPSEGSAPGTSE SATPESGPGSEPATSGSETPGTSESATPESGPGTSESATPESGPGTSTEPSEGSAPGTSESA GSEPATSGSETPGTSTEPSEGSAPGSPAGSPTSTEEGTSESATPESGPGTSTEPSE GSAPGTSTEPSEGSAPGSPAGSPTSTEEGTST AE1716 GTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGTSTEPSEGSAPGSEPATSGSETPGS 107 PAGSPTSTEEGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGTSESATPESGPGTSE 2012/046326 {EITEN Amino Acid Sequence ID SATPESGPGTSTEPSEGSAPGSEPATSGSETPGSEPATSGSETPGTSESATPESGPGTSESA TPESGPGSEPATSGSETPGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGTSTEPSE GSAPGSEPATSGSETPGSPAGSPTSTEEGTSESATPESGPGSPAGSPTSTEEGTSTEPSEGS APGSEPATSGSETPGSPAGSPTSTEEGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEE GTSTEPSEGSAPGSEPATSGSETPGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGS STEEGTSESATPESGPGSEPATSGSETPGTSTEPSEGSAPGSPAGSPTSTEEGTST EPSEGSAPGTSESATPESGPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGSEPAT GTSESATPESGPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPT STEEGSPAGSPTSTEEGTSTEPSEGSAPGSEPATSGSETPGSEPATSGSETPGTSESATPES GPGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEE GSPAGSPTSTEEGTSESATPESGPGSPAGSPTSTEEGTSTEPSEGSAPGSEPATSGSETPGS PAGSPTSTEEGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGSPA GSPTSTEEGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGSPAGSPTSTEEGTSTEP GTSTEPSEGSAPGSEPATSGSETPGSPAGSPTSTEEGTSESATPESGPGSEPATSG SETPGSPAGSPTSTEEGTSESATPESGPGTSE AE1812 GTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGT 108 STEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSE SATPESGPGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGSPAGSPTSTEEGTSESA TPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGTSTEPSE GSAPGTSTEPSEGSAPGTSESATPESGPGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGS APGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSTEPSEGSAPGSEPATSGSETP GSEPATSGSETPGTSESATPESGPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGS PAGSPTSTEEGTSTEPSEGSAPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTST EPSEGSAPGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGSPAGSPTSTEEGTSESA TPESGPGSEPATSGSETPGTSESATPESGPGTSESATPESGPGSEPATSGSETPGTSTEPSE GSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSESATPES GPGSEPATSGSETPGTSTEPSEGSAPGSEPATSGSETPGSPAGSPTSTEEGTSESATPESGP GTSESATPESGPGTSESATPESGPGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGT SESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSESATPESGPGSEP ATSGSETPGTSESATPESGPGTSESATPESGPGTSTEPSEGSAPGSEPATSGSETPGTSESA TPESGPGSPAGSPTSTEEGTSTEPSEGSAPGSEPATSGSETPGSPAGSPTSTEEGTSESATP ESGPGSPAGSPTSTEEGTSTEPSEGSAPGSEP AE1908 SGSETPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSTEPSEGSAPGS 109 PAGSPTSTEEGTSESATPESGPGSPAGSPTSTEEGTSTEPSEGSAPGSEPATSGSETPGTST EPSEGSAPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGTSESATPESGPGTSTEP GTSESATPESGPGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGTSESATP ESGPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGS APGSEPATSGSETPGSEPATSGSETPGSEPATSGSETPGSEPATSGSETPGTSESATPESGP GTSESATPESGPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGT STEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGSEPATSGSETPGSPAGSPTSTEEGTSE SATPESGPGTSTEPSEGSAPGSEPATSGSETPGTSESATPESGPGTSESATPESGPGTSTEP SEGSAPGSEPATSGSETPGSPAGSPTSTEEGTSESATPESGPGTSESATPESGPGTSTEPSE GSAPGSEPATSGSETPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSTEPSEGS APGSEPATSGSETPGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGSEPATSGSETP GTSESATPESGPGTSESATPESGPGSPAGSPTSTEEGTSTEPSEGSAPGSPAGSPTSTEEGS PAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSTEPSEGSAPGTST EPSEGSAPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSTEP SEGSAPGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGSPAGSPTSTEEGTSESATP ESGPGSPAGSPTSTEEGTSESATPESGPGSEP AE2004 GTSTEPSEGSAPGSEPATSGSETPGTSTEPSEGSAPGTSTEPSEGSAPGSEPATSGSETPGS 110 A PAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSTEPSEGSAPGTST EPSEGSAPGSPAGSPTSTEEGTSESATPESGPGTSESATPESGPGSPAGSPTSTEEGTSTEP SEGSAPGTSESATPESGPGTSTEPSEGSAPGSEPATSGSETPGTSESATPESGPGSEPATSG SETPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGSPAGSPTSTEEGTSESATPES GPGSPAGSPTSTEEGTSTEPSEGSAPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEE GTSESATPESGPGTSTEPSEGSAPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGS PAGSPTSTEEGTSESATPESGPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSE SATPESGPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSTEP SEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGSEPATSGSETPGSPAGSPTSTEEGTSESATP PCT/U82012/046326 XTEN Amino Acid Sequence ID Name ESGPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGTSTEPSEGSAPGTSESATPES GPGSEPATSGSETPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGSPAGSPTSTEE GTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGS PAGSPTSTEEGTSTEPSEGSAPGSPAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGSEP ATSGSETPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEP SEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGSPAGSPT STEEGTSTEPSEGSAPGTSESATPESGPGTSE AG948 GSSTPSGATGSPGTPGSGTASSSPGASPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPG 111 TPGSGTASSSPGTPGSGTASSSPGSSPSASTGTGPGTPGSGTASSSPGSSPSASTGTGPGSS TPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGSSTPSGATGSPGASPGTSSTGSPGASP GTSSTGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGSSPSASTGTGPGASPG TSSTGSPGSSPSASTGTGPGASPGTSSTGSPGTPGSGTASSSPGTPGSGTASSSPGSSTPSG ATGSPGSSTPSGATGSPGSSTPSGATGSPGASPGTSSTGSPGSSPSASTGTGPGASPGTSS TGSPGASPGTSSTGSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGTPGSGTAS SSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTG PGSSPSASTGTGPGSSTPSGATGSPGASPGTSSTGSPGTPGSGTASSSPGSSPSASTGTGP GSSTPSGATGSPGASPGTSSTGSPGSSTPSGATGSPGTPGSGTASSSPGSSPSASTGTGPG SSTPSGATGSPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGTPGSGTASSSPGSS PSASTGTGPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGTPGSGTASSSPGSSTP SGATGSPGSSPSASTGTGPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGTPGSG TASSSPGSSTPSGATGSPGASPGTSSTGSPGTPGSGTASSSPGTPGSGTASSSPGSSTPSGA PGSGTASSSPGASPGTSSTGSPGSSTPSGATGSPGSSTPSGATGSPGTPGSGTAS SSPGSSTPSGATGSPGSSTPSGATGSP AG1044 GTPGSGTASSSPGTPGSGTASSSPGSSPSASTGTGPGTPGSGTASSSPGASPGTSSTGSPG 112 TPGSGTASSSPGSSPSASTGTGPGSSTPSGATGSPGASPGTSSTGSPGASPGTSSTGSPGSS PSASTGTGPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGTPGSGTASSSPGTPG SPGASPGTSSTGSPGSSTPSGATGSPGSSPSASTGTGPGTPGSGTASSSPGASPG TSSTGSPGTPGSGTASSSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGASPGTS STGSPGSSTPSGATGSPGSSTPSGATGSPGTPGSGTASSSPGSSPSASTGTGPGSSTPSGAT GSPGASPGTSSTGSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTG SPGTPGSGTASSSPGASPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGASPGTSSTGSP GASPGTSSTGSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGASPGTSSTGSPG ASSSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGTPGSGTASSSPGSS TPSGATGSPGSSTPSGATGSPGASPGTSSTGSPGSSPSASTGTGPGSSPSASTGTGPGASP GTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSPSASTGTGPGTPGSGTASSSPGSSTPS GATGSPGSSTPSGATGSPGASPGTSSTGSPGSSPSASTGTGPGASPGTSSTGSPGSSPSAS SSPSASTGTGPGASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPGASPGTSS SPGTSSTGSPGTPGSGTASSSPGTPGSGTASSSPGTPGSGTASSSPGSSTPSGAT GSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGTPGSGTASSSPGSSPSASTGT GPGASPGTSSTGSPGSSTPSGATGSPGTPGSGTASSSPGSST AG1140 GASPGTSSTGSPGSSPSASTGTGPGSSTPSGATGSPGASPGTSSTGSPGASPGTSSTGSPG 113 SSTPSGATGSPGTPGSGTASSSPGASPGTSSTGSPGTPGSGTASSSPGTPGSGTASSSPGSS TPSGATGSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSPS ASTGTGPGSSPSASTGTGPGASPGTSSTGSPGTPGSGTASSSPGASPGTSSTGSPGSSTPS GTPGSGTASSSPGSSPSASTGTGPGSSTPSGATGSPGSSPSASTGTGPGSSTPSG ATGSPGASPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGASPGTSSTGSPGSSTPSGA TGSPGASPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGTPGSGTASSSPGASPGTSST GSPGTPGSGTASSSPGTPGSGTASSSPGSSPSASTGTGPGASPGTSSTGSPGSSTPSGATG SPGASPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGSSPSASTGTGPGSSPSASTGTGP GASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPG TPGSGTASSSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGTPGSGTASSSPGSS PSASTGTGPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGASPGTSSTGSPGTPG SGTASSSPGASPGTSSTGSPGSSTPSGATGSPGSSTPSGATGSPGTPGSGTASSSPGSSTPS GATGSPGSSTPSGATGSPGASPGTSSTGSPGSSPSASTGTGPGSSTPSGATGSPGSSTPSG ATGSPGSSPSASTGTGPGSSPSASTGTGPGSSTPSGATGSPGASPGTSSTGSPGSSPSAST GTGPGTPGSGTASSSPGASPGTSSTGSPGSSPSASTGTGPGASPGTSSTGSPGSSTPSGAT GSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGSST AG1236 GSSPSASTGTGPGTPGSGTASSSPGSSPSASTGTGPGSSPSASTGTGPGTPGSGTASSSPG 114 ASPGTSSTGSPGSSTPSGATGSPGTPGSGTASSSPGASPGTSSTGSPGTPGSGTASSSPGTP PCT/U82012/046326 {EITEN Amino Acid Sequence ID SSPGSSPSASTGTGPGSSPSASTGTGPGSSTPSGATGSPGASPGTSSTGSPGSSPS ASTGTGPGTPGSGTASSSPGTPGSGTASSSPGSSTPSGATGSPGASPGTSSTGSPGSSPSA STGTGPGTPGSGTASSSPGTPGSGTASSSPGASPGTSSTGSPGSSTPSGATGSPGSSTPSG SSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGSSPSASTGTGPGSSTPSGA TGSPGASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSST GSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGASPGTSSTGSPGSSTPSGATG SGTASSSPGSSPSASTGTGPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSP GSSTPSGATGSPGASPGTSSTGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPG SSPSASTGTGPGTPGSGTASSSPGTPGSGTASSSPGASPGTSSTGSPGTPGSGTASSSPGA SPGTSSTGSPGTPGSGTASSSPGASPGTSSTGSPGSSTPSGATGSPGASPGTSSTGSPGSSP SASTGTGPGTPGSGTASSSPGTPGSGTASSSPGSSPSASTGTGPGTPGSGTASSSPGASPG TSSTGSPGSSTPSGATGSPGTPGSGTASSSPGASPGTSSTGSPGTPGSGTASSSPGTPGSG TASSSPGSSTPSGATGSPGTPGSGTASSSPGSSPSASTGTGPGSSTPSGATGSPGTPGSGT ASSSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTGSPGTPGSGTA SSSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGASP AG1332 GSSTPSGATGSPGSSPSASTGTGPGTPGSGTASSSPGSSPSASTGTGPGASPGTSSTGSPG 115 SSPSASTGTGPGTPGSGTASSSPGASPGTSSTGSPGSSTPSGATGSPGSSPSASTGTGPGSS TPSGATGSPGASPGTSSTGSPGTPGSGTASSSPGASPGTSSTGSPGSSTPSGATGSPGSSTP SGATGSPGSSPSASTGTGPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSPSA STGTGPGTPGSGTASSSPGASPGTSSTGSPGTPGSGTASSSPGASPGTSSTGSPGASPGTS STGSPGTPGSGTASSSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSTPSGAT GSPGASPGTSSTGSPGSSPSASTGTGPGSSTPSGATGSPGSSPSASTGTGPGSSTPSGATG SPGTPGSGTASSSPGSSPSASTGTGPGSSTPSGATGSPGASPGTSSTGSPGASPGTSSTGSP GSSPSASTGTGPGASPGTSSTGSPGSSTPSGATGSPGASPGTSSTGSPGTPGSGTASSSPG TPGSGTASSSPGSSPSASTGTGPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSS TPSGATGSPGTPGSGTASSSPGTPGSGTASSSPGSSPSASTGTGPGSSTPSGATGSPGSSTP PGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGSPGSSTPS GATGSPGASPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGASPGTSSTGSPGASPGTS TPGSGTASSSPGTPGSGTASSSPGSSPSASTGTGPGTPGSGTASSSPGASPGTSST TPSGATGSPGTPGSGTASSSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATG SPGTPGSGTASSSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGSSPSASTGTGP GSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGSPGTPG AG1428 GTPGSGTASSSPGSSTPSGATGSPGASPGTSSTGSPGSSTPSGATGSPGTPGSGTASSSPG 116 TPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGASPGTSSTGSPGSSPSASTGTGPGSS TPSGATGSPGASPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGASPGTSSTGSPGASP GTSSTGSPGTPGSGTASSSPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGTPGS GTASSSPGTPGSGTASSSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGSSPSAS TGTGPGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGTPGSGTA SSSPGSSPSASTGTGPGASPGTSSTGSPGSSTPSGATGSPGASPGTSSTGSPGSSPSASTGT GPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGSSPSASTGTG PGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSP GASPGTSSTGSPGSSTPSGATGSPGTPGSGTASSSPGTPGSGTASSSPGSSPSASTGTGPG SSTPSGATGSPGASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPGSSPSASTGTGPGA SPGTSSTGSPGSSTPSGATGSPGTPGSGTASSSPGASPGTSSTGSPGTPGSGTASSSPGASP GTSSTGSPGSSTPSGATGSPGSSTPSGATGSPGASPGTSSTGSPGSSPSASTGTGPGTPGS GTASSSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGASPGTSSTGSPGSSTPSG ATGSPGTPGSGTASSSPGSSPSASTGTGPGSSTPSGATGSPGSSTPSGATGSPGSSPSAST GTGPGSSTPSGATGSPGTPGSGTASSSPGSSPSASTGTGPGTPGSGTASSSPGSSTPSGAT GSPGSSPSASTGTGPGSSPSASTGTGPGTPGSGTASSSPGASP AG1524 GSSTPSGATGSPGTPGSGTASSSPGTPGSGTASSSPGASPGTSSTGSPGSSTPSGATGSPG 117 TPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSTPSGATGSPGTPGSGTASSSPGTP GSGTASSSPGSSPSASTGTGPGSSTPSGATGSPGSSPSASTGTGPGTPGSGTASSSPGASP GTSSTGSPGSSTPSGATGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGS GTASSSPGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSG ATGSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGTPGSGTA SSSPGTPGSGTASSSPGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASS SPGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPGSSPSASTGTGP GSSPSASTGTGPGTPGSGTASSSPGTPGSGTASSSPGASPGTSSTGSPGSSTPSGATGSPG TPGSGTASSSPGASPGTSSTGSPGTPGSGTASSSPGTPGSGTASSSPGSSTPSGATGSPGSS XTEN Amino Acid Sequence ID Name TPSGATGSPGTPGSGTASSSPGSSPSASTGTGPGSSTPSGATGSPGSSTPSGATGSPGSSPS ASTGTGPGTPGSGTASSSPGSSPSASTGTGPGASPGTSSTGSPGSSPSASTGTGPGTPGSG TASSSPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGTPGSGTASSSPGSSTPSGA TGSPGTPGSGTASSSPGASPGTSSTGSPGSSTPSGATGSPGSSTPSGATGSPGSSTPSGAT GSPGTPGSGTASSSPGSSPSASTGTGPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTG SPGASPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGASPGTSSTGSPGSSTPSGATGSP GASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPGTPG AG1620 GSSTPSGATGSPGSSTPSGATGSPGTPGSGTASSSPGSSPSASTGTGPGTPGSGTASSSPG 118 ASPGTSSTGSPGSSTPSGATGSPGASPGTSSTGSPGTPGSGTASSSPGASPGTSSTGSPGSS PSASTGTGPGTPGSGTASSSPGASPGTSSTGSPGSSTPSGATGSPGSSPSASTGTGPGSSTP SGATGSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPGASPGT SSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGSSPSAST GTGPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGASPGTSST GSPGTPGSGTASSSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGSSPSASTGT GPGTPGSGTASSSPGSSPSASTGTGPGSSTPSGATGSPGASPGTSSTGSPGSSTPSGATGS PGTPGSGTASSSPGSSPSASTGTGPGASPGTSSTGSPGSSTPSGATGSPGASPGTSSTGSP GASPGTSSTGSPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPG TPGSGTASSSPGSSPSASTGTGPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGSS TPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGSSTPSGATGSPGASPGTSSTGSPGSSPS PGTPGSGTASSSPGASPGTSSTGSPGSSPSASTGTGPGSSTPSGATGSPGSSPSA STGTGPGSSTPSGATGSPGSSPSASTGTGPGTPGSGTASSSPGTPGSGTASSSPGSSTPSG SSTPSGATGSPGTPGSGTASSSPGSSPSASTGTGPGSSTPSGATGSPGSSPSAST GTGPGSSPSASTGTGPGSSTPSGATGSPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTAS SSPGTPGSGTASSSPGTPGSGTASSSPGSSTPSGATGSPGSST AG1716 SSTGSPGSSPSASTGTGPGSSTPSGATGSPGSSPSASTGTGPGTPGSGTASSSPG 119 SSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGSSTPSGATGSPGTPGSGTASSSPGSS PSASTGTGPGSSTPSGATGSPGASPGTSSTGSPGSSPSASTGTGPGSSPSASTGTGPGTPG SGTASSSPGASPGTSSTGSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTGSPGSSTPS GTPGSGTASSSPGSSPSASTGTGPGSSPSASTGTGPGSSPSASTGTGPGTPGSGT ASSSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSPSASTGTGPGASPGTSST GSPGASPGTSSTGSPGTPGSGTASSSPGSSPSASTGTGPGASPGTSSTGSPGTPGSGTASS SPGSSTPSGATGSPGSSTPSGATGSPGASPGTSSTGSPGTPGSGTASSSPGSSPSASTGTGP GTPGSGTASSSPGASPGTSSTGSPGSSTPSGATGSPGASPGTSSTGSPGASPGTSSTGSPG TPGSGTASSSPGTPGSGTASSSPGSSPSASTGTGPGSSPSASTGTGPGSSPSASTGTGPGTP GSGTASSSPGASPGTSSTGSPGSSTPSGATGSPGASPGTSSTGSPGSSPSASTGTGPGASP GTSSTGSPGSSPSASTGTGPGASPGTSSTGSPGSSPSASTGTGPGSSPSASTGTGPGTPGS PGASPGTSSTGSPGTPGSGTASSSPGTPGSGTASSSPGASPGTSSTGSPGSSTPSG ATGSPGSSTPSGATGSPGSSPSASTGTGPGSSTPSGATGSPGTPGSGTASSSPGSSPSAST GTGPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSST GSPGTPGSGTASSSPGSSPSASTGTGPGSSTPSGATGSPGASPGTSSTGSPGASPGTSSTG SPGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGSPGTPG AG1812 GSSTPSGATGSPGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPG 120 SSPSASTGTGPGASPGTSSTGSPGSSTPSGATGSPGSSTPSGATGSPGASPGTSSTGSPGSS PSASTGTGPGTPGSGTASSSPGTPGSGTASSSPGASPGTSSTGSPGSSTPSGATGSPGSSTP SGATGSPGSSPSASTGTGPGTPGSGTASSSPGASPGTSSTGSPGSSTPSGATGSPGTPGSG GSSPSASTGTGPGSSTPSGATGSPGTPGSGTASSSPGSSPSASTGTGPGTPGSGT ASSSPGASPGTSSTGSPGSSTPSGATGSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGAT GSPGSSTPSGATGSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGSSTPSGATG SPGTPGSGTASSSPGSSPSASTGTGPGTPGSGTASSSPGASPGTSSTGSPGTPGSGTASSSP GASPGTSSTGSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGTPGSGTASSSPG ASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGASPGTSSTGSPGSSTPSGATGSPGSS TPSGATGSPGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGTPG SGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGASPG TSSTGSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTGSPGSSTPSGATGSPGTPGSG TASSSPGSSPSASTGTGPGASPGTSSTGSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGA TGSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGSSTPSGAT GSPGSSPSASTGTGPGSSPSASTGTGPGSSTPSGATGSPGASPGTSSTGSPGASPGTSSTG SPGTPGSGTASSSPGASPGTSSTGSPGSSTPSGATGSPGASP AG1908 GSSPSASTGTGPGSSPSASTGTGPGSSPSASTGTGPGTPGSGTASSSPGSSPSASTGTGPG 121 PCT/U82012/046326 {EITEN Amino Acid Sequence ID SSPSASTGTGPGASPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGTPGSGTASSSPGA SPGTSSTGSPGTPGSGTASSSPGTPGSGTASSSPGSSPSASTGTGPGSSTPSGATGSPGSSP SASTGTGPGASPGTSSTGSPGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGSPGTPGS GTASSSPGTPGSGTASSSPGASPGTSSTGSPGTPGSGTASSSPGTPGSGTASSSPGSSPSAS SSTPSGATGSPGASPGTSSTGSPGSSTPSGATGSPGSSPSASTGTGPGSSPSAST GTGPGSSTPSGATGSPGASPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGASPGTSST GSPGASPGTSSTGSPGTPGSGTASSSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASS SPGASPGTSSTGSPGSSTPSGATGSPGTPGSGTASSSPGSSPSASTGTGPGSSPSASTGTGP GSSTPSGATGSPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGTPGSGTASSSPG SSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGSPGSS TPSGATGSPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGTPGSGTASSSPGTPG SGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGSSTPS GATGSPGTPGSGTASSSPGSSPSASTGTGPGASPGTSSTGSPGSSTPSGATGSPGSSPSAS TGTGPGSSTPSGATGSPGASPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGSSPSAST GTGPGSSTPSGATGSPGASPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGSSTPSGAT GSPGSSTPSGATGSPGASPGTSSTGSPGSSPSASTGTGPGSSP AG2004 STGTGPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPG 122 A SSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGSSPSASTGTGPGTPGSGTASSSPGA SPGTSSTGSPGSSTPSGATGSPGTPGSGTASSSPGTPGSGTASSSPGSSTPSGATGSPGSST PSGATGSPGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGASPG TSSTGSPGTPGSGTASSSPGTPGSGTASSSPGSSPSASTGTGPGSSTPSGATGSPGASPGTS STGSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTGSPGTPGSGTA SSSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASS SPGASPGTSSTGSPGTPGSGTASSSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSP GASPGTSSTGSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGSSTPSGATGSPG SSTPSGATGSPGASPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGASPGTSSTGSPGSS PSASTGTGPGTPGSGTASSSPGSSPSASTGTGPGTPGSGTASSSPGASPGTSSTGSPGASP GTSSTGSPGTPGSGTASSSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGTPGS GTASSSPGSSTPSGATGSPGSSTPSGATGSPGASPGTSSTGSPGSSPSASTGTGPGSSTPSG ATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGSSTPSGATGSPGASPGTSS TGSPGTPGSGTASSSPGTPGSGTASSSPGSSPSASTGTGPGASPGTSSTGSPGSSTPSGAT GSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATG SPGTPGSGTASSSPGSSPSASTGTGPGSSPSASTGTGPGASP AE72B SPAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSE 123 PATSGSETPG AE72C TSESATPESGPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTS 124 TEPSEGSAPG AE108A TEEGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSA 125 ATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTS AE108B GSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGTSESATPESGPGS 126 EPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAP AE144A STEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSE 127 GPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSPAGS PTSTEEGSPAGSPTSTEEGS AE144B SEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGSP 128 AGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSPAGSPTSTEEGSPAG SPTSTEEGTSTEPSEGSAPG AE180A TSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSPAGSPTSTEEGSPAGSPTS 129 TEEGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGTSESATPESGPGSEPATSGSET PGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGSEPATS AE2 1 6A TSTEPSEGSAPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPE 130 SGPGSPAGSPTSTEEGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSESATPESG ATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPG TSTEPSEGSAPGSEPATSGSETPGTSESAT AE252A ESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSESATPES 131 GPGSEPATSGSETPGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGTSTEPSEGSAP GTSESATPESGPGTSESATPESGPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGS PAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGSEPATSGSETPGTSESATPESGPGTST EPSE WO 22617 PCT/U82012/046326 XTEN Amino Acid Sequence ID Name AEZ88A TPESGPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSG 132 SETPGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSE TPGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGP GTSESATPESGPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGT STEPSEGSAPGTSTEPSEGSAPGSEPATSGSETPGTSESA AE324A PESGPGSPAGSPTSTEEGSPAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGTSTEPSEG 133 ESATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESG PGTSTEPSEGSAPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPG SPAGSPTSTEEGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGTS ESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGTSTE PSEGSAPGSEPATS AE360A TSTEPSEGSAPGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGSPAGSPTS 134 TEEGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSESATPESG PGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSESATPESGPG SEPATSGSETPGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGTSTEPSEGSAPGTS ESATPESGPGTSESATPESGPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAG SPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGSEPATSGSETPGTSESAT AE396A PESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSPAGSPTS 135 TEEGSPAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGTSESATPESG PGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPG SPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSPAGSPTSTEEGSP AGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGTSESATPESGPGSEPA TSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPS AE432A EGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSESATPE 136 SGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSPAGSPTSTE EGSPAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPG SEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGSP TEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSPAGSPTSTEEGSPAG SPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGTSESATPESGPGSEPATS GSETPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGSEPATS AE468A TSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPE 137 SGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSA PGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPG TSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTS ESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSES ATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSESAT PESGPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEG TEPSEGSAPGSEPATSGSETPGTSESAT AE504A EGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTS 138 TEEGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSET PGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEG SPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTS ESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSES ATPESGPGSEPATSGSETPGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGTSTEPS EGSAPGTSESATPESGPGTSESATPESGPGTSESATPESGPGSEPATSGSETPGSEPATSGS ETPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGSEPATSGSETPGTSESATPESG PGTSTEPS AE540A TPESGPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSE 139 GSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGS APGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSESATPESGP GSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSPAGSPTSTEEGS PAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSEP ATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGSPAGS PTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSPAGSPTSTEEGSPAGSPT STEEGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGTSESATPESGPGSEPATSGSE TPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEP AE576A TPESGPGTSESATPESGPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATP 140 ESGPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGS APGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETP PCT/U82012/046326 XTEN Amino Acid Sequence ID Name GTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGS STEEGSPAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGTSE SATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEP SEGSAPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSPAGSPT STEEGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGTSESATPES GPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAP GSEPATSGSETPGTSESA AE612A GSETPGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGSPAGSPTS 141 TEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSA PSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEG TSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTS ESATPESGPGTSTEPSEGSAPGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGSPAG SPTSTEEGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSESAT PESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSESATPE SGPGSEPATSGSETPGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGTSTEPSEGSA PGTSESATPESGPGTSESATPESGPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPG SPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGSEPATSGSETPGTSESAT AE648A PESGPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSTEPSEGSAPGTSTEPSEG 142 SAPGTSESATPESGPGTSESATPESGPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSET PGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPG TSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGSE PATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSES ATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGTSTEPS EGSAPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPE SGPGTSTEPSEGSAPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESG PGSPAGSPTSTEEGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPG TSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGTS TEPSEGSAPGSEPATSGSETPGTSESAT AE684A EGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTSTEPSEG 143 SAPGTSESATPESGPGSEPATSGSETPGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESG PGTSESATPESGPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPG TSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTS TEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSES PGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSPAGSP TSTEEGSPAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGTSESATPE SGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSA SPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSPAGSPTSTEEG SPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGTSESATPESGPGSE PATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGSEPA AE720A PGSEPATSGSETPGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGTSTEPS 144 EGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTSTEPSEG SAPGTSESATPESGPGSEPATSGSETPGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESG PGTSESATPESGPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPG TSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTS TEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSES ATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSPAGSP TSTEEGSPAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGTSESATPE SGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSA PGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSPAGSPTSTEEG SPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGTSESATPESGPGSE PATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSTE AE756A TSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGTSTEPS 145 EGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTSTEPSEG SAPGTSESATPESGPGSEPATSGSETPGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESG PGTSESATPESGPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPG TSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTS TEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSES ATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSPAGSP XTEN Amino Acid ce ID Name TSTEEGSPAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGTSESATPE PATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSA PGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSPAGSPTSTEEG SPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGTSESATPESGPGSE PATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGSEPA TSGSETPGTSES AE792A EGSAPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSESATPE 146 SGPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSA PGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSTEPSEGSAPG TSTEPSEGSAPGTSESATPESGPGTSESATPESGPGSPAGSPTSTEEGTSESATPESGPGSE PATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTE PGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSESAT PESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEG SAPGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGSPAGSPTSTEEGTSESATPESG PGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPG TSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTS ESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSES ATPESGPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSTEPS EGSAPGTSTEPSEGSAPGSEPATSGSETPGTSESATPESGPGTSTEPS AE828A TSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPE 147 SGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSA PGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPG TSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSTEPSEGSAPGTSTEPSEGSAPGTS ESATPESGPGTSESATPESGPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSES ATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPS EGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGSEPATSGS ETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSESATPESG PGSPAGSPTSTEEGSPAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPG TSESATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTS TEPSEGSAPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSPAG SPTSTEEGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGTSESAT PESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEG SAPGSEPATSGSETPGTSESAT AG72A GPGSSPSASTGTGPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTGS 148 PGTPGSGTASS AG72B GSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPG 149 ASSSP AG72C SPSASTGTGPGASPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGSSTPSGATGSPGSST 150 PSGATGSPGA AG108A SASTGTGPGSSPSASTGTGPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGASPG 151 TSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGASP AG108B PGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSP 152 GSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGTPGSGTASSS AG144A PGSSPSASTGTGPGSSPSASTGTGPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGP 153 GASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGASPGTSSTGSPG ASPGTSSTGSPGTPGSGTASSS AG144B PSGATGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGSSPS 154 ASTGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSA STGTGPGASPGTSSTGSPGASP AG180A TSSTGSPGSSPSASTGTGPGSSPSASTGTGPGTPGSGTASSSPGSSTPSGATGSPGSSPSAS 155 TGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGASPGTSS TGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGASPGTSSTGSPGTPGS AGZ 1 6A SSPSASTGTGPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSS 156 TGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGASPGTSSTGSPGASPGTSST GSPGTPGSGTASSSPGSSTPSGATGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATG SPGSSPSASTGTGPGSSPSASTGTGPGSSTPSG AG252A TSSTGSPGSSPSASTGTGPGSSPSASTGTGPGTPGSGTASSSPGSSTPSGATGSPGSSPSAS 157 TGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGASPGTSS TGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGASPGTSSTGSPGTPGSGTAS XTEN Amino Acid Sequence ID Name SSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGSSTPSGATGSPGSSTPSGATGS PGASPG AGZ88A TSSTGSPGSSPSASTGTGPGSSPSASTGTGPGTPGSGTASSSPGSSTPSGATGSPGSSPSAS 158 TGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGASPGTSS TGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGASPGTSSTGSPGTPGSGTAS SSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGSSTPSGATGSPGSSTPSGATGS PGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGTPGS AG324A TSSTGSPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGASPGTS 159 STGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTA SSSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTG SPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSP GASPGTSSTGSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTGSPGSSPSASTGTGPG TPGSGTASSSPGSSTP AG360A PGASPGTSSTGSPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGASPGTS 160 STGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGAT GSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGT GPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTG PGASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTGSP GSSPSASTGTGPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGASPG AG396A GATGSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGSPGTPGSGT 161 ASSSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTA SSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATG SPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGTPGSGTASSSP GSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGSPG ATGSPGSSPSASTGTGPGASPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGSS TPSGATGSPGSSTPSGATGSPGASPGT AG432A GATGSPGSSTPSGATGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSG 162 ATGSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTA SSSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASS PSGATGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSP GSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGTPGSGTASSSPG ATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGSPGSS TPSGATGSPGSSPSASTGTGPGASPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGSSTP AG468A TSSTGSPGSSPSASTGTGPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGASPGTS 163 SSTPSGATGSPGSSTPSGATGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGAT GSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTG SPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSP GTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPG SSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGTP GSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGASP GTSSTGSPGSSTPSGATGSPGSSPSASTGTGPGASPG AG504A TSSTGSPGSSPSASTGTGPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGASPGTS 164 STGSPGSSTPSGATGSPGSSTPSGATGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGAT GSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTG SPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSP GTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPG SSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGTP SSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGASP GTSSTGSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTGSPGSSPSASTGTGPGTPGS GTASSSPGSSTP AG540A TSSTGSPGASPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGASPGTSSTGSPGASPGTS 165 STGSPGASPGTSSTGSPGSSTPSGATGSPGSSTPSGATGSPGASPGTSSTGSPGTPGSGTA SSSPGSSTPSGATGSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTG SPGASPGTSSTGSPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSP GASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPG TPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGA SPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASP GTSSTGSPGASPGTSSTGSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTGSPGSSPSA WO 22617 XTEN Amino Acid Sequence ID Name STGTGPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGASPG AG576A TSSTGSPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGSSPSAS 166 TGTGPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGSSTPSGA STPSGATGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGAT GSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASS SPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSP GSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPG SSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGTPGSGTASSSPGSS TPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGSPGSSTP SGATGSPGSSPSASTGTGPGASPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGSSTPS GATGSPGSSTPSGATGSPGASPG AG612A STGSPGTPGSGTASSSPGSSTPSGATGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGAT 167 GSPGSSPSASTGTGPGSSPSASTGTGPGSSTPSGATGSPGSSTPSGATGSPGASPGTSSTG SPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSP GASPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPG STGSPGSSTPSGATGSPGSSTPSGATGSPGASPGTSSTGSPGTPGSGTASSSPGSS TPSGATGSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTGSPGASP GTSSTGSPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGASPG TSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSG TASSSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSS TGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTS AG648A GTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGSSTPSGATGSPGSSTPSG 168 ATGSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGASPGTSS TGSPGASPGTSSTGSPGASPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGASPGTSST GSPGASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPGSSTPSGATGSPGASPGTSSTG SGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGP GASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPG ASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSS TPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGSSPS ASTGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSA STGTGPGASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPGSSPSASTGTGPGASPGTS STGSPGSSPSASTGTGPGTPGSGTASSSPGSSTP AG684A PGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGSSTPSG 169 ATGSPGSSTPSGATGSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTA SSSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGSSPSASTGTGPGTPGSGTASS SPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPGSSTPSGATGSP GASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSTPSGATGSPG SSPSASTGTGPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGASPGTSSTGSPGA SPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPG SGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSPSA STGTGPGSSPSASTGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSAST GTGPGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPGSSPSASTG TGPGASPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATG SPGASPG AG720A TSSTGSPGTPGSGTASSSPGSSTPSGATGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSG 170 ATGSPGSSPSASTGTGPGSSPSASTGTGPGSSTPSGATGSPGSSTPSGATGSPGASPGTSS TGSPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGASPGTSSTGSPGASPGTSST GSPGASPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTG SPGASPGTSSTGSPGSSTPSGATGSPGSSTPSGATGSPGASPGTSSTGSPGTPGSGTASSSP GSSTPSGATGSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTGSPG ASPGTSSTGSPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGA SPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGTPG SGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPG TSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTS ASPGTSSTGSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTGSPGSSPSASTG TGPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGASPG AG756A TSSTGSPGSSPSASTGTGPGSSPSASTGTGPGTPGSGTASSSPGSSTPSGATGSPGSSPSAS 171 TGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGASPGTSS TGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGASPGTSSTGSPGTPGSGTAS XTEN Amino Acid Sequence ID Name SSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGSSTPSGATGSPGSSTPSGATGS PGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGASPGTSSTGSP GASPGTSSTGSPGASPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGASPGTSSTGSPG ASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPGSSTPSGATGSPGASPGTSSTGSPGTP GSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGASP GTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGASPG TSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSG ATGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGSSPSAST GTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTG TGPGASPGTSSTGSPGASPG AG792A TSSTGSPGSSPSASTGTGPGSSPSASTGTGPGTPGSGTASSSPGSSTPSGATGSPGSSPSAS 172 ASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGASPGTSS TGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGASPGTSSTGSPGTPGSGTAS TPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGSSTPSGATGSPGSSTPSGATGS PGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGASPGTSSTGSP GASPGTSSTGSPGASPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGASPGTSSTGSPG ASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPGSSTPSGATGSPGASPGTSSTGSPGTP SSPGSSTPSGATGSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGASP GTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGASPG TSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSG ATGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGSSPSAST GTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTG TGPGASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPGSSPSASTGTGPGASPG AG828A TSSTGSPGSSPSASTGTGPGSSPSASTGTGPGTPGSGTASSSPGSSTPSGATGSPGSSPSAS 173 TGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGASPGTSS TGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGASPGTSSTGSPGTPGSGTAS SSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGSSTPSGATGSPGSSTPSGATGS PGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGASPGTSSTGSP SSTGSPGASPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGASPGTSSTGSPG ASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPGSSTPSGATGSPGASPGTSSTGSPGTP GSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGASP GTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGASPG TSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSG ATGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGSSPSAST GTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTG TGPGASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTG SPGSSPSASTGTGPGTPGSGTASSSPGSSTP AG288_ GTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPG 1699 DE ASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGA SPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSST PSGATGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGSSPS ASTGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSP In other embodiments, the CFXTEN composition ses one or more petitive XTEN sequences of lengths ranging from about 36 to about 3000 amino acid residues, wherein at least about 80%, or at least about 90%, or about 91%, or about 92%, or about 93%, or about 94%, or about 95%, or about 96%, or about 97%, or about 98%, or about 99% to about 100% of the sequence consists of non- overlapping 36 amino acid sequence motifs selected from one or more of the polypeptide sequences of Tables 13-17, either as a family sequence, or where motifs are selected from two or more families of motifs.

In those embodiments wherein the XTEN component of the CFXTEN fusion protein has less than 100% of its amino acids consisting of 4, 5, or 6 types of amino acid selected from glycine (G), e (A), serine (S), threonine (T), glutamate (E) and proline (P), or less than 100% of the sequence consisting of the sequence motifs from Table 3 or the XTEN sequences of Tables 4, and 13-17, the other amino acid residues of the XTEN are selected from any of the other 14 natural L-amino acids, but are preferentially selected from hydrophilic amino acids such that the XTEN sequence contains at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least about 99% hydrophilic amino acids. The XTEN amino acids that are not glycine (G), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P) are either interspersed throughout the XTEN sequence, are located within or between the sequence motifs, or are concentrated in one or more short stretches of the XTEN sequence, e. g., to create a linker n the XTEN and the FVIII ents. In such cases where the XTEN component of the CFXTEN comprises amino acids other than glycine (G), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P), it is preferred that less than about 2% or less than about 1% of the amino acids be hydrophobic es such that the ing sequences generally lack secondary structure, e. g., not having more than 2% alpha s or 2% heets, as determined by the methods disclosed herein.

Hydrophobic residues that are less favored in construction ofXTEN include tryptophan, phenylalanine, tyrosine, leucine, isoleucine, valine, and methionine. Additionally, one can design the XTEN sequences to contain less than 5% or less than 4% or less than 3% or less than 2% or less than 1% or none of the following amino acids: cysteine (to avoid disulfide ion and oxidation), methionine (to avoid ion), gine and glutamine (to avoid desamidation). Thus, in some embodiments, the XTEN component of the CFXTEN fusion protein comprising other amino acids in addition to glycine (G), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P) have a sequence with less than 5% of the residues contributing to alpha-helices and beta-sheets as measured by the Chou-Fasman thm and have at least 90%, or at least about 95% or more random coil formation as measured by the GOR algorithm. 3. Length of Sequence In r aspect, the invention provides XTEN of varying lengths for incorporation into CFXTEN compositions wherein the length of the XTEN sequence(s) are chosen based on the property or function to be ed in the fusion protein. Depending on the intended property or function, the CFXTEN compositions comprise short or intermediate length XTEN located internal to the FVIH sequence or between FVHI s and/or longer XTEN sequences that can serve as carriers, located in the fusion proteins as described herein. While not intended to be limiting, the XTEN or fragments of XTEN include short segments of about 6 to about 99 amino acid residues, intermediate lengths of about 100 to about 399 amino acid residues, and longer lengths of about 400 to about 1000 and up to about 3000 amino acid residues. Thus, the XTEN for incorporation into the subject CFXTEN encompass XTEN or fragments ofXTEN with lengths of about 6, or about 12, or about 36, or about 40, or about 42, or about 72 or about 96, or about 144, or about 288, or about 400, or about 500, or about 576, or about 600, or about 700, or about 800, or about 864, or about 900, or about 1000, or about 1500, or about 2000, or about 2500, or up to about 3000 amino acid es in length. atively, the XTEN sequences can be about 6 to about 50, about 50 to about 100, about 100 to 150, about 150 to 250, about 250 to 400, about 400 to about 500, about 500 to about 900, about 900 to 1500, about 1500 to 2000, or about 2000 to about 3000 amino acid residues in length. The precise length of an XTEN incorporated into the subject CFXTEN can vary without adversely affecting the activity of a CFXTEN composition. In one ment, one or more of the XTEN used in the CFXTEN disclosed herein has 36 amino acids, 42 amino acids, 144 amino acids, 288 amino acids, 576 amino acids, or 864 amino acids in length and may be selected from one of the XTEN family sequences; i.e., AD, AE, AF, AG, AM, AQ, BC or BD. In another embodiment, two or more of the XTEN used in the CFXTEN disclosed herein has 36 amino acids, 42 amino acids, 144 amino acids, 288 amino acids, 576 amino acids, or 864 amino acids in length and may be selected from two of the XTEN family sequences; i.e., AD, AE, AF, AG, AM, AQ, BC or BD, with combinations of AE and AG family sequences preferred. In some embodiments, CFXTEN comprising one or more of the XTEN used herein contain XTEN selected from any one of the sequences in Table 4, which may be linked to the FVIII component directly or Via spacer ces disclosed herein.

In ular CFXTEN configuration designs, where the XTEN serve as a flexible linker, or are inserted in external loops or unordered regions of the FVIII sequence to increase the bulk, flexibility, or hydrophilicity of the , or are ed to interfere with clearance receptors for FVIII to e pharmacokinetic properties, or to interfere with binding of FVIII inhibitors or other VIII antibodies, or where a short or intermediate length ofXTEN is used to facilitate tissue penetration or to vary the strength of interactions of the CFXTEN fusion protein with its target, or where it is desirable to distribute the cumulative length ofXTEN in segments of short or intermediate length at multiple ons within the FVIII sequence, the invention contemplates CFXTEN compositions with one, two, three, four, five or more short or intermediate XTEN sequences inserted between or within one or more FVIII domains or within external loops, or at other sites in the FVIII sequence such as, but not limited to, locations at or proximal to the insertion sites identified in Table 5, Table 6, Table 7, Table 8, and Table 9 or as illustrated in FIGS. 8-9. In one embodiment of the foregoing, the CFXTEN fusion protein contains multiple XTEN segments, e. g., at least two, or at least three, or at least four, or at least five or more XTEN segments in which the XTEN segments can be identical or they can be different and wherein the CFXTEN retains at least 10%, 20%, 30%, 40%, 50%, 60%, 70% or more of the procoagulant activity of native FVIII when assayed by one of the assays disclosed herein. In other particular CFXTEN configuration s, where the XTEN serves as a carrier to increase the bulk of the fusion n, or to vary the strength of interactions of the CFXTEN fusion protein with its target, or to enhance the cokinetic ties of the fusion n, the invention contemplates CFXTEN compositions with one or more intermediate or longer length XTEN sequences inserted at the C-terminus, within the B domain (or the residual of the BDD sequence) between or within one or more FVIII domains, within al loops, or at other sites in the FVIII sequence such as, but not limited to, insertion sites identified in Table 5, Table 6, Table 7, Table 8, and Table 9 or as illustrated in FIGS. 8-9. However, it is believed that the incorporation of multiple XTEN of short to intermediate lengths into CFXTEN compositions confers enhanced properties on the fusion proteins compared to CFXTEN fusion proteins with the same number of amino acids in fewer but longer length XTEN, yet still results in compositions with procoagulant activity and extended ife; the ale of which is detailed herein regarding the derived radii of multiple XTEN.

In the ments wherein the CFXTEN fusion proteins comprise multiple XTEN sequences, the tive length of the total residues in the XTEN sequences is greater than about 100 to about 3000, or about 200 to about 2000, or about 400 to about 1000 amino acid residues and the XTEN can be identical or they can be ent in sequence, net charge, or in length. In one embodiment of CFXTEN comprising multiple XTEN, the individual XTEN sequences each exhibit at least about 80% sequence identity, or alternatively 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% ce identity compared to a motif or an XTEN selected from Tables 3, 4, and 13-17 or a fragment thereof, when lly aligned with a sequence of comparable length.

As bed more fully below, s are disclosed in which the CFXTEN are designed by selecting the length of the XTEN and its site of oration within the CFXTEN to confer a target half- life, retention of procoagulant actiVity, reduced g to FVIII inhibitors or an enhanced physicochemical property (e.g., stability or solubility) of a CFXTEN fusion protein, encoding ucts are created and expressed and the recombinant CFXTEN fusion proteins are isolated and recovered. In l, XTEN cumulative lengths longer that about 400 residues incorporated into the CFXTEN itions result in longer half-life compared to shorter cumulative lengths, e.g., shorter than about 280 residues. In one embodiment, CFXTEN fusion proteins designs are contemplated that comprise at least a single XTEN as a carrier, with a long sequence length of at least about 400, or at least about 600, or at least about 800, or at least about 900, or at least about 1000 or more amino acids. In another embodiment, multiple XTEN are incorporated into the fusion protein to achieve tive lengths of at least about 400, or at least about 600, or at least about 800, or at least about 900, or at least about 1000 or more amino acids, wherein the XTEN can be identical or they can be different in sequence or length. As used herein, “cumulative length” is intended to encompass the total length, in amino acid residues, when more than one XTEN is incorporated into the CFXTEN fusion protein. Both of the ing embodiments are designed to confer increased bioavailability and/or increased terminal half-life after administration to a subject compared to CFXTEN comprising shorter cumulative XTEN lengths, yet still result in a procoagulant activity and hemostasis effect. When administered subcutaneously or intramuscularly, the Cmax is d but the area under the curve (AUC) is increased in comparison to a comparable dose of a CFXTEN with shorter cumulative length XTEN or FVIII not linked to XTEN, thereby contributing to the ability to maintain effective levels of the CFXTEN composition for a longer period of time and permitting increased periods of 2, 4, 7, 10, 14 or 21 days between dosing, as described more fully below. Thus, the XTEN confers the property of a depot to the administered CFXTEN, in addition to the other physicochemical properties described herein.

When XTEN are used as a carrier, the invention takes advantage of the discovery that increasing the length of the non-repetitive, unstructured polypeptides es the unstructured nature of the XTENs and correspondingly enhances the physical/chemical and pharmacokinetic properties of WO 22617 fusion proteins comprising the XTEN carrier. As described more fully in the es, proportional increases in the length of the XTEN, even if created by a repeated order of single family ce motifs (e. g., the four AE motifs of Table 3), result in a sequence With a higher percentage (e. g., 90% or more) of random coil formation, as determined by GOR algorithm, or reduced content of alpha-helices or beta- sheets (e. g., less than 2%), as ined by Chou-Fasman algorithm, compared to shorter XTEN lengths. In addition, increasing the length of the unstructured polypeptide fusion partner, as described in the Examples, results in a fusion protein With a disproportionate increase in terminal half-life (e.g., as much as 50, 100, 200 or more hours) compared to fusion proteins With unstructured polypeptide partners With shorter ce lengths. The enhanced pharmacokinetic properties of the CFXTEN in comparison to FVIII not linked to XTEN are described more fully, below.

In another aspect, the invention provides methods to create XTEN of short or intermediate lengths from longer ” XTEN sequences, Wherein the longer donor XTEN sequence is ted at the N—terminus, or the C-terminus, or a fragment is created from the interior of a donor sequence, thereby resulting in a short or intermediate length XTEN. In non-limiting es, as schematically depicted in A—C, an AG sequence of 864 amino acid residues can be truncated to yield an AG sequence With 144 residues, an AG sequence With 288 residues, an AG sequence With 576 residues, or other intermediate lengths, While the AE sequence of 864 residues (as depicted in D, E) can be truncated to yield multiple AE ces of 144 residues, an AE sequence With 288 or 576 residues or other shorter or intermediate lengths. It is specifically contemplated that such an approach can be utilized with any of the XTEN embodiments described herein or with any of the sequences listed in Tables 4 or 13-17 to result in XTEN of a desired length. In preferred ments, the CFXTEN comprising multiple XTEN have XTEN exhibiting at least about 80%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99%, or 100% sequence identity to sequences selected from AE42_1, , AE42_3, AG42_1, AG42_2, AG42_3, AG42_4, AE144_1A, AE144_2A, AE144_2B, AE144_3A, AE144_3B, AE144_4A, 4B, AE144_5A, AE144_6B, AG144_1, AG144_2, AG144_A, AG144_B, AG144_C, AG144_F, 3, 4, AE288_1, AE288_2, AG288_1, AG288_2, and AG288_DE. 4. Net charge In other embodiments, the unstructured characteristic of an XTEN polypeptide can be enhanced by incorporation of amino acid residues with a net charge and/or reduction of the overall percentage (e. g. less than 5%, or 4%, or 3%, or 2%, or 1%) of hydrophobic amino acids in the XTEN sequence. The overall net charge and net charge density is lled by modifying the content of charged amino acids in the XTEN sequences, either positive or negative, With the net charge typically represented as the percentage of amino acids in the polypeptide contributing to a charged state beyond those residues that are cancelled by a residue With an opposite charge. In some embodiments, the net charge density of the XTEN of the compositions may be above +0.1 or below -0.1 charges/residue. By “net charge density” of a protein or peptide herein is meant the net charge diVided by the total number of amino acids in the protein or propeptide. In other embodiments, the net charge of an XTEN can be about 0%, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10% about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, or about 20% or more. Based on the net charge, some XTENs have an isoelectric point (pI) of 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, or even 6.5. In preferred embodiments, the XTEN will have an isoelectric point between 1.5 and 4.5 and carry a net negative charge under physiologic conditions.

Since most tissues and surfaces in a human or animal have a net negative charge, in some embodiments the XTEN sequences are designed to have a net negative charge to ze ecific interactions between the XTEN ning compositions and various surfaces such as blood vessels, healthy tissues, or various receptors. Not to be bound by a particular theory, an XTEN can adopt open conformations due to electrostatic repulsion between individual amino acids of the XTEN polypeptide that individually carry a net negative charge and that are distributed across the sequence of the XTEN polypeptide. In some embodiments, the XTEN ce is designed with at least 90% or 95% of the charged residues separated by other residues such as serine, alanine, threonine, proline or glycine, which leads to a more uniform bution of charge, better expression or purification behavior. Such a distribution of net negative charge in the extended sequence lengths ofXTEN can lead to an ctured conformation that, in turn, can result in an effective se in hydrodynamic radius. In preferred embodiments, the negative charge of the subject XTEN is conferred by incorporation of glutamic acid residues. lly, the glutamic residues are spaced uniformly across the XTEN sequence. In some cases, the XTEN can contain about 10-80, or about 15-60, or about 20-50 glutamic residues per 20kDa of XTEN that can result in an XTEN with charged residues that would have very similar pKa, which can increase the charge homogeneity of the product and sharpen its isoelectric point, enhance the physicochemical properties of the resulting CFXTEN filsion protein for, and hence, simplifying ation procedures. For example, where an XTEN with a negative charge is desired, the XTEN can be selected solely from an AB family sequence, which has approximately a 17% net charge due to incorporated glutamic acid, or can include varying proportions of glutamic acid-containing motifs of Table 3 to provide the desired degree of net charge. Non-limiting examples of AE XTEN include, but are not limited to the 36, 42, 144, 288, 576, 624, 864, and 912 AB family ces ofTables 4 and 14 or fragments thereof In one embodiment, an XTEN sequence of Tables 4, or 13-17 can be modified to include additional glutamic acid residues to e the desired net negative charge. ingly, in one ment the invention provides XTEN in which the XTEN sequences contain about 1%, 2%, 4%, 8%, 10%, 15%, 17%, 20%, 25%, or even about 30% glutamic acid. In one ment, the invention contemplates incorporation of up to 5% aspartic acid residues into XTEN in addition to ic acid in order to achieve a net negative charge.

In other embodiments, where no net charge is d, the XTEN can be selected from, for example, AG XTEN components, such as the AG motifs of Table 3, or those AM motifs of Table 3 that have no net charge. Non-limiting examples of AG XTEN include, but are not limited to 36, 42, 144, 288, 576, and 864 AG family sequences of Tables 4 and 16, or fragments thereof In another embodiment, the XTEN can comprise varying proportions of AE and AG motifs (in order to have a net charge that is deemed l for a given use or to maintain a given physicochemical property.

Not to be bound by a ular , the XTEN of the CFXTEN compositions with the higher net charge are expected to have less non-specific interactions with various negatively-charged surfaces such as blood vessels, tissues, or various receptors, which would further contribute to reduced active clearance. Conversely, it is ed that the XTEN of the CFXTEN compositions with a low (or no) net charge would have a higher degree of interaction with es that can potentiate the actiVity of the associated coagulation factor, given the known contribution of cell (e.g., platelets) and vascular surfaces to the coagulation process and the ity of activation of coagulation factors (Zhou, R., et al., Biomaterials (2005) 26(16):2965-2973; , F., et al. Biochemistry (2000) 39(32):9850—9858).

The XTEN of the compositions of the present invention generally have no or a low content of positively charged amino acids. In some embodiments, the XTEN may have less than about 10% amino acid es with a positive , or less than about 7%, or less than about 5%, or less than about 2%, or less than about 1% amino acid residues with a positive charge. However, the invention contemplates ucts where a limited number of amino acids with a positive charge, such as lysine, are incorporated into XTEN to permit conjugation between the epsilon amine of the lysine and a reactive group on a peptide, a linker bridge, or a reactive group on a drug or small molecule to be ated to the XTEN backbone. In one embodiment of the ing, the XTEN of the subject CFXTEN has between about 1 to about 100 lysine residues, or about 1 to about 70 lysine residues, or about 1 to about 50 lysine residues, or about 1 to about 30 lysine residues, or about 1 to about 20 lysine residues, or about 1 to about lysine residues, or about 1 to about 5 lysine residues, or alternatively only a single lysine residue.

Using the foregoing lysine-containing XTEN, fusion proteins can be constructed that comprise XTEN, a FVIII coagulation , plus a chemotherapeutic agent or other coagulation factor or cofactor useful in the treatment of coagulopathy conditions, wherein the maximum number of molecules of the agent incorporated into the XTEN component is determined by the numbers of lysines or other amino acids with reactive side chains (e.g., cysteine) incorporated into the XTEN.

As hydrophobic amino acids impart structure to a polypeptide, the invention provides that the content of hydrophobic amino acids in the XTEN will typically be less than 5%, or less than 2%, or less than 1% hydrophobic amino acid content. In one embodiment, the amino acid content of nine and tryptophan in the XTEN component of a CFXTEN fusion protein is typically less than 5%, or less than 2%, and most preferably less than 1%. In another embodiment, the XTEN of the subject CFXTEN itions will have a sequence that has less than 10% amino acid residues with a positive charge, or less than about 7%, or less that about 5%, or less than about 2% amino acid residues with a positive charge, the sum of methionine and tryptophan residues will be less than 2%, and the sum of asparagine and glutamine residues will be less than 5% of the total XTEN sequence.

. Low immunogenicity In another aspect, the XTEN ces provided herein have a low degree of genicity or are substantially non-immunogenic. Several factors can contribute to the low immunogenicity of WO 22617 XTEN, e. g., the non-repetitive sequence, the unstructured conformation, the high degree of solubility, the low degree or lack of self-aggregation, the low degree or lack of proteolytic sites within the sequence, and the low degree or lack of epitopes in the XTEN sequence.

Conformational es are formed by regions of the protein surface that are composed of multiple discontinuous amino acid sequences of the protein antigen. The precise g of the protein brings these ces into a well-defined, stable l configurations, or epitopes, that can be recognized as “foreign” by the host humoral immune , resulting in the production of antibodies to the protein or the activation of a cell-mediated immune response. In the latter case, the immune se to a protein in an individual is heavily influenced by T-cell e recognition that is a function of the peptide binding specificity of that individual’s HLA—DR allotype. Engagement of a MHC Class II peptide complex by a cognate T-cell receptor on the surface of the T-cell, together with the cross-binding of certain other co-receptors such as the CD4 molecule, can induce an activated state within the T-cell. tion leads to the release of cytokines further activating other lymphocytes such as B cells to produce antibodies or activating T killer cells as a full cellular immune response.

The ability of a peptide to bind a given MHC Class II molecule for tation on the surface of an APC (antigen presenting cell) is dependent on a number of factors; most notably its primary sequence. In one embodiment, a lower degree of immunogenicity is achieved by designing XTEN sequences that resist antigen processing in antigen presenting cells, and/or choosing sequences that do not bind MHC receptors well. The invention provides CFXTEN fusion proteins with ntially non- repetitive XTEN polypeptides designed to reduce binding with MHC II receptors, as well as avoiding formation of epitopes for T-cell receptor or antibody binding, resulting in a low degree of immunogenicity. nce of immunogenicity can attribute to, at least in part, a result of the conformational lity ofXTEN sequences; i.e., the lack of secondary structure due to the selection and order of amino acid es. For example, of ular interest are sequences having a low tendency to adapt compactly folded conformations in aqueous solution or under physiologic conditions that could result in conformational epitopes. The administration of fusion proteins comprising XTEN, using conventional therapeutic practices and dosing, would generally not result in the formation of neutralizing antibodies to the XTEN sequence, and also reduce the immunogenicity of the FVIII fusion partner in the CFXTEN compositions.

In one embodiment, the XTEN sequences utilized in the subject fusion proteins can be substantially free of epitopes recognized by human T cells. The elimination of such epitopes for the purpose of generating less immunogenic proteins has been disclosed usly; see for e WO 98/52976, WO 02/079232, and WO 00/3317 which are incorporated by reference herein. Assays for human T cell epitopes have been described (Stickler, M., et al. (2003) JImmunol Methods, 281: 95-108).

Of particular interest are peptide sequences that can be oligomerized without generating T cell es or man sequences. This is achieved by g direct repeats of these sequences for the presence of T-cell epitopes and for the occurrence of 6 to 15-mer and, in particular, 9-mer sequences that are not human, and then altering the design of the XTEN sequence to eliminate or disrupt the e sequence.

WO 22617 In some embodiments, the XTEN sequences are substantially non-immunogenic by the restriction of the numbers of epitopes of the XTEN predicted to bind MHC receptors. With a reduction in the numbers of epitopes e of binding to MHC receptors, there is a concomitant reduction in the potential for T cell activation as well as T cell helper function, reduced B cell activation or upregulation and d antibody production. The low degree of predicted T-cell epitopes can be determined by epitope prediction algorithms such as, e. g., TEPITOPE (Stumiolo, T., et al. (1999) Nat hnol, 17: 555-61), as shown in Example 46. The TEPITOPE score of a given peptide frame within a protein is the log of the Kd (dissociation constant, y, off-rate) of the binding of that peptide frame to multiple of the most common human MHC alleles, as disclosed in Stumiolo, T. et al. (1999) Nature Biotechnology 17:555). The score ranges over at least 20 logs, from about 10 to about -10 (corresponding to binding constraints of 10e10 Kd to 10e'10 Kd), and can be reduced by avoiding hydrophobic amino acids that serve as anchor residues during peptide display on MHC, such as M, I, L, V, F. In some embodiments, an XTEN ent incorporated into a CFXTEN does not have a predicted T-cell epitope at a PE threshold score of about -5, or -6, or -7, or -8, or -9, or at a TEPITOPE score of -10. As used herein, a score of “-9” is a more ent TEPITOPE threshold than a score of -5.

In r embodiment, the inventive XTEN sequences, including those incorporated into the subject CFXTEN fusion ns, are rendered substantially non-immunogenic by the restriction of known proteolytic sites from the sequence of the XTEN, reducing the processing ofXTEN into small peptides that can bind to MHC 11 receptors. In another embodiment, the XTEN sequence is rendered ntially non-immunogenic by the use a ce that is substantially devoid of secondary structure, conferring resistance to many ses due to the high entropy of the structure. Accordingly, the reduced TEPITOPE score and ation of known proteolytic sites from the XTEN render the XTEN compositions, including the XTEN of the CFXTEN fusion protein compositions, substantially unable to be bound by mammalian receptors, including those of the immune system or active clearance receptors that target FVIII. In one embodiment, an XTEN of a CFXTEN fusion protein can have >100 nM Kd binding to a mammalian receptor, or greater than 500 nM Kd, or greater than 1 uM Kd towards a mammalian cell e receptor or circulating polypeptide receptor.

Additionally, the non-repetitive sequence and corresponding lack of epitopes ofXTEN limit the ability of B cells to bind to or be activated by XTEN. A repetitive sequence is recognized and can form multivalent contacts with even a few B cells and, as a consequence of the cross-linking of multiple T-cell independent receptors, can stimulate B cell proliferation and antibody tion. In contrast, while an XTEN can make contacts with many different B cells over its extended ce, each individual B cell may only make one or a small number of contacts with an individual XTEN due to the lack of repetitiveness of the sequence. Not being to be bound by any theory, XTENs typically have a much lower tendency to stimulate proliferation of B cells and thus an immune response. In one embodiment, the CFXTEN have reduced immunogenicity as compared to the corresponding FVIII that is not fused to an XTEN. In one embodiment, the administration of up to three parenteral doses of a CFXTEN to a mammal result in detectable anti-CFXTEN IgG at a serum dilution of 1:100 but not at a dilution of 1:1000. In another embodiment, the administration of up to three parenteral doses of a CFXTEN to a mammal result in detectable anti-FVIII IgG at a serum dilution of 1:100 but not at a dilution of 1:1000. In another ment, the administration of up to three parenteral doses of a CFXTEN to a mammal result in able anti-XTEN IgG at a serum dilution of 1:100 but not at a dilution of 1:1000. In the foregoing embodiments, the mammal can be a mouse, a rat, a rabbit, or a cynomolgus monkey.

An additional feature of XTENs with non-repetitive sequences relative to sequences with a high degree of repetitiveness is non-repetitive XTENs form weaker contacts with antibodies. dies are multivalent molecules. For instance, IgGs have two cal binding sites and Ing contain 10 identical binding sites. Thus antibodies against repetitive sequences can form multivalent contacts with such repetitive sequences with high avidity, which can affect the potency and/or elimination of such repetitive sequences. In contrast, antibodies against non-repetitive XTENs may yield monovalent interactions, resulting in less likelihood of immune clearance such that the CFXTEN compositions can remain in circulation for an increased period of time. In addition, it is believed, as schematically portrayed in the flexible unstructured nature of XTEN provides steric shielding of FVIII regions proximal to the XTEN site of insertion and providing steric hindrance to binding by FVIII inhibitors.

] In another aspect, a subject XTEN useful as a fusion partner has a high hydrodynamic radius; a property that in some ments confers a corresponding increased apparent molecular weight to the CFXTEN fusion protein incorporating the XTEN, while in other embodiments enhances steric hindrance to FVIII tors and to anti-FVIII antibodies, reducing their ability to bind to CFXTEN. As detailed in Example 26, the linking ofXTEN to therapeutic n sequences results in CFXTEN compositions that can have increased hydrodynamic radii, increased apparent molecular , and increased nt molecular weight factor compared to a therapeutic protein not linked to an XTEN. For example, in therapeutic applications in which prolonged half-life is desired, compositions in which an XTEN with a high hydrodynamic radius is incorporated into a fusion protein comprising a therapeutic protein can effectively enlarge the hydrodynamic radius of the composition beyond the glomerular pore size of approximately 3-5 nm (corresponding to an apparent molecular weight of about 70 kDa) (Caliceti. 2003.

Pharmacokinetic and biodistribution ties of poly(ethylene glycol)-protein ates. Adv Drug Deliv Rev 55 :1261-1277), resulting in reduced renal nce of circulating proteins with a corresponding increase in terminal half-life and other enhanced pharmacokinetic properties. The ynamic radius of a protein is conferred by its molecular weight as well as by its structure, including shape or compactness. Not to be bound by a particular theory, the XTEN can adopt open conformations due to electrostatic repulsion between dual charges of the peptide or the inherent lity imparted by the particular amino acids in the sequence that lack potential to confer secondary structure. The open, extended and ctured conformation of the XTEN polypeptide can have a greater proportional hydrodynamic radius ed to polypeptides of a comparable ce length and/or molecular weight that have secondary and/or ry structure, such as typical globular proteins.

Methods for determining the hydrodynamic radius are well known in the art, such as by the use of size WO 22617 2012/046326 exclusion chromatography (SEC), as described in US. Patent Nos. 6,406,632 and 7,294,513. Example 26 demonstrates that increases in XTEN length result in proportional increase in the hydrodynamic radius, apparent molecular weight, and/or nt molecular weight factor, and thus permit the tailoring of CFXTEN to desired cut-off values of apparent molecular weights or hydrodynamic radii.

Accordingly, in certain embodiments, the CFXTEN fusion n can be configured with an XTEN such that the fusion protein can have a hydrodynamic radius of at least about 5 nm, or at least about 8 nm, or at least about 10 nm, or about 12 nm, or about 15 nm, or about 20 nm, or about 30 nm or more. In the foregoing embodiments, the large hydrodynamic radius conferred by the XTEN in a CFXTEN fusion protein can lead to reduced clearance of the resulting fusion protein, an increase in terminal half-life, and an increase in mean residence time.

Generally, the actual molecular weight of the mature form of FVIII ent is about 265 kDa, while in the case of a FVIII BDD, it is about 165 kDa. The actual molecular weight of a CFXTEN fusion protein for comprising a FVIII BDD plus one or more XTEN ranges from about 200 to about 270 kDa, depending on the length of the XTEN components. As described in the Examples, when the molecular weights of the CFXTEN fusion proteins are derived from size exclusion chromatography analyses, the open conformation of the XTEN due to the low degree of secondary structure results in an increase in the apparent molecular weight of the fusion proteins into which they are incorporated. In some embodiments, the CFXTEN comprising a FVIII and at least one or more XTEN exhibits an apparent lar weight of at least about 400 kD, or at least about 500 kD, or at least about 700 kD, or at least about 1000 kD, or at least about 1400 kD, or at least about 1600 kD, or at least about 1800kD, or at least about 2000 kD. Accordingly, the CFXTEN fusion proteins comprising one or more XTEN exhibit an apparent molecular weight that is about 1.3-fold greater, or about 2-fold greater, or about 3- fold greater or about 4-fold greater, or about 8-fold greater, or about 10-fold greater, or about 12-fold r, or about 15-fold greater than the actual molecular weight of the fusion protein. In one embodiment, the ed CFXTEN fusion protein of any of the embodiments disclosed herein exhibit an apparent molecular weight factor under logic conditions that is r than about 1.3, or about 2, or about 3, or about 4, or about 5, or about 6, or about 7, or about 8, or about 10, or greater than about 15.

In another embodiment, the CFXTEN fusion protein has, under physiologic conditions, an apparent molecular weight factor that is about 3 to about 20, or is about 5 to about 15, or is about 8 to about 12, or is about 9 to about 10 relative to the actual molecular weight of the fusion protein. It is believed that the increased apparent molecular weight of the subject CFXTEN compositions es the pharmacokinetic properties of the fusion proteins by a combination of factors, which e reduced active clearance, reduced g by FVIII tors, and reduced loss in capillary and venous bleeding.

IV). CFXTEN COMPOSITIONS ] The present invention es compositions comprising fusion proteins having factor VIII linked to one or more XTEN sequences, wherein the fusion protein acts to replace or augment the amount of existing FVIII in the intrinsic or contact activated coagulation pathway when administered into a subject. The invention addresses a elt need in increasing the terminal half-life of exogenously stered factor VIII to a subject in need f. One way to increase the circulation half-life of a therapeutic protein is to ensure that renal clearance or metabolism of the n is reduced.

Another way to increase the terminal half-life is to reduce the active clearance of the therapeutic protein, whether mediated by ors, active metabolism of the protein, or other endogenous mechanisms. Both may be achieved by conjugating the protein to a polymer, which, on one hand, is capable of conferring an increased molecular size (or hydrodynamic radius) to the protein and, hence, reduced renal clearance, and, on the other hand, interferes with g of the protein to clearance receptors or other proteins that contribute to metabolism or clearance. Thus, certain objects of the t invention include, but are not limited to, providing improved FVIII les with a longer circulation or terminal half-life, decreasing the number or ncy of necessary administrations of FVIII compositions, retaining at least a portion of the ty compared to native ation factor VIII, and/or enhancing the ability to treat coagulation deficiencies and uncontrolled bleedings more efficiently, more effectively, more economically, and/or with greater safety compared to presently available factor VIII preparations.

Accordingly, the present invention provides recombinant factor VIII fusion protein compositions comprising an FVIII ntly linked to one or more extended recombinant ptides (“XTEN”), resulting in a CFXTEN fusion protein composition. The term “CFXTEN”, as used herein, is meant to encompass fusion polypeptides that se at least one payload region comprising a FVIII or a portion of a FVIII that is capable of gulant ty associated with a FVIII coagulation factor and at least one other region comprising one or more XTEN polypeptides that may be interspersed within the payload region and/or attached to the terminus. In one embodiment, the FVIII is native FVIII. In another embodiment, the FVIII is a sequence variant, fragment, homolog, or mimetic of a natural sequence that retains at least a portion of the procoagulant actiVity of native FVIII, as disclosed herein.

Non-limiting examples of FVIII suitable for inclusion in the compositions include the sequences of Table l or sequences having at least 80%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% sequence identity to a sequence of Table 1. In a preferred embodiment, the FVIII is a B-domain deleted (BDD) FVIII sequence variant, such as those BDD sequences from Table l or other such sequences known in the art. In another preferred embodiment, the CFXTEN comprises a B-domain d (BDD) FVIII sequence t sed with the native 19 amino acid signal sequence, which is cleaved during the maturation of the protein.

The compositions of the invention include fusion ns that are useful, when administered to a subject in need thereof, for mediating or preventing or ameliorating a condition associated with factor VIII deficiencies or defects in endogenously produced FVIII, or bleeding disorders associated with trauma, surgery, factor VIII deficiencies or defects. Of particular interest are CFXTEN fusion protein compositions for which an increase in a pharmacokinetic parameter, increased solubility, increased stability, or some other ed pharmaceutical property compared to native FVIII is sought, or for which increasing the terminal half-life would improve efficacy, safety, or result in reduced dosing frequency and/or improve patient management. The CFXTEN fusion proteins of the embodiments disclosed herein t one or more or any combination of the improved properties and/or the embodiments as detailed herein. In some embodiments, the CFXTEN fusion composition remains at a level above a threshold value of at least 0.01-0.05, or 0.05 to 0.1, or 0.1 to 0.4 IU/ml when administered to a subject, for a longer period of time when compared to a FVIII not linked to XTEN and administered at a comparable dose to a subject in need thereof (e. g., a subject such as a human or mouse or monkey with hemophilia A).

] The FVIII of the subject compositions, particularly those disclosed in Table 1, together with their ponding nucleic acid and amino acid sequences, are available in public databases such as Chemical Abstracts Services Databases (e. g., the CAS Registry), GenBank, The sal n Resource (UniProt), subscription provided ses such as GenSeq (e.g., Derwent), as well as in the patent and primary literature. Polynucleotide sequences applicable for expressing the subject CFXTEN sequences may be a wild type polynucleotide ce encoding a given FVIH (e. g., either full length or mature), or in some instances the sequence may be a t of the wild type polynucleotide sequence (e. g., a polynucleotide which encodes the wild type biologically active protein, wherein the DNA sequence of the polynucleotide has been optimized, for example, for sion in a particular species, or a polynucleotide ng a variant of the wild type protein, such as a site directed mutant or an allelic variant. It is well within the ability of the skilled artisan to use a wild-type or consensus cDNA sequence or a codon-optimized variant of a FVIII to create CFXTEN constructs contemplated by the invention using methods known in the art and/or in conjunction with the guidance and methods ed herein, and described more fully in the Examples.

In one embodiment, a CFXTEN fusion protein comprises a single FVIH molecule exhibiting at least about 80% sequence identity, or alternatively 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least about 99%, or 100% sequence identity to a sequence of Table 1 linked to a single XTEN (e. g., an XTEN as described above) including, but not limited to sequences of the AE or AG family with 42, 144, 288, 576, or 864 amino acids, as set forth in Table 4. In another embodiment, the CFXTEN comprises a single FVIH linked to two XTEN, wherein the XTEN may be identical or they may be different. In another embodiment, the CFXTEN fusion protein ses a single FVIH molecule linked to one, two, three, four, five, six or more XTEN sequences, in which the FVIII is a sequence that has at least about 80% sequence identity, or alternatively 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least about 99%, or 100% sequence identity compared to a protein sequence selected from Table 1, when optimally d, and the one or more XTEN are each having at least about 80% ce identity, or alternatively 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least about 99%, or 100% sequence identity compared to one or more sequences selected from any one of Tables 3, 4, and 13-17, when optimally aligned. In the ing embodiment, where the CFXTEN has two or more XTEN, the XTEN may be identical or they may be different sequences. In yet another embodiment, the CFXTEN fusion protein comprises a single FVIH 2012/046326 exhibiting at least about 80% ce identity, or alternatively 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least about 99%, or 100% sequence identity compared to sequences of comparable length selected from Table 1, when optimally aligned, with the portions persed with and linked by three, four, five, six or more XTEN sequences that may be identical or may be different and wherein each has at least about 80% sequence identity, or alternatively 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least about 99%, or 100% sequence identity compared to sequences selected from any one of Tables 3, 4, and 13-17, or nts thereof, when optimally aligned. In yet r embodiment, the invention provides a CFXTEN fusion protein comprising a sequence with at least about 80% sequence identity, or alternatively 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least about 99%, or 100% sequence identity to a sequence from Table 21, when optimally aligned. 1. CFXTEN Fusion Protein Configurations The invention provides CFXTEN fusion protein compositions with the CF and XTEN components linked in specific N— to inus configurations.

In one embodiment of the CFXTEN composition, the invention provides a fusion protein of formula I: (XTEN)X-CF-(XTEN)y 1 wherein independently for each occurrence, CF is a factor VIII as defined herein, including sequences having at least about 80%, or at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% or 100% sequence identity with sequenced from Table 1; X is either 0 or 1 and y is either 0 or 1 wherein x+y 31; and XTEN is an extended inant polypeptide as described herein, including, but not limited to sequences having at least about 80%, or at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% or 100% sequence identity to sequences set forth in Table 4. Accordingly, the CFXTEN fusion composition can have XTEN-CF, F-XTEN, or CF-XTEN urations.

In another embodiment of the CFXTEN composition, the invention provides a fusion protein of formula II: (XTEN)X-(S)x-(CF)-(XTEN) y 11 wherein ndently for each occurrence, CF is a factor VIII as defined herein, including sequences having at least about 80%, or at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% or 100% sequence identity to sequences set forth in Table 1; S is a spacer sequence having between 1 to about 50 amino acid residues that can ally include a cleavage sequence or amino acids compatible with restrictions sites; x is either 0 or 1 and y is either 0 or 1 wherein x+y 21; and XTEN is an extended inant polypeptide as described herein including, but not limited to sequences having at least about 80%, or at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% or 100% sequence identity to sequences set forth in Table 4.

In another embodiment of the CFXTEN composition, the invention provides a recombinant factor VIII fusion n, wherein the fusion protein is of formula III: (XTEN)X-(S)X-(CF)-(S)y-(XTEN)y 111 wherein independently for each ence, CF is a factor VIII as defined herein, including sequences having at least about 80%, or at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% or 100% sequence identity to sequence set for in Table 1; S is a spacer sequence having between 1 to about 50 amino acid residues that can optionally include a cleavage sequence or amino acids compatible with restrictions sites; X is either 0 or 1 and y is either 0 or 1 wherein X+y 21; and XTEN is an extended recombinant polypeptide as described herein including, but not limited to sequences having at least about 80%, or at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% or 100% sequence ty to ces set forth in Table 4.

In another embodiment of the CFXTEN composition, the ion provides a recombinant factor VIII fusion protein of formula IV: (A1)-(XTEN)u-(A2)-(XTEN)V-(B)-(XTEN)W-(A3)-(XTEN)x-(C1)-(XTEN)y-(C2)-(XTEN)Z wherein independently for each occurrence, A1 is an A1 domain of FVIII; A2 is an A2 domain of FVIII; A3 is an A3 domain of FVIII; B is a B domain of FVIII which can be a fragment or a splice variant of the B domain; C1 is a C1 domain of FVIII; C2 is a C2 domain of FVIII; V is either 0 or 1; w is either 0 or 1; X is either 0 or 1; y is either 0 or 1; y is either 0 or 1 with the proviso that u + V + X + y+z 31; and XTEN is an extended recombinant polypeptide as described herein including, but not d to sequences having at least about 80%, or at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% or 100% sequence identity to sequences set forth in Table 4.

In another embodiment of the CFXTEN composition, the ion provides a recombinant factor VIII fusion protein of formula V: (XTENx-(sx -(A1)-(S)b-(XTEN)u-(S)b-(A2)-(S)c-(XTEN)V-(S)c-(B)-(S)d-(XTEN)w-(S)d-(A3)—(S)e- (XTEN)x-(S)e-(C1)-(s)r(XTEN)y-(S)r(cz)-(S)g-(XTEN)Z V wherein independently for each occurrence, A1 is an A1 domain of FVIII; A2 is an A2 domain of FVIII; A3 is an A3 domain of FVIII; B is a B domain of FVIII which can be a fragment or a splice t of the B domain; C1 is a C1 domain of FVIII; C2 is a C2 domain of FVIII; S is a spacer ce having between 1 to about 50 amino acid residues that can optionally e a cleavage sequence or amino acids compatible with restrictions sites; a is either 0 or 1; b is either 0 or 1; c is either 0 or 1; d is either 0 or 1; e is either 0 or 1; f is either 0 or 1; g is either 0 or 1; t is either 0 or 1; u is either 0 or 1; V is either 0 or 1; w is 0 or 1, X is either 0 or 1; y is either 0 or 1; z is either 0 or 1 with the proviso that t + u + V + w+ X + y + z 31; and XTEN is an eXtended recombinant polypeptide as described herein including, but not limited to sequences haVing at least about 80%, or at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% or 100% sequence identity to sequences set forth in Table 4. In another embodiment of formula V, the spacer sequence is glycine or a sequence selected from Tables 11 and 12.

In r embodiment of the CFXTEN composition, the invention provides a recombinant factor VIII fusion protein of formula VI: (XTENX—(SX-(Al)—(S)b-(XTEN)V-(S)b-(A2)-(S)c-(XTEN)W-(S)c-(A3)—(S)d-(XTEN)x-(S)d-(C1)- (s)e-(XTEN)y-(8)6-(C2)—(S)r(XTEN)Z VI wherein independently for each occurrence, A1 is an A1 domain of FVIII; A2 is an A2 domain of FVIII; A3 is an A3 domain of FVIII; C1 is a C1 domain of FVIII; C2 is a C2 domain of FVIII; S is a spacer sequence having between 1 to about 50 amino acid residues that can optionally include a cleavage sequence or amino acids compatible with restrictions sites; a is either 0 or 1; b is either 0 or 1; c is either 0 or 1; dis either 0 or 1; e is either 0 or 1; fis either 0 or 1; uis either 0 or 1; Vis either 0 or 1; Wis 0 or 1, X is either 0 or 1; y is either 0 or 1; z is either 0 or 1 with the proviso that u + V + w+ X + y + z 31; and XTEN is an extended recombinant polypeptide as described herein including, but not limited to sequences having at least about 80%, or at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% or 100% sequence identity to sequences set forth in Table 4. In another embodiment of formula V, the spacer sequence is glycine or a sequence selected from Tables 11 and 12.

In another embodiment of the CFXTEN composition, the ion provides a recombinant factor VIII fusion protein of formula VII: XTEN)X-(CS)x-(S)x-(FVIII_1-745)-(S)y-(XTEN)y-(S)y-(FVIII_1635-2332)-(S)Z-(CS)Z- (XTEN)Z VII wherein independently for each occurrence, SP is a signal peptide, ably with sequence MQIELSTCFFLCLLRFCFS (SEQ ID NO: 1611), CS is a ge sequence listed in Table 12, S is a spacer sequence having n 1 to about 50 amino acid residues that can optionally include amino acids compatible with restrictions sites, “FVIII_1-745” is residues 1-745 of Factor FVIII and “FVIII_l635-2332” is residues 1635-2332 of FVIII, X is either 0 or 1, y is either 0 or 1, and z is either 0 or 1, wherein x+y+z >2; and XTEN is an eXtended recombinant polypeptide as bed herein including, but not limited to sequences having at least about 80%, or at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% or 100% sequence identity sequences set forth in Table 4. In one embodiment of formula VII, the spacer sequence is GPEGPS (SEQ ID NO: 1612). In another embodiment of formula V, the spacer sequence is glycine or a ce selected from Tables 11 and 12.

In r embodiment of the CFXTEN composition, the invention provides a recombinant factor VIII fusion protein of formula VIII: S)a-(XTEN)V-(S)a-(A2)-(B1)—(S)b-(XTEN)w-(S)b-(B2)-(A3)—(S)c-(XTEN)x-(S)c-(C1)—(S)d- y-(S)d-(C2)-(S)e-(XTEN)Z VIII wherein ndently for each occurrence, A1 is an A1 domain of FVIII; A2 is an A2 domain of FVIII; B1 is a fragment of the B domain that can have from residue 741 to 743-750 of FVIII or alternatively from about residue 741 to about residues 745 of FVIII; B2 is a fragment of the B domain that can have from es 1635-1686 to 1689 of FVIII or alternatively from about residue 1640 to about residues 1689 of FVIII; A3 is an A3 domain of FVIII; C1 is a C1 domain of FVIII; C2 is a C2 domain of FVIII; S is a spacer sequence having between 1 to about 50 amino acid residues that can optionally include a cleavage sequence or amino acids compatible With restrictions sites; a is either 0 or 1; b is either 0 or 1; c is either 0 or 1; d is either 0 or 1; e is either 0 or 1; f is either 0 or 1; u is either 0 or 1; v is either 0 or 1; W is 0 or 1, X is either 0 or 1; y is either 0 or 1; z is either 0 or 1 With the proviso that u + v + w+ X + y + z 21; and XTEN is an extended recombinant polypeptide as bed herein including, but not d to ces having at least about 80%, or at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% or 100% sequence identity to sequences set forth in Table 4. In one embodiment of formula VIII, the spacer sequence is GPEGPS (SEQ ID NO: 1612). In another embodiment of a V, the spacer sequence is glycine or a sequence selected from Tables 11 and 12.

In another embodiment of the CFXTEN composition, the invention provides a recombinant factor VIII fusion protein of formula IX: (A1N)'(S)a'(XTEN)t'(S)b'(A1C)'(A2 N)-(S)c-(XTEN)u-(S)d-(A2c)-(BN)-(S)e-(XTEN)v-(S)r(Bc)-(A3N)- (S)g'(XTEN)W'(S)h'(A3C)'(C1N)'(S)i'(XTEN)x'(S)j'(C1C)'(C2N)'(S)k'(XTEN)y'(S)1'(C2C)'(S)m'(XTEN)z Wherein independently for each occurrence, AlN is a fragment of the A1 domain from at least residue number 1 (numbered relative to native, mature FVIII) to no more than residue number 371, A1C is a fragment of the A1 domain from at least residue number 2 to no more than residue number 372; A2N is a fragment of the A2 domain from at least residue number 373 to no more than residue number 739, Me is a fragment of the A2 domain from at least residue number 374 to no more than residue number 740; BN is a fragment of the B domain from at least residue number 741 to no more than residue number 1647, BC is a fragment of the B domain from at least residue number 742 to no more than residue number 1648; A3N is a fragment of the A3 domain from at least residue number 1649 to no more than residue number 2019, A3C is a fragment of the A3 domain from at least e number 1650 to no more than e number 2019; ClN is a fragment of the C1 domain from at least residue number 2020 to no more than residue number 2171, C1C is a fragment of the C1 domain from at least residue number 2021 to no more than residue number 2172; C2N is a fragment of the C2 domain from at least residue number 2173 to no more than residue number 2331, C2C is a fragment of the C2 domain from at least residue number 2174 to no more than residue number 2332; S is a spacer sequence having between 1 to about 50 amino acid es that can optionally include a cleavage sequence or amino acids compatible With restrictions sites; a is either 0 or 1; b is either 0 or 1; c is either 0 or 1; d is either 0 or 1; e is either 0 or 1; f is either 0 or 1; g is either 0 or 1; h is either 0 or 1; i is either 0 or 1; j is either 0 or 1; k is either 0 or 1; l is either 0 or 1; mis either 0 or 1; t is either 0 or 1; uis either 0 or 1; vis either 0 or 1; Wis 0 or 1, X is either 0 or 1; y is either 0 or 1; z is either 0 or 1 With the proviso that t + u + v + w+ X + y + z 31; and XTEN is an ed inant ptide as described herein including, but not limited to sequences having at least 90% identity to sequences set forth in Table 4. In one embodiment of formula IX, the spacer sequence is GPEGPS (SEQ ID NO: 1612). In another embodiment of formula IX, the spacer sequence is glycine or a sequence selected from Tables 11 and 12.

The embodiments of formulae IV-VIII encompass CFXTEN configurations wherein one or more XTEN of lengths g from about 6 amino acids to >_1000 amino acids (e. g., sequences selected from any one of Tables 3, 4, and 13-17 or fragments thereof, or sequences exhibiting at least about 90- 99% or more sequence identity thereto) are inserted and linked between adjoining domains of the factor VIII or are linked to the N— or C-terminus of the FVIII. In other embodiments of formulae V-VIII, the invention further provides configurations wherein the XTEN are linked to FVIII domains Via spacer sequences which can optionally comprise amino acids compatible with restrictions sites or can include cleavage sequences (e. g., the sequences of Tables 11 and 12, described more fully below) such that the XTEN ng sequence can be, in the case of a restriction site, integrated into a CFXTEN construct and, in the case of a cleavage sequence, the XTEN can be released from the fusion protein by the action of a protease riate for the ge sequence.

The ments of formulae VI -VIII differ from those of formula V in that the FVIII component of formulae VI-VIII are only the B-domain deleted forms (“FVIII BDD”) of factor VIII that retain short residual sequences of the B-domain, non-limiting examples of sequences of which are provided in Table 1, wherein one or more XTEN or nts ofXTEN of lengths ranging from about 6 amino acids to 11000 amino acids (e. g., sequences selected from any one of Tables 3, 4, and 13-17) are inserted and linked between adjoining domains of the factor VIII and/or between the remnants of the B domain residues, such as those of Table 8. The ment of formula IX generally differs from those of the other formulae in that the one or more XTEN are each inserted within domains of FVIII rather than n domains, and/or has an XTEN linked to the C-terminus of the FVIII (or is linked Via a spacer sequence to the C-terminus of the FVIII).

In some embodiments of a CFXTEN, the fusion protein comprises a in deleted form of FVIII wherein the B-domain deletion starts from a first position at about amino acid residue number 745 and ends at a second position at amino acid residue number 1635 to about 1690 with reference to the full- length human factor VIII sequence and an XTEN links the first position and the second position of the B- domain deletion. In one embodiment of the foregoing, the first position and the second position of the B- domain deletion are selected from the positions of Table 8. In another embodiment of the foregoing, at least one XTEN links the first and second position wherein the at least one XTEN links factor VIII amino acid e 745 and amino acid residue 1640, or amino acid residue 741 and amino acid residue 1640, or amino acid residue 741 and amino acid residue 1690, or amino acid e 745 and amino acid e 1667, or amino acid e 745 and amino acid residue 1657, or amino acid residue 745 and amino acid residue 1657, or amino acid residue 747 and amino acid e 1642, or amino acid residue 751 and amino acid residue 1667. In one embodiment of the , n the factor VIII comprises an XTEN linking a first on and a second position of a B-domain deletion described in the embodiments of this paragraph, the XTEN is a sequence haVing at least 80%, or at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% or 100% sequence identity compared to a ce of comparable length selected from any one of Table 4, Table 13, Table 14, Table 15, Table 16, and Table 17, when optimally aligned, wherein the CFXTEN retains at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90% of the procoagulant activity of native FVIII.

The invention contemplates all possible permutations of insertions ofXTEN between or within the domains of FVIII or at or proximal to the insertion points of Table 5, Table 6, Table 7, Table 8, and Table 9 or those illustrated in FIGS. 8-9, with optional linking of an additional XTEN to the N— or C- terminus of the FVIII, optionally linked via an additional cleavage sequence selected from Table 12, resulting in a CFXTEN ition; miting examples of which are portrayed in FIGS. 5 and 12.

In one ment, the CFXTEN comprises a FVIII BDD sequence of Table 1 in which one or more XTEN that each has at least about 80%, or at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% or more sequence identity compared to a sequence from any one of Tables 3, 4, and 13-17 or fragments thereof are inserted between any two of the residual B domain amino acids of the FVIII BDD sequence, resulting in a single chain FVIII fusion protein, wherein the CFXTEN retains at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90% of the procoagulant activity of native FVIII. In the ing embodiment, the CFXTEN can have an additional XTEN sequence of any one of Tables 4, and 13-17 linked to the N— or C-terminus of the fusion protein. In another embodiment, a CFXTEN comprises at least a first XTEN inserted at a site set forth in Table 8, wherein the CFXTEN retains at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90% of the procoagulant activity of native FVIII. In one embodiment of a fusion protein of formula VII, the CFXTEN comprises a FVIII BDD sequence of Table 1 in which two or more XTEN that each has at least about 80%, or at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99%, or 100% ce identity compared to a sequence from any one of Tables 3, 4, and 13-17 or nts thereof are linked to a FVIII-BDD sequence in which at least one XTEN is inserted from about 3 to about 20 amino acid residues to the C-terminus side of the FVIII cleavage site amino acid R740 and from about 3 to about 20 amino acid es to the N—terminus side of the FVIII cleavage site amino acid R1689 of the residual B domain amino acids of the FVIII BDD sequence, resulting in a single chain FVIII fusion protein, and one or two XTEN are linked by a cleavage sequence to the N— and/or C-terminus of the FVIII-BDD sequence, wherein the CFXTEN ts at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90% of the procoagulant activity of native FVIII after release of the XTEN by cleavage of the cleavage sequences.

In one ment, the A3 domain comprises an a3 acidic region or a portion thereof. In another ment, at least one XTEN is inserted within the a3 acidic region or the portion thereof, N- terminus of the a3 acidic region or the n thereof, C-terminus of the a3 acidic region or the portion WO 22617 thereof, or a combination thereof. In certain embodiments, at least one XTEN is inserted within the C2 domain, N—terminus of C2 domain, C-terminus of C2 domain, or a ation thereof. In still other embodiments, the Factor VIII comprises all or portion of B domain. In yet other embodiments, at least one XTEN is inserted within all or a portion of B domain, N—terminus of B domain, C-terminus of B domain, or a combination thereof 2. CFXTEN Fusion Protein Configurations with Internal XTEN In r aspect, the invention provides CFXTEN configured with one or more XTEN sequences located internal to the FVIII ce. In one embodiment, invention provides CFXTEN configured with one or more XTEN sequences located internal to the FVIII ce to confer properties such as, but not limited to, increased stability, increased resistance to proteases, increased resistance to clearance mechanisms including but not limiting to interaction with clearance ors or FVIII inhibitors, and increased hydrophilicity, compared to FVIII without the incorporated XTEN.

The invention contemplates that different configurations or sequence variants of FVIII can be utilized as the platform into which one or more XTEN are ed. These configurations include, but are not limited to, native FVIII, FVIII BDD, and single chain FVIII (scFVIII), and variants of those configurations. In the case of scFVIII, the invention provides CFXTEN that can be constructed by replacing one or multiple amino acids of the processing site of FVIII. In one embodiment, the scFVIII ed in the CFXTEN is created by replacing the R1648 in the FVIII sequence TR (SEQ ID NO: 1698) with glycine or alanine to prevent proteolytic sing to the heterodimer form. It is specifically contemplated that any of the CFXTEN embodiments disclosed herein with a 1648 FVIII residue can have a glycine or alanine substitution for the arginine at position 1648. In some embodiments, the invention provides CFXTEN comprising scFVIII wherein parts of the sequence surrounding the R1648 processing site are replaced with XTEN, as illustrated in FIGS. 10A and 10B. In one embodiment, at least about 60%, or about 70%, or about 80%, or about 90%, or about 95%, or about 97% or more of the B-domain is ed with an XTEN sequence disclosed herein, including one or more of the R740, R1648, or R1689 cleavage sites. In another embodiment, the CFXTEN has the FVIII sequence of the B-domain between the FXIa ge sites at R740 and R1689 (with at least 1-5 adjacent B-domain amino acids also retained between the cut site and the start of the XTEN to permit the se to access the cut site) ed with XTEN. In another embodiment, the CFXTEN has the FVIII ce of the B-domain between the FXIa cleavage site at N745 and P1640 replaced with XTEN. In other embodiments, the ion provides CFXTEN FVIII BDD sequence variants in which portions of the B-domain are d but only one of the FXI R740 or R1689 activation sites (and 1-5 adjacent amino acids of the B-domain) are left within the construct, wherein the XTEN remains attached at one end to either the light or heavy chain after cleavage by FXIa, as illustrated in and 5D. In one embodiment of the foregoing, the CFXTEN comprises a FVIII BDD ce in which the amino acids between N745 to P1640 or between S743 to Q1638 or between P747 to V1642 or between N745 and Q1656 or between N745 and S1657 or between N745 and T1667 or between N745 and Q1686 or between R747 and V1642 or between T751 and T1667 are deleted and an XTEN sequence is linked between these amino acids, connecting the heavy and light chains, and can further se additional XTEN inserted either in external surface loops, between FVIII domains, or at the N— or C-termini of the FVIII BDD sequence, such as one or more insertion sites from Table 5, Table 6, Table 7, Table 8, and Table 9 or those illustrated in FIGS. 8-9. In another embodiment of the foregoing, the CFXTEN comprises a FVIII BDD sequence in which the amino acids between K713 to Q1686 or between residues 741 and 1648 are deleted and an XTEN linked between the two amino acids, and additional XTEN can be inserted either in e loops, between FVIII domains, or at the N— or ini of the FVIII BDD sequence, including but not limited to one or more insertion sites from Table 5, Table 6, Table 7, Table 8, and Table 9 or those illustrated in FIGS. 8-9. In some embodiments such CFXTEN ces can have one or more XTEN exhibiting at least about 80%, or at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99%, or 100% sequence identity to an XTEN sequence from any one of Tables 4 and 13-17.

] The invention contemplates other CFXTEN with al XTEN in s urations; schematics of exemplary configurations are illustrated in FIGS. 5 and 10. The regions suitable for XTEN insertion sites include the known domain ries of FVIII, exon boundaries, known surface (external) loops and solvent accessible surface area sites identified by X-ray crystallography analysis, and structure models derived from molecular c tions of FVIII, s with a low degree of order (assessed by programs described in FIGS. 7 legend), regions of low homology/lack of conservation across different species, and hydrophilic regions. In another embodiment, XTEN insertion sites were selected based on FVIII putative clearance receptor binding sites. In another embodiment, CFXTEN comprises XTEN inserted at ons not within close proximity to mutations implicated in hemophilia A listed in the Haemophilia A Mutation, Search, Test and Resource Site (HAMSTeRS) database were eliminated (Kemball-Cook G, et al. The factor VIII Structure and Mutation Resource Site: HAMSTeRS version 4. Nucleic Acids Res. (1998) 26(1):216-219). In another embodiment, potential sites for XTEN insertion include residues within FVIII epitopes that are capable of being bound by anti-FVIII antibodies occurring in sensitized hemophiliacs and that do not otherwise serve as protein interactive sites. Regions and/or sites that are considered for exclusion as XTEN insertion sites include es/regions of factor VIII that are important in various ctions ing other clotting proteins, residues surrounding each arginine activating/inactivating cleavage site acted on by the proteases thrombin, factor Xa, activated protein C, residues surrounding the signal peptide processing site (residue 1) if the construct contains the signal peptide, regions known to interact with other proteins such as FIXa, FX/FXa, in, activated protein C, protein S cofactor to Protein C, von Willebrand , sites known to interact with phospholipid cofactors in coagulation, residues involved in domain interactions, residues coordinating Ca++ or Cu++ ions, cysteine residues involved in S-S intramolecular bonds, nted amino acid insertion and point mutation sites in FVIII ed in hemophilia A subjects affecting procoagulant activity, and mutation sites in FVIII made in a research lab that affect procoagulant activity. Sites considered for either insertion (to prolong half-life) or for exclusion (needed to remove spent FVIIIa or FXa) e regions known to interact with n sulfate proteoglycan (HSPG) or low-density lip oprotein receptor-related protein (LPR).

By analysis of the foregoing criteria, as described in Example 34, different insertion sites or ranges of insertions sites across the FVIII BDD sequence have been identified and/or confirmed as ates for insertion of XTEN, non-limiting examples of which are listed in Table 5, Table 6, Table 7, Table 8, and Table 9 and are shown schematically in FIGS. 8 and 9. In one embodiment, CFXTEN comprise XTEN insertions between the individual domains of FVIII, i.e., between the Al and A2, or n the A2 and the B, or between the B and the A3, or between the A3 and the C1, or n the Cl and the C2 s. In r embodiment, CFXTEN comprises XTEN inserted within the B domain or between remnant residues of the BDD sequence. In another embodiment, CFXTEN comprises XTEN inserted at known exon boundaries of the encoding FVIII gene as exons represent evolutionary conserved sequence modules that have a high probability of functioning in the context of other protein sequences. In another embodiment, CFXTEN comprise XTEN inserted within surface loops identified by the x-ray structure of FVIII. In another embodiment, CFXTEN comprise XTEN inserted within regions of low order identified as having low or no detected electron density by X-ray structure is.

In another embodiment, CFXTEN se XTEN inserted within regions of low order, predicted by structure prediction algorithms such as, but not limited to dex, RONN, and Kyte & lle thms. In another embodiment, CFXTEN comprise XTEN inserted within sequence areas of high frequency of hydrophilic amino acids. In another embodiment, CFXTEN comprise XTEN inserted within epitopes e of being bound by naturally-occurring anti-FVIII antibodies in sensitized hemophiliacs.

In another embodiment, CFXTEN comprise XTEN inserted within sequence areas of low ce conservation and/or differences in sequence segment length across FVIII sequences from different species. In another embodiment, CFXTEN comprise XTEN linked to the N—terminus and/or C-terminus.

In r embodiment, the invention provides CFXTEN configurations with inserted XTEN selected from two or more of the ia from the embodiments listed above. In another embodiment, the invention provides CFXTEN configurations with at least one, atively at least two, alternatively at least three, alternatively at least four, alternatively at least five or more XTEN inserted into a factor VIII sequence wherein the points of insertion are at or proximal to the N— or C-terminus side of the at least one, two, three, four, or five, or six or more amino acids selected from the insertion residue amino acids of Table 5, Table 6, Table 7, Table 8, and Table 9 or those illustrated in FIGS. 8-9, or alternatively within one, or within two, or within three, or within four, or within five, or within six amino acids of the insertion residue amino acids from Table 5, Table 6, Table 7, Table 8, and Table 9, or within the various spans of the insertion residue amino acids schematically portrayed for an exemplary FVIII BDD sequence in As described above, the one or more intemally—located XTEN or a fragment ofXTEN can have a sequence length of 6 to 1000 or more amino acid residues. In some embodiments, wherein the CFXTEN have one or two or three or four or five or more XTEN sequences internal to the FVIII, the XTEN sequences can be identical or can be different. In one embodiment, each internally-located XTEN has at least about 80% sequence identity, or alternatively 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity compared to comparable lengths or fragments ofXTEN or motifs selected from any one of Tables 3, 4, and 13-17, when optimally aligned. In another embodiment, the invention provides a CFXTEN configured with one or more XTEN inserted internal to a FVIII BDD sequence with at least about 80% sequence identity, or atively 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity compared to a sequence of Table 1, wherein the insertions are located at the insertion points or range of insertion points indicated in Table 5, Table 6, Table 7, Table 8, and Table 9, or within the range of insertions as illustrated in It will be understood by those of skill in the art that an XTEN ed within the FVIII sequence at an insertion point of Table 5, Table 6, Table 7, Table 8, and Table 9 is linked by its N— and C-termini to flanking FVIH amino acids (or via a linking spacer or cleavage ces, as bed above), while an XTEN linked to the N— or C-terminus of FVIII would only be linked to a single FVIII amino acid (or to a linking spacer or cleavage sequence amino acid, as described above). By way of example only, variations of CFXTEN with three internal XTEN could have: XTEN (as described herein) incorporated n FVHI BDD residues 741 and 1640, residues 18 and 19, and es 1656 and 1657; or XTEN incorporated between FVHI BDD residues 741 and 1640, residues 1900 and 1901, and at the C-terminus at residue 2332; or XTEN incorporated between FVHI BDD residues 26 and 27, residues 1656 and 1657, and residues 1900 and 1901; or XTEN incorporated n FVHI BDD residues 741 and 1640, residues 1900 and 1901, and at the C-terminus at residue 2332.

In evaluating the CFXTEN fusion ns with XTEN inserted in the locations from Table 5, it was discovered that insertions in certain regions of the FVIII sequence resulted in CFXTEN with good expression and retention of procoagulant activity. Accordingly, in preferred embodiments, the ion provides CFXTEN fusion ns configured with one, or two, or three, or four, or five, or six or more XTEN, each having at least about 80% sequence identity, or alternatively 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence ty compared to an XTEN selected from any one of Tables 4, and 13-17 inserted internal or linked to a FVIII BDD sequence with at least about 80% sequence identity, or alternatively 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% ce identity compared to a sequence of Table 1, wherein the insertions are located at an insertion point within one, or two, or three, or four, or five, or six or more ranges set forth in Table 7. 1n the foregoing embodiments, the CFXTEN fusion ns with the XTEN insertions retain at least about %, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% or more of the procoagulant activity compared to the corresponding FVIII not linked to XTEN.

In evaluating the CFXTEN fusion ns with XTEN inserted in one or more locations from Table 5, it was surprisingly discovered that a high tage of fusion proteins with the XTEN insertions retained procoagulant activity, as described in Example 25. Accordingly, the invention provides CFXTEN fusion proteins configured with one, two, three, four, five, six or more XTEN wherein WO 22617 the resulting fusion protein exhibits at least about 10%, or 20%, or 30%, or 40%, or 50%, or 60%, or 70%, or 80%, or 90% or more of the procoagulant activity compared to the corresponding FVIII not linked to XTEN when assayed by a coagulation assay described herein. In a preferred embodiment, the invention provides CFXTEN fusion proteins sing one, or two, or three, or four, or five, or six or more XTEN, each having at least about 80% sequence identity, or alternatively 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity compared to an XTEN selected from any one of Tables 4, and 13-17 linked to a FVIII BDD sequence with at least about 80% sequence identity, or alternatively 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence ty compared to a sequence of Table 1, wherein the insertions are located at one or more insertion points selected from Table 5, Table 6, Table 7, Table 8, and Table 9, and wherein the resulting fusion protein exhibits at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70% or more procoagulant activity compared to the corresponding FVIII not linked to XTEN, when assayed in vitro by an assay bed herein (e. g., a chromogenic assay). As the subject CFXTEN fusion proteins typically exhibit increased terminal half-life compared to native FVHI, it will be appreciated by one of skill in the art that a CFXTEN with lower procoagulant activity relative to an equimolar amount of native FVIH would nevertheless be acceptable when administered as a therapeutic ition to a subject in need therof. In another embodiment, the CFXTEN fusion proteins sing one, or two, or three, or four, or five or more XTEN, each having at least about 80% sequence identity, or alternatively 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity compared to an XTEN selected from any one of Tables 4, and 13-17 linked to a FVIII BDD sequence with at least about 80% sequence identity, or alternatively 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity compared to a sequence of Table 1, wherein the insertions are d at one or more ion points or the range of insertion points selected from Table , Table 6, Table 7, Table 8, and Table 9, wherein the resulting fusion n exhibits at least about 0.5 IU/ml, or at least about 0.75 lU/ml, or at least about 1.0 lU/ml, or at least about 1.5 lU/ml, or at least about 2.0 IU/ml, or at least about 2.5 lU/ml, or at least about 3 lU/ml, or at least about 4 lU/ml, or at least about 5 lU/ml, or at least about 7 lU/ml, or at least about 10 lU/ml, or at least about 20 lU/ml, or at least about 30 lU/ml FVIII activity when expressed in cell culture medium and assayed in a chromogenic assay, wherein the culture and expression are according to methods described herein; e.g., the methods of e 25.

It is believed that the discovery of the insertions sites wherein the FVIH s at least a portion of its procoagulant activity would also permit the insertion of other peptides and polypeptides with either unstructured or structured characteristics that are ated with the prolongation of half-life when fused to a FVIII protein in one or more of those same sites. Non-limiting examples include albumin, n fragments, Fc fragments of immunoglobulins, the B subunit of the C-terminal peptide (CTP) of human chorionic gonadotropin, a HAP sequence, a transferrin, the PAS polypeptides of US.

Pat Application No. 20100292130, polyglycine linkers, polyserine linkers, peptides and short polypeptides of 6-40 amino acids of two types of amino acids selected from glycine (G), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P) with varying degrees of secondary structure from less than 50% to greater than 50%, amongst , would be suitable for insertion in the identified active insertions sites of FVIII.

In the fusion protein embodiments described herein, the CFXTEN fusion protein can fithher comprise one or more cleavage sequence from Table 12 or other sequences known in the art, the cleavage sequence being located between or within 6 amino acid es of the intersection of the FVIII and the XTEN ces, which may include two cleavage sequences in a given internal XTEN sequence. In one embodiment, the CFXTEN comprising cleavage ces has two identical cleavage sequences, each located at or near the respective ends of one or more internal XTEN such that the XTEN is released from the fusion protein when cleaved by the protease that binds to and cleaves that sequence.

The sequences that can be cleaved are described more fully below and exemplary sequences are provided in Table 12.

Table 5: Insertion ons for XTEN linked to the FVIII BDD seguence FVIH BDD XTEN Insertion Insertion FVH? N0. . . Downstream Domaln P01nt Resume Sequence 1 0 (N-terminus) ATR A1 2 3 R RYY A1 3 17 M QSD A1 4 18 Q SDL A1 22 G ELP A1 6 24 L PVD A1 7 26 V DAR A1 8 28 A RFP A1 9 32 P RVP A1 3 8 F PFN A1 11 40 F NTS A1 12 41 N TSV A1 13 60 N IAK A1 14 61 I AKP A1 65 R PPW A1 16 81 Y DTV A1 17 111 G AEY A1 18 116 D QTS A1 19 119 S QRE A1 120 Q REK A1 21 128 V FPG A1 22 129 F PGG A1 23 130 P GGS A1 24 182 G SLA A1 185 A KEK A1 26 188 K TQT A1 27 205 G KSW A1 28 210 S ETK A1 29 211 E TKN A1 216 L MQD A1 31 220 R DAA A1 32 222 A ASA A1 W0 22617 FVHI BDD XTEN Insertion Insertion FVH? Pomt. ReSIdue.

Downstream Domaln —Seb 33 223 A SAR A1 34 224 s ARA A1 230 K MHT A1 36 243 p GL1 A1 37 244 G L1G A1 3 8 250 R KSV A1 39 318 D GME A1 40 333 P QLR A1 42 334 Q LRM A1 43 336 R MKN a1 44 339 N NEE a1 45 345 D YDD a1 46 357 V VRF a1 47 367 S FIQ a1 48 370 s RPY a1 49 375 A KKH A2 50 376 K KHP A2 51 378 H PKT A2 52 399 V LAP A2 53 403 D DRS A2 54 405 R SYK A2 55 409 S QYL A2 56 416 P QRI A2 57 434 E TFK A2 58 43 8 T REA A2 59 441 A IQH A2 60 442 1 QHE A2 61 463 I IFK A2 62 487 Y SRR A2 63 490 R LPK A2 64 492 P KGV A2 65 493 K GVK A2 66 494 G VKH A2 67 500 D FPI A2 68 506 G EIF A2 69 518 E DGP A2 70 556 K ESV A2 71 565 Q IMS A2 72 566 I MSD A2 73 598 P AGV A2 74 599 A GVQ A2 75 603 L EDP A2 76 616 s ING A2 77 686 G LWI A2 78 713 K NTG A2 79 719 Y EDS A2 80 730 L LSK A2 81 733 K NNA A2 82 745 N PPV B 83 1640 P PVL B 84 1652 R TTL B 85 1656 Q SDQ A3 86 1685 N QSP A3 FVHI BDD XTEN Insertion Insertion FVH? P01nt. ReSIdue.

Downstream Domaln 87 171 1 M SSS A3 88 1713 S SPH A3 89 1720 N RAQ A3 90 1724 S GSV A3 91 1725 G SVP A3 92 1726 S VPQ A3 93 1741 G SFT A3 94 1744 T QPL A3 95 1749 R GEL A3 96 1773 V TFR A3 97 1792 Y EED A3 98 1793 E EDQ A3 99 1796 Q RQG A3 100 1798 Q GAE A3 101 1799 G AEP A3 102 1802 P RKN A3 103 1803 R KNF A3 104 1807 V KPN A3 105 1808 K PNE A3 106 1827 K DEF A3 107 1844 E KDV A3 108 1861 N TLN A3 109 1863 L NPA A3 1 10 1896 E RNC A3 1 1 1 1900 R APC A3 1 12 1904 N IQM A3 1 13 1905 I QME A3 1 14 1910 P TFK A3 1 15 1920 A ING A3 1 16 1937 D QRI A3 1 17 1981 G VFE A3 1 18 2019 N KCQ A3 1 19 2020 K CQT C1 120 2044 G QWA C1 121 2068 F SW1 C1 122 2073 V DLL C1 123 2090 R QKF C1 124 2092 K FSS C1 125 2093 F SSL C1 126 21 1 1 K WQT C1 127 21 15 Y RGN C1 128 2120 T GTL C1 129 2125 V FFG C1 130 2171 L NSC C1 131 2173 S CSM C2 132 2188 A QIT C2 133 2223 V NNP C2 134 2224 N NPK C2 135 2227 K EWL C2 136 2268 G HQW C2 137 2277 N GKV C2 13 8 2278 G KVK C2 139 2290 F TPV C2 140 2332 Y C terminus of FVIII CT Indicates an insertion point for XTEN based on the amino acid number of mature full-length human FVHI, wherein the insertion could be either on the N- or C-terminal side of the indicated amino acid Downstream sequence in FVIII BDD with 746-1639 deletion Table 6. Exemplagy insertion locations for XTEN linked to a FVIII polypeptide FVHI BDD XTEN Insertion FVIII D1§t3“°6.fr°m No. . . Downstream insertion Insertion Point . Domain.

Se . uence residue 9 32 P RVP A1 -3, --6 31 220 R DAA A1 - 34 224 S ARA A1 +5 43 336 R MKN a1 -1, --6 44 339 N NEE a1 -4, --5 52 399 V LAP A2 -6, ——3 56 416 P QRI A2 +6 75 603 L EDP A2 _6, --6 85 1656 Q SDQ B —3, --6 87 1711 M SSS A3 -6, --1 91 1725 G SVP A3 --6 1 13 1905 I QME A3 --6 114 1910 P TFK A3 -5, --6 Distance from insertion residue refers to the ve number of amino acids away from the N-terminus (negative numbers) or C-terminus (positive numbers) of the designated insertion residue (residue “0”) where an insertion may be made. The designation “-X” refers to an insertion site which is X amino acids away on the inal side of the designated insertion residue. Similarly, the designation “+X” refers to an insertion site which is X amino acids away on the C-terminal side of the designated insertion For e, “-1, +2” indicates that the insertion is made at the N-terminus or C-terminus of amino acid residues denoted -1, 0, +1 or +2.

Table 7. Further exemplagy insertion locations for XTEN linked to a FVIII polypeptide XTEN Insertion First ion FVIII Domain Point Range Residue 3 18-32 Q A1 8 40 F A1 18 21 1-224 E A1 27 336-403 R A1, A2 43 599 A A2 47 745-1640 N B 50 1656-1728 Q B, A3 57 1796-1804 R A3 65 1900-1912 R A3 81 2171-2332 L C1,C2 indicates range of insertion sites ed relative to the amino acid number of mature human FVIII PCT/U82012/046326 Table 8. Exemplary XTEN insertion locations within B-domain deleted variants of a FVIII polypeptide XTEN Insertion First Insertion Second Insertion Point Range Residue Residue 740-1640 R P 740-1690 R S 741-1648 S R 743-163 8 S Q 745-163 8 N Q 745-1640 N P 745-1656 N Q 745-1657 N S 745-1667 N T 86 N Q 42 R V 751-1667 T T indicates the amino acids linked Within the B-domain deleted variant and nt A3 domain, With the amino acids numbered relative to the amino acid number of mature human FVIII indicates the amino acids linked by an XTEN inserted in the BDD-FVHI Table 9. Exemplary insertion locations for XTEN linked to a FVIII polypeptide resulting in procoagulant activity A F 111 BDD F III XTEN Insertlon N0. ion ReSidue Dywnmam Danain Point ——_____%gm_— 2 3 R RYY A1 4 18 Q SDL A1 22 G ELP A1 7 26 V DAR A1 11 40 F NTS A1 18 116 D QTS A1 19 119 S QRE A1 26 188 K TQT A1 29 211 E TKN A1 216 L MQD A1 31 220 R DAA A1 34 224 S ARA A1 230 K MHT A1 40 333 P QLR A1 43 336 R MKN a1 44 339 N NEE a1 52 399 V LAP A2 53 403 D DRS A2 55 409 s QYL A2 56 416 P QRI A2 60 442 l QHE A2 62 487 Y SRR A2 63 490 R LPK A2 66 494 G VKH A2 69 518 E DGP A2 74 599 A GVQ A2 75 603 L EDP A2 2012/046326 . FVIII BDD FVIII XTEN Insertion No. Insertion e ream Domain Pomt Sequence 78 713 K NTG A2 82 745 N PPV B 85 1656 Q SDQ A3 87 1711 M SSS A3 89 1720 N RAQ A3 91 1725 G SVP A3 99 1796 Q RQG A3 102 1802 P RKN A3 110 1896 E RNC A3 111 1900 R APC A3 112 1904 N IQM A3 113 1905 I QME A3 114 1910 P TFK A3 121 2068 F SWI C1 130 2171 L NSC C1 135 2227 K EWL C2 137 2277 N GKV C2 140 2332 Y C terminus of FVIII C2 Downstream ce in FVIII BDD with 39 deletion In another aspect, the invention provides libraries of components and methods to create the libraries d from nucleotides encoding FVIII segments, XTEN, and FVIII segments linked to XTEN that are useful in the preparation of genes encoding the subject CFXTEN. In a first step, a library of genes encoding FVIII and XTEN inserted into the various single sites at or within 1-6 amino acids of an insertion site identified in Table 5 or illustrated in FIGS. 8-9 are created, expressed, and the CFXTEN recovered and evaluated for activity and pharmacokinetics as illustrated in . Those CFXTEN showing enhanced properties are then used to create genes encoding a FVIII segment and the insertion site plus an XTEN, with components from each ed insertion represented in the library, as illustrated in . In one embodiment, the library components are assembled using standard recombinant techniques in combinatorial n, as rated in , resulting in permutations of CFXTEN with multiple internal and N- and C-terminus XTEN, that can include the insertion sites of or proximal to those Table 5, Table 6, Table 7, Table 8 and Table 9, or as illustrated in FIGS. 8-9. The resulting constructs would then be evaluated for activity and enhanced pharmacokinetics, and those candidates resulting in CFXTEN with enhanced properties, e.g., d active clearance, resistance to proteases, reduced immunogenicity, and enhance pharmacokinetics, compared to FVIII not linked to XTEN, are evaluated further. 3. XTEN Permissive Loops As described in detail elsewhere herein and as illustrated in FIGS.33-3 6, the inventors have recognized that each FVIII “A” domain comprise at least two “XTEN permissive loops” into which XTEN sequences can be inserted without eliminating procoagulant activity of the recombinant protein, or the ability of the recombinant proteins to be expressed in Vivo or in Vitro in a host cell. The inventors have identified the XTEN permissive loops as regions with, among other attributes, high surface or WO 22617 solvent exposure and high conformational flexibility. The Al domain comprises an XTEN permissive loop-l (Al -1) region and an XTEN permissive loop-2 (Al -2) region, the A2 domain comprises an XTEN permissive loop-l (A2-l) region and an XTEN sive loop-2 (A2-2) , the A3 domain comprises an XTEN permissive loop-l (A3-l) region and an XTEN permissive loop-2 (A3-2) region..

In certain aspects a recombinant FVIII protein as described above comprises at least one XTEN sequence inserted into at least one of the XTEN permissive loops Al-l, A1-2, A2-1, A2-2, A3-1, or A3- 2, wherein the recombinant FVIII protein has procoagulant ty and can be expressed in Vivo or in Vitro in a host cell. In n aspects a recombinant FVIII protein as described above comprises at least two XTEN sequences inserted into FVIII, e. g., into two different XTEN permissive loops Al-l, A1-2, A2-l, A2-2, A3-l, or A3 -2, wherein the recombinant FVIII protein has procoagulant activity and can be sed in Vivo or in Vitro in a host cell. Alternatively, a recombinant FVIII protein as described above can comprise two or more XTEN sequences inserted into a single XTEN permissive loop either with our without XTEN sequences inserted into other XTEN permissive loops, n the recombinant FVIII protein has procoagulant actiVity and can be expressed in Vivo or in Vitro in a host cell. In certain aspects a recombinant FVIII protein as bed above can comprise at least one XTEN sequence ed into at least one of the XTEN permissive loops as described above, and can further comprise one or more XTEN sequences inserted into a3, wherein the recombinant FVIII protein has procoagulant actiVity and can be expressed in Vivo or in Vitro in a host cell. In certain aspects, a recombinant FVIII protein of the invention can comprise three, four, five, six or more XTEN sequences inserted into one or more XTEN permissive loops or into a3, wherein the recombinant FVIII protein has procoagulant actiVity and can be expressed in Vivo or in Vitro in a host cell.

In certain aspects a recombinant FVIII protein as bed above ses at least one XTEN sequence inserted into a3, wherein the recombinant FVIII protein has procoagulant actiVity and can be expressed in Vivo or in Vitro in a host cell. In certain aspects a recombinant FVIII protein of the invention comprises at least one XTEN sequence inserted into a3, and further comprises one or more XTEN ces inserted into one or more XTEN permissive loops as described above, wherein the recombinant FVIII protein has procoagulant actiVity and can be expressed in Vivo or in Vitro in a host cell.

The inventors have recognized that a recombinant FVIII protein of the invention comprises at least two XTEN permissive loops in each of the FVIII A domain regions which allows for insertion of an XTEN sequence while haVing procoagulant actiVity and still being able to be expressed in Vivo or in Vitro by a host cell. Various crystal structures of FVIII have been determined, of varying degrees of resolution. These structures of FVIII and FVIIIa, determined by X-ray crystallography and molecular c simulation, were used to generate models of accessible e area and mational flexibility for FVIII. For example, the crystal structure of human FVIII has been determined by Shen et al. Blood 111: 1240-1247 (2008) and Ngo et al. Structure 16: 597-606 (2008). The data for these structures is available from the Protein Data Bank (pdb.org) under Accession s 2R7E and 3CDZ, respectively.

The predicted secondary structure of the heavy and light chains of human FVIII according to the Shen et al. crystal structure is reproduced in FIGS. 37A and 37B. The various beta strands predicted from the Shen et al. crystal structure are numbered consecutively in FIGS. 8A and 8B. In certain embodiments, the XTEN permissive loops A1-1, A1-2, A2-1, A2-2, A3-1, and A3 -2 are contained within surface-exposed, flexible loop structures in the A domains of FVIII. A1-1 is located between beta strand 1 and beta strand 2, A1-2 is located between beta strand 11 and beta strand 12, A2-1 is located between beta strand 22 and beta strand 23, A2-2 is located between beta strand 32 and beta strand 33, A3-1 is d between beta strand 38 and beta strand 39 and A3-2 is located n beta strand 45 and beta strand 46, according to the ary ure of mature FVIII stored as Accession Number 2R7E of the PDB database (PDB:2R7E) and as shown in FIGS. 8A and 8B. The secondary structure of PDB Accession Number 2R7E shown in FIGS. 8A and 8B corresponds to the standardized ary structure assignment ing to the DSSP program (Kabsch and Sander, Biopolymers, 22:2577-2637 (1983)).

The DSSP secondary structure of the mature FVIII stored as PDB Accession Number 2R7E can be accessed at the DSSP database, available at the world wide web site swift.cmbi.ru.n1/gV/dssp/ (last accessed February 9, 2012) (Joosten et al., 39(Suppl. 1): D411-D419 (2010)).

In n aspects, a surface-exposed, flexible loop structure comprising A1-1 corresponds to a region in native mature human FVIII from about amino acid 15 to about amino acid 45 of . In certain aspects, A1-1 corresponds to a region in native mature human FVIII from about amino acid 18 to about amino acid 41 of . In certain aspects, the surface-exposed, flexible loop structure sing A1-2 corresponds to a region in native mature human FVIII from about amino acid 201 to about amino acid 232 of . In certain aspects, A1-2 corresponds to a region in native mature human FVIII from about amino acid 218 to about amino acid 229 of . In certain aspects, the surface-exposed, flexible loop structure comprising A2-1 corresponds to a region in native mature human FVIII from about amino acid 395 to about amino acid 421 of . In certain aspects, A2-1 corresponds to a region in native mature human FVIII from about amino acid 397 to about amino acid 418 of . In certain aspects, the surface-exposed, flexible loop structure comprising A2-2 ponds to a region in native mature human FVIII from about amino acid 577 to about amino acid 635 of . In certain aspects, A2-2 corresponds to a region in native mature human FVIII from about amino acid 595 to about amino acid 607 of . In certain aspects, the surface-exposed, flexible loop ure sing A3-1 corresponds to a region in native mature human FVIII from about amino acid 1705 to about amino acid 1732 of . In n aspects, A3-1 corresponds to a region in native mature human FVIII from about amino acid 1711 to about amino acid 1725 of .

In certain s, the surface-exposed, flexible loop structure comprising A3-2 ponds to a region in native mature human FVIII from about amino acid 1884 to about amino acid 1917 of In certain aspects, A3 -2 corresponds to a region in native mature human FVIII from about amino acid 1899 to about amino acid 1911 of .

In certain aspects a recombinant FVIII protein of the invention comprises one or more XTEN sequences inserted into one or more XTEN permissive loops of FVIII, or into the a3 region, wherein the recombinant FVIII protein has procoagulant activity and can be sed in Vivo or in Vitro in a host cell. XTEN sequences to be inserted include those that increase the in Vivo half-life or the in Vivo or in Vitro stability of FVIII.

In certain aspects, a recombinant FVIII protein of the invention comprises an XTEN sequences inserted immediately downstream of one or more amino acids corresponding to one or more amino acids in mature native human FVIII including, but not limited to: amino acid 18 of , amino acid 26 of , amino acid 40 of , amino acid 220 of , amino acid 224 of , amino acid 399 of , amino acid 403 of , amino acid 599 of , amino acid 603 of , amino acid 1711 of , amino acid 1720 of , amino acid 1725 of , amino acid 1900 of , amino acid 1905 of , amino acid 1910 of , or any ation thereof, including corresponding insertions in EDD-variants of FVIII described herein.

In certain aspects, a recombinant FVIII protein of the invention comprises at least one XTEN sequence inserted into the a3 region of FVIII, either alone or in ation with one or more XTEN sequences being inserted into the XTEN permissive loops of the A domains (e. g., Al-l, A1-2, A2-1, A2- 2, A3-1, or A3 -2 as described above), wherein the inant FVIII protein has procoagulant actiVity and can be expressed in Vivo or in Vitro in a host cell. In certain aspects, at least one XTEN sequence is inserted into the a3 region immediately downstream of an amino acid which corresponds to amino acid 1656 of . In certain aspects, a recombinant FVIII protein of the invention ses an XTEN sequence ed into the a3 region as described, and further includes one or more XTEN sequences inserted immediately downstream of one or more amino acids corresponding to one or more amino acids in mature native human FVIII including, but not limited to: amino acid 18 of , amino acid 26 of , amino acid 40 of , amino acid 220 of , amino acid 224 of , amino acid 399 of , amino acid 403 of , amino acid 599 of , amino acid 603 of , amino acid 1711 of , amino acid 1720 of , amino acid 1725 of , amino acid 1900 of , amino acid 1905 of , amino acid 1910 of , or any combination thereof.

It will be understood by one of skill in the art that the foregoing s of permissive loops of a native FVIII protein into which a heterologous n can be inserted are also applicable to the B- domain deleted FVIII variants described herein; e. g., sequences set forth in Table 1. In practicing the present ion, it will be understood that a BDD-FVIII sequence of Table 1 can be substituted for the recombinant FVIII n of the various embodiments described above, and it is ed that the resulting constructs will similarly retain procoagulant actiVity. 4. Interference with FVIII binding agents It is an object of the present invention to provide procoagulant CFXTEN fusion protein compositions for use in human patients suffering from coagulopathies, such as haemophilia A, who have native or acquired antibodies, tors, or other proteins or molecules that bind to FVIII that affect the actiVity or half-life of CFXTEN fusion proteins, n the CFXTEN retain a greater amount of procoagulant ty compared to the corresponding FVIII not linked to XTEN. As used herein, “FVIII binding agent” means any molecule capable of binding to native FVIII or to a recombinant factor VIII fusion protein of the invention comprising factor VIII or a fragment thereof, whether native, derived, or produced inantly. It is specifically contemplated that FVIII binding agent includes anti-FVIII antibodies and FVIII inhibitors, amongst other proteins capable of specifically binding to FVIII. In one aspect, the invention provides procoagulant CFXTEN fiJsion proteins that exhibit d binding to an anti-FVIII antibody or FVIII inhibitor that eres with the procoagulant activity of FVIII. As used herein, “anti-FVIII antibody” or “anti-factor VIII antibody” means an antibody capable of binding FVIII or a FVIII component of a CFXTEN of the invention, said dy including but not limited to the antibodies of Table 10 or polyclonal antibody from a hemophilia A t with FVIII inhibitors. The term antibody es monoclonal antibodies, polyclonal antibodies, antibody fragments and antibody fragment clones. As used herein, “FVIII inhibitor” or “anti-FVIII inhibitor antibody” means an antibody capable of binding FVIII or a FVIII component of a CFXTEN of the invention and that reduces by any means the procoagulant actiVity of FVIII or the FVIII component of a CFXTEN. In another aspect, the invention provides CFXTEN fusion ns that retain procoagulant actiVity in the presence of a FVIII inhibitor. In another aspect, the invention provides CFXTEN fusion proteins comprising FVIII that exhibit increased terminal half-life in the presence of a FVIII g agent ed to the FVIII not linked to XTEN.

] The majority of inhibitory antibodies to human factor VIII act by binding to epitopes located in the A2 domain or the C2 domain of factor VIII, disrupting specific functions associated with these s, (US. Patent No. 6,770,744; Fulcher et al. Localization of human factor FVIII inhibitor epitopes to two ptide fragments. Proc. Natl. Acad. Sci. USA (1985) 82:7728-7732; Scandella et al. Epitope mapping of human factor VIII inhibitor antibodies by deletion analysis of fVIII fragments expressed in Escherichia coli. Proc. Natl. Acad. Sci. USA (1988) 85:6152-6156). While 68% percent of inhibitory dies are reported to be directed against the A2 and/or C2 domain, 3% act against the A1 domain and 46% against the a3 acidic region (LaVigne-Lissalde, G., et al. Characteristics, mechanisms of , and epitope mapping of actor VIII antibodies. Clin ReV Allergy Immunol (2009) 37:67-79). For example, certain heavy chain-specific inhibitors react with the 18.3-kD amino-terminal segment of the A2 domain (Scandella D, et al. 198 8); Lollar P et al. Inhibition of human factor VIIIa by anti-A2 subunit antibodies. J Clin Invest 1994;93:2497). FVIII contains a phospholipid binding site in the C2 domain n amino acids 2302 and 2332, and there is also a von Willebrand factor binding site in the C2 domain that acts in conjunction with amino acids 1649-1689 in the A3 . The C2 domain also has epitopes that, when bound by inhibitors, block the activation of FVIII by thrombin or factor Xa.

Inhibitors g specifically to the light chain recognize epitopes in the A3 domain or a major antigenic region in the C2 domain and can result in reduced procoagulant actiVity by preventing the binding of FVIII to phospholipid or reducing the dissociation rate of FVIII from von Willebrand factor (Gilles JG, et al. Anti-factor VIII dies of hemophiliac patients are frequently directed s nonfunctional determinants and do not exhibit isotypic restriction. Blood (1993) 82:2452; Shima M, et al. A factor VIII neutralizing monoclonal antibody and a human tor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine. Thromb Haemost (1993) 69:240). Non-limiting examples of monoclonal FVIII tors are listed in Table 9. In patients with high-titer tors, there is an increased risk of developing recurrent bleeding in particular joints, which may ultimately result in decreased quality of life, disability, or death from excessive blood loss (US. Pat. Application No. 20120065077; Zhang et al., Clinic. Rev. Allerg. Immunol., 37:114-124 ; Gouw and van den Berg, Semin. Thromb. Hemost., 35 :723-734 (2009)) While not intending to be bound by any ular theory, it is believed that the ctured characteristic of the XTEN incorporated into the CFXTEN fusion proteins permits the XTEN to adopt conformations that result in steric hindrance to inhibitors that would otherwise bind to FVIII epitopes.

As illustrated in as the incorporated XTEN assumes various random coil conformations, it spatially covers regions of the FVIII component of the fusion n and sterically interferes with the ability of an inhibitor to bind to a FVIII epitope.

In one embodiment, the invention provides CFXTEN exhibiting procoagulant ty and reduced binding in the presence of an antibody binding to the C2 domain of factor VIII compared to the corresponding factor VIII not linked to XTEN and/or to native FVIII. In another embodiment, the invention provides CFXTEN ting procoagulant activity and reduced binding in the presence of an dy g to the A2 domain of Factor VIII compared to the corresponding factor VIII not linked to XTEN or to native FVIII. In another embodiment, the invention provides CFXTEN exhibiting procoagulant activity and reduced binding in the presence of antibodies binding to the A2 and the C2 domain of Factor VIII, compared to the corresponding factor VIII not linked to XTEN or to native FVIII.

In one embodiment, the invention provides CFXTEN exhibiting procoagulant activity and reduced g, compared to the ponding FVIII not linked to XTEN, in the presence of an antibody selected from the group consisting of the antibodies of Table 10. In one embodiment, the CFXTEN fusion protein exhibits reduced binding to the dy GMA8021. In another embodiment, the CFXTEN fusion protein exhibits d binding to the antibody GMA8008. In another embodiment, the CFXTEN fusion protein exhibits reduced binding to the antibody ESH4. In another embodiment, the CFXTEN fusion protein exhibits reduced binding to the antibody ESH8. In another embodiment, the CFXTEN fusion protein exhibits d binding to the antibody B02C11. In another ment, the CFXTEN fusion protein exhibits reduced binding and a greater degree of procoagulant activity, ed to the corresponding FVIII not linked to XTEN, in the presence of plasma from a hemophilia A t with polyclonal antibody FVIII inhibitors, wherein the r degree of procoagulant activity is determined by an in Vitro assay such as a Bethesda assay or other assay described herein.

The CFXTEN exhibiting reduced binding by FVIII inhibitors can have one, or two, or three, or four, or five, or six or more individual XTEN, embodiments of which are disclosed herein. In the foregoing embodiments of this paragraph, a CFXTEN exhibits at least 5%, or 10%, or 15%, or 20%, or %, or 40%, or 50%, or 60%, or 70% or less binding to the antibody when assessed in Vitro in an assay capable of assaying the binding of an antibody to FVIII, such as assays described herein below or those known in the art. Alternatively, the reduced binding of the subject CFXTEN to the binding antibodies can be assessed by retention of a higher degree of gulant activity in the presence of the 2012/046326 antibody compared to FVIII not linked to XTEN, as described in the Examples. Thus, in the embodiments ning to reduced binding by FVIII tors described herein, a CFXTEN ts, when reacted with the anti-FVIH antibody, at least 5%, or 10%, or 15%, or 20%, or 30%, or 40%, or 50%, or 60%, or 70%, or 80%, or 100%, or 200%, or 300%, or 400%, or 500% or more activity in a ation assay (such as described herein below) compared to the corresponding FVIII not linked to XTEN and reacted with the antibody. In the foregoing, the anti-FVHI antibody can be an antibody from Table 9 or a circulating anti-FVHI antibody from a hemophilia A subject. In another embodiment, the invention provides CFXTEN in which the assayed fusion protein, when assayed utilizing the Bethesda assay and an anti-FVHI antibody selected from Table 10 or a polyclonal anti-FVHI antibody ation such as, but not limited to, plasma from a hemophilia A subject with FVIII inhibitors, results in a Bethesda titer with at least about 2, 4, 6, 8, 10, 12, 15, 20, 30, 40, 50, 60, 70, 80, 100, or 200 fewer Bethesda units compared to a FVIII not linked to XTEN and assayed under comparable conditions. In another embodiment, the invention provides CFXTEN in which the assayed fusion protein results in less than 50%, or less than 40%, or less than 30%, or less than 25%, or less than 20%, or less than 15%, or less than 14%, or less than 13%, or less than 12%, or less than 11%, or less than 10% of the Bethesda Units ed to a FVIII not linked to XTEN when assayed under comparable conditions utilizing the da assay and a polyclonal anti-FVHI antibody preparation such as, but not limited to, plasma from a hemophilia A subject with FVHI inhibitors.

Table 10: Anti-factor VIII antibodies Antibody Epitope Inhibitor Titer Reference Designation BU/mg C2 Domain US. 6,770,744 BOZCH 20000 Met2199/Phe2200 Blood (2007) 110:4234—4242 C2 Domain NMC VIII-5 US. 6,770,744 Glu2181-Val2243 ESH2 Light Chain ADI Light Chain US. 744 ESH4 39 2303-2332 Blood (2007) 110:4234—4242 C2 Domain US. 6,770,744 ESH8 10000 2248-2285 Blood {2007} 110:4234—4242 RHDS (LMBP C1 Domain US Pat. Appllcatlon 20090263380 6165CB; . US Pat. ation 20090263380 LE2E9 C1 Domam Blood (2000) 95:156-163 154 C2 Domain 1300 Blood (2007) 110:4234—4242 F85 C2 Domain 6 Blood (2007) 110:4234—4242 131 .00 C2 Domain 5 Blood 2007 110:4234—4242 E137 C2 Domain 6 Blood (2007) 34—4242 189 C2 Domain 1900 Blood (2007) 110:4234—4242 1117 C2 Domain 1800 Blood (2007) 110:4234—4242 ll 09 Meg9137;111:23200 1500 Blood (2007) 110:4234—4242 1135 C2 Domain 930 Blood (2007) 110:4234—4242 3C6 C2 Domain 71 Blood (2007) 110:4234—4242 31312 (3131:5113? 2600 Blood (2007) 110:4234—4242 Antibody Epitope Inhibitor Titer Reference Designation BU/mg 13102 C2 Domain 3800 Blood 2007 110:4234—4242 3G6 C2 Domain 25000 Blood (2007) 110:4234—4242 2—77 C2 Domain 25000 Blood (2007) 110:4234—4242 B45 C2 Domain 21000 Blood (2007) 110:4234—4242 B9 C2 Domain 31000 Blood 2007 110:4234—4242 1311 C2 Domain 3300 Blood 2007 110:4234—4242 B75 C2 Domain Indeterminate Blood (2007) 110:4234—4242 3105 Valg2213712nzl2n227 08 Blood (2007) 110:4234—4242 F77 C2 Domain 26000 Blood 2007 34—4242 13178 C2 Domain 18000 Blood (2007) 110:4234—4242 F67 C2 Domain 21000 Blood (2007) 110:4234—4242 (399 13712nzl2n227 15000 Blood (2007) 110:4234—4242 (386 C2 Domain 4300 Blood (2007) 34—4242 114 C2 Domain 44000 Blood (2007) 110:4234—4242 155 C2 Domain 10000 Blood (2007) 110:4234—4242 2»—--l 17 C2 Domain >0.4 Blood 2007 34—4242 A2 domain GMAOIZ GVIA 497-510; 584-593 GVIA8001 A3 Domain 1 5 6 GVIA GVIA8002 A1 Domain <1 GVIA GVIA8003 C2 Domain GVIA GVIA8004 A1 Domain GVIA GVIA8005 A1A3/A1 Domain GVIA GVIA8006 c2 Domain GVIA 08 C2 Domain 1047 GVIA GVIA8009 A2 Domain 7923 GVIA GVIA801 0 LC Domain GVIA GVIA801 1 C1 Domain 97 GVIA GVIA8012 A1A3 Domain 204 GVIA GVIA8013 A3C2 Domain 3 0 GVIA GVIA8014 C2 Domain 7799 GVIA GVIA8015 A2 Domain 17079 GVIA GVIA801 6 A2 Domain <1 GVIA 17 A2 Domain 3 34 GVIA GVIA801 8 LC Domain 242 GVIA GVIA8019 CR-LC Domain GVIA GVIA8020 A1A3 Domain 196 GVIA GVIA8021 A2 Domain 33928 GVIA 4A4 A2 Domain 40000 231mm) Haemost (2009) 7.658- 3136 C2 Domain 41 Blood (2007) 110:4234—4242 an Diagnostica Inc. internet site, URL located on the World Wide Web at americandiagnostica.c0m/html/Pr0duct_Detail.asp?idCategorF5&idSubCategor3F104&idpr0=ESH-8 as it existed on January 12, 2012 Green Mountain Antibodies internet site, URL located on the World Wide Web at greenmoab.com/product_details/16316/215 82.html as it existed on January 12, 2012 Assays For Inhibitor and Antibody Binding The fusion ns of the invention may be assayed to confirm reduced binding by FVIII inhibitors using methods known in the art. The assays that can be used include, but are not d to, competitive and non-competitive assay systems using techniques such as Western blots, radioimmunoassays, ELISA, “sandwich” immunoassays, precipitation assays, precipitin reactions, gel diffusion itin reactions, immunodiffusion assays, agglutination assays, immunoradiometric assays, fluorescent immunoassays, clotting assays, factor VIII tor assays to name but a few. Such assays are routine and well known in the art (see, e. g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York, which is orated by reference herein in its entirety). Exemplary are described briefly below but are not intended by way of limitation.

The Bethesda assay and the Nijmegen modification of the Bethesda assay are factor VIII inhibitor assays well-known as methods to detect FVIII inhibitors (Kasper CK, et al. Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh. (1975) 34(2):612).

However, the assays can be modified to assay binding of inhibitors to FVIII compositions using inhibitors such as onal or monoclonal anti-FVIII antibodies, including the antibodies of Table 10, and methods such as described in e 52. Briefly, the modified Bethesda assay involves mixing titered volumes of the test sample with an equal volume of an inhibitor at a set concentration. The mixtures are incubated for 2 hours at 37°C prior to analysis of the factor concentration by a coagulation assay such as a chromogenic assay. rly, a reference plasma with native factor VIII level is ted that then assayed as the ve control. The nt is the titer resulting in 50% of the FVIII activity of the positive control, ed as Bethesda units. In the Nijimegen modification of the Bethesda assay, the assay samples are stabilized with imidazole buffer and the control sample is mixed with deficient plasma instead of buffer (Verbruggen B, et al. The en modification of the Bethesda assay for factor VIII:C inhibitors: ed city and reliability. Thromb Haemost. (1995) 73(2):247-251).

Western blot analysis generally comprises preparing protein samples, electrophoresis of the protein samples in a rylamide gel (e. g., 8%—20% GE depending on the molecular weight of the antigen), transferring the protein sample from the polyacrylamide gel to a membrane such as nitrocellulose, PVDF or nylon, blocking the membrane in blocking solution (e. g., PBS with 3% BSA or non-fat milk), washing the membrane in washing buffer (e. g., PBS-Tween 20), blocking the ne with primary antibody (the antibody of interest) diluted in blocking buffer, washing the membrane in washing buffer, blocking the membrane with a secondary antibody (which recognizes the primary antibody, e. g., an anti-human antibody) conjugated to an enzymatic substrate (e. g., horseradish peroxidase or alkaline phosphatase) or radioactive molecule (e.g., 32 P or 125 I) diluted in blocking buffer, washing the membrane in wash buffer, and detecting the presence of the antigen. One of skill in the art would be dgeable as to the parameters that can be modified to increase the signal detected and to reduce the background noise. For further discussion regarding western blot protocols see, e. g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 10.8.1.

ELISA assays can detect antibodies to FVIII independent of their ability to block the procoagulant activity of FVIII, and have been ed for the ion of VIII ping in hemophilia A patients. In a population of 131 ts with hemophilia A with inhibitors, the ELISA technique resulted in 97.7% ivity and 78.8% specificity, and had a high negative predictive value (98.6%) [Martin, P. G., et al. Evaluation of a novel ELISA screening test for detection of factor VIII inhibitory antibodies in haemophiliacs. Clin Lab ol (1999) 21 :125-128]. Other investigators have found a highly significant correlation between the Bethesda titer and the absorbance values in an ELISA assay for detecting anti-FVIII Abs (Towfighi, F., et al. Comparative measurement of anti-factor VIII antibody by Bethesda assay and ELISA reveals restricted isotype profile and epitope city. Acta Haematol (2005) 114:84-90), with the added advantage of the ability to detect non-inhibitory VIII antibodies. Assay protocols comprise preparing the binding ligand, which may include a sample comprising either factor VIII polypeptide or the CFXTEN fusion protein, g the well of a 96 well microtiter plate with the antibody, adding the ligand test sample and incubating, then adding a detection antibody and incubating prior to washing and adding a alkaline atase- or peroxidase-conjugated ary antibody and incubating for an additional period before the addition of TMB substrate and processing for reading by spectrophotometer at 450nm. In ELISAs the antibody or inhibitor of interest does not have to be conjugated to a detectable compound; instead, a second antibody (which recognizes the antibody or inhibitor of interest) conjugated to a detectable compound may be added to the well.

Further, instead of coating the well with the antibody, the ligand may be coated to the well. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected as well as other variations of ELISAs known in the art (see, e. g., Ausubel et al, eds, 1994, Current Protocols in lar Biology, Vol. 1, John Wiley & Sons, Inc., New York at 11.2.1).

Standard or modified coagulation assays are used to measure d binding of FVIII binding agents. In one exemplary method (further described in Example 28), the optimal concentration of a given FVIII inhibitor to utilize in the assay is first determined by a titration experiment using varying amounts of the inhibitory antibody incubated at 37°C for 2 hrs with the base vector expressing ype FVIII containing a His/Myc double tag. The FVIII ty is measured by the Coatest assay ure described herein. The lowest concentration that results in optimal inhibition of FVIII activity is employed in the assay. In the assay, the FVIII inhibitor antibody at the optimal concentration is mixed with individual test samples and incubated at 37°C for 2 hrs. The resulting test s are then ted and utilized in the Coatest activity assay, along with untreated aliquots of the CFXTEN and positive control in order to assess the al and baseline FVIII activity for each test sample.

The invention provides methods of making CFXTEN that exhibit reduced binding to FVIII binding agents, including FVIII inhibitors, and retention of gulant activity. In one embodiment, the method to make a CFXTEN with reduced binding to FVIII inhibitors comprises the steps of selecting a FVIII sequence with at least 90% sequence identity to a sequence of Table 1, selecting one, two, three, four, five, or six or more XTEN each with at least 70%, or at least 80%, or at least 90%, or at least 95 - 99% sequence identity to XTEN sequences of comparable length from Table 4, creating expression constructs designed to locate said XTEN at or proximal to locations selected from Table 5, Table 6, Table 7, Table 8, and Table 9, expressing and recovering the ing CFXTEN, and assaying the resulting fusion ns in an assay bed herein in order to confirm the reduced binding of the CFXTEN fusion protein. By the inventive method, a CFXTEN exhibits at least 5% reduced, or at least % reduced, or at least 15% reduced, or at least 20% reduced, or at least 25% reduced, or at least 40% reduced, or at least 50% reduced, or at least 60% reduced, or at least 70% reduced, or at least 80% reduced g to a FVIII binding agent including, but not limited to the antibodies of Table 10 or anti- FVIII antibodies from a hemophilia A subj ect, and retains at least about 10%, or at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70% procoagulant actiVity compared to the ponding FVIII not linked to XTEN.

Up to 8-10% of hemophilia A patients have antibodies that bind FVIII without affecting its procoagulant properties; they are not, therefore rized as FVIII inhibitors. However, the binding of dies to FVIII is believed to lead to immune complexes that are cleared by the innate immune response or are more susceptible to proteolytic degradation (Kazatchkine MD. Circulating immune complexes containing anti-VIII antibodies in multi-transfused patients with haemophilia A. Clin Exp Immunol. (1980) 39(2):315-320). Accordingly, it is an object of the invention to provide CFXTEN fusion proteins comprising one or more XTEN that t reduced g of antibodies to FVIII that are not inhibitors, wherein the ation or clearance of the CFXTEN is reduced at least 5%, or 10%, or 15%, or 20%, or 30%, or 40%, or 50%, or 60%, or 70% or less compared to a corresponding FVIII not linked to XTEN or to native FVIII bound by such antibodies. The reduced binding of dies to CFXTEN compared to FVIII not linked to XTEN or to native FVIII can be assayed by in Vitro and in vivo methods. In Vitro s include the aforementioned ELISA and Western blot methods. The reduced degradation or clearance of CFXTEN can be assessed in vivo by use of animal models or in human clinical trials. In one type of trial, factor VIII or CFXTEN are administered separately, preferably by intravenous infusion, to cohorts of patients haVing factor VIII deficiency who have antibodies that promote degradation or clearance of eutic human factor VIII. The dosage of the administered test article is in a range between 5 and 50 IU/kg body weight, ably 10-45 IU/kg, and most preferably 40 IU/kg body weight. Approximately 1 hour after each administration, the recovery of factor VIII or CFXTEN from blood samples is measured in a functional one-stage or chromogenic coagulation assay to assess actiVity and by ELISA, HPLC, or similar assay to qualify the amount of intact factor VIII equivalent. Samples are taken again approximately 5-10 hours after infusion, and recovery is measured. Total recovery and the rate of disappearance of factor VIII from the samples is predictive of the antibody titer, and the comparison of results from the factor VIII and CFXTEN indicates the degree of reduced clearance and/or degradation of the CFXTEN. In one embodiment, the CFXTEN fusion n exhibits at least 5% reduced, or at least 10% d, or at least 15% reduced, or at least 20% reduced, or at least 25% reduced, or at least 40% reduced, or at least 50% reduced, or at least 60% reduced, or at least 70% reduced, or at least 80% reduced binding to an anti-FVIII antibody that promotes clearance but does not otherwise inhibit the procoagulant activity of intact native FVIII. In another embodiment, the CFXTEN fusion protein exhibits at least 5% reduced, or at least 10% reduced, or at least 15% reduced, or at least 20% reduced, or at least 25% reduced, or at least 40% reduced, or at least 50% d, or at least 60% reduced, or at least 70% reduced, or at least 80% reduced binding to an anti-FVIII antibody that promotes the degradation of FVIII. In the foregoing embodiments of this paragraph, the reduced binding of the anti-FVIII antibody is alternatively characterized by an increased KD value of the FVIII antibody to the fusion protein compared to the FVIII of at least ld, or three- fold, or old, or five-fold, or 10-fold, or 33-fold, or 100-fold, or 330-fold, or at least 1000-fold ed to the g to the corresponding FVIII not linked to XTEN. In one embodiment, the CFXTEN fusion proteins comprising one or more XTEN exhibiting reduced reactivity to an anti-FVIII antibody exhibits an increased terminal ife when administered to a subject with anti-FVIII antibodies of at least 48 h, or at least 72 h, or at least 96 h, or at least 120 h, or at least 144 h, or at least 14 days, or at least 21 days compared to FVIII not linked to XTEN. In the ing ment, the subject can be a human hemophilia A subject or it can be a mouse hemophilia A subject with circulating anti-FVIII antibodies.

Another aspect of the present invention is the use of CFXTEN fusion protein for a specific therapy of a coagulopathy in a subject with a FVIII inhibitor. The invention provides a method of treating a subject with circulating FVIII tor(s) sing the step of administering a clotting- effective amount of a CFXTEN fusion protein to the subject wherein the fusion protein exhibits r gulant ty and/or clotting-effective concentrations of longer duration compared to either a corresponding factor VIII not linked to XTEN or compared to native factor VIII administered to the subject using a comparable amount and route of administration. In one embodiment of the method, the FVIII inhibitor in the subject is an anti-FVIII antibody. In another embodiment, the FVIII inhibitor is a neutralizing anti-FVIII antibody. In one embodiment, the FVIII tor is an VIII antibody that binds to the A1 domain of FVIII. In another embodiment, the FVIII inhibitor is an anti-FVIII antibody that binds to the A2 domain of FVIII. In another embodiment, the FVIII inhibitor is an anti-FVIII antibody that binds to the A3 domain of FVIII. In r embodiment, the FVIII tor is an anti- FVIII antibody that binds to the C1 domain of FVIII. In another embodiment, the FVIII inhibitor is an anti-FVIII antibody that binds to the C2 domain of FVIII. In r embodiment, the FVIII inhibitor is an anti-FVIII antibody that binds to both the C2 and A2 domain of FVIII. In another embodiment, the FVIII inhibitor binds to a FVIII epitope capable of being bound by one or more antibodies of Table 10.

In another embodiment, the FVIII inhibitor is a polyclonal antibody from a hemophilia A subject with FVIII inhibitor antibodies.

An obj ect of the present invention is the creation of CFXTEN with XTEN inserted to maximize the steric interference of FVIII binding agents that would otherwise bind to FVIII and neutralize procoagulant activity or result in the clearance or degradation of FVIII. Accordingly, in one approach the invention provides CFXTEN comprising one or more XTEN wherein the XTEN are inserted proximal to a binding site of a FVIII inhibitor or anti-FVIII antibody. In one embodiment, an XTEN is linked to the FVIII at a on selected from Table 5, Table 6, Table 7, Table 8, and Table 9 that is within about 50, or about 100, or about 150, or about 200, or about 250, or about 300 amino acids of a FVIII epitope that is bound by an antibody of Table 10. In another embodiment, the XTEN is linked to the FVIII within about 50, or about 100, or about 150, or about 200, or about 250, or about 300 amino acids of a FVIII epitope in the A2 or C2 domain that is bound by an antibody of Table 10. Accordingly, the ion provides CFXTEN fusion proteins comprising one or more XTEN wherein binding by FVIII inhibitors to the FVIII component of the fusion n is reduced compared to the corresponding FVIII not linked to XTEN or to native FVIII and the CFXTEN retains procoagulant actiVity. In the foregoing embodiments hereinabove described in this paragraph, the fusion proteins can be assayed by the assays described herein below, the assays of the Examples, or other assays known in the art, and the inhibitors can be an dy of Table 10, can be polyclonal anti-FVIII, or can be blood or plasma from a hemophilia A subject with FVIII inhibitors.

In r aspect, CFXTEN are designed to maximize the regions over which XTEN can adopt random coil conformations covering the fusion protein, thereby resulting in steric hindrance for anti- FVIII antibodies that would otherwise bind epitopes on the FVIII component of the fusion protein. It is believed that the incorporation of multiple XTEN into a CFXTEN provides a higher total hydrodynamic radius of the XTEN component compared to CFXTEN with fewer XTEN yet haVing approximately the same total ofXTEN amino acids. Empirically, the hydrodynamic radius for a protein can be calculated based on size exclusion chromatography, and results of several fusion proteins using such methods are described in the Examples. Alternatively, the radius for XTEN polypeptides, such as those incorporated in the embodiments disclosed herein, can be approximated by mathematical formulae because the limited types of amino acids utilized have known teristics that can be quantified. In one embodiment, the m radius of a single XTEN polypeptide is calculated (hereinafter “XTEN Radius”) according to the formula given by Equation II: XTEN Radius = N length 0.2037) + 3.4627 11 In another embodiment, the sum of the m of the XTEN Radii for all XTEN segments in a CFXTEN is calculated (hereinafter “Sum XTEN Radii”) according to the formula given by Equation III: Z XTEN i =1 Sum XTEN Radii = 111 wherein: n = the number ofXTEN segments and i is an iterator In another embodiment, the ratio of the SUM XTEN Radii of a CFXTEN comprising multiple XTEN to that of an XTEN Radius for a single XTEN of an lent length (in total amino acid es to that of the ) is calculated (hereinafter “Ratio XTEN Radii”) according to the formula given by Equation IV: W0 2013/122617 [L1 XTEN Radiusi .1 [L1XTEN Length] * 0.2037) + 3.4627 Ratio XTEN Radii = ( IV wherein: n = the number ofXTEN segments and i is an iterator ] In applying the Equations to the XTEN, it will be understood by one of skill in the art that the calculated values represent maximum values that could vary or be reduced depending on the host cell utilized for expression of the XTEN polypeptide. It is believed that while E. coli expression would result in XTEN that achieves the calculated values, expression in eukaryotic host cells in which XTEN may be glycosylated could result in a radius of the polypeptide less than the maximum calculated value. Such differences can be quantified by methods such as size exclusion chromatography, the s of which are detailed in the Examples.

In order to design CFTEN that maximize the area over which XTEN can adopt random coil conformations, it was ered that CFXTEN s with Ratio XTEN Radii above 2 provide greater coverage over the fusion protein than designs with values <2. Accordingly, in one embodiment the invention provides CFXTEN in which the Ratio XTEN Radii is at least 2.0, or 2.1, or 2.2, or 2.3, or 2.4, or 2.5, or 2.6, or 2.7, or 2.8, or 2.9, or 3.0, or 3.1, or 3.2, or 3.3, or 3.4, or 3.5 or r. In some ments, the invention provides CFXTEN in which the Ratio XTEN Radii is at least 20-35 or greater comprise at least three XTEN with each XTEN having at least 42 to about 288 amino acids and wherein at least two of the XTEN are linked to the fusion protein with no less than about 100, or about 200, or about 300, or about 400, or about 500 amino acids of separation between the two XTEN. In other embodiments, the invention provides CFXTEN in which the Ratio XTEN Radii is at least 20-35 or greater comprise at least four XTEN with each XTEN having at least 42 to about 288 amino acids and wherein at least three of the XTEN are linked to the fusion protein with no less than about 100, or about 200, or about 300, or about 400 amino acids of separation between any two of the three XTEN.

In another embodiment, the invention provides a CFXTEN in which the Ratio XTEN Radii is at least 20-35 or greater, the CFXTEN comprises at least three XTEN with each XTEN having at least 42 to about 288 amino acids and n at least two of the three of the XTEN linked to the fusion protein are ted by an amino acid sequence of at least 100, or about 200, or about 300 to about 400 amino acids, and the third XTEN is linked within the B domain (or fragment thereof) or within the C domain (or the terminus thereof). In another embodiment, the invention provides a CFXTEN in which the Ratio XTEN Radii is at least 20-35 or greater, the CFXTEN ses at least four XTEN with each XTEN having at least 42 to about 288 amino acids and wherein at least three of the four of the XTEN linked to the fusion protein are ted by an amino acid ce of at least 300 to about 400 amino acids and the fourth XTEN is linked within the B domain (or fragment thereof) or within the C domain (or the terminus thereof).

In yet other embodiments, the invention provides CFXTEN in which the Ratio XTEN Radii is at least 20-35 or greater, the CFXTEN comprises at least five XTEN with four XTEN having at least 42 to about 144 amino acids wherein at least four of the XTEN are linked to the fusion protein with no less than about 100, 200, or about 300, or about 400 amino acids of separation between any two of the four XTEN and a fifth XTEN is linked Within the B domain (or nt thereof) or Within the C domain (or the terminus thereof). In one embodiment, the invention provides a CFXTEN in Which the Ratio XTEN Radii is at least 20-35 or greater, the CFXTEN comprises at least five XTEN With four XTEN having at least 42 to about 144 amino acids Wherein at least three of the XTEN linked to the fusion protein are ted by an amino acid sequence of at least 300 to about 400 amino acids, the fourth XTEN is linked Within the B domain (or fragment thereof) and a fifth XTEN is linked Within the C domain (or the terminus thereof).

In one aspect, the invention provides CFXTEN in Which the Ratio XTEN Radii is at least 2.0, or 2.1, or 2.2, or 2.3, or 2.4, or 2.5, or 2.6, or 2.7, or 2.8, or 2.9, or 3.0, or 3.1, or 3.2, or 3.3, or 3.4, or 3.5 or greater, and the composition does not comprise certain sequences. In one embodiment of the foregoing, the invention provides CFXTEN in Which the Ratio XTEN Radii is at least 20-35 or greater With the proviso that the fusion protein does not comprise a sequence from any one of Table 50 or Table 51. In another embodiment of the foregoing, the ion provides CFXTEN in Which the Ratio XTEN Radii is at least 20-35 or greater With the proviso that the fusion protein does not comprise a sequence haVing an AG family XTEN ce. In r embodiment of the foregoing, the invention provides CFXTEN in Which the Ratio XTEN Radii is at least 20-35 or greater With the proviso that the fusion protein does not se a sequence selected from GTPGSGTASSSP (SEQ ID NO: 31), GSSTPSGATGSP (SEQ ID NO: 32), GSSPSASTGTGP (SEQ ID NO: 33), GASPGTSSTGSP (SEQ ID NO: 34). In another embodiment of the foregoing, the invention es CFXTEN in Which the Ratio XTEN Radii is at least 20-35 or greater With the proviso that the fusion protein does not se any one of the sequences selected from TASSSP (SEQ ID NO: 31), GSSTPSGATGSP (SEQ ID NO: 32), STGTGP (SEQ ID NO: 33), GASPGTSSTGSP (SEQ ID NO: 34) and GSEPATSGSETPGTSESATPESGPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGSEPATSG SETPGSEPATSGSETPGSEPATSGSETPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTST EPSEGSAP (SEQ ID NO: 59). In another embodiment of the foregoing, the invention provides CFXTEN in Which the Ratio XTEN Radii is at least 20-35 or greater With the proviso that the fusion protein does not comprise a sequence selected from GSEPATSGSETPGTSESATPESGPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGSEPATSG SETPGSEPATSGSETPGSEPATSGSETPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTST EPSEGSAP (SEQ ID NO: 59), PGSSPSASTGTGPGSSPSASTGTGPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGASPGTS STGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGTP GSGTASSS (SEQ ID NO: 71), or PGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSG ATGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGA SPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTG SPGASPGTSSTGSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTGSPGSSPSASTGTGPGTPGSG TASSSPGSSTPSGATGS (SEQ ID NO: 80). In another embodiment of the foregoing, the invention provides CFXTEN in which the Ratio XTEN Radii is at least 2.0-3.5 or greater with the o that the fusion protein does not comprise an XTEN sequence ting of GSEPATSGSETPGTSESATPESGPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGSEPATSG SETPGSEPATSGSETPGSEPATSGSETPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTST EPSEGSAP (SEQ ID NO: 59), PGSSPSASTGTGPGSSPSASTGTGPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGASPGTS STGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGTP GSGTASSS (SEQ ID NO: 71), or PGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSG ATGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGA SPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTG SPGASPGTSSTGSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTGSPGSSPSASTGTGPGTPGSG TASSSPGSSTPSGATGS (SEQ ID NO: 80).

In one aspect, the present invention provides methods to create CFXTEN with XTEN inserted to maximize the steric interference of FVIII binding agents that would otherwise bind to FVIII and neutralize procoagulant activity or result in the clearance or degradation of FVIII. Accordingly, in one embodiment, the invention provides a method comprising the steps of selecting a FVIII sequence with at least 90% sequence identity to a sequence of Table 1, selecting three or more XTEN from Table 4 in which the Ratio XTEN Radii is at least 2.0, or 2.1, or 2.2, or 2.3, or 2.4, or 2.5, or 2.6, or 2.7, or 2.8, or 2.9, or 3.0, or 3.1, or 3.2, or 3.3, or 3.4, or 3.5 or greater, creating sion constructs designed to locate said XTEN at or proximal to locations selected from Table 5, Table 6, Table 7, Table 8, and Table 9, wherein the three or more XTEN are at least 300 to 400 amino acids, expressing and recovering the resulting CFXTEN, and assaying the ing fusion proteins in an assay described herein in order to confirm the reduced binding of the CFXTEN fusion protein. By the inventive method, a CFXTEN exhibits at least 5% reduced, or at least 10% reduced, or at least 15% reduced, or at least 20% reduced, or at least 25% reduced, or at least 40% reduced, or at least 50% reduced, or at least 60% reduced, or at least 70% reduced, or at least 80% reduced binding to a FVIII binding agent including, but not limited to the antibodies of Table 10, and ts procoagulant actiVity.

. CFXTEN Fusion Protein Configurations with Spacer and Cleavage Sequences ] In another aspect, the invention provides CFXTEN red with one or more spacer sequences orated into or adjacent to the XTEN that are designed to incorporate or enhance a onality or property to the composition, or as an aid in the assembly or manufacture of the fusion protein itions. Such properties include, but are not limited to, inclusion of cleavage sequence(s) to permit release of components, inclusion of amino acids ible with nucleotide ctions sites to permit e of XTEN-encoding nucleotides to FVIII-encoding nucleotides or that facilitate construction of expression vectors, and linkers designed to reduce steric hindrance in s of CFXTEN fusion proteins. 2012/046326 ] In an ment, a spacer sequence can be uced between an XTEN ce and a FVIII component to decrease steric hindrance such that the FVIII component may assume its d ry structure and/or interact appropriately with its target substrate or processing enzyme. For spacers and methods of identifying desirable spacers, see, for example, , et al. (2003) Protein Engineering —879, specif1cally incorporated by reference herein. In one embodiment, the spacer comprises one or more peptide sequences that are between 1—50 amino acid residues in length, or about 1—25 residues, or about 1-10 residues in length. Spacer sequences, ive of cleavage sites, can comprise any of the natural L amino acids, and will preferably have XTEN-like properties in that the majority of residues will be hydrophilic amino acids that are sterically ered such as, but not limited to, glycine (G), alanine (A), serine (S), threonine (T), glutamate (E), proline (P) and aspartate (D). The spacer can be a single glycine residue, polyglycines or polyalanines, or is inately a mixture of combinations of glycine, serine and alanine residues. In one embodiment, a spacer sequence, exclusive of cleavage site amino acids, has about 1 to 10 amino acids that consist of amino acids selected from glycine (G), alanine (A), serine (S), threonine (T), ate (E), and proline (P) and are substantially devoid of secondary structure; e. g., less than about 10%, or less than about 5% as determined by the Chou-Fasman and/or GOR algorithms. In one embodiment, the spacer sequence is GPEGPS (SEQ ID NO: 1612). In another embodiment, the spacer sequence is GPEGPS (SEQ ID NO: 1612) linked to a cleavage sequence of Table 12. In addition, spacer sequences are designed to avoid the introduction of T-cell epitopes which can, in part, be achieved by avoiding or limiting the number of hydrophobic amino acids utilized in the spacer; the determination of epitopes is described above and in the Examples.

In a particular embodiment, the CFXTEN fusion protein comprises one or more spacer sequences linked at the junction(s) between the payload FVIII sequence and the one or more XTEN incorporated into the fusion protein, n the spacer sequences comprise amino acids that are compatible with nucleotides encoding restriction sites. In r embodiment, the CFXTEN fusion n comprises one or more spacer sequences linked at the junction(s) between the payload FVIII sequence and the one more XTEN incorporated into the fusion protein wherein the spacer sequences comprise amino acids that are compatible with nucleotides encoding restriction sites and the amino acids and the one more spacer sequence amino acids are chosen from glycine (G), alanine (A), serine (S), ine (T), glutamate (E), and proline (P). In another embodiment, the CFXTEN fusion protein comprises one or more spacer sequences linked at the junction(s) between the payload FVIII sequence and one more XTEN incorporated into the fusion protein wherein the spacer sequences comprise amino acids that are compatible with nucleotides encoding ction sites and the one more spacer sequences are chosen from the sequences of Table 11. The exact sequence of each spacer sequence is chosen to be compatible with cloning sites in expression s that are used for a particular CFXTEN construct. In one embodiment, the spacer sequence has properties compatible with XTEN. In one embodiment, the spacer sequence is GAGSPGAETA (SEQ ID NO: 178). For XTEN sequences that are incorporated internal to the FVIII sequence, each XTEN would generally be flanked by two spacer sequences comprising amino acids compatible with restriction sites, while XTEN attached to the N— or C-terminus would only require a single spacer sequence at the junction of the two components and another at the opposite end for incorporation into the vector. As would be apparent to one of ordinary skill in the art, the spacer sequences comprising amino acids compatible with restriction sites that are internal to FVIII could be d from the construct when an entire CFXTEN gene is synthetically ted.

Table 11: Spacer Seguences Compatible with Restriction Sites Spacer Sequence Restriction Enzyme GSPG (SEQ ID NO: 174) BsaI ETET (SEQ ID NO: 175) BsaI PGSSS (SEQ ID NO: 176) BbsI GAP AscI GPA FseI GPSGP (SEQ ID NO: 177) SfiI AAA SacII TG AgeI GT KpnI GAGSPGAETA (SEQ ID NO: 178) SfiI ASS XhoI In another aspect, the present invention provides CFXTEN urations with cleavage sequences incorporated into the spacer sequences. In some embodiments, spacer sequences in a CFXTEN fusion protein composition comprise one or more cleavage sequences, which are identical or different, wherein the cleavage ce may be acted on by a protease, as shown in , to release FVIII, a FVIII component (e. g., the B domain) or XTEN sequence(s) from the fusion protein. In one embodiment, the incorporation of the cleavage sequence into the CFXTEN is ed to permit release of the FVIII component that becomes active or more active (with respect to its ability serve as a membrane binding site for factors IXa and X) upon its release from the XTEN. In the foregoing embodiment, the procoagulant activity of FVIII component of the CFXTEN is increased after cleavage by at least 30%, or at least 40%, or at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90% compared to the intact . The cleavage sequences are located sufficiently close to the FVIII sequences, lly within 18, or within 12, or within 6, or within 2 amino acids of the FVIII sequence, such that any remaining residues attached to the FVIII after cleavage do not appreciably interfere with the activity (e.g., such as binding to a clotting n) of the FVIII, yet provide ient access to the protease to be able to effect cleavage of the cleavage sequence. In some cases, the CFXTEN sing the cleavage sequences will also have one or more spacer sequence amino acids n the FVIII and the cleavage sequence or the XTEN and the cleavage sequence to facilitate access of the protease; the spacer amino acids comprising any natural amino acid, including e, serine and alanine as red amino acids. In one embodiment, the cleavage site is a sequence that can be cleaved by a protease endogenous to the mammalian subject such that the CFXTEN can be cleaved after administration to a subject. In such case, the CFXTEN can serve as a prodrug or a circulating depot for the FVIII. In a ular construct of the foregoing, the CFXTEN would have one or two XTEN linked to the N— and/or the C-terminus of a BDD via a cleavage ce that can be acted upon by an activated coagulation factor, and would have an additional XTEN located between the processing amino acids at position R740 and R1689 such that the XTEN could be released, leaving a form of FVIII similar to native activated FVIII. In one embodiment of the foregoing construct, the FVIII that is released from the fusion protein by cleavage of the cleavage sequence exhibits at least about a two-fold, or at least about a three-fold, or at least about a four-fold, or at least about a five-fold, or at least about a six-fold, or at least about a eight-fold, or at least about a ten-fold, or at least about a 20-fold se in ty compared to the intact CFXTEN fusion protein.

Examples of cleavage sites contemplated by the ion e, but are not d to, a polypeptide sequence cleavable by a mammalian endogenous protease selected from FXIa, FXIIa, kallikrein, FVIIIa, FVIIIa, FXa, FIIa (thrombin), Elastase-2, granzyme B, MMP-l2, , MMP-l7 or MMP-20, or by non-mammalian proteases such as TEV, enterokinase, PreScissionTM protease virus 3C protease), and sortase A. Sequences known to be cleaved by the foregoing proteases and others are known in the art. Exemplary cleavage sequences contemplated by the invention and the tive cut sites within the sequences are presented in Table 12, as well as sequence variants thereof.

For CFXTEN sing incorporated cleavage sequence(s), it is generally preferred that the one or more cleavage sequences are substrates for activated clotting proteins. For example, thrombin (activated clotting factor II) acts on the sequence LTPRSLLV (SEQ ID NO: 1618) [Rawlings N.D., et al. (2008) Nucleic Acids Res, 36: D320], which is cut after the arginine at position 4 in the sequence. Active FIIa is produced by cleavage of FII by FXa in the ce of phospholipids and calcium and is down stream from factor VIII in the coagulation pathway. Once activated, its natural role in coagulation is to cleave fibrinogen, which then in turn, begins clot formation. FIIa activity is tightly controlled and only occurs when coagulation is necessary for proper hemostasis. By incorporation of the LTPRSLLV sequence (SEQ ID NO: 1618) into the CFXTEN between and linking the FVIII and the XTEN components, the XTEN is removed from the adjoining FVIII concurrent with activation of either the extrinsic or intrinsic coagulation pathways when coagulation is required logically, thereby selectively ing FVIII.

In another embodiment, the invention provides CFXTEN with orated FXIa cleavage sequences between the FVIII and XTEN component(s) that are acted upon only by initiation of the intrinsic coagulation system, wherein a gulant form of FVIII is released from XTEN by FXIa to participate in the coagulation cascade. While not intending to be bound by any particular theory, it is believed that the CFXTEN of the foregoing embodiment would sequester the FVIII away from the other ation factors except at the site of active clotting, thus allowing for larger doses (and therefore longer dosing intervals) with minimal safety concerns.

Thus, cleavage sequences, particularly those susceptible to the gulant activated clotting proteins listed in Table 12, would provide for ned release of FVIII that, in certain embodiments of the CFXTEN, can provide a higher degree of activity for the FVIII component released from the intact form of the CFXTEN, as well as additional safety margin for high doses of CFXTEN administered to a subject. In one embodiment, the ion provides CFXTEN comprising one or more ge sequences operably oned to release the FVIII from the fusion protein upon cleavage, wherein the one or more cleavage sequences has at least about 86%, or at least about 92%, or 100% sequence identity to a sequence selected from Table 12.

In some embodiments, only the two or three amino acids flanking both sides of the cut site (four to six amino acids total) are incorporated into the cleavage sequence that, in turn, is incorporated into the CFXTEN of the embodiments, providing, e.g., XTEN release sites. In other embodiments, the incorporated cleavage sequence of Table 12 can have one or more deletions or insertions or one or two or three amino acid substitutions for any one or two or three amino acids in the known ce, wherein the deletions, insertions or substitutions result in reduced or enhanced tibility but not an e of susceptibility to the protease, resulting in an ability to tailor the rate of release of the FVIII from the XTEN. Exemplary substitutions within cleavage ces that are utilized in the CFXTEN of the invention are shown in Table 12.

Table 12: Protease Cleavage Seguences Eggaggmjg @2312? 8&3; Minimalcmsne SENgD equence FXIa KLTRtAET 179 KD/FL/T/RlVA/VE/GT/GV FXIa DFTRVVVG 18o KD/FL/T/RlVA/VE/GT/GV FXIIa VGG 181 NA Kallikrein SPFRlSTGG 182 -/-/FL/RY¢SR/RT/—/— FVIIa LQVRVIVGG 183 NA FIXa PLGRVIVGG 184 -/-/G/R¢-/—/—/— FXa IEGRtTVGG 185 FP/RlSTI/VFSHG FIIa (thrombin) LTPRVSLLV 186 —/—/PLA/R¢SAG/—/—/— Elastase-2 LGPVVSGVP 187 —/—/—/v1ATt—/—/—/— me-B VAGDISLEE 188 V/-/-/Dt-/-/-/- MMP-12 GPAGVLGGA 189 G/PA/—/GtL/—/G/— 19o MMP-13 GPAGVLRGA 191 G/P/—/GtL/—/GA/— 192 MMP-17 APLGVLRLR 193 -/PS/-/—¢LQ/—/LT/— MMP-2O PALPtLVAQ 194 NA TEV ENLYFQtG 195 ENLYFQtG/s 196 Enterokinase DDDKMVGG 197 DDDKMVGG 198 (Pizgieizzieoigll) 200 LEVLFQtGP 199 LEVLFQIGP Sortase A LPKTtGSEs 201 L/P/KEAD/TlG/JEKS/S 202 lindicates cleavage site NA: not applicable the listing of multiple amino acids before, between, or after a slash te alternative amino acids that can be substituted at the position; - indicates that any amino acid may be substituted for the corresponding amino acid indicated in the middle column 6. Exemplary CFXTEN Fusion Protein Sequences Non-limiting examples of sequences of fusion proteins containing a single FVIII linked to one or more XTEN are presented in Table 21 . The exemplary amino acid sequences of Table 21 (and the DNA ces that encode them) contain his tags for purification purposes that, as would be apparent to one of skill in the art, can be deleted from the sequence without having an effect on the procoagulant activity of the CFXTEN fusion protein. In one embodiment, the CFXTEN of Table 21 further comprise amino acids on the N—terminus corresponding to that of native human FVIII (namely, the sequence TCFFLCLLRFCFS (SEQ ID NO: 1611)) to aid in the sion and secretion of the CFXTEN fusion n. In one embodiment, a CFXTEN composition comprises a fusion protein haVing at least about 80% sequence ty compared to a CFXTEN from Table 21, alternatively at least about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity as compared to a CFXTEN from Table 21, when optimally aligned. In another embodiment, a CFXTEN ition comprises a fusion protein from Table 21 in which the C- terminal his-his-his-his-his-his sequence (SEQ ID NO: 1700) deleted. However, the invention also contemplates substitution of any of the FVIII sequences of Table l for a FVIII component of the CFXTEN of Table 21, and/or substitution of any sequence of any one of Tables 3, 4, and l3-l7 for an XTEN component of the CFXTEN of Table 21. Generally, the resulting CFXTEN of the foregoing examples retain at least a portion of the gulant actiVity of the corresponding FVIII not linked to the XTEN. In the foregoing fusion proteins hereinabove described in this paragraph, the CFXTEN fusion protein can further comprise one or more cleavage sequences; e.g., a ce from Table 12, the cleavage sequence being d between the FVIII and the XTEN sequences or between adjacent FVIII domains linked by XTEN. In some embodiments comprising cleavage sequence(s), the intact CFXTEN composition has less actiVity but a longer half-life in its intact form compared to a ponding FVIII not linked to the XTEN, but is designed such that upon administration to a t, the FVIII component is gradually released from the fusion protein by cleavage at the cleavage sequence(s) by endogenous proteases, pon the FVIII component exhibits procoagulant activity.

The CFXTEN compositions of the embodiments can be evaluated for actiVity using assays or in vivo parameters as described herein (e. g., in vitro coagulation assays, assays of Table 49, or a codynamic effect in a preclinical hemophilia model or in clinical trials in humans, using methods as described in the Examples or other methods known in the art for assessing FVIII actiVity) to determine the suitability of the configuration or the FVIII sequence variant, and those CFXTEN compositions (including after cleavage of any incorporated XTEN-releasing cleavage sites) that retain at least about %, or about 40%, or about 50%, or about 55%, or about 60%, or about 70%, or about 80%, or about 90%, or about 95% or more activity ed to native FVIII sequence are ered suitable for use in the treatment of FVIII-related conditions.

V). PROPERTIES OF THE CFXTEN COMPOSITIONS OF THE INVENTION (a) Pharmacokinetic Properties of CFXTEN It is an object of the present invention to provide CFXTEN fusion proteins and pharmaceutical compositions comprising CFXTEN with ed pharmacokinetics compared to FVIII not linked to XTEN. The pharmacokinetic properties of a FVIII ed by linking a given XTEN to the FVIII include, but are not limited to, terminal half-life, area under the curve (AUC), Cmax, volume of distribution, ining the biologically active CFXTEN above a minimum effective blood unit concentration for a longer period of time compared to the FVIII not linked to XTEN. The enhanced properties permit less frequent dosing and/or a longer-lived procoagulant effect compared to a comparable dose of FVIII not linked to XTEN. Enhancement of one or more of these ties can resulting benefits in the treatment of factor VIII-related conditions.

Exogenously administered factor VIII has been reported to have a al half-life in humans of approximately 12-14 hours when complexed with normal von Willebrand factor protein, whereas in the absence of von Willebrand factor, the half-life of factor VIII is reduced to 2 hours (Tuddenham EG, et al., Br J Haematol. (1982) 52(2):259-267; Bjorkman, S., et al. Clin Pharmacokinet. (2001) 40:815). As a result of the enhanced properties conferred by XTEN, the CFXTEN, when used at the dose and dose regimen ined to be appropriate for the subject and its underlying condition, can achieve a circulating concentration resulting in a desired procoagulant or clinical effect for an extended period of time compared to a comparable dose of the ponding FVIII not linked to XTEN. As used herein, a “comparable dose” means a dose with an equivalent moles/kg or International Units/kg (IU/kg) for the composition that is administered to a t. It will be understood in the art that a ”comparable dose" of FVIII not linked to XTEN would represent a lesser weight of drug but would have essentially the same IUs or mole-equivalents of CFXTEN in the dose.

An international unit (“IU”) of factor VIII is defined in the art as the coagulant actiVity present in 1 ml of normal human plasma. A normal, non-hemophilic individual human is expected to have about 100 IU/dL factor VIII ty. In hemophilia A, the doses ed to treat are dependent on the condition. For minor bleeding, doses of native or recombinant factor VIII of 20 to 40 IU/kg are typically administered, as necessary. For moderate bleeding, doses of 30 to 60 IU/kg are administered as necessary, and for major bleeding, doses of 80 to 100 IU/kg may be required, with repeat doses of 20 to IU/kg given every 8 to 12 hours until the bleeding is resolved. For prophylaxis against bleeding in patients with severe hemophilia A, the usual doses of native or recombinant FVIII preparations are 20 to 40 lU/kg body weight at intervals of about 2 to 3 days. A rd on for estimating an appropriate dose of a composition sing FVIII is: Required units = body weight (kg) x desired factor VIII rise (IU/dL or % of normal) x 0.5 (IU/kg per IU/dL).

In many cases, the therapeutic levels for FVIII in subjects of different ages or degree of disease have been ished and are available in published literature or are stated on the drug label for approved products ning the FVIII. For example, the Subcommittee on Factor VIII and Factor IX of the ific and Standardization Committee of the International Society on Thrombosis and Haemostasis posted, on the ISTH Website 29 November, 2000, that the most widely used measure of hemophilia A is established by determining the circulating trations of plasma FVIII procoagulant levels, with persons with <l% (< 0.01 IU/ml) factor VIII defined as severe; 1-5% (0.01 - 0.05 IU/ml) as moderately severe; and >5-40% (0.05 - <0.40 IU/ml) as mild, where normal is 1 IU/ml of factor VIIIC (100%). The therapeutic levels can be established for new compositions, including those CFXTEN and pharmaceutical compositions comprising CFXTEN of the disclosure, using standard methods. In practicing the present invention, it will be tood that any dosage of CFXTEN that is effective may be used for treating bleeding episodes or maintaining asis. The methods for establishing the therapeutic levels and dosing les for a given composition are known to those of skill in the art (see, e. g., n & 's The Pharmacological Basis of Therapeutics, 11th Edition, McGraw—Hill (2005)). For example, by using dose-escalation studies in subjects with the target condition to determine efficacy or a desirable cologic effect, ance of adverse events, and determination of circulating blood levels, the eutic blood levels for a given subject or population of subjects can be determined for a given drug or biologic. The dose escalation studies would evaluate the activity of a CFXTEN through studies in a subject or group of hemophilia A subjects. The studies would monitor blood levels of procoagulant, as well as physiological or clinical parameters as known in the art or as described herein for one or more parameters associated with the factor VIII-related condition, or clinical parameters ated with a beneficial outcome, together with observations and/or measured parameters to determine the no effect dose, adverse events, minimum effective dose and the like, together with measurement of pharmacokinetic parameters that ish the determined or d circulating blood levels. The results can then be correlated with the dose administered and the blood concentrations of the therapeutic that are coincident with the foregoing determined parameters or effect levels. By these methods, a range of doses and blood concentrations can be correlated to the m effective dose as well as the maximum dose and blood concentration at which a desired effect occurs or is maintained and the period for which it can be maintained, thereby establishing the therapeutic blood levels and dosing schedule for the composition.

Thus, by the foregoing methods, a Cmin blood level is established, below which the CFXTEN fusion protein would not have the desired pharmacologic effect and a Cmax blood level, above which side effects such as thrombosis may occur (Brobrow, RS, JABFP (2005) 18(2):]47-149), establishing the therapeutic window for the composition.

One of skill in the art can, by the means disclosed herein or by other methods known in the art, confirm that the administered CFXTEN remains at therapeutic blood levels to in hemostasis for the desired interval or requires adjustment in dose or length or sequence of XTEN. Further, the determination of the appropriate dose and dose frequency to keep the CFXTEN within the therapeutic window establishes the therapeutically effective dose regimen; the schedule for stration of multiple consecutive doses using a therapeutically effective dose of the fusion protein to a subject in need f resulting in consecutive Cmax peaks and/or Cmin troughs that remain above eutically- effective concentrations and result in an improvement in at least one measured parameter relevant for the target condition. In one embodiment, the CFXTEN or a pharmaceutical compositions comprising CFXTEN administered at an appropriate dose to a subject results in blood concentrations of the CFXTEN fusion protein that remains above the minimum ive concentration to maintain hemostasis for a period at least about two-fold longer compared to the corresponding FVIII not linked to XTEN and administered at a comparable dose; alternatively at least about three-fold longer; alternatively at least about four-fold longer; alternatively at least about five-fold longer; atively at least about siX-fold longer; alternatively at least about seven-fold longer; alternatively at least about eight-fold ; alternatively at least about nine-fold longer, alternatively at least about ld longer, or at least about twenty-fold longer or greater ed to the corresponding FVIII not linked to XTEN and administered at a comparable dose. As used herein, an “appropriate dose” means a dose of a drug or biologic that, when administered to a subject, would result in a desirable therapeutic or pharmacologic effect (e.g., asis) and/or a blood concentration within the therapeutic window.

] In practicing the invention, CFXTEN with longer terminal half-life are generally preferred, so as to improve patient convenience, to increase the interval between doses and to reduce the amount of drug ed to achieve a sustained effect. The enhanced PK parameters allow for reduced dosing of the subject compositions, compared to FVIII not linked to XTEN, particularly for those hemophilia A subjects receiving e prophylaxis.

As described more fully in the Examples pertaining to pharmacokinetic characteristics of fusion proteins comprising XTEN, it was observed that increasing the total length of the XTEN, singly or in combination, confers a disproportionate increase in the terminal half-life of a fusion protein comprising the XTEN. Accordingly, the invention provides CFXTEN fusion proteins and pharmaceutical itions comprising CFXTEN wherein the CFXTEN exhibits an enhanced half-life when administered to a t. In some embodiments, the invention provides monomeric CFXTEN fusion proteins sing one or more XTEN wherein the number and location of the XTEN are selected to confer an increase in the terminal half-life for the CFXTEN administered to a subject compared to the corresponding FVIII not linked to the XTEN and administered at a able dose, wherein the increase is at least about two-fold longer, or at least about three-fold, or at least about four-fold, or at least about five-fold, or at least about six-fold, or at least about seven-fold, or at least about eight-fold, or at least about nine-fold, or at least about ten-fold, or at least about 15-fold, or at least a 20-fold, or at least a 40-fold or greater increase in terminal ife compared to the FVIII not linked to the XTEN. In other embodiments, the invention provides CXTEN compositions and pharmaceutical compositions comprising CFXTEN wherein the stration of a composition to a subject in need thereof results in a terminal half-life that is at least 12 h greater, or at least about 24 h greater, or at least about 48 h r, or at least about 96 h greater, or at least about 144 h greater, or at least about 7 days r, or at least about 14 days greater, or at least about 21 days greater compared to a comparable dose of FVIII not linked to XTEN. In another embodiment, administration of a coagulation-effective dose of a CFXTEN fusion protein to a subject in need f can result in a gain in time between utive doses ary to maintain blood levels of about 0.1 IU/ml of at least 48 h, or at least 72 h, or at least about 96 h, or at least about 120 h, or at least about 7 days, or at least about 14 days, or at least about 21 days between consecutive doses compared to a FVIII not linked to XTEN and administered at a comparable dose.

In one embodiment, the present invention provides CFXTEN fusion proteins and pharmaceutical compositions comprising CFXTEN that exhibit, when administered to a subject in need thereof, an increase in AUC of at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90%, or at least about a 100%, or at least about 150%, or at least about 200%, or at least about 300%, or at least about 500%, or at least about 1000%, or at least about a 2000% compared to the corresponding FVIII not linked to the XTEN and administered to a subject at a comparable dose. The pharmacokinetic parameters of a CFXTEN can be determined by rd methods involving , the taking of blood samples at timed intervals, and the assaying of the protein using ELISA, HPLC, radioassay, clotting , the assays of Table 49, or other methods known in the art or as described herein, followed by standard calculations of the data to derive the half-life and other PK ters.

In one embodiment, a smaller IU amount of about two-fold less, or about three-fold less, or about four-fold less, or about five-fold less, or about siX-fold less, or about eight-fold less, or about 10- fold less or greater of the fusion protein is administered in ison to the corresponding FVIII not linked to the XTEN under a dose n needed to maintain hemostasis and the fusion protein achieves a comparable area under the curve as the corresponding IU amount of the FVIII not linked to the XTEN needed to in hemostasis. In another embodiment, the CFXTEN fusion n or a pharmaceutical itions comprising CFXTEN requires less frequent administration for routine laxis of a hemophilia A subject, wherein the dose of fusion protein is administered about every four days, about every seven days, about every 10 days, about every 14 days, about every 21 days, or about monthly to the t, and the fusion protein achieves a comparable area under the curve as the corresponding FVIII not linked to the XTEN and administered to the subject. In yet other embodiments, an accumulative smaller IU amount of about 5%, or about 10%, or about 20%, or about 40%, or about 50%, or about 60%, or about 70%, or about 80%, or about 90% less of the fusion n is administered to a subject in comparison to the corresponding IU amount of the FVIII not linked to the XTEN under a dose regimen needed to maintain a blood concentration of 0.1 IU/ml, yet the fusion protein achieves at least a comparable area under the curve as the corresponding FVIII not linked to the XTEN. The accumulative smaller IU amount is measure for a period of at least about one week, or about 14 days, or about 21 days, or about one month.

In one aspect, the invention provides CFXTEN compositions designed to reduce binding by FVIII binding agents, thereby increasing the al half-life of CFXTEN administered to a subject, while still retaining procoagulant activity. It is believed that the CFXTEN of the present invention have comparatively higher and/or ned activity achieved by reduced active clearance of the molecule by the addition of unstructured XTEN to the FVIII coagulation . The clearance mechanisms to remove FVIII from the circulation have yet to be fully elucidated. Uptake, elimination, and inactivation of coagulation proteins can occur in the circulatory system as well as in the extravascular space.

Coagulation factors are complex proteins that interact with a large number of other proteins, lipids, and receptors, and many of these ctions can contribute to the elimination of CFs from the circulation.

The protein von rand factor is an example of a FVIII binding agent that binds to FVIII. Factor VIII and von Willebrand factor (VWF) circulate in the blood as a tight, non-covalently linked complex in which VWF serves as a carrier that likely butes to the protection of FVIII from active cleavage mechanisms, yet nevertheless s in a limitation on the terminal ife of FVIII. For example: (i) VWF stabilizes the heterodimeric structure of FVIII; (ii) VWF protects FVIII from lytic degradation by phospholipid-binding proteases like activated protein C and activated FX (FXa); (iii) VWF interferes with binding of FVIII to negatively charged phospholipid surfaces exposed within activated platelets; (iV) VWF inhibits binding of FVIII to activated FIX (FIXa), thereby denying FVIII access to the FX-activating complex; and (V) VWF prevents the cellular uptake of FVIII (Lenting, P.J., et al., J osis and Haemostasis (2007) 5(7):1353-1360). In on, LDL receptor-related n (LRPl, also known as crogobulin receptor or CD91) has been identified as a candidate clearance receptor for FVIII, with LRPl binding sites identified on both chains of the heterodimer form of FVIII (Lenting PJ, et al.,. J Biol Chem (1999) 274: 23734—23739; Saenko EL, et al., J Biol Chem (1999) 274: 37685—37692). LRPs are involved in the clearance of a diversity of ligands including proteases, inhibitors of the Kunitz type, protease serpin complexes, lipases and lipoproteins (Narita, et al., Blood (1998) 2:555-560). It has been shown that the light chain, but not the heavy chain, of factor VIII binds to surface-exposed LRPl receptor protein (Lentig et al. (J Biol Chem (1999) 274(34):23734-23739; and US. Pat. No. 6,919,311), which suggests that LRPl may play an essential role in the active clearance of proteins like FVIII. While the VWF—FVIII interaction is of high y (<1 nM), the complex is nevertheless in a dynamic equilibrium, such that a small but significant portion of the FVIII molecules (5—8%) ate as a free protein (Leyte A, et al., m J (1989) 257: 679—683; Noe DA.

Haemostasis (1996) 26: 289—3 03). As such, a portion of native FVIII is unprotected by VWF, allowing active clearance mechanisms to remove the unprotected FVIII from the circulation.

In one embodiment, the invention provides CFXTEN that associate with VWF but have enhanced protection from active clearance receptors conferred by the incorporation of two more XTEN at one or more locations within the FVIII molecule (e. g., ons selected from Table 5, Table 6, Table 7, Table 8, and Table 9 or FIGS. 8-9), wherein the XTEN interfere with the interaction of the resulting CFXTEN with those clearance receptors with the result that the pharmacokinetic properties of the CFXTEN is enhanced compared to the corresponding FVIII not linked to XTEN. In another embodiment, the invention provides CFXTEN that have reduced binding affinity with VWF of at least % less, or about 10%, or about 20%, or about 40%, or about 50%, or about 60%, or about 70% less, but are nevertheless configured to have enhanced protection from active clearance ors conferred by the incorporation ofXTEN at one or more locations within the FVIII molecule, wherein the XTEN interfere with the interaction of factor VIII with those receptors. In the foregoing embodiments, the CFXTEN have an increased terminal half-life of at least about 12 h, or 24 h, or 48 h, or 72 h, or 96 h, or 120 h, or 144 h, or 7 days, or 10 days, or 14 days, or 21 days compared to the FVIII not linked to XTEN. The invention provides a method to create CFXTEN with reduced clearance n the CFXTEN fusion proteins created with the multiple insertions are ted for inhibition of binding to clearance receptors, compared to FVIII not linked to XTEN, using in vitro binding assays or in vivo pharmacokinetic models described herein or other assays known in the art, and selecting those that demonstrate reduced binding yet retain procoagulant FVIII actiVity. In addition, the foregoing fusion proteins can be optimized to have increased Ratio XTEN Radii of at least 2.0-3.5 in order to achieve pharmacokinetic properties that are further enhanced. Table 5, Table 6, Table 7, Table 8, and Table 9 and FIGS. 8-9 provide non-limiting examples ofXTEN insertion points within the factor VIII sequence. Using such insertion points, the invention contemplates CFXTEN compositions that have configurations with multiple XTEN inserted with about 100, or about 200, or about 300, or about 400, or about 500 amino acids separating at least three XTEN to further increase the protection against active nce mechanisms and, hence, increase the terminal half-life of the CFXTEN. Not to be bound by a particular theory, the XTEN of the CFXTEN compositions with high net charge (e.g., CFXTEN comprising AE family XTEN) are expected, as described above, to have less non-specific interactions with various negatively-charged surfaces such as blood vessels, tissues, or various receptors, which would r bute to reduced active clearance.

Conversely, the XTEN of the CFXTEN compositions with a low (or no) net charge (e. g., CFXTEN comprising AG family XTEN) are expected to have a higher degree of interaction with surfaces that, while contributing to active clearance, can potentiate the ty of the ated coagulation factor, given the known contribution of cell (e.g., platelets) and vascular es to the coagulation process and the intensity of activation of coagulation factors (Zhou, R., et al., Biomaterials (2005) 26(16):2965-2973; London, F., et al. Biochemistry (2000) 39(32):9850—985 8). The invention, in part, takes advantage of the fact that certain ligands wherein reduced g to a nce receptor, either as a result of a sed on—rate or an increased off-rate, may be effected by the obstruction of a or site by an inserted XTEN forming random coil, resulting in the d binding. The choice of the particular configuration of the CFXTEN fusion protein can be tested by methods disclosed herein to confirm those configurations that reduce the degree of binding to a clearance receptor such that a reduced rate of active nce is achieved. In one embodiment, the CFXTEN comprises a FVIII-XTEN sequence that has one or more XTEN ed at locations selected from Table 5, Table 6, Table 7, Table 8, and Table 9 or FIGS. 8-9 wherein the al half-life of the CFXTEN is increased at least about two-fold, or at least about three- fold, or at least about four-fold, or at least about five-fold, or at least about six-fold, or at least about eight-fold, or at least about ten-fold, or at least about twenty-fold compared to a FVIII not linked to an XTEN. In another embodiment, the CFXTEN comprises a FVIII-XTEN sequence that has a first and at least a second XTEN inserted at a first and second location ed from Table 5, Table 6, Table 7, Table 8, and Table 9 or FIGS. 8-9 wherein the terminal half-life of the CFXTEN is increased at least about two-fold, or at least about three-fold, or at least about four-fold, or at least about five-fold, or at least about six-fold, or at least about eight-fold, or at least about ten-fold, or at least about twenty-fold compared to a FVIII not linked to an XTEN. In yet another ment, the CFXTEN comprises a FVIII-XTEN sequence that orates multiple XTEN sequences using three of more XTEN insertion locations selected from Table 5, Table 6, Table 7, Table 8, and Table 9 or FIGS. 8-9 separated by about 100, or about 200, or about 300, or about 400, or about 500 amino acids, n the terminal half-life of the CFXTEN is increased at least about two-fold, or at least about fold, or at least about four-fold, or at least about five-fold, or at least about six-fold, or at least about eight-fold, or at least about ten-fold, or at least about twenty-fold compared to a FVIII not linked to an XTEN. In the foregoing embodiments hereinabove described in this paragraph, the XTEN orated into the CFXTEN urations can be identical or they can be different, and can have at least about 80%, or 90%, or 91%, or 92%, or 93%, or 94%, or 95%, or 96%, or 97%, or 98%, or 99%, sequence identity to a sequence from any one of Tables 3, 4, and 13-17, and can optionally include one or more cleavage sequences from Table 12, facilitating release of one or more of the XTEN from the CFXTEN fusion protein.

In one embodiment, the invention provides CFXTEN that e the pharmacokinetics of the fusion protein by linking one or more XTEN to the FVIII component of the fusion protein n the fusion protein has an increase in apparent molecular weight factor of at least about two-fold, or at least about three-fold, or at least about four-fold, or at least about five-fold, or at least about six-fold, or at least about seven-fold, or at least about fold, or at least about ten-fold, or at least about twelve-fold, or at least about -fold, and wherein the terminal half-life of the CFXTEN when administered to a t is increased at least about two-fold, or at least about four-fold, or at least about eight-fold, or at least about 10-fold or more compared to the corresponding FVIII not linked to XTEN. In the foregoing embodiment, wherein at least two XTEN molecules are orated into the CFXTEN, the XTEN can be identical or they can be of a different sequence composition, net charge, or length. The XTEN can have at least about 80%, or 90%, or 91%, or 92%, or 93%, or 94%, or 95%, or 96%, or 97%, or 98%, or 99%, sequence identity to a sequence from any one of Tables 3, 4, and 13-17, and can optionally include one or more cleavage sequences from Table 12, facilitating release of one or more of the XTEN from the CFXTEN fusion protein.

] Thus, the invention es CFXTEN compositions in which the degree of activity, bioavailability, half-life or ochemical characteristic of the fusion protein can be tailored by the selection and placement of the type and length of the XTEN in the CFXTEN compositions. Accordingly, the invention contemplates compositions in which a FVIII from Table 1 and XTEN or XTEN fragment from any one of Tables 3, 4, or 13-17 are produced, for example, in a configuration selected from any one of formulae I-VIII or the XTEN are inserted at locations ed from Table 5, Table 6, Table 7, Table 8, and Table 9 or FIGS. 8-9 such that the construct has the desired property.

The invention provides methods to produce the CFXTEN compositions that can maintain the FVIII component at therapeutic levels in a subject in need f for at least a two-fold, or at least a three-fold, or at least a old, or at least a five-fold greater period of time compared to comparable dosages of the corresponding FVIII not linked to XTEN. In one embodiment of the method, the subject is receiving routine prophylaxis to prevent bleeding episodes. In another embodiment of the method, the subject is receiving treatment for a bleeding episode. In another embodiment of the method, the subject 2012/046326 is receiving treatment to raise the circulating blood concentration of procoagulant FVIII above 1%, or above 1-5%, or above 5-40% relative to FVIII concentrations in normal plasma. “Procoagulant” as used herein has its general meaning in the art and generally refers to an ty that promotes clot formation, either in an in vitro assay or in vivo. The method to produce the compositions that can maintain the FVIII ent at eutic levels includes the steps of selecting one or more XTEN riate for conjugation to a FVIII to provide the desired pharmacokinetic properties in View of a given dose and dose regimen, creating a gene construct that encodes the CFXTEN in one of the configurations disclosed herein, transforming an riate host cell with an sion vector comprising the encoding gene, expressing the fusion protein under suitable culture conditions, recovering the CFXTEN, administration of the CFXTEN to a mammal followed by assays to verify the pharmacokinetic properties and the actiVity of the CFXTEN fusion protein (e.g., the ability to maintain hemostasis or serve as a procoagulant) and the safety of the administered composition. Those compositions exhibiting the desired properties are selected for further use. CFXTEN created by the methods provided herein can result in increased efficacy of the stered composition by, amongst other properties, maintaining the circulating concentrations of the procoagulant FVIII component at eutic levels for an enhanced period of time.

The invention provides methods to assay the CFXTEN fusion proteins of differing composition or configuration in order to provide CFXTEN with the desired degree of gulant and therapeutic activity and pharmacokinetic properties, as well as a ent safety profile. Specific in vitro and in vivo assays or animal models are used to assess the activity and functional characteristics of each configured CFXTEN and/or FVHI ent to be incorporated into CFXTEN, including but not limited to the assays of the Examples, those assays of Table 49, as well as the following assays or other such assays known in the art for assaying the properties and effects of FVHI. Functional assays can be conducted that allow determination of ation activity, such as age clotting assay and two- stage ng assay wcliffe TW, Semin Thromb Hemost. (2002) 28(3):247-256), activated partial prothrombin (aPTT) assays (Belaaouaj AA et al., J. Biol. Chem. (2000) 275:27123-8; ollier JA.

Haemost (1994) 71 :339-46), chromogenic FVIH assays (Lethagen, S., et al., Scandinavian J Haematology (1986) 37:448—453), or animal model pharmacodynamic assays including bleeding time or thrombelastography (TEG or ROTEM), among others. Other assays include determining the binding affinity of a CFXTEN for the target substrate using binding or competitive binding assays, such as Biacore assays with chip-bound receptors or binding proteins or ELISA assays, as described in US Patent ,534,617, assays described in the Examples herein, radio-receptor assays, or other assays known in the art. Other assays to determine the binding of FVIH tors to CFXTEN include the Bethesda assay or the Nijmegen modification of the Bethesda assay. The foregoing assays can also be used to assess FVHI sequence variants (assayed as single components or as CFXTEN fusion proteins) and can be compared to the native FVIII to determine whether they have the same degree of procoagulant actiVity as the native CF, or some fraction thereof such that they are suitable for inclusion in CFXTEN; e. g., at least about %, or at least about 20$, or about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90% of the activity compared to the native FVIH.

Dose optimization is important for all drugs. A therapeutically effective dose or amount of the CFXTEN varies according to factors such as the disease state, age, seX, and weight of the individual, and the ability of the stered fusion protein to elicit a desired response in the individual. For example, a standardized single dose of FVIII for all patients presenting with diverse bleeding conditions or abnormal clinical parameters (e.g., neutralizing antibodies) may not always be ive. Hemophilia A patients with trauma, who have undergone surgery, or that have high titers of FVIII inhibitory antibodies generally will require higher and more frequent dosing. Generally, dosage level is adjusted in frequency, duration, and units in keeping with the ty and duration of each patient's bleeding episode. ingly, the CFXTEN is included in the pharmaceutically acceptable carrier, delivery vehicle, or stabilizer in an amount sufficient to deliver to a patient a therapeutically effective amount of the fusion protein to stop bleeding, as measured by standard clotting assays. A consideration of these factors is well within the purview of the ordinarily skilled clinician for the purpose of determining the therapeutically or pharmacologically effective amount of the CFXTEN and the appropriated dosing schedule, versus that amount that would result in insufficient potency such that clinical improvement or the arrest of bleeding is not achieved.

The invention provides methods to establish a dose regimen for the CFXTEN pharmaceutical compositions of the invention. The methods include administration of consecutive doses of a therapeutically effective amount of the CFXTEN pharmaceutical composition using variable periods of time between doses to determine that interval of dosing ent to achieve and/or maintain the desired parameter, blood level or al effect; such consecutive doses of a therapeutically ive amount at the effective interval establishes the therapeutically effective dose regimen for the CFXTEN for a factor VIII-related disease state or condition. A prophylactically effective amount refers to an amount of CFXTEN required for the period of time necessary to prevent a physiologic or clinical result or event; e.g., delayed onset of a ng episode or maintaining blood concentrations of procoagulant FVIH or equivalent above a threshold level (e. g., 1-5% to 5-40% of ). In the methods of treatment, the dosage amount of the CFXTEN that is administered to a subject ranges from about 5 to 300 dose, or from about 10 to 100 lU/kg/dose, or from about 20 to about 65 lU/kg/dose, or from about 20 to about 40 lU/kg/dose for a subject. A suitable dosage may also depend on other factors that may influence the response to the drug; e. g., bleeding episodes generally requiring higher doses at more nt intervals compared to prophylaxis.

In some ments, the method comprises administering a therapeutically-effective amount of a pharmaceutical composition comprising a CFXTEN fusion protein composition and at least one pharmaceutically acceptable carrier to a subject in need thereof, wherein the stration results in a greater improvement in at least one parameter or physiologic condition associated with a FVIII deficiency or coagulopathy, or s in a more favorable clinical outcome mediated by the FVIH component of the CFXTEN compared to the effect on the parameter, ion or clinical outcome mediated by administration of a pharmaceutical composition comprising a FVIII not linked to XTEN and administered at a comparable dose. Non-limiting examples of parameters that are improved include blood concentration of procoagulant FVIII, a reduced activated partial prothrombin (aPTT) assay time, a reduced one-stage or two-stage ng assay time, delayed onset of a bleeding episode, a reduced chromogenic FVIII assay time, a reduced bleeding time, resolution of a bleeding event, or a reduced Bethesda titer to the CFXTEN relative to native FVIII. In one embodiment of the foregoing, the improvement is achieved by administration of the CFXTEN pharmaceutical composition at a dose that es a circulating concentration of procoagulant FVIII (or equivalent) above a threshold level (e.g., 1-5% to 5-40% of normal FVIII levels), thereby establishing the therapeutically effective dose. In another embodiment of the ing, the improvement is achieved by administration of multiple utive doses of the CFXTEN pharmaceutical composition using a therapeutically effective dose n that maintains a circulating concentration of procoagulant FVIII (or equivalent) above a threshold level (e.g., 1-5% to 5-40% of normal FVIII ) for the length of the dosing period. In another embodiment of the method, the stration of at least two consecutive doses of the CFXTEN pharmaceutical composition using a therapeutically effective dose regimen maintains a circulating concentration of procoagulant FVIII (or equivalent) above about 1%,, 2%, 3%, 4%, 5%, 10%, 15%, 20%, %, or 40% of normal FVIII levels for a period that is at least about three-fold longer; alternatively at least about four-fold longer; alternatively at least about ld longer; alternatively at least about six- fold longer; alternatively at least about seven-fold longer; alternatively at least about eight-fold longer; atively at least about nine-fold longer or at least about ten-fold longer compared to a FVIII not linked to XTEN and stered using a therapeutically effective dose regimen In one ment, the CFXTEN or a pharmaceutical compositions comprising CFXTEN administered at a therapeutically ive dose regimen results in a gain in time of at least about three- fold longer; alternatively at least about four-fold longer; atively at least about five-fold longer; alternatively at least about siX-fold longer; alternatively at least about seven-fold longer; alternatively at least about eight-fold longer; alternatively at least about old longer or at least about ten-fold longer between at least two consecutive Cmax peaks and/or Cmin troughs for blood levels of the fusion protein compared to the corresponding biologically active protein of the fusion protein not linked to the XTEN and administered at a comparable dose regimen to a subject. In another embodiment, the CFXTEN administered at a eutically effective dose regimen results in a comparable ement in one, or two, or three or more measured ters using less frequent dosing or a lower total dosage in IUs of the fusion protein of the pharmaceutical composition compared to the corresponding biologically active protein component(s) not linked to the XTEN and administered to a subject using a therapeutically ive dose regimen for the FVIII. The measured parameters include any of the clinical, biochemical, or physiological parameters disclosed herein, or others known in the art for assessing subjects with factor VIII-related conditions. (b) Pharmacology and Pharmaceutical Properties of CFXTEN The present invention provides CFXTEN itions comprising FVIII covalently linked to XTEN that have enhanced pharmaceutical and pharmacology properties compared to FVIII not linked to XTEN, as well as methods to enhance the therapeutic and/or gulant effect of the FVIII components of the compositions. In addition, the invention provides CFXTEN compositions with enhanced properties compared to those art-known fusion proteins of factor VIII containing albumin, immunoglobulin polypeptide partners, polypeptides of shorter length and/or polypeptide partners with repetitive sequences. In addition, CFXTEN fusion proteins e cant advantages over chemical conjugates, such as pegylated constructs of FVIII, notably the fact that recombinant CFXTEN fusion proteins can be made in host cell expression systems, which can reduce time and cost at both the research and development and manufacturing stages of a product, as well as result in a more homogeneous, defined product with less toxicity from both the t and metabolites of the CFXTEN compared to pegylated conjugates.

As therapeutic agents, the CFXTEN possesses a number of advantages over therapeutics not comprising XTEN, including one or more of the following non-limiting properties: increased solubility, increased thermal stability, reduced immunogenicity, increased apparent molecular weight, reduced renal clearance, reduced proteolysis, reduced metabolism, enhanced therapeutic efficiency, less frequent dosage regimen with increased time between doses capable of maintaining hemostasis in a subject with ilia A, the ability to administer the CFXTEN composition subcutaneously or intramuscularly, a “tailored” rate of absorption when stered subcutaneously or intramuscularly, enhanced lyophilization stability, enhanced serum/plasma stability, increased terminal half-life, sed solubility in blood stream, decreased binding by lizing dies, decreased active clearance, tailored substrate g affinity, stability to degradation, stability to freeze-thaw, ity to proteases, stability to ubiquitination, ease of administration, compatibility with other pharmaceutical excipients or rs, persistence in the subject, increased stability in storage (e. g., increased shelf-life), and the like. The net effect of the enhanced ties is that the use of a CFXTEN composition can result in an overall enhanced therapeutic effect compared to a FVIII not linked to XTEN, result in economic benefits associated with less frequent , and/or result in improved patient compliance when stered to a subject with a factor VIII-related condition.

The invention provides CFXTEN compositions and pharmaceutical compositions comprising CFXTEN wherein the administration of the composition results in an improvement in at least one of the clinical or biochemical parameters disclosed herein as being useful for assessing the subject diseases, conditions or disorders. Non-limiting examples of parameters that are ed include blood concentrations of procoagulant FVIII, a reduced activated partial prothrombin (aPTT) assay time, a reduced one-stage or age clotting assay time, delayed onset of a bleeding episode, a reduced chromogenic FVIII assay time, a reduced bleeding time, resolution of a bleeding event, or a reduced Bethesda titer to the CFXTEN ve to native FVIII. The enhanced pharmacokinetic properties of the subject CFXTEN s using an accumulatively lower IU dose of fusion protein to in the parameter ed to the corresponding FVIII component not linked to the XTEN. In one ment, the total dose in IUs of an CFXTEN of the embodiments needed to achieve and maintain the improvement in the at least one parameter for about 2-7 days is at least about three-fold lower, or at least about four-fold, or at least about five-fold, or at least about six-fold, or at least about eight-fold, or at least about 10-fold lower compared to the corresponding FVIII component not linked to the XTEN. In another embodiment, the total dose in IUs of a subject CFXTEN needed to achieve and maintain the improvement in the at least one parameter over two, three or four consecutive doses is at least about three-fold lower, or at least about four-fold, or at least about five-fold, or at least about six-fold, or at least about eight-fold, or at least about d lower compared to the corresponding FVIII component not linked to the XTEN. Alternatively, the invention provides certain embodiments of CFXTEN wherein the period between consecutive strations that results in achieving and ining the improvement in at least one parameter is at least about three-fold, or at least about four-fold, or at least about five-fold, or at least about six-fold, or at least about eight-fold, or at least about 10-fold longer ed to the corresponding FVIII component not linked to the XTEN and administered at a comparable IU dose. Alternatively, the invention provides n embodiments of CFXTEN wherein stration of 25 IU/kg results in a 30% improvement in a aPTT assay (or similar coagulation assay) time in a hemophilia A subject compared to 25 IU/kg of the corresponding FVIII not linked to XTEN when assayed at about 2-7 days after administration. In yet another embodiment, the invention provides CFXTEN n administration of 25 IU/kg results in a 30% improvement in a bleeding time assay time in a hemophilia A subject compared to 25 IU/kg of the ponding FVIII not linked to XTEN when assayed at about 2-7 days after administration.

] In one embodiment, XTEN as a fusion partner increases the solubility of the FVIII payload.

Accordingly, where enhancement of the pharmaceutical or physicochemical properties of the FVIII is ble, such as the degree of aqueous solubility or stability, the length and/or the motif family composition of the XTEN sequences incorporated into the fusion protein may each be selected to confer a different degree of solubility and/or stability on the respective fusion proteins such that the overall pharmaceutical properties of the CFXTEN composition are enhanced. The CFXTEN fusion proteins can be constructed and assayed, using methods described , to confirm the physicochemical properties and the choice of the XTEN length sequence or location adjusted, as needed, to result in the d properties. In one embodiment, the CFXTEN has an aqueous solubility that is at least about 25% greater compared to a FVIII not linked to the XTEN, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 75%, or at least about 100%, or at least about 200%, or at least about 300%, or at least about 400%, or at least about 500%, or at least about 1000% greater than the corresponding FVIII not linked to XTEN.

The invention es methods to produce and recover expressed CFXTEN from a host cell with enhanced solubility and ease of recovery compared to FVIII not linked to XTEN. In one embodiment, the method includes the steps of transforming a eukaryotic host cell with a cleotide encoding a CFXTEN with one or more XTEN components of cumulative sequence length greater than about 100, or greater than about 200, or greater than about 400, or r than about 600, or greater than about 800, or greater than about 1000, or greater than about 2000, or greater than about 3000 amino acid residues, expressing the CFXTEN fusion protein in the host cell under suitable culture and induction conditions, and recovering the expressed fusion protein in soluble form. In one embodiment, the one or more XTEN of the CFXTEN fusion proteins each have at least about 80% sequence identity, or about 90%, or about 91%, or about 92%, or about 93%, or about 94%, or about 95%, or about 96%, or about 97%, or about 98%, or about 99%, to about 100% sequence identity compared to one or more XTEN selected from any one of Tables 4, and 13-17, or fragments thereof, and the FVIII have at least about 80% sequence identity, or about 90%, or about 91%, or about 92%, or about 93%, or about 94%, or about 95%, or about 96%, or about 97%, or about 98%, or about 99%, or 100% sequence identity compared to a FVIII selected from Table 1, and the CFXTEN components are in an N— to C-terminus configuration selected from any one of the uration embodiments disclosed herein.

VI). USES OF THE CFXTEN COMPOSITIONS The invention provides methods and ns for achieving a beneficial effect in a factor VIII- related condition by the administration of compositions comprising . As used herein, “factor VIII-related condition” is intended to include, but is not limited to factor VIII def1ciencies, ng disorders related to factor VIII deficiency, hemophilia A, neutralization of factor VIII by anti-FVIII antibodies or other factor VIII tors, and bleeding episodes resulting from trauma or surgery or vascular injury and other such conditions that can be ameliorated or corrected by administration of FVIII to a subject. The inventive s achieve a beneficial effect while addressing disadvantages and/or limitations of other s of treatment using factor VIII ations that have a relatively short terminal half-life, require frequent administrations, are neutralized by inhibitors or have unfavorable pharmacoeconomics.

Hemostasis is ted by multiple protein factors, and such proteins, as well as analogues thereof, have found utility in the treatment of factor VIII-related conditions. However, the use of commercially-available FVIII has met with less than optimal success in the management of subjects afflicted with such conditions. In particular, dose optimization and frequency of dosing is important for FVIII used in maintaining circulating FVIII concentrations above threshold levels needed for hemostasis, as well as the treatment or prevention of bleeding episodes in hemophilia A subjects. The fact that commercially-available FVIII ts have a short ife necessitates nt dosing in order to achieve clinical benefit, which results in difficulties in the ment of such patients.

As established by the Subcommittee on Factor VIII and Factor IX of the Scientific and rdization Committee of the ational Society on Thrombosis and Haemostasis (posted on the ISTH Website 29 November, 2000), the most widely used measure of the severity of hemophilia A is established by determining the circulating concentrations of plasma FVIII procoagulant levels, with s with <1% (< 0.01 IU/ml) factor VIII defined as severe; 1-5% (0.01 - 0.05 IU/ml) as moderately severe; and >5-40% (0.05 - <0.40 IU/ml) as mild, where normal is 1 IU/ml of factor VIIIC (100%).

The invention provides methods of treating a subject suffering from or at risk of developing a factor VIII-related condition. More particularly, the invention provides methods for treating or ting controlling bleeding in subject. The subject can be any animal but preferably is a human. In one embodiment, the method comprises administering a coagulation-effective amount of a CFXTEN composition to the subject in need f In another embodiment, the method comprises the step of administering to the t with a bleed a ation-effective amount of a pharmaceutical composition that includes a CFXTEN, wherein the administration results in an arrest or attenuation of the bleeding.

As used herein, “coagulation-effective amount” is an amount of a FVIII composition that, when administered to a subject, is sufficient to effect hemostasis or other beneficial or d therapeutic (including preventative) result. In cing the present invention, it will be understood that a coagulation-effective amount can be administered in one or more administrations. Precise coagulationeffective amounts of the pharmaceutical composition to be stered will be guided by the judgment of the practitioner, however, the unit dose will generally depend on the severity or cause of the bleeding and the amount of pre-eXisting FVIII in the subject. In a particular embodiment of the method of treating a bleed, a ation-effective amount of a pharmaceutical compositions comprising CFXTEN is administered to a subject ing from a bleeding episode, wherein the stration results in the resolution of the bleeding for a duration at least two-fold, or at least three-fold, or at least four-fold longer compared to a FVIII not linked to XTEN and administered to a comparable subject with a comparable bleed at a comparable dose.

In r embodiment, the administration of a coagulation-effective amount of a CFXTEN composition to a subject with a factor VIII-related condition results in a 10%, or 20%, or 30%, or 40%, or 50%, or 60%, or 70% or greater improvement of one or more biochemical, physiological or al parameters associated with the FVIII condition, compared to the FVIII not linked to XTEN, when measured at between 2 and 7 days after administration. In another embodiment, the stration of a coagulation-effective amount of a CFXTEN composition to the subject in need thereof results in an improvement of one or more mical, physiological or clinical parameters associated with the FVIII condition for a period at least two-fold longer, or at least four-fold longer, or at least five-fold longer, or at least siX-fold longer ed to period achieved by a FVIII not linked to XTEN and administered at a comparable dose. Non-limiting examples of parameters that are improved for a longer duration include blood concentrations of procoagulant FVIII, a reduced activated partial prothrombin (aPTT) assay time, a reduced one-stage or two-stage clotting assay time, delayed onset of a bleeding episode, a d chromogenic FVIII assay time, a reduced bleeding time, among other FVIII-related parameters known in the art. In the foregoing embodiments of the paragraph, the administered CFXTEN comprises a FVIII with at least about 80%, or at least about 90%, or at least about 95%, or at least about 97%, or at least about 99% sequence identity to a factor VIII of Table l and one or more XTEN sequences with at least about 80%, or at least about 90%, or at least about 95%, or at least about 97%, or at least about 99% sequence identity to an XTEN of Table 4 inserted into the FVIII at one or more ons selected from Table 5, Table 6, Table 7, Table 8, and Table 9, or as depicted in FIGS. 8-9. In certain embodiments, at least one XTEN insertion site of the CFXTEN is ed from amino acids 32, 220, 224, 336, 339, 390, 399, 416, 603, 1656, 1711, 1725, 1905 and 1910 (numbered relative to mature native human FVHI).

In a ular embodiment of the method of ent, a coagulation-effective amount of CFXTEN fusion protein administered to a subject suffering from hemophilia A is sufficient to increase the circulating FVIII gulant concentration to greater than 0.05 IU/ml and to maintain hemostasis for at least about 24 h, or at least about 48 h, or at least about 72 h, or at least about 96 h, or at least about 120 h, or at least about 144 h, or at least about 168 h, or greater. In another embodiment, the administration of a coagulation-effective amount of a pharmaceutical composition comprising CFXTEN to a subject in need thereof results in a r reduction in a one-stage ng assay time of at least about 5%, or about 10%, or about 20%, or about 30%, or about 40%, or about 50%, or about 60%, or about 70%, or more in a blood sample from the subject at 2-7 days after the administration compared to the assay time in a subject after administration of a comparable amount of the corresponding FVIII not linked to XTEN. In another embodiment, the administration of a therapeutically effective amount of a CFXTEN or a pharmaceutical compositions comprising CFXTEN to a subject in need thereof s in a greater reduction in the activated partial prothrombin time of at least about 5%, or about 10%, or about %, or about 30%, or about 40%, or about 50%, or about 60%, or about 70%, or more in a blood sample from the t 2-7 days after administration compared to the activated partial prothrombin time in a subject after administration of a comparable amount of the corresponding FVIII not linked to XTEN. In another embodiment, the administration of a CFXTEN or a pharmaceutical compositions comprising CFXTEN to a subject in need thereof using a therapeutically effective amount results in nance of activated partial prothrombin times Within 30% of normal in a blood sample from the subject for a period of time that is at least ld, or at least about fold, or at least about four-fold longer compared to that of a FVIII not linked to XTEN and administered to a subject using a comparable dose.

In one ment of the method of treatment, the CFXTEN fusion protein is formulated and administered as a ceutical composition comprising the CFXTEN in admixture With a ceutically acceptable excipient. Methods for making pharmaceutical formulations are well known in the art. Techniques and formulations lly may be found in Remington's Pharmaceutical Sciences, 18th Edition, Mack Publishing Co., , Pa. 1990 (See, also, Wang and Hanson, Parenteral Formulations of Proteins and Peptides: Stability and Stabilizers, Journal of Parenteral Science and Technology Technical Report No. , 10, Supp. 42-2S (1988)).

In another aspect, the invention provides a regimen for ng a hemophilia A patient, said regimen comprising a composition comprising a CFXTEN fusion protein. In one embodiment of the regimen for treating a hemophilia A patient, the regimen further comprises the step of determining the amount of pharmaceutical composition comprising the CFXTEN needed to achieve hemostasis in the patient. In some embodiments of the regimen, (i) a smaller 1U amount of about two-fold less, or about three-fold less, or about four-fold less, or about five-fold less, or about six-fold less, or about eight-fold less, or about 10-fold less of the pharmaceutical ition comprising CFXTEN is administered to a subject in need thereof in comparison to the corresponding coagulation factor not linked to the XTEN under an otherwise same dose regimen, and the fusion protein achieves a comparable area under the curve (based on IU/ml) and/or a comparable therapeutic effect as the corresponding FVIII not linked to the XTEN; (ii) the ceutical composition is administered less frequently (e. g., every three days, about every seven days, about every 10 days, about every 14 days, about every 21 days, or about monthly) in comparison to the corresponding FVIII not linked to the XTEN under an otherwise same dose amount, and the fusion protein achieves a comparable area under the curve and/or a comparable therapeutic effect as the ponding coagulation factor not linked to the XTEN; or (iii) an accumulative smaller IU amount of at least about 20%, or about 30%, or about 40%, or about 50%, or about 60%, or about 70%, or about 80%, or about 90% less of the pharmaceutical composition is administered in comparison to the corresponding FVIII not linked to the XTEN under an otherwise same dose schedule and the CFXTEN fusion protein es a comparable therapeutic effect as the corresponding FVIII not linked to the XTEN. The accumulative smaller IU amount is measured for a period of at least about one week, or about 14 days, or about 21 days, or about one month. In the ing embodiments, the therapeutic effect can be determined by any of the measured ters described herein, including but not limited to blood tration of procoagulant FVIII, a reduced ted partial prothrombin (aPTT) assay time, a d one-stage or two-stage ng assay time, delayed onset of a bleeding episode, a reduced chromogenic FVIII assay time, a d bleeding time, resolution of a bleeding event, or a reduced Bethesda titer to the CFXTEN relative to native FVIII, fibrinogen levels, or other assays known in the art for assessing coagulopathies of FVIII. In another embodiment, the ion provides CFXTEN for use in a regimen for a treating a hemophilia A subject comprising administering an CFXTEN composition in two or more successive doses to the subject at an effective amount, wherein the tration results in at least a 10%, or 20%, or 30%, or 40%, or 50%, or 60%, or 70%, or 80%, or 90% r improvement of at least one, two, or three parameters associated with the disease compared to a FVIII not linked to XTEN and administered using a comparable dose.

In one , the present invention relates to a method of preventing or treating the bleeding in a patient, optionally a haemophilia A patient, having pre-eXisting inhibitor(s) against FVIII. Inhibitory antibodies against FVIII commonly develop in hemophiliacs, where the overall incidence of developing an inhibitor is 15 -3 0%, particularly in haemophiliacs who are heavily exposed to FVIII concentrates (Algiman et al. l dies to factor VIII (anti-hemophilic factor) in healthy individuals. PNAS USA (1992) 89: 3795-3799). However, inhibitory antibodies also occur in patients in auto-immune disorders, malignancies (such as lymphoproliferative disorders, lymphomas and solid tumors), during pregnancy and in the post-partum state. Inhibition can also occur when antibodies interfere with the binding of FVIII to FIX and FX. Simultaneously or alternatively, anti-FVIII antibodies can interfere with the binding of von Willebrand factor and/or phospholipids to FVIII, affecting coagulation and/or ife of FVIII. The presence of inhibitory antibodies is often first detected with ms such as easy bruising and uncontrolled bleeding, and is y referred to as acquired hemophilia. Anti-FVIII antibodies can be determined by different methods including quantitation of anti-FVIII activity in coagulation assays, ELISA for FVIII inhibitors and purification using chromatography and immunoadsorption (Algiman et al., 1992). Accordingly, the inventive methods are used in the treatment or prevention of any condition associated with or characterized by the presence of inhibitory antibodies to FVIII. In one embodiment, the invention provides a method of treating a patient haVing a pre-eXisting inhibitor t FVIII, the method comprising the step of administering to the patient a coagulation- effective amount of a CFXTEN fusion protein that must be administered to achieve hemostasis, n the coagulation-effective amount of fusion protein administered is reduced in comparison to the amount of FVIII not linked to XTEN (or native FVIII) that must be stered to achieve hemostasis. In the method, the reduced amount of CFXTEN is about two-fold, or three-fold, or four-fold, or five-fold less in IU/kg compared to the corresponding FVIII not linked to XTEN. In another embodiment of the method, the amount of CFXTEN that is administered as a dose to achieve hemostasis is at least 20 to 40 IU/kg less, or 30 to 60 IU/kg less, or 40 to 80 IU/kg less, or 60 to 100 IU/kg less, or 100 to 140 IU/kg less, or 120 to 180 IU/kg less, or 140 to 200 IU/kg less compared to the corresponding FVIII not linked to XTEN or to native FVIII ed to achieve hemostasis. In another embodiment, the invention provides a method of treating a bleeding episode in a hemophilia A subject haVing a titer of at least 10, or 20, or 30, or 40, or 50, or 75, or 100, or 150, or 200 or more Bethesda units against a FVIII not linked to XTEN, wherein the dose of CFXTEN fusion protein required to arrest the ng epidose is at least two-fold, or three-fold, or four-fold, or five-fold, or six-fold, or fold, or eight-fold, or nine-fold, or 10-fold less in comparison to the amount of FVIII not linked to XTEN (or native FVIII) that must be administered to achieve hemostasis in a comparable subject. It will be understood by one of skill in the art that the amount of gulant stered to in hemostasis will depend on the severity of FVIII deficiency and/or the frequency or duration of bleeding.

A particular object of the present invention relates to use of CFXTEN with reduced g by FVIII tors that bind the A2 and/or C2 domains of Factor VIII as a drug. Such a drug is advantageously used for maintaining hemostasis in a patient suffering from haemophilia, wherein such patient has ating FVIII inhibitors directed against the A2 domain and/or C2 domain of Factor VIII.

In one embodiment, the invention provides a method of treatment, the method comprising the step of administering to the patient with a A2 -binding inhibitor a coagulation-effective amount of a CFXTEN fusion protein, wherein the CFXTEN exhibits at least 10%, or 20%, or 30%, or 40%, or 50%, or 60%, or 70%, or 80% or less binding to an inhibitor that binds the A2 domain of FVIII, ed to the FVIII not linked to XTEN or to native FVIII, and wherein the stration results in hemostasis.

In another embodiment, the invention provides a method of ent, the method comprising the step of administering to the patient with a C2 domain-binding inhibitor a coagulation-effective amount of a CFXTEN fusion protein, wherein the CFXTEN exhibits at least 10%, or 20%, or 30%, or 40%, or 50%, or 60%, or 70%, or 80% or less binding to an inhibitor that binds the C2 domain of FVIII, compared to the FVIII not linked to XTEN or to native FVIII, and n the administration results in hemostasis.

The reduced binding of the subject CFXTEN can be assayed directly by ELISA that detects FVIII inhibitors, or measured indirectly by demonstration of reduced inhibition of FVIII actiVity of the CFXTEN compared to native FVIII in the presence of an inhibitor as measured by a factor VIII chromogenic test or one-step assay as described herein, or other suitable coagulation methods known in the art. Alternatively, the subject CFXTEN can be measured for reduced (or absence of) tion in the presence of known tors by use of a modified Bethesda assay. ing to a particular aspect of the present invention, a CFXTEN useful in the methods has reduced reactivity to one or more antibodies from Table 10, as well as lly-occurring antibodies found in hemophilia ts. For g purposes, such and other inhibitory antibodies can be obtained from humans (i.e. from the serum of patients which have inhibitory antibodies) or can be obtained from mice, guinea pigs, horses, goats, non- human primates and other mammals by immunization with FVIII, or fragments thereof, more ularly with a nt comprising the all or part of the A2 or C2 domain, whether in polyclonal or monoclonal form.

The invention r contemplates that the CFXTEN used in accordance with the methods provided herein can be administered in conjunction with other treatment methods and itions (e. g., other coagulation proteins) useful for treating factor VIII-related conditions, or conditions for which coagulation factor is adjunctive therapy; e. g., bleeding episodes due to injury or surgery.

] In another aspect, the invention provides methods of preparing a drug for a factor VIII-related condition, comprising ing a factor VIII sequence selected from Table 1 with one or more XTEN selected from Table 4 inserted in one or more insertion sites selected from Table 5, Table 6, Table 7, Table 8, and Table 9 to result in a drug that retains at least a portion of the activity of the native FVIII.

The invention provides a method of preparing a pharmaceutical composition, comprising the step of combining the drug of the ing embodiment with at least one pharmaceutically acceptable carrier.

In one embodiment of the method of preparing a drug for a factor VIII-related condition, the factor VIII has a sequence with at least about 80%, or at least about 90%, or at least about 95%, or at least about 97%, or at least about 99% sequence identity compared to a sequence selected from Table 1 and the one or more XTEN has a sequence with at least about 80%, or at least about 90%, or at least about 95%, or at least about 97%, or at least about 99% sequence identity compared to a ce selected from any one of Tables 3, 4, and 13-17, or a fragment thereof, wherein the one or more XTEN are inserted in one or more ons selected from Table 5, Table 6, Table 7, Table 8, and Table 9. In a particular embodiment of the foregoing, at least one XTEN insertion site is selected from amino acids 32, 220, 224, 336, 339, 390, 399, 416, 603, 1656, 1711, 1725, 1905 and 1910 (numbered relative to mature native human .In another embodiment of the method, the CFXTEN comprises a sequence with at least about 80%, or at least about 90%, or at least about 95%, or at least about 97%, or at least about 99% sequence identity compared to a sequence selected from any one of Table 21.

In another aspect, the invention provides a method of making the CFXTEN itions to achieve desired pharmacokinetic, cologic or pharmaceutical properties. In general, the steps in the design and production of the inventive fusion protein compositions, as illustrated in FIGS. 11-13, include: (1) the selection of a FVIII (e. g., native proteins, sequences of Table 1, analogs or derivatives with activity) to treat the particular condition; (2) selecting one or more XTEN (e. g., sequences with at least 80% identity to sequences set forth in Table 4) that will confer the desired pharmacokinetic and physicochemical characteristics on the ing CFXTEN (e.g., the administration of the CFXTEN composition to a subject results in the fusion protein being maintained above 0.05-0.4 IU/ml for a greater period ed to FVIII not linked to XTEN); (3) establishing a desired N— to C-terminus configuration of the CFXTEN to achieve the desired y or PK parameters (e.g., selecting one or more insertion sites from Table 5, Table 6, Table 7, Table 8, and Table 9); (4) establishing the design of the expression vector encoding the configured CFXTEN; (5) transforming a suitable host with the sion vector; and (6) expressing and recovering the resultant isolated CFXTEN fusion protein. In one embodiment of the method of making CFXTEN, the XTEN for insertion are evaluated by the application of Equation IV to maximize the Ratio XTEN Radii for the fusion protein construct, with the XTEN resulting in values greater than 2.0, or 2.1, or 2.2, or 2.3, or 2.4, or 2.5, or 2.6, or 2.7, or 2.8, or 2.9. or 3.0 being preferred.

For those CFXTEN for which an se in half-life or an increased period of time spent above the minimum coagulation-effective concentration is desired, the XTEN chosen for incorporation generally have at least about 144, or about 288, or about 432, or about 576, or about 864, or about 875, or about 912, or about 923 amino acid residues where a single XTEN is to be incorporated into the . In another embodiment, the CFXTEN comprises a first XTEN of the foregoing lengths, and at least a second XTEN of about 36, or about 42, or about 72, or about 144, or about 288, or about 576, or about 864, or about 875, or about 912, or about 923, or about 1000 or more amino acid residues. The on of the XTEN within the fusion protein can include one, two, three, four, five or more locations ed from Table 5, Table 6, Table 7, Table 8, and Table 9 or FIGS. 8-9. In one embodiment, the method of design es an insertion ofXTEN into the FVIII of at least one site selected from amino acids 32, 220, 224, 336, 339, 390, 399, 416, 603, 1656, 1711, 1725, 1905 and 1910 red ve to mature native human FVIII).

In another aspect, the invention provides s of making CFXTEN compositions to improve ease of manufacture, result in increased stability, increased water solubility, and/or ease of formulation, as compared to the native FVIII. In one embodiment, the invention includes a method of increasing the water solubility of a FVIII comprising the step of linking the FVIII with at least about 80%, or about 90%, or about 95% identity to a sequence from Table 1 to one or more XTEN at one, two, three, four, five or more locations selected from Table 5, Table 6, Table 7, Table 8, and Table 9 or FIGS. 8-9 wherein the XTEN is a ce with at least about 80%, or about 90%, or about 95% sequence identity compared to a sequence from any one of Tables 3, 4, and 13-17 such that a higher concentration in soluble form of the resulting CFXTEN can be achieved, under physiologic conditions, compared to the FVIII in an un-fused state. In a particular embodiment, the CFXTEN comprises a FVIII linked to two, three, four, or five XTEN having at least about 24, or about 36, or about 48, or about 60, or about 72, or about 84, or about 96, or about 144, or about 288 amino acid residues inserted at sites selected from Table 5, Table 6, Table 7, Table 8, and Table 9 or FIGS. 8-9, in which the solubility of the fusion protein under physiologic conditions is at least three-fold greater than the corresponding FVIII not linked to XTEN, or alternatively, at least four-fold, or five-fold, or six-fold, or seven-fold, or eight-fold, or nine- fold, or at least 10-fold, or at least 20-fold, or at least 30-fold, or at least 50-fold, or at least 60-fold or greater than FVIII not linked to XTEN. Factors that contribute to the property ofXTEN to confer increased water solubility of CFs when incorporated into a fusion protein e the high solubility of the XTEN fusion partner and the low degree of self-aggregation between molecules ofXTEN in solution, as well as expanding the hydrophilicity of FVIII al loops into which the XTEN is inserted. In some ments, the method results in a CFXTEN fiJsion protein wherein the water solubility is at least about 20%, or at least about 30% r, or at least about 50% greater, or at least about 75% greater, or at least about 90% greater, or at least about 100% greater, or at least about 150% greater, or at least about 200% greater, or at least about 400% greater, or at least about 600% greater, or at least about 800% greater, or at least about 1000% greater, or at least about 2000% greater under physiologic conditions, compared to the ed FVIII. In one embodiment, the XTEN of the CFXTEN fusion protein is a sequence with at least about 80%, or about 90%, or about 95% sequence identity compared to a ce from any one of Tables 3, 4, and 13-17. In another embodiment, the invention includes a method of increasing the shelf-life of a FVIII comprising the step of linking the FVIII with one or more XTEN at one or more sites selected from Table 5, Table 6, Table 7, Table 8, and Table 9, wherein the shelf-life of the resulting CFXTEN is extended compared to the FVIII in an un-fused state. As used herein, life refers to the period of time over which the procoagulant activity of a FVIII or CFXTEN that is in solution, lyophilized or in some other storage formulation s stable without undue loss of activity or that remains within release specifications established for the pharmaceutical ition. A FVIII that degrades or aggregates generally has reduced functional activity or reduced bioavailability compared to one that s in solution. Factors that contribute to the ability of the method to extend the shelf life of FVIII when incorporated into a fusion protein include increased water solubility, reduced self-aggregation in solution, and increased heat ity of the XTEN fusion partner. In particular, the low tendency ofXTEN to aggregate facilitates methods of formulating pharmaceutical preparations containing higher drug concentrations of CFs, and the heat-stability ofXTEN contributes to the property of CFXTEN fusion proteins to remain soluble and functionally active for extended periods. The method results in CFXTEN fusion proteins with prolonged or extended shelf-life that exhibit greater activity relative to a FVIII standard that has been ted to the same storage and handling conditions. The rd may be the un—fused full-length FVIII or a cially-available FVIII pharmaceutical ition. In one embodiment, the method includes the step of formulating the isolated CFXTEN with one or more pharmaceutically acceptable excipients that e the ability of the XTEN to retain its unstructured conformation and for the CFXTEN to remain soluble in the formulation for a time that is greater than that of the corresponding un—fused FVIII. In one embodiment, the method comprises linking a FVIII selected from Table 1 to one or more XTEN selected from any one of Tables 3, 4, and 13-17 inserted at one or more sites selected from Table 5, Table 6, Table 7, Table 8, and Table 9 and ng with at least one pharmaceutically acceptable excipient to create a pharmaceutical ition that retains greater than about 100% of the procoagulant activity, or greater than about 105%, 110%, 120%, 130%, 150% or 200% of the procoagulant activity of a FVIII standard subjected to the same storage and handling conditions when compared at a time point of at least 90 days, or at least 6 months, or at least 12 WO 22617 months. Shelf-life may also be assessed in terms of functional activity ing after storage, normalized to functional activity when storage began. In some embodiments, CFXTEN pharmaceutical compositions of the invention retain about 50% more procoagulant activity, or about 60%, 70%, 80%, or 90% more of the procoagulant ty of a FVIII standard when subjected to the same conditions for the same period of up to 2 weeks, or 4 weeks, or 6 weeks or longer under various temperature conditions. In one embodiment, the CFXTEN pharmaceutical composition retains at least about 50%, or about 60%, or at least about 70%, or at least about 80%, and most preferably at least about 90% or more of its original activity in solution when heated at 80°C for 10 min. In another embodiment, the CFXTEN ceutical composition retains at least about 50%, preferably at least about 60%, or at least about 70%, or at least about 80%, or atively at least about 90% or more of its original activity in solution when heated or maintained at 37°C for about 7 days. In another embodiment, CFXTEN pharmaceutical composition retains at least about 80% or more of its onal activity after re to a temperature of about 30°C to about 70°C over a period of time of about one hour to about 18 hours. In the foregoing embodiments above described in this paragraph, the retained activity of the CFXTEN pharmaceutical compositions is at least about two-fold, or at least about three-fold, or at least about four- fold, or at least about five-fold, or at least about six-fold greater at a given time point than that of a corresponding ceutical composition comprising FVIII not linked to the XTEN.

VII). THE NUCLEIC ACIDS SEQUENCES OF THE INVENTION The present ion provides isolated polynucleic acids encoding CFXTEN chimeric fusion proteins and sequences complementary to polynucleic acid molecules encoding CFXTEN chimeric fusion proteins, including homologous variants thereof. In another aspect, the invention encompasses methods to produce polynucleic acids encoding CFXTEN chimeric fusion proteins and sequences complementary to polynucleic acid molecules encoding CFXTEN chimeric fusion protein, ing homologous variants thereof. In general, and as illustrated in FIGS. 11-13, the methods of producing a cleotide sequence coding for a CFXTEN fusion protein and expressing the resulting gene product include assembling nucleotides encoding FVIII and XTEN, ligating the components in frame, orating the encoding gene into an sion vector appropriate for a host cell, transforming the appropriate host cell with the expression vector, and ing the host cell under conditions causing or permitting the fusion protein to be expressed in the transformed host cell, thereby producing the biologically-active CFXTEN polypeptide, which is recovered as an isolated fusion n by standard protein purification methods known in the art. Standard recombinant techniques in molecular biology is used to make the cleotides and expression vectors of the present invention.

In accordance with the invention, nucleic acid sequences that encode CFXTEN (or its ment) are used to generate recombinant DNA molecules that direct the expression of CFXTEN fusion proteins in appropriate host cells. For the purposes of the invention, nucleic acid encoding a signal peptide corresponding to that of native human FVIII ing MQIELSTCFFLCLLRFCFS (SEQ ID NO: 1611)) can be added to any of the encoding constructs described herein to aid in the expression and secretion of the CFXTEN fusion protein. In one embodiment, the nucleic acid add is ATGCAAATAGAGCTCTCCACCTGCTTCTTTCTGTGCCTTTTGCGATTCTGCTTTAGT (SEQ ID NO: 1613), or the complement thereof.

Several cloning gies are suitable for performing the present invention, many of which is used to generate a construct that comprises a gene coding for a fusion protein of the CFXTEN ition of the present invention, or its complement. In some embodiments, the cloning strategy is used to create a gene that encodes a monomeric CFXTEN that comprises at least a first FVIII and at least a first XTEN polypeptide, or their complement. In one embodiment of the foregoing, the gene ses a ce encoding a FVIII or sequence variant. In other embodiments, the cloning strategy is used to create a gene that encodes a monomeric CFXTEN that comprises nucleotides encoding at least a first molecule of FVIII or its complement and a first and at least a second XTEN or their complement that is used to transform a host cell for expression of the fusion protein of the CFXTEN composition. In the ing embodiments hereinabove described in this paragraph, the genes can further comprise nucleotides ng spacer sequences that also encode cleavage sequence(s).

In designing a desired XTEN sequences, it was discovered that the non-repetitive nature of the XTEN of the inventive compositions is achieved despite use of a ”building block" molecular approach in the on of the XTEN-encoding sequences. This was achieved by the use of a library of polynucleotides ng peptide sequence motifs, described above, that are then d and/or multimerized to create the genes encoding the XTEN sequences (see FIGS. 11 and 12 and Examples).

Thus, while the ) of the expressed fusion protein may consist of multiple units of as few as four ent sequence motifs, because the motifs themselves consist of non-repetitive amino acid sequences, the overall XTEN sequence is rendered non-repetitive. Accordingly, in one embodiment, the XTEN- encoding polynucleotides comprise multiple polynucleotides that encode non-repetitive sequences, or motifs, operably linked in frame and in which the resulting expressed XTEN amino acid sequences are non-repetitive.

In one approach, a construct is first prepared containing the DNA sequence corresponding to CFXTEN fusion protein. DNA encoding the FVIII of the compositions is obtained synthetically, from a commercial source, or from a cDNA library ed using standard methods from tissue or isolated cells believed to possess FVIII mRNA and to express it at a detectable level. If necessary, the coding sequence can be obtained using tional primer extension procedures as described in Sambrook, et al. to detect precursors and processing intermediates of mRNA that may not have been reverse- , supra, transcribed into cDNA. One can then use polymerase chain reaction (PCR) methodology to y the target DNA or RNA coding sequence to obtain sufficient material for the preparation of the CFXTEN constructs containing the FVIII gene. Assays can then be conducted to confirm that the hybridizing full- length genes are the d FVIII gene(s). By these conventional methods, DNA can be conveniently obtained from a cDNA library prepared from such sources. The FVIII ng gene(s) can also created by standard tic procedures known in the art (e. g., automated nucleic acid synthesis using, for example one of the s described in Engels et al. (Agnew. Chem. Int. Ed. Engl., 28:716-734 1989)), 2012/046326 using DNA sequences obtained from ly available databases, patents, or literature references. Such procedures are well known in the art and well described in the scientific and patent literature. For example, sequences can be obtained from Chemical cts Services (CAS) Registry Numbers (published by the an Chemical Society) and/or GenBank Accession Numbers (e.g., Locus ID, NP_XXXXX, and XP_XXXXX) Model Protein identifiers available through the National Center for Biotechnology Information (NCBI) webpage, available on the world wide web at ncbi.nlm.nih.gov that correspond to s in the CAS Registry or GenBank database that contain an amino acid sequence of the protein of st or of a fragment or variant of the protein. In one embodiment, the FVIII encoding gene encodes a protein sequence from Table l, or a fragment or variant thereof A gene or polynucleotide encoding the FVIII portion of the subject CFXTEN protein, in the case of an expressed fusion protein that comprises a single FVIII, is then cloned into a construct, which is a d or other vector under control of appropriate transcription and translation sequences for high level protein expression in a biological system. In a later step, a second gene or polynucleotide coding for the XTEN is genetically fused to the nucleotides encoding the N- and/or C-terminus of the FVIII gene by cloning it into the construct adjacent and in frame with the gene(s) coding for the FVIII. This second step occurs through a ligation or multimerization step. In the foregoing embodiments hereinabove described in this paragraph, it is to be understood that the gene ucts that are created can alternatively be the complement of the respective genes that encode the respective fusion proteins.

The gene encoding for the XTEN can be made in one or more steps, either fully synthetically or by synthesis combined with tic processes, such as restriction enzyme-mediated cloning, PCR and overlap extension, ing methods more fully described in the Examples. The methods disclosed herein can be used, for example, to ligate short sequences of polynucleotides encoding XTEN into longer XTEN genes of a desired length and sequence. In one embodiment, the method ligates two or more codon—optimized oligonucleotides encoding XTEN motif or segment ces of about 9 to 14 amino acids, or about 12 to 20 amino acids, or about 18 to 42 amino acids, or about 42 to about 144 amino acids, or about 144 to about 288 amino acids, or 288 to about 864 amino acids or longer, or any ation of the foregoing ranges of motif or t lengths.

Alternatively, the disclosed method is used to multimerize XTEN-encoding sequences into longer sequences of a desired length; e. g., a gene ng 36 amino acids ofXTEN can be dimerized into a gene encoding 72 amino acids, then 144, then 288, etc. Even with multimerization, XTEN ptides can be constructed such that the XTEN-encoding gene has low or virtually no repetitiveness h design of the codons selected for the motifs of the shortest unit being used, which can reduce recombination and increase stability of the encoding gene in the transformed host.

] Genes encoding XTEN with non-repetitive ces are assembled from oligonucleotides using standard techniques of gene synthesis. The gene design can be performed using algorithms that optimize codon usage and amino acid composition. In one method of the invention, a library of relatively short XTEN-encoding polynucleotide constructs is created and then assembled, as described above. The resulting genes are then assembled with genes ng FVIII or regions of FVIII, as rated in FIGS. 11 and 12, and the resulting genes used to transform a host cell and produce and recover the CFXTEN for evaluation of its properties, as described herein.

In another aspect, the invention provides isolated nucleic acids comprising a polynucleotide sequence encoding the CFXTEN fusion protein embodiments described herein. In one embodiment, the isolated c acid comprises a polynucleotide sequence selected from (a) a ce having at least about 80% sequence identity, or about 90%, or about 91%, or about 92%, or about 93%, or about 94%, or about 95%, or about 96%, or about 97%, or about 98%, or about 99%, to about 100% sequence identity ed to a ce of comparable length selected from Table 21, when optimally aligned, or (b) the ment of the polynucleotide of (a). In another embodiment, the isolated nucleic acid comprises the sequence ATGCAAATAGAGCTCTCCACCTGCTTCTTTCTGTGCCTTTTGCGATTCTGCTTTAGT (SEQ ID NO: 1613) linked to the 5’ end of the nucleic acid of (a) or the complement of the sequence linked to the 3’ end of (b). cleotide ies In another aspect, the invention provides libraries of polynucleotides that encode XTEN sequences that are used to assemble genes that encode XTEN of a desired length and sequence.

In certain embodiments, the XTEN-encoding y constructs comprise polynucleotides that encode polypeptide segments of a fixed length. As an initial step, a library of oligonucleotides that encode motifs of 9-14 amino acid residues can be assembled. In a preferred embodiment, libraries of oligonucleotides that encode motifs of 12 amino acids are assembled.

] The XTEN-encoding sequence segments can be dimerized or multimerized into longer encoding sequences, as depicted schematically in . Dimerization or erization can be performed by ligation, overlap extension, PCR ly or similar cloning techniques known in the art.

This process of can be repeated multiple times until the resulting XTEN-encoding sequences have reached the organization of sequence and desired length, providing the XTEN-encoding genes. As will be iated, a library of polynucleotides that encodes, e. g., 12 amino acid motifs can be zed and/or ligated into a library of polynucleotides that encode 36 amino acids. Libraries encoding motifs of different lengths; e. g., 9-14 amino acid motifs leading to libraries encoding 27 to 42 amino acids are contemplated by the invention. In turn, the library of polynucleotides that encode 27 to 42 amino acids, and preferably 36 amino acids (as bed in the Examples) can be serially dimerized into a library containing successively longer lengths of polynucleotides that encode XTEN sequences of a desired length for incorporation into the gene encoding the CFXTEN fusion protein, as disclosed herein.

A more efficient way to optimize the DNA sequence encoding XTEN is based on combinatorial libraries. The gene encoding XTEN can be designed and synthesized in segment such that multiple codon versions are ed for each segment. These segments can be randomly assembled into a library of genes such that each library member encodes the same amino acid sequences but library s comprise a large number of codon versions. Such libraries can be screened for genes that result in evel sion and/or a low abundance of truncation products. The process of combinatorial WO 22617 gene assembly is illustrated in . The genes in are assembled from 6 base fragments and each fragment is available in 4 different codon versions. This allows for a theoretical diversity of 4096.

In some embodiments, libraries are assembled of polynucleotides that encode amino acids that are limited to c sequence XTEN families; e. g., the AD, AE, AF, AG, AM, or AQ ces of Table 4. In other embodiments, libraries comprise sequences that encode two or more of the motif family sequences from Table 3. The names and sequences of representative, non-limiting polynucleotide sequences of libraries that encode 36mers are presented in Tables 13-17, and the methods used to create them are bed more fully in the respective Examples. In other embodiments, libraries that encode XTEN are constructed from segments of polynucleotide codons linked in a randomized sequence that encode amino acids wherein at least about 80%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% of the codons are selected from the group consisting of s for glycine (G), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P) amino acids. The ies can be used, in turn, for serial dimerization or ligation to achieve polynucleotide sequence libraries that encode XTEN sequences, for example, of 42, 48, 72, 144, 288, 576, 864, 875, 912, 923, 1318 amino acids, or up to a total length of about 3000 amino acids, as well as intermediate lengths, in which the encoded XTEN can have one or more of the properties disclosed herein, when sed as a component of a CFXTEN filSiOIl protein. In some cases, the polynucleotide library sequences may also include onal bases used as ”sequencing islands,” described more fully below. is a schematic flowchart of representative, non-limiting steps in the ly of a XTEN polynucleotide construct and a CFXTEN polynucleotide construct in the embodiments of the invention. Individual oligonucleotides 501 are annealed into sequence motifs 502 such as a 12 amino acid motif (“12-mer”), which is ligated to additional sequence motifs from a y to create a pool that encompasses the desired length of the XTEN 504, as well as ligated to a smaller concentration of an oligo containing BbsI, and KpnI restriction sites 503. The resulting pool of ligation products is gelpurified and the band with the desired length ofXTEN is cut, resulting in an isolated XTEN gene with a stopper sequence 505. The XTEN gene is cloned into a stuffer . In this case, the vector encodes an optional CBD sequence 506 and a GFP gene 508. Digestion is than performed with BbsI/HindIII to remove 507 and 508 and place the stop codon. The resulting product is then cloned into a BsaI/HindIII ed vector containing a gene encoding the FVIII, resulting in the gene 500 encoding an FVIII- XTEN fusion protein.

One may clone the library of XTEN-encoding genes into one or more expression s known in the art. To facilitate the identification of xpressing library s, one can construct the library as fusion to a reporter protein. Non-limiting examples of suitable reporter genes are green fluorescent protein, luciferace, alkaline phosphatase, and beta-galactosidase. By screening, one can identify short XTEN sequences that can be expressed in high concentration in the host organism of choice. Subsequently, one can generate a library of random XTEN dimers and repeat the screen for high level of expression. Subsequently, one can screen the resulting constructs for a number of properties such as level of sion, protease stability, or binding to antiserum.

One aspect of the invention is to provide polynucleotide sequences ng the components of the fusion protein wherein the creation of the sequence has undergone codon optimization. Of particular interest is codon optimization with the goal of improving expression of the polypeptide compositions and to improve the genetic stability of the encoding gene in the production hosts. For e, codon optimization is of ular importance for XTEN ces that are rich in glycine or that have very repetitive amino acid sequences. Codon optimization is performed using computer programs fsson, C., et al. (2004) Trends hnol, 22: 346-53), some of which ze ribosomal pausing (Coda Genomics Inc.). In one embodiment, one can perform codon optimization by constructing codon libraries where all members of the library encode the same amino acid sequence but where codon usage is varied. Such libraries can be screened for highly expressing and genetically stable members that are particularly suitable for the large-scale production of XTEN-containing products. When ing XTEN sequences one can consider a number of properties. One can minimize the repetitiveness in the ng DNA sequences. In addition, one can avoid or minimize the use of codons that are rarely used by the production host (e.g. the AGG and AGA arginine codons and one leucine codon in E. coli). In the case of E. coli, two glycine codons, GGA and GGG, are rarely used in highly expressed proteins. Thus codon optimization of the gene ng XTEN sequences can be very desirable. DNA ces that have a high level of glycine tend to have a high GC content that can lead to instability or low expression levels. Thus, when possible, it is preferred to choose codons such that the GC-content of XTEN- encoding sequence is suitable for the production organism that will be used to manufacture the XTEN.

In one embodiment, polynucleotide libraries are constructed using the disclosed methods wherein all members of the library encode the same amino acid sequence but where codon usage for the respective amino acids in the sequence is varied or optimized for the intended host cell. Such libraries can be screened for highly sing and genetically stable members that are particularly suitable for the large-scale production of XTEN-containing products. In one embodiment, the libraries are zed for expression in a eukaryotic host cell.

Optionally, one can sequence clones in the library to eliminate isolates that contain undesirable sequences. The initial library of short XTEN sequences allows some ion in amino acid ce.

For instance one can randomize some codons such that a number of hilic amino acids can occur in a particular position. During the process of iterative multimerization one can screen the resulting library members for other characteristics like solubility or protease resistance in addition to a screen for high- level expression.

Once the gene that encodes the XTEN of d length and properties is selected, it is genetically fused at the desired location to the nucleotides encoding the FVIII ) by cloning it into the construct adjacent and in frame with the gene coding for FVIII, or alternatively between nucleotides encoding adjacent s of the FVIII, or alternatively within a sequence encoding a given FVIII domain, or alternatively in frame with nucleotides encoding a spacer/cleavage sequence linked to a WO 22617 terminal XTEN. The ion provides various permutations of the foregoing, ing on the CFXTEN to be encoded. For example, a gene encoding a CFXTEN fusion protein sing a FVIII and two XTEN, such as embodied by formula VI, as ed above, the gene would have polynucleotides encoding FVIII, encoding two XTEN, which can be identical or different in composition and sequence length. In one non-limiting embodiment of the foregoing, the FVIII polynucleotides would encode factor VIII and the polynucleotides encoding the C-terminus XTEN would encode an XTEN of 288 amino acids and the polynucleotides encoding an internal XTEN adjacent to the C-terminus of the A2 domain would encode an XTEN of 144 amino acids. The step of cloning the FVIII genes into the XTEN construct can occur through a ligation or multimerization step, as shown in . The constructs encoding CFXTEN fusion ns can be designed in different configurations of the components XTEN, CF, and spacer sequences, such as the configurations of formulae I-VIII. In one embodiment, the construct comprises polynucleotide sequences complementary to, or those that encode a monomeric polypeptide of components in the ing order (5’ to 3’) FVIII, an XTEN internal to the B domain, and a C-terminal XTEN. In another ment, the construct comprises polynucleotide sequences complementary to, or those that encode a monomeric polypeptide of components in the following order (5’ to 3’) FVIIII, spacer sequence linked to the C-terminus, and XTEN. The spacer polynucleotides can optionally comprise sequences encoding cleavage ces. As will be apparent to those of skill in the art, multiple permutations of FVIII domains and ed XTEN are possible.

Homology, sequence similarity or sequence identity of nucleotide or amino acid sequences may also be determined conventionally by using known software or computer ms such as the BestFit or Gap pairwise ison programs (GCG Wisconsin Package, Genetics Computer Group, 575 Science Drive, Madison, Wis. 53711). t uses the local homology algorithm of Smith and Waterman (Advances in Applied Mathematics. 1981. 2: 482-489), to find the best segment of identity or similarity between two sequences. Gap performs global alignments: all of one sequence with all of r similar sequence using the method leman and Wunsch, (Journal of Molecular y. 1970. 48:443- 453). When using a sequence alignment program such as BestFit, to determine the degree of sequence homology, similarity or identity, the default setting may be used, or an appropriate scoring matrix may be selected to optimize identity, similarity or homology scores.

Nucleic acid sequences that are “complementary” are those that are capable of base-pairing according to the standard Watson-Crick complementarity rules. As used herein, the term “complementary sequences” means nucleic acid sequences that are substantially complementary, as may be assessed by the same nucleotide ison set forth above, or as defined as being capable of hybridizing to the polynucleotides that encode the CFXTEN sequences under stringent conditions, such as those described herein.

The ing polynucleotides encoding the CFXTEN chimeric fusion proteins can then be individually cloned into an expression vector. The nucleic acid sequence is ed into the vector by a variety of procedures. In l, DNA is inserted into an riate restriction endonuclease site(s) using techniques known in the art. Vector components generally include, but are not limited to, one or more of a signal sequence, an origin of ation, one or more marker genes, an er element, a promoter, and a transcription termination sequence. Construction of suitable vectors containing one or more of these components employs standard ligation ques which are known to the skilled n.

Such techniques are well known in the art and well described in the ific and patent literature.

Various vectors are publicly available. The vector may, for example, be in the form of a plasmid, cosmid, Viral particle, or phage that may conveniently be subjected to recombinant DNA procedures, and the choice of vector will often depend on the host cell into which it is to be introduced.

Thus, the vector may be an autonomously replicating vector, i.e., a vector, which exists as an extrachromosomal entity, the replication of which is independent of chromosomal ation, e. g., a plasmid. Alternatively, the vector may be one which, when introduced into a host cell, is integrated into the host cell genome and replicated together with the chromosome(s) into which it has been integrated.

Representative plasmids are illustrated in , with encoding regions for ent configurations of FVIII and XTEN components portrayed.

The invention provides for the use of plasmid vectors containing ation and control sequences that are compatible with and recognized by the host cell, and are ly linked to the CFXTEN gene for controlled expression of the CFXTEN fusion proteins. The vector ordinarily carries a replication site, as well as sequences that encode proteins that are capable of providing phenotypic ion in transformed cells. Such vector sequences are well known for a variety of bacteria, yeast, and Viruses. Useful expression vectors that can be used e, for example, segments of chromosomal, non-chromosomal and synthetic DNA sequences. ”Expression vector” refers to a DNA construct containing a DNA sequence that is operably linked to a suitable control sequence capable of effecting the expression of the DNA encoding the fusion protein in a le host. The requirements are that the vectors are replicable and Viable in the host cell of choice. Low— or high-copy number vectors may be used as desired.

Other suitable vectors include, but are not limited to, derivatives of SV40 and pcDNA and known bacterial ds such as col El, pCRl, pBR322, 2, pET, pGEX as described by Smith, et al., Gene 57:31-40 (1988), pMB9 and derivatives thereof, plasmids such as RP4, phage DNAs such as the numerous derivatives of phage I such as NM98 9, as well as other phage DNA such as M13 and filamentous single stranded phage DNA; yeast plasmids such as the 2 micron plasmid or derivatives of the 2m plasmid, as well as centomeric and ative yeast shuttle vectors; vectors useful in eukaryotic cells such as vectors useful in insect or ian cells; s derived from combinations of plasmids and phage DNAs, such as plasmids that have been modified to employ phage DNA or the expression control sequences; and the like. Yeast expression systems that can also be used in the present invention include, but are not limited to, the non-fusion pYES2 vector (Invitrogen), the fusion sA, B, C (Invitrogen), pRS vectors and the like.

The control sequences of the vector include a promoter to effect transcription, an optional operator sequence to control such transcription, a sequence encoding suitable mRNA ribosome g sites, and ces that control termination of transcription and translation. The promoter may be any WO 22617 DNA sequence, Which shows transcriptional activity in the host cell of choice and may be derived from genes encoding proteins either homologous or heterologous to the host cell.

Examples of suitable promoters for directing the ription of the DNA encoding the FVIH polypeptide variant in mammalian cells are the SV40 promoter (Subramani et al., Mol. Cell. Biol. 1 (1981), 854-864), the MT-l (metallothionein gene) promoter (Palmiter et al., Science 222 (1983), 809- 814), the CMV promoter (Boshart et al., Cell 41 :521-530, 1985) or the adenovirus 2 major late promoter (Kaufman and Sharp, Mol. Cell. Biol, -1319, 1982). The vector may also carry sequences such as UCOE (ubiquitous chromatin opening elements).

Examples of suitable promoters for use in filamentous fungus host cells are, for instance, the ADH3 promoter or the tpiA promoter. Examples of other useful promoters are those derived from the gene ng A. oryzae TAKA amylase, Rhizomucor miehei aspartic proteinase, A. niger l (X- amylase, A. niger acid stable (x-amylase, A. niger or A. awamoriglucoamylase (gluA), Rhizomucor miehei lipase, A. oryzae alkaline protease, A. oryzae triose phosphate isomerase or A. nidulans acetamidase.

Preferred are the TAKA—amylase and gluA promoters.

Promoters suitable for use in expression vectors with prokaryotic hosts include the B-lactamase and lactose promoter systems [Chang et al., Nature, 275:615 (1978); Goeddel et al., Nature, 281 :544 (1979)], alkaline phosphatase, a tryptophan (trp) promoter system [Goeddel, Nucleic Acids Res., 8:4057 (1980); EP 36,776], and hybrid ers such as the tac promoter [deBoer et al., Proc. Natl. Acad. Sci.

USA, 80:21-25 (1983)], all is operably linked to the DNA encoding CFXTEN polypeptides. Promoters for use in bacterial systems can also contain a Shine-Dalgarno (S.D.) sequence, ly linked to the DNA encoding CFXTEN polypeptides.

The invention plates use of other expression systems including, for example, a baculovirus expression system With both non-fusion transfer vectors, such as, but not limited to pVL941 s, et al., Virology -402 ), pVL1393 (Invitrogen), pVL1392 (Summers, et al., Virology 84:390- 402 (1978) and anitrogen) and pBlueBaclll (anitrogen), and fusion transfer vectors such as, but not d to, pAc7 00 (Summers, et al., Virology 84:390-402 (1978)), pAc701 and pAc70- 2 (same as pAc700, With different reading frames), pAc36O anitrogen) and pBlueBacHisA, B, C (; Invitrogen) can be used.

Examples of suitable promoters for directing the transcription of the DNA encoding the FVIH polypeptide t in mammalian cells are the CMV promoter (Boshart et al., Cell 41 :521-530, 1985), the SV40 promoter (Subramani et al., Mol. Cell. Biol. 1 (1981), 854-864), the MT-1 (metallothionein gene) promoter (Palmiter et al., Science 222 (1983), 809-814), the adenovirus 2 major late er (Kaufman and Sharp, Mol. Cell. Biol, 2:1304-1319, 1982). The vector may also carry sequences such as UCOE (ubiquitous chromatin opening elements).

The DNA ces encoding the CFXTEN may also, if ary, be operably connected to a suitable terminator, such as the hGH terminator ter et al., Science 222, 1983, pp. 809-814) or the TP11 terminators (Alber and Kawasaki, J. Mol. Appl. Gen. 1, 1982, pp. 4) or ADH3 (McKnight et al., The EMBO J. 4, 1985, pp. 2093-2099). Expression vectors may also contain a set of RNA splice sites located ream from the promoter and upstream from the insertion site for the CFXTEN sequence itself, including splice sites obtained from adenovirus. Also contained in the expression s is a polyadenylation signal located downstream of the insertion site. Particularly preferred polyadenylation signals include the early or late polyadenylation signal from SV40 (Kaufman and Sharp, ibid.), the polyadenylation signal from the adenovirus 5 Elb region, the hGH terminator (DeNoto et al. Nucl. Acids Res. 93719-3730, 1981). The expression vectors may also include a noncoding viral leader sequence, such as the adenovirus 2 tripartite leader, d between the promoter and the RNA splice sites; and enhancer sequences, such as the SV40 enhancer.

To direct the CFXTEN of the present invention into the secretory pathway of the host cells, a secretory signal sequence (aka, a leader sequence, a prepro sequence, or a pre sequence) may be included in the recombinant vector. The secretory signal ce is operably linked to the DNA sequences encoding the CFXTEN, usually positioned 5’ to the DNA sequence encoding the CFXTEN fusion protein. The secretory signal sequence may be that, normally associated with the native FVIII protein or may be from a gene encoding another secreted protein. Non-limiting examples include OmpA, PhoA, and DsbA for E. coli expression, ppL-alpha, DEX4, invertase signal peptide, acid phosphatase signal peptide, CPY, or INUl for yeast expression, and 1L2L, SV40, IgG kappa and IgG lambda for mammalian expression. Signal sequences are lly proteolytically d from the protein during the translocation and secretion process, generating a defined N-terminus. Methods are disclosed in Arnau, er al., Protein sion and Purification 48: 1-13 (2006).

The procedures used to ligate the DNA sequences coding for the , the promoter and optionally the terminator and/or ory signal sequence, respectively, and to insert them into le vectors ning the information necessary for replication, are well known to persons skilled in the art (cf., for instance, Sambrook, J. et al., “Molecular g: A Laboratory Manual,” 3ml n, Cold Spring Harbor Laboratory Press, 2001). In this manner, a chimeric DNA molecule coding for a ric CFXTEN fusion protein is generated within the construct. Optionally, this chimeric DNA molecule may be transferred or cloned into another construct that is a more appropriate expression vector. At this point, a host cell capable of expressing the chimeric DNA le can be transformed with the chimeric DNA molecule.

Non-limiting examples of mammalian cell lines for use in the present ion are the COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), BHK-21 (ATCC CCL 10)) and BHK-293 (ATCC CRL 1573; Graham et al., J. Gen. Virol. 36:59-72, 1977), BHK-570 cells (ATCC CRL 10314), CHO-Kl (ATCC CCL 61), CHO-S (Invitrogen 11619-012), and 293-F (Invitrogen R790-7), and the parental and derivative cell lines known in the art useful for expression of FVIII. A tk-ts13 BHK cell line is also available from the ATCC under accession number CRL 1632. In addition, a number of other cell lines may be used within the present invention, including Rat Hep I (Rat ma; ATCC CRL 1600), Rat Hep 11 (Rat hepatoma; ATCC CRL 1548), TCMK (ATCC CCL 139), Human lung (ATCC HB 8065), NCTC 1469 (ATCC CCL 9.1), CHO (ATCC CCL 61) and DUKX cells b and Chasin, Proc. Natl.

Acad. Sci. USA 77:4216-4220, 1980).

Examples of suitable yeasts cells include cells of Saccharomyces spp. or Schizosaccharomyces spp., in particular strains of Saccharomyces siae or romyces kluyveri . Methods for transforming yeast cells With heterologous DNA and producing heterologous ptides there from are described, e.g. in US. Pat. No. 4,599,311, US. Pat. No. 4,931,373, US. Pat. No. 4,870,008, 5,037,743, and US. Pat. No. 4,845,075, all of Which are hereby incorporated by reference. Transformed cells are selected by a phenotype determined by a selectable marker, commonly drug ance or the ability to grow in the absence of a particular nutrient, e. g. leucine. A preferred vector for use in yeast is the PCT] vector disclosed in US. Pat. No. 4,931,373. The DNA sequences encoding the CFXTEN may be ed by a signal sequence and optionally a leader sequence, e.g. as described above. Further examples of suitable yeast cells are strains of Kluyveromyces, such as K. lactis, Hansenula e. g. H. polymorpha or Pichia P. is (cf. Gleeson et al., J. Gen. Microbiol. , , e.g. 132, 1986, pp. 3459-3465; US. Pat. No. 279). Examples of other fungal cells are cells of filamentous fungi, e. g. Aspergillus spp., Neurospora spp., Fusarium spp. or Trichoderma spp., in particular strains ofA. oryzae, A. nidulans or A. niger. The use ofAspergillus spp. for the expression of proteins is described in, e. g., EP 272 277, EP 238 023, EP 184 438 The ormation of F. oxysporum may, for instance, be carried out as described by ier et al., 1989 Gene 78: 147-156. The transformation of Trichoderma spp. may be performed for instance as described in EP 244 234.

Other suitable cells that can be used in the t invention include, but are not limited to, prokaryotic host cells strains such as Escherichia coli, (e. g., strain DH5-oc), Bacillus subtilis, Salmonella typhimurium, or strains of the genera of Pseudomonas, Streptomyces and Staphylococcus. Non-limiting examples of suitable prokaryotes include those from the genera: Actinoplanes; Archaeoglobus; Bdellovibrio; Borrelia; Chloroflexus; Enterococcus; Escherichia; Lactobacillus; ia; Oceanobacillus; ccus; Pseudomonas; Staphylococcus; Streptococcus; Streptomyces; Thermoplasma; and Vibrio.

Methods of transfecting mammalian cells and expressing DNA sequences introduced in the cells are described in e. g., Kaufman and Sharp, J. Mol. Biol. 159 (1982), 601-621; Southern and Berg, J.

Mol. Appl. Genet. 1 , 327-341; Loyter et al., Proc. Natl. Acad. Sci. USA 79 (1982), 422-426; Wigler et al., Cell 14 (1978), 725; Corsaro and Pearson, Somatic Cell Genetics 7 (1981), 603, Graham and van der Eb, Virology 52 (1973), 456; and Neumann et al., EMBO J. 1 (1982), 5.

Cloned DNA sequences are introduced into ed mammalian cells by, for example, calcium phosphate-mediated transfection (Wigler et al., Cell 14:725-732, 1978; Corsaro and Pearson, Somatic Cell Genetics 7:603-616, 1981; Graham and Van der Eb, Virology 52d:456-467, 1973), ection With many commercially available reagents such as FuGENEG Roche Diagnostics, Mannheim, Germany) or lipofectamine ogen) or by electroporation (Neumann et al., EMBO J. 1:841-845, 1982). To identify and select cells that express the exogenous DNA, a gene that confers a selectable phenotype (a able marker) is generally introduced into cells along With the gene or cDNA of interest. Preferred selectable markers include genes that confer resistance to drugs such as neomycin, hygromycin, cin, zeocin, and methotrexate. The selectable marker may be an amplifiable selectable marker. A preferred amplif1able selectable marker is a dihydrofolate reductase (DHFR) ce. Further examples of selectable markers are well known to one of skill in the art and include reporters such as enhanced green fluorescent protein (EGFP), beta-galactosidase (B-gal) or chloramphenicol transferase (CAT). able markers are reviewed by Thilly (Mammalian Cell logy, Butterworth Publishers, Stoneham, Mass., incorporated herein by reference). The person skilled in the art will easily be able to choose suitable able markers. Any known selectable marker may be employed so long as it is e of being expressed simultaneously with the c acid encoding a gene product.

Selectable markers may be uced into the cell on a separate plasmid at the same time as the gene of interest, or they may be introduced on the same plasmid. If, on the same plasmid, the selectable marker and the gene of interest may be under the control of different promoters or the same promoter, the latter ement producing a dicistronic message. Constructs of this type are known in the art (for example, Levinson and Simonsen, US. Pat. No. 4,713,339). It may also be advantageous to add additional DNA, known as “carrier DNA,” to the mixture that is introduced into the cells.

After the cells have taken up the DNA, they are grown in an riate grth medium, typically 1-2 days, to begin expressing the gene of interest. As used herein the term “appropriate grth medium” means a medium containing nts and other components required for the grth of cells and the expression of the CFXTEN of interest. Media generally e a carbon , a nitrogen source, essential amino acids, essential sugars, Vitamins, salts, phospholipids, protein and grth factors.

For production of gamma-carboxylated proteins, the medium will contain Vitamin K, preferably at a concentration of about 0.1 [Lg/ml to about 5 [Lg/ml. Drug selection is then d to select for the grth of cells that are expressing the selectable marker in a stable n. For cells that have been transfected with an amplif1able selectable marker the drug concentration may be increased to select for an increased copy number of the cloned sequences, thereby increasing expression levels. Clones of stably transfected cells are then screened for expression of the FVIH polypeptide variant of interest.

The transformed or transfected host cell is then cultured in a suitable nutrient medium under conditions permitting expression of the CFXTEN polypeptide after which the resulting peptide may be red from the culture as an isolated fusion protein. The medium used to culture the cells may be any conventional medium suitable for growing the host cells, such as minimal or complex media containing riate supplements. le media are available from commercial suppliers or may be prepared according to published recipes (e. g. in catalogues of the American Type Culture Collection). The culture conditions, such as temperature, pH and the like, are those usly used with the host cell selected for expression, and will be apparent to the ordinarily skilled n.

Gene expression may be measured in a sample directly, for example, by conventional Southern blotting, Northern blotting to quantitate the transcription of mRNA [Thomas, Proc. Natl. Acad. Sci. USA, 77:5201-5205 (1980)], dot blotting (DNA analysis), or in situ hybridization, using an appropriately labeled probe, based on the sequences provided herein. Alternatively, antibodies may be employed that can recognize specif1c duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes. The antibodies in turn may be labeled and the assay may be carried out where the duplex is bound to a surface, so that upon the formation of duplex on the surface, the presence of dy bound to the duplex can be detected.

Gene expression, alternatively, may be measured by immunological of fluorescent methods, such as immunohistochemical staining of cells or tissue sections and assay of cell e or body fluids or the detection of selectable markers, to quantitate directly the expression of gene product. Antibodies useful for histochemical staining and/or assay of sample fluids may be either onal or polyclonal, and may be prepared in any mammal. iently, the dies may be prepared against a native sequence FVIII polypeptide or against a synthetic e based on the DNA sequences provided herein or against exogenous sequence fused to FVIII and encoding a specific antibody epitope.

Examples of selectable markers are well known to one of skill in the art and include reporters such as enhanced green fluorescent n (EGFP), beta-galactosidase (5-gal) or chloramphenicol acetyltransferase (CAT).

Expressed CFXTEN polypeptide product(s) may be purified via methods known in the art or by methods disclosed herein. Procedures such as gel ion, affinity purification (e. g., using an anti- FVIII antibody column), salt fractionation, ion exchange chromatography, size exclusion chromatography, yapatite adsorption chromatography, hydrophobic interaction chromatography and gel electrophoresis may be used; each tailored to r and purify the fusion protein produced by the respective host cells. Additional purification may be achieved by conventional chemical purification means, such as high performance liquid chromatography. Some expressed CFXTEN may require refolding during isolation and purification. Methods of purification are described in Robert K. Scopes, Protein Purification: Principles and Practice, Charles R. Castor (ed.), Springer-Verlag 1994, and Sambrook, et al., supra. Multi-step purification separations are also described in Baron, et al., Crit. Rev.

Biotechnol. 10:179-90 (1990) and Below, et al., J. Chromatogr. A. 679:67-83 (1994). For therapeutic purposes it is red that the CFXTEN fusion proteins of the invention are substantially pure. Thus, in a preferred embodiment of the ion the CFXTEN of the invention is purified to at least about 90 to 95% neity, preferably to at least about 98% homogeneity. Purity may be assessed by, e. g., gel ophoresis, HPLC, and amino-terminal amino acid cing..

VIII). PHARMACEUTICAL COMPOSITIONS The present invention provides pharmaceutical compositions comprising CFXTEN. In one embodiment, the pharmaceutical composition comprises a CFXTEN fusion n disclosed herein admixed with at least one pharmaceutically acceptable carrier. CFXTEN polypeptides of the present ion can be formulated according to known methods to prepare pharmaceutically useful compositions, whereby the polypeptide is combined in admixture with a pharmaceutically acceptable carrier vehicle, such as aqueous solutions, buffers, solvents and/or pharmaceutically acceptable suspensions, emulsions, stabilizers or excipients. Examples of non-aqueous solvents include propyl ethylene glycol, polyethylene glycol and vegetable oils. Formulations of the pharmaceutical compositions are prepared for storage by mixing the active CFXTEN ingredient having the desired degree of purity with optional physiologically acceptable carriers, excipients (e. g., sodium chloride, a calcium salt, sucrose, or polysorbate) or stabilizers (e. g., e, trehalose, se, arginine, a calcium salt, glycine or histidine), as described in ton's Pharmaceutical Sciences 16th n, Osol, A.

Ed. (1980), in the form of lyophilized formulations or aqueous solutions.

The pharmaceutical composition may be supplied as a lyophilized powder to be reconstituted prior to administration. In another embodiment, the pharmaceutical composition may be supplied in a liquid form in a Vial, the contents of which can be administered directly to a patient. Alternatively, the composition is supplied as a liquid in a pre-filled syringe for administration of the composition. In another embodiment, the composition is supplied as a liquid in a pre-fllled Vial that can be incorporated into a pump.

The pharmaceutical itions can be administered by any suitable means or route, including subcutaneously, subcutaneously by on pump, intramuscularly, and intravenously. It will be appreciated that the preferred route will vary with the e and age of the recipient, and the severity of the ion being treated.

In one embodiment, the CFXTEN pharmaceutical composition in liquid form or after reconstitution (when supplied as a lyophilized ) comprises coagulation factor VIII with an actiVity of at least 50 IU/ml, or at least 100 IU/ml, or at least 200 IU/ml, or at least 300 IU/ml, or at least 400 IU/ml, or an actiVity of at least 500 IU/ml, or an actiVity of at least 600 IU/ml, which composition is capable of increasing factor VIII actiVity to at least 1.5% of the normal plasma level in the blood for at least about 12 hours, or at least about 24 hours, or at least about 48 hours, or at least about 72 hours, or at least about 96 hours, or at least about 120 hours after stration of the factor VIII pharmaceutical composition to a subject in need of e prophylaxis. In another embodiment, the CFXTEN pharmaceutical composition in liquid form or after reconstitution (when supplied as a lyophilized powder) comprises coagulation factor VIII with an actiVity of at least 50 IU/ml, or at least 100 IU/ml, or at least 200 IU/ml, or at least 300 IU/ml, or at least 400 IU/ml, or at least 500 IU/ml, or an actiVity of at least 600 IU/ml, which composition is capable of increasing factor VIII actiVity to at least 2.5% of the normal plasma level in the blood for at least about 12 hours, or at least about 24 hours, or at least about 48 hours, or at least about 72 hours, or at least about 96 hours, or at least about 120 hours after administration to a subject in need of routine laxis. It is specifically plated that the pharmaceutical compositions of the foregoing can be formulated to include one or more ents, buffers or other ingredients known in the art to be compatible with administration by the intravenous route or the subcutaneous route or the intramuscular route. Thus, in the embodiments hereinabove described in this paragraph, the pharmaceutical composition is administered subcutaneously, intramuscularly or intravenously.

The compositions of the invention may be formulated using a variety of excipients. Suitable excipients include microcrystalline ose (e. g. Avicel PH102, Avicel PH101), polymethacrylate, thyl acrylate, methyl methacrylate, trimethylammonioethyl methacrylate chloride) (such as Eudragit RS-3OD), hydroxypropyl methylcellulose (Methocel K1 00M, m CR Methocel K1 00M, el E5, Opadry®), ium stearate, talc, triethyl citrate, aqueous ethylcellulose dispersion (Surelease®), and protamine sulfate. The slow release agent may also comprise a carrier, which can comprise, for example, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents. Pharmaceutically acceptable salts can also be used in these slow release agents, for e, mineral salts such as hydrochlorides, hydrobromides, phosphates, or sulfates, as well as the salts of organic acids such as acetates, proprionates, malonates, or benzoates. The composition may also n liquids, such as water, saline, glycerol, and ethanol, as well as substances such as wetting agents, emulsifying agents, or pH buffering . Liposomes may also be used as a carrier.

In another embodiment, the compositions of the present invention are ulated in liposomes, which have demonstrated utility in delivering beneficial active agents in a controlled manner over prolonged periods of time. Liposomes are closed bilayer membranes containing an entrapped aqueous volume. Liposomes may also be unilamellar es sing a single membrane bilayer or multilamellar vesicles with multiple membrane bilayers, each separated from the next by an aqueous layer. The structure of the resulting membrane bilayer is such that the hydrophobic (non-polar) tails of the lipid are oriented toward the center of the bilayer while the hilic (polar) heads orient towards the aqueous phase. In one embodiment, the liposome may be coated with a flexible water soluble polymer that avoids uptake by the organs of the mononuclear phagocyte system, primarily the liver and spleen. Suitable hydrophilic polymers for surrounding the liposomes include, without limitation, PEG, polyvinylpyrrolidone, polyvinylmethylether, polymethyloxazoline, polyethyloxazoline, polyhydroxypropyloxazoline, polyhydroxypropylmethacrylamide, polymethacrylamide, polydimethylacrylamide, polyhydroxypropylmethacrylate, polyhydroxethylacrylate, hydroxymethylcellulose hydroxyethylcellulose, polyethyleneglycol, polyaspartamide and hydrophilic peptide ces as described in US. Pat. Nos. 024; 6,126,966; 6,056,973; 6,043,094, the contents of which are incorporated by reference in their entirety. Additional liposomal technologies are described in US. Pat. Nos. 6,759,057; 6,406,713; 6,352,716; 6,316,024; 191; 6,126,966; 6,056,973; 6,043,094; 5,965,156; 5,916,588; 5,874,104; 5,215,680; and 4,684,479, the contents ofwhich are incorporated herein by reference. These be mes and lipid-coated microbubbles, and methods for their manufacture. Thus, one skilled in the art, considering both the disclosure of this ion and the sures of these other patents could produce a liposome for the extended release of the polypeptides of the present ion.

For liquid formulations, a desired property is that the formulation be supplied in a form that can pass h a 25, 28, 30, 31, 32 gauge needle for intravenous, intramuscular, intraarticular, or subcutaneous administration.

Syringe pumps may also be used as slow release agents. Such devices are described in US.

Pat. Nos. 4,976,696; 185; 5,017,378; 6,309,370; 6,254,573; 173; 4,398,908; 6,572,585; ,298,022; 5,176,502; 5,492,534; 5,318,540; and 4,988,337, the contents of which are incorporated herein by reference. One skilled in the art, ering both the disclosure of this invention and the disclosures of these other patents could produce a syringe pump for the extended release of the compositions of the present ion.

IX). PHARMACEUTICAL KITS In another aspect, the invention provides a kit to facilitate the use of the CFXTEN polypeptides. The kit comprises the pharmaceutical composition provided herein, a container and a label or package insert on or associated with the container. Suitable itiers include, for example, bottles, Vials, syringes, etc, formed frem a variety 0f materials such as glass or c. The container holds a pharmaceutical composition as a fermulatien that is effective for treating the elated ion and may have a sterile access pert (for example the ner maybe an intravenous on bag or a vial having a stepper pierceable by a hypedermie injection needle). The package insert can list the approved indications for the drug, instructions for the reconstitution and/or stration of the drug for the use for the approved indication, appropriate dosage and safety information, and information identifying the lot and expiration of the drug. In another embodiment of the foregoing, the kit can comprise a second container that can carry a suitable diluent for the pharmaceutical composition, the use of which will provide the user with the appropriate tration to be delivered to the subject.

Example 1: uction ofXTEN_AD36 motif segments The following example describes the construction of a collection of codon—optimized genes encoding motif sequences of 36 amino acids. As a first step, a stuffer vector pCWO359 was constructed based on a pET vector and that includes a T7 promoter. pCWO359 encodes a cellulose binding domain (CBD) and a TEV protease recognition site followed by a stuffer sequence that is flanked by BsaI, BbsI, and KpnI sites. The BsaI and BbsI sites were inserted such that they generate compatible overhangs after digestion. The stuffer sequence is followed by a truncated version of the GFP gene and a His tag. The stuffer sequence contains stop codons and thus E. coli cells carrying the stuffer plasmid pCWO359 form non-fluorescent es. The stuffer vector pCWO359 was digested with BsaI and KpnI to remove the stuffer segment and the resulting vector fragment was isolated by agarose gel purification. The sequences were designated XTEN_AD3 6, reflecting the AD family of motifs. Its segments have the amino acid sequence [X]3 where X is a 12mer peptide with the sequences: GESPGGSSGSES (SEQ ID NO: 19), GPGESS (SEQ ID NO: 20), GSSESGSSEGGP (SEQ ID NO: 21), or GSGGEPSESGSS (SEQ ID NO: 22). The insert was obtained by annealing the following pairs of phosphorylated tic oligonucleotide pairs: Aleor: AGGTGAATCTCCDGGTGGYTCYAGCGGTTCYGARTC (SEQ ID NO: 1619) ADlrev: YTCRGAACCGCTRGARCCACCHGGAGATTC (SEQ ID NO: 1620) AD2for: AGGTAGCGAAGGTTCTTCYGGTCCDGGYGARTCYTC (SEQ ID NO: 1621) AD2rev: ACCTGARGAYTCRCCHGGACCRGAAGAACCTTCGCT (SEQ ID NO: 1622) AD3for: AGGTTCYTCYGAAAGCGGTTCTTCYGARGGYGGTCC (SEQ ID NO: 1623) PCT/U82012/046326 AD3reV: ACCTGGACCRCCYTCRGAAGAACCGCTTTCRGARGA (SEQ ID NO: 1624) AD4for: AGGTTCYGGTGGYGAACCDTCYGARTCTGGTAGCTC (SEQ ID NO: 1625) We also annealed the phosphorylated oligonucleotide 3KpnIstopperFor: AGGTTCGTCTTCACTCGAGGGTAC (SEQ ID NO: 1626) and the non-phosphorylated oligonucleotide pr_3KpnIstopperReV: CCTCGAGTGAAGACGA (SEQ ID NO: 1627). The annealed oligonucleotide pairs were ligated, which resulted in a mixture of products with varying length that represents the varying number of 12mer repeats ligated to one pnI segment. The products corresponding to the length of 36 amino acids were isolated from the mixture by preparative agarose gel electrophoresis and ligated into the BsaI/KpnI ed r vector pCWO35 9. Most of the clones in the resulting library ated LCWO401 showed green fluorescence after induction, which shows that the sequence ofXTEN_AD36 had been ligated in frame with the GFP gene and that most sequences of XTEN_AD36 had good expression .

We screened 96 isolates from library LCWO401 for high level of fluorescence by stamping them onto agar plate containing IPTG. The same isolates were evaluated by PCR and 48 isolates were identified that contained segments with 36 amino acids as well as strong fluorescence. These es were sequenced and 39 clones were identified that contained correct XTEN_AD36 segments. The file names of the nucleotide and amino acid ucts and the sequences for these segments are listed in Table 13.

Table 13: DNA and Amino Acid Seguences for AD 36-mer motifs (SEQ ID NOS 203-278, res ectivel in order of a earance File name Amino acid sequence Nucleotide sequence LCWO401_001_ GSGGEPSESGSSGESPGG GGTGGCGAACCGTCCGAGTCTGGTAGCTCA GFP-\_A0 1 .ab1 SSGSESGESPGGSSGSES GGTGAATCTCCGGGTGGCTCTAGCGGTTCCGAGTCA GGTGAATCTCCTGGTGGTTCCAGCGGTTCCGAGTCA LCWO401_002_ GSEGSSGPGESSGESPGG GGTAGCGAAGGTTCTTCTGGTCCTGGCGAGTCTTCA GFP-\_B01 .ab1 SSGSESGSSESGSSEGGP GGTGAATCTCCTGGTGGTTCCAGCGGTTCTGAATCA GGTTCCTCCGAAAGCGGTTCTTCCGAGGGCGGTCCA LCWO401_003_ GSSESGSSEGGPGSSESG GGTTCCTCTGAAAGCGGTTCTTCCGAAGGTGGTCCA GFP-\_C0 1 .ab1 SSEGGPGESPGGSSGSES GGTTCCTCTGAAAGCGGTTCTTCTGAGGGTGGTCCA GGTGAATCTCCGGGTGGCTCCAGCGGTTCCGAGTCA LCWO401_004_ SESGSSGSSESG GGTTCCGGTGGCGAACCGTCTGAATCTGGTAGCTCA GFP-\_D0 1 .abl SSEGGPGSGGEPSESGSS GGTTCTTCTGAAAGCGGTTCTTCCGAGGGTGGTCCA GGTTCTGGTGGTGAACCTTCCGAGTCTGGTAGCTCA LCWO401_007_ GSSESGSSEGGPGSEGSS GGTTCTTCCGAAAGCGGTTCTTCTGAGGGTGGTCCA GFP-\_F0 1 .ab1 GSEGSSGPGESS GGTAGCGAAGGTTCTTCCGGTCCAGGTGAGTCTTCA GGTAGCGAAGGTTCTTCTGGTCCTGGTGAATCTTCA LCWO401_008_ GSSESGSSEGGPGESPGG GGTTCCTCTGAAAGCGGTTCTTCCGAGGGTGGTCCA GFP-\_G0 1 .ab1 GSEGSSGPGESS GGTGAATCTCCAGGTGGTTCCAGCGGTTCTGAGTCA GGTAGCGAAGGTTCTTCTGGTCCAGGTGAATCCTCA LCWO401_012_ GSGGEPSESGSSGSGGEP GGTTCTGGTGGTGAACCGTCTGAGTCTGGTAGCTCA H0 1 .ab1 SESGSSGSEGSSGPGESS GGTTCCGGTGGCGAACCATCCGAATCTGGTAGCTCA GGTAGCGAAGGTTCTTCCGGTCCAGGTGAGTCTTCA LCWO401_015_ GSSESGSSEGGPGSEGSS GGTTCTTCCGAAAGCGGTTCTTCCGAAGGCGGTCCA GFP-\_A02.ab1 GPGESSGESPGGSSGSES GGTAGCGAAGGTTCTTCTGGTCCAGGCGAATCTTCA GGTGAATCTCCTGGTGGCTCCAGCGGTTCTGAGTCA 1_016_ GSSESGSSEGGPGSSESG GGTTCCTCCGAAAGCGGTTCTTCTGAGGGCGGTCCA GFP-\_B02.ab1 SSEGGPGSSESGSSEGGP GGTTCCTCCGAAAGCGGTTCTTCCGAGGGCGGTCCA GGTTCTTCTGAAAGCGGTTCTTCCGAGGGCGGTCCA File name Amino acid sequence tide sequence LCW0401_020_ GSGGEPSESGSSGSEGSS GGTTCCGGTGGCGAACCGTCCGAATCTGGTAGCTCA GFP-\_E02.ab1 GPGESSGSSESGSSEGGP GGTAGCGAAGGTTCTTCTGGTCCAGGCGAATCTTCA GGTTCCTCTGAAAGCGGTTCTTCTGAGGGCGGTCCA LCW0401_022_ GSGGEPSESGSSGSSESG GGTTCTGGTGGTGAACCGTCCGAATCTGGTAGCTCA GFP-\_F02.ab1 SSEGGPGSGGEPSESGSS GGTTCTTCCGAAAGCGGTTCTTCTGAAGGTGGTCCA GGTTCCGGTGGCGAACCTTCTGAATCTGGTAGCTCA LCW0401_024_ SESGSSGSSESG GGTTCTGGTGGCGAACCGTCCGAATCTGGTAGCTCA GFP-\_G02.ab1 GESPGGSSGSES GGTTCCTCCGAAAGCGGTTCTTCTGAAGGTGGTCCA GGTGAATCTCCAGGTGGTTCTAGCGGTTCTGAATCA LCW0401_026_ SESGSSGESPGG GGTTCTGGTGGCGAACCGTCTGAGTCTGGTAGCTCA GFP-\_H02.ab1 SSGSESGSEGSSGPGESS GGTGAATCTCCTGGTGGCTCCAGCGGTTCTGAATCA GGTAGCGAAGGTTCTTCTGGTCCTGGTGAATCTTCA LCW0401_027_ GSGGEPSESGSSGESPGG GGTTCCGGTGGCGAACCTTCCGAATCTGGTAGCTCA GFP-\_A03.ab1 SSGSESGSGGEPSESGSS GGTGAATCTCCGGGTGGTTCTAGCGGTTCTGAGTCA GGTTCTGGTGGTGAACCTTCCGAGTCTGGTAGCTCA LCW0401_028_ GSSESGSSEGGPGSSESG TCTGAAAGCGGTTCTTCTGAGGGCGGTCCA GFP-\_B03.ab1 GSSESGSSEGGP TCCGAAAGCGGTTCTTCCGAGGGCGGTCCA GGTTCTTCCGAAAGCGGTTCTTCTGAAGGCGGTCCA LCW0401_030_ GESPGGSSGSESGSEGSS GGTGAATCTCCGGGTGGCTCCAGCGGTTCTGAGTCA GFP-\_C03.ab1 GPGESSGSEGSSGPGESS GGTAGCGAAGGTTCTTCCGGTCCGGGTGAGTCCTCA GGTAGCGAAGGTTCTTCCGGTCCTGGTGAGTCTTCA LCW0401_031_ GSGGEPSESGSSGSGGEP GGTTCTGGTGGCGAACCTTCCGAATCTGGTAGCTCA GFP-\_D03.ab1 SESGSSGSSESGSSEGGP GGTTCCGGTGGTGAACCTTCTGAATCTGGTAGCTCA GGTTCTTCTGAAAGCGGTTCTTCCGAGGGCGGTCCA LCW0401_033_ GSGGEPSESGSSGSGGEP GGTTCCGGTGGTGAACCTTCTGAATCTGGTAGCTCA GFP-\_E03.ab1 SESGSSGSGGEPSESGSS GGTTCCGGTGGCGAACCATCCGAGTCTGGTAGCTCA GGTTCCGGTGGTGAACCATCCGAGTCTGGTAGCTCA LCW0401_037_ GSGGEPSESGSSGSSESG GGTTCCGGTGGCGAACCTTCTGAATCTGGTAGCTCA GFP-\_F03.ab1 SSEGGPGSEGSSGPGESS GGTTCCTCCGAAAGCGGTTCTTCTGAGGGCGGTCCA GGTAGCGAAGGTTCTTCTGGTCCGGGCGAGTCTTCA LCW0401_038_ GSGGEPSESGSSGSEGSS GGTTCCGGTGGTGAACCGTCCGAGTCTGGTAGCTCA GFP-\_G03.ab1 GPGESSGSGGEPSESGSS GAAGGTTCTTCTGGTCCGGGTGAGTCTTCA GGTTCTGGTGGCGAACCGTCCGAATCTGGTAGCTCA LCW0401_039_ SESGSSGESPGG GGTTCTGGTGGCGAACCGTCCGAATCTGGTAGCTCA GFP-\_H03.ab1 SSGSESGSGGEPSESGSS GGTGAATCTCCTGGTGGTTCCAGCGGTTCCGAGTCA GGTTCTGGTGGCGAACCTTCCGAATCTGGTAGCTCA LCW0401_040_ GSSESGSSEGGPGSGGEP GGTTCTTCCGAAAGCGGTTCTTCCGAGGGCGGTCCA GFP-\_A04.ab1 SESGSSGSSESGSSEGGP GGTTCCGGTGGTGAACCATCTGAATCTGGTAGCTCA GGTTCTTCTGAAAGCGGTTCTTCTGAAGGTGGTCCA LCW0401_042_ GSEGSSGPGESSGESPGG GGTAGCGAAGGTTCTTCCGGTCCTGGTGAGTCTTCA GFP-\_C04.ab1 SSGSESGSEGSSGPGESS GGTGAATCTCCAGGTGGCTCTAGCGGTTCCGAGTCA GGTAGCGAAGGTTCTTCTGGTCCTGGCGAGTCCTCA LCW0401_046_ GSSESGSSEGGPGSSESG GGTTCCTCTGAAAGCGGTTCTTCCGAAGGCGGTCCA GFP-\_D04.ab1 SSEGGPGSSESGSSEGGP TCCGAAAGCGGTTCTTCTGAGGGCGGTCCA GGTTCCTCCGAAAGCGGTTCTTCTGAGGGTGGTCCA LCW0401_047_ GSGGEPSESGSSGESPGG GGTGGCGAACCTTCCGAGTCTGGTAGCTCA GFP-\_E04.ab1 SSGSESGESPGGSSGSES GGTGAATCTCCGGGTGGTTCTAGCGGTTCCGAGTCA GGTGAATCTCCGGGTGGTTCCAGCGGTTCTGAGTCA 1_051_ GSGGEPSESGSSGSEGSS GGTTCTGGTGGCGAACCATCTGAGTCTGGTAGCTCA GFP-\_F04.ab1 GPGESSGESPGGSSGSES GGTAGCGAAGGTTCTTCCGGTCCAGGCGAGTCTTCA GGTGAATCTCCTGGTGGCTCCAGCGGTTCTGAGTCA LCW0401_053_ GESPGGSSGSESGESPGG GGTGAATCTCCTGGTGGTTCCAGCGGTTCCGAGTCA GFP-\_H04.ab1 SSGSESGESPGGSSGSES GGTGAATCTCCAGGTGGCTCTAGCGGTTCCGAGTCA GGTGAATCTCCTGGTGGTTCTAGCGGTTCTGAATCA LCW0401_054_ GSEGSSGPGESSGSEGSS GGTAGCGAAGGTTCTTCCGGTCCAGGTGAATCTTCA GFP-\_A05.ab1 GSGGEPSESGSS GAAGGTTCTTCTGGTCCTGGTGAATCCTCA GGTTCCGGTGGCGAACCATCTGAATCTGGTAGCTCA LCW0401_059_ GSGGEPSESGSSGSEGSS GGTTCTGGTGGCGAACCATCCGAATCTGGTAGCTCA GFP-\_D05.ab1 GPGESSGESPGGSSGSES GGTAGCGAAGGTTCTTCTGGTCCTGGCGAATCTTCA GGTGAATCTCCAGGTGGCTCTAGCGGTTCCGAATCA File name Amino acid sequence Nucleotide sequence LCW0401_060_ GSGGEPSESGSSGSSESG GGTTCCGGTGGTGAACCGTCCGAATCTGGTAGCTCA GFP-\_E05.ab1 SSEGGPGSGGEPSESGSS GGTTCCTCTGAAAGCGGTTCTTCCGAGGGTGGTCCA GGTTCCGGTGGTGAACCTTCTGAGTCTGGTAGCTCA LCW0401_061_ GSSESGSSEGGPGSGGEP GGTTCCTCTGAAAGCGGTTCTTCTGAGGGCGGTCCA GFP-\_F05.ab1 SESGSSGSEGSSGPGESS GGTGGCGAACCATCTGAATCTGGTAGCTCA GGTAGCGAAGGTTCTTCCGGTCCGGGTGAATCTTCA 1_063_ GSGGEPSESGSSGSEGSS GGTTCTGGTGGTGAACCGTCCGAATCTGGTAGCTCA GFP-\_H05.ab1 GPGESSGSEGSSGPGESS GGTAGCGAAGGTTCTTCTGGTCCTGGCGAGTCTTCA GGTAGCGAAGGTTCTTCTGGTCCTGGTGAATCTTCA LCW0401_066_ GSGGEPSESGSSGSSESG GGTTCTGGTGGCGAACCATCCGAGTCTGGTAGCTCA GFP-\_B06.ab1 SSEGGPGSGGEPSESGSS GGTTCTTCCGAAAGCGGTTCTTCCGAAGGCGGTCCA GGTTCTGGTGGTGAACCGTCCGAATCTGGTAGCTCA LCW0401_067_ GSGGEPSESGSSGESPGG GGTTCCGGTGGCGAACCTTCCGAATCTGGTAGCTCA GFP-\_C06.ab1 SSGSESGESPGGSSGSES GGTGAATCTCCGGGTGGTTCTAGCGGTTCCGAATCA GGTGAATCTCCAGGTGGTTCTAGCGGTTCCGAATCA LCW0401_069_ GSGGEPSESGSSGSGGEP GGTTCCGGTGGTGAACCATCTGAGTCTGGTAGCTCA GFP-\_D06.ab1 GESPGGSSGSES GGTTCCGGTGGCGAACCGTCCGAGTCTGGTAGCTCA GGTGAATCTCCGGGTGGTTCCAGCGGTTCCGAATCA LCW0401_070_ GSEGSSGPGESSGSSESG GGTAGCGAAGGTTCTTCTGGTCCGGGCGAATCCTCA GFP-\_E06.ab1 SSEGGPGSEGSSGPGESS GGTTCCTCCGAAAGCGGTTCTTCCGAAGGTGGTCCA GGTAGCGAAGGTTCTTCCGGTCCTGGTGAATCTTCA LCW0401_078_ SSEGGPGESPGG GGTTCCTCTGAAAGCGGTTCTTCTGAAGGCGGTCCA GFP-\_F06.ab1 SSGSESGESPGGSSGSES GGTGAATCTCCGGGTGGCTCCAGCGGTTCTGAATCA GGTGAATCTCCTGGTGGCTCCAGCGGTTCCGAGTCA 1_079_ GSEGSSGPGESSGSEGSS GGTAGCGAAGGTTCTTCTGGTCCAGGCGAGTCTTCA GFP-\_G06.ab1 GPGESSGSGGEPSESGSS GGTAGCGAAGGTTCTTCCGGTCCTGGCGAGTCTTCA GGTTCCGGTGGCGAACCGTCCGAATCTGGTAGCTCA Example 2: uction ofXTEN_AE36 ts A codon y encoding XTEN sequences of 36 amino acid length was constructed. The XTEN sequence was ated XTEN_AE36. Its segments have the amino acid sequence [X]3 where X is a 12mer peptide with the sequence: GSPAGSPTSTEE (SEQ ID NO: 23), GSEPATSGSETP (SEQ ID NO: 24), TPESGP (SEQ ID NO: 25), or GTSTEPSEGSAP (SEQ ID NO: 26). The insert was obtained by annealing the following pairs of orylated synthetic oligonucleotide pairs: AElfor: AGGTAGCCCDGCWGGYTCTCCDACYTCYACYGARGA (SEQ ID NO: 1628) AElreV: ACCTTCYTCRGTRGARGTHGGAGARCCWGCHGGGCT (SEQ ID NO: 1629) AE2for: AGGTAGCGAACCKGCWACYTCYGGYTCTGARACYCC (SEQ ID NO: 1630) AE2reV: ACCTGGRGTYTCAGARCCRGARGTWGCMGGTTCGCT (SEQ ID NO: 1631) AE3for: AGGTACYTCTGAAAGCGCWACYCCKGARTCYGGYCC (SEQ ID NO: 1632) AE3reV: ACCTGGRCCRGAYTCMGGRGTWGCGCTTTCAGARGT (SEQ ID NO: 1633) AE4for: AGGTACYTCTACYGAACCKTCYGARGGYAGCGCWCC (SEQ ID NO: 1634) AE4reV: ACCTGGWGCGCTRCCYTCRGAMGGTTCRGTAGARGT (SEQ ID NO: 1635) We also annealed the phosphorylated oligonucleotide 3KpnIstopperFor: AGGTTCGTCTTCACTCGAGGGTAC (SEQ ID NO: 1626) and the non-phosphorylated oligonucleotide pr_3KpnIstopperReV: CCTCGAGTGAAGACGA (SEQ ID NO: 1627). The annealed oligonucleotide pairs were ligated, which ed in a mixture of products with varying length that represents the varying number of 12mer repeats ligated to one BbsI/KpnI segment. The products ponding to the length of 36 amino acids were isolated from the mixture by preparative agarose gel electrophoresis and ligated into the BsaI/Kpnl digested stuffer vector pCWO35 9. Most of the clones in the resulting library designated LCWO402 showed green fluorescence after induction which shows that the sequence of XTEN_AE36 had been ligated in frame with the GFP gene and most sequences of XTEN_AE36 show good expression.

We screened 96 isolates from library LCWO402 for high level of fluorescence by stamping them onto agar plate containing IPTG. The same isolates were evaluated by PCR and 48 es were identified that contained segments with 36 amino acids as well as strong cence. These isolates were sequenced and 37 clones were identified that contained correct XTEN_AE36 segments. The file names of the nucleotide and amino acid constructs and the sequences for these segments are listed in Table l 4.

Table 14: DNA and Amino Acid ces for AE 36-mer motifs (SEQ ID NOS 279-352, res ectivel in order of a earance File name Amino acid seguence Nucleotide ce LCWO402_002_ GSPAGSPTSTEEGTSE GGTAGCCCGGCAGGCTCTCCGACCTCTACTGAGGAA GFP-\_A07.ab1 SATPESGPGTSTEPSE GGTACTTCTGAAAGCGCAACCCCGGAGTCCGGCCCA GSAP GGTACCTCTACCGAACCGTCTGAGGGCAGCGCACCA LCWO402_003_ GTSTEPSEGSAPGTST GGTACTTCTACCGAACCGTCCGAAGGCAGCGCTCCA GFP-\_B07.ab1 EPSEGSAPGTSTEPSE GGTACCTCTACTGAACCTTCCGAGGGCAGCGCTCCA GSAP GGTACCTCTACCGAACCTTCTGAAGGTAGCGCACCA LCWO402_004_ GTSTEPSEGSAPGTSE GGTACCTCTACCGAACCGTCTGAAGGTAGCGCACCA GFP-\_C07.ab1 GPGTSESATP GGTACCTCTGAAAGCGCAACTCCTGAGTCCGGTCCA ESGP GGTACTTCTGAAAGCGCAACCCCGGAGTCTGGCCCA LCWO402_005_ GTSTEPSEGSAPGTSE GGTACTTCTACTGAACCGTCTGAAGGTAGCGCACCA GFP-\_D07.ab1 SATPESGPGTSESATP GGTACTTCTGAAAGCGCAACCCCGGAATCCGGCCCA ESGP GGTACCTCTGAAAGCGCAACCCCGGAGTCCGGCCCA LCWO402_006_ GSEPATSGSETPGTSE GGTAGCGAACCGGCAACCTCCGGCTCTGAAACCCCA E07.ab1 SATPESGPGSPAGSPT GGTACCTCTGAAAGCGCTACTCCTGAATCCGGCCCA STEE CCGGCAGGTTCTCCGACTTCCACTGAGGAA LCWO402_008_ GTSESATPESGPGSEP TCTGAAAGCGCAACCCCTGAATCCGGTCCA F07.ab1 ATSGSETPGTSTEPSE GAACCGGCTACTTCTGGCTCTGAGACTCCA GSAP GGTACTTCTACCGAACCGTCCGAAGGTAGCGCACCA 2_009_ GSPAGSPTSTEEGSPA GGTAGCCCGGCTGGCTCTCCAACCTCCACTGAGGAA G07.ab1 GSPTSTEEGSEPATSG GGTAGCCCGGCTGGCTCTCCAACCTCCACTGAAGAA SETP GGTAGCGAACCGGCTACCTCCGGCTCTGAAACTCCA LCWO402_01 1_ GSPAGSPTSTEEGTSE GGTAGCCCGGCTGGCTCTCCTACCTCTACTGAGGAA GFP-\_A08.ab1 SATPESGPGTSTEPSE GGTACTTCTGAAAGCGCTACTCCTGAGTCTGGTCCA GSAP GGTACCTCTACTGAACCGTCCGAAGGTAGCGCTCCA LCWO402_012_ GSPAGSPTSTEEGSPA GGTAGCCCTGCTGGCTCTCCGACTTCTACTGAGGAA GFP-\_B08.ab1 GSPTSTEEGTSTEPSE GGTAGCCCGGCTGGTTCTCCGACTTCTACTGAGGAA GSAP TCTACCGAACCTTCCGAAGGTAGCGCTCCA LCWO402_013_ GTSESATPESGPGTST GGTACTTCTGAAAGCGCTACTCCGGAGTCCGGTCCA GFP-\_C08.ab1 EPSEGSAPGTSTEPSE GGTACCTCTACCGAACCGTCCGAAGGCAGCGCTCCA GSAP GGTACTTCTACTGAACCTTCTGAGGGTAGCGCTCCA LCWO402_014_ GTSTEPSEGSAPGSPA GGTACCTCTACCGAACCTTCCGAAGGTAGCGCTCCA GFP-\_D08.ab1 GSPTSTEEGTSTEPSE GGTAGCCCGGCAGGTTCTCCTACTTCCACTGAGGAA GSAP GGTACTTCTACCGAACCTTCTGAGGGTAGCGCACCA LCWO402_015_ GSEPATSGSETPGSPA GGTAGCGAACCGGCTACTTCCGGCTCTGAGACTCCA GFP-\_E08.ab1 GSPTSTEEGTSESATP GGTAGCCCTGCTGGCTCTCCGACCTCTACCGAAGAA ESGP GGTACCTCTGAAAGCGCTACCCCTGAGTCTGGCCCA LCWO402_016_ GTSTEPSEGSAPGTSE GGTACTTCTACCGAACCTTCCGAGGGCAGCGCACCA GFP-\_F08.ab1 SATPESGPGTSESATP GGTACTTCTGAAAGCGCTACCCCTGAGTCCGGCCCA WO 22617 2012/046326 File name Amino acid sequence Nucleotide sequence ESGP GGTACTTCTGAAAGCGCTACTCCTGAATCCGGTCCA LCW0402_020_ GTSTEPSEGSAPGSEP GGTACTTCTACTGAACCGTCTGAAGGCAGCGCACCA GFP-\_G08.ab1 ATSGSETPGSPAGSPT GGTAGCGAACCGGCTACTTCCGGTTCTGAAACCCCA STEE GGTAGCCCAGCAGGTTCTCCAACTTCTACTGAAGAA LCW0402_023_ GSPAGSPTSTEEGTSE GGTAGCCCTGCTGGCTCTCCAACCTCCACCGAAGAA GFP-\_A09.ab1 SATPESGPGSEPATSG GGTACCTCTGAAAGCGCAACCCCTGAATCCGGCCCA SETP GGTAGCGAACCGGCAACCTCCGGTTCTGAAACCCCA LCW0402_024_ GTSESATPESGPGSPA TCTGAAAGCGCTACTCCTGAGTCCGGCCCA GFP-\_B09.ab1 GSPTSTEEGSPAGSPT GGTAGCCCGGCTGGCTCTCCGACTTCCACCGAGGAA STEE GGTAGCCCGGCTGGCTCTCCAACTTCTACTGAAGAA LCW0402_025_ GTSTEPSEGSAPGTSE GGTACCTCTACTGAACCTTCTGAGGGCAGCGCTCCA GFP-\_C09.ab1 SATPESGPGTSTEPSE GGTACTTCTGAAAGCGCTACCCCGGAGTCCGGTCCA GSAP GGTACTTCTACTGAACCGTCCGAAGGTAGCGCACCA LCW0402_026_ GSPAGSPTSTEEGTST CCGGCAGGCTCTCCGACTTCCACCGAGGAA GFP-\_D09.ab1 EPSEGSAPGSEPATSG TCTACTGAACCTTCTGAGGGTAGCGCTCCA SETP GGTAGCGAACCGGCAACCTCTGGCTCTGAAACCCCA LCW0402_027_ GSPAGSPTSTEEGTST GGTAGCCCAGCAGGCTCTCCGACTTCCACTGAGGAA E09.ab1 APGTSTEPSE GGTACTTCTACTGAACCTTCCGAAGGCAGCGCACCA GSAP GGTACCTCTACTGAACCTTCTGAGGGCAGCGCTCCA LCW0402_032_ GSEPATSGSETPGTSE GAACCTGCTACCTCCGGTTCTGAAACCCCA GFP-\_H09.ab1 SATPESGPGSPAGSPT GGTACCTCTGAAAGCGCAACTCCGGAGTCTGGTCCA STEE GGTAGCCCTGCAGGTTCTCCTACCTCCACTGAGGAA LCW0402_034_ GTSESATPESGPGTST GGTACCTCTGAAAGCGCTACTCCGGAGTCTGGCCCA GFP-\_A10.ab1 EPSEGSAPGTSTEPSE GGTACCTCTACTGAACCGTCTGAGGGTAGCGCTCCA GSAP GGTACTTCTACTGAACCGTCCGAAGGTAGCGCACCA LCW0402_036_ GSPAGSPTSTEEGTST GGTAGCCCGGCTGGTTCTCCGACTTCCACCGAGGAA GFP-\_C10.ab1 EPSEGSAPGTSTEPSE GGTACCTCTACTGAACCTTCTGAGGGTAGCGCTCCA GSAP GGTACCTCTACTGAACCTTCCGAAGGCAGCGCTCCA LCW0402_039_ GTSTEPSEGSAPGTST TCTACCGAACCGTCCGAGGGCAGCGCTCCA GFP-\_E10.ab1 EPSEGSAPGTSTEPSE GGTACTTCTACTGAACCTTCTGAAGGCAGCGCTCCA GSAP GGTACTTCTACTGAACCTTCCGAAGGTAGCGCACCA LCW0402_040_ GSEPATSGSETPGTSE GGTAGCGAACCTGCAACCTCTGGCTCTGAAACCCCA F10.ab1 SATPESGPGTSTEPSE GGTACCTCTGAAAGCGCTACTCCTGAATCTGGCCCA GSAP GGTACTTCTACTGAACCGTCCGAGGGCAGCGCACCA LCW0402_041_ GTSTEPSEGSAPGSPA GGTACTTCTACCGAACCGTCCGAGGGTAGCGCACCA GFP-\_G10.ab1 GSPTSTEEGTSTEPSE GGTAGCCCAGCAGGTTCTCCTACCTCCACCGAGGAA GSAP GGTACTTCTACCGAACCGTCCGAGGGTAGCGCACCA LCW0402_050_ GSEPATSGSETPGTSE GGTAGCGAACCGGCAACCTCCGGCTCTGAAACTCCA GFP-\_A11.ab1 SATPESGPGSEPATSG GGTACTTCTGAAAGCGCTACTCCGGAATCCGGCCCA SETP GGTAGCGAACCGGCTACTTCCGGCTCTGAAACCCCA LCW0402_051_ SGSETPGTSE GGTAGCGAACCGGCAACTTCCGGCTCTGAAACCCCA GFP-\_B11.ab1 SATPESGPGSEPATSG TCTGAAAGCGCTACTCCTGAGTCTGGCCCA SETP GGTAGCGAACCTGCTACCTCTGGCTCTGAAACCCCA LCW0402_059_ GSEPATSGSETPGSEP GGTAGCGAACCGGCAACCTCTGGCTCTGAAACTCCA GFP-\_E11.ab1 ATSGSETPGTSTEPSE GGTAGCGAACCTGCAACCTCCGGCTCTGAAACCCCA GSAP GGTACTTCTACTGAACCTTCTGAGGGCAGCGCACCA LCW0402_060_ GTSESATPESGPGSEP GGTACTTCTGAAAGCGCTACCCCGGAATCTGGCCCA GFP-\_F11.ab1 ATSGSETPGSEPATSG GGTAGCGAACCGGCTACTTCTGGTTCTGAAACCCCA SETP GGTAGCGAACCGGCTACCTCCGGTTCTGAAACTCCA LCW0402_061_ GTSTEPSEGSAPGTST GGTACCTCTACTGAACCTTCCGAAGGCAGCGCTCCA GFP-\_G11.ab1 EPSEGSAPGTSESATP TCTACCGAACCGTCCGAGGGCAGCGCACCA ESGP TCTGAAAGCGCAACCCCTGAATCCGGTCCA LCW0402_065_ GSEPATSGSETPGTSE GGTAGCGAACCGGCAACCTCTGGCTCTGAAACCCCA GFP-\_A12.ab1 SATPESGPGTSESATP GGTACCTCTGAAAGCGCTACTCCGGAATCTGGTCCA ESGP GGTACTTCTGAAAGCGCTACTCCGGAATCCGGTCCA LCW0402_066_ GSEPATSGSETPGSEP GGTAGCGAACCTGCTACCTCCGGCTCTGAAACTCCA GFP-\_B12.ab1 ATSGSETPGTSTEPSE GGTAGCGAACCGGCTACTTCCGGTTCTGAAACTCCA GSAP GGTACCTCTACCGAACCTTCCGAAGGCAGCGCACCA LCW0402_067_ GSEPATSGSETPGTST GGTAGCGAACCTGCTACTTCTGGTTCTGAAACTCCA GFP-\_C12.ab1 EPSEGSAPGSEPATSG GGTACTTCTACCGAACCGTCCGAGGGTAGCGCTCCA SETP GGTAGCGAACCTGCTACTTCTGGTTCTGAAACTCCA File name Amino acid sequence Nucleotide sequence 2_069_ GTSTEPSEGSAPGTST GGTACCTCTACCGAACCGTCCGAGGGTAGCGCACCA GFP-N_D12.ab1 EPSEGSAPGSEPATSG GGTACCTCTACTGAACCGTCTGAGGGTAGCGCTCCA SETP GGTAGCGAACCGGCAACCTCCGGTTCTGAAACTCCA LCW0402_073_ GTSTEPSEGSAPGSEP GGTACTTCTACTGAACCTTCCGAAGGTAGCGCTCCA GFP-N_F12.ab1 TPGSPAGSPT GGTAGCGAACCTGCTACTTCTGGTTCTGAAACCCCA STEE GGTAGCCCGGCTGGCTCTCCGACCTCCACCGAGGAA LCW0402_074_ GSEPATSGSETPGSPA GGTAGCGAACCGGCTACTTCCGGCTCTGAGACTCCA GFP-N_G12.ab1 GSPTSTEEGTSESATP GGTAGCCCAGCTGGTTCTCCAACCTCTACTGAGGAA ESGP GGTACTTCTGAAAGCGCTACCCCTGAATCTGGTCCA LCW0402_075_ GTSESATPESGPGSEP GGTACCTCTGAAAGCGCAACTCCTGAGTCTGGCCCA GFP-N_H12.ab1 ATSGSETPGTSESATP GGTAGCGAACCTGCTACCTCCGGCTCTGAGACTCCA ESGP TCTGAAAGCGCAACCCCGGAATCTGGTCCA Example 3: Construction ofXTEN_AF36 segments A codon y encoding sequences of 36 amino acid length was constructed. The sequences were designated XTEN_AF36. Its segments have the amino acid sequence [X]3 where X is a 12mer peptide with the sequence: GSTSESPSGTAP (SEQ ID NO: 27), GTSTPESGSASP (SEQ ID NO: 28), GTSPSGESSTAP (SEQ ID NO: 29), or GSTSSTAESPGP (SEQ ID NO: 30). The insert was obtained by annealing the following pairs of phosphorylated synthetic oligonucleotide pairs: AF 1 for: AGGTTCTACYAGCGAATCYCCKTCTGGYACYGCWCC (SEQ ID NO: 1636) AP 1rev: ACCTGGWGCRGTRCCAGAMGGRGATTCGCTRGTAGA (SEQ ID NO: 1637) AF2for: AGGTACYTCTACYCCKGAAAGCGGYTCYGCWTCTCC (SEQ ID NO: 1638) AF2reV: ACCTGGAGAWGCRGARCCGCTTTCMGGRGTAGARGT (SEQ ID NO: 1639) AF3for: AGGTACYTCYCCKAGCGGYGAATCTTCTACYGCWCC (SEQ ID NO: 1640) AF3reV: ACCTGGWGCRGTAGAAGATTCRCCGCTMGGRGARGT (SEQ ID NO: 1641) AF4for: AGGTTCYACYAGCTCTACYGCWGAATCTCCKGGYCC (SEQ ID NO: 1642) AF4reV: ACCTGGRCCMGGAGATTCWGCRGTAGAGCTRGTRGA (SEQ ID NO: 1643) We also annealed the phosphorylated ucleotide 3KpnIstopperFor: AGGTTCGTCTTCACTCGAGGGTAC (SEQ ID NO: 1626) and the non-phosphorylated oligonucleotide pr_3KpnIstopperRev: CCTCGAGTGAAGACGA (SEQ ID NO: 1627). The annealed oligonucleotide pairs were ligated, which ed in a mixture of products with varying length that represents the varying number of 12mer s ligated to one BbsI/KpnI segment The products corresponding to the length of 36 amino acids were isolated from the mixture by preparative e gel electrophoresis and ligated into the BsaI/KpnI digested stuffer vector pCWO35 9. Most of the clones in the resulting library designated LCWO403 showed green fluorescence after induction which shows that the sequence ofXTEN_AF36 had been ligated in frame with the GFP gene and most ces of XTEN_AF36 show good expression.

We screened 96 isolates from library 3 for high level of fluorescence by stamping them onto agar plate containing IPTG. The same isolates were evaluated by PCR and 48 isolates were fied that contained segments with 36 amino acids as well as strong cence. These isolates were sequenced and 44 clones were identified that contained correct XTEN_AF36 segments. The file names of the nucleotide and amino acid constructs and the ces for these segments are listed in Table 15.

Table 15: DNA and Amino Acid Seguences for AF 36-mer motifs (SEQ ID NOS 353-440, res ectivel in order of a earance File name Amino acid sequence Nucleotide ce LCW0403_004_ GTSTPESGSASPGTSP GGTACTTCTACTCCGGAAAGCGGTTCCGCATCTCCA GFP-\_A01.abl SGESSTAPGTSPSGES TCTCCTAGCGGTGAATCTTCTACTGCTCCAG STAP GTACCTCTCCTAGCGGCGAATCTTCTACTGCTCCA LCW0403_005_ ESSTAPGSTS GGTACTTCTCCGAGCGGTGAATCTTCTACCGCACCA GFP-\_B01.abl STAESPGPGTSPSGES GGTTCTACTAGCTCTACCGCTGAATCTCCGGGCCCAG STAP GTACTTCTCCGAGCGGTGAATCTTCTACTGCTCCA LCW0403_006_ GSTSSTAESPGPGTSP GGTTCCACCAGCTCTACTGCTGAATCTCCTGGTCCAG GFP-\_C01.abl SGESSTAPGTSTPESG GTACCTCTCCTAGCGGTGAATCTTCTACTGCTCCAGG SASP TACTTCTACTCCTGAAAGCGGCTCTGCTTCTCCA LCW0403_007_ GSTSSTAESPGPGSTS ACCAGCTCTACTGCAGAATCTCCTGGCCCAG GFP-\_D01.abl STAESPGPGTSPSGES GTTCCACCAGCTCTACCGCAGAATCTCCGGGTCCAG STAP GTACTTCCCCTAGCGGTGAATCTTCTACCGCACCA LCW0403_008_ GSTSSTAESPGPGTSP GGTTCTACTAGCTCTACTGCTGAATCTCCTGGCCCAG GFP-\_E01.abl SGESSTAPGTSTPESG GTACTTCTCCTAGCGGTGAATCTTCTACCGCTCCAGG SASP TACCTCTACTCCGGAAAGCGGTTCTGCATCTCCA LCW0403_010_ GSTSSTAESPGPGTST GGTTCTACCAGCTCTACCGCAGAATCTCCTGGTCCAG GFP-\_F01.abl PESGSASPGSTSESPS GTACCTCTACTCCGGAAAGCGGCTCTGCATCTCCAG GTAP GTTCTACTAGCGAATCTCCTTCTGGCACTGCACCA LCW0403_011_ GSTSSTAESPGPGTST GGTTCTACTAGCTCTACTGCAGAATCTCCTGGCCCAG GFP-\_G01.abl PESGSASPGTSTPESG GTACCTCTACTCCGGAAAGCGGCTCTGCATCTCCAG SASP CTACCCCTGAAAGCGGTTCTGCATCTCCA LCW0403_012_ GSTSESPSGTAPGTSP GGTTCTACCAGCGAATCTCCTTCTGGCACCGCTCCAG GFP-\_H01.abl APGSTSESPS GTACCTCTCCTAGCGGCGAATCTTCTACCGCTCCAGG GTAP TTCTACTAGCGAATCTCCTTCTGGCACTGCACCA LCW0403_013_ GSTSSTAESPGPGSTS GGTTCCACCAGCTCTACTGCAGAATCTCCGGGCCCA GFP-\_A02.abl STAESPGPGTSPSGES GGTTCTACTAGCTCTACTGCAGAATCTCCGGGTCCAG STAP GTACTTCTCCTAGCGGCGAATCTTCTACCGCTCCA LCW0403_014_ GSTSSTAESPGPGTST GGTTCCACTAGCTCTACTGCAGAATCTCCTGGCCCAG GFP-\_B02.abl PESGSASPGSTSESPS GTACCTCTACCCCTGAAAGCGGCTCTGCATCTCCAG GTAP CCAGCGAATCCCCGTCTGGCACCGCACCA LCW0403_015_ GSTSSTAESPGPGSTS GGTTCTACTAGCTCTACTGCTGAATCTCCGGGTCCAG GFP-\_C02.abl STAESPGPGTSPSGES GTTCTACCAGCTCTACTGCTGAATCTCCTGGTCCAGG STAP TACCTCCCCGAGCGGTGAATCTTCTACTGCACCA LCW0403_017_ GSTSSTAESPGPGSTS GGTTCTACCAGCTCTACCGCTGAATCTCCTGGCCCAG GFP-\_D02.abl ESPSGTAPGSTSSTAE GTTCTACCAGCGAATCCCCGTCTGGCACCGCACCAG SPGP GTTCTACTAGCTCTACCGCTGAATCTCCGGGTCCA 3_018_ GSTSSTAESPGPGSTS GGTTCTACCAGCTCTACCGCAGAATCTCCTGGCCCA E02.abl STAESPGPGSTSSTAE GGTTCCACTAGCTCTACCGCTGAATCTCCTGGTCCAG SPGP GTTCTACTAGCTCTACCGCTGAATCTCCTGGTCCA LCW0403_019_ PSGTAPGSTS GGTTCTACTAGCGAATCCCCTTCTGGTACTGCTCCAG GFP-\_F02.abl STAESPGPGSTSSTAE GTTCCACTAGCTCTACCGCTGAATCTCCTGGCCCAGG SPGP TTCCACTAGCTCTACTGCAGAATCTCCTGGTCCA LCW0403_023_ GSTSESPSGTAPGSTS GGTTCTACTAGCGAATCTCCTTCTGGTACCGCTCCAG GFP-\_H02.abl ESPSGTAPGSTSESPS GTTCTACCAGCGAATCCCCGTCTGGTACTGCTCCAGG GTAP TTCTACCAGCGAATCTCCTTCTGGTACTGCACCA LCW0403_024_ GSTSSTAESPGPGSTS GGTTCCACCAGCTCTACTGCTGAATCTCCTGGCCCAG GFP-\_A03.abl STAESPGPGSTSSTAE GTTCTACCAGCTCTACTGCTGAATCTCCGGGCCCAGG SPGP TTCCACCAGCTCTACCGCTGAATCTCCGGGTCCA LCW0403_025_ GSTSSTAESPGPGSTS GGTTCCACTAGCTCTACCGCAGAATCTCCTGGTCCAG B03.abl STAESPGPGTSPSGES GTTCTACTAGCTCTACTGCTGAATCTCCGGGTCCAGG STAP TACCTCCCCTAGCGGCGAATCTTCTACCGCTCCA LCW0403_028_ GSSPSASTGTGPGSST GGTTCTAGCCCTTCTGCTTCCACCGGTACCGGCCCAG GFP-\_D03.abl PSGATGSPGSSTPSGA GTAGCTCTACTCCGTCTGGTGCAACTGGCTCTCCAGG TGSP TAGCTCTACTCCGTCTGGTGCAACCGGCTCCCCA WO 22617 File name Amino acid sequence Nucleotide sequence LCWO403_029_ GTSPSGESSTAPGTST GGTACTTCCCCTAGCGGTGAATCTTCTACTGCTCCAG GFP-\_E03.ab1 PESGSASPGSTSSTAE GTACCTCTACTCCGGAAAGCGGCTCCGCATCTCCAG SPGP GTTCTACTAGCTCTACTGCTGAATCTCCTGGTCCA LCWO403_030_ GSTSSTAESPGPGSTS GGTTCTACTAGCTCTACCGCTGAATCTCCGGGTCCAG GFP-\_F03.ab1 STAESPGPGTSTPESG GTTCTACCAGCTCTACTGCAGAATCTCCTGGCCCAGG SASP TACTTCTACTCCGGAAAGCGGTTCCGCTTCTCCA LCWO403_031_ GTSPSGESSTAPGSTS TCTCCTAGCGGTGAATCTTCTACCGCTCCAG GFP-\_G03.ab1 STAESPGPGTSTPESG GTTCTACCAGCTCTACTGCTGAATCTCCTGGCCCAGG SASP TACCCCGGAAAGCGGCTCCGCTTCTCCA LCWO403_033 PSGTAPGSTS GGTTCTACTAGCGAATCCCCTTCTGGTACTGCACCAG GFR\_H01mfi STAESPGPGSTSSTAE GTTCTACCAGCTCTACTGCTGAATCTCCGGGCCCAGG SPGP TTCCACCAGCTCTACCGCAGAATCTCCTGGTCCA LCWO403_035 AESPGPGSTS GGTTCCACCAGCTCTACCGCTGAATCTCCGGGCCCA GFR\_A04dfi ESPSGTAPGSTSSTAE GGTTCTACCAGCGAATCCCCTTCTGGCACTGCACCA SPGP GGTTCTACTAGCTCTACCGCAGAATCTCCGGGCCCA LCWO403_036 GSTSSTAESPGPGTSP GGTTCTACCAGCTCTACTGCTGAATCTCCGGGTCCAG GFPJ\_B04abT SGESSTAPGTSTPESG GTACTTCCCCGAGCGGTGAATCTTCTACTGCACCAG SASP GTACTTCTACTCCGGAAAGCGGTTCCGCTTCTCCA LCWO403_039 GSTSESPSGTAPGSTS GGTTCTACCAGCGAATCTCCTTCTGGCACCGCTCCAG GFPJ\_C04abT ESPSGTAPGTSPSGES GTTCTACTAGCGAATCCCCGTCTGGTACCGCACCAG STAP GTACTTCTCCTAGCGGCGAATCTTCTACCGCACCA LCWO403_041 GSTSESPSGTAPGSTS GGTTCTACCAGCGAATCCCCTTCTGGTACTGCTCCAG GFR\_D04dfi ESPSGTAPGTSTPESG GTTCTACCAGCGAATCCCCTTCTGGCACCGCACCAG SASP GTACTTCTACCCCTGAAAGCGGCTCCGCTTCTCCA LCWO403_044 GTSTPESGSASPGSTS GGTACCTCTACTCCTGAAAGCGGTTCTGCATCTCCAG GFPJ\_E04abT STAESPGPGSTSSTAE CTAGCTCTACCGCAGAATCTCCGGGCCCAG SPGP GTTCTACTAGCTCTACTGCTGAATCTCCTGGCCCA LCWO403_046 GSTSESPSGTAPGSTS GGTTCTACCAGCGAATCCCCTTCTGGCACTGCACCA GFP:\_F04abT ESPSGTAPGTSPSGES GGTTCTACTAGCGAATCCCCTTCTGGTACCGCACCAG STAP GTACTTCTCCGAGCGGCGAATCTTCTACTGCTCCA LCWO403_047 GSTSSTAESPGPGSTS ACTAGCTCTACCGCTGAATCTCCTGGCCCAG o4mfi STAESPGPGSTSESPS GTTCCACTAGCTCTACCGCAGAATCTCCGGGCCCAG GTAP GTTCTACTAGCGAATCCCCTTCTGGTACCGCTCCA LCWO403_049 GSTSSTAESPGPGSTS GGTTCCACCAGCTCTACTGCAGAATCTCCTGGCCCA GFR\_H04MH STAESPGPGTSTPESG GGTTCTACTAGCTCTACCGCAGAATCTCCTGGTCCAG SASP GTACCTCTACTCCTGAAAGCGGTTCCGCATCTCCA LCWO403_051 GSTSSTAESPGPGSTS GGTTCTACTAGCTCTACTGCTGAATCTCCGGGCCCAG 05dfi STAESPGPGSTSESPS GTTCTACTAGCTCTACCGCTGAATCTCCGGGTCCAGG GTAP TTCTACTAGCGAATCTCCTTCTGGTACCGCTCCA LCWO403_053 GTSPSGESSTAPGSTS GGTACCTCCCCGAGCGGTGAATCTTCTACTGCACCA GFPJ\_BOSabT ESPSGTAPGSTSSTAE GGTTCTACTAGCGAATCCCCTTCTGGTACTGCTCCAG SPGP GTTCCACCAGCTCTACTGCAGAATCTCCGGGTCCA LCWO403_054 PSGTAPGTSP GGTTCTACTAGCGAATCCCCGTCTGGTACTGCTCCAG GFPJ\_C053bT SGESSTAPGSTSSTAE GTACTTCCCCTAGCGGTGAATCTTCTACTGCTCCAGG SPGP TTCTACCAGCTCTACCGCAGAATCTCCGGGTCCA 3_057 GSTSSTAESPGPGSTS GGTTCTACCAGCTCTACCGCTGAATCTCCTGGCCCAG GFR\_D05dfi ESPSGTAPGTSPSGES GTTCTACTAGCGAATCTCCGTCTGGCACCGCACCAG STAP GTACTTCCCCTAGCGGTGAATCTTCTACTGCACCA LCWO403_058 GSTSESPSGTAPGSTS GGTTCTACTAGCGAATCTCCTTCTGGCACTGCACCAG GFPJ\_E053bT ESPSGTAPGTSTPESG GTTCTACCAGCGAATCTCCGTCTGGCACTGCACCAG SASP GTACCTCTACCCCTGAAAGCGGTTCCGCTTCTCCA 3_060 GTSTPESGSASPGSTS GGTACCTCTACTCCGGAAAGCGGTTCCGCATCTCCA GFP:\_F05abT ESPSGTAPGSTSSTAE GGTTCTACCAGCGAATCCCCGTCTGGCACCGCACCA SPGP GGTTCTACTAGCTCTACTGCTGAATCTCCGGGCCCA LCWO403_063 GSTSSTAESPGPGTSP ACTAGCTCTACTGCAGAATCTCCGGGCCCA GFR\_GOimfi SGESSTAPGTSPSGES GGTACCTCTCCTAGCGGTGAATCTTCTACCGCTCCAG STAP GTACTTCTCCGAGCGGTGAATCTTCTACCGCTCCA LCWO403_064_ ESSTAPGTSP GGTACCTCCCCTAGCGGCGAATCTTCTACTGCTCCAG GFP-\_H05.ab1 SGESSTAPGTSPSGES GTACCTCTCCTAGCGGCGAATCTTCTACCGCTCCAGG STAP TACCTCCCCTAGCGGTGAATCTTCTACCGCACCA LCWO403_065_ GSTSSTAESPGPGTST GGTTCCACTAGCTCTACTGCTGAATCTCCTGGCCCAG File name Amino acid sequence Nucleotide sequence GFP-\_A06.ab1 PESGSASPGSTSESPS GTACTTCTACTCCGGAAAGCGGTTCCGCTTCTCCAGG GTAP TTCTACTAGCGAATCTCCGTCTGGCACCGCACCA LCW0403_066_ GSTSESPSGTAPGTSP GGTTCTACTAGCGAATCTCCGTCTGGCACTGCTCCAG B06.ab1 SGESSTAPGTSPSGES GTACTTCTCCTAGCGGTGAATCTTCTACCGCTCCAGG STAP TACTTCCCCTAGCGGCGAATCTTCTACCGCTCCA LCW0403_067_ GSTSESPSGTAPGTST GGTTCTACTAGCGAATCTCCTTCTGGTACCGCTCCAG GFP-\_C06.ab1 PESGSASPGSTSSTAE GTACTTCTACCCCTGAAAGCGGCTCCGCTTCTCCAGG SPGP TTCCACTAGCTCTACCGCTGAATCTCCGGGTCCA LCW0403_068_ GSTSSTAESPGPGSTS GGTTCCACTAGCTCTACTGCTGAATCTCCTGGCCCAG GFP-\_D06.ab1 STAESPGPGSTSESPS GTTCTACCAGCTCTACCGCTGAATCTCCTGGCCCAGG GTAP TTCTACCAGCGAATCTCCGTCTGGCACCGCACCA LCW0403_069_ GSTSESPSGTAPGTST GGTTCTACTAGCGAATCCCCGTCTGGTACCGCACCA GFP-\_E06.ab1 PESGSASPGTSTPESG GGTACTTCTACCCCGGAAAGCGGCTCTGCTTCTCCAG SASP GTACTTCTACCCCGGAAAGCGGCTCCGCATCTCCA LCW0403_070_ GSTSESPSGTAPGTST GGTTCTACTAGCGAATCCCCGTCTGGTACTGCTCCAG GFP-\_F06.ab1 PESGSASPGTSTPESG GTACTTCTACTCCTGAAAGCGGTTCCGCTTCTCCAGG SASP TACTCCGGAAAGCGGTTCTGCATCTCCA Example 4: Construction _AG36 segments A codon y encoding sequences of 36 amino acid length was constructed. The sequences were designated XTEN_AG36. Its segments have the amino acid sequence [X]3 where X is a 12mer peptide with the sequence: GTPGSGTASSSP (SEQ ID NO: 31), GSSTPSGATGSP (SEQ ID NO: 32), GSSPSASTGTGP (SEQ ID NO: 33), or GASPGTSSTGSP (SEQ ID NO: 34). The insert was obtained by annealing the ing pairs of phosphorylated synthetic oligonucleotide pairs: AGlfor: AGGTACYCCKGGYAGCGGTACYGCWTCTTCYTCTCC (SEQ ID l\O: 1644) AGlreV: ACCTGGAGARGAAGAWGCRGTACCGCTRCCMGGRGT (SEQ ID NO: 1645) AG2for: AGGTAGCTCTACYCCKTCTGGTGCWACYGGYTCYCC (SEQ ID l\O: 1646) AG2reV: ACCTGGRGARCCRGTWGCACCAGAMGGRGTAGAGCT (SEQ ID NO: 1647) : TAGCCCKTCTGCWTCYACYGGTACYGGYCC (SEQ ID l\O: 1648) AG3reV: ACCTGGRCCRGTACCRGTRGAWGCAGAMGGGCTAGA (SEQ ID V0: 1649) AG4for: AGGTGCWTCYCCKGGYACYAGCTCTACYGGTTCTCC (SEQ ID NO: 1650) : ACCTGGAGAACCRGTAGAGCTRGTRCCMGGRGAWGC (SEQ ID V0: 1651) We also annealed the phosphorylated oligonucleotide 3KpnIstopperFor: AGGTTCGTCTTCACTCGAGGGTAC (SEQ ID NO: 1626) and the non-phosphorylated oligonucleotide nIstopperRev: GTGAAGACGA (SEQ ID NO: 1627). The ed oligonucleotide pairs were ligated, which resulted in a mixture of products with varying length that represents the varying number of 12mer repeats ligated to one BbsI/KpnI segment. The products corresponding to the length of 36 amino acids were isolated from the e by preparative agarose gel ophoresis and ligated into the BsaI/KpnI digested stuffer vector pCWO35 9. Most of the clones in the resulting library designated LCWO404 showed green fluorescence after induction which shows that the sequence ofXTEN_AG36 had been ligated in frame with the GFP gene and most sequences of XTEN_AG36 show good expression.

We screened 96 isolates from library LCWO404 for high level of fluorescence by stamping them onto agar plate containing IPTG. The same isolates were evaluated by PCR and 48 isolates were fied that contained segments with 36 amino acids as well as strong fluorescence. These isolates were sequenced and 44 clones were identified that contained correct XTEN_AG36 segments. The file names of the nucleotide and amino acid constructs and the sequences for these segments are listed in Table 16.

Table 16: DNA and Amino Acid ces for AG 36-mer motifs (SEQ ID NOS 8, res ectivel in order of a earance File name Amino acid sequence Nucleotide sequence 4_001_ SSTGSPGTPGS TCCCCGGGCACTAGCTCTACCGGTTCTCCA A07.ab1 GTASSSPGSSTPSGATG GGTACTCCTGGTAGCGGTACTGCTTCTTCTTCTCCAG SP GTAGCTCTACTCCTTCTGGTGCTACTGGTTCTCCA LCW0404_003_ GATGSPGSSPS GGTAGCTCTACCCCTTCTGGTGCTACCGGCTCTCCAG GFP-\_B07.ab1 ASTGTGPGSSTPSGATG GTTCTAGCCCGTCTGCTTCTACCGGTACCGGTCCAGG SP TAGCTCTACCCCTTCTGGTGCTACTGGTTCTCCA 4_006_ GASPGTSSTGSPGSSPS GGTGCATCTCCGGGTACTAGCTCTACCGGTTCTCCAG GFP-\_C07.ab1 ASTGTGPGSSTPSGATG GTTCTAGCCCTTCTGCTTCCACTGGTACCGGCCCAGG SP TAGCTCTACCCCGTCTGGTGCTACTGGTTCCCCA LCW0404_007_ GTPGSGTASSSPGSSTPS GGTACTCCGGGCAGCGGTACTGCTTCTTCCTCTCCAG GFP-\_D07.ab1 GATGSPGASPGTSSTGS GTAGCTCTACCCCTTCTGGTGCAACTGGTTCCCCAGG P TGCATCCCCTGGTACTAGCTCTACCGGTTCTCCA LCW0404_009_ GTPGSGTASSSPGASPG GGTACCCCTGGCAGCGGTACTGCTTCTTCTTCTCCAG GFP-\_E07.ab1 TSSTGSPGSRPSASTGT GTGCTTCCCCTGGTACCAGCTCTACCGGTTCTCCAGG GP TTCTAGACCTTCTGCATCCACCGGTACTGGTCCA LCW0404_01 1_ GASPGTSSTGSPGSSTPS GGTGCATCTCCTGGTACCAGCTCTACCGGTTCTCCAG GFP-\_F07.ab1 GATGSPGASPGTSSTGS GTAGCTCTACTCCTTCTGGTGCTACTGGCTCTCCAGG P TGCTTCCCCGGGTACCAGCTCTACCGGTTCTCCA LCW0404_012_ GTPGSGTASSSPGSSTPS GGTACCCCGGGCAGCGGTACCGCATCTTCCTCTCCA GFP-\_G07.ab1 GATGSPGSSTPSGATGS GGTAGCTCTACCCCGTCTGGTGCTACCGGTTCCCCAG P GTAGCTCTACCCCGTCTGGTGCAACCGGCTCCCCA LCW0404_014_ GASPGTSSTGSPGASPG GGTGCATCTCCGGGCACTAGCTCTACTGGTTCTCCAG GFP-\_H07.ab1 TSSTGSPGASPGTSSTGS GTGCATCCCCTGGCACTAGCTCTACTGGTTCTCCAGG P TGCTTCTCCTGGTACCAGCTCTACTGGTTCTCCA LCW0404_015_ GSSTPSGATGSPGSSPS GGTAGCTCTACTCCGTCTGGTGCAACCGGCTCCCCA GFP-\_A08.ab1 PGASPGTSSTG GGTTCTAGCCCGTCTGCTTCCACTGGTACTGGCCCAG SP GTGCTTCCCCGGGCACCAGCTCTACTGGTTCTCCA LCW0404_016_ GSSTPSGATGSPGSSTPS GGTAGCTCTACTCCTTCTGGTGCTACCGGTTCCCCAG GFP-\_B08.ab1 GATGSPGTPGSGTASSS CTACTCCTTCTGGTGCTACTGGTTCCCCAGG P TACTCCGGGCAGCGGTACTGCTTCTTCCTCTCCA LCW0404_017_ GSSTPSGATGSPGSSTPS GGTAGCTCTACTCCGTCTGGTGCAACCGGTTCCCCAG GFP-\_C08.ab1 GATGSPGASPGTSSTGS GTAGCTCTACTCCTTCTGGTGCTACTGGCTCCCCAGG P TGCATCCCCTGGCACCAGCTCTACCGGTTCTCCA LCW0404_0 1 8_ GTPGSGTASSSPGSSPS CCTGGTAGCGGTACCGCATCTTCCTCTCCAG GFP-\_D08.ab1 ASTGTGPGSSTPSGATG GTTCTAGCCCTTCTGCATCTACCGGTACCGGTCCAGG SP TAGCTCTACTCCTTCTGGTGCTACTGGCTCTCCA LCW0404_023_ GASPGTSSTGSPGSSPS GGTGCTTCCCCGGGCACTAGCTCTACCGGTTCTCCAG GFP-\_F08.ab1 ASTGTGPGTPGSGTASS GTTCTAGCCCTTCTGCATCTACTGGTACTGGCCCAGG SP TACTCCGGGCAGCGGTACTGCTTCTTCCTCTCCA LCW0404_025_ GSSTPSGATGSPGSSTPS GGTAGCTCTACTCCGTCTGGTGCTACCGGCTCTCCAG GFP-\_G08.ab1 GATGSPGASPGTSSTGS GTAGCTCTACCCCTTCTGGTGCAACCGGCTCCCCAGG P TGCTTCTCCGGGTACCAGCTCTACTGGTTCTCCA LCW0404_029_ GTPGSGTASSSPGSSTPS GGTACCCCTGGCAGCGGTACCGCTTCTTCCTCTCCAG GFP-\_A09.ab1 GATGSPGSSPSASTGTG GTAGCTCTACCCCGTCTGGTGCTACTGGCTCTCCAGG P TTCTAGCCCGTCTGCATCTACCGGTACCGGCCCA LCW0404_030_ GSSTPSGATGSPGTPGS GGTAGCTCTACTCCTTCTGGTGCAACCGGCTCCCCAG GFP-\_B09.ab1 GTASSSPGTPGSGTASS CGGGCAGCGGTACCGCATCTTCCTCTCCAG SP GTACTCCGGGTAGCGGTACTGCTTCTTCTTCTCCA LCW0404_03 1_ TASSSPGSSTPS GGTACCCCGGGTAGCGGTACTGCTTCTTCCTCTCCAG GFP-\_C09.ab1 GATGSPGASPGTSSTGS GTAGCTCTACCCCTTCTGGTGCAACCGGCTCTCCAGG 2012/046326 File name Amino acid sequence Nucleotide ce P TGCTTCTCCGGGCACCAGCTCTACCGGTTCTCCA LCW0404_034_ GSSTPSGATGSPGSSTPS GGTAGCTCTACCCCGTCTGGTGCTACCGGCTCTCCAG GFP-\_D09.ab1 GATGSPGASPGTSSTGS GTAGCTCTACCCCGTCTGGTGCAACCGGCTCCCCAG P CCCCGGGTACTAGCTCTACCGGTTCTCCA LCW0404_035_ GASPGTSSTGSPGTPGS GGTGCTTCTCCGGGCACCAGCTCTACTGGTTCTCCAG GFP-\_E09.ab1 GTASSSPGSSTPSGATG GTACCCCGGGCAGCGGTACCGCATCTTCTTCTCCAG SP GTAGCTCTACTCCTTCTGGTGCAACTGGTTCTCCA LCW0404_036_ GSSPSASTGTGPGSSTPS GGTTCTAGCCCGTCTGCTTCCACCGGTACTGGCCCAG GFP-\_F09.ab1 GTPGSGTASSS GTAGCTCTACCCCGTCTGGTGCAACTGGTTCCCCAGG P TACCCCTGGTAGCGGTACCGCTTCTTCTTCTCCA 4_037_ GASPGTSSTGSPGSSPS GGTGCTTCTCCGGGCACCAGCTCTACTGGTTCTCCAG GFP-\_G09.ab1 ASTGTGPGSSTPSGATG GTTCTAGCCCTTCTGCATCCACCGGTACCGGTCCAGG SP TAGCTCTACCCCTTCTGGTGCAACCGGCTCTCCA LCW0404_040_ GASPGTSSTGSPGSSTPS TCCCCGGGCACCAGCTCTACCGGTTCTCCA GFP-\_H09.ab1 GATGSPGSSTPSGATGS GGTAGCTCTACCCCGTCTGGTGCTACCGGCTCTCCAG P GTAGCTCTACCCCGTCTGGTGCTACTGGCTCTCCA LCW0404_041_ GTPGSGTASSSPGSSTPS GGTACCCCTGGTAGCGGTACTGCTTCTTCCTCTCCAG GFP-\_A10.ab1 GATGSPGTPGSGTASSS GTAGCTCTACTCCGTCTGGTGCTACCGGTTCTCCAGG P TACCCCGGGTAGCGGTACCGCATCTTCTTCTCCA LCW0404_043_ GSSPSASTGTGPGSSTPS GGTTCTAGCCCTTCTGCTTCCACCGGTACTGGCCCAG GFP-\_C10.ab1 GATGSPGSSTPSGATGS GTAGCTCTACCCCTTCTGGTGCTACCGGCTCCCCAGG P TAGCTCTACTCCTTCTGGTGCAACTGGCTCTCCA 4_045_ GASPGTSSTGSPGSSPS GGTGCTTCTCCTGGCACCAGCTCTACTGGTTCTCCAG GFP-\_D10.ab1 ASTGTGPGSSPSASTGT GTTCTAGCCCTTCTGCTTCTACCGGTACTGGTCCAGG GP TTCTAGCCCTTCTGCATCCACTGGTACTGGTCCA LCW0404_047_ GTPGSGTASSSPGASPG GGTACTCCTGGCAGCGGTACCGCTTCTTCTTCTCCAG GFP-\_F10.ab1 TSSTGSPGASPGTSSTGS GTGCTTCTCCTGGTACTAGCTCTACTGGTTCTCCAGG P TGCTTCTCCGGGCACTAGCTCTACTGGTTCTCCA LCW0404_048_ GSSTPSGATGSPGASPG GGTAGCTCTACCCCGTCTGGTGCTACCGGTTCCCCAG GFP-\_G10.ab1 PGSSTPSGATGS GTGCTTCTCCTGGTACTAGCTCTACCGGTTCTCCAGG P TAGCTCTACCCCGTCTGGTGCTACTGGCTCTCCA LCW0404_049_ GSSTPSGATGSPGTPGS GGTAGCTCTACCCCGTCTGGTGCTACTGGTTCTCCAG GFP-\_H10.ab1 GTASSSPGSSTPSGATG CGGGCAGCGGTACTGCTTCTTCCTCTCCAGG SP TAGCTCTACCCCTTCTGGTGCTACTGGCTCTCCA LCW0404_050_ GASPGTSSTGSPGSSPS GGTGCATCTCCTGGTACCAGCTCTACTGGTTCTCCAG GFP-\_A11.ab1 ASTGTGPGSSTPSGATG GTTCTAGCCCTTCTGCTTCTACCGGTACCGGTCCAGG SP TAGCTCTACTCCTTCTGGTGCTACCGGTTCTCCA LCW0404_051_ GSSTPSGATGSPGSSTPS GGTAGCTCTACCCCGTCTGGTGCTACTGGCTCTCCAG GFP-\_B11.ab1 GATGSPGSSTPSGATGS GTAGCTCTACTCCTTCTGGTGCTACTGGTTCCCCAGG P TAGCTCTACCCCGTCTGGTGCAACTGGCTCTCCA LCW0404_052_ GASPGTSSTGSPGTPGS GGTGCATCCCCGGGTACCAGCTCTACCGGTTCTCCA GFP-\_C11.ab1 GTASSSPGASPGTSSTG GGTACTCCTGGCAGCGGTACTGCATCTTCCTCTCCAG SP GTGCTTCTCCGGGCACCAGCTCTACTGGTTCTCCA 4_053_ GSSTPSGATGSPGSSPS GGTAGCTCTACTCCTTCTGGTGCAACTGGTTCTCCAG GFP-\_D11.ab1 ASTGTGPGASPGTSSTG GTTCTAGCCCGTCTGCATCCACTGGTACCGGTCCAGG SP TGCTTCCCCTGGCACCAGCTCTACCGGTTCTCCA LCW0404_057_ SSTGSPGSSTPS GGTGCATCTCCTGGTACTAGCTCTACTGGTTCTCCAG GFP-\_E11.ab1 GATGSPGSSPSASTGTG CTACTCCGTCTGGTGCAACCGGCTCTCCAGG P TTCTAGCCCTTCTGCATCTACCGGTACTGGTCCA LCW0404_060_ GTPGSGTASSSPGSSTPS GGTACTCCTGGCAGCGGTACCGCATCTTCCTCTCCAG GFP-\_F11.ab1 GATGSPGASPGTSSTGS CTACTCCGTCTGGTGCAACTGGTTCCCCAGG P TGCTTCTCCGGGTACCAGCTCTACCGGTTCTCCA LCW0404_062_ GSSTPSGATGSPGTPGS GGTAGCTCTACCCCGTCTGGTGCAACCGGCTCCCCA GFP-\_G11.ab1 GTASSSPGSSTPSGATG GGTACTCCTGGTAGCGGTACCGCTTCTTCTTCTCCAG SP GTAGCTCTACTCCGTCTGGTGCTACCGGCTCCCCA LCW0404_066_ GSSPSASTGTGPGSSPS GGTTCTAGCCCTTCTGCATCCACCGGTACCGGCCCAG GFP-\_H11.ab1 ASTGTGPGASPGTSSTG GTTCTAGCCCGTCTGCTTCTACCGGTACTGGTCCAGG SP TGCTTCTCCGGGTACTAGCTCTACTGGTTCTCCA LCW0404_067_ TASSSPGSSTPS GGTACCCCGGGTAGCGGTACCGCTTCTTCTTCTCCAG GFP-\_A12.ab1 GATGSPGSNPSASTGTG GTAGCTCTACTCCGTCTGGTGCTACCGGCTCTCCAGG P TTCTAACCCTTCTGCATCCACCGGTACCGGCCCA 2012/046326 File name Amino acid sequence Nucleotide sequence LCWO404_068_ GSSPSASTGTGPGSSTPS GGTTCTAGCCCTTCTGCATCTACTGGTACTGGCCCAG GFP-\_B12.ab1 GATGSPGASPGTSSTGS GTAGCTCTACTCCTTCTGGTGCTACCGGCTCTCCAGG P TGCTTCTCCGGGTACTAGCTCTACCGGTTCTCCA LCWO404_069_ GSSTPSGATGSPGASPG GGTAGCTCTACCCCTTCTGGTGCAACCGGCTCTCCAG GFP-\_C12.ab1 TSSTGSPGTPGSGTASSS CCCCGGGTACCAGCTCTACCGGTTCTCCAG P GTACTCCGGGTAGCGGTACCGCTTCTTCCTCTCCA LCWO404_070_ GSSTPSGATGSPGSSTPS GGTAGCTCTACTCCGTCTGGTGCAACCGGTTCCCCAG GFP-\_D12.ab1 GSSTPSGATGS CTACCCCTTCTGGTGCAACCGGCTCCCCAGG P TAGCTCTACCCCTTCTGGTGCAACTGGCTCTCCA LCWO404_073_ GASPGTSSTGSPGTPGS GGTGCTTCTCCTGGCACTAGCTCTACCGGTTCTCCAG GFP-\_E12.ab1 GTASSSPGSSTPSGATG GTACCCCTGGTAGCGGTACCGCATCTTCCTCTCCAGG SP TAGCTCTACTCCTTCTGGTGCTACTGGTTCCCCA LCWO404_075_ GSSTPSGATGSPGSSPS GGTAGCTCTACCCCGTCTGGTGCTACTGGCTCCCCAG F12.ab1 ASTGTGPGSSPSASTGT GTTCTAGCCCTTCTGCATCCACCGGTACCGGTCCAGG GP TTCTAGCCCGTCTGCATCTACTGGTACTGGTCCA LCWO404_080_ GASPGTSSTGSPGSSPS GGTGCTTCCCCGGGCACCAGCTCTACTGGTTCTCCAG GFP-\_G12.ab1 ASTGTGPGSSPSASTGT GTTCTAGCCCGTCTGCTTCTACTGGTACTGGTCCAGG GP TTCTAGCCCTTCTGCTTCCACTGGTACTGGTCCA LCWO404_081_ GASPGTSSTGSPGSSPS GGTGCTTCCCCGGGTACCAGCTCTACCGGTTCTCCAG GFP-\_H12.ab1 ASTGTGPGTPGSGTASS GTTCTAGCCCTTCTGCTTCTACCGGTACCGGTCCAGG SP TACCCCTGGCAGCGGTACCGCATCTTCCTCTCCA Example 5: Construction ofXTEN_AE864 XTEN_AE864 was constructed from serial dimerization ofXTEN_AE36 to AE72, 144, 288, 576 and 864. A collection ofXTEN_AE72 segments was constructed from 37 different segments of XTEN_AE36. Cultures of E. coli harboring all 37 different 36-amino acid segments were mixed and plasmid was isolated. This plasmid pool was digested with Bsal/Ncol to generate the small fragment as the insert. The same plasmid pool was digested with Bbsl/Ncol to generate the large fragment as the vector. The insert and vector fragments were d ing in a doubling of the length and the ligation mixture was transformed into ld(DE3) cells to obtain colonies of XTEN_AE72.

This library of XTEN_AE72 segments was designated LCWO406. All clones from LCWO406 were combined and dimerized again using the same process as bed above yielding library LCWO410 ofXTEN_AE144. All clones from LCWO410 were combined and dimerized again using the same s as described above yielding library LCWO414 of E288. Two es LCWO414.001 and LCWO414.002 were randomly picked from the library and ced to verify the identities. All clones from LCWO414 were combined and dimerized again using the same process as described above yielding library LCWO418 ofXTEN_AES76. We screened 96 es from library 8 for high level of GFP fluorescence. 8 isolates with right sizes of inserts by PCR and strong fluorescence were sequenced and 2 es (LCWO418.018 and LCWO418.052) were chosen for future use based on sequencing and expression data.

The specific clone pCWO432 ofXTEN_AE864 was constructed by combining LCWO418.018 of XTEN_AE576 and LCWO414.002 ofXTEN_AE288 using the same dimerization process as described above.

Example 6: Construction ofXTEN_AM144 A collection ofXTEN_AM144 segments was constructed starting from 37 ent segments of XTEN_AE36, 44 segments ofXTEN_AF36, and 44 ts ofXTEN_AG36.

Cultures of E. coli that harboring all 125 different 36-amino acid segments were mixed and plasmid was isolated. This plasmid pool was digested with BsaI/NcoI to generate the small fragment as the . The same d pool was ed with BbsI/NcoI to generate the large fragment as the vector. The insert and vector fragments were ligated resulting in a doubling of the length and the ligation mixture was transformed into BL21Gold(DE3) cells to obtain colonies of XTEN_AM72.

This library of XTEN_AM72 segments was ated LCWO461. All clones from LCWO461 were combined and dimerized again using the same process as described above yielding library LCWO462. 1512 Isolates from library LCWO462 were screened for protein expression. Individual colonies were transferred into 96 well plates and cultured overnight as starter cultures. These starter cultures were diluted into fresh autoinduction medium and cultured for 20-3 Oh. Expression was measured using a fluorescence plate reader with excitation at 395 nm and emission at 510 nm. 192 isolates showed high level expression and were submitted for DNA sequencing. Most clones in library LCWO462 showed good sion and similar physicochemical properties suggesting that most ations of XTEN_AM36 segments yield useful XTEN sequences. Thirty isolates from LCWO462 were chosen as a preferred collection of XTEN_AM144 segments for the construction of unctional ns that contain multiple XTEN segments. The file names of the nucleotide and amino acid constructs and the sequences for these segments are listed in Table 17.

Table 17: DNA and amino acid seguences for AM144 segments [SEQ ID NOS 529-594, res ectivel in order of a earance Clone Sequence Trimmed n Sequence _r1 GGTACCCCGGGCAGCGGTACCGCATCTTCCTCTCCAGGTAGC GTPGSGTASSSPGS TCTACCCCGTCTGGTGCTACCGGTTCCCCAGGTAGCTCTACCC STPSGATGSPGSSTP GTGCAACCGGCTCCCCAGGTAGCCCGGCTGGCTCTC SGATGSPGSPAGSP CTACCTCTACTGAGGAAGGTACTTCTGAAAGCGCTACTCCTG TSTEEGTSESATPES AGTCTGGTCCAGGTACCTCTACTGAACCGTCCGAAGGTAGCG GPGTSTEPSEGSAP CTCCAGGTTCTAGCCCTTCTGCATCCACCGGTACCGGCCCAGG GSSPSASTGTGPGS TTCTAGCCCGTCTGCTTCTACCGGTACTGGTCCAGGTGCTTCT GTGPGASP CCGGGTACTAGCTCTACTGGTTCTCCAGGTACCTCTACCGAAC SPGTSTEPS CGTCCGAGGGTAGCGCACCAGGTACCTCTACTGAACCGTCTG EGSAPGTSTEPSEG AGGGTAGCGCTCCAGGTAGCGAACCGGCAACCTCCGGTTCTG SAPGSEPATSGSETP AAACTCCA _r5 GGTTCTACCAGCGAATCCCCTTCTGGCACTGCACCAGGTTCTA GSTSESPSGTAPGST CTAGCGAATCCCCTTCTGGTACCGCACCAGGTACTTCTCCGAG SESPSGTAPGTSPSG CGGCGAATCTTCTACTGCTCCAGGTACCTCTACTGAACCTTCC ESSTAPGTSTEPSEG GAAGGCAGCGCTCCAGGTACCTCTACCGAACCGTCCGAGGGC SAPGTSTEPSEGSAP AGCGCACCAGGTACTTCTGAAAGCGCAACCCCTGAATCCGGT GTSESATPESGPGA CCAGGTGCATCTCCTGGTACCAGCTCTACCGGTTCTCCAGGTA SPGTSSTGSPGSSTP GCTCTACTCCTTCTGGTGCTACTGGCTCTCCAGGTGCTTCCCC SGATGSPGASPGTS GGGTACCAGCTCTACCGGTTCTCCAGGTTCTACTAGCGAATCT STGSPGSTSESPSGT CCTTCTGGCACTGCACCAGGTTCTACCAGCGAATCTCCGTCTG APGSTSESPSGTAP GCACTGCACCAGGTACCTCTACCCCTGAAAGCGGTTCCGCTT GTSTPESGSASP CTCCA LCW462_r9 GGTACTTCTACCGAACCTTCCGAGGGCAGCGCACCAGGTACT GTSTEPSEGSAPGT TCTGAAAGCGCTACCCCTGAGTCCGGCCCAGGTACTTCTGAA SESATPESGPGTSES AGCGCTACTCCTGAATCCGGTCCAGGTACCTCTACTGAACCTT ATPESGPGTSTEPSE Clone Sequence Trimmed Protein Sequence CTGAGGGCAGCGCTCCAGGTACTTCTGAAAGCGCTACCCCGG GSAPGTSESATPES AGTCCGGTCCAGGTACTTCTACTGAACCGTCCGAAGGTAGCG GPGTSTEPSEGSAP CACCAGGTACTTCTACTGAACCTTCCGAAGGTAGCGCTCCAG GTSTEPSEGSAPGS GTAGCGAACCTGCTACTTCTGGTTCTGAAACCCCAGGTAGCC SETPGSPA CGGCTGGCTCTCCGACCTCCACCGAGGAAGGTGCTTCTCCTG GSPTSTEEGASPGT GCACCAGCTCTACTGGTTCTCCAGGTTCTAGCCCTTCTGCTTC SSTGSPGSSPSASTG TACCGGTACTGGTCCAGGTTCTAGCCCTTCTGCATCCACTGGT TGPGSSPSASTGTG ACTGGTCCA P LCW462_r10 GGTAGCGAACCGGCAACCTCTGGCTCTGAAACCCCAGGTACC GSEPATSGSETPGT TCTGAAAGCGCTACTCCGGAATCTGGTCCAGGTACTTCTGAA SESATPESGPGTSES AGCGCTACTCCGGAATCCGGTCCAGGTTCTACCAGCGAATCT ATPESGPGSTSESPS CCTTCTGGCACCGCTCCAGGTTCTACTAGCGAATCCCCGTCTG GTAPGSTSESPSGT GTACCGCACCAGGTACTTCTCCTAGCGGCGAATCTTCTACCGC APGTSPSGESSTAP ACCAGGTGCATCTCCGGGTACTAGCTCTACCGGTTCTCCAGGT GASPGTSSTGSPGS TCTAGCCCTTCTGCTTCCACTGGTACCGGCCCAGGTAGCTCTA SPSASTGTGPGSSTP CTGGTGCTACTGGTTCCCCAGGTAGCTCTACTCCGTC SGATGSPGSSTPSG AACCGGTTCCCCAGGTAGCTCTACTCCTTCTGGTGCT ATGSPGSSTPSGAT ACTGGCTCCCCAGGTGCATCCCCTGGCACCAGCTCTACCGGTT GSPGASPGTSSTGS CTCCA P _r15 GGTGCTTCTCCGGGCACCAGCTCTACTGGTTCTCCAGGTTCTA GASPGTSSTGSPGS GCCCTTCTGCATCCACCGGTACCGGTCCAGGTAGCTCTACCCC SPSASTGTGPGSSTP TTCTGGTGCAACCGGCTCTCCAGGTACTTCTGAAAGCGCTACC SGATGSPGTSESAT CCGGAATCTGGCCCAGGTAGCGAACCGGCTACTTCTGGTTCT SEPATSGSE GAAACCCCAGGTAGCGAACCGGCTACCTCCGGTTCTGAAACT TPGSEPATSGSETP CCAGGTACTTCTGAAAGCGCTACTCCGGAGTCCGGTCCAGGT GTSESATPESGPGT ACCTCTACCGAACCGTCCGAAGGCAGCGCTCCAGGTACTTCT GSAPGTSTE ACTGAACCTTCTGAGGGTAGCGCTCCAGGTACCTCTACCGAA PSEGSAPGTSTEPSE CCGTCCGAGGGTAGCGCACCAGGTACCTCTACTGAACCGTCT STEPSEGS GAGGGTAGCGCTCCAGGTAGCGAACCGGCAACCTCCGGTTCT APGSEPATSGSETP GAAACTCCA LCW462_r16 GGTACCTCTACCGAACCTTCCGAAGGTAGCGCTCCAGGTAGC GTSTEPSEGSAPGSP CCGGCAGGTTCTCCTACTTCCACTGAGGAAGGTACTTCTACCG AGSPTSTEEGTSTEP AACCTTCTGAGGGTAGCGCACCAGGTACCTCTGAAAGCGCAA SEGSAPGTSESATP CTCCTGAGTCTGGCCCAGGTAGCGAACCTGCTACCTCCGGCT ESGPGSEPATSGSE CTGAGACTCCAGGTACCTCTGAAAGCGCAACCCCGGAATCTG TPGTSESATPESGP GTAGCCCGGCTGGCTCTCCTACCTCTACTGAGGAAG GSPAGSPTSTEEGT GTACTTCTGAAAGCGCTACTCCTGAGTCTGGTCCAGGTACCTC SESATPESGPGTSTE TACTGAACCGTCCGAAGGTAGCGCTCCAGGTAGCGAACCTGC PGSEPATS TACTTCTGGTTCTGAAACTCCAGGTACTTCTACCGAACCGTCC GSETPGTSTEPSEGS GAGGGTAGCGCTCCAGGTAGCGAACCTGCTACTTCTGGTTCT APGSEPATSGSETP GAAACTCCA LCW462_r20 GGTACTTCTACCGAACCGTCCGAAGGCAGCGCTCCAGGTACC GTSTEPSEGSAPGT TCTACTGAACCTTCCGAGGGCAGCGCTCCAGGTACCTCTACC STEPSEGSAPGTSTE GAACCTTCTGAAGGTAGCGCACCAGGTACTTCTACCGAACCG PSEGSAPGTSTEPSE TCCGAAGGCAGCGCTCCAGGTACCTCTACTGAACCTTCCGAG GSAPGTSTEPSEGS GGCAGCGCTCCAGGTACCTCTACCGAACCTTCTGAAGGTAGC APGTSTEPSEGSAP GCACCAGGTACTTCTACCGAACCTTCCGAGGGCAGCGCACCA GTSTEPSEGSAPGT GGTACTTCTGAAAGCGCTACCCCTGAGTCCGGCCCAGGTACT SESATPESGPGTSES TCTGAAAGCGCTACTCCTGAATCCGGTCCAGGTACTTCTACTG ATPESGPGTSTEPSE AACCTTCCGAAGGTAGCGCTCCAGGTAGCGAACCTGCTACTT GSAPGSEPATSGSE CTGGTTCTGAAACCCCAGGTAGCCCGGCTGGCTCTCCGACCT GSPTSTEE CCACCGAGGAA LCW462_r23 GGTACTTCTACCGAACCGTCCGAGGGCAGCGCTCCAGGTACT SEGSAPGT TCTACTGAACCTTCTGAAGGCAGCGCTCCAGGTACTTCTACTG STEPSEGSAPGTSTE AACCTTCCGAAGGTAGCGCACCAGGTTCTACCAGCGAATCCC PSEGSAPGSTSESPS CTTCTGGTACTGCTCCAGGTTCTACCAGCGAATCCCCTTCTGG GTAPGSTSESPSGT CACCGCACCAGGTACTTCTACCCCTGAAAGCGGCTCCGCTTCT APGTSTPESGSASP CCAGGTAGCGAACCTGCAACCTCTGGCTCTGAAACCCCAGGT GSEPATSGSETPGT ACCTCTGAAAGCGCTACTCCTGAATCTGGCCCAGGTACTTCTA ESGPGTSTE CTGAACCGTCCGAGGGCAGCGCACCAGGTACTTCTACTGAAC PSEGSAPGTSTEPSE CGTCTGAAGGTAGCGCACCAGGTACTTCTGAAAGCGCAACCC GSAPGTSESATPES Clone Sequence Trimmed n Sequence CGGAATCCGGCCCAGGTACCTCTGAAAGCGCAACCCCGGAGT GPGTSESATPESGP CCGGCCCA LCW462_r24 GGTAGCTCTACCCCTTCTGGTGCTACCGGCTCTCCAGGTTCTA GSSTPSGATGSPGS GCCCGTCTGCTTCTACCGGTACCGGTCCAGGTAGCTCTACCCC SPSASTGTGPGSSTP TTCTGGTGCTACTGGTTCTCCAGGTAGCCCTGCTGGCTCTCCG SGATGSPGSPAGSP ACTTCTACTGAGGAAGGTAGCCCGGCTGGTTCTCCGACTTCTA SPAGSPTST CTGAGGAAGGTACTTCTACCGAACCTTCCGAAGGTAGCGCTC EEGTSTEPSEGSAP CAGGTGCTTCCCCGGGCACTAGCTCTACCGGTTCTCCAGGTTC GASPGTSSTGSPGS TAGCCCTTCTGCATCTACTGGTACTGGCCCAGGTACTCCGGGC SPSASTGTGPGTPG AGCGGTACTGCTTCTTCCTCTCCAGGTTCTACTAGCTCTACTG SGTASSSPGSTSSTA CTGAATCTCCTGGCCCAGGTACTTCTCCTAGCGGTGAATCTTC ESPGPGTSPSGESST TACCGCTCCAGGTACCTCTACTCCGGAAAGCGGTTCTGCATCT APGTSTPESGSASP LCW462_r27 GGTACCTCTACTGAACCTTCTGAGGGCAGCGCTCCAGGTACT GTSTEPSEGSAPGT TCTGAAAGCGCTACCCCGGAGTCCGGTCCAGGTACTTCTACT SESATPESGPGTSTE GAACCGTCCGAAGGTAGCGCACCAGGTACTTCTACTGAACCG PSEGSAPGTSTEPSE TCTGAAGGTAGCGCACCAGGTACTTCTGAAAGCGCAACCCCG GSAPGTSESATPES GAATCCGGCCCAGGTACCTCTGAAAGCGCAACCCCGGAGTCC SATPESGP GGCCCAGGTACTCCTGGCAGCGGTACCGCTTCTTCTTCTCCAG GTPGSGTASSSPGA CTCCTGGTACTAGCTCTACTGGTTCTCCAGGTGCTTC SPGTSSTGSPGASP TCCGGGCACTAGCTCTACTGGTTCTCCAGGTAGCCCTGCTGGC GTSSTGSPGSPAGS TCTCCGACTTCTACTGAGGAAGGTAGCCCGGCTGGTTCTCCG PTSTEEGSPAGSPTS ACTTCTACTGAGGAAGGTACTTCTACCGAACCTTCCGAAGGT TEEGTSTEPSEGSAP AGCGCTCCA LCW462_r28 GGTAGCCCAGCAGGCTCTCCGACTTCCACTGAGGAAGGTACT GSPAGSPTSTEEGT TCTACTGAACCTTCCGAAGGCAGCGCACCAGGTACCTCTACT STEPSEGSAPGTSTE GAACCTTCTGAGGGCAGCGCTCCAGGTACCTCTACCGAACCG PSEGSAPGTSTEPSE TCTGAAGGTAGCGCACCAGGTACCTCTGAAAGCGCAACTCCT GSAPGTSESATPES GAGTCCGGTCCAGGTACTTCTGAAAGCGCAACCCCGGAGTCT GPGTSESATPESGP GGTACCCCGGGTAGCGGTACTGCTTCTTCCTCTCCAG GTPGSGTASSSPGS GTAGCTCTACCCCTTCTGGTGCAACCGGCTCTCCAGGTGCTTC STPSGATGSPGASP TCCGGGCACCAGCTCTACCGGTTCTCCAGGTACCTCTACTGAA GTSSTGSPGTSTEPS CCTTCTGAGGGCAGCGCTCCAGGTACTTCTGAAAGCGCTACC EGSAPGTSESATPE CCGGAGTCCGGTCCAGGTACTTCTACTGAACCGTCCGAAGGT TEPSEGSAP AGCGCACCA LCW462_r3 8 GGTAGCGAACCGGCAACCTCCGGCTCTGAAACTCCAGGTACT GSEPATSGSETPGT TCTGAAAGCGCTACTCCGGAATCCGGCCCAGGTAGCGAACCG ESGPGSEPA GCTACTTCCGGCTCTGAAACCCCAGGTAGCTCTACCCCGTCTG TSGSETPGSSTPSGA GTGCAACCGGCTCCCCAGGTACTCCTGGTAGCGGTACCGCTT TGSPGTPGSGTASS CTTCTTCTCCAGGTAGCTCTACTCCGTCTGGTGCTACCGGCTC SPGSSTPSGATGSP CCCAGGTGCATCTCCTGGTACCAGCTCTACCGGTTCTCCAGGT GASPGTSSTGSPGS AGCTCTACTCCTTCTGGTGCTACTGGCTCTCCAGGTGCTTCCC STPSGATGSPGASP CGGGTACCAGCTCTACCGGTTCTCCAGGTAGCGAACCTGCTA SPGSEPATS CTTCTGGTTCTGAAACTCCAGGTACTTCTACCGAACCGTCCGA GSETPGTSTEPSEGS GGGTAGCGCTCCAGGTAGCGAACCTGCTACTTCTGGTTCTGA APGSEPATSGSETP AACTCCA LCW462_r39 GGTACCTCTACTGAACCTTCCGAAGGCAGCGCTCCAGGTACC GTSTEPSEGSAPGT TCTACCGAACCGTCCGAGGGCAGCGCACCAGGTACTTCTGAA STEPSEGSAPGTSES AGCGCAACCCCTGAATCCGGTCCAGGTAGCCCTGCTGGCTCT ATPESGPGSPAGSP CCGACTTCTACTGAGGAAGGTAGCCCGGCTGGTTCTCCGACT TSTEEGSPAGSPTST GAGGAAGGTACTTCTACCGAACCTTCCGAAGGTAGC EEGTSTEPSEGSAP GCTCCAGGTAGCCCGGCTGGTTCTCCGACTTCCACCGAGGAA GSPAGSPTSTEEGT GGTACCTCTACTGAACCTTCTGAGGGTAGCGCTCCAGGTACC STEPSEGSAPGTSTE TCTACTGAACCTTCCGAAGGCAGCGCTCCAGGTGCTTCCCCG PSEGSAPGASPGTS AGCTCTACTGGTTCTCCAGGTTCTAGCCCGTCTGCTT STGSPGSSPSASTGT CTACTGGTACTGGTCCAGGTTCTAGCCCTTCTGCTTCCACTGG SASTGTGP TACTGGTCCA LCW462_r41 GGTAGCTCTACCCCGTCTGGTGCTACCGGTTCCCCAGGTGCTT GSSTPSGATGSPGA CTCCTGGTACTAGCTCTACCGGTTCTCCAGGTAGCTCTACCCC SPGTSSTGSPGSSTP GTCTGGTGCTACTGGCTCTCCAGGTAGCCCTGCTGGCTCTCCA PGSPAGSP ACCTCCACCGAAGAAGGTACCTCTGAAAGCGCAACCCCTGAA TSTEEGTSESATPES Clone ce Trimmed Protein Sequence TCCGGCCCAGGTAGCGAACCGGCAACCTCCGGTTCTGAAACC GPGSEPATSGSETP CCAGGTGCATCTCCTGGTACTAGCTCTACTGGTTCTCCAGGTA GASPGTSSTGSPGS GCTCTACTCCGTCTGGTGCAACCGGCTCTCCAGGTTCTAGCCC STPSGATGSPGSSPS TTCTGCATCTACCGGTACTGGTCCAGGTTCTACCAGCGAATCC ASTGTGPGSTSESPS CCTTCTGGTACTGCTCCAGGTTCTACCAGCGAATCCCCTTCTG GTAPGSTSESPSGT GCACCGCACCAGGTACTTCTACCCCTGAAAGCGGCTCCGCTT APGTSTPESGSASP CTCCA LCW462_r42 GGTTCTACCAGCGAATCTCCTTCTGGCACCGCTCCAGGTTCTA GSTSESPSGTAPGST CTAGCGAATCCCCGTCTGGTACCGCACCAGGTACTTCTCCTAG SESPSGTAPGTSPSG ATCTTCTACCGCACCAGGTACCTCTGAAAGCGCTAC ESSTAPGTSESATPE TCCGGAGTCTGGCCCAGGTACCTCTACTGAACCGTCTGAGGG SGPGTSTEPSEGSAP TAGCGCTCCAGGTACTTCTACTGAACCGTCCGAAGGTAGCGC GTSTEPSEGSAPGT ACCAGGTACCTCTACTGAACCTTCTGAGGGCAGCGCTCCAGG STEPSEGSAPGTSES TACTTCTGAAAGCGCTACCCCGGAGTCCGGTCCAGGTACTTCT ATPESGPGTSTEPSE ACTGAACCGTCCGAAGGTAGCGCACCAGGTAGCTCTACCCCG GSAPGSSTPSGATG TCTGGTGCTACCGGTTCCCCAGGTGCTTCTCCTGGTACTAGCT SPGASPGTSSTGSP CTACCGGTTCTCCAGGTAGCTCTACCCCGTCTGGTGCTACTGG GSSTPSGATGSP CTCTCCA _r43 ACTAGCTCTACTGCAGAATCTCCGGGCCCAGGTACCT GSTSSTAESPGPGTS CTCCTAGCGGTGAATCTTCTACCGCTCCAGGTACTTCTCCGAG PSGESSTAPGTSPSG CGGTGAATCTTCTACCGCTCCAGGTTCTACTAGCTCTACCGCT GSTSSTAES GAATCTCCGGGTCCAGGTTCTACCAGCTCTACTGCAGAATCTC PGPGSTSSTAESPGP CTGGCCCAGGTACTTCTACTCCGGAAAGCGGTTCCGCTTCTCC GTSTPESGSASPGTS AGGTACTTCTCCTAGCGGTGAATCTTCTACCGCTCCAGGTTCT PSGESSTAPGSTSST ACCAGCTCTACTGCTGAATCTCCTGGCCCAGGTACTTCTACCC GTSTPESGS CGGAAAGCGGCTCCGCTTCTCCAGGTTCTACCAGCTCTACCG ASPGSTSSTAESPGP CTGAATCTCCTGGCCCAGGTTCTACTAGCGAATCTCCGTCTGG GSTSESPSGTAPGTS CACCGCACCAGGTACTTCCCCTAGCGGTGAATCTTCTACTGCA PSGESSTAP LCW462_r45 GGTACCTCTACTCCGGAAAGCGGTTCCGCATCTCCAGGTTCTA GTSTPESGSASPGST CCAGCGAATCCCCGTCTGGCACCGCACCAGGTTCTACTAGCT SESPSGTAPGSTSST CTACTGCTGAATCTCCGGGCCCAGGTACCTCTACTGAACCTTC AESPGPGTSTEPSE CGAAGGCAGCGCTCCAGGTACCTCTACCGAACCGTCCGAGGG GSAPGTSTEPSEGS CAGCGCACCAGGTACTTCTGAAAGCGCAACCCCTGAATCCGG APGTSESATPESGP TCCAGGTACCTCTGAAAGCGCTACTCCGGAGTCTGGCCCAGG GTSESATPESGPGT TACCTCTACTGAACCGTCTGAGGGTAGCGCTCCAGGTACTTCT STEPSEGSAPGTSTE ACTGAACCGTCCGAAGGTAGCGCACCAGGTACTTCTGAAAGC PGTSESATP GCTACTCCGGAGTCCGGTCCAGGTACCTCTACCGAACCGTCC ESGPGTSTEPSEGS GAAGGCAGCGCTCCAGGTACTTCTACTGAACCTTCTGAGGGT APGTSTEPSEGSAP AGCGCTCCC _r47 TCTACCGAACCGTCCGAGGGTAGCGCACCAGGTACC GTSTEPSEGSAPGT TCTACTGAACCGTCTGAGGGTAGCGCTCCAGGTAGCGAACCG STEPSEGSAPGSEPA GCAACCTCCGGTTCTGAAACTCCAGGTACTTCTACTGAACCGT TSGSETPGTSTEPSE CTGAAGGTAGCGCACCAGGTACTTCTGAAAGCGCAACCCCGG GSAPGTSESATPES AATCCGGCCCAGGTACCTCTGAAAGCGCAACCCCGGAGTCCG GPGTSESATPESGP GCCCAGGTGCATCTCCGGGTACTAGCTCTACCGGTTCTCCAG GASPGTSSTGSPGS GTTCTAGCCCTTCTGCTTCCACTGGTACCGGCCCAGGTAGCTC GTGPGSSTP TACCCCGTCTGGTGCTACTGGTTCCCCAGGTAGCTCTACTCCG PGSSTPSG TCTGGTGCAACCGGTTCCCCAGGTAGCTCTACTCCTTCTGGTG ATGSPGSSTPSGAT CTACTGGCTCCCCAGGTGCATCCCCTGGCACCAGCTCTACCG GSPGASPGTSSTGS GTTCTCCA P LCW462_r54 GGTAGCGAACCGGCAACCTCTGGCTCTGAAACTCCAGGTAGC GSEPATSGSETPGS GAACCTGCAACCTCCGGCTCTGAAACCCCAGGTACTTCTACT EPATSGSETPGTSTE GAACCTTCTGAGGGCAGCGCACCAGGTAGCGAACCTGCAACC PSEGSAPGSEPATS TCTGGCTCTGAAACCCCAGGTACCTCTGAAAGCGCTACTCCT GSETPGTSESATPES GAATCTGGCCCAGGTACTTCTACTGAACCGTCCGAGGGCAGC GPGTSTEPSEGSAP GCACCAGGTAGCTCTACTCCGTCTGGTGCTACCGGCTCTCCAG GSSTPSGATGSPGS GTAGCTCTACCCCTTCTGGTGCAACCGGCTCCCCAGGTGCTTC STPSGATGSPGASP TCCGGGTACCAGCTCTACTGGTTCTCCAGGTAGCTCTACCCCG GTSSTGSPGSSTPSG TCTGGTGCTACCGGTTCCCCAGGTGCTTCTCCTGGTACTAGCT ATGSPGASPGTSST CTACCGGTTCTCCAGGTAGCTCTACCCCGTCTGGTGCTACTGG GSPGSSTPSGATGS Clone Sequence Trimmed Protein Sequence CTCTCCA P LCW462_r55 GGTACTTCTACCGAACCGTCCGAGGGCAGCGCTCCAGGTACT GTSTEPSEGSAPGT TCTACTGAACCTTCTGAAGGCAGCGCTCCAGGTACTTCTACTG GSAPGTSTE CCGAAGGTAGCGCACCAGGTACTTCTGAAAGCGCTA PSEGSAPGTSESATP CTCCGGAGTCCGGTCCAGGTACCTCTACCGAACCGTCCGAAG ESGPGTSTEPSEGS GCAGCGCTCCAGGTACTTCTACTGAACCTTCTGAGGGTAGCG APGTSTEPSEGSAP CTCCAGGTTCTACTAGCGAATCTCCGTCTGGCACTGCTCCAGG PSGTAPGTS TCCTAGCGGTGAATCTTCTACCGCTCCAGGTACTTCC PSGESSTAPGTSPSG CCTAGCGGCGAATCTTCTACCGCTCCAGGTAGCCCGGCTGGC ESSTAPGSPAGSPTS TCTCCTACCTCTACTGAGGAAGGTACTTCTGAAAGCGCTACTC TEEGTSESATPESGP CTGAGTCTGGTCCAGGTACCTCTACTGAACCGTCCGAAGGTA GTSTEPSEGSAP GCGCTCCA LCW462_r57 GGTACTTCTACTGAACCTTCCGAAGGTAGCGCTCCAGGTAGC GTSTEPSEGSAPGS GAACCTGCTACTTCTGGTTCTGAAACCCCAGGTAGCCCGGCT EPATSGSETPGSPA CCGACCTCCACCGAGGAAGGTAGCCCGGCAGGCTCT GSPTSTEEGSPAGSP CCGACCTCTACTGAGGAAGGTACTTCTGAAAGCGCAACCCCG TSESATPES GAGTCCGGCCCAGGTACCTCTACCGAACCGTCTGAGGGCAGC GPGTSTEPSEGSAP GCACCAGGTACCTCTACTGAACCTTCCGAAGGCAGCGCTCCA GTSTEPSEGSAPGT GGTACCTCTACCGAACCGTCCGAGGGCAGCGCACCAGGTACT STEPSEGSAPGTSES TCTGAAAGCGCAACCCCTGAATCCGGTCCAGGTAGCTCTACT ATPESGPGSSTPSG CCGTCTGGTGCAACCGGCTCCCCAGGTTCTAGCCCGTCTGCTT ATGSPGSSPSASTG CCACTGGTACTGGCCCAGGTGCTTCCCCGGGCACCAGCTCTA TGPGASPGTSSTGS CTGGTTCTCCA P LCW462_r61 GGTAGCGAACCGGCTACTTCCGGCTCTGAGACTCCAGGTAGC GSEPATSGSETPGSP CCTGCTGGCTCTCCGACCTCTACCGAAGAAGGTACCTCTGAA AGSPTSTEEGTSES AGCGCTACCCCTGAGTCTGGCCCAGGTACCTCTACTGAACCTT PGTSTEPSE CCGAAGGCAGCGCTCCAGGTACCTCTACCGAACCGTCCGAGG GSAPGTSTEPSEGS GCAGCGCACCAGGTACTTCTGAAAGCGCAACCCCTGAATCCG APGTSESATPESGP GTCCAGGTACCTCTACTCCGGAAAGCGGTTCCGCATCTCCAG GTSTPESGSASPGST GTTCTACCAGCGAATCCCCGTCTGGCACCGCACCAGGTTCTA TAPGSTSST CTAGCTCTACTGCTGAATCTCCGGGCCCAGGTACTTCTGAAA AESPGPGTSESATP GCGCTACTCCGGAGTCCGGTCCAGGTACCTCTACCGAACCGT STEPSEGS CCGAAGGCAGCGCTCCAGGTACTTCTACTGAACCTTCTGAGG APGTSTEPSEGSAP GTAGCGCTCCA LCW462_r64 GGTACTTCTACCGAACCGTCCGAGGGCAGCGCTCCAGGTACT GTSTEPSEGSAPGT TCTACTGAACCTTCTGAAGGCAGCGCTCCAGGTACTTCTACTG STEPSEGSAPGTSTE AACCTTCCGAAGGTAGCGCACCAGGTACCTCTACCGAACCGT PSEGSAPGTSTEPSE CTGAAGGTAGCGCACCAGGTACCTCTGAAAGCGCAACTCCTG GSAPGTSESATPES AGTCCGGTCCAGGTACTTCTGAAAGCGCAACCCCGGAGTCTG GPGTSESATPESGP GCCCAGGTACTCCTGGCAGCGGTACCGCATCTTCCTCTCCAG TASSSPGS GTAGCTCTACTCCGTCTGGTGCAACTGGTTCCCCAGGTGCTTC STPSGATGSPGASP TCCGGGTACCAGCTCTACCGGTTCTCCAGGTTCCACCAGCTCT GTSSTGSPGSTSSTA ACTGCTGAATCTCCTGGTCCAGGTACCTCTCCTAGCGGTGAAT ESPGPGTSPSGESST CTTCTACTGCTCCAGGTACTTCTACTCCTGAAAGCGGCTCTGC APGTSTPESGSASP TTCTCCA LCW462_r67 GGTAGCCCGGCAGGCTCTCCGACCTCTACTGAGGAAGGTACT GSPAGSPTSTEEGT TCTGAAAGCGCAACCCCGGAGTCCGGCCCAGGTACCTCTACC SESATPESGPGTSTE GAACCGTCTGAGGGCAGCGCACCAGGTACTTCTGAAAGCGCA PSEGSAPGTSESATP ACCCCTGAATCCGGTCCAGGTAGCGAACCGGCTACTTCTGGC ESGPGSEPATSGSE TCTGAGACTCCAGGTACTTCTACCGAACCGTCCGAAGGTAGC TPGTSTEPSEGSAP GCACCAGGTAGCCCGGCTGGTTCTCCGACTTCCACCGAGGAA GSPAGSPTSTEEGT GGTACCTCTACTGAACCTTCTGAGGGTAGCGCTCCAGGTACC STEPSEGSAPGTSTE TCTACTGAACCTTCCGAAGGCAGCGCTCCAGGTACTTCTACC PSEGSAPGTSTEPSE TCCGAGGGCAGCGCTCCAGGTACTTCTACTGAACCT GSAPGTSTEPSEGS TCTGAAGGCAGCGCTCCAGGTACTTCTACTGAACCTTCCGAA APGTSTEPSEGSAP GGTAGCGCACCA LCW462_r69 GGTACTTCTCCGAGCGGTGAATCTTCTACCGCACCAGGTTCTA GTSPSGESSTAPGST CTAGCTCTACCGCTGAATCTCCGGGCCCAGGTACTTCTCCGAG SSTAESPGPGTSPSG CGGTGAATCTTCTACTGCTCCAGGTACCTCTGAAAGCGCTACT GTSESATPE CCGGAGTCTGGCCCAGGTACCTCTACTGAACCGTCTGAGGGT SGPGTSTEPSEGSAP AGCGCTCCAGGTACTTCTACTGAACCGTCCGAAGGTAGCGCA GTSTEPSEGSAPGSS Clone Sequence Trimmed n Sequence CCAGGTTCTAGCCCTTCTGCATCTACTGGTACTGGCCCAGGTA PSASTGTGPGSSTPS GCTCTACTCCTTCTGGTGCTACCGGCTCTCCAGGTGCTTCTCC GATGSPGASPGTSS GGGTACTAGCTCTACCGGTTCTCCAGGTACTTCTACTCCGGAA TGSPGTSTPESGSAS AGCGGTTCCGCATCTCCAGGTACTTCTCCTAGCGGTGAATCTT PGTSPSGESSTAPGT CTACTGCTCCAGGTACCTCTCCTAGCGGCGAATCTTCTACTGC SPSGESSTAP TCCA LCW462_r70 GGTACCTCTGAAAGCGCTACTCCGGAGTCTGGCCCAGGTACC GTSESATPESGPGT TCTACTGAACCGTCTGAGGGTAGCGCTCCAGGTACTTCTACTG STEPSEGSAPGTSTE AACCGTCCGAAGGTAGCGCACCAGGTAGCCCTGCTGGCTCTC PSEGSAPGSPAGSP CGACTTCTACTGAGGAAGGTAGCCCGGCTGGTTCTCCGACTT TSTEEGSPAGSPTST AGGAAGGTACTTCTACCGAACCTTCCGAAGGTAGCG EEGTSTEPSEGSAP CTCCAGGTTCTAGCCCTTCTGCTTCCACCGGTACTGGCCCAGG STGTGPGS TAGCTCTACCCCTTCTGGTGCTACCGGCTCCCCAGGTAGCTCT STPSGATGSPGSSTP ACTCCTTCTGGTGCAACTGGCTCTCCAGGTAGCGAACCGGCA SGATGSPGSEPATS ACTTCCGGCTCTGAAACCCCAGGTACTTCTGAAAGCGCTACT GSETPGTSESATPES CCTGAGTCTGGCCCAGGTAGCGAACCTGCTACCTCTGGCTCT GPGSEPATSGSETP GAAACCCCA LCW462_r72 GGTACTTCTACCGAACCGTCCGAAGGCAGCGCTCCAGGTACC GTSTEPSEGSAPGT TCTACTGAACCTTCCGAGGGCAGCGCTCCAGGTACCTCTACC STEPSEGSAPGTSTE TCTGAAGGTAGCGCACCAGGTAGCTCTACCCCGTCT PSEGSAPGSSTPSG GGTGCTACCGGTTCCCCAGGTGCTTCTCCTGGTACTAGCTCTA ATGSPGASPGTSST CTCCAGGTAGCTCTACCCCGTCTGGTGCTACTGGCTC GSPGSSTPSGATGS TCCAGGTACTTCTGAAAGCGCAACCCCTGAATCCGGTCCAGG PGTSESATPESGPGS TAGCGAACCGGCTACTTCTGGCTCTGAGACTCCAGGTACTTCT EPATSGSETPGTSTE ACCGAACCGTCCGAAGGTAGCGCACCAGGTTCTACTAGCGAA PSEGSAPGSTSESPS TCTCCTTCTGGCACTGCACCAGGTTCTACCAGCGAATCTCCGT GTAPGSTSESPSGT CTGGCACTGCACCAGGTACCTCTACCCCTGAAAGCGGTTCCG APGTSTPESGSASP CTTCTCCA LCW462_r73 GGTACCTCTACTCCTGAAAGCGGTTCTGCATCTCCAGGTTCCA GTSTPESGSASPGST CTAGCTCTACCGCAGAATCTCCGGGCCCAGGTTCTACTAGCTC SSTAESPGPGSTSST TACTGCTGAATCTCCTGGCCCAGGTTCTAGCCCTTCTGCATCT AESPGPGSSPSAST ACTGGTACTGGCCCAGGTAGCTCTACTCCTTCTGGTGCTACCG GTGPGSSTPSGATG CAGGTGCTTCTCCGGGTACTAGCTCTACCGGTTCTCC GTSSTGSP AGGTAGCGAACCGGCAACCTCCGGCTCTGAAACCCCAGGTAC GSEPATSGSETPGT CTCTGAAAGCGCTACTCCTGAATCCGGCCCAGGTAGCCCGGC SESATPESGPGSPA AGGTTCTCCGACTTCCACTGAGGAAGGTTCTACTAGCGAATC GSPTSTEEGSTSESP TCCTTCTGGCACTGCACCAGGTTCTACCAGCGAATCTCCGTCT SGTAPGSTSESPSGT GGCACTGCACCAGGTACCTCTACCCCTGAAAGCGGTTCCGCT APGTSTPESGSASP TCTCCC LCW462_r78 GGTAGCCCGGCTGGCTCTCCTACCTCTACTGAGGAAGGTACT GSPAGSPTSTEEGT TCTGAAAGCGCTACTCCTGAGTCTGGTCCAGGTACCTCTACTG SESATPESGPGTSTE AACCGTCCGAAGGTAGCGCTCCAGGTTCTACCAGCGAATCTC PSEGSAPGSTSESPS CTTCTGGCACCGCTCCAGGTTCTACTAGCGAATCCCCGTCTGG GTAPGSTSESPSGT ACCAGGTACTTCTCCTAGCGGCGAATCTTCTACCGCA APGTSPSGESSTAP ACCTCTACCGAACCTTCCGAAGGTAGCGCTCCAGGT GTSTEPSEGSAPGSP AGCCCGGCAGGTTCTCCTACTTCCACTGAGGAAGGTACTTCT AGSPTSTEEGTSTEP ACCGAACCTTCTGAGGGTAGCGCACCAGGTAGCGAACCTGCA SEGSAPGSEPATSG GGCTCTGAAACCCCAGGTACCTCTGAAAGCGCTACT SETPGTSESATPESG CCTGAATCTGGCCCAGGTACTTCTACTGAACCGTCCGAGGGC PGTSTEPSEGSAP LCW462_r79 GGTACCTCTACCGAACCTTCCGAAGGTAGCGCTCCAGGTAGC GTSTEPSEGSAPGSP CCGGCAGGTTCTCCTACTTCCACTGAGGAAGGTACTTCTACCG AGSPTSTEEGTSTEP AACCTTCTGAGGGTAGCGCACCAGGTACCTCCCCTAGCGGCG SEGSAPGTSPSGESS AATCTTCTACTGCTCCAGGTACCTCTCCTAGCGGCGAATCTTC TAPGTSPSGESSTAP TACCGCTCCAGGTACCTCCCCTAGCGGTGAATCTTCTACCGCA GTSPSGESSTAPGST CCAGGTTCTACCAGCGAATCCCCTTCTGGTACTGCTCCAGGTT SESPSGTAPGSTSES CTACCAGCGAATCCCCTTCTGGCACCGCACCAGGTACTTCTAC PSGTAPGTSTPESGS CCCTGAAAGCGGCTCCGCTTCTCCAGGTAGCGAACCTGCAAC ASPGSEPATSGSETP CTCTGAAACCCCAGGTACCTCTGAAAGCGCTACTCCT GTSESATPESGPGT GAATCTGGCCCAGGTACTTCTACTGAACCGTCCGAGGGCAGC STEPSEGSAP GCACCA Clone Sequence Trimmed Protein Sequence LCW462_r87 GGTAGCGAACCGGCAACCTCTGGCTCTGAAACCCCAGGTACC GSEPATSGSETPGT AGCGCTACTCCGGAATCTGGTCCAGGTACTTCTGAA SESATPESGPGTSES AGCGCTACTCCGGAATCCGGTCCAGGTACTTCTCCGAGCGGT ATPESGPGTSPSGES GAATCTTCTACCGCACCAGGTTCTACTAGCTCTACCGCTGAAT STAPGSTSSTAESPG GCCCAGGTACTTCTCCGAGCGGTGAATCTTCTACTGC PGTSPSGESSTAPGS TCCAGGTTCTACTAGCGAATCCCCGTCTGGTACTGCTCCAGGT TSESPSGTAPGTSPS ACTTCCCCTAGCGGTGAATCTTCTACTGCTCCAGGTTCTACCA GESSTAPGSTSSTA GCTCTACCGCAGAATCTCCGGGTCCAGGTAGCTCTACTCCGTC ESPGPGSSTPSGAT TGGTGCAACCGGTTCCCCAGGTAGCTCTACCCCTTCTGGTGCA GSPGSSTPSGATGS ACCGGCTCCCCAGGTAGCTCTACCCCTTCTGGTGCAAACTGG PGSSTPSGANWLS CTCTCC LCW462_r88 GGTAGCCCTGCTGGCTCTCCGACTTCTACTGAGGAAGGTAGC GSPAGSPTSTEEGSP CCGGCTGGTTCTCCGACTTCTACTGAGGAAGGTACTTCTACCG AGSPTSTEEGTSTEP AACCTTCCGAAGGTAGCGCTCCAGGTACCTCTACTGAACCTT SEGSAPGTSTEPSE CCGAAGGCAGCGCTCCAGGTACCTCTACCGAACCGTCCGAGG STEPSEGS GCAGCGCACCAGGTACTTCTGAAAGCGCAACCCCTGAATCCG APGTSESATPESGP GTCCAGGTGCATCTCCTGGTACCAGCTCTACCGGTTCTCCAGG GASPGTSSTGSPGS TAGCTCTACTCCTTCTGGTGCTACTGGCTCTCCAGGTGCTTCC STPSGATGSPGASP CCGGGTACCAGCTCTACCGGTTCTCCAGGTAGCTCTACCCCGT SPGSSTPSG CTGGTGCTACTGGTTCTCCAGGTACTCCGGGCAGCGGTACTG ATGSPGTPGSGTAS CTTCTTCCTCTCCAGGTAGCTCTACCCCTTCTGGTGCTACTGG SSPGSSTPSGATGSP CTCTCCA LCW462_r89 GGTAGCTCTACCCCGTCTGGTGCTACTGGTTCTCCAGGTACTC GSSTPSGATGSPGT CGGGCAGCGGTACTGCTTCTTCCTCTCCAGGTAGCTCTACCCC PGSGTASSSPGSSTP TTCTGGTGCTACTGGCTCTCCAGGTAGCCCGGCTGGCTCTCCT SGATGSPGSPAGSP ACTGAGGAAGGTACTTCTGAAAGCGCTACTCCTGAG TSTEEGTSESATPES TCTGGTCCAGGTACCTCTACTGAACCGTCCGAAGGTAGCGCT GPGTSTEPSEGSAP CCAGGTACCTCTGAAAGCGCAACTCCTGAGTCTGGCCCAGGT GTSESATPESGPGS AGCGAACCTGCTACCTCCGGCTCTGAGACTCCAGGTACCTCT EPATSGSETPGTSES GAAAGCGCAACCCCGGAATCTGGTCCAGGTACTTCTACTGAA ATPESGPGTSTEPSE CCGTCTGAAGGTAGCGCACCAGGTACTTCTGAAAGCGCAACC GSAPGTSESATPES CCGGAATCCGGCCCAGGTACCTCTGAAAGCGCAACCCCGGAG GPGTSESATPESGP TCCGGCCCA Example 7: Construction ofXTEN_AM288 ] The entire library LCWO462 was dimerized as described in Example 6 resulting in a library of XTEN_AM288 clones ated LCWO463. 1512 isolates from library LCWO463 were screened using the protocol described in Example 6. 176 highly expressing clones were sequenced and 40 preferred M288 segments were chosen for the construction of multifunctional proteins that contain multiple XTEN ts with 288 amino acid residues.

Example 8: Construction ofXTEN_AM432 We ted a library ofXTEN_AM432 segments by ining segments from library 2 _AM144 segments and segments from library LCWO463 ofXTEN_AM288 ts. This new library ofXTEN_AM432 segment was designated LCWO464. Plasmids were isolated from cultures of E. coli harboring LCWO462 and LCWO463, tively. 1512 isolates from library LCWO464 were screened using the protocol described in Example 6. 176 highly expressing clones were sequenced and 39 preferred XTEN_AM432 segment were chosen for the construction of longer XTENs and for the construction of multifunctional proteins that contain multiple XTEN segments with 432 amino acid residues.

In parallel we constructed library LMSOlOO ofXTEN_AM432 segments using preferred segments ofXTEN_AM144 and M288. Screening this library yielded 4 isolates that were selected for further construction e 9: uction ofXTEN_AM875 The stuffer vector pCWO359 was digested with BsaI and KpnI to remove the stuffer t and the resulting vector fragment was isolated by agarose gel purification.

We annealed the phosphorylated ucleotide BsaI-AscI-KpnIforP: AGGTGCAAGCGCAAGCGGCGCGCCAAGCACGGGAGGTTCGTCTTCACTCGAGGGTAC (SEQ ID NO: 1652) and the non-phosphorylated oligonucleotide BsaI-AscI-KpnIrev: CCTCGAGTGAAGACGAACCTCCCGTGCTTGGCGCGCCGCTTGCGCTTGC (SEQ ID NO: 1653) for introducing the sequencing island A (SI-A) which encodes amino acids GASASGAPSTG (SEQ ID NO: 1654) and has the restriction enzyme AscI recognition nucleotide sequence GGCGCGCC inside.

The annealed oligonucleotide pairs were ligated with BsaI and KpnI digested stuffer vector pCWO359 ed above to yield pCWO466 containing SI-A. We then generated a y ofXTEN_AM443 ts by recombining 43 preferred XTEN_AM432 segments from e 8 and SI-A segments from pCWO466 at C-terminus using the same dimerization process described in Example 5. This new library of XTEN_AM443 segments was designated LCWO479.

We generated a library ofXTEN_AM875 segments by recombining segments from library LCWO479 ofXTEN_AM443 segments and 43 preferred M432 segments from Example 8 using the same dimerization s described in example 5. This new library of XTEN_AM875 segment was designated LCWO481.

] Example 10: Construction ofXTEN_AM1318 We annealed the phosphorylated oligonucleotide BsaI-FseI-KpnIforP: AGGTCCAGAACCAACGGGGCCGGCCCCAAGCGGAGGTTCGTCTTCACTCGAGGGTAC (SEQ ID NO: 1655) and the non-phosphorylated oligonucleotide BsaI-FseI-KpnIrev: CCTCGAGTGAAGACGAACCTCCGCTTGGGGCCGGCCCCGTTGGTTCTGG (SEQ ID NO: 1656) for introducing the sequencing island B (SI-B) which encodes amino acids GPEPTGPAPSG (SEQ ID NO: 1657) and has the restriction enzyme FseI recognition nucleotide sequence GGCCGGCC inside.

The annealed oligonucleotide pairs were ligated with BsaI and KpnI digested r vector pCWO359 as used in Example 9 to yield 7 containing SI-B. We then generated a library ofXTEN_AM443 segments by ining 43 preferred XTEN_AM432 segments from Example 8 and SI-B segments from pCWO467 at C-terminus using the same zation process described in e 5. This new library of XTEN_AM443 segments was designated LCWO480.

We generated a library ofXTEN_AM13 1 8 segments by recombining segments from library LCWO48O ofXTEN_AM443 segments and segments from library LCWO481 _AM875 segments using the same dimerization process as in Example 5. This new library ofXTEN_AM13 1 8 segment was designated LCWO487.

WO 22617 Example 11: uction ofXTEN_AD864 Using the several consecutive rounds of dimerization, we assembled a collection of D864 sequences starting from ts ofXTEN_AD36 listed in Example 1. These sequences were assembled as described in Example 5. Several isolates from XTEN_AD864 were evaluated and found to show good expression and excellent lity under physiological conditions. One intermediate construct of XTEN_ADS76 was sequenced. This clone was evaluated in a PK experiment in cynomolgus monkeys and a half-life of about 20 h was measured.

Example 12: Construction ofXTEN_AF864 Using the several consecutive rounds of zation, we assembled a collection of XTEN_AF864 sequences starting from segments ofXTEN_AF36 listed in Example 3. These sequences were assembled as described in Example 5. Several isolates from XTEN_AF864 were ted and found to show good expression and excellent solubility under physiological conditions. One intermediate uct of XTEN_AF54O was sequenced. This clone was evaluated in a PK ment in cynomolgus monkeys and a half-life of about 20h was measured. A full length clone ofXTEN_AF864 had excellent solubility and showed half-life exceeding 60h in cynomolgus s. A second set ofXTEN_AF sequences was assembled including a sequencing island as described in Example 9.

] Example 13: Construction ofXTEN_AG864 Using the several consecutive rounds of dimerization, we assembled a collection of XTEN_AG864 sequences starting from segments ofXTEN_AD36 listed in Example 1. These sequences were assembled as described in Example 5. l es from XTEN_AG864 were evaluated and found to show good expression and excellent lity under physiological conditions. A full length clone of XTEN_AG864 had excellent solubility and showed half-life exceeding 60h in cynomolgus monkeys.

Example 14: Methods of producing and evaluating CFXTEN with internal and terminal XTEN The design, construction and evaluation of CFXTEN comprising FVIH and one or more XTEN is accomplished using a systematic approach. The regions suitable for XTEN insertion sites include, but are to limited to regions at or proximal to the known domain ries of FVHI, exon boundaries, known e loops, regions with a low degree of order, and hydrophilic regions. By analysis of the foregoing, different regions across the sequence of the FVHI B domain deleted (BDD) sequence have been identified as ion sites for XTEN, non-limiting examples of which are listed in Tables 5-8, and shown schematically in FIGS. 8 and 9. Initially, individual ucts are created (using methods described, below) in which DNA encoding a single XTEN or XTEN fragment of a length ranging from 6 to 2004 amino acid residues is inserted into the FVHI sequence corresponding to or near (e. g., within 6 amino acids) each of the single insertion sites identified in Table 5, Table 6, Table 7, Table 8, and Table 9, and the resulting constructs are expressed and the red protein then ted for their effects on retention of procoagulant activity using, e. g., one of the in vitro assays of Table 49. For example, using the methods described below, constructs are made in which an XTEN sequence is inserted within the Al A2, B, A3, C1 and C2 domain sequences of FVIII, as well as linked to the C-terminus, and the resulting expressed fusion proteins are evaluated in a chromogenic assay of Table 49, ed to a FVIII not linked to XTEN. CFXTEN fusion proteins can be r classified acting to high, intermediate and low categories based on the activities they exhibit. In those cases where the CFXTEN exhibits activity that is comparable or modestly reduced compared to FVIII, the insertion site is deemed ble. In those cases where the activity is intermediate, the insertion site can be adjusted from 1-6 amino acids towards the N— or C-terminus of the insertion site and/or the length or net charge of the XTEN may be altered and the resulting construct(s) luated to determine r the activity is improved. Alternatively, the XTEN is inserted into the construct with flanking cleavage sites; preferably sites that are susceptible to cleavage by proteases found in clotting assays, such that the XTEN is released during the activation of the FVIII component, thereby providing additional information about the suitability of the XTEN insertion site in the fusion protein.

Once all of the individual ion sites are evaluated and the favorable insertion sites are identified, libraries of ucts are created with two, three, four, five or more XTEN inserted in the permutations of ble sites. The length and net charge of the XTEN (e.g., XTEN of the AE versus AG family) are varied in order to ascertain the s of these variables on FVIII ty and physicochemical properties of the fusion protein. CFXTEN constructs that retain a desired degree of in vitro procoagulant FVIII activity are then ted in vivo using mouse and/or dog models of hemophilia A, as described in Examples below, or other models known in the art. In addition, constructs are assayed in the presence of FVIII tors and other anti-FVIII dies to determine constructs that retain activity. In addition, CFXTEN constructs are made that incorporate cleavage sequences at or near the junction(s) of FVIII and XTEN (e. g., sequences from Table 8) designed to release the XTEN and are ted for enhancement of FVIII activity and effects on terminal half-life. By the iterative process of making constructs combining ent insertion sites, varying the length and composition qualities of the XTEN (e. g., different XTEN families), and evaluation, the skilled artisan obtains, by the foregoing methods, CFXTEN with desired properties, such as but not limited to of procoagulant FVIII activity, reduced binding with FVIII inhibitors, enhanced pharmacokinetic properties, ability to administer to a subject by different routes, and/or enhanced pharmaceutical properties.

Example 15: Methods of producing and evaluating CFXTEN containing FVIII and AE_XTEN ] A general scheme for producing and evaluating CFXTEN compositions is presented in , and forms the basis for the general description of this Example. Using the disclosed methods and those known to one of ordinary skill in the art, together with guidance provided in the illustrative es, a d artesian can create and evaluate CFXTEN fusion proteins comprising XTEN and FVIII or variants of FVIII known in the art. The Example is, therefore, to be construed as merely illustrative, and not limitative of the s in any way whatsoever; numerous variations will be apparent to the ordinarily skilled artisan. In this Example, a CFXTEN of a factor VIII BDD linked to an XTEN of the AE family of motifs is created.

The general scheme for producing polynucleotides encoding XTEN is presented in FIGS. 11 and 12. is a schematic flowchart of representative steps in the assembly of an XTEN polynucleotide construct in one of the embodiments of the invention. Individual oligonucleotides 501 are ed into sequence motifs 502 such as a 12-amino acid motif (“12-mer”), which is ligated to additional sequence motifs from a library that can multimerize to create a pool that encompasses the desired length of the XTEN 504, as well as ligated to a smaller concentration of an oligo containing BbsI, and KpnI restriction sites 503. The motif libraries include specific sequence XTEN families; e. g., AD, AE, AF, AG, AM, or AQ sequences of Table 3. As illustrated in , the XTEN length, in this case, is 36 amino acid residues, but longer lengths are also achieved by this general process. For example, erization is performed by on, overlap extension, PCR assembly or similar cloning techniques known in the art that, in this case, result in a uct with 288 amino acid residues. The resulting pool of ligation ts is gel-purified and the band with the desired length ofXTEN is cut, ing in an isolated XTEN gene with a stopper sequence 505. The XTEN gene can be cloned into a stuffer vector.

In this case, the vector encodes an optional CBD sequence 506 and a GFP gene 508. Digestion is then performed with BbsI/HindIII to remove 507 and 508 and place the stop codon. The resulting t is then cloned into a BsaI/HindIII digested vector containing a gene encoding the FVIII, resulting in the gene 500 encoding a CFXTEN fusion protein with a 288 amino acid XTEN linked to the C-terminus of the factor VIII. As would be apparent to one of ordinary skill in the art, the methods are applied to create constructs in alternative rations and with g XTEN lengths or in multiple locations.

] DNA sequences encoding FVIII are conveniently obtained by standard procedures known in the art from a cDNA library prepared from an riate cellular source, from a genomic library, or may be created synthetically (e. g., automated nucleic acid synthesis) using DNA ces obtained from publicly available databases, patents, or literature references. In the present example, a FVIII B domain deleted (BDD) variant is prepared as described in Example 17. A gene or polynucleotide encoding the FVIII portion of the protein or its complement is then cloned into a construct, such as those described herein, which can be a plasmid or other vector under control of appropriate ription and ation sequences for high level protein expression in a biological system. A second gene or polynucleotide coding for the XTEN portion or its ment is cally fused to the nucleotides encoding the terminus of the FVIII gene by cloning it into the construct adjacent and in frame with the gene coding for the CF, through a ligation or multimerization step. In this manner, a chimeric DNA molecule coding for (or complementary to) the CFXTEN fusion n is generated within the construct. Optionally, a gene encoding for a second XTEN is inserted and ligated in-frame internally to the nucleotides encoding the FVIII-encoding region. The constructs are designed in different configurations to encode various insertion sites of the XTEN in the FVIII sequence, including those of Table 5, Table 6, Table 7, Table 8, and Table 9 or those illustrated in FIGS. 8-9. Optionally, this ic DNA molecule is transferred or cloned into r construct that is a more appropriate expression vector; e. g., a vector appropriate for a ian host cell such as CHO, BHK and the like. At this point, a host cell capable of expressing the chimeric DNA molecule is transformed with the chimeric DNA molecule, described more completely, below, or by nown methods, depending on the type of ar host, as bed supra.

] Host cells containing the XTEN-FVIH expression vector are cultured in conventional nutrient media modified as appropriate for activating the promoter. The culture ions, such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be nt to the ordinarily skilled artisan. After expression of the fusion protein, culture broth is harvested and separated from the cell mass and the resulting crude extract retained for purification of the fusion protein.

Gene expression is measured in a sample directly, for example, by conventional Southern blotting, Northern blotting to quantitate the transcription of mRNA [Thomas, Proc. Natl. Acad. Sci. USA, 77:5201-5205 (1980)], dot blotting (DNA analysis), or in situ hybridization, using an appropriately labeled probe, based on the ces provided herein. Alternatively, gene expression is ed by immunological of fluorescent methods, such as immunohistochemical staining of cells to quantitate ly the expression of gene product. Antibodies useful for histochemical ng and/or assay of sample fluids may be either monoclonal or polyclonal, and may be prepared in any mammal.

Conveniently, the dies may be prepared against the FVIII sequence polypeptide using a synthetic e based on the sequences provided herein or against exogenous sequence fused to FVHI and encoding a specific antibody epitope. Examples of selectable s are well known to one of skill in the art and include reporters such as enhanced green fluorescent protein (EGFP), beta-galactosidase (B- gal) or chloramphenicol transferase (CAT).

] The CFXTEN polypeptide product is purified Via methods known in the art. Procedures such as gel filtration, affinity ation, salt onation, ion exchange chromatography, size exclusion chromatography, hydroxyapatite adsorption chromatography, hydrophobic interaction chromatography or gel electrophoresis are all techniques that may be used in the purification. Specific methods of purification are described in Robert K. Scopes, n Purification: Principles and Practice, Charles R.

Castor, ed., Springer-Verlag 1994, and Sambrook, et al., supra. Multi-step ation separations are also described in Baron, et al., Crit. Rev. Biotechnol. 10:179-90 (1990) and Below, et al., J. Chromatogr.

A. 679:67-83 (1994).

As illustrated in , the isolated CFXTEN fusion proteins are characterized for their chemical and activity properties. An isolated fusion protein is characterized, e. g., for ce, purity, apparent molecular weight, solubility and stability using standard methods known in the art. The fusion protein meeting expected standards is evaluated for actiVity, which can be measured in Vitro or in Vivo by ing one of the factor VIII-associated parameters described herein, using one or more assays disclosed herein, or using the assays of the Examples or Table 49.

In addition, the CFXTEN FVIII fusion protein is administered to one or more animal species to determine standard pharmacokinetic parameters and pharmacodynamic properties, as described in Examples 25 and 26.

By the iterative process of producing, expressing, and recovering CFXTEN constructs, followed by their characterization using methods disclosed herein or others known in the art, the CFXTEN compositions comprising CF and an XTEN are produced and evaluated to confirm the expected properties such as enhanced lity, enhanced stability, improved pharmacokinetics and reduced immunogenicity, leading to an overall enhanced therapeutic activity compared to the ponding unfused FVIII. For those fusion proteins not possessing the desired properties, a different sequence or configuration is constructed, expressed, isolated and evaluated by these methods in order to obtain a composition with such properties.

Example 16: Construction of expression plasmids for BDD FVIII ] I. uction of B domain deleted FVIII (BDD FVIII) expression vectors The expression vector encoding BDD FVIII was created by cloning the BDD FVIII open reading frame into the pcDNA4 vector (Invitrogen, CA) containing a polyA to allow for optimal mammalian expression of the FVIII gene, resulting in a construct designated pBC0100. Several natural sites were identified within this construct for cloning use, including BsiWI 48, AflII 381, PshAI 1098, KpnI 1873, BamHI 1931, PflMI 3094, ApaI 3574, XbaI 4325, NotI 4437, XhoI 4444, BstEII 4449, AgeI 4500, PmeI 4527. To facilitate assay development, nucleotides encoding Myc and His tag were introduced into the FVIII open reading frame. pBC0100 was PCR amplified using the following primers: 1) F8-BsiWI-F: tattccCGTACchcgccaccATGCAAATAGAGCTCTCCACCT (SEQ ID NO: 1658); 2) F8-nostop-XhoI-R1: GGTGACCTCGAGcgtagaggtcctgtgcctcg (SEQ ID NO: 1659) to introduce BsiWI and XhoI in appropriate locations. The PCR product was digested with BsiWI and XhoI. PcDNA4-Myc-His/C was digested with Acc651 and XhoI, which generated two ts of 5003 and 68 bps. The 5003bps product was ligated with the digested PCR’ed FVIII fragment and used for DH5alpha transformation. The enzymes Acc65I and BsiWI create compatible ends but this ligation destroys the site for future ion. The ing construct was ated pBC0102 (pcDNA4- FVIII_3-Myc-His). To facilitate the design and execution of future cloning strategies, especially ones involving the creation of BDD FVIII expression constructs that contain multiple XTEN insertions, we ed additional unique restriction enzyme sites to orate, including BsiWI 908, NheI 1829 and ClaI 3281. The introduction of these sites was done via the QuikChange method (Agilent, CA) individually. The resulting construct was designated pBC0112 (pcDNA4-FVIII_4-Myc-His). To avoid problems that may arise from the linker peptides that connects between Myc/His and FVIII/Myc, and to remove restriction enzyme sites that are preferred for future XTEN ion, we mutated the sequences encoding the peptide sequences from ARGHPF (SEQ ID NO: 1660) to AETA (SEQ ID NO: 178) (between FVIII and Myc), NMHTG (SEQ ID NO: 1661) to SPATG (SEQ ID NO: 1662) (between Myc and His) via the QuikChange method. The construct was ated pBC0114 (pcDNA4-FVIII_4- AETA—Myc-SPATG-His ('GAGSPGAETA' and ' disclosed as SEQ ID NOS 178 and 1662, respectively)) (sequence in Table 21), which was used as the base vector for the design and creation of other expression vectors incorporating XTEN sequences. Expression and FVIII activity data for this construct are ted in II. Construction of B domain deleted FVIII (BDD FVIII) expression vectors WO 22617 The gene encoding BDD FVIII is synthesized by GeneArts (Regensburg, Germany) in the cloning vector pMK (pMK-BDD FVIII). The BDD FVIII proteins contain 1457 amino acids at a total molecular weight of 167539.66. There are 6 domains within the wild-type FVIII protein, the A1, A2, B, A3, C1 and C2 s. In the BDD FVIII protein, most of the B domain has been deleted as it was shown to be an ctured domain and the removal of the domain does not alter critical functions of this protein. The pMK vector used by GeneArts contains no promoter, and can not be used as an expression vector. Restriction enzyme sites NheI on the 5’ end and SfiI, SalI and XhoI on the 3’ end are introduced to facilitate subcloning of the DNA sequence encoding BDD FVIII into expression s, such as 9-HS (Millipore). Several unique restriction enzyme sites are also introduced into the FVIII ce to allow further manipulation (e. g., insertion, mutagenesis) of the DNA sequences.

Unique sites listed with their cut site e, but are not limited to: SacI 391, AfiII 700, SpeI 966, PshAI 1417, Acc6512192, KpnI 2192, BamHI 2250, HindIII 2658, PfoI 2960, PflMI 3413, ApaI 3893, Bsp1201 3893, SwaI 4265, OliI 4626, XbaI 4644, and BstBI 4673. . The HindIII site s at the very end of the A2 domain and can potentially be used for modification of the B domain. The synthesized pMK-BDD FVIII from GeneArts does not contain a stop codon. The stop codon is introduced by amplifying a 127 bp fragment of FVIII using the following primers: 5’- GTGAACTCTCTAGACCCACCG-3’ (SEQ ID NO: 1663); 5’- CTCCTCGAGGTCGACTCAGTAGAGGTCCTGTGCCTCG-3’ (SEQ ID NO: 1664). The fragment is digested with XbaI and SalI, and ligated to XbaI /SalI digested pMK-BDD FVIII. The ligated DNA mixture is used to transform DH5a bacterial cells. Transformants are ed by DNA miniprep and the desired constructs are confirmed by DNA sequencing. The uct named pBCOO27 (pMK-BDD FVIII-STOP) contains coding sequences that encode the BDD FVIII protein. The pBC0027 construct is then ed with NheI /SalI, and d with NheI/SalI ed CET1019-HS vector (Millipore). The CET1019-HS vector contains a human CMV promoter and a UCOE sequence to facilitate gene expression. The ligated DNA mixture is used to transform DH5a bacterial cells. ormants are screened by DNA ep and the desired constructs are confirmed by DNA sequencing. The final construct is designated pBCOO25 (CET1019-HS-BDD FVIII-STOP), which encodes the BDD FVIII protein under the control of a human CMV promoter. Introduction of the pBCOO25 construct into mammalian cells is expected to allow sion of the BDD FVIII protein with procoagulant activity.

Example 17: Construction of expression plasmids for BDD FVIII Containing XTEN 1. B domain AE42 Insertion Two PCR reactions were run in parallel to insert XTEN_AE42 into the remaining B domain region of the BDD FVIII constructs. The PCR reactions involved the following primers: cgaaagcgctacgcctgagaGTGGCCCTGGCTCTGAGCCAGCCACCTCCGGCTCTGAAACCCCTGCCTC GAGCccaccagtcttgaaacgcc (SEQ ID NO: 1665); TGATATGGTATCATCATAATCGATTTCCTCTTGATCTGACTG (SEQ ID NO: 1666); agcttgaggatccagagttc (SEQ ID NO: 1667); tctcaggcgtagcgctttchTTGTCCCCTCTTCTGTTGAGGTGGGGGAGCCAGCAGGAGAACCTGGCG CGCCgttttgagagaagcttcttggt (SEQ ID NO: 1668). The PCR products then served as templates, and a second PCR was performed to introduce the XTEN_AE42 into the FVIII encoding tide sequences flanked by BamHI and ClaI. This PCR product was digested with BamHI and ClaI simultaneously with the digestion of PBCOl 14 with the same two enzymes. The PCR product was ligated to the digested vector. This construct was ated pBC0135 4-FVIII_4XTEN_AE42-GAGSPGAETA—Myc- SPATG-His) ('GAGSPGAETA' and 'SPATG' disclosed as SEQ ID NOS 178 and 1662, tively), and encodes the BDD FVIII with an AE42 XTEN incorporated within the residual B-domain. 2. AE42 Insertion and R1648A mutation The QuikChange method (Agilent, CA) was employed to introduce an R1648A mutation into PBC0135. This construct was designated pBC0149 (pcDNA4-FVIII_4XTEN_AE42-GAGSPGAETA- Myc-SPATG-His_R1648A) ('GAGSPGAETA' and 'SPATG' disclosed as SEQ ID NOS 178 and 1662, respectively), eliminating that FVIII processing site. 3. B domain AE288 ion XTEN_AE288 was PCR amplified using the following primers: tctcaaaacGGCGCGCCAggtacctcagagtctgctacc (SEQ ID NO: 1669) and tggtggGCTCGAGGCtggcgcactgccttc (SEQ ID NO: 1670). PBCOO75 was used as the template for this PCR reaction. The PCR product was digested with AscI and XhoI, and PBC0135 was ed with the same enzymes. The PCR product was ligated to the PBC0135 fragment. This construct was designated pBC0136 (pcDNA4-FVIII_4XTEN_AE288-GAGSPGAETA—Myc-SPATG-His) ('GAGSPGAETA' and 'SPATG' disclosed as SEQ ID NOS 178 and 1662, tively), and encodes the BDD FVIII with an AE288 XTEN incorporated within the residual B-domain. 4. AE288 Insertion and R1648A mutation XTEN_AE288 was PCR ied using the following primers: tctcaaaacGGCGCGCCAggtacctcagagtctgctacc (SEQ ID NO: 1671) and tggtggGCTCGAGGCtggcgcactgccttc (SEQ ID NO: 1672). Construct pBCOO75 was used as the template for this PCR reaction. The PCR product was digested with AscI and XhoI, and pBC0149 was digested with the same enzymes. The PCR product was ligated to the pBC0149 fragment. This construct was designated pBC0137 (pcDNA4-FVIII_4XTEN_AE288-GAGSPGAETA—Myc-SPATG-His R1648A) PGAETA' and ' disclosed as SEQ ID NOS 178 and 1662, tively) and contains an AE288 XTEN sequence internal to the B domain, with the R1648A mutation eliminating that FVIII processing site. 3. B domain AE144 AG144 AG288 Insertions with and without R1648A mutations Select XTEN nts were PCR ied to introduce AscI and XhoI sites to the 5’ and 3’ end respectively. The PCR product was digested with AscI and XhoI, and pBC0135 (for R1648) or pBC0149 (for A1648) were digested with the same enzymes. The PCR product was d to the pBC0135 or pBC0149 vector. These constructs were designated pSDOOOS, 6, 7, 8, 17 and 18.

Construction of expression plasmids for BDD FVIII with XTEN insertion at the C terminus 1. C terminal AE288 insertion XTEN_AE288 was PCR amplified using the following primers: ggggccgaaacggccggtacctcagagtctgctacc (SEQ ID NO: 1673) and tgttcggccgtttcggcccctggcgcactgccttc (SEQ ID NO: 1674). The construct pBC0075 was used as the te for this PCR reaction. The PCR product was digested with SfiI, and pBC0114 was digested with the same enzyme. The PCR product was d to the digested pBC0114 fragment. This construct was designated pBC0145 4- 4-XTEN_AE288-GAGSPGAETA—Myc-SPATG-His) ('GAGSPGAETA' and 'SPATG' disclosed as SEQ ID NOS 178 and 1662, respectively), and encodes an AE288 sequence at the C-terminus of the BDD FVIII. ] 2. C terminal AG288 insertion XTEN _AG288 was designed and synthesized by DNA2.0 (Menlo Park, CA). The synthesized gene was PCR amplified using the ing primers: ggggccgaaacggccccgggagcgtcacc (SEQ ID NO: 1675) and tgttcggccgtttcggcccctgacccggttgcccc (SEQ ID NO: 1676). The PCR product was digested with SfiI, and PBC0114 based vector was digested with the same enzyme. The PCR product was ligated to the digested PBC0114 fragment. This construct was designated pBC0146 4-FVIII_4- XTEN_AG288-GAGSPGAETA—Myc-SPATG-His) ('GAGSPGAETA' and 'SPATG' disclosed as SEQ ID NOS 178 and 1662, respectively), and encodes an AG288 ce at the C-terminus of the BDD FVIII. 3. C terminal AE/AG144 288 864 insertions AscI and XhoI sites were introduced into the 4 based vector via QuikChange methods using the primers: 5037-PBC0114-AscI-XhoI-F: CAGGACCTCTACGGCGCgccagcctcgaGCGAACAAAAACTCATCTCAGAAGAGG (SEQ ID NO: 1677); 503 8-PBC01 14-AscI-XhoI-R: CCTCTTCTGAGATGAGTTTTTGTTCGthgaggctgchCGCCGTAGAGGTCCTG (SEQ ID NO: 1678). Various XTEN fragments were PCR amplified with AscI and XhoI introduced into the 5’ and 3’ end respectively. The PCR product was ligated to the digested PBC0114 vector. These constructs were designated pSD0013, 4, pSD0015, pSD0016, pSD0019 and pSD0020.

Construction of expression plasmids for BDD FVIII with inter- and intra- domain XTEN insertions 1. AE7 AE42 and AEl44 Insertions Four distinct strategies are used for insertion of AE42 into the designated sites (e.g., the natural or introduced restriction sites BsiWI 48, AflII 381, PshAI 1098, KpnI 1873, BamHI 1931, PflMI 3094, ApaI 3574, XbaI 4325, NotI 4437, XhoI 4444, BstEII 4449, AgeI 4500, PmeI 4527, BsiWI 908, NheI 1829 and ClaI 3281) within the BDD FVIII encoding sequence, each contributing to the creation of several constructs. By design, these insertions of AE42 create AscI and XhoI sites flanked on either side of the insertion allowing for uction/substitution of longer XTENs, as well as XTEN with different sequences or incorporated cleavage ces, as needed. Specifically, the constructs that contain XTEN_144 insertions are listed in Table 21. These insertions were created by replacing either AE7 or AE42 with a PCRed XTEN_144 fragment flanked by AscI and XhoI sites. 2012/046326 2. Double PCR-mediated method Two PCR reactions are run in parallel to insert XTEN_AE42 into the ated site. The two PCR reactions introduce XTEN on either the 3’ or the 5’ end via use of a long primer that contains l XTEN. The PCR products then serve as templates, and a second PCR is performed to uce the XTEN_AE42 into the FVIH encoding nucleotide sequences flanked by select ction enzyme sites.

This PCR product is digested with the appropriate enzymes simultaneously with the digestion of PBC0114 using the same two enzymes. The PCR product is ligated to the ed vector. Using this , ucts are created designated pBC0126, pBC0127, pBC0128, and pBC0129, resulting in AE42 insertions at the R3, R3, P130, L216 locations respectively. The sequences are listed in Table 21.

Select XTEN_l44 sequences can then be PCRed to introduce Ascl and Xhol sites on either end of the fragment, and ligate to digested FVHI-XTEN_AE42 construct. For instance, pSD0053 was created by replacing the AE42 of pBC0129 with XTEN_AE144. Other XTEN_l44 constructs were created via the same strategy and are listed in Table 21. 3. QuikChange mediated two step cloning method The QuikChange method is employed to uce XTEN_AE7 encoding sequences that are flanked by Ascl and Xhol into designated sites. The resulting intermediate construct is then digested with Ascl and Xhol. E42 or XTEN_AE144 is PCR amplified to introduce the two sites and digested accordingly. The vector and insert are then ligated to create the final constructs. The sequences are listed in Table 21. 4. Three PCR type II ction enzyme mediated ligation method Three PCR reactions are performed to create two pieces of FVIII encoding fragments flanked by one type I restriction enzyme that correlates with a unique site within the FVHI_4 gene and one type II enzyme (e. g. Bsal, Bbsl, Bqul), the third PCR reaction created the XTEN_AE42 flanked by two type II restriction enzyme sites. The three PCR fragments are digested with appropriate enzymes and ligated into one linear piece that contains the XTEN_AE42 insertion within a fragment of FVIII encoding sequences. This product is then digested with appropriate unique enzymes within the FVIII encoding ces and ligated to the 4 construct ed with the same enzymes, and result in constructs designated pBC0130 (with XTEN insertion at residue P333), pBC0132 (with XTEN insertion at residue D403), pBC0133 (with XTEN insertion at residue R490). The sequences are listed in Table 21. Select XTEN_l44 ces can then be PCRed to introduce Ascl and Xhol sites on either end of the fragment, and ligate to digested FVIH-XTEN_AE42 construct. For instance, pSD0001 and pSD0003 were created by replacing the AE42 of pBC0132 with XTEN_AE144 and XTEN_AG144 respectively. Other XTEN_l44 constructs listed in Table 21 were created via the same strategy. 5. Custom gene sis Custom gene synthesis is med by GeneArt (Regensburg, Germany). The genes are ed so that they include nucleotides encoding the XTEN_AE42 inserted in the designated site(s) and the genes are flanked by two unique restriction enzyme sites selected within the FVHI_4 gene. The synthesized genes and PBC0114 are digested with appropriate enzymes and ligated to create the final product with the BDD FVIII incorporating the XTEN_AE42 between the restriction sites. Select XTEN_144 sequences can then be PCRed to introduce AscI and Xhol sites on either end of the fragment, and ligate to digested FVIII-XTEN_AE42 construct.

Construction of expression plasmids with dual XTEN insertions in the B domain and at the C terminus The construct pBC0136, which encodes the BDD FVIII with an AE288 XTEN incorporated within the residual B-domain, is digested with BamHI and ClaI, and the resulting 1372bps fragment from this digestion is the insert. The construct pBC0146 is digested with BamHI and ClaI, and the 9791bps piece from this digestion is the vector. The vector and insert are ligated together to create pBC0209, containing an AE288 insertion within the B domain and an AG288 on the C terminus. The same strategy is utilized to create constructs containing two AE288 insertions in the B domain and at the C terminus, respectively, using PBC0145 as the vector.

Construction of expression plasmids with le XTEN insertions The construct pBC0127, which encodes an AE42 XTEN at the R3 position of FVHI, is ed with BsiWI and Aflll, and the resulting 468bps fragment from this digestion is the . The uct pBC0209 is digested with BsiWI and AflH, the 10830bps piece from this digestion is the vector. The vector and insert are ligated together to create a uct designated pBC0210, containing an AE42 insertion in the A1 , an extra three ATR amino acid to restore the signal cleavage sequence, an AE288 XTEN insertion within the B domain and an AG288 on the C terminus. The same methodology is used to create ucts encoding multiple XTEN at the natural and introduced restriction sites; e. g., BsiW148, AflII 381, PshAl 1098, KpnI 1873, BamHI 1931, PflMI 3094, ApaI 3574, Xba14325, NotI 4437, XhoI 4444, BstEII 4449, AgeI 4500, PmeI 4527, BsiWI 908, NheI 1829 and Clal 3281. uction of BDD FVHI-Internal-XTEN_AE288 expression vectors Two BsaI restriction enzyme sites are introduced into the PBC0027 pMK-BDD FVIII construct between the base pair 2673 and 2674 using the QuikChange method following manufacturer’s ol (Agilent Technologies, CA). The inserted DNA sequences are gggtctcccgcgccagggtctccc, and the resulting construct is ated pBC0205 (sequence in Table 21). The DNA ce encoding AE288 (or other variants and lengths of XTEN; e. g. AE42, AG42, AG288, AM288) is then PCR’ed with primers that introduce BsaI sites on both the 5’ and 3’. The pBC0205 vector and the insert 288) are then digested with BsaI and ligated to create pBC0206, which encodes the FVIII gene with an XTEN_AE288 insertion within the B domain (sequence in Table 21). The pBC0206 construct is then digested with NheI /SalI, and ligated with NheI/Sall digested CET1019-HS vector (Millipore). The 9-HS vector contains a human CMV promoter and a UCOE ce to facilitate gene expression. The ligated DNA e is used to transform DH5a bacterial cells. ormants are screened by DNA miniprep and the desired constructs are confirmed by DNA sequencing. The final construct is designated pBC0207 (CET1019-HS-BDD FVHI-STOP), which s the BDD FVIII protein under the control of a human CMV promoter (sequence in Table 21). Introduction of the pBC0207 construct into mammalian cells is expected to allow expression of the BDD FVIII protein with an internal XTEN_AE288. The same protocol is used to introduce, transform and express constructs containing other variants and lengths of XTEN; e. g. AE42, AG42, AG288, AM288, AE864, AG864, or other XTEN of Table 4.

Construction of BDD FVIII-/—XTEN_AE864 expression vectors The BDD FVIII fragment with NheI and SfiI flanking the 5’ and 3’ end is generated by digesting the pBC0025 construct. This digested fragment is then ligated to a NheI/SfiI digested pSecTag vector (pBCOO48 pSecTag-FVIII-/—XTEN_AE864) encoding the FVIII followed by the XTEN_AE864 sequence. The ligated DNA mixture is used to transform DH5a bacterial cells. Transformants are screened by DNA miniprep and the desired ucts are confirmed by DNA sequencing. The final construct is 0, which encodes the BDD FVIII-/—XTEN_AE864 protein under the control of a human CMV promoter. Introduction of the pBCOO6O construct into mammalian cells is expected to s the FVIII protein with a C terminal XTEN fusion (BDD FVIII-/—XTEN_AE864) with procoagulant activity. uction of BDD /FXI/—XTEN_AE864 expression s The BDD FVIII fragment with NheI and SfiI flanking the 5’ and 3’ end is generated by digesting the pBC0025 construct. This digested fragment is then ligated to a NheI/SfiI digested pSecTag vector (pBCOO47 pSecTag-FVIII-/FXI/—XTEN_AE864) encoding the FVIII followed by the FXI cleavage sequence (/FXI/) and XTEN_AE864. The ligated DNA mixture is used to transform DHSa bacterial cells. Transformants are screened by DNA miniprep and the desired constructs are confirmed by DNA sequencing. The final construct is pBCOOS l, which encodes the BDD FVIII-/FXI/— XTEN_AE864 protein under the control of a human CMV promoter. Introduction of the pBCOOSl construct into mammalian cells is expected to s the FVIII protein with a C terminal XTEN fusion (BDD FVIII-/FXI/—XTEN_AE864), which could be subsequently cleaved by FXI, therefore liberating the BDD FVIII protein with procoagulant activity.

Construction of BDD FVIII-/FXI/—XTEN expression vectors comprising AE288 or AG288 The fused AE864 XTEN sequence in pBCOO6O is replaced by digesting the XTEN ces AE288 and AG288 with BsaI and HindIII. A subsequent ligation step using the respective AE288 or AG288 XTEN fragment and indIII digested pBCOOS 1 allows the ge of the AE288 or AG288 sequences into the BDD FVIII expression . The resulting final ucts are pBCOO6l for BDD FVIII-AE288 and pBCOO62 for BDD FVIII-AG288. Introduction of the pBCOO6l construct into mammalian cells is ed to express the FVIII protein with a C-terminal AE288 XTEN fusion (BDD FVIII-/—XTEN_AE288) with procoagulant ty. Introduction of the pBCOO62 construct into mammalian cells is expected to express the FVIII protein with a C-terminal AG288 XTEN fusion (BDD FVIII-/—XTEN_AG288) with procoagulant activity.

Construction of BDD FVIII-/FXI/—XTEN sion vectors with alternate XTEN ] The fused XTEN sequence in pBCOOS l is replaced by digesting DNA encoding other XTEN sequences (e. g. other variants and lengths of XTEN; e.g. AE42, AG42, AG288, AM288) with BsaI and HindIII. A ligation using the XTEN nt and indIII digested pBCOOS 1 allows the exchange of the various XTEN-encoding sequences into the BDD FVIII expression , providing the alternate constructs. Introduction of the alternate constructs into mammalian cells is expected to express the FVIII protein with a C-terminal XTEN (BDD /FXI/—XTEN) that can be subsequently cleaved by FXI, releasing the FVIII, resulting in procoagulant FVIII fusion with procoagulant activity. e 18: uction of expression ds for FVIII signal peptide-XTEN-/FXI/— BDD FVIII Construction of expression vectors for FVIII signal peptide-XTEN_AE864 The coding sequences for the FVIII signal peptide is generated by annealing the following two oligos: 5’- CTAGCATGCAAATAGAGCTCTCCACCTGCTTCTTTCTGTGCCTTTTGCGATTCTGCTTTAGTG GGTCTCC-3’ (SEQ ID NO: 1679); 5’- ACCTGGAGACCCACTAAAGCAGAATCGCAAAAGGCACAGAAAGAAGCAGGTGGAGAGCTC TATTTGCATG-3’ (SEQ ID NO: 1680). The annealed oligos are flanked by the NheI and BsaI restriction enzyme sites on either end, and is ligated to saI digested pCWO645 vector which encodes the FVII-XTEN_AE864. The ligated DNA mixture is used to transform DH5a bacterial cells.

Transformants is screened by DNA miniprep and the desired constructs are confirmed by DNA sequencing. The final construct is designated pBC0029, which encodes the signal peptide- XTEN_AE864 protein under the l of a human CMV promoter. This construct is used as an intermediate construct for ng an expression construct with XTEN fused on the N-terminus of the FVIII protein, and can also be used as a master plasmid for creating expression constructs that allow XTEN fusion on the N-terminus of a secreted protein.

Construction of signal peptide-XTEN_AE864-/FXI/—BDD FVIII expression vectors An l800bp fragment within the FVIII coding region is amplified using s that uce NheI-BbsI-/FXI/—AgeI sites on the 5’ and endogenous KpnI restriction enzyme on the 3’ end. The NheI/KpnI digested FVIII fragment is ligated with NheI/KpnI digested pBC0027 vector. The ligated DNA mixture is used to transform DH5a bacterial cells. Transformants are screened by DNA miniprep and the desired constructs are confirmed by DNA sequencing. The resulting construct is designated pBC0052, which contains sequences that encode the /FXI/—FVIII protein without the FVIII signal peptide. This uct is used as an intermediate construct for ng an expression construct with XTEN fused on the N-terminus of the FVIII protein.

The pBC0052 vector is digested with BbsI/XhoI s, and is used to ligate with Bbsi/XhoI digested pBC0029. The ligated DNA mixture is used to transform DH5a bacterial cells. Transformants are screened by DNA miniprep and the desired constructs are confirmed by DNA sequencing. The final construct is designated pBCOOS3, which encodes the signal peptide-XTEN_AE864-/FXI/—BDD FVIII protein under the control of a human CMV er. Introduction of the pBCOOS3 construct into mammalian cells is expected to express the FVIII protein with an N-terminal XTEN fiJsion (signal peptide-XTEN_AE864-/FXI/—BDD FVIII), which could be subsequently cleaved by FXI, ore liberating the BDD FVIII protein.

Construction of signal peptide-XTEN —BDD FVIII expression vectors The fused XTEN sequence in pBC0053 can be replaced by digesting other XTEN fragments (e. g. AM, AF, AG) with Bsal and Bbsl. A ligation using the XTEN fragment and BsaI/Bbsl digested pBC0053 allows the exchange of various XTEN pieces (e. g. AM, AF, AG) into the BDD FVIII expression vector. Various XTEN fusions can increase the half lives of these proteins differently, allowing modification of the properties (e. g. efficacy, potency) of these proteins. Introduction of any of these fusion constructs into mammalian cells is expected to express the FVIII protein with an inal XTEN fusion (signal peptide-XTEN-/FXl/-BDD FVHI), in which the fused XTEN peptide can be subsequently cleaved by FXI, generating the BDD FVIII protein.

Example 19: Construction of BDD FVIII with interdomain XTEN insertion Construction of BDD FVIII expression vectors with an XTEN insertion at the A2-B domain boundaries The pBC0027 construct (pMK—BDD FVIll-STOP) is a cloning vector designed to contain the BDD FVIH protein coding sequences, but not a promoter positioned to initiate the sion of BDD FVHI. This uct is used for manipulation of the coding sequences of BDD FVIII as the vector backbone contains very few restriction enzyme sites. therefore allowing easy g strategies. The BDD FVIH proteins n 1457 amino acids at a total molecular weight of .66. There are 6 domains within the wild-type FVIII protein, the Al, A2, B, A3, C1 and C2 domains. In the BDD FVIII protein, most of the B domain has been d as it is believed to be an unstructured domain and the removal of the domain does not alter critical ons of this protein. However, the B domain boundaries seem to be ent positions for creating XTEN fusions to allow extension of the protein half lives.

Within the pBC0027 construct, there is a unique Hindlll restriction enzyme site at the boundary of A2-B junction. The XTEN (e.g., sequences of Tables 4, or 13-17) are amplified using primers that introduce a Hindlll and FXI cleavage site on either end of the XTEN coding sequence. The fused XTEN sequence can be altered by amplifying various XTEN fragments. Various XTEN fusions can increase the half lives of these proteins ently, allowing ation of the properties (e.g. efficacy, potency) of these ns. The l-/FXl/-XTEN-/FXl/-Hindlll fragment is digested with l and ligated with l digested pBC0027. The ligated DNA mixture is used to transform DH5a bacterial cells.

Transformants are screened by DNA miniprep and the desired constructs are ed by DNA sequencing. The final construct is designated pBC0054, which encodes the BDD FVIII protein with an interdomain XTEN fusion (FVlll(Al -A2)-/FXl/-XTEN-/FXl/-FVHI(Cl-C2)) but not a promoter to initiate gene expression.

The pBC0054 construct is digested with Nhel /Sall, and ligated with Nhel/Sall digested CETlOl9-HS vector (Millipore). The 9-HS vector contains a human CMV promoter and a UCOE sequence to facilitate gene expression. The d DNA mixture is used to transform DH5a bacterial cells. Transformants are screened by DNA miniprep and the desired constructs are confirmed by DNA sequencing. The final construct is designated pBCOOSS (CETlOl9-HS- FVIII(Al-A2)-/FXl/- XTEN-/FXl/-FVHI(Cl-C2)), which encodes the BDD FVIII protein with an interdomain (inter-A2/B WO 22617 domain) XTEN fusion (FVIII(A1-A2)-/FXI/—XTEN-/FXI/—FVIII(C1-C2)) under the control of a human CMV promoter. Introduction of the pBC0055 construct into mammalian cells is ed to express the BDD FVIII protein with an interdomain XTEN fusion (A1 -A2)-/FXI/-XTEN-/FXI/-FVIII(C1- C2)), which could be subsequently cleaved by FXI, therefore ting the BDD FVIII n.

Construction of BDD FVIII sion vectors with an XTEN insertion at the A1-A2 domain boundaries The pBC0027 construct is designed as a template for two PCR reactions using the ing four s: (Reaction I) 5’-ATGATGGCATGGAAGCCTAT-3’ (SEQ ID NO: 1681); 5’- ATCCCTCACCTTCGCCAGAACCTTCAGAACCCTCACCTTCAGAACCTTCACCAGAACCTTCA CCATCTTCCGCTTCTTCATTATTTTTCAT-3’ (SEQ ID NO: 1682).

(Reaction II) 5’- TTCTGGCGAAGGTGAGGGATCTGAAGGCGGTTCTGAAGGTGAAGGTGGCTCTGAGGGTTCC GATGATGATCTTACTGATTCTGAAAT-3’ (SEQ ID NO: 1683); 5 ’- TATTCTCTGTGAGGTACCAGC-3’ (SEQ ID NO: 1684).

The PCR products generated are 150bps and 800 bps respectively. The 800 bp product is used as the template for the next round of PCR reaction with the 150bp t as one primer and 5 ’- TATTCTCTGTGAGGTACCAGC-3’ (SEQ ID NO: 1685) as the other. The product for the second round of PCR is 930 bps and is digested with PshAI and ACC651 restriction enzymes. This PshAI/Acc651 flanked DNA fragment is ligated with PshAI/Acc651 digested pBC0027. The ligated DNA mixture is used to transform DH5a bacterial cells. Transformants is screened by DNA miniprep and the desired constructs are confirmed by DNA sequencing. The final construct is designated pBC0058 (pMK-BDD FVIII-D345-XTEN_Y36), which encodes the BDD FVIII protein with an interdomain (inter-A1/A2 domain) XTEN fusion after the D345 residue.

] The pBC0058 construct is digested with NheI /SalI, and ligated with NheI/SalI digested CET1019-HS vector pore). The CETlOl9-HS vector contains a human CMV promoter and a UCOE sequence to facilitate gene expression. The ligated DNA mixture is used to transform DH5a bacterial cells. Transformants are screened by DNA miniprep and the desired ucts are confirmed by DNA cing. The final construct is designated pBC0059 (CET1019-HS-BDD FVIII D345- XTEN_Y36), which encodes the BDD FVIII protein with an interdomain (inter-A1/A2 domain) XTEN fusion after the D345 residue under the control of a human CMV promoter. Introduction of the pBC0059 construct into mammalian cells is expected to express the BDD FVIII protein with an interdomain XTEN fusion (BDD FVIII D345-XTEN_Y36).

Example 20: uction of FVIII with intradomain XTEN insertion Construction of BDD FVIII expression vectors with an XTEN insertion after P598 (within the A2 domain) The coding sequences for XTEN_Y36 is amplified using PCR techniques with the following primers: 5 ’- PCT/U82012/046326 GAAGCTGGTACCTCACAGAGAATATACAACGCTTTCTCCCCAATCCAGGTGAAGGTTCTGGT GAAGG-3’ (SEQ ID NO: 1686) ’-AACTCTGGATCCTCAAGCTGCACTCCAGCTTCGGAACCCTCAGAGCC-3’ (SEQ ID NO: 1 687).

The 184 bp PCR product is flanked by the KpnI and BamHI restriction enzyme sites on either end, and is ligated to KpnII/BamHI digested pBC0027 vector which encodes the BDD FVIII gene. The ligated DNA mixture is used to transform DH5a bacterial cells. Transformants are screened by DNA miniprep and the d constructs are med by DNA sequencing. The final construct is designated pBC0056, which contains DNA sequences ng the FVIII protein with an XTEN_Y36 fusion after the P598 e. This cloning strategy is used to introduce various forms ofXTEN into the BDD FVIII protein by altering the template for the PCR reaction and changing the primers ingly.

The pBC0056 construct is digested with NheI /SalI, and ligated with NheI/SalI digested CET1019-HS vector (Millipore). The CET1019-HS vector contains a human CMV promoter and a UCOE sequence to facilitate gene expression. The ligated DNA mixture is used to transform DH5a bacterial cells. Transformants are screened by DNA miniprep and the desired constructs are confirmed by DNA sequencing. The final construct is designated pBC0057 (CET1019-HS- FVIII P598- XTEN_Y32), which s the BDD FVIII protein with an intradomain (within A2 ) XTEN fusion under the control of a human CMV promoter. Introduction of the pBC0057 construct into mammalian cells is expected to express the BDD FVIII protein with an intradomain XTEN fusion (FVIII P598-XTEN_Y32).

Construction of BDD FVIII sion vectors with other omain XTEN insertions To introduce various XTEN segments into other intradomain sites within BDD FVIII (e. g., the XTEN of Tables 4, or 13-17), primers are designed that amplify XTEN with an overhang that can anneal with BDD FVIII. The coding sequence of FVIII (pMK-BDD FVIII) is designed with various unique restriction enzyme sites to allow these ic insertions. The unique restriction enzymes are listed below with their cut site: NheI 376, SacI 391, AfiII 700, SpeI 966, PshAI 1417, 2192, KpnI 2192, BamHI 2250, HindIII 2658, PfoI 2960, PflMI 3413, ApaI 3893, Bsp1201 3893, SwaI 4265, CHI 4626, XbaI 4644, BstBI 4673, SalI4756, and XhoI 4762. The NheI and SalI sites on either end of the coding sequence are used to insert the DNA fragment into a human CMV promoter driven vector, the CET1019-HS (Millipore) for expression in mammalian cells. These constructs express the BDD FVIII protein with an XTEN fusion with sequences listed in Table 21.

Example 21: Construction of FVIII with XTEN insertions CFXTEN with two XTEN: To obtain CFXTEN with two XTEN insertions in various regions (from ini to C- termini: A1 -R1, A1-R2, A2-R1, A2-R2, B domain, a3, A3-R1, A3-R2, C-termini), cts that expressed fusions with single-XTEN insertions that retained FVIII ty were utilized. The coding sequence of FVIII (pBC0114 pcDNA4-FVIII_4-X10-Myc-SPATG-His extra RE) ('SPATG' disclosed as SEQ ID NO: 1662) was designed with various unique restriction enzyme sites to allow these specific combinations. The unique restriction enzymes are listed in Table 18 below with their relative sites between different regions: BsiWI en N-termini and A1 -R1), AflII (between A1 -R1 and A1-R2), Nhel (between A1-R2 and , KpnI (between A2-R1 and A2-R2), BamHl (between A2-R2 and B domain), Clal (between a3 and A3-R1), PflMI (between A3 -R1 and A3-R2), Xbal (between A3-R2 and C-termini), Agel (between FVIII C-termini and stop codon). Building blocks and restriction enzymes for cloning the ies were chosen, as listed in the table below. The chosen components in each region were mixed at molar ratio of 1 :1, and two sets of DNA mixtures were digested with unique restriction enzymes. DNA fragments were separated with 1% agarose gel and purified by Qiagen gel extraction kit.

DNA with XTEN insertion in the first desired region was regarded as the insert (the smaller DNA nt in agarose gel), while DNA with XTEN insertion in the second d region was regarded as vector (the bigger DNA fragment in agarose gel). The insert and vector were ligated in order to reconstitute the plasmid. The ligated DNA e was used to transform DH50L E. coli ent host cells. Transformants were screened by rolling circle amplification (RCA) and Sanger sequencing to cover imately 3-4 times the potential library size. Unique clones were fied and minipreped. Two distinct restriction digestions were then used to further confirm the integrity ofXTEN in each region. The amino acid and the encoding DNA sequences for the resulting CFXTEN fusion proteins are listed in Table 21.

CFXTEN with one or two XTEN insertions within the B/a3 domain and C terminus: The B/a3 domain and inus of FVIII are unstructured regions that tolerated XTEN insertions well. The B/a3 domain further mediated interactions with other cofactors, including the von Willibrand Factor. To investigate the optimal XTEN insertions at the B/a3 domain, select deletions and mutations of the region were made via PCR-based mutagenesis methods. Select PCR reactions and the vectors were digested with unique restriction enzymes as listed in Table 18. DNA fragments were ted with 1% agarose gel and purified by Qiagen gel extraction kit. DNA with XTEN ion in the first d region was regarded as the insert (the smaller DNA fragment in agarose gel), while DNA with XTEN insertion in the second desired region was regarded as vector (the bigger DNA fragment in agarose gel). The insert and vector were ligated in order to reconstitute the plasmid. The ligated DNA mixture was used to transform DH50t E. coli competent host cells. Transformants were ed by colony PCR and Sanger sequencing to cover approximately 8X the potential library size. Unique clones were identified and minipreped. One three-enzyme restriction digestion was then used to further confirm the integrity ofXTEN in each region. The amino acid and the encoding DNA sequences for the resulting CFXTEN fusion proteins are listed in Table 21.

Table 18. Clonin desi n for FVIII libraries with two XTEN ions pSD0005, pSD0006, pSD0007, pSD0008, LSD0001 pSD0017, pSD0018, pBC0136, pBC0137 pSD0013 (C-termini) NheI -- ClaI (B-domain) pSD0005, pSD0006, pSD0007, pSD0008, LSD0002 pSD0017, pSD0018, pBC013 6, pBC013 7 pSD0014 (C-termini) NheI -- ClaI (B-domain) W0 2013/122617 PCT/U82012/046326 Library . Vector components Restriction Insert components (XTEN region) ID QETEN re ion; en mes pSD0005, pSD0006, pSD0007, pSD0008, LSD0003 pSD0017,pSD0018,pBC0136,pBC0137 pSD0019 (C-termini) NheI--C1aI (B-domain) pSD0005, pSD0006, pSD0007, pSD0008, LSD0004 pSD0017,pSD0018,pBC0136,pBC0137 pSD0020 (C-termini) NheI--C1aI ain) pSD0045,pSD0046,pSD0048,pSD0049, LSD0005 pSD0001(A2-R1) Bs1WI AflII. __ pSD0050,pSD0051,pSD0052 (A1-R1) ,pSD0046,pSD0048,pSD0049, LSD0006 2(A2-R1) Bs1WI AflII. __ pSD0050,pSD0051,pSD0052 (A1-R1) pSD0045,pSD0046,pSD0048,pSD0049, LSD0007 pSD0003 (A2 R1) . _ Bs1WI AflII 0,pSD0051,pSD0052 (A1-R1) pSD0045,pSD0046,pSD0048,pSD0049, LSD0008 pSD0004(A2 R1) . _ Bs1WI AflII pSD0050,pSD0051,pSD0052 (A1-R1) pSD0045, pSD0046, pSD0049, pSD0050, BsiWI--AflII LSD0037 pSD0032 ) pSD0051, pSD0052 (A1-R1) pSD0045, pSD0046, pSD0049, LSD0038 pSD0039 (a3) BamHI__ClaI pSD0050,pSD0051,pSD0052 ) LSD0039 pSD0039 (a3) pSD0032, pSD0001, pSD0003 (AZ-R1) BamHI--C1aI pSD0045, pSD0046, pSD0049, LSD0040 pSD0040,pSD0010,pSD0041 (A3 R1) __ _ ClaI XbaI pSD0050,pSD0051,pSD0052 (A1-R1) LSD0041 pSD0040, 0, pSD0041 (A3-R1) pSD0032, pSD0001, pSD0003 (AZ-R1) C1aI--XbaI pSD0062, pSD0063, pSD0043, pSD0044 pSD0045, pSD0046, pSD0049, LSD0042 CM Xbal__ (A3-R2) pSD0050,pSD0051,pSD0052(Al-R1) 3 ?” pSD0063’ pSD0043’ pSD0044 pSD0032, pSD0001, pSD0003 (A2-R1) C1aI--XbaI LSD0044 F213???” pSD0063’ pSD0043’ pSD0044 pSD0040, 0, pSD0041 (A3-R1) PflMI+XbaI LSD0045 pSD0039 (a3) pSD0040, pSD0010, pSD0041 (A3-R1) -C1aI pSD0062, 3, pSD0043, LSD0046 pSD0039 (a3) BamHI__ClaI pSD0044(A3_R2) LSD0047 pSD0046(A1-R1) pSD0001,pSD0003 (AZ-R1) BsiWI—-AflII LSD0048 pSD0045,pSD0051(A1-R1) pSD0003 (AZ-R1) BsiWI--AflII 6 PCR product 300603 Domam andC BamHI+PflMI termim) pNL0007 PCR product ”13990300603 Domam andC C1aI--PflMI termim) pNL0008 PCR product ”139903009 (B Domam andC C1aI--PflMI termim) pNL0009 PCR product pSD0039 (a3 Domain) BamHI+AscI pNL0010 LSD0003.006 (B Domain and C termini) pNL0009 (a3 Domain) XbaI+AgeI Example 22: Construction of BDD FVIII sion vectors with 3-5 XTEN insertions at sites 18/26 403 745/1656 1720 1900 or 2332 FVHI-fusion constructs With XTEN insertions at sites 18/26, 403, 745/1656, 1720, 1900 or 2332 were chosen to ine and te constructs with 3, 4, 5 or 6 XTEN ions.

Construction of BDD FVIII expression vectors with 3-5 XTEN insertions at sites 26, 403, 1656, 1720, or 1900 The chosen constructs with single XTEN at the desired sites were: O, pSDOOOl, pSDOO39, pSDOOlO, and pSDOO62. Constructs with double XTENs at the desired sites included LSD0005.002, LSDOO38.001, LSDOO40.002, LSDOO42.013, LSDOO39.010, LSDOO41.008, LSDOO43.008, LSDOO45.002, LSDOO46.002, and LSDOO44.002. ng blocks and restriction enzymes for cloning the constructs were chosen, as listed in Table 19 below. Chosen components were digested with unique restriction enzymes. DNA of inserts and vectors were separated with 1% agarose gel and purified by Qiagen gel extraction kit. The insert and vector were ligated, and then transformed into DH50t E. coli competent host cells. Four colonies for each construct were analyzed by RCA and DNA sequencing. Clones with desired XTEN insertions were minipreped. Restriction digestions were then used to further confirm the integrity ofXTEN in each region. The amino acid and the encoding DNA sequences for the resulting CFXTEN fusion ns are listed in Table 21. The resulting ucts were numbered 7 to pSDOO92. uction of BDD FVIII expression vectors with 4-6 XTEN insertions at sites 18, 403, 1656, 1720, 1900 or 2332 Constructs pSDOO77 to pSDOO92 served as building blocks to generate 4- to 6-XTEN constructs with insertions at 18, 403, 1656, 1720, 1900 and 2332. Building block constructs and ction enzymes for cloning the constructs were chosen, as listed in Table 19 below. Chosen components were digested with unique restriction enzymes. DNA of inserts and vectors were separated with 1% agarose gel and purified by Qiagen gel extraction kit. The insert and vector were ligated, and then ormed into DH50t E. coli competent host cells. Eight colonies for each construct were analyzed by colony PCR and DNA sequencing. Clones with desired XTEN ions were minipreped.

Restriction digestions were then used to further m the integrity ofXTEN in each region. The amino acid and the encoding DNA sequences for the resulting CFXTEN fusion proteins are listed in Table 21.

The resulting constructs were numbered pBCO247 to 7, pNLOO22, 23, 24, 25, and 30 Construction of BDD FVIII expression vectors with 4-6 XTEN insertions at sites 18, 403, 745, 1720, 1900 or 2332 ucts pBCO247 to pBCO252, pBCO255, pNLOO22 to pNLOO25 served as building blocks to generate 4- to 6-XTEN constructs with insertions at 18, 403, 745, 1720, 1900 and 2332. Building block constructs and ction enzymes for cloning the constructs were chosen, as listed in Table 19 below. Chosen components were digested with unique restriction enzymes. DNA of inserts and vectors were separated with 1% agarose gel and purified by Qiagen gel extraction kit. The insert and vector were ligated, and then ormed into DH50t E. coli competent host cells. Eight colonies for each construct were analyzed by colony PCR and DNA sequencing. Clones with desired XTEN insertions were minipreped. Restriction digestions were then used to further confirm the ity ofXTEN in each region. The amino acid and the encoding DNA sequences for the resulting CFXTEN fusion proteins are listed in Table 21. The resulting constructs were numbered pBCO25 8 to pBCO268.

Table 19: Cloning design for FVIII libraries with 3-5 XTEN insertions at sites 26, 403, 1656, 1720, or 1900 Cfiljgza Insert components (XTEN ) Vi§¥E§T§22:31ts gign pSDOO77 pSDOOSO (Al-R1) LSDOO39.010 (AZ-R1, a3) BsiWI+AflII 8 pSDOOlO (A3-R1) LSD0005.002 (Al-R1, A2-R1) Xba1 pSDOO79 pSDOO62 (A3-R2) LSD0005.002 (Al-R1, A2-R1) ClaI--Xba1 pSDOO8O pSDOOSO (Al-R1) LSDOO45.002 (a3, A3-R1) BsiWI—-Afl11 pSDOO81 pSDOOSO (Al-R1) LSDOO46.002 (a3, A3-R2) BsiWI--AflII pSDOO82 O (Al-R1) LSDOO44.002 (A3-R1, A3-R2) BsiWI--AflII pSDOO83 pSDOOlO (A3-R1) LSDOO39.010 (AZ-R1, a3) ClaI--Xba1 pSDOO84 pSDOO62 ) LSDOO39.010 (AZ-R1, a3) ClaI--Xba1 pSDOO85 pSDOO62 (A3-R2) LSDOO41.008 (AZ-R1, A3-R1) PflMI--Xba1 pSDOO86 2 (A3-R2) LSDOO45.002 (a3, A3-R1) PflMI--Xba1 pSDOO87 LSDOO39.010 (AZ-R1, a3) LSDOO40.002 (Al-R1, A3-R1) NheI--Cla1 pSDOO88 LSDOO39.010 (AZ-R1, a3) LSDOO42.013 (Al-R1, A3-R2) NheI--C1a1 pSDOO89 LSDOO44.002 (A3-R1, A3-R2) LSD0005.002 (Al-R1, A2-R1) ClaI--Xba1 pSDOO9O LSDOO44.002 , A3-R2) LSDOO38.001 (Al-R1, a3) ClaI--Xba1 1 LSDOO44.002 (A3-R1, A3-R2) LSDOO39.010 (AZ-R1, a3) Xba1 pSDOO92 LSDOO44.002 (A3-R1, A3-R2) 7 (Al-R1, A2-R1, a3) Xba1 pBC0247 pSDOO77 LSD0050.003 \heI--BstBI pBC0248 pSDOO78 LSD0050.003 \heI--BstBI pBC0249 pSDOO79 LSD0050.003 \heI--BstBI pBC0250 pSDOO8O 0.003 \heI--BstBI 1 pSDOO82 0.003 \heI--BstBI pBC0252 pSDOO8O LSD0050.003 \heI--BstBI pBC0253 pSDOO87 LSD0050.003 \heI--BstBI 4 8 LSD0050.003 \heI--BstBI pBC0255 pSDOO89 LSD0050.003 \heI--BstBI pBC0256 pSDOO9O LSD0050.003 \heI--BstBI pBC0257 pSDOO92 LSD0050.003 \heI--BstBI pNL0022 LSDOOO3.009 pSDOO83 XbaI--Agel pNL0023 LSDOOO3.009 pSDOO84 XbaI--Agel pNL0024 LSDOOO3.009 pSDOO85 XbaI--Agel pNL0025 LSDOOO3.009 pSDOO86 XbaI--Agel pNLOO3O LSDOOO3.009 pSDOO91 XbaI--Agel pBC0258 LSDOOO3.006 pBC0247 BamHI--Cla1 pBC0259 LSDOOO3.006 pBC0248 BamHI--Cla1 nggza Insert components (XTEN region) veg§¥Ec§?§:gfinlts sttrigign pBC026O LSDOOO3.006 pBC0249 BamHI--Cla1 Example 23: Construction of CFXTEN expression vectors with three or four XTENs: the first XTEN in the B domain, the second XTEN at the C-terminus, and the third or fourth XTEN insertion within the A1 or A2 or A3 domains ies of CFXTEN fusion proteins were constructed with three XTEN insertions by combining coagulation-active clones with XTEN insertions in the Al, A2, or A3 domains and clones with XTEN inserted within the B domain and at the inus. Additional libraries were constructed with a fourth XTEN added in the Al, A2, or A3 domains to select members of the 3 XTEN libraries. The design of the cloning scheme is summarized in the table below. DNA was prepared for the inserts and vectors by restriction enzyme ion and agarose gel ation. After ligating the inserts with the corresponding vectors, the ligated DNA mixture was used to transform DH50t competent E. coli host cells. ormants were screened by RCA and sequencing to cover approximately 3-4 times the potential library size. Unique clones were identified and mini-prepped. Three distinct restriction digestions were then used to further confirm the integrity of each XTEN. The amino acid and the encoding DNA ces for the resulting CFXTEN fusion proteins are listed in Table 21.

Table 20: Clonin desi n for FVIII libraries with 3 XTEN insertions at sites B domain C-termini and A1/A2/A3 domain Library Insert components (XTEN Vector 0011119011911“ Restriction ID region) (XTEN region) enzymes LSD0003.006 (B domain and C- pSD0045, pSD0046, pSD0049, pSD0050, 9 BamHI Ag“__ 1, pSD0052 (Al-R1) LSD0003.009 (B domain and C- pSD0045, pSD0046, pSD0049, pSD0050, O BamHI Ag“__ pSD0051, pSD0052 (Al-R1) LSD0051 igfig3‘006 (B domam and C' pSD0032, pSD0001, 3 (AZ-R1) BamHI--Agel WO 22617 pSD0062, pSD0063, pSD0043, LSD0056 LSD0003.009 (B domam and C-termlm). . . C1aI+XbaI pSD0044 (A3-R2) pBC0274 pSD0009 (A3_R1) LSD0003.006 (B domain and C-teimini) C1aI--Xbal pNL0004 (A3_R2) LSD0003.006 (B domain and C-teimini) C1aI--Xbal pBC0276 pBC0280 (A1_R1) LSD0003.006 (B domain and C-teimini) pBC0277 pBC0281 (A2_R1) 3.006 (B domain and C-teimini) pBC0278 pBC0282 (A3_R1) LSD0003.006 (B domain and C-teimini) C1aI--Xbal .BC0279 .BC0283 A3 R2 LSD0003.006 B domain and C-teimini ClaI--Xbal L09_01 pBC0284 (CT) 39135013555:: é89’ 290’ 291’ 292’ Agel L09_01 pSD0014 (CT) 39135013555:: :fgffgé89’ 290’ 291’ 292’ XbaI--Agel pBC0285, 286, 287, 288, 289, 290, 291, 292, L09_01 pSD0020 (CT) Xbal Agel__ 293 (B domain and A3_R2) Table 21: DNA and Amino Acid Se uences of FVIII-XTEN Constructs Construct Amino acid sequence disclosed as DNA sequence disclosed as Name SEQ ID NO: SEQ ID NO: pBC01 14 595 596 pBC0126 597 598 pBC0127 599 600 pBC0165 601 602 3 603 604 4 605 606 pBC0166 607 608 pBC0185 609 610 pBC0167 61 1 612 pBC0128 613 614 pBC0168 615 616 pBC0129 617 618 pBC0169 619 620 pBC0130 621 622 pBC0131 623 624 pBC0132 625 626 pBC0170 627 628 pBC0133 629 630 pBC0171 631 632 4 633 634 2 635 636 pBC0135 637 63 8 pBC0149 639 640 pBC0136 641 642 pBC0137 643 644 pBC0138 645 646 pBC0139 647 648 pBC0140 649 650 pBC0173 651 652 pBC0174 653 654 pBC0175 655 656 pBC0176 657 658 pBC0177 659 660 pBC0178 661 662 pBC0141 663 664 pBC0179 665 666 pBC0180 667 668 pBC0142 669 670 3 671 672 pBC0181 673 674 pBC0182 675 676 pBC0144 677 678 pBC0145 679 680 pBC0146 681 682 1 683 684 pSD0002 685 686 pSD0003 687 688 pSD0004 689 690 pSD0005 691 692 pSD0006 693 694 pSD0007 695 696 pSD0008 697 698 pSD0009 699 700 pSD0010 701 702 pSD0011 703 704 pSD0012 705 706 pSD0013 707 708 pSD0014 709 710 pSD0017 711 712 pSD0018 713 714 pSD0019 715 716 0 717 718 pSD0015 719 720 pSD0016 721 722 pSD0021 723 724 pSD0022 725 726 pSD0023 727 728 pSD0024 729 730 pSD0025 731 732 6 733 734 pSD0027 735 736 pSD0028 737 738 pSD0029 739 740 0 741 742 pSD0031 743 744 pSD0032 745 746 pSD0033 747 748 pSD0034 749 750 pSD0035 751 752 pSD0036 753 754 pSD0037 755 756 pSD0038 757 758 pSD0039 759 760 pSD0040 761 762 pSD0041 763 764 pSD0042 765 766 pSD0043 767 768 pSD0044 769 770 pSD0062 771 772 pSD0063 773 774 pSD0045 775 776 pSD0046 777 778 2012/046326 pSD0047 779 780 8 781 782 pSD0049 783 784 pSD0050 785 786 1 787 788 pSD0052 789 790 pSD0053 791 792 pSD0054 793 794 pSD0055 795 796 pSD0056 797 798 pSD0057 799 800 pSD0058 801 802 pSD0059 803 804 pSD0060 805 806 pSD0061 807 808 LSD0001.002 809 810 LSD0001.005 811 812 LSD0001.006 813 814 LSD0001.011 815 816 LSD0001.012 817 818 LSD0001.013 819 820 LSD0001.016 821 822 LSD0001.021 823 824 LSD0002.001 825 826 LSD0002.002 827 828 LSD0002.014 829 830 LSD0003.004 831 832 3.006 833 834 LSD0003.009 835 836 LSD0003.014 837 838 4.010 839 840 LSD0004.011 841 842 LSD0004.014 843 844 LSD0004.016 845 846 LSD0004.022 847 848 LSD0003.016 849 850 LSD0005.002 851 852 LSD0005.004 853 854 LSD0005.005 855 856 LSD0005.011 857 858 LSD0005.018 859 860 LSD0006.002 861 862 LSD0006.005 863 864 LSD0006.007 865 866 LSD0006.011 867 868 LSD0007.002 869 870 LSD0007.004 871 872 LSD0007.013 873 874 LSD0008.001 875 876 LSD0008.002 877 878 LSD0008.006 879 880 LSD0008.009 881 882 LSD0008.017 883 884 LSD0002.025 885 886 2.013 887 888 3.025 889 890 LSD0004.025 891 892 LSD0003.005 893 894 7.008 895 896 LSD0044.002 897 898 LSD0044.005 899 900 LSD0044.039 901 902 LSD0044.022 903 904 LSD0044.003 905 906 LSD0044.001 907 908 LSD003 8.001 909 910 LSD003 8.003 911 912 LSD003 8.008 913 914 LSD003 8.012 915 916 LSD003 8.013 917 918 LSD003 8.015 919 920 LSD0039.001 921 922 LSD0039.003 923 924 LSD0039.010 925 926 LSD0045.001 927 928 LSD0045.002 929 930 LSD0042.014 931 932 2.023 933 934 LSD0042.006 935 936 LSD0042.013 937 938 LSD0042.001 939 940 LSD0042.039 941 942 LSD0042.047 943 944 LSD0042.003 945 946 LSD0042.004 947 948 LSD0042.008 949 950 LSD0042.038 951 952 LSD0042.082 953 954 LSD0042.040 955 956 LSD0037.002 957 958 LSD0037.009 959 960 LSD0037.011 961 962 LSD0047.002 963 964 LSD0047.005 965 966 LSD0048.007 967 968 LSD0046.001 969 970 6.002 971 972 LSD0046.003 973 974 LSD0040.011 975 976 LSD0040.042 977 978 LSD0040.002 979 980 LSD0040.008 981 982 LSD0040.021 983 984 LSD0040.037 985 986 LSD0040.046 987 988 LSD0040.003 989 990 LSD0040.006 991 992 LSD0040.007 993 994 VV()2013/122617 LSD0040.010 995 996 LSD0040.039 997 998 LSD0040.052 999 1000 LSD0041.001 1001 1002 1.004 1003 1004 LSD0041.006 1005 1006 LSD0041.008 1007 1008 LSD0041.010 1009 1010 LSD0041.014 1011 1012 LSD0041.016 1013 1014 LSD0041.035 1015 1016 LSD0043.001 1017 1018 LSD0043.002 1019 1020 LSD0043.005 1021 1022 LSD0043.006 1023 1024 LSD0043.007 1025 1026 LSD0043.008 1027 1028 LSD0043.015 1029 1030 LSD0043.029 1031 1032 LSD0043.043 1033 1034 pSD0077 1035 1036 pSD0078 1037 1038 pSD0079 1039 1040 pSD0080 1041 1042 pSD0081 1043 1044 pSD0082 1045 1046 pSD0083 1047 1048 pSD0084 1049 1050 pSD0085 1051 1052 pSD0086 1053 1054 pSD0087 1055 1056 pSD0088 1057 1058 pSD0089 1059 1060 pSD0090 1061 1062 pSD0091 1063 1064 2 1065 1066 9.002 1067 1068 LSD0049.008 1069 1070 LSD0049.011 1071 1072 LSD0049.012 1073 1074 LSD0049.020 1075 1076 9.021 1077 1078 LSD0050.002 1079 1080 LSD0050.003 1081 1082 LSD0050.007 1083 1084 LSD0050.010 1085 1086 0.012 1087 1088 LSD0050.014 1089 1090 LSD0051.002 1091 1092 LSD0051.003 1093 1094 LSD0052.001 1095 1096 LSD0052.003 1097 1098 LSD0053.021 1099 1100 LSD0053.022 1101 1102 VV()2013/122617 53.024 1103 1104 LSD0054021 1105 1106 LSD0054025 1107 1108 LSD0054026 1109 1110 LSI)0055.021 1111 1112 LSD0055022 1113 1114 LSD0055026 1115 1116 LSD0056021 1117 1118 LSD0056024 1119 1120 6025 1121 1122 *0\10001 1123 1124 *01’ L0002 1125 1126 ’U/333/ L0003 1127 1128 L0004 1129 1130 L0005 1131 1132 L0006 1133 1134 "0’5 L0007 1135 1136 33/L0008 1137 1138 L0009 1139 1140 mm 1141 1142 chmz44 1143 1144 chmz45 1145 1146 chmz46 1147 1148 chmz47 1149 1150 pBC0248 1151 1152 chmz49 1153 1154 pBC0250 1155 1156 pBC0251 1157 1158 chmzsz 1159 1160 pBC0253 1161 1162 pBCD254 1163 1164 pBC0255 1165 1166 pBC0256 1167 1168 pBC0257 1169 1170 ch0259 1171 1172 pBC0260 1173 1174 chmzéz 1175 1176 pBC0263 1177 1178 pBCD264 1179 1180 pBC0266 1181 1182 pBC0267 1183 1184 pBC0268 1185 1186 pN10016 1187 1188 pN10017 1189 1190 pN10018 1191 1192 leoozz 1193 1194 3 1195 1196 pN10024 1197 1198 leoozs 1199 1200 leooso 1201 1202 LSD0057001 1203 1204 LSD0057004 1205 1206 LSD0057005 1207 1208 LSD0057010 1209 1210 VV()2013/122617 LSD0058003 1211 1212 LSD0058005 1213 1214 LSD0058006 1215 1216 LSD0059.002 1217 1218 LSD0059.003 1219 1220 LSD0059.005 1221 1222 LSD0059.006 1223 1224 LSD0060001 1225 1226 LSD0060003 1227 1228 LSD0060004 1229 1230 LSD006L002 1231 1232 LSD006L007 1233 1234 LSD006L008 1235 1236 LSD006L012 1237 1238 LSD0062001 1239 1240 LSD0062002 1241 1242 LSD0062006 1243 1244 2007 1245 1246 LSD0063001 1247 1248 LSD0063003 1249 1250 LSD0063011 1251 1252 LSD0064017 1253 1254 LSD0064018 1255 1256 LSD0064020 1257 1258 LSD0064021 1259 1260 LSD0065001 1261 1262 LSD0065007 1263 1264 LSD0065014 1265 1266 LSD0066001 1267 1268 LSD0066002 1269 1270 LSD0066009 1271 1272 LSD0066011 1273 1274 LSD0067004 1275 1276 LSD0067005 1277 1278 LSD0067006 1279 1280 LSD0067008 1281 1282 LSD0068001 1283 1284 LSD0068002 1285 1286 LSD0068005 1287 1288 LSD0068010 1289 1290 LSD0069004 1291 1292 LSD0069008 1293 1294 LSD0070.003 1295 1296 LSD0070.004 1297 1298 LSD0070.005 1299 1300 LSD007L001 1301 1302 L002 1303 1304 LSD007L008 1305 1306 LSD0072.001 1307 1308 2.002 1309 1310 LSD0072.003 1311 1312 LSI)0073.002 1313 1314 LSI)0073.004 1315 1316 LSD0073.006 1317 1318 VV()2013/122617 LSD0074.007 1319 1320 LSD0074.010 1321 1322 LSD0074.01 1 1323 1324 LSD0075.003 1325 1326 LSD0075.004 1327 1328 LSD0075.007 1329 1330 LSD0076.002 1331 1332 LSD0076.003 1333 1334 pSD0093 1335 1336 pSD0094 1337 1338 pSD0095 1339 1340 pSD0096 1341 1342 pSD0097 1343 1344 pSD0098 1345 1346 pSD0099 1347 1348 pSD0100 1349 1350 pSD0101 1351 1352 pSD0102 1353 1354 3 1355 1356 pSD0104 1357 1358 pcs0001 1359 1360 pcs0002 1361 1362 pcs0003 1363 1364 pcs0004 1365 1366 pcs0005 1367 1368 6 1369 1370 pBC0269 1371 1372 pBC0270 1373 1374 pBC0271 1375 1376 pBC0272 1377 1378 pBC0273 1379 1380 pBC0274 1381 1382 pBC0275 1383 1384 pBC0276 1385 1386 pBC0277 1387 1388 8 1389 1390 pBC0279 1391 1392 pBC0280 1393 1394 1 1395 1396 pBC0282 1397 1398 pBC0283 1399 1400 pBC0284 1401 1402 pBC0285 1403 1404 pBC0286 1405 1406 pBC0287 1407 1408 pBC0288 1409 1410 pBC0289 1411 1412 pBC0290 1413 1414 pBC0291 1415 1416 pBC0292 1417 1418 pBC0293 1419 1420 pBC0294 1421 1422 pBC0295 1423 1424 pBC0296 1425 1426 pBC0297 1427 1428 pBC0298 1429 1430 pBC0299 1431 1432 pBC0300 1433 1434 pBC0301 1435 1436 pBC0302 1437 1438 pBC0303 1439 1440 pBC0304 1441 1442 pBC0305 1443 1444 pBC0306 1445 1446 pBC0307 1447 1448 8 1449 1450 pBC0309 1451 1452 pBC0310 1453 1454 pBC0311 1455 1456 pBC0312 1457 1458 pBC0313 1459 1460 pBC0314 1461 1462 pBC0315 1463 1464 pBC0316 1465 1466 pBC0317 1467 1468 pBC0318 1469 1470 pBC0319 1471 1472 pBC0320 1473 1474 pBC0321 1475 1476 PBC0322 1477 1478 PBC0323 1479 1480 pNL0040 1481 1482 pNL0041 1483 1484 pNL0042 1485 1486 pNL0043 1487 1488 Example 24: Transfection of Mammalian Cells, Expression of FVIII-XTEN and Assessment of FVIII Activity ian cells, including but not limited to CH0, BHK, COS, and HEK293, are suitable for transformation with the vectors of the Examples, above, in order to express and recover FVIII-XTEN fusion protein. The following are details for methods used to express BDD FVlll and FVIll-XTEN fusion protein constructs pBCOl l4, 5, pBCOl36, pBCOl37, pBCOl45, pBCOl46, and pBCOl49 by transient transfection, which includes electroporation and chemical (PEI) transfection methods.

Adherent HEK293 cells purchased from ATCC were revived in medium of vendor’s endation and passaged for a few generations before multiple vials were frozen in the medium with 5% DMSO. One vial was d and ed one more time before transfection. The HEK293 cells were plated 1-2 days before ection at a density of approximately 7X 105 per ml in one T175 per ection, using 35 ml medium. On the day of transfection the cells were nized, detached and counted, then rinsed in the medium until an even cell suspension was achieved. The cells were counted and an riate volume of cells (based on cell count above) were transferred to 50mL centrifuge tube, WO 22617 such that there were approximately 4 X 10° cells per transfection. Cells were centrifuged for 5min at 500 RCF, the supernatant discarded, and the cells resuspended in 10ml of D-PBS.

Electroporation: For electroporation, an appropriate volume of resuspension buffer was added using a micropipette (supplied in the NeonTM Transfection System 100 uL Kit), such that 110 pl of buffer was available per transfection. te volumes of 110 pl of cell suspension were added to each Eppendorf tube containing 11 ul of plasmid DNA for each of the individual FVIII-XTEN constructs for a total of 6 ug (volume of DNA may be less, qs to 11 ul with sterile H20). A NeonTM ection Device was used for transfection. The program was set to electroporate at 1100v for a pulse width of 20ms, for a total of two pulses. A NeonTM Tube (supplied in the NeonTM Transfection System 100 uL Kit) was placed into NeonTM Pipette Station. A volume of 3 mL of Electrolytic Buffer E2 ied in the NeonTM Transfection System 100 uL Kit) was added to the NeonTM Tube. NeonTM Pipettes and 100 pl NeonTM Tips were used to electroporate 100 pl of cell-plasmid DNA mixture using the NeonTM Pipette Station.

The electroporation was executed and when complete, the NeonTM e was removed from the Station and the pipette with the transfected cells was used to transfer the cells, with a circular motion, into a 100 mm x 20mm petri plate containing 10 ml of Opti-MEM I Reduced-Serum Medium (1X, Invitrogen), such that transfected cells were evenly distributed on plate. The cells for each ection were incubated at 37°C for expression. On day 3 post-transfection, a 10% volume of salt solution of 10mM Hepes, 5mM CaClg, and 4M NaCl was added to each cell e and gently mixed for 30 minutes. Each cell culture was transferred to a 50 ml conical centrifuge tube and was centrifuged at 3000 rpm for 10 minutes at 4°C.

The supematants for each culture were placed into a new 50 ml conical tube and then split into ts of 5x1 ml in Eppendorf and 2x15ml conical tubes for assay or were flash frozen before g for expression of FVIII-XTEN in ELISA and performance in an FVIII activity assay, as described herein.

Chemical transfection: Chemical transfection can be accomplished using standard methods known in the art. In the present e, PEI is utilized, as described.

Suspension 293 Cells are seeded the day before transfection at 7 x 105 cells/mL in sufficient Freestyle 293 (Invitrogen) medium to provide at least 30 ml working volume, and incubated at 37°C. On the day of transfection, an aliquot of 1.5 ml of the transfection medium is held at room temperature, to which 90 uL of lmg/ml PEI is added and vortexed briefly. A volume of 30 ul of DNA encoding the FVIII-XTEN_AE288 construct (concentration of lmg/ml) is added to the PEI solution, which is vortexed for 30 sec. The mixture is held at room temperature for 5-15 min. The I mixture is added to the HEK293 cells and the suspension is incubated at 37°C using pre-established shake flask ions.

About four hours after the addition of the DNA/PEI mix, a 1x volume of expansion media is added and the cells incubated at 37°C for 5 days. On the day of harvest, a 10% volume of salt solution of 10mM Hepes, 5mM CaClg, and 4M NaCl is added to the cell culture and gently mixed for 30 minutes. The cell culture is erred to a 50 ml conical centrifuge tube and is centrifuged at 4000 rpm for 10 minutes at 4°C. The supernatant is placed into a new 50 ml conical tube and then split into aliquots of 5x1 ml in Eppendorf and 2x15ml conical tubes for assay or are flash frozen before testing for expression of FVIII- XTEN in ELISA and/or performance in an FVIII activity assay, as bed herein.

] Generation of stable pools and cell lines that produce FVIII-XTEN Stable pools are generated by culturing transfected cells for 3-5 weeks in medium containing selection antibiotics such as puromycin, with medium change every 2-3 days. Stable cells can be used for either production or generation of stable clones. For stable cell line selection during primary screening, cells from stable pools either from on—going passaging or revived from frozen vials are seeded in 96-well plates at a target density of 0.5 cell/well. About 1 week after seeding spent medium from wells with single cell cluster as observed under microscope are tested for expression of FVIII by ty assay or antigen measurement.

For additional rounds of screening, normalized numbers of cells are seeded in multi-well plates.

Spent medium is harvested and tested for FVIII tration by ELISA and FVIII activity assay. Cells would also be ted from the plates and counted using Vi-Cell. Clones are ranked by (l) FVIII titers according to ELISA and activity; (2) ratios of ELISA titer/cell count and activity titer/cell count; and (3) integrity and homogeneity of products produced by the clones as measured by n blots. A number of clones for each of the constructs are ed from the primary screening for additional rounds of screening.

For the second round of screening, cells in 96-well plates for the top clones ed from primary screening are first expanded in T25 flasks and then seeded in duplicate 24-well plates. Spent medium is ted from the plates for FVIII activity and antigen quantification and cells harvested and counted by Vi-Cell. Clones are ranked and then selected according to titers by ELISA and activity assay, ELISA titer/cell and activity titer/cell count ratios. Frozen vials are prepared for at least 5-10 clones and again these clones were screened and ranked according to titers by ELISA and activity, and ratios of ELISA titer/cell count and activity titer/cell count, and product integrity and homogeneity by Western blot, and 2-3 clones are selected for productivity evaluation in shake flasks. Final clones are selected based on specific productivity and product quality.

Production of FVIII-XTEN secreted in cell culture medium by sion 293 stable HEK293 stable cell clones selected by the ing methods are seeded in shake flasks at 1-2 X 105 cells/ml in expression medium. Cell count, cell viability, FVIII activity and n expression titers are monitored daily. On the day when FVIII activity and antigen titers and product quality are optimal, the culture is ted by either centrifugation/sterile filtration or depth filtration/sterile ion. The filtrate is either used immediately for tial flow filtration (TFF) processing and purification or stored in -80°C freezer for TFF processing and purification later.

Example 25: Purification and Characterization of CFXTEN Constructs Exemplary methods for the purification and characterization of CFXTEN constructs with one or more XTEN follow.

Purification of FVII-XTEN AE864 by FVIII affinity chromatography CFXTEN containing supernatant is filtered using a Cuno ZetaPlus Biocap filter and a Cuno BioAssure capsule and subsequently concentrated by tial flow filtration using a ore Pellicon 2 Mini cartridge with a 30,000 Da MWCO. Using the same tangential flow filtration cartridge the sample is ered into 10 mM histidine, 20 mM calcium chloride, 300 mM sodium chloride, and 0.02% Tween 80 at pH 7.0. lect resin (GE 1701) selectively binds FVIII or B domain deleted FVIII using a 13kDa recombinant protein ligand coupled to a chromatography resin. The resin is equilibrated with 10 mM histidine, 20 mM calcium chloride, 300 mM sodium chloride, and 0.02% Tween 80 at pH 7.0 and the supernatant loaded. The column is washed with 20 mM histidine, 20 mM calcium de, 300 mM sodium chloride, and 0.02% Tween 80 at pH 7.0, then is washed with 20 mM histidine, 20 mM calcium chloride, 1.0 M sodium chloride, and 0.02% Tween 80 at pH 7.0, and eluted with 20 mM ine, 20 mM calcium chloride, 1.5 M sodium chloride, and 0.02% Tween 80 dissolved in 50% ethylene glycol at pH 7.0.

Concentration and Buffer Exchange by Tangential Flow Filtration and Diafiltration Supernatant batches totaling at least 10 L in , from stable CHO cells lines expressing CFXTEN are filtered using a Cuno ZetaPlus Biocap filter and a Cuno BioAssure capsule. They are subsequently concentrated approximately 20-fold by tangential flow ion using a Millipore Pellicon 2 Mini cartridge with a 30,000 Da MWCO. Using the same tangential flow filtration cartridge the sample is diafiltered with 10 mM histidine, 20 mM calcium chloride, 300 mM sodium chloride, and 0.02% Tween 80 at pH 7.0 10 mM tris pH 7.5, 1 mM EDTA with 5 volumes worth of buffer exchange.

Samples are divided into 50 ml aliquots and frozen at -80°C.

Purification of CFXTEN by Anion Exchange Chromatography Using an Akta FPLC system the sample is purified using a SuperQ-650M column. The column is equilibrated into buffer A (0.02 mol/L imidazole, 0.02 mol/L glycine ethylester hydrochloride, 0.1 5 mol/L, NaC1, 2.5% glycerol, pH 6.9) and the sample . The sample is eluted using buffer B (5 mmol/L histidine HCl (His/HCI), 1.15 mol/L NaCl, pH 7.0). The 215 nm chromatogram is used to monitor the elution . The eluted fractions are assayed for FVIH by ELISA, SDS-PAGE or activity assay. Peak fractions are pooled and stored or subjected to thrombin activation immediately (O’Brien et al., Blood (1990) 75:1664-1672). Fractions are assayed for FVIH activity using an aPTT based factor assay. A Bradford assay is performed to ine the total amount of protein in the load and elution fractions.

] Purification of CFXTEN by Hydrophobic ction Chromatography CFXTEN samples in Buffer A (50 mmol/l histidine, 1 mmol/l CaCl 2, 1 M NaCl, and 0.2 g/l Tween 80®, pH 7.0) are loaded onto a toyopearl ether 650M resin equilibrated in Buffer A. The column is washed with 10 column volumes of Buffer A to remove DNA, incorrectly folded forms and FVIH, and other contaminant proteins. The CFXTEN is eluted with Buffer B (25 mmol/l histidine, 0.5 mmol/l CaCl 2 and 0.4 mol/l NaCl, pH 7.0) as a single step elution (US patent 6005082). Fractions are assayed for FVIH activity using an aPTT based factor assay. A Bradford assay is performed to determine the total amount of n in the load and elution fractions.

Removal of Aggregated protein from monomeric CFXTEN with Anion Exchange Chromatography Using an Akta FPLC system the sample is purified using a macrocap Q column. The column is brated into buffer A (20 mM MES, lmM CaCl2, pH 7.0) and the sample is loaded. The sample is eluted using a linear gradient of 30% to 80% buffer B (20 mM MES, lmM CaC12, pH 7.0 + 500 mM NaCl) over 20 column volumes. The 215 nm chromatogram is used to monitor the elution profile. The fractions corresponding to the early portion of the elution contain primarily monomeric protein, while the late portion of the elution contains primarily the aggregated species. Fractions from the macrocapQ column is analyzed via size exclusion chromatography with 60 cm BioSep G4000 column to determine which to pool to create an aggregate free sample.

Activation of FVIII by Thrombin Purified FVIII in 5 mmol/L histidine HCl (His/HCI), 1.15 mol/L NaCl, pH 7.0 is treated with thrombin at a 1:4 ratio of units of human thrombin to units FVIII, and the sample is incubated at 37°C for up to 2 hours. To monitor the tion s, aliquots of this sample are then withdrawn, and acetone precipitated by the addition of 4.5 vol ice-cold acetone. The sample is incubated on ice for 10 minutes, and the precipitate is ted by centrifugation at 13,000 g in a microfuge for 3 minutes. The acetone is removed, and the precipitate is resuspended in 30 ML SDS-PAGE reducing sample buffer and boiled for 2 minutes. Samples are then assayed by SDS-PAGE or western blot. The conversion of FVIII t0 FVIIIa is ed by looking for the conversion of the heavy chain into 40 and 50 kDa fragments and the conversion of the light chain into a 70 kDa nt (O’Brien et al., Blood (1990) 4-1672).

SEC Analysis of CFXTEN ] FVII-XTEN purified by affinity and anion exchange chromatography is analyzed by size exclusion chromatography with 60 cm BioSep G4000 column. A monodispersed population with a hydrodynamic radius of ~10 nm/ apparent MW 0f~1.7 MDa (XTEN—288 fusion) or ~12 nm/ an nt MW of 5.3 MDa (XTEN—864 fusion) is indicative of an ation-free sample. CFXTEN is ed to have an apparent molecular weight factor up to or about 8 (for an XTEN—288 fusion with FVIII) or up to or about ~15 (for an XTEN—864 fusion with FVIII).

ELISA based Concentration Determination of CFXTEN ] The quantitative determination of factor VIII / CFXTEN antigen concentrations using the double antibody enzyme linked immuno-sorbent assay (ELISA) is med using proven antibody gs (VisuLizeTM FVIII Antigen kit, Affinity Biologicals, Ontario Canada). Strip wells are pre- coated with sheep polyclonal antibody to human FVIII. Plasma samples are diluted and applied to the wells. The FVIII antigen that is t binds to the coated antibody. After washing away unbound material, peroxidase-labeled sheep detecting antibody is applied and allowed to bind to the ed FVIII. The wells are again washed and a solution of TMB (the peroxidase substrate tetramethylbenzidine) is applied and d to react for a fixed period of time. A blue color develops which changes to yellow upon quenching the reaction with acid. The color formed is measured spectrophotometrically in a microplate reader at 450 nm. The absorbance at 450 nm is directly proportional to the quantity of FVIII antigen captured onto the well. The assay is calibrated using either the calibrator plasma provided in the kit or by substituting a CFXTEN standard in an appropriate matrix.

Assessment of CFXTEN Activity via a FXa Coupled Chromogenic ate Assay Using the ChromogeniX Coamatic Factor VIII (ChromogeniX, cat# 82258563) the activity of FVIII or CFXTEN comprising FVIII is assessed as follows. In the presence of calcium ions and phospholipids, factor X is activated to factor Xa by factor IXa. This activation is greatly stimulated by factor VIII which acts as a cofactor in this reaction. By using optimal s of Ca2+, phospholipid and factor IXa, and an excess of factor X, the rate of activation of factor X is linearly related to the amount of factor VIII. Factor Xa hydrolyses the chromogenic substrate S-2765 thus liberating the chromophoric group, pNA. The color is then read spectrophotometrically at 405 nm. The generated factor Xa and thus the ity of color is proportional to the factor VIII actiVity in the sample. Hydrolysis of S-2765 by thrombin formed is prevented by the addition of the synthetic thrombin inhibitor I-2581 together with the substrate. The actiVity of an unknown sample is determined by comparing final A405 of that sample to those from a standard curve constructed from known FVIII amounts. By also determining the amount of FVIII antigen present in the samples (Via A280 or ELISA), a specific actiVity of a sample is ine to tand the relative potency of a particular preparation of FVIII. This enables the relative ncy of ent isolation strategies or construct designs for CFXTEN fusions to be assessed for activity and ranked. ] aPTT Based Assays for CFXTEN Activity Determination CFXTEN acts to replace FVIII in the sic or contact activated coagulation pathway. The actiVity of this coagulation pathway is assessed using an activated partial thromboplastin time assay . FVIII activity specifically is ed as follows: a standard curve is prepared by diluting normal control plasma (Pacific Hemostasis cat# 100595) ld with FVIII deficient plasma (cat# 100800) and then conducting 6, 4-fold serial dilutions again with factor VIII deficient plasma. This creates a standard curve with points at 500, 130, 31, 7.8, 2.0, 0.5 and 0.1 IU/ml of activity, where one unit of actiVity is defined as the amount of FVIIIC actiVity in 1 ml of normal human plasma. A FVIII- deficient plasma also is included to determine the background level of actiVity in the null plasma. The sample is prepared by adding CFXTEN to FVIII deficient plasma at a ratio of 1:10 by volume. The samples is tested using an aPTT assay as follows. The samples are incubated at 37C in a molecular devices plate reader spectrophotometer for 2 minutes at which point an equal volume of aPTT reagent (Pacific Hemostasis cat# 100402) is added and an additional 3 minute 37C incubation performed. After the incubation the assay is activated by adding one volume of calcium chloride (Pacific asis cat# 100304). The turbidity is monitored at 450 nm for 5 minutes to create reaction s. The aPTT time, or time to onset of ng activity, is defined as the first time where OD405 nm sed by 0.06 over baseline. A log — linear standard curve is created with the log of ty relating linearly to the aPTT time. From this the actiVity of the sample in the plate well is determined and then the actiVity in the sample is determined by multiplying by 11 to account for the dilution into the FVIII deficient plasma.

By also determining the amount of FVIII antigen present in the samples (Via A280 or ELISA), a specific activity of a sample can be determine to tand the relative potency of a particular preparation of FVIII. This enables the ve efficiency of different isolation strategies or construct designs for CFXTEN fusions to be ranked.

Western Blot Analysis of FVIII / FVIII-XTEN expressed proteins Samples were run on a 8% homogeneous SDS gel and uently transferred to PVDF membrane. The samples in lanes l-15 were: MW Standards, FVIII(42.5 ng), pBC0100B, pBC0114A, pBC0100, pBC0114, pBC0126, pBC0127 (8/5/11; #9), pBC0128, pBC0135, pBC0136, pBC0137, , pBC0149, and pBC0146, respectively. The membrane was initially blocked with 5% milk then probed with anti-FVIII monoclonal antibody, 2, specific to the A2 domain of the heavy chain (Ansong C, Miles SM, Fay PJ.J Thromb Haemost. 2006 Apr;4(4):842-7). Insertion ofXTEN288 in the B-domain was observed for 6 (lane 8, ) and pBC0137 (lane 9, ), whereas XTEN288 insertion at the C-terminus was observed for pBC0146 (lane 12, ). All of the assayed FVIII-XTEN proteins revealed the presence of single chain protein with molecular weight of at least 21 kDa higher than that of pBC01 14 base uct or FVIII standard. In on, AE42 ion was observed for pBC0135 (lane 7, ) and pBC0149 (lane 11, ) with the single chain running NS kDa higher than that of pBC01 14 base protein and heavy chain running at NS kDa higher than 90 kDa band of the base protein.

Assay of sed FVIII by ELISA To verify and quantitate the expression of FVIII-XTEN fusion proteins of the constructs by cell culture, an ELISA assay was established. e antibodies, either SAF8C-AP (Affinity Biologicals), or GMA—8002 (Green Mountain Antibodies), or GMAOll dies (Green Mountain Antibodies) for FVIII-LC ELISA) or by GMA016 antibodies were immobilized onto wells of an ELISA plate. The wells were then incubated with blocking buffer (lx PBS/3% BSA) to prevent non-specific binding of other proteins to the anti-FVIII antibody. FVIII standard dilutions (~50 ng-0.024 ng range), quality controls, and cell culture media samples were then incubated for 1.5 h in the wells to allow binding of the sed FVIII protein to the coated antibody. Wells were then washed extensively, and bound n is incubated with anti-FVIII detection antibody, SAF8C-Biotinylated (Affinity Biologicals). Then streptaVidin-HRP, which binds the biotin ated to the FVIII detection antibody, is added to the well and incubated for l h. Finally, OPD ate is added to the wells and its hydrolysis by HRP enzyme is monitored with a plate reader at 490 nm wavelength. Concentrations of FVIII-containing samples were then calculated by comparing the colorimetric response at each culture dilution to a standard curve. The results, in Table 22, below, show that FVIII-XTEN of the various constructs are expressed at 0.4 - l [Lg/ml in the cell culture media. The results obtained by ELISA and the actiVity data indicate that FVIII- XTEN fusion ns were very well expressed using the described transfection methods. Furthermore, under the experimental conditions, the results demonstrate that the specific actiVity values of the FVIII- XTEN proteins were similar or greater than that of pBC01 14 base construct (expressing BDD FVIII) and support that XTEN insertion into the C-terminus or B-domain of FVIII results in preservation of FVIII protein function.

Chromogenic Activity Assay for CFXTEN fusion n BDD FVIII and CFXTEN fusion n constructs pBC0114, 5, pBC0136, pBC0137, pBC0145, pBC0146, and pBC0149, in various configurations, including XTEN AE288 and AG288 inserted at the C-terminus of the FVIII BDD ce and FVIII-XTEN fusion proteins with AE42 and AE288 inserted after residue 745 (or residue 743) and before residue 1640 (or residue 1638) of the B- domain (including constructs with the P1648 sing site d to alanine), were expressed in transiently transfected Freestyle 293 cells, as described above, and tested for procoagulant activity. The procoagulant activity of each of the FVIII-XTEN proteins present in cell e medium was assessed using a Chromogenix Coamatic® Factor VIII assay, an assay in which the activation of factor X was linearly related to the amount of factor VIII in the sample. The assay was performed according to manufacturer’s instructions using the end-point method, which was measured ophotometrically at OD405 nm. A standard curve was created using purified FVIII protein at concentrations of 250, 200, 150, 100, 75, 50, 37.5, 25, 12.5, 6.25, 3.125 and 1.56 mU/ml. Dilutions of factor VIII rd, quality controls, and samples were prepared with assay buffer and PEI culture medium to account for the effect of the medium in the assay performance. Positive controls consist of purified factor VIII protein at 20, 40, and 80 mU/ml concentrations and cell culture medium of pBC01 14 FVIII base construct, lacking the XTEN insertions. Negative controls consisted of assay buffer or PEI culture medium alone. The cell culture media of the FVIII-XTEN ucts were ed as described, above, and were tested in replicates at 1:50, 1:150, and 1:450 dilutions and the actiVity of each was calculated in U/ml. Each FVIII- XTEN construct exhibited procoagulant actiVity that was at least comparable, and in some cases greater than that of the base construct ve l, and support that under the conditions of the experiments, the linkage of XTEN, including AE288 or AG288, at the C-terminus of FVIII or insertion of XTEN, including AE42 or AE288 within the B-domain resulted in retention or even enhancement of FVIII procoagulant actiVity= Table 22: Results of ELISA and Chromogenic FVIII activity assays FVIII- Act1v1ty. . Concentration. Specrfic Actmty. . .

XTEN Description of Construct (IU/ml) (IU/mg) Construct BDD FVIII base construct used for FVIII construct with XTE\I AG288 pBC0146 -“ 12759 inserted at the C-terminus of FVIII FVIII construct with XTE\I AE288 pBC0145 -“ 4844 ed at the C-terminus of FVIII FVIII construct with XTE\I AE42 inserted between residue 745 and 1640 pBC0149 4.9 55 81 ed between residue 745 and 1640 and with Ar1648 to Ala mutation FVIII construct with XTE\I AE288 inserted between residue 745 and 1640 pBC0137 1.9 0.3 6013 inserted between residue 745 and 1640 and with 8 to Ala mutation Coatest Assay for Cell e Sample Activity Assay containing CFXTEN fusion protein Using the Coatest assay, the activity of FVIII or CFXTEN comprising FVIH is assessed as follows.

Assay Matrix: All wells in the same plate were adjusted to the same percentage of media to control for matrix effects. The test s were diluted such that the OD405 reading would fall within the linear range of the standard. The range of concentrations for the FVIH standard was 100 mU/mL to 0.78 mU/mL, prepared by four-fold serial dilutions of the FVlll standard in 1X Coatest buffer (DiaPharma) plus the pre-determined percentage of culture media.

The Coatest SP FVIII (DiaPharma) reagent package includes the 10X Coatest buffer stock solution, factor lXa + factor X, phospholipid, nd substrate. The 1x Coatest solution was prepared by adding 9X volume of cold dngO to 1X volume of the stock. The cell culture media was then added to the prepared 1X on at a pre-determined ratio to normalize the percentage of matrix in all test wells. Factor lXa + factor X, phospholipid, and substrate were reconstituted according to cturer’s recommendations.

Coatest Assay Procedure: Assay reagents were ed and kept on ice until . 25 [ll of the diluted test samples and standards were added to a 96 well plate in duplicate. 50 pl of phospholipid/factor lXa/factor X was added to each well and mixed by gently tapping the side of the plate. Plates were incubated at 37°C for 5 min on a 37°C plate heater. 25 pl of C3C12 was added to each well and mixed. The plates were incubated at 37°C for 5 min on a plate heater. 50 ul of substrate was then added to each well, mixed, and the plates incubated at 37°C for an onal 5-10 min until the top standard developed an OD405 reading of about 1.5. 25 [ll of 20% acetic acid was added to each well with mixing to stop the reaction and wells were read at OD405 using a SpectraMAX® plus (Molecular Devices) spectrophotometer. Data analysis was performed using the x program (verion 5.2). The LLOQ varied per assay, but was generally 0.0039 lU/ml.

: The data are presented in Tables 23-26. Table 23 presents results from CFXTEN fusion proteins wih XTEN inserted in single sites chosed on the basis of criteria described herein, including Example 34. The pBC00114 FVIII positive control showed good expression and FVIII activity.

Of the 106 single-XTEN fusion proteins assayed, 68% retained measurable FVIH activity, with 30% exhibiting 3+ to 4+ activity in the coagulation assay. -one percent of the fusion proteins assayed had results below the limits of quantitation (which may be due to poor expression, reflected in the corresponding expression ELISA results). All four B-domain insertion ucts exhibited good activity, as did the inal linked constructs, indicating that these are likely favorable insertion sites The s of the single insertion site data guided the creation ofXTEN constructs with 2 XTEN insertions, the results of which are presented in Table 24. Overall, the positivity rate was 67%, with 31% of fusion proteins exhibiting 3+ to 4+ activity in the coagulation assay. 2012/046326 The results of the foregoing data guided the creation of XTEN constructs With 3 XTEN insertions, the results of Which are presented in Table 25. Overall, 92% of the samples had measurable FVIII activity, With fully 79% exhibiting 3+ to 4+ activity in the coagulation assay.

A limited number of constructs With 4 XTEN inserted in the Al, A2 and A3 domains were created and assayed, With 4 of 5 ting FVIH actiVity (Table 26), ting that insertion of multiple XTEN does not compromise the ability of the resulting fusion proteins to retain FVIII actiVity.

Conclusions: Under the ions of the experiments, the results t that the criteria used to select XTEN ion sites are valid, that insertion of one or more XTEN into the selected sites of FVIII is more likely than not to result in retention of gulant actiVity of the resulting CFXTEN molecule, and that insertion of three XTEN appears to result in a greater proportion of fusion proteins retaining high levels of FVIII procoagulant actiVity compared to single or double XTEN insertion constructs.

Table 23: Results of Coagulation Activity Assays for CFXTEN comprising one XTEN 11188652011 Domain Construct Activity 13%;???“ pBC01 14 +——+ +——+ 3 A1 pBC0126 LLOQ* LLOQ 3 A1 pBC0127 —— —— 18 A1 pBC0165 22 A1 pBC0183 +——+ 26 A1 pBC0184 40 A1 pBC0166 60 A1 pBC0185 LLOQ LLOQ 1 16 A1 pBC0167 LLOQ LLOQ 130 A1 pBC0128 LLOQ LLOQ 188 A1 pBC0168 216 A1 pBCO 129 230 A1 pBC0169 LLOQ LLOQ 333 A1 pBC0130 3 75 A2 pBC013 1 LLOQ +++ 403 A2 pBC0132 442 A2 pBC0170 490 A2 pBC0133 —— 518 A2 pBC0171 LLOQ -- 599 A2 pBC0134 ++ 713 A2 pBC0172 —— 745 B pBC0135 745 B 9 745 B pBC0136 ++ ++ 745 B pBC0137 1720 A3 pBC013 8 1796 A3 pBC0139 —— 1802 A3 pBCO 140 —— 1827 A3 pBC0173 LLOQ LLOQ 1861 A3 pBC0174 LLOQ LLOQ 1896 A3 5 LLOQ LLOQ 1900 A3 pBC0176 +——+ +——+ 1904 A3 pBC0177 —— -- VV()2013/122617 Inserfion Expression Domain uct Activity Site ELISA 1937 A3 pBC0178 LLOQ LLOQ 2019 A3 pBC0141 LLOQ + 2068 C1 chnl79 ++ ++ 2111 C1 chnlso LLOQ LLOQ 2120 C1 chnl42 LLOQ 2171 C2 pBC0143 2188 C2 pBC0181 2227 C2 chnlsz 2277 C2 chn144 2332 CT chnl45 2332 CT chn146 403 A2 pSD0001 599 A2 pSD0002 403 A2 pSD0003 599 A2 pSD0004 745 B pSD0005 745 UUUUUU pSD0006 745 pSD0007 745 pSD0008 1720 A3 pSD0009 1720 A3 pSD0010 2171 C2 pSD0011 2171 C2 pSD0012 2332 CT‘ 3 2332 CT‘ 4 745 0303 pSD0017 745 pSD0018 2332 CT‘ pSD0019 2332 CT‘ pSD0020 2332 CT‘ pSD0015 2332 CT‘ pSD0016 0 1J4enn pSD0021 32 A1 pSD0022 65 A1 pSD0023 81 A1 pSD0024 119 A1 pSD0025 211 A1 pSD0026 220 A1 pSD0027 224 A1 pSD0028 336 A1 pSD0029 339 A1 pSD0030 378 A2 pSD0031 LLOQ 399 A2 2 409 A2 3 416 A2 pSD0034 487 A2 pSD0035 LLOQ 494 A2 pSD0036 LLOQ 500 A2 pSD0037 LLOQ 603 A2 pSD0038 1656 A3 pSD0039 +——+ 1656 A3 pN1009** ++++ 2012/046326 Insertion Expression Domain Construct ty Site ELISA 1711 A3 pSD0040 ++ + 1725 A3 pSD0041 LLOQ 1749 A3 pSD0042 LLOQ LLOQ 1905 A3 pSD0043 1910 A3 pSD0044 + 1900 A3 2 1900 A3 pSD0063 18 A1 pSD0045 18 A1 pSD0046 22 A1 pSD0047 LLOQ LLOQ 22 A1 pSD0048 LLOQ LLOQ 26 A1 pSD0049 26 A1 pSD0050 40 A1 pSD0051 40 A1 pSD0052 216 A1 pSD0053 LLOQ 216 A1 pSD0054 LLOQ 375 A2 pSD0055 LLOQ 442 A2 pSD0056 LLOQ 442 A2 pSD0057 LLOQ 1796 A3 pSD0058 LLOQ 1796 A3 pSD0059 1802 A3 pSD0060 1802 A3 1 LLOQ *LLOQ: below the limits of quantitation ** pNL009 includes a deletion of 745-1656 Table 24: Results of ation Activity Assays for CFXTEN comprising two XTEN Insertion 1 Insertion 2 Insertion Insertion Domain A Domain Construct Activity Site Site 745 Dd 2332 CT LSD0001.002 +++ 745 2332 CT 1.005 +++ 745 2332 CT LSD0001.006 +++ 745 2332 CT LSD0001.011 +++ 745 2332 CT LSD0001.012 +++ 745 2332 CT LSD0001.013 +++ 745 2332 CT LSD0001.016 +++ 745 LSD0001.021 2332 CT +++ 745 2332 CT LSD0002.001 +++ 745 wwwwwwwwwwwwwwwwww 2332 CT LSD0002.002 +++ 745 2332 CT LSD0002.014 +++ 745 2332 CT LSD0003.004 +++ 745 2332 CT LSD0003.006 +++ 745 2332 CT LSD0003.009 +++ 745 2332 CT LSD0003.014 + 745 2332 CT LSD0004.010 +++ 745 2332 CT LSD0004.011 LLOQ 745 2332 CT LSD0004.014 +++ 745 2332 CT LSD0004.016 +++ Insertion 1 Insertion 2 11156111011 Domain Insnrnon Domain Construct Activity 8116 Sam 745 B 2332 CT LSD0004.022 +++ 745 B 2332 CT 3.016 +++ 0745 B 2332 CT pNLOO6 0745 B 2332 CT pNLOO7 0745 B 2332 CT pNLOO8 ++ 1656 213 2332 CT pNLOlO 26 A1 403 A2 5.002 ++ 26 A1 403 A2 LSD0005.004 ++ 40 A1 403 A2 LSD0005.005 ++ 40 A1 403 A2 LSD0005.011 ++ 18 A1 403 A2 LSD0005.018 ++ 26 A1 599 A2 LSD0006.002 + 40 A1 599 A2 6.005 ++ 40 A1 599 A2 LSD0006.007 ++ 40 A1 599 A2 LSD0006.011 +++ 40 A1 403 A2 LSD0007.002 + 40 A1 403 A2 LSD0007.004 + 26 A1 403 A2 LSD0007.013 ++ 26 A1 599 A2 LSD0008.001 ++ 40 A1 599 A2 LSD0008.002 ++ 26 A1 599 A2 LSD0008.006 + 18 A1 599 A2 LSD0008.009 ++ 40 A1 599 A2 LSD0008.017 + 745 B 2332 CT LSD0002.025 +++ 745 B 2332 CT 2.013 +++ 745 B 2332 CT LSD0003.025 +++ 745 B 2332 CT LSD0004.025 +++ 745 B 2332 CT LSD0003.005 ++ 26 A1 403 A2 LSD0007.008 ++ 1720 A3 1900 A3 LSD0044.002 LLOQ 1725 A3 1900 A3 LSD0044.005 LLOQ 1720 A3 1900 A3 LSD0044.039 LLOQ 1711 A3 1905 A3 4.022 LLOQ 1720 A3 1905 A3 LSD0044.003 LLOQ 1725 A3 1905 A3 LSD0044.001 LLOQ 1656 A3 26 A1 LSD003 8.001 ++ 1656 A3 18 A1 LSD003 8.003 ++ 1656 A3 18 A1 LSD0038.008 +++ 1656 A3 40 A1 LSD0038.012 ++ 1656 A3 40 A1 LSD0038.013 ++ 1656 A3 26 A1 LSD0038.015 ++ 1656 A3 399 A2 LSD0039.001 + 1656 A3 403 A2 LSD0039.003 ++ 1656 A3 403 A2 LSD0039.010 ++ 1656 A3 1725 A3 LSD0045.001 + 1656 A3 1720 A3 LSD0045.002 ++ 1900 A3 18 A1 LSD0042.014 + 1900 A3 18 A1 LSD0042.023 + 1900 A3 26 A1 LSD0042.006 + 1900 A3 26 A1 LSD0042.013 ++ 1900 A3 40 A1 LSD0042.001 + 1900 A3 40 A1 LSD0042.039 + Insertion 1 Insertion 2 Insertion Domain Insertion Domain uct Activity Site Site 1900 A3 26 A1 LSD0042.047 + 1905 A3 18 A1 LSD0042.003 + 1905 A3 40 A1 LSD0042.004 LLOQ 1905 A3 26 A1 LSD0042.008 LLOQ 1905 A3 26 A1 LSD0042.038 LLOQ 1905 A3 40 A1 LSD0042.082 LLOQ 1910 A3 26 A1 LSD0042.040 LLOQ 18 A1 399 A2 LSD0037.002 ++ 26 A1 399 A2 7.009 + 40 A1 399 A2 LSD0037.011 ++ 18 A1 403 A2 LSD0047.002 ++ 18 A1 403 A2 LSD0047.005 + 18 A1 403 A2 LSD0048.007 + 1656 A3 1900 A3 LSD0046.001 ++ 1656 A3 1900 A3 LSD0046.002 + 1656 A3 1905 A3 LSD0046.003 + 1711 A3 40 A1 LSD0040.011 LLOQ 1711 A3 26 A1 0.042 LLOQ 1720 A3 26 A1 LSD0040.002 + 1720 A3 40 A1 LSD0040.008 + 1720 A3 18 A1 LSD0040.021 + 1720 A3 26 A1 LSD0040.037 LLOQ 1720 A3 18 A1 LSD0040.046 + 1725 A3 26 A1 LSD0040.003 LLOQ 1725 A3 40 A1 LSD0040.006 LLOQ 1725 A3 26 A1 0.007 LLOQ 1725 A3 18 A1 LSD0040.010 LLOQ 1725 A3 40 A1 LSD0040.039 LLOQ 1725 A3 18 A1 LSD0040.052 + 1720 A3 403 A2 LSD0041.001 + 1720 A3 399 A2 LSD0041.004 LLOQ 1711 A3 403 A2 LSD0041.006 LLOQ 1720 A3 403 A2 LSD0041.008 LLOQ 1725 A3 403 A2 LSD0041.010 LLOQ 1725 A3 403 A2 LSD0041.014 LLOQ 1725 A3 399 A2 LSD0041.016 LLOQ 1711 A3 403 A2 LSD0041.035 LLOQ 1900 A3 399 A2 LSD0043.001 LLOQ 1900 A3 403 A2 LSD0043.002 LLOQ 1905 A3 403 A2 LSD0043.005 LLOQ 1900 A3 399 A2 LSD0043.006 LLOQ 1900 A3 403 A2 LSD0043.007 LLOQ 1900 A3 403 A2 LSD0043.008 LLOQ 1905 A3 399 A2 LSD0043.015 LLOQ 1905 A3 403 A2 LSD0043.029 LLOQ 1910 A3 403 A2 LSD0043.043 LLOQ Table 25: Results of Coagulation Activity Assays for CFXTEN comprising three XTEN Insertion 1 Insertion 2 Insertion 3 ion . Insertion . Insertion . . .

. Domain Site Site.

Domain Domain uct ActiVity Site.

PCT/L S2012/046326 hmmfionl Insertion 2 Insertion 3 Insertion A Domain Insseitgon Domain Insortion Domain Construct Site Activity Site 26 A1 403 A2 1656 A3 pSD0077 +++ 26 A1 403 A2 1720 A3 pSD0078 ++ 26 A1 403 A2 1900 A3 pSD0079 ++ 26 A1 1656 A3 1720 A3 pSD0080 +++ 26 A1 1656 A3 1900 A3 pSD0081 LLOQ 26 A1 1720 A3 1900 A3 2 403 A2 1656 A3 1720 A3 pSD0083 +++ 403 A2 1656 A3 1900 A3 pSD0084 +++ 403 A2 1720 A3 1900 A3 pSD0085 1656 A3 1720 A3 1900 A3 6 +++ 18 A1 745 B 2332 CT LSD0049.002 +++ 26 A1 745 B 2332 CT LSD0049.008 +++ 26 A1 745 B 2332 CT LSD0049.011 +++ 40 A1 745 B 2332 CT LSD0049.012 +++ 40 A1 745 B 2332 CT LSD0049.020 +++ 18 A1 745 B 2332 CT LSD0049.021 +++ 40 A1 745 B 2332 CT LSD0050.002 +++ 18 A1 745 B 2332 CT LSD0050.003 +++ 26 A1 745 B 2332 CT LSD0050.007 LLOQ 18 A1 745 B 2332 CT LSD0050.010 +++ 26 A1 745 B 2332 CT LSD0050.012 +++ 40 A1 745 B 2332 CT LSD0050.014 +++ 403 A2 745 B 2332 CT LSD0051.002 +++ 399 A2 745 B 2332 CT LSD0051.003 +++ 403 A2 745 B 2332 CT LSD0052.001 +++ 399 A2 745 B 2332 CT LSD0052.003 +++ 1725 A3 745 B 2332 CT LSD0053.021 LLOQ 1720 A3 745 B 2332 CT 3.022 +++ 1711 A3 745 B 2332 CT LSD0053.024 +++ 1720 A3 745 B 2332 CT LSD0054.021 +++ 1711 A3 745 B 2332 CT LSD0054.025 ++ 1725 A3 745 B 2332 CT LSD0054.026 +++ 1900 A3 745 B 2332 CT LSD0055.021 +++ 1905 A3 745 B 2332 CT LSD0055.022 +++ 1900 A3 745 B 2332 CT LSD0055.026 +++ 1900 A3 745 B 2332 CT LSD0056.021 +++ 1900 A3 745 B 2332 CT LSD0056.024 +++ 1910 A3 745 B 2332 CT LSD0056.025 +++ 0745 B 1900 A3 2332 CT pBC0294* 0745 B 1900 A3 2332 CT * 0745 B 1900 A3 2332 CT ch0296* 0745 B 1900 A3 2332 CT * 0745 B 1900 A3 2332 CT ch0298* 0745 B 1900 A3 2332 CT ch0299* 0745 B 1900 A3 2332 CT pBCO300* 0745 B 1900 A3 2332 CT pBC0301* 0745 B 1900 A3 2332 CT pBC0302* 0745 B 1900 A3 2332 CT pBCO303* 0745 B 1900 A3 2332 CT pBC0304* 0745 B 1900 A3 2332 CT pBCO305* 0745 B 1900 A3 2332 CT pBC0306* 0745 B 1900 A3 2332 CT pBCO307* PCT/L S2012/046326 Insertion 1 ion 2 Insertion 3 Ingeitelon Domain Insseitgon Domain 3161011 Domain Construct Activity 0745 B 1900 A3 2332 CT pBC0308* 0745 B 1900 A3 2332 CT pBC0309* 0745 B 1900 A3 2332 CT pBC0310* 0745 B 1900 A3 2332 CT pBC0311* 0745 B 1900 A3 2332 CT pBC0312* 0745 B 1900 A3 2332 CT pBC0313* 0745 B 1900 A3 2332 CT pBC0314* 0745 B 1900 A3 2332 CT pBC0315* 0745 B 1900 A3 2332 CT pBC0316* 0745 B 1900 A3 2332 CT pBC0317* 0745 B 1900 A3 2332 CT pBC0318* 0745 B 1900 A3 2332 CT pBC0319* 0745 B 1900 A3 2332 CT pBC0320* 0018 A1 0745 B 2332 CT ch0269* 0403 A2 0745 B 2332 CT ch0270* 1720 A3 0745 B 2332 CT pBC0271* 1900 A3 0745 B 2332 CT pBC0272* 0403 A2 0745 B 2332 CT ch0273* 1720 A3 0745 B 2332 CT 4* 1900 A3 0745 B 2332 CT * 0018 A1 0745 B 2332 CT ch0276* 0403 A2 0745 B 2332 CT ch0277* 1720 A3 0745 B 2332 CT ch0278* 1900 A3 0745 B 2332 CT ch0279* *Construct with R1648A mutation Table 26: Results of Coagulation Activity Assays for CFXTEN comprising four XTEN XTEN XTEN XTEN XTEN XTEN XTEN Construct ID Activity Insert 1 Insert 2 Insert 3 Insert 4 Insert 5 Insert 6 26 403 1656 1720 pSD0087 26 403 1656 1900 8 26 403 1720 1900 pSD0089 LLOQ 26 1656 1720 1900 0 403 1656 1720 1900 pSD0091 0040 0403 745 2332 ' LSD0058.006* 0018 0409 745 2332 LSD0059.002* 0040 0409 745 2332 LSD0059.006* 0040 0409 745 2332 LSD0060.001* 0018 0409 745 2332 LSD0060.003* 0040 1720 745 2332 LSD0061.002* 0026 1720 745 2332 LSD0061.007* 0018 1720 745 2332 LSD0061.008* 0018 1720 745 2332 LSD0061.012* 0018 1720 745 2332 LSD0062.001* 0026 1720 745 2332 LSD0062.002* 0018 1720 745 2332 LSD0062.006* 0018 1900 745 2332 LSD0063.001* 0018 1900 745 2332 - - LSD0064.017* 0026 1900 745 2332 - - LSD0064.020* 0040 1900 745 2332 ' ' LSD0064.021* 0040 1905 745 2332 ' ' LSD0065.001* -- 0018 1905 745 2332 - - LSD0065.014* -- 0040 1905 745 2332 - - LSD0066.001* -- 0026 1905 745 2332 ' ' LSD0066.002* -- 0018 1905 745 2332 - - LSD0066.009* 0018 1905 745 2332 - - LSD0066.011* 0018 1910 745 2332 ' ' LSD0067.004* 0018 1910 745 2332 ' ' 7.005* -- 0040 1910 745 2332 - - LSD0067.006* -- 0026 1910 745 2332 - - LSD0067.008* -- 0018 1910 745 2332 ' ' LSD0068.001* -- 0026 1910 745 2332 - - LSD0068.002* -- 0040 1910 745 2332 - - LSD0068.005* -- 0018 1910 745 2332 - - LSD0068.010* ++ 0409 1720 745 2332 ' ' LSD0069.004* -- 0403 1720 745 2332 - - LSD0069.008* -- 0409 1720 745 2332 ' ' LSD0070.003* -- 0403 1720 745 2332 ' ' LSD0070.004* 0403 1720 745 2332 - - LSD0070.005* 0403 1900 745 2332 - - LSD0071.001* 0403 1900 745 2332 - - LSD0071.002* + 0409 1900 745 2332 - - LSD0071.008* 0403 1900 745 2332 - - LSD0072.001* 0403 1900 745 2332 ' ' LSD0072.002* -- 0409 1900 745 2332 ' ' 2.003* -- 0409 1905 745 2332 - - LSD0073.002* -- 0403 1905 745 2332 - - LSD0073.004* -- 0403 1905 745 2332 ' ' LSD0073.006* -- 0403 1905 745 2332 - - LSD0074.007* ++ 0409 1905 745 2332 - - LSD0074.010* -- 0403 1905 745 2332 ' ' LSD0074.011* -- 0409 1910 745 2332 ' ' LSD0075.004* -- 0403 1910 745 2332 - - LSD0075.007* -- 0403 1910 745 2332 - - LSD0076.002* -- 0403 1910 745 2332 ' ' LSD0076.003* -- 0403 1910 745 2332 - - 3* -- 1720 1900 745 2332 - - pSD0094* ++ 1720 1905 745 2332 ' ' pSD0095* -- 1720 1910 745 2332 ' ' pSD0097* -- 1720 1910 745 2332 - - 8* -- 0403 1656 1720 2332 ' ' pNL0022 -- 0403 1656 1900 2332 ' ' pNL0023 -- 0403 1720 1900 2332 ' ' pNL0024 LLOQ 1656 1720 1900 2332 ' ' pNL0025 -- 0018 0403 1656 2332 ' ' pBC0247 ++ 0018 0403 1720 2332 ' ' pBC0248 -- 0018 0403 1900 2332 ' ' pBC0249 -- 0018 1656 1720 2332 ' ' pBC0250 -- 0018 1656 1900 2332 ' ' 1 0018 1720 1900 2332 ' ' 2 LLOQ 0018 0403 0745 2332 ' ' LSD57.005 0018 0745 1720 2332 ' ' LSD62.001 0018 0745 1900 2332 ' ' pBC0262 0403 0745 1720 2332 ' ' LSD70.004 -- 0403 0745 1900 2332 ' ' pBC0266 -- 0745 1720 1900 2332 ' ' pBC0268 -- 0188 1900 0745 2332 - - pCS0001* ND 0599 1900 0745 2332 - - pCS0002* ND 2068 1900 0745 2332 - - pCS0003* ND 2171 1900 0745 2332 - - pCS0004* ND 2227 1900 0745 2332 - - pCS0005* ND 2277 1900 0745 2332 - - pCS0006* ND 0403 1656 1720 1900 2332 - pNL0030 LLOQ 0018 0403 1656 1720 2332 -- - 3 0018 0403 1656 1900 2332 -- - pBC0254 0018 0403 1720 1900 2332 - pBC0255 LLOQ 0018 1656 1720 1900 2332 -- - pBC0256 0018 0403 0745 1720 2332 -- - pBC0259* 0018 0403 0745 1900 2332 -- - pBC0260* 0018 0745 1720 1900 2332 -- - pBC0263 0403 0745 1720 1900 2332 - pBC0267 LLOQ 0018 0403 1656 1720 1900 2332 pBC0257 LLOQ 0018 0403 0745 1720 1900 2332 pBC0264 LLOQ *Construct with R1648A mutation Example 26: Determination ofXTEN Radii and related parameters In order to quantify the hydrodynamic radii of the XTEN components of CFXTEN fusion proteins and how the value of multiple XTEN versus single XTEN , a series of formulae were created based on empirically-derived data from size exclusion tography assays of various fusion proteins comprising one or more XTEN. It is ed that the incorporation of multiple XTEN into a CFXTEN provides a higher total hydrodynamic radius of the XTEN component compared to CFXTEN with fewer XTEN yet having approximately the same total ofXTEN amino acids. The maximum radius WO 22617 of a single XTEN polypeptide is ated (hereinafter “XTEN Radius”) according to the formula given by Equation 11: XTEN Radius = («/XTEN length 0.2037) + 3.4627 11 The sum of the maximum of the XTEN Radii for all XTEN segments in a CFXTEN is calculated (hereinafter “Sum XTEN Radii”) ing to the formula given by Equation III: Z XTEN Radius1- i =1 Sum XTEN Radii = 111 wherein: n = the number ofXTEN segments and i is an or ] The ratio of the SUM XTEN Radii of a CFXTEN comprising multiple XTEN to that of an XTEN Radius for a single XTEN of an equivalent length (in total amino acid residues to that of the CFXTEN) is calculated nafter “Ratio XTEN Radii”) according to the formula given by Equation [1.21 XTEN Radiusi Ratio XTEN Radii = (1 ;;1XTEN Lengthg * 0.2037) + 3.4627 wherein: n = the number ofXTEN segments and i is an iterator RLults: Equation 11 was d to XTEN of lengths 144, 288, 576 and 864. The results are presented in Table 27. Equation IV was applied to various CFXTEN fusion proteins described herein with two, three, or four XTEN. The Ratio ofXTEN Radii has a value of l for all CFXTEN that contain a single XTEN. The Ratio XTEN Radii are presented in Table 28. The Ratio ofXTEN Radii for pSDOO92, which contains 5 XTEN insertions, has a value of 3.31. Collectively, the results indicate that the inclusion of multiple XTEN increases the Ratio XTEN Radii to values greater than 2, with four insertions resulting in higher values than three insertions.

Table 27: Results of Radii Calculations for CFXTEN comprising XTEN XEN Len; XTEN Radius Table 28: s of Radii Calculations for CFXTEN comprising XTEN Ratio Insert . Insert . Insert Domain Domain Domam. Insert XTEN Site Site Site Site Domain Construct Radii -_-_-_-_—_ -——-—-—— -——-—-—— PCT/U82012/046326 Insertion 1 Insertion 2 Insertion 3 Insertion 4 Ratio 13:31 Insert Insert Domain Domam. Domain Insert XTEN Site Site Site Domain Construct Radii 745 B 2332 CT 1.006 1.71 745 B 2332 CT 1.011 1.71 745 B 2332 CT LSD0001.012 1.71 745 B 2332 CT LSD0001.013 1.67 745 B 2332 CT 1.016 1.67 745 B 2332 CT LSD0001.021 1.67 745 B 2332 CT LSD0002.001 1.67 745 B 2332 CT LSD0002.002 1.67 745 B 2332 CT LSD0002.004 1.71 745 B 2332 CT LSD0002.008 1.67 745 B 2332 CT LSD0002.014 1.67 745 B 2332 CT LSD0003.001 1.67 745 B 2332 CT LSD0003.004 1.66 745 B 2332 CT LSD0003.006 1.67 745 B 2332 CT LSD0003.009 1.67 745 B 2332 CT LSD0003.014 1.66 745 B 2332 CT LSD0003.018 1.67 745 B 2332 CT LSD0004.010 1.66 745 B 2332 CT LSD0004.011 1.67 745 B 2332 CT LSD0004.014 1.66 745 B 2332 CT LSD0004.016 1.66 745 B 2332 CT LSD0004.022 1.66 745 B 2332 CT LSD0003.016 1.67 26 A1 403 A2 LSD0005.002 1.71 26 A1 403 A2 LSD0005.004 1.71 40 A1 403 A2 LSD0005.005 1.71 40 A1 403 A2 LSD0005.011 1.71 18 A1 403 A2 LSD0005.018 1.71 26 A1 599 A2 LSD0006.002 1.71 40 A1 599 A2 LSD0006.005 1.71 40 A1 599 A2 LSD0006.007 1.71 40 A1 599 A2 LSD0006.011 1.71 40 A1 403 A2 LSD0007.002 1.71 40 A1 403 A2 LSD0007.004 1.71 26 A1 403 A2 LSD0007.013 1.71 26 A1 599 A2 LSD0008.001 1.71 40 A1 599 A2 8.002 1.71 26 A1 599 A2 LSD0008.006 1.71 18 A1 599 A2 LSD0008.009 1.71 40 A1 599 A2 LSD0008.017 1.71 745 B 2332 CT LSD0002.025 1.71 745 B 2332 CT LSD0002.013 1.67 745 B 2332 CT LSD0003.025 1.67 745 B 2332 CT 4.025 1.67 745 B 2332 CT LSD0003.005 1.66 26 A1 403 A2 LSD0007.008 1.71 1720 A3 1900 A3 LSD0044.002 1.71 1725 A3 1900 A3 LSD0044.005 1.71 1720 A3 1900 A3 LSD0044.039 1.71 171 1 A3 1905 A3 LSD0044.022 1.71 1720 A3 1905 A3 LSD0044.003 1.71 Insertion 1 Insertion 2 Insertion 3 Insertion 4 Ratio 13:31 Insert Insert Domain Domam. Domain Insert XTEN Site Site Site Domain uct Radii 1725 A3 1905 A3 LSD0044.001 1.71 1656 A3 26 A1 LSD0038.001 1.71 1656 A3 18 A1 LSD003 8.003 1.71 1656 A3 18 A1 LSD0038.008 1.71 1656 A3 40 A1 LSD0038.012 1.71 1656 A3 40 A1 LSD0038.013 1.71 1656 A3 26 A1 LSD0038.015 1.71 1656 A3 399 A2 LSD0039.001 1.71 1656 A3 403 A2 LSD0039.003 1.71 1656 A3 403 A2 LSD0039.010 1.71 1656 A3 1725 A3 LSD0045.001 1.71 1656 A3 1720 A3 LSD0045.002 1.71 1900 A3 18 A1 LSD0042.014 1.71 1900 A3 18 A1 LSD0042.023 1.71 1900 A3 26 A1 LSD0042.006 1.71 1900 A3 26 A1 LSD0042.013 1.71 1900 A3 40 A1 LSD0042.001 1.71 1900 A3 40 A1 2.039 1.71 1900 A3 26 A1 LSD0042.047 1.71 1905 A3 18 A1 LSD0042.003 1.71 1905 A3 40 A1 LSD0042.004 1.71 1905 A3 26 A1 LSD0042.008 1.71 1905 A3 26 A1 LSD0042.038 1.71 1905 A3 40 A1 LSD0042.082 1.71 1910 A3 26 A1 2.040 1.71 18 A1 399 A2 LSD0037.002 1.71 26 A1 399 A2 LSD0037.009 1.71 40 A1 399 A2 LSD0037.011 1.71 18 A1 403 A2 LSD0047.002 1.71 18 A1 403 A2 LSD0047.005 1.71 18 A1 403 A2 LSD0048.007 1.71 1656 A3 1900 A3 LSD0046.001 1.71 1656 A3 1900 A3 LSD0046.002 1.71 1656 A3 1905 A3 LSD0046.003 1.71 1711 A3 40 A1 LSD0040.011 1.71 1711 A3 26 A1 LSD0040.042 1.71 1720 A3 26 A1 LSD0040.002 1.71 1720 A3 40 A1 LSD0040.008 1.71 1720 A3 18 A1 LSD0040.021 1.71 1720 A3 26 A1 LSD0040.037 1.71 1720 A3 18 A1 LSD0040.046 1.71 1725 A3 26 A1 LSD0040.003 1.71 1725 A3 40 A1 0.006 1.71 1725 A3 26 A1 0.007 1.71 1725 A3 18 A1 LSD0040.010 1.71 1725 A3 40 A1 LSD0040.039 1.71 1725 A3 18 A1 LSD0040.052 1.71 1720 A3 403 A2 LSD0041.001 1.71 1720 A3 399 A2 LSD0041.004 1.71 1711 A3 403 A2 LSD0041.006 1.71 1720 A3 403 A2 LSD0041.008 1.71 Insertion 1 Insertion 2 Insertion 3 Insertion 4 Ratio Insert . Insert . Insert Domain Domaln Domaln.

Site Site Site Insert Slte . XTBN Domaln Construct Radn 1725 A3 403 A2 LSD0041.010 1.71 1725 A3 403 A2 LSD0041.014 1.71 1725 A3 399 A2 LSD0041.016 1.71 1711 A3 403 A2 1.035 1.71 1900 A3 399 A2 LSD0043.001 1.71 1900 A3 403 A2 LSD0043.002 1.71 1905 A3 403 A2 LSD0043.005 1.71 1900 A3 399 A2 LSD0043.006 1.71 1900 A3 403 A2 LSD0043.007 1.71 1900 A3 403 A2 LSD0043.008 1.71 1905 A3 399 A2 LSD0043.015 1.71 1905 A3 403 A2 3.029 1.71 1910 A3 403 A2 LSD0043.043 1.71 26 A1 403 A2 1656 A3 pSD0077 2.30 26 A1 403 A2 1720 A3 pSD0078 2.30 26 A1 403 A2 1900 A3 pSD0079 2.30 26 A1 1656 A3 1720 A3 pSD0080 2.30 26 A1 1656 A3 1900 A3 pSD0081 2.30 26 A1 1720 A3 1900 A3 pSD0082 2.30 403 A2 1656 A3 1720 A3 pSD0083 2.30 403 A2 1656 A3 1900 A3 pSD0084 2.30 403 A2 1720 A3 1900 A3 pSD0085 2.30 1656 A3 1720 A3 1900 A3 pSD0086 2.30 26 A1 403 A2 1656 A3 1720 A3 pSD0087 2.83 26 A1 403 A2 1656 A3 1900 A3 pSD0088 2.83 26 A1 403 A2 1720 A3 1900 A3 pSD0089 2.83 26 A1 1656 A3 1720 A3 1900 A3 pSD0090 2.83 403 A2 1656 A3 1720 A3 1900 A3 pSD0091 2.83 26 A1 403 A2 1656 A3 1720 A3 pSD0092 2.83 18 A1 745 B 2332 CT 9.002 2.24 26 A1 745 B 2332 CT LSD0049.008 2.24 26 A1 745 B 2332 CT LSD0049.011 2.24 40 A1 745 B 2332 CT LSD0049.012 2.24 40 A1 745 B 2332 CT LSD0049.020 2.24 18 A1 745 B 2332 CT LSD0049.021 2.24 40 A1 745 B 2332 CT 0.002 2.24 18 A1 745 B 2332 CT LSD0050.003 2.24 26 A1 745 B 2332 CT LSD0050.007 2.24 18 A1 745 B 2332 CT LSD0050.010 2.24 26 A1 745 B 2332 CT LSD0050.012 2.24 40 A1 745 B 2332 CT LSD0050.014 2.24 403 A2 745 B 2332 CT LSD0051.002 2.24 399 A2 745 B 2332 CT LSD0051.003 2.24 403 A2 745 B 2332 CT LSD0052.001 2.24 399 A2 745 B 2332 CT LSD0052.003 2.24 1725 A3 745 B 2332 CT LSD0053.021 2.24 1720 A3 745 B 2332 CT LSD0053.022 2.24 1711 A3 745 B 2332 CT LSD0053.024 2.24 1720 A3 745 B 2332 CT LSD0054.021 2.24 1711 A3 745 B 2332 CT 4.025 2.24 1725 A3 745 B 2332 CT LSD0054.026 2.24 Insertion 1 Insertion 2 Insertion 3 Insertion 4 Ratio Insert Insert Site . XTEN Domain Construct Radn 1900 B 1905 B 1900 B 1900 B 1900 B 1910 B Exam le 27: Bindin Interference of XTEN t0 anti-FVIII Antibod The y ofXTEN inserted into different ons of CFXTEN fusion proteins to affect the binding of VIII dies was determined by ch ELISA assays. Two anti-FVIII antibodies; i.e. GMA—8021 (Green Mountain Antibodies, Burlington, VT) and ESH8 (American Diagnostica Inc., Stamford, CT), that bind to the A2 and C2 s, respectively were ed as capture antibodies. A non-XTEN containing FVIII-His-Myc protein was used as a calibration standard and positive control for all ELISAs. Ten CFXTEN fusion proteins with single XTEN insertions in either the Al, A2 or A3 domains were created that onally contained His and Myc affinity tags. The protein concentrations of each test sample was normalized to 100% based on an anti-His capture-anti-Myc detection ELISA run concurrently on the same plate as the anti-FVIII antibody capture-anti-Myc detection ELISA.

Briefly, appropriate wells on a 96-well plate were coated with GMA—8021, ESH8 or anti-His antibody ght at 4°C, then were washed and blocked with BSA. Equal volumes of the respective control or fusion proteins were introduced into ate wells and allowed to interact with coated GMA- 8021, ESH8 or anti-His antibody for 2h at room ature. After incubation, d material was washed away and a rabbit anti-Myc detection antibody was added and incubated for an additional h at room temperature. The plate was then washed and a peroxidase-conjugated donkey anti-rabbit secondary antibody was introduced and incubated for 1h at room temperature. The plate was washed again, followed by the addition of TMB substrate and the reaction was allowed to proceed for 5-20 min.

H2SO4 was introduced to stop the reaction and absorbance was read by spectrophotometer at 450nm.

RLults: The results are presented in Table 29. Collectively, the results demonstrate that the two antibodies against the CFXTEN fusion proteins with XTEN inserted into the A2 domain exhibited reduced binding of FVIII ed to CFXTEN with XTEN inserted into the Al or A3 domain when the anti-FVIII capture antibody was GMA—8021 (with binding affinity to the A2 domain). In contrast, there was no discernible pattern of inhibition or enhancement of binding by any of the CFXTEN when the anti- FVIII capture antibody was ESH8, with binding affinity to the C2 domain.

Table 29: Bindin Interference of XTEN t0 anti-FVIII Antibod XTEN insertion Concentration on aFVIII/Myc + tration on aHis/Myc Sample Tested (Domain, site, His/M GMA—SOZl/Myc (A2 ESHS/Myc XTEN) yc domain) ((12 domain) FVIII-His-Myc 100% 104% FVIII-XTEN—His- A2, 403, AE144 100% 103%: 1% 141%:24% Myc A2, 403, AG144 100% 104% :: 6% 129% :: 12% A2, 399, AE144 100% 100% :: 8% 140% :: 18% A3, 1656, AG144 100% 153% 158% A1, 18, AE144 100% 129% 130% A1,18, AG144 100% 150% 131% A1, 26, AE144 100% 155% 87% A1, 26, AG144 100% 157% 147% A1, 40, AE144 100% 137% 147% A1, 40, AG144 100% 164% :: 0% 153% :: 18% aFVIII/Myc = GMA—8021/Myc or ESH8/Myc antibody condition; aHis/Myc = anti-His/Myc antibody Example 28: Activity Assay of CFXTEN fusion proteins in the presence of FVIII inhibitors Inhibitor Testing Titration Procedure: Select antibodies ting FVIII procoagulant activity were purchased from cial sources. The antibodies target select domains of FVIII (e. g. A2, A3, C1, C2) and inhibit FVIII- dependent gulant ty. In order to establish the l concentration of FVIII inhibitors to utilize in the assay, an initial titration experiment was performed using varying amounts of each inhibitory antibody incubated at 37°C for 2 hrs with the base vector sing wild-type FVIII with a His/Myc double tag, and a second sample with antibody and at least one CFXTEN fusion protein. The samples were then utilized in a coagulation assay to determine the FVIII ty. The activity was measured by the Coatest assay procedure described . The concentration that resulted in optimal tion of FVIII activity was determined for each antibody individually.

Inhibitor Testing Procedure: The FVIII tor antibodies were then used at their optimal concentration for assay of test samples. CFXTEN and positive control samples were individually incubated with each antibody at 37°C for 2 hrs and the samples were then collected and utilized in the Coatest activity assay, along with untreated aliquots of the CFXTEN and positive control. In some cases, CFXTEN constructs with a R1648A mutation were tested to determine the effect, if any, of this mutation on resistance to inhibitors as measured by the retention of FVIII activity.

] Res—ults: The results of the titration experiment are shown in . The data indicate a right-shift of approximately 0.7 order of magnitude in the amount of antibody required to inhibit the procoagulant activity of the CFXTEN LSD0049.002 to the 50% level, compared to FVIII positive control, indicating that the CFXTEN with three XTEN insertions (at ion points corresponding to amino acid residue 18, 745 and 2332 of the BDD-FVIII) had lower binding with the antibody compared to FVIII, reflected in the retention of coagulation activity.

] The results of the Coatest assays are ted in Tables 30 and 31, for the FVIII inhibitor antibodies GMA8008 and GMA8021, respectively. All of the untreated CFXTEN fusion protein constructs tested exhibited procoagulant activity, as did the pBCOOl 14 FVIII positive control. The positive control sample pre-incubated with FVIH inhibitor antibodies resulted in a sharp decrease in the measured coagulation activity to 0.05-O.15 (5-15%) relative to the untreated sample, as did the majority of the CFXTEN constructs treated with the GMA8008 antibody to the C2 . However, three CFXTEN fusion proteins retained at least twice the relative remaining activity compared to the FVIII control; LSDOO49.020, LSD0053.024, and LSD0056.025, each with three XTEN inserts.

The CFXTEN s showed a lower degree of inhibition with the GMA8021 antibody to the A2 domain ed to untreated s that was further reduced by either the additional numbers of XTEN inserts (tabular data shown in Table 30). shows the graph of median values of the ratio to control of retained activity g a linear relationship between numbers ofXTEN ed and reduced inhibition to the GMA8021 antibody ve to the inhibition of the FVIII control. Similarly, the means i S.E. for the ratio to control values were 2.26i0.l2 for l XTEN, 3.48+O.26 for 2 XTEN and 5.70i0.29 for 3 XTEN insertions. CFTXEN with at least three XTEN inserts treated with the GMA8021 antibody had at least 4.5 to 9.2-fold greater retention of FVIII activity compared to FVIII control. In addition, in those CFXTEN with three XTEN ions, constructs with a higher degree of separation (in numbers of amino acid residues) between any two insertions appeared to result in a higher degree of procoagulant activity and, hence, less binding by the FVIH inhibitor antibody, compared to insertions red more closely; e.g. on the C-terminal side of the B-domain. The assay results of constructs with the R1648A mutation appeared to be comparable to those t the mutation.

Conclusions: The results support that, under the conditions of the experiments, insertion of XTEN into FVIH resulted in protection against binding by FVIII inhibitors, with retention of procoagulant activity, and that inclusion of multiple XTEN inserts increased ance to, in particular, the A2 domain tor antibody. Lastly, there appears to be an effect by having spatial tion between the XTEN inserts.

Table 30: Results of Coagulation Assay with CFXTEN treated with antibody GMA8008 to C2 Domain Construct RelaF‘Y" Ratio t0 XTEN XTEN XTEN Remaining . . . . ons Name l Insertlon 1 Insertion 2 Insertion 3 pBC0114 CT 0.05-0.15 l pBC0149 0.1 0.8 0745_AE42_1 0018_AE144_5 pSD0045 0.3 l . l A pSD0046 0.3 1.0 0018_AG144_F pSD0050 0.2 0.9 0026_AG144_F 0040_AE144_5 pSD0051 0.3 1.3 A pSD0052 0.2 1.0 0040_AG144_F 0403_AE144_2 pSD0001 0.2 0.9 A pBC0136 0.2 1.2 0745_AE288_1 7 0.2 1.1 0745_AE288_1 R1648A W0 2013/122617 2012/046326 Construct Relarwe Ratio to XTEN XTEN XTEN Remalnmg .

Name Control Insertlon 1. Insertion 2. . Mutatlons . Insertion 3 Actmty. pSD0013 0.1 0.9 2332_AE144_6B pSD0014 0.1 0.8 G144_1 BC0145 0.1 0.6 2332 AE288 1 pSD0019 0.1 0.5 E288_1 pBC0146 0.1 0.7 2332_AG288_1 pSD0015 0.1 0.8 2332_AE864 8.008 0.1 0.9 0018_AG144_F 1656_AG144_C LSD003 8.013 0.1 0.6 0040_AG144_F 1656_AG144_C LSD003.09 0.1 0.9 0745_AE144_3B 2332_AE288_1 LSD003.06 0.0 0.8 0745_AE144_3B 2332_AE288_1 R1648A LSD0046.001 0.0 0.6 1656_AG144_C 1900_AG144_C 0403_AE144_2 1656_AG144_ PSD077 0.1 1.0 G144_F A C 1720_AG144_ PSD080 0.1 1.0 G144_F 1656_AG144_C C 0403_AE144_2 1720_AG144_ PSD083 0.1 0.8 A 1656_AG144_C C E144_2 1900_AE144_ PSD084 0.1 0.9 A 1656_AG144_C 4A 0018_AE144_5 2332_AE288_ LSD0050.010 0.1 0.7 A 0745_AE144_3B 1 0018_AE144_5 2332_AE288_ LSD0049.021 0.0 0.6 A 0745_AE144_3B 1 R1648A 2332_AE288_ LSD0049.002 0.1 0.9 0018 AG144 F 0745 AE144 3B 1 R1648A 0026_AE144_5 2332_AE288_ LSD0049.008 0.1 0.9 A 0745_AE144_3B 1 R1648A 2332_AE288_ LSD0049.011 0.1 0.9 0026_AG144_F 0745_AE144_3B 1 R1648A 0040_AE144_5 E288_ LSD0049.020 0.2 2.6 A 0745_AE144_3B 1 R1648A 2332_AE288_ LSD0050.002 0.0 0.2 G144_F 0745_AE144_3B 1 1711_AE144_4 2332_AE288_ LSD0053.024 0.2 2.5 A 0745_AE144_3B 1 2332_AE288_ LSD0054.021 0.2 1.5 1720_AG144_C 0745_AE144_3B 1 1900_AE144_4 E288_ LSD0055.021 0.2 1.6 A 0745_AE144_3B 1 R1648A 2332_AE288_ LSD0056.021 0.2 1.6 1900_AG144_C 0745_AE144_3B 1 2332_AE288_ LSD0056.025 0.3 2.0 1910_AG144_C 0745_AE144_3B 1 proportion of activity remaining relative to corresponding untreated sample The ratio of the relative remaining activity (relative to its own control) compared to FVIII pBC0114 positive control Table 31: Results of Coagulation Assay with CFXTEN treated with antibody GMA8021 to A2 Domain AetiVity Control pBC0114 0.05-0.15 1 pBCO 149 0.2 1.3 0745_AE42_1 pSD0045 0.3 2.7 0018_AE144_5A pSD0046 0.2 2.1 0018_AG144_F pSD0050 0.2 2.4 0026_AG144_F pSD0051 0.3 3.1 0040_AE144_5A pSD0052 0.3 2.7 0040_AG144_F pSD0001 0.2 1.6 0403 AE144 2A pBC0136 0.3 2.4 0745_AE288_1 pBC0137 0.3 2.4 0745_AE288_1 R1648A pSD0013 0.2 1.8 2332_AE144_6B pSD0014 0.2 2.1 2332_AG144_1 pBC0145 0.3 2.1 2332_AE288_1 pSD0019 0.3 2.3 2332_AE288_1 pBC0146 0.3 2.1 2332_AG288_1 pSD0015 0.3 2.8 2332_AE864 LSD0038.008 0.4 3.0 0018_AG144_F 1656_AG144_C LSD0038.013 0.4 3.0 0040_AG144_F 1656_AG144_C LSD003.09 0.3 3.6 0745_AE144_3B E288_1 LSD003.06 0.3 3.4 0745 AE144 3B 2332 AE288 1 R1648A 6.001 0.2 4.4 G144_C 1900_AG144_C PSD077 0.4 5.8 0026_AG144_F 0403_AE144_2A 1656_AG144_C PSD080 0.4 5.7 0026_AG144_F 1656_AG144_C 1720_AG144_C PSD083 0.3 5.0 0403_AE144_2A 1656_AG144_C 1720_AG144_C PSD084 0.3 4.5 E144_2A 1656_AG144_C 1900_AE144_4A LSD0050.010 0.4 6.7 0018_AE144_5A 0745_AE144_3B 2332_AE288_1 LSD0049.021 0.4 6.7 E144_5A 0745_AE144_3B 2332_AE288_1 R1648A 9.002 0.5 9.2 0018_AG144_F 0745_AE144_3B 2332_AE288_1 R1648A LSD0049.008 0.4 5.9 0026_AE144_5A 0745_AE144_3B 2332_AE288_1 R1648A LSD0049.011 0.4 5.6 0026_AG144_F 0745_AE144_3B 2332_AE288_1 R1648A LSD0049.020 0.3 5.0 0040_AE144_5A 0745_AE144_3B 2332_AE288_1 R1648A 0.002 0.3 6.2 0040 AG144 F 0745 AE144 3B 2332 AE288 1 LSD0053 .024 0.3 4.5 1711_AE144_4A E144_3B 2332_AE288_1 LSD0054.021 0.5 5.2 1720_AG144_C 0745_AE144_3B E288_1 LSD0055.021 0.5 5.4 E144_4A 0745_AE144_3B 2332_AE288_1 R1648A LSD0056.021 0.5 5.1 1900_AG144_C 0745_AE144_3B 2332_AE288_1 LSD0056.025 0.5 4.8 1910_AG144_C 0745_AE144_3B 2332_AE288_1 proportion of activity ing relative to corresponding untreated sample The ratio of the relative remaining activity (relative to its own control) compared to FVlll 4 positive control Example 29: Protein ation of CFXTEN fusion proteins pBC0145 and pBC0146 Two CFXTEN constructs with C-terminal XTEN were utilized to ish a purification method. For both pBC0145 with a C-terminal XTEN of 288 amino acids of the AE family (see sequence in Table 21) and pBC0146 with a C-terminal XTEN of 288 amino acids of the AG family (see sequence in Table 21), a tial flow filtration (TFF) step was used to buffer ge the ed conditioned media from cell culture. Products were then captured using a strong anion exchange chromatography resin, and then further purified using VIIIS elect affinity chromatography (GE care). An additional size exclusion tography (GE Healthcare) was applied to FVIII-pBC0146 as a third polish step to remove high molecule weight species. The purity of both fusion proteins was deemed acceptable by HPLC-SEC and was further confirmed by SDS-PAGE analysis of the two CFXTEN ucts showing CFXTEN products at expected sizes. The specific ty of both molecules was comparable to B- domain deleted FVIII, as measured by aPTT coagulation assay and ELISA determination of FVIII concentration.

Example 30: Pharmacokinetics of CFXTEN fusion proteins 5 and pBC0146 in HemA and FVIIINWF DKO mice Male FVIII knock-out (HemA) mice or VWF double knock-out (DKO) mice, 8-12 weeks old, were d with a single intravenous administration of either recombinant BDD-FVIII, the CFXTEN pBC0145 0r pBC0146 fusion purified proteins (from Example 23) at 200 IU/kg dose (n=4/time point). At select time points, blood samples were collected via vena cava sampling. In HemA mice, blood samples were collected at 5 min, 1 4, 8, 16, 20, 24, 32, and 48 hrs post-dosing for rBDD-FVIII, and at 5 min, 8, 16, 24, 32, 48, 55 and 72 hrs post-dosing for pBC0145 and pBC0146 fusion proteins. In the FVIII/VWF DKO mice, blood samples were collected at 5min, 30 min and 1hr osing for rBDD-FVIII, and at 5 min, 4, 8, 16 and 24 hr post-dosing for the pBC0145 and pBC0146 fusion proteins.

Plasma FVIII activity was measured by FVIII chromogenic assay and the PK profile was analyzed by the WinNonlin program.

Res—ults: As show in Table 32 and , CFXTEN with the AE C-terminus XTEN insertion (pBC0145) ted 1.6-fold and old FVIII half-life (Tl/2) extension compared to rBDD FVIII in HemA mice and FVIII/VWF DKO mice, respectively. The CFXTEN with the AG C-terminus XTEN insertion (pBC0146) had 1.4-fold and 14.4-fold extended half-life compared to rBDD-FVIII in the HemA mice and FVIII/VWF DKO mice, respectively. The magnitude of the FVIII half-life extension conferred by XTEN insertion was much more pronounced in the FVIII/VWF DKO mice compared to the HemA mice, demonstrated by the 14-fold longer FVIII half-life from both FVIII-AE-XTEN and FVIII-AG- XTEN compared to rBDD-FVIII. In addition, in comparison to VIII, FVIII with C-terminal AE 0r AG-XTEN insertion also had significantly improved FVIII recovery at the 5 min al, reduced clearance and volume of distribution, and increased AUC in the DKO mice. Under the conditions of the experiment, CFXTEN with C-terminus XTEN insertions demonstrated great potential on FVIII half-life ion, and, when combined with other FVIII intra-domain insertions could potentially r extend FVIII half-life.

Table 32: cokinetic parameters of CFXTEN in HemA and FVIIINWF DKO mice min AUC D Mouse Tm MRT C1 Vss — Tm Fold Mouse . Treatment Recovery (hrkngU/m Strain (hr) (hr) (mL/hr/kg) (mL/kg) Increase Strain.

(%) L/mIU) 73 11.88 16.47 3.81 62.74 0.26 1.6 HemA pBC0146 64 10.54 13.31 5.66 75.34 0.18 1.4 HemA r3731]; 89 7.58 11.02 4.33 47.68 0.23 FVIII/ pBC0145 74 3.38 3.76 13.06 63.68 0.0765 13.9 VWF FVIII/ pBC0146 61 3.45 3.61 17.40 86.63 0.0575 14.2 r3731]; 23 0.24 0.24 460.62 161.51 0.0022 Compared to rBDD-FVIII Example 31: Cell e and concentration of cell culture media for CFXTEN fusion proteins pSD0050 and pSD0062 CFXTEN construct variants pSD0050 with an intradomain AG XTEN of 144 amino acids inserted after amino acid residue 26 of BDD FVIII with an omain AE XTEN of 144 , pSDOO62 amino acids inserted after residue 1900 of BDD FVIII (Note: amino acid numbering based full length FVIII), as well as a construct encoding rBDD-FVIII, were transfected into HEK293F cells (Invitrogen, Carlsbad, CA) using polyethyleneimine (PEI, Polysciences Inc. Warrington, PA). The transiently transfected cells were grown in 293 Free Style medium media (Invitrogen, ad, CA) for 4 days and 50-100 ml cell culture media were then concentrated 10- to 20-fold by Centricon Spin Column (100 kDa MW cut-oft) to reach 10-30 IU/ml FVIII activity. The concentrated materials were then flash-frozen and stored at -80°c for future in vitro analysis and in vivo pharmacokinetic studies. ] e 32: Pharmacokinetics of CFXTEN fusion proteins pSD0050 and pSD0062 in HemA and FVIIINWF DKO mice Male HemA or FVIII/VWF double knock-out (DKO) mice, 8-12 weeks old, were treated with a single intravenous administration of cell culture concentrates from Example 31 containing either recombinant BDD-FVIII, the CFXTEN O or pBD062 at 100-300 IU/kg (n=3/group). At select time points, blood samples were collected Via retro orbital bleeds from the same set of mice. In HemA mice, blood samples were collected at 5 min, 24 hr and 48 hr post-dosing, while in VWF DKO mice blood samples were collected at 5 min, 8 hr and 16 hr. The FVIII activity of plasma samples and cell culture concentrates were analyzed by a FVIII chromogenic assay, and the PK profile of rBDD FVIII and FVIII-XTEN variants were analyzed using the WinNonlin program.

] Res—ults: The PK profiles of the two CFXTEN intradomain insertion variants pSD0050 and pSDOO62 and rBDD-FVIII in HemA mice and FVIII/VWF DKO mice are shown in and Table 33. In HemA mice, a comparable initial recovery at the 5 min interval was observed for the three test FVIII molecules. Both CFXTEN fusion proteins demonstrated two-fold longer half-life compared to wild-type III. In FVIII-VWF DKO mice, because of the loss ofVWF protection, rBDD-FVIII had only a 15 min plasma half-life. In the case of the two CFXTEN, however, ife were extended to 3.15 hr and 3.83 hr, respectively; values that are comparable to the CFXTEN with 288 C-terminus XTEN ions (Example 24), suggesting that further extension of the XTEN length at a given insertion point may not be necessary. Under the experimental conditions, the study s clearly trate that intradomain insertion of an XTEN with 144 amino acid residues not only preserved FVIII ty, but also provided r FVIII half-life benefit as the C-terminus 288 amino acid XTEN insertion variants, suggesting that the combination of the FVIII intradomain and C-terminus ions may allow r extension of FVIII half-life.

Table 33: Pharmacokinetic parameters of CFXTEN in HemA and FVIIINWF DKO mice Mouse Treatment Rejcbriigry Tm MRT Cl VSS (hrfgtlrrcilfi?mL Tm POM Stram (hr) (hr) (mL/hI/kg) (mL/kg) Increase (%) /mIU) pSD0050 40 14.12 14.25 5.27 75.03 0.19 2.3 HemA pSD0062 43 12.96 14.79 4.24 62.67 0.24 2.1 Tl?‘1?11131_ 47 6.19 2.62 6.35 16.62 0.16 pSD0050 34 3.15 2.59 21.73 56.28 0.05 ~12 FVIII/ 3.83 3.71 18.51 68.69 0.05 ~15 VWF pSD0062 DKO T331? 23 ~0.25 Compared to rBDD-FVIII Example 33: Pharmacokinetic analysis of CFXTEN fusion polypeptides in rats The pharmacokinetics of various CFXTEN fusion ns, compared to FVIII alone, are tested in Sprague-Dawley rats. CFXTEN and FVIII are administered to female Sprague-Dawley rats (n=3) IV through a r vein catheter at 3-10 ug/rat. Blood samples (0.2 mL) are collected into pre-chilled heparinized tubes at predose, 0.08, 0.5, 1, 2, 4, 8, 24, 48, 72 hour time points, and processed into plasma.

Quantitation of the test articles is performed by ELISA assay using an anti-FVIII antibody for both capture and detection. A non-compartmental analysis is performed in WinNonLin with all time points included in the fit to determine the PK ters. Results are expected to show increased terminal half- life and area under the curve, and a reduced volume of distribution for the CFXEN compared to FVIII alone, and the results are used in conjunction with results from coagulation and pharmacodynamic assays to select those fusion protein configurations with desired properties.

Example 34: Analysis of FVIII for XTEN insertion sites The selection ofXTEN ion sites within the factor VIII molecule was performed by predicting the locations of permissive sites within loop ures or otherwise flexible surface exposed structural elements. For these analyses, the atomic coordinates of two independently determined X-ray crystallographic structures of FVIII were use (Shen BW, et al. The tertiary structure and domain organization of coagulation factor VIII. Blood. (2008) Feb 1;111(3):1240-1247; Ngo JC, et al. l structure of human factor VIII: implications for the formation of the factor IXa-factor VIIIa complex.

Structure (2008)16(4):597-606), as well as those of factor VIII and factor VIIIa derived from molecular dynamic simulation (MDS) (Venkateswarlu, D. Structural investigation of zymogenic and activated forms of human blood coagulation factor VIII: a ational molecular dynamics study. BMC Struct Biol. (2010) 10:7). Atomic coordinates in Protein Data Bank (PDB) format were ed to identify regions of the FVIII/FVIIIa predicted to have a high degree solvent accessible e area using the algorithms ASAView (Ahmad S, et al. ASAView: database and tool for t accessibility entation in proteins. BMC Bioinformatics (2004) 5:51) and GetArea (Rychkov G, Petukhov M.

Joint neighbors imation of macromolecular solvent accessible surface area. J Comput Chem (2007) 28(12):1974-1989). The resulting set of sites was then further prioritized on the basis of high predicted atomic positional fluctuation based on the basis of the published results of the MDS study.

Sites within the acidic peptide regions flanking the A1, A2, and A3 domains, as well as those that appeared by visual inspection to be in areas other than surface exposed loops were deprioritized. The resulting set of ial sites was evaluated on the basis of pecies sequence conservation, with those sites in regions of high sequence conservation among 20 vertebrate species being ranked more favorably. Additionally, putative clearance receptor binding sites, FVIII interaction sites with other molecules (such as vWF, FIX), domain and exon boundaries were also considered in fusion site selection. Finally, sites within close proximity to mutations implicated in ilia A listed in the Haemophilia A Mutation, Search, Test and Resource Site (HAMSTeRS) database were ated (Kemball-Cook G, et al. The factor VIII Structure and on Resource Site: HAMSTeRS version 4.

Nucleic Acids Res. (1998) 26(1):216-219). Based on these criteria, the construction of 42 FVIII-XTEN variants was proposed for XTEN insertions. Of these, three represent XTEN insertions within the residual B domain sequence, two represent ions to the C-terminus of the factor VIII molecule, and 37 ent XTEN insertions within structurally def1nedinter- and intradomain structural elements; i.e., residues 3, 18, 22, 26, 40, 60, 116, 130, 188, 216, 230, 333, 375, 403, 442, 490, 518, 599, 713, 745, 1720, 1796,1802,1827, 1861,1896, 1900,1904,1937, 2019, 2068, 2111, 2120, 2171, 2188, 2227, 2277, and 2332.

Example 35: Functional analysis of FVIII-XTEN constructs Two FVIII-XTEN fusion proteins, FVIII-AE288 0) and FVIII-AG288 (F8X-41), contain an AE288_1 XTEN or an AG288_1 XTEN, respectively, fused at the inus of FVIII C2 domain. To determine if FVIII ty was retained after XTEN fusion, HEK293 cells were transfected separately with these two FVIII-XTEN fusion constructs by using polyethylenimine (PEI) in serum-free medium. At 3 or 5 days post-transfection, the cell culture supernatant was tested for FVIII activity by a two-stage chromogenic assay. Purified recombinant FVIII, calibrated against WHO international standard, was used to establish the standard curve in the geinic assay. The fusion protein products of both F8X-40 and F8X-41 constructs were expressed at levels comparable to those of wild- type BDD-FVIII constructs. (Table 34).

PCT/U82012/046326 Table 34. FVIII Titer of FVIII-XTEN fusion roteins in transient transfection cell culture FVIII Molecules FVIII O66a pBC 0114a F8X~40 F8X~41 awn B a. Both FVIII 066 and pBC 0114 contain B-domain deleted FVIII without XTEN . b. The F8X-4lsample was from a 3-day transfection while other samples were from a 5-day transient transfection.

Example 36: Functional is of FVIII-XTEN constructs: FVIII activity and PK properties The ife extension ial of the F8X-4O and F8X-4l constructs was evaluated in FVIII and von Willebrand factor double knock-out mice by hydrodynamic plasmid DNA injection, with a FVIIIFc DNA construct serving as a ve control. Mice were randomly divided into 3 groups with 4 mice per group. Plasmid DNA encoding BDD c fusion protein, F8X-4O or F8X-4l, all sharing the same DNA vector backbone, was administered to mice in the respective groups. Approximately 100 micrograms of the appropriate plasmid DNA was injected into each mouse via hydrodynamic injection, and blood plasma samples were collected at 24 hours and 48 hours post-injection. The plasma FVIII activity was measured by a two-stage chromogenic assay using calibrated recombinant FVIII as a standard. As shown in , samples from the F8X-4O and F8X-4l groups showed higher plasma FVIII titers than did those from the BDD FVIIIFC, suggesting FVIII fusion with XTEN prolongs the half- life of FVIII in viva. Taken together, these data support the conclusion that XTEN fusion proteins retained FVIII activity in transient transfection and exhibited prolonged ating half-life in an animal model.

Example 37: Pharmacodynamic evaluation of CFXTEN in animal models The in vivo pharmacologic activity of CFXTEN fusion proteins are ed using a variety of nical models of bleeding ing but not limited to those of hemophilia, surgery, trauma, ocytopenia/platelet ction, clopidogrel/heparin—induced bleeding and hydrodynamic injection. These models are developed in multiple species including mice, rat, rabbits, and dogs using methods equivalent to those used and published for other FVIII approaches. CFXTEN compositions are provided in an aqueous buffer compatible with in vivo administration (for example: phosphate-buffered saline or Tris-buffered saline). The compositions are administered at appropriate doses, dosing frequency, dosing schedule and route of administration as optimized for the particular model. Efficacy determinations e measurement of FVIII activity, one-stage clotting assay, FVIII chromogenic assay, activated partial prothrombin time (aPTT), bleeding time, whole blood clotting time (WBCT), thrombelastography (TEG or ROTEM), among others.

In one example of a PD model, CFXTEN and FVIII are administered to genetically-deficient or experimentally-induced HemA mice. At various time points post-administration, levels of FVIII and CFXTEN are measured by ELISA, activity of FVIII and CFXTEN is ed by commercially- available FVIII ty kits and clotting time is measured by aPTT assay. l, the results can indicate that the CFXTEN constructs may be more efficacious at inhibiting bleeding as ed to FVIII and/or equivalent in y to comparable dosage of FVIII with less frequent or more convenient dosing intervals.

In a mouse bleeding challenge PD model CFXTEN and FVIII are administered to genetically- deficient or experimentally-induced HemA mice and effect on hemostatic challenge is ed. atic challenge can include tail transaction challenge, hemarthropthy challenge, joint bleeding or saphenous vein nge among . At various time points post-administration levels of FVIII and CFXTEN are measured by ELISA, activity of FVIII and CFXTEN are measured by commercially available FVIII activity kit, bleeding time is measured and clotting time is measured by aPTT assay.

Overall the results are expected to indicate that the CFXTEN constructs are more ious at inhibiting bleeding as compared to FVIII and/or equivalent in potency to comparable dosage of FVIII With less frequent or more convenient dosing intervals, and the results are used in conjunction With results from coagulation and other assays to select those fusion protein configurations With desired properties.

In a dog PD model, CFXTEN and FVIII are administered to genetically-deficient hemophiliac dogs. At various time points post administration, levels of FVIII and CFXTEN are measured by ELISA, activity of FVIII and CFXTEN are measured by commercially available FVIII activity kit and clotting time is measured by aPTT assay. Overall the results indicates that the CFXTEN constructs may be more efficacious at inhibiting bleeding as compared to FVIII and/or equivalent in y to able dosage of FVIII With less frequent or more convenient dosing, and the results are used in conjunction With results from coagulation and other assays to select those fusion protein configurations With desired properties.

In a dog bleeding challenge PD model CFXTEN and FVIII are administered to genetically deficient hemophiliac dogs and effect on hemostatic challenge is measured. atic challenge includes cuticle bleeding time among others. At various time points post-administration levels of FVIII and CFXTEN are ed by ELISA, activity of FVIII and CFXTEN are measured by commercially available FVIII activity kit, bleeding time is measured and clotting time are measured by aPTT assay.

Overall the results indicate that the CFXTEN constructs may be more efficacious at ting bleeding as compared to FVIII and/or equivalent in potency to comparable dosage of FVIII With less frequent or more convenient dosing intervals, and the results are used in conjunction With results from coagulation and other assays to select those fusion protein configurations With desired properties.

] Additional preclinical models of bleeding include but are not limited to those of hemophilia, surgery, trauma, thrombocytopenia/platelet dysfunction, clopidogrel/heparin—induced bleeding and ynamic ion. These models can developed in multiple species including mice, rat, rabbits, and dogs using methods equivalent to those used and published for other FVIII approaches. Overall the results indicate that the CFXTEN ucts may be more efficacious at inhibiting bleeding as compared to FVIII and/or equivalent in potency to able dosage of FVIII with less frequent or more ient dosing intervals, and the results are used in conjunction With results from coagulation and other assays to select those l protein configurations With d properties.

PCT/U82012/046326 Example 38: CFXTEN with cleavage sequences C-terminal XTEN releasable by FXIa A CFXTEN fusion protein consisting of an XTEN protein fused to the C-terminus of FVIII is created with an XTEN release site cleavage ce placed in between the FVIII and XTEN components, as depicted in . Exemplary sequences are provided in Table 51. In this case, the release site cleavage ce is incorporated into the CFXTEN that contains an amino acid sequence that is recognized and cleaved by the FXIa protease (EC 3.4.21.27, Uniprot P03951). Specifically the amino acid sequence KLTRAET (SEQ ID NO: 1688) is out after the arginine of the sequence by FXIa protease. FXI is the procoagulant protease located immediately before FVIII in the intrinsic or t activated coagulation y. Active FXIa is ed from FXI by proteolytic cleavage of the zymogen by FXIIa. Production of FXIa is tightly controlled and only occurs when coagulation is ary for proper hemostasis. Therefore, by incorporation of the KLTRAET cleavage sequence (SEQ ID NO: 1688), the XTEN domain is only be removed from FVIII rent with activation of the intrinsic coagulation pathway and when coagulation is required physiologically. This creates a situation where the CFXTEN fusion protein is processed in one onal manner during the activation of the intrinsic pathway. inal XTEN releasable by FIIa [thrombin] ] A CFXTEN fusion protein consisting of an XTEN protein fused to the C-terminus of FVIII is d with an XTEN release site cleavage sequence placed in between the FVIII and XTEN ents, as depicted in . In this case, the release site contains an amino acid sequence that is recognized and cleaved by the FIIa protease (EC 3.4.21.5, Uniprot P00734). Specifically the sequence LTPRSLLV (SEQ ID NO: 1618) [Rawlings N.D., et a1. (2008) Nucleic Acids Res, 36: D320], is out after the arginine at position 4 in the sequence. Active FIIa is produced by cleavage of FII by FXa in the presence of phospholipids and m and is down stream from factor IX in the coagulation pathway.

Once activated its l role in coagulation is to cleave fibrinogen (, which then in turn, begins clot ion. FIIa activity is tightly controlled and only occurs when coagulation is ary for proper hemostasis. Therefore, by incorporation of the LTPRSLLV sequence (SEQ ID NO: 1618), the XTEN domain is only removed from FVIII rent with activation of either the extrinsic or intrinsic coagulation pathways, and when coagulation is required physiologically. This creates a situation where CFXTEN fusion is processed in one additional manner during the activation of coagulation.

C-terminal XTEN releasable by Elastase-2 A CFXTEN fusion protein consisting of an XTEN protein fused to the C-terminus of FVIII is created with an XTEN release site cleavage sequence placed in between the FVIII and XTEN components, as ed in . Exemplary sequences are provided in Table 51. In this case, the release site contains an amino acid sequence that is recognized and cleaved by the e1astase-2 protease (EC 3.4.21.37, t P08246). Specifically the sequence LGPVSGVP (SEQ ID NO: 1689) [Rawlings N.D., et a1. (2008) Nucleic Acids Res, 36: D320], is out after position 4 in the sequence. Elastase is constitutively expressed by neutrophils and is present at all times in the circulation. Its activity is tightly WO 22617 2012/046326 controlled by serpins and is therefore minimally active most of the time. Therefore as the long lived CFXTEN circulates, a fraction of it is cleaved, creating a pool of shorter-lived FVIII to be used in ation. In a desirable feature of the inventive composition, this creates a circulating pro-drug depot that constantly es a prophylactic amount of FVIII.

] C-terminal XTEN releasable by MMP-12 A CFXTEN fusion protein consisting of an XTEN protein fused to the C-terminus of FVIII is created with an XTEN release site cleavage sequence placed in n the FVIII and XTEN components, as depicted in . Exemplary sequences are ed in Table 51. In this case, the release site contains an amino acid sequence that is recognized and cleaved by the MMP-12 protease (EC 3.4.24.65, Uniprot P39900). Specifically the sequence GPAGLGGA (SEQ ID NO: 1690) [Rawlings N.D., et al. (2008) Nucleic Acids Res., 36: D320], is cut after position 4 of the sequence. MMP-12 is constitutively expressed in whole blood. Therefore as the long lived CFXTEN ates, a fraction of it is cleaved, creating a pool of shorter-lived FVIII to be used in coagulation. In a desirable feature of the inventive composition, this creates a circulating pro-drug depot that constantly releases a prophylactic amount of FVIII.

C-terminal XTEN able by MMP-13 A CFXTEN fusion n ting of an XTEN protein fused to the inus of FVIII is created with an XTEN release site cleavage sequence placed in between the FVIII and XTEN components, as ed in . Exemplary sequences are provided in Table 51. In this case, the release site contains an amino acid sequence that is recognized and cleaved by the MMP-13 protease (EC 3424-, Uniprot P45452). ically the sequence GPAGLRGA (SEQ ID NO: 1691) [Rawlings N.D., et al. (2008) Nucleic Acids Res., 36: D320], is cut after position 4. MMP-13 is constitutively expressed in whole blood. Therefore as the long lived CFXTEN circulates, a fraction of it is cleaved, creating a pool of shorter-lived FVIII to be used in coagulation. In a desirable feature of the inventive composition, this creates a circulating pro-drug depot that constantly releases a prophylactic amount of FVIII.

C-terminal XTEN releasable by MMP-17 A CFXTEN fusion n consisting of an XTEN protein fused to the inus of FVIII is created with an XTEN release site cleavage sequence placed in between the FVIII and XTEN components, as depicted in . Exemplary sequences are provided in Table 51. In this case, the release site contains an amino acid sequence that is recognized and cleaved by the MMP-2O protease (EC.3.4.24.-, Uniprot Q9ULZ9). Specifically the sequence APLGLRLR (SEQ ID NO: 1692) [Rawlings N.D., et al. (2008) Nucleic Acids Res., 36: D320], is cut after position 4 in the sequence. MMP-17 is constitutively expressed in whole blood. Therefore as the long lived CFXTEN circulates, a fraction of it is cleaved, creating a pool of shorter-lived FVIII to be used in ation. In a desirable feature of the inventive composition, this creates a circulating pro-drug depot that ntly releases a prophylactic amount of FVIII.

C-terminal XTEN releasable by MMP-20 A CFXTEN fusion protein consisting of an XTEN protein fused to the C-terminus of FVIII is created with an XTEN release site cleavage sequence placed in between the FVIII and XTEN components, as depicted in . ary sequences are provided in Table 51. In this case, the release site contains an amino acid sequence that is recognized and cleaved by the MMP-2O se (EC.3.4.24.-, Uniprot 060882). Specifically the ce PALPLVAQ (SEQ ID NO: 1693) [Rawlings N.D., et a1. (2008) Nucleic Acids Res., 36: D320], is cut after position 4 (depicted by the arrow). MMP- is constitutively expressed in whole blood. Therefore as the long lived CFXTEN circulates, a fraction of it is cleaved, creating a pool of shorter-lived FVIII to be used in coagulation. In a desirable feature of the inventive composition, this creates a circulating pro-drug depot that constantly es a prophylactic amount of FVIII.

Optimization of the release rate ofXTEN Variants of the foregoing Examples can be created in which the release rate ofXTEN incorporated at the C-terminus, the N—terminus, or internal XTEN is altered. As the rate ofXTEN release by an XTEN release protease is dependent on the sequence of the XTEN release site, by varying the amino acid sequence in the XTEN release site one can control the rate ofXTEN release. The sequence specificity of many proteases is well known in the art, and is documented in l data bases.

In this case, the amino acid specificity of proteases is mapped using combinatorial libraries of substrates [Harris, J. L., et a1. (2000) Proc Natl Acad Sci U S A, 97: 7754] or by ing the cleavage of substrate mixtures as illustrated in [Schellenberger, V., et a1. (1993) Biochemistry, 32: 4344]. An alternative is the identification of optimal protease cleavage sequences by phage display [Matthews, D., et a1. (1993) Science, 260: 1113]. Constructs are made with t sequences and assayed for XTEN release using standard assays for detection of the XTEN ptides.

Example 39: Human al Trial Designs for Evaluating CFXTEN comprising FVIII Kogenate® FS is recombinant human coagulation factor VIII, intended for ing hemostasis in ilia A subjects. Due to its short half— life, Kogenate is dosed intravenously every other day for prophylaxis and 8 to every 12 h in treatment of bleeds until asis is achieved. It is believed that fusion of one or more XTEN to FVIII improves the half-life of the protein, enabling a reduced dosing frequency using such CFXTEN-containing fusion protein compositions.

Clinical trials are designed such that the y and advantages of CFXTEN, relative to Kogenate or other commercially available FVIII preparations, can be verified in humans. Such studies comprises three phases. First, a Phase I safety and cokinetics study in adult patients is conducted to determine the maximum tolerated dose and cokinetics and pharmacodynamics in humans (either normal subjects or patients with ilia), as well as to define potential toxicities and adverse events to be tracked in future studies. The Phase I studies are conducted in which single rising doses of CFXTEN compositions are administered by the route (e.g., subcutaneous, intramuscular, or intravenously) and biochemical, PK, and clinical parameters are measured at defined intervals. This permits the determination of the m effective dose and the maximum tolerated dose and establishes the threshold and m concentrations in dosage and circulating drug that constitute the therapeutic window for the respective components, as well as bioavailability when stered by the intramuscular or subcutaneous routes. From this information, the dose and dose schedule that permits less frequent stration of the CFXTEN compositions, yet retains the pharmacologic response, is obtained. Thereafter, clinical trials are ted in patients with the condition, verifying the effectiveness of the CFXTEN compositions under the dose conditions, which can be conducted in comparison to a positive control such as Kogenate to establish the ed properties of the CFXTEN compositions.

Phase II and III clinical trials are conducted in patients suffering from any disease in which factor VIII may be expected to provide clinical benefit. For example, the CFXTEN is used in clinical trials for treatment of indications approved for use of factor VIII; such indications include bleeding episodes in ilia A, patients with inhibitors to factor VIII, prevention of bleeding in surgical interventions or invasive procedures in hemophilia A patients with tors to factor VIII, treatment of ng episodes in patients with congenital factor VIII deficiency, and prevention of bleeding in surgical interventions or invasive procedures in patients with congenital factor VIII deficiency.

CFXTEN may also be indicated for use in additional patient populations. A phase II dosing study is conducted in hemophilia A patients where pharmacodynamic, coagulation, ng and other physiologic, PK, safety and clinical parameters and clinical endpoints riate for trials are measured as a on of the dosing of the fusion proteins compositions, yielding dose-ranging ation on doses that is appropriate for a subsequent Phase III trial, in addition to collecting safety data d to e events. The PK parameters are correlated to the physiologic, clinical and safety parameter data to establish the eutic window and the therapeutic dose regimen for the CFXTEN composition, permitting the clinician to establish the appropriate dose ranges for the composition. In one trial, hemophilia A patients with factor VIII inhibitors would be evaluated to ish doses and dose regimen of CFXTEN pharmaceutical compositions that result in achieVing and maintaining hemostasis and preventing or attenuating bleeding episodes. Finally, a phase III efficacy study is conducted wherein patients are administered the CFXTEN pharmaceutical composition and a positive control (such as a commercially-available Kogenate) are stered using a dosing schedule deemed appropriate given the pharmacokinetic and pharmacodynamic properties of the respective compositions derived from the Phase II findings, with all agents administered for an appropriately extended period of time to e the study endpoints. Parameters that are monitored include aPTT assay, one- or age clotting assays, control of bleeding episodes, or the ence of spontaneous bleeding episodes; ters that are tracked relative to the placebo or positive control groups. Efficacy outcomes are determined using standard statistical methods. Toxicity and adverse event markers are also be followed in this study to verify that the compound is safe when used in the manner described. In another phase III trial, hemophilia A patients with factor VIII inhibitors would be evaluated to establish the effectiveness of CFXTEN pharmaceutical compositions in achieVing and maintaining hemostasis and preventing or attenuating bleeding episodes.

Example 40: Analytical size exclusion chromatography ofXTEN fusion proteins with diverse ds ] Size ion chromatography es were performed on fusion proteins containing various therapeutic proteins and unstructured inant proteins of increasing length. An exemplary assay used a TSKGel-G4000 SWXL (7.8mm X 300m) column in which 40 ug of purified glucagon fusion protein at a concentration of 1 mg/ml was separated at a flow rate of 0.6 ml/min in 20 mM phosphate pH 6.8, 114 mM NaCl. Chromatogram profiles were monitored using OD214nm and OD280nm. Column calibration for all assays were performed using a size exclusion calibration standard from BioRad; the markers include thyroglobulin (670 kDa), bovine gamma-globulin (158 kDa), chicken ovalbumin (44 kDa), equine myoglobuin (17 kDa) and vitamin B12 (1.35 kDa). Representative chromatographic profiles of on-Y288, Glucagon-Y144, Glucagon-Y72, Glucagon-Y36 are shown as an overlay in . The data show that the apparent molecular weight of each compound is tional to the length of the attached XTEN sequence. r, the data also show that the apparent molecular weight of each construct is significantly larger than that expected for a globular protein (as shown by comparison to the standard proteins run in the same assay). Based on the SEC analyses for all constructs evaluated, including a CFXTEN ition, the apparent molecular weights, the apparent molecular weight factor (expressed as the ratio of apparent molecular weight to the calculated molecular weight) and the hydrodynamic radius (RH in nm) are shown in Table 35. The results indicate that oration of different XTENs of 576 amino acids or greater confers an apparent molecular weight for the fusion protein of approximately 339 kDa to 760, and that XTEN of 864 amino acids or greater confers an apparent molecular weight greater than approximately 800 kDA. The results of tional increases in apparent molecular weight to actual molecular weight were consistent for fusion proteins d with XTEN from several different motif families; i.e., AD, AE, AF, AG, and AM, with increases of at least four-fold and ratios as high as about 17-fold. Additionally, the incorporation ofXTEN fusion partners with 576 amino acids or more into fusion proteins with the s payloads (and 288 residues in the case of glucagon fused to Y288) resulted with a hydrodynamic radius of 7 nm or greater, well beyond the glomerular pore size of approximately 3-5 nm. Accordingly, it is expected that fusion proteins comprising growth and XTEN have reduced renal clearance, contributing to increased terminal half-life and improving the therapeutic or biologic effect relative to a corresponding un—fused biologic payload protein.

Table 35: SEC analysis of s ptides Apparent Construct KEEN or nt Therapeutic Molecular 1181011 . MW Name PI‘OtelIl Weight partner (kDa) Factor uct XTEN or Therapeutic Actual Apparent Sgibiliflgi‘ RH mm“ MW Name Protein MW (kDa) Weight (11m) partner (kDa) Factor AC89 AF120 Glucagon 14.1 76.4 5.4 4.3 AC88 AF108 Glucagon 13.1 61.2 4.7 3.9 AC73 AF144 Glucagon 16.3 95.2 5.8 4.7 AC53 AG576 GFP 74.9 339 4.5 7.0 AC39 AD576 GFP 76.4 546 7.1 7.7 AC41 AE576 GFP 80.4 760 9.5 8.3 AC52 AF576 GFP 78.3 526 6.7 7.6 AC398 AE288 FVII 76.3 650 8.5 8.2 AC404 AE864 FVII 129 1900 14.7 10.1 AC85 AE864 Exendin-4 83.6 938 11.2 8.9 AC114 AM875 Exendin-4 82.4 1344 16.3 9.4 AC143 AM875 hGH 100.6 846 8.4 8.7 AC227 AM875 IL-1ra 95.4 1103 11.6 9.2 AC228 AM1318 IL-1ra 134.8 2286 17.0 10.5 Example 41: Pharmacokinetics of extended polypeptides fused to GFP in cynomolgus monkeys The pharmacokinetics of GFP-L288, 76, GFP-XTEN_AF576, EN_Y576 and XTEN_AD836-GFP were tested in cynomolgus monkeys to determine the effect of composition and length of the unstructured polypeptides on PK parameters. Blood samples were analyzed at various times after injection and the tration of GFP in plasma was measured by ELISA using a polyclonal dy against GFP for capture and a biotinylated preparation of the same polyclonal antibody for detection. Results are summarized in . They show a surprising increase of half-life with increasing length of the XTEN sequence. For example, a half-life of 10 h was determined for GFP- XTEN_L288 (with 288 amino acid residues in the XTEN). Doubling the length of the unstructured polypeptide fusion partner to 576 amino acids increased the half-life to 20-22 h for multiple fusion protein constructs; i.e., GFP-XTEN_L576, GFP-XTEN_AF576, GFP-XTEN_Y576. A further se of the unstructured polypeptide fusion partner length to 836 residues resulted in a half-life of 72-75 h for XTEN_AD836-GFP. Thus, increasing the polymer length by 288 residues from 288 to 576 residues sed in Vivo half-life by about 10 h. However, sing the polypeptide length by 260 residues from 576 residues to 836 residues sed half-life by more than 50 h. These results show that there is a surprising threshold of unstructured ptide length that results in a greater than proportional gain in in vivo half-life. Thus, fusion proteins sing extended, unstructured polypeptides are expected to have the property of enhanced pharmacokinetics compared to polypeptides of shorter lengths.

Example 42: Serum ity ofXTEN A fusion protein containing XTEN_AE864 fused to the N—terminus of GFP was incubated in monkey plasma and rat kidney lysate for up to 7 days at 37°C. Samples were withdrawn at time 0, Day 1 and Day 7 and analyzed by SDS PAGE followed by detection using n analysis and detection with antibodies against GFP as shown in . The sequence of XTEN_AE864 showed negligible signs of degradation over 7 days in plasma. However, XTEN_AE864 was rapidly degraded in rat kidney lysate over 3 days. The in Vivo stability of the fusion protein was tested in plasma s wherein the GFP_AE864 was immunoprecipitated and analyzed by SDS PAGE as described above. Samples that were withdrawn up to 7 days after ion showed very few signs of degradation. The results demonstrate the resistance of CFXTEN to degradation due to serum proteases; a factor in the enhancement of pharmacokinetic properties of the CFXTEN fusion proteins. e 43: Increasing solubility and stability of a e payload by linking to XTEN ] In order to evaluate the ability ofXTEN to enhance the physicochemical properties of solubility and stability, fusion proteins of glucagon plus shorter-length XTEN were prepared and evaluated. The test articles were prepared in Tris-buffered saline at neutral pH and characterization of the Gog-XTEN solution was by e-phase HPLC and size exclusion chromatography to affirm that the protein was homogeneous and non-aggregated in solution. The data are ted in Table 36. For ative purposes, the solubility limit of unmodified glucagon in the same buffer was ed at 60 uM (0.2 mg/mL), and the result demonstrate that for all lengths ofXTEN added, a substantial se in solubility was attained. antly, in most cases the glucagon-XTEN fusion proteins were prepared to achieve target concentrations and were not evaluated to determine the maximum solubility limits for the given construct. However, in the case of glucagon linked to the AF-144 XTEN, the limit of solubility was determined, with the result that a 60-fold increase in lity was achieved, compared to glucagon not linked to XTEN. In addition, the glucagon-AF 144 CFXTEN was evaluated for stability, and was found to be stable in liquid formulation for at least 6 months under refrigerated conditions and for approximately one month at 37°C (data not shown).

The data support the conclusion that the linking of short-length XTEN polypeptides to a biologically active protein such as glucagon can markedly enhance the solubility properties of the protein by the resulting fusion protein, as well as confer ity at the higher protein concentrations.

Table 36: Solubility of Glucagon-XTEN constructs Test Article Solubility Glucagon 6O uM Glucagon-Y36 >370 [1V1 Glucagon-Y72 >293 uVI Glucagon-AF108 >145 uVI Glucagon-AF12O >160 uVI Glucagon-Y144 >497 uVI Glucagon-AE144 >467 uVI Glucagon-AF144 >3600 [1M Glucagon-Y288 >163 uVI Example 44: Analysis of sequences for ary structure by prediction algorithms Amino acid ces can be assessed for ary structure via certain computer programs or algorithms, such as the well-known Chou-Fasman algorithm (Chou, P. Y., et al. (1974) Biochemistry, 13: ) and the Garnier-Osguthorpe-Robson, or “GOR” method (Garnier J, Gibrat JF, Robson B. (1996). GOR method for predicting protein secondary structure from amino acid sequence. Methods l 0-553). For a given sequence, the algorithms can predict whether there exists some or no secondary structure at all, expressed as total and/or percentage of residues of the sequence that form, for example, alpha-helices or beta-sheets or the percentage of residues of the sequence predicted to result in random coil formation.

Several representative sequences from XTEN “families” have been assessed using two algorithm tools for the Chou-Fasman and GOR methods to assess the degree of secondary ure in these sequences. The Chou-Fasman tool was provided by William R. Pearson and the University of Virginia, at the pport” et site, URL located on the World Wide Web at .fasta.bioch.virginia.edu/fasta_www2/fasta_www.cgi?rm=misc1 as it existed on June 19, 2009. The GOR tool was provided by Pole lnformatique Lyonnais at the Network Protein Sequence Analysis internet site, URL located on the World Wide Web at .npsa-pbil.ibcp.fr/cgi-bin/secpred_gor4.p1 as it existed on June 19, 2008.

As a first step in the analyses, a single XTEN sequence was analyzed by the two algorithms.

The AE864 composition is an XTEN with 864 amino acid residues created from multiple copies of four 12 amino acid sequence motifs consisting of the amino acids G, S, T, E, P, and A. The sequence motifs are characterized by the fact that there is limited repetitiveness within the motifs and within the overall sequence in that the sequence of any two consecutive amino acids is not ed more than twice in any one 12 amino acid motif, and that no three uous amino acids of full-length the XTEN are identical.

Successively longer portions of the AP 864 sequence from the N—terminus were analyzed by the Chou- Fasman and GOR algorithms (the latter es a minimum length of 17 amino acids). The sequences were analyzed by entering the FASTA format sequences into the prediction tools and running the analysis. The results from the analyses are presented in Table 37.

The results indicate that, by the Chou-Fasman calculations, short XTEN of the AE and AG families, up to at least 288 amino acid residues, have no alpha-helices or beta-sheets, but s of predicted percentage of random coil by the GOR thm vary from 78-99%. With sing XTEN lengths of 504 residues to r than 1300, the XTEN analyzed by the Chou-Fasman algorithm had ted percentages of alpha-helices or beta-sheets of 0 to about 2%, while the calculated percentages of random coil increased to from 94-99%. Those XTEN with alpha-helices or beta-sheets were those sequences with one or more instances of three contiguous serine residues, which resulted in predicted beta-sheet formation. However, even these sequences still had approximately 99% random coil formation.

The data provided herein suggests that 1) XTEN created from le sequence motifs of G, S, T, E, P, and A that have limited repetitiveness as to contiguous amino acids are predicted to have very low amounts of alpha-helices and beta-sheets; 2) that increasing the length of the XTEN does not appreciably increase the probability of helix or beta-sheet formation; and 3) that progressively increasing the length of the XTEN sequence by addition of non-repetitive s consisting of the amino acids G, S, T, E, P, and A results in increased tage of random coil formation. Results further indicate that XTEN sequences defined herein (including e. g., XTEN created from ce motifs of G, S, T, E, P, and A) have limited repetitiveness (including those With no more than two identical contiguous amino acids in any one motif) are expected to have very limited secondary structure.

Any order or combination of sequence motifs from Table 3 can be used to create an XTEN polypeptide that will result in an XTEN sequence that is substantially devoid of secondary structure, though three contiguous serines are not preferred. The unfavorable property of three contiguous series however, can be ameliorated by sing the length of the XTEN. Such sequences are expected to have the characteristics described in the CFXTEN embodiments of the invention disclosed herein.

Table 37: CHOU-FASMAN and GOR prediction calculations of polypeptide seguences SEQ ID No. Chou-Fasman GOR SEQ NAME N0: Residues Calculation Calculation AE36-- R'd651 ue ttl:H:0E:00 a S 1489 36 94.44% LCW0402_002 percent: H: 0.0 E: 0.0 AE36-. R'd651 ue ttl:H:0E:00 a S 1490 36 94.44% LCW0402_003 t: H: 0.0 E: 0.0 AG36-- R'd“1 ue 0E:00 a S 1491 36 77.78% LCW0404_001 percent: H: 0.0 E: 0.0 AG36-. Residue totals: H: 0 E: 0 1492 36 83.33 % LCW0404_003 percent: H: 0.0 E: 0.0 Residue totals: H: 0 E: 0 AE42_1 1493 42 90.48% percent: H: 0.0 E: 0.0 Residue totals: H: 0 E: 0 AE42 1 1494 42 90.48% — percent: H: 0.0 E: 0.0 Residue totals: H: 0 E: 0 AG42 1 1495 42 88.10% — t: H: 0.0 E: 0.0 Residue totals: H: 0 E: 0 AG42_2 1496 42 8810‘Vi 0 percent: H: 0.0 E: 0.0 Residue totals: H: 0 E: 0 AE144 1497 144 98.61% t: H: 0.0 E: 0.0 Residue totals: H: 0 E: 0 AG144 1 1498 144 91.67% _ percent: H: 0.0 E: 0.0 Residue totals: H: 0 E: 0 AE288 1499 288 99.31% percent: H: 0.0 E: 0.0 Residue : H: 0 E: 0 AG288_2 1500 288 92 71I percent: H: 0.0 E: 0.0 Residue : H: 0 E: 0 AF504 1501 504 94.44% percent: H: 0.0 E: 0.0 Residue totals: H: 7 E: 0 AD 576 1502 576 99.65%)0 percent: H: 1.2 E: 00 AE576 1503 576 Residue totals: H: 2 E: 0 99.65% WO 22617 SEQ I No. Ch0u~Fasman GOR SEQ NAME N0: Residues Calculation Calculation t: H: 0.4 E: 0.0 Res'd1 ue Gastt1:H: 0 E: 3 AG576 1504 576 99.31% percent: H: 0.4 E: 0.5 Residue : H: 2 E: 0 AF540 1505 540 99.65 percent: H: 0.4 E: 0.0 Res1due totals: H: 0 E: 0 AD836 1506 836 98.44% percent: H: 0.0 E: 0.0 R'd651 ue tt1:H:2E:30 a S AE864 1507 864 99.77% t: H: 0.2 E: 0.4 Residue totals: H: 2 E: 0 AF864 1508 875 95.20%)0 percent: H: 0.2 E: 00 R'd651 ue tt1:H:0E:00 a S AG864 1509 864 94.91% percent: H: 0.0 E: 0.0 R'd651 ue tt1:H:7E:30 a S AM875 1510 875 98.63% percent: H: 0.8 E: 0.3 R”due' t0 a St 1 :H: 7 E: 0 AM1318 1511 1318 99.17% percent: H: 0.7 E: 0.0 Residue totals: H: 4 E: 3 AM923 1512 924 98.70%)0 percent: H: 0.4 E: 03 Residue totals: H: 8 E: 3 AE912 1513 913 )0 percent: H: 0.9 E: 0.3 Residue totals: H: 0 E: 0 BC 864 1514 99.77%)0 percent: H: 0 E; 0 H: alpha-helix E: beta-sheet Example 45: Analysis of polypeptide sequences for repetitiveness In this e, different polypeptides, including several XTEN sequences, were assessed for repetitiveness in the amino acid sequence. Polypeptide amino acid sequences can be assessed for repetitiveness by quantifying the number of times a shorter subsequence appears within the overall polypeptide. For example, a polypeptide of 200 amino acid residues length has a total of 165 overlapping 36-amino acid “blocks” (or “3 6-mers”) and 198 3-mer “subsequences”, but the number of unique 3-mer subsequences will depend on the amount of repetitiveness within the sequence. For the analyses, different polypeptide sequences were assessed for repetitiveness by determining the subsequence score obtained by ation of the following equation: @333 > , , . .) Subsequence score = “33"“: {Zalfiffiig l wherein: m = (amino acid length of polypeptide) — (amino acid length of subsequence) + 1; and Countl- = cumulative number of occurrences of each unique subsequence within sequence,- In the es of the t e, the subsequence score for the polypeptides of Table 38 were determined using the foregoing equation in a er program using the algorithm depicted in , n the subsequence length was set at 3 amino acids. The resulting subsequence score is a reflection of the degree of repetitiveness within the polypeptide.

The results, shown in Table 38, indicate that the unstructured polypeptides ting of 2 or 3 amino acid types have high subsequence scores, while those of consisting of the 12 amino acid motifs of the six amino acids G, S, T, E, P, and A with a low degree of internal repetitiveness, have subsequence scores of less than 10, and in some cases, less than 5. For example, the L288 sequence has two amino acid types and has short, highly repetitive sequences, resulting in a subsequence score of 50.0. The polypeptide J288 has three amino acid types but also has short, repetitive sequences, resulting in a subsequence score of 33.3. Y576 also has three amino acid types, but is not made of al repeats, reflected in the subsequence score of 15.7 over the first 200 amino acids. W576 consists of four types of amino acids, but has a higher degree of internal repetitiveness, e. g., “GGSG” (SEQ ID NO: 1694),”, ing in a subsequence score of 23.4. The AD576 consists of four types of 12 amino acid motifs, each consisting of four types of amino acids. Because of the low degree of internal repetitiveness of the individual motifs, the overall subsequence score over the first 200 amino acids is 13.6. In contrast, XTEN’s consisting of four motifs contains six types of amino acids, each with a low degree of internal repetitiveness have lower subsequence scores; i.e., AE864 (6.1), AF864 (7.5), and AM875 (4.5), while XTEN consisting of four motifs containing five types of amino acids were ediate; i.e., AE864, with a score of 7.2.

Conclusions: The results indicate that the combination of 12 amino acid subsequence , each consisting of four to six amino acid types that are non-repetitive, into a longer XTEN polypeptide results in an overall sequence that is substantially non-repetitive, as ted by overall subsequence scores less than 10 and, in many cases, less than 5. This is despite the fact that each subsequence motif may be used multiple times across the sequence. In st, polymers created from smaller numbers of amino acid types resulted in higher subsequence , with polypeptides consisting of two amino acid type having higher scores that those consisting of three amino acid types.

Table 38: Subseguence score calculations of ptide seguences Seq Name SEQ ID NO: Score J288 1515 33.3 K288 1516 46.9 L288 1517 50.0 Y288 1518 26.8 Q576 1519 18.5 U576 1520 18.1 W576 1521 23.4 Y576 1522 15.7 AE288 1523 6.0 AG288_1 1524 6.9 AD576 1525 13.6 AE576 1526 6.1 Seq Name SEQ ID NO: Score AF54O 1527 8.8 AF504 1528 7.0 AE864 1529 6.1 AF864 1530 7.5 AG864 1531 7.2 AG868 1532 7.5 AM875 1533 4.5 AE912 1534 4.5 AM923 1535 45 AM1296 1536 4.5 Example 46: Calculation of TEPITOPE scores TEPITOPE scores of 9mer peptide sequence can be calculated by adding pocket potentials as described by Sturniolo [Sturniolo, T., et al. (1999) Nat Biotechnol, 17: 555]. In the present Example, separate Tepitope scores were calculated for dual HLA alleles. Table 39 shows as an e the pocket potentials for HLA0101 B, which occurs in high frequency in the Caucasian population. To ate the TEPITOPE score of a e with sequence Pl-P2-P3-P4-P5-P6-P7-P8-P9, the corresponding individual pocket potentials in Table 39 were added. The HLA0101B score of a 9mer peptide with the sequence FDKLPRTSG (SEQ ID NO: 1695) is the sum of 0, -l.3, 0, 0.9, 0, -l.8, 0.09, 0, To evaluate the TEPITOPE scores for long es one can repeat the process for all 9mer subsequences of the sequences. This s can be repeated for the proteins encoded by other HLA alleles. Tables 40-43 give pocket potentials for the protein ts of HLA alleles that occur with high frequency in the Caucasian population.

TEPITOPE scores calculated by this method range from approximately -10 to +10. r, 9mer peptides that lack a hydrophobic amino acid (FKLMVWY (SEQ ID NO: 1696)) in P1 position have calculated TEPITOPE scores in the range of -1009 to -989. This value is biologically meaningless and reflects the fact that a hydrophobic amino acid serves as an anchor residue for HLA binding and peptides lacking a hydrophobic residue in P1 are considered non binders to HLA. Because most XTEN sequences lack hobic residues, all combinations of 9mer subsequences will have TEPITOPEs in the range in the range of -1009 to -989. This method confirms that XTEN polypeptides may have few or no predicted T-cell epitopes.

Table 39: Pocket otential for HLA0101B allele.

WEE” —mnnninnI-I —mnnnlnnl-I WO 22617 Amino Acid P1 P2 P3 P4 P5 P6 P7 P8 P9 D _ -2 _ Table 40: Pocket potential for HLA0301B allele.

Amino acid P1 P2 P3 P4 P5 P6 P7 P8 P9 A -999 O O O - O O - O C -999 O O O - O O - O .3 - Amino acid Amino acid EQTJD'J 9.0.0.0 OOLAOOI—I‘ .0ch NNOO‘N‘ ._I,'_.<'3._I H'oxkom -I>UIt—t-I> o I 0 llll llll I—IN HN' llll ' III—I I—kI—I- \I I—I I ._I 0 00 I I _o U.) W I—II—I I—II—I oI—ILI] I I—k \l I IIN9 AI—I IO U) I Io U) gr II I—KI—K I—I .I—K )—I )—I .I—K .5 9.0\OOO‘ II II I—KI—K 55' $3.0 oo\l' II I OI .._...5 O 00 O U} 0 0 )—k .0..00. . U) 0 O\ .'_I .5 MPG/Ow )—I N. I I H LII I .00].. s5 U) .0 [\D .0 00 I )—k I .0 [\D I .0 \l Ifi O O O \l I I—I 0 IO I—I I .'_I N 00;. 5N;_‘I—I oOm ll I—AO_ No II ._o_"xo II I no 5...\I I )—I .5 O 0 .0 00 I I—I O\ I I I—I LI] I I—I [\D I I I-I Table 42: Pocket potential for HLA0701B allele.

Amino acid P1 P2 P3 P4 P5 P6 P7 P8 P9 A O Amino acid p—I "UN "U L») "d.5 *UU} "U OK "U x] "U 00 "UQ l D—I D—I I I L» .5 W p—Ip—I p—Ip—I OD—IL11 I H. L») I II I—‘O I—‘LII ON LII-P I I H. I—I Eb II I—II—I L») ._I .I—I )—I )—I .I—I.5 II .053. #00 II II .053. 000 I—‘N OON II O 00 0 LA I ._I ._I I IO O\ D—I .5 I I0 L11 MPG/Orv NI—A .NN. ll K I—‘Lll III II _b—KD—K b—KD—K OI—I "\I'_." III II .99.. cow Io L» 00Mac D—I LII o O\ o -I> <5 L» ,4 o o D—I -I> I ('3 I—A o O I 0 -'> .N D—I .0 m .0. \o I .0_. 5. o I N. 0L <5 I—A O I b—k I_I I IO 0 I—I -I> I O 00 0 0 O 00 IO Lo I | ._I I—I \l I I—‘ l—‘ Table 43: Pocket ial for HLA1501B allele.

Amino acid Example 46: Assessment of insertion ofXTEN into permissive loops.

XTEN AE42-4 Insertion The construction and expression of FVIH with XTEN AE42 insertions were described in Example 17 and 24. Thus, Where residue X designates the site of insertion and residue Z designates the next residue in the native FVIII ptide sequence, the polypeptide resulting from insertion ofXTEN AE42 would contain the sequence: X-GAPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPASS-Z (SEQ ID NO: 1697) 16 different sites in the FVIII sequence were selected for XTEN AE42 insertion, and these were designed Batch 1. An additional 21 sites selected for XTEN AE42 insertion were designed Batch 2. tively, the Batch 1 and Batch 2 sites represent 12 sites in the Al domain, 7 sites in the A2 domain, sites in the A3 domain, 4 sites in the Cl domain, and 3 sites in the C2 . Locations of Batch 1 and 2 sites in the 3-D structure of FVIII are depicted in .

The location of these Batch 1 and Batch 2 insertion sites results in 37 constructs designated pSDOOOl- 4, pSDOOO9- pSDOOl2, pSDOO23- pSDOO32, pSDOO34- pSDOO63 [the ing ranges include all intermediate numbers, as well], the sequences of which are set forth in Table 21 and the insertions sites of which are set forth in Table 23.

In Vitro assays To assess FVIII tolerability to XTEN AE42-4 insertion, the FVIII actiVity in e media samples from FVIII-XTEN cell cultures was analyzed using a FVIII chromogenic assay. Antigen expression levels were analyzed by FVIII-HC (FVIII heavy chain) and FVIII-LC (FVIII light chain) ELISA.

FVIII ActiVity Measurement by genic Assay ] The FVIII actiVity was measured using the COATEST® SP FVIII kit from DiaPharma (lot# N0890l9) and all incubations were performed on a 37°C plate heater with shaking. Cell culture harvests from transient transfection media of FVIII-XTEN AE42-4 ts from 6 well plates were diluted to the desired FVIII actiVity range using lx FVIII T® buffer. FVIII standards were prepared in 1x FVIII COATEST® buffer containing mock transfection media with matching culture media concentration as the testing sample. The range of recombinant Factor VIII I) standard was from 100 mIU/mL to 0.78 mIU/mL. The standards, diluted cell culture samples, and a pooled normal human plasma assay control were added to Immulon® 2HB 96-well plates in duplicates (25 uL/well).

] Freshly prepared IXa/FX/Phospholipid mix (50 uL), 25 [LL of 25mM CaCl2, and 50 [LL of FXa substrate were added sequentially into each well, with 5 minutes incubation between each addition. After incubating with the substrate, 25 [LL of 20% acetic acid was added to terminate the color reaction, and the absorbance at 405 nm was measured with a SpectraMAX® plus (Molecular DeVices) instrument.

Data analysis was performed using SoftMax Pro software on 5.2). The Lowest Level of Quantification (LLOQ) was 39 mIU/mL. s are presented in Table 22.

Expression Measurement by FVIII-HC and FVIII-LC ELISA Expression of variants was quantified using ELISA. The FVIII antigen expression levels of DNA constructs corresponding to XTEN ions in the Al and A2 domains of FVIII were analyzed by FVIII-LC ELISA. The FVIII antigen expression levels of DNA constructs corresponding to XTEN insertions in the A3, C1 and C2 s of FVIII were analyzed by FVIII-HC ELISA. Results are presented in Table 22.

WO 22617 FVIII-XTEN antigens in cell culture media after harvest were captured by GMA011 antibodies (Green Mountain Antibodies) for FVIII-LC ELISA) or by GMA016 antibodies (Green Mountain Antibodies) for FVIII-HC ELISA. Immulon® 2HB 96-well plates were coated with 100ul/well of anti- FVIII antibody (2ug/ml) by overnight incubation at 40C. Plates were then washed four times with Phosphate Buffer saline with Tween-20 (PBST) and blocked with blocking buffer (PBST with 10% heat inactivated horse serum) for 1 hour at room temperature.

Cell culture harvests from transient ection media of FVIII-XTEN variants from a 6-well plate were diluted to the desired FVIII antigen range using 1x blocking buffer. FVIII standards were prepared in 1x FVIII blocking buffer containing mock ection media with matching media concentration as the g samples. The range of rFVIII standard was from 50 ng/mL to 0.39 ng/mL.

Standards, diluted cell culture samples, and a pooled normal human plasma assay control were added into Immulon® 2HB 96-well plates in duplicates (100 uL/well) and incubated at 370C for 2 hours.

Following four times g with PBST, 100 pl of HRP-sheep FVIII antibody (Affinity Biologicals, F8C-EIC-D) were added into each well and plates were incubated for 1 hour at 370C. After another four washes with PBST, 100 pl ofTMB Super Sensitive Substrate ) were added to each well, followed by 5-10 min color development. To ate the color on, 50 [LL of H2SO4 were added to each well, and the absorbance of at 450 nm was measured with a SpectraMAX plus (Molecular Devices) instrument.

Data analysis was performed using SoftMax Pro software (version 5.4). The Lowest Level of Quantification (LLOQ) was 0.0039 ug/mL. Results are presented in Table 22.

Permissive sites into which XTEN sequences were inserted without eliminating procoagulant actiVity of the recombinant protein, or the y of the recombinant proteins to be expressed in the host cell were clustered within loops in each of the three A domains of FVIII. shows the location of insertion sites in the recombinant FVIII proteins that showed FVIII ty on domains A1, A2 and A3. shows a structural representation depicting the location of insertion sites in the recombinant FVIII proteins that showed FVIII actiVity.

The sive sites clustered in t exposed, highly flexible surface loops (XTEN permissive loops). The A1 domain loops were located in a region corresponding imately to amino acid positions 15 to 45, and 201 to 232, respectively, in the sequence of mature human FVIII ().

The A2 domain loops were d in a region corresponding imately to amino acid positions 395 to 421, and 577 to 635, respectively, in the sequence of mature human FVIII (). The A3 domain loops were located in a region corresponding approximately to amino acid positions 1705 to 1732, and 1884 to 1917, respectively, in the sequence of mature human FVIII (). FIGS. 37A and 37B show the location of the XTEN permissive loops relative to secondary structure elements in the tridimensional structure of FVIII.

Example 47: CFXTEN with insertions ofXTEN having 144 amino acids Analysis of the preliminary data presented above (Example 46) suggested the existence of defined regions within the linear ptide sequences and 3-D structures of the FVIII A domains that can accommodate the insertion ofXTEN sequences. To test this hypothesis and further define the boundaries of putative regions that can accommodate the insertion ofXTEN sequences without loss of FVIII activity, 23 additional insertion sites not present in either Batch 1 or 2 were chosen and designated Batch 3.

Batch 3 constructs were generated by the insertion of a 144 residue XTEN AE polypeptide, comprising amino acid residues Gly (G), Ala (A), Pro (P), Ser (S), Thr (T), and Glu (E), or a 144 residue XTEN AG polypeptide, comprising amino acid es Gly (G), Ala (A), Pro (P), Ser (S), and Thr (T).

Five different version of the 144 residue AE ptide were generated and designated XTEN-AEl44- 2A, XTEN-AEl44-3B, XTEN-AEl44-4A, XTEN-AEl44-5A, XTEN-AEl44-6B. The amino acid ces are as set forth in Table 4. Five different versions of the 144 residue polypeptide were generated and designated XTEN-AGl44-l, XTEN-AGl44-A, XTEN-AGl44-B, XTEN-AGl44-C, and XTEN-AGl44-F. The amino acid sequences are as set forth in Table 4.

] The 144 residue XTEN encoding DNA sequence was introduced by the chemical synthesis of DNA segments (DNA 2.0, d City, CA) spanning the t unique ction sites within the base vector on either side of the site of insertion.

The DNA sequences corresponding to the XTEN 144 peptides were inserted such that the resulting DNA construct would encode a FVIII protein in which the XTEN 144 protein sequence is inserted immediatelym the residue indicated in the site selection, and flanked by AscI and X1101 sites.

In on to these sites, those sites from Batch 1 and 2 at which insertion of the XTEN AE42 polypeptide did not h FVIII procoagulant acitivity were modified by excision of the AE42 polypeptide encoding DNA t with restriction enzymes AscI and X7101, and introduction ofXTEN AEl44 and XTEN AGl44 coding ces at the same sites. The location of these Batch 1, Batch 2 and Batch insertion sites is summarized in Table III. presents a structural representation of FVIII showing the on of the XTEN l44 insertion sites.

A total of 48 constructs with 144 XTEN inserts were created. The constructs are pSDOOOl- pSDOOO4, pSDOOO9-pSDOOl2, pSDOO23-63 [the foregoing ranges include all intermediate numbers, as well], the sequences of which are set forth in Table 21 and the insertion sites of which are detailed in Table 22.

Expression of FVIII-XTEN 144 Variants FVIII variants with XTEN l44 insertions were tranfected into HEK293F cells (Invitrogen, ad, CA) using hyleneimine (PEI, Polysciences Inc. Warrington, PA) or Lipofectamine transfection reagent (Invitrogen, Carlsbad, CA). The transiently transfected cells were grown in 293 Free Style medium or a e of 293 Free Style and CD Opti CHO media (Invitrogen, Carlsbad, CA). The cell culture medium was harvested 3-5 days after transfection and analyzed for FVIII expression by chromogenic FVIII activity assay and FVIII ELISA conducted as bed herein.

Cell culture media from transient transfection were concentrated 10-fold in Centricon® spin columns (lOOkd cut-off). Concentrated material was then flash frozen and stored at -80°C for future in vitro analysis and in vivo PK studies.

In vitro assays To assess FVIII tolerability to insertions, the FVIII activity in culture media samples from cell cultures was analyzed using a FVIII chromogenic assay. Antigen expression levels were analyzed by FVIII-HC (FVIII heavy chain) and FVIII-LC (FVIII light chain) ELISA.

FVIII Activity Measurement by Chromogenic Assay and Expression Measurement by FVIII- HC and FVIII-LC ELISA Chromogenic and ELISA assay methods were conducted as described. The s obtained are summarized in Table 23. sive sites into which XTEN sequences were inserted without ating procoagulant activity of the recombinant protein, or the ability of the inant proteins to be expressed in the host cell clustered within loops in each of the three A domains of FVIII. The same XTEN permissive loop regions tolerating the shorter XTEN sequences inserted were found to tolerate the insertion of the longer XTEN sequences. shows the location ofXTEN 144 insertion sites in the recombinant FVIII proteins that showed FVIII activity on domains A], A2 and A3. shows a structural entation depicting the location of insertion sites in the recombinant FVIII ns that showed FVIII activity.

These observation indicate that two regions within each of the A domains of FVIII are able to accommodate insertion ofXTEN sequences without loss of FVIII or activity. A structural depiction of these so-called XTEN permissive loops (FIGS. 40 and 4]) demonstrate that they occupy structurally analogous ons in each of the A domains and project from one face of the FVIII molecule. The identified XTEN permissive loops correspond to highly flexible loops located between beta strands in the three-dimensional structures of the Al, A2, and A3 domains, as shown in FIGS. 37A and 37B.

The in vivo evaluation ofXTEN 144 insertions on FVIII ife Extension, as determined by pharmacokinetics, is described in Example 32.

Example 48: Rescue or enhancement of FVIII expression by insertion of an XTEN sequence within the a3 acidic peptide region of FVIII. nt HEK293 cells were transfected (as described in e 24) with FVIII-XTEN DNA constructs in which the coding ce of a B-domain deleted factor VIII contained 2 to 4 XTEN insertions of 144 amino acid residues each, of composition and insertion location as indicated in Table 44, below. At 5 days post-transfection, cell culture supernatants were assayed for FVIII activity by the chromogenic assay (as described in Example 25). Results are shown in Table 44.

Table 44. Expression levels of FVIII Activity by CFXTEN variants containing an XTEN at position 1720 and one, two, or three additional XTEN insertions.

Construct , on, and Type ofXTEN Insertion Activity Name (mm/mm 1720 LSD0040.002 26 AGl44 AGl44 175 _—403 AE144_ 1720 __ WO 22617 AG144 1656 1720 LSD0045.002 AG144 AG144 2598 1656 1720 PSD080.002 26 AG144 AG144 AG144 1081 1656 1720 PSD083.001 403 AE144 AG144 AG144 789 1720 PSD082.001 26 AG144 AG144 1900 AE144 <LLOQ 1656 1720 .003 26 AG144 AG144 AG144 1900 AE144 316 For the e of comparison, all FVIII-XTEN constructs had an AG144 XTEN insertion at amino acid position 1720 (numbered relative to full-length factor VIII) within the A3 domain.

Expression levels of FVIII-XTEN varians were determined by chromogenic assay and expressed in units of mIU/mL. Constructs with a single additional XTEN insertion at either position 26 in the A1 domain (LSD0040.002) or on 403 in the A2 domain (LSD0041.008) yielded expression levels of 175 and 279 mIU/mL, respectively. In contrast, a construct with a single additional XTEN insertion at on 1656 within the a3 acidic peptide yielded an expression level of 2598 mIU/mL, demonstrating enhancement of expression level for the a3 XTEN insertion construct relative to the A1 and A2 insertion constructs. In addition, in comparison to the FVIII-XTEN uct with XTEN insertions at ons 26 in the A1 domain and 1720 in the A3 domain 40.002), the construct with an additional XTEN insertion at position 1656 within the a3 acidic peptide region (PSD080.002) yielded significantly higher expression (175 and 1081 mIU/mL, respectively). Consistent with these findings, the construct with XTEN insertions at positions 403 in the A2 domain and 1720 in the A3 domain (LSD0041.008) yielded an expression level of 279 mIU/mL, s an additional XTEN insertion at position 1656 within the a3 acidic peptide region (PSD083.001) resulted in an increase in the expression level to 789 mIU/mL.

Lastly, the FVIII-XTEN construct with an XTEN ion at position 26 within the A1 domain and two XTEN ions at positions 1720 and 1900 within the A3 domain (PSD082.001) did not yield activity above the lower limit of quantitation. However, the FVIII-XTEN construct with an additional XTEN insertion within the a3 acidic peptide region (PSD090.003) resulted in detectable activity, demonstrating that inclusion of an XTEN sequence within the a3 domain can result in recovery of expression (as measured by activity) in FVIII-XTEN constructs that are ise expressed at levels below the lower limit of quantitation. Under the conditions of the experiment, the results support the sion that insertion ofXTEN at the 1656 position and, by extension, within the a3 region, results in enhanced expression of procoagulant FVIII-XTEN compositions.

Example 49: Effect ofXTEN insertion 0n FVIII ty measured by aPTT A one stage activated partial prothrombin (aPTT) coagulation assay was employed in addition to the chromogenic assay (as described in Example 25) to determine FVIII ty of various FVIII- XTEN fusion proteins.

Method: The FVIII-XTEN aPTT activity was measured using the Sysmex CA—lSOO instrument (Siemens care Diagnostics Inc.,Tarrytown, NY). To create a standard curve for the assay, WHO factor VIII standard was diluted with 2% mock transfection media to 100 mU/mL and a two-fold serial dilution series was then performed, with the last standard being 0.78 mU/mL. FVIII-XTEN cell culture samples were first diluted at 1:50 with aPTT assay buffer, further dilutions were made with 2% mock transfection media when needed.

After dilution, the aPTT assay was performed using Sysmex instrument as follow: 50 [ll of diluted standards and samples were mixed with 50 ul human FVIII def1cient plasma and then 50 ul of aPTT reagent. The mixture was incubated at 37°C for 4 min, and following tion, 50 ul of CaClz was added to the mixture, and the clotting time was measured immediately.

To ine test samples FVIII actiVity, the clotting time of the standards were plotted using semi-log scale (Clotting time: ; Standard concentration: Log) to extrapolates the equation between ng time and FVIII actiVity, and FVIII-XTEN actiVity was then calculated t the standard curve. The assay sensitiVity was 40 mU/mL factor VIII.

RLults: The results are summarized in FIGS. 44-46. When single XTEN of 144 or 288 amino acids were inserted into the FVIII, all of the FVIII-XTEN fusion proteins exhibiting ty in the chromogenic assay were also active in aPTT assay. The aPTT actiVity ed the trend of chromogenic assay, for example, those molecules that showed low FVIII actiVity in the genic assay also had low aPTT values. Generally, the aPTT results for the fusion proteins were lower than those obtained by the chromogenic assay, with a chromogenic to aPTT ratio of 1.1 up to 2.2, as illustrated in , for the single XTEN insertions. The FVIII-XTEN fusion proteins with multiple XTEN insertions, in general, showed further reductions in aPTT actiVity in comparison to chromogenic assay. Assays of FVIII-XTEN with two XTEN insertions showed actiVity with all constructs, but with chromogenic/aPTT ratios approaching 4, in some instances (). Assays of XTEN with some three XTEN insertions also showed ty in both assays, with chromogenic/aPTT ratios approaching 5, in some instances (), while the ratios for the BDD-FVIII control were more comparable (right side of FIG 46). Additionally, the site ofXTEN insertion appeared to contribute to the differences seen between aPTT and chromogenic actiVities. For example, while some les with 2 XTEN insertions resulted in up to 4-fold lower actiVity than chromogenic values, the aPTT actiVity of other FVIII molecules with 2 XTEN were fairly comparable to chromogenic activity (). Some molecules with 3 XTEN insertions showed up to 5 —fold lower than chromogenic activities, other FVIII molecules with 3 XTEN have aPTT actiVity less than 2-fold lower than chromogenic actiVity (). Under the conditions of the experiment, the results t the conclusion that FVIII-XTEN fusion n constructs do retain procoagulant actiVity, but that the chromogenic assay lly provides higher actiVity levels than that in the aPTT assay system ed in the study.

Example 50: Evaluations of the Effect ofXTEN Insertion Site onf FVIII Half-life Extension Methods: Six FVIII-XTEN fusion proteins with single XTEN AG-144 insertions at defined locations were tested in FVIII/VWF DKO mice (as generally described in Example 32) to te the effect ofXTEN insertion site on FVIII half-life. Six representative XTEN variants d in table 1) with XTEN insertion in either within A1, A2, a3, A3-region1 (A3-R1), A3-region 2 (A3-R2) or at the C- terminus were selected for this study, and BDD-FVIII generated from the base vector was used as the control. FVIII/VWF DKO mice were treated with a single intravenous administration of transient transfaction cell e media concentrate from the six FVIII-XTEN constructs (or positive control media) at 100-200 IU/kg, and plasma samples were subsequently ted at 5min, 7 hours and 16 hours post-dosing. Plasma FVIII activity was tested using the FVIII chromogenic assay and XTEN half- life was estimated using the WinNonlin program. The study data are summarized in Table 45 and FIG RLults: A significantly longer half-life was observed for all FVIII-XTEN variants tested compared to BDD-FVIII control, but the degree of the half-life increase varied, with the variant with XTEN at the 403 insertion site conferring the least half-life extension at 10-fold (in comparison to control), while the 1900 insertion variant conferred the most half-life extension at 18-fold. The differences ofXTEN ion site on FVIII ife extension may reflect the roles of different FVIII domains in FVIII clearance in vivo.

Table 45: FVIII-XTEN single AG-144 insertion variants PK in FVIIINWF DKO mice BDD- pSD pSD- pSD- pSD- pSD- pSD- Treatment FVIII -050 0003 0039 0010 063 014 Insertion site None 26 403 1656 1720 1900 CT Recovery 21.3 33.8 34.8 36.0 33.6 39.6 32.4 th/rz 0.25 3.15 2.4 3.3 4.28 4.54 3.91 t1/2 Increase 13 10 13 17 18 16 (fold) ] Example 51: Evaluations of the Additive Effect ofXTEN ions 0n FVIII Half-life ion.

Methods: To evaluate the effects of multiple XTEN insertions on FVIII-XTEN fusion protein half-life, the half-livesof FVIII-XTEN variants with 1-3 XTEN insertions were determined in FVIII- XTEN DKO mice using the cell culture concentrate from five ucts (as generally described in Example 32). Five XTEN variants were tested in the study: pSD-062, with AE144 ion at position 1900 (numbered relative to full-length factor VIII); 05 with AE144 in the FVIII B domain (B-domain amino acid position 745); pSD-0019 with AE288 at the FVIII C-terminus (CT); LSD0003.006 with AE144 inserted in the B-domain and AE288 inserted at the C-terminus, and LSD0055.021 with three XTEN ofAE144, AE144, and AE288 inserted at position 1900, with the B domain and at the C-terminus. The FVIII-XTEN half-life values were estimated using the WinNonlin program.

Results: The study results are ized in Table 46, and the PK curves are shown in . The study results clearly demonstrated the additive effect of multiple XTEN insertions on FVIII half- life extension. With single XTEN insertions, the half-life of FVIII was ed from 0.25 hr to 3.2-4.0 hr, a 13 tol6-fold increase. When the B and CT XTEN insertions were combined together, the FVIII half-life was further extended to 10.6 hr, a 42-fold prolongation. Finally, in the case of a third XTEN insertion added at position 1900 to the B/CT construct, the half-life reached 16 hr in the FVIII-VWF DKO mice, a 64-fold increase.

Table 46: Additive effect ofXTEN insertions 0n FVIII tm in FVIIINWF DKO mice BDD- pSD pSD— pSD— LSD- LSD- FVIII -062 0005 0019 0003.006 0055.021 Insertion s1te 0.25 3.8 3.2 4.0 10.6 16.0 t1/2Increase 13 (fold) - Example 52: Evaluation of FVIII-XTEN Interference with the Binding of Anti-FVIII Antibodies using the Bethesday Assay ] The ability ofXTEN insertions in the FVIII molecule to interfer with binding by pre-existing anti-FVIII antibodies to the XTEN fusion n was evaluated in order to determine their utility in treating patients with anti-FVIII inhibitory antibodies.

Methods: To assess the binding of anti-FVIII antibodies, two FVIII-XTEN variants 8, with 144 XTEN inserted at the locations of 26/403/1656/1900; and PSD-090, with 144 XTEN inserted at the locations of 26/1656/1720/1900) were tested in comparison with Refacto (a marketed rFVIII) against plasma samples from three hemophilia A patients with factor VIII inhibitors (designated 04-483, 05-505, and -2079), as well as a sheep anti-FVIII poly-clonal antibody from Affinity Biologicals Inc (F8C-EIA—C). The Bethesda titer of the four anti-FVIII ab against the two XTEN variants (pSD- 088 and pSD-090) and the Refacto control were determined using d da assay methods, detailed as follows. Heat inactivated anti-FVIII dy samples at various ons were incubated with 1 IU/mL of each FVIII variant (diluted in 1X in FVIII chromogenic assay ) at a 1:1 ratio. The antibody mixtures were then incubated for 2 hours in a 37°C incubator. After the incubation, the samples were diluted for d with 1 x FVIII chromogenic assay buffer, and 25 [AL of diluted mixture were then used for a FVIII chromogenic assay, The percentage of remaining FVIII activity was calculated against the post-incubation activity of a known non-neutralizing sample. Bethesda units were calculated using the following formula: BU=dilution factor X rcent of remaining activity) + 6. 643 8).

: The results are listed in Table 47. Decreased Bethesda unit (BU) titers were observed for all four antibodies when tested against the two FVIII-XTEN variants, in comparison with Refacto. A to 8-fold fold decrease against PSD-088 and a 3 to 5-fold decrease against pSD-090, respectively, were obtained. The inhibition curves against FVIII variants for each antibody were plotted () and compared to Refacto, and demonstrates a clear left-shift of the inhibition curve for the two FVIII-XTEN molecules,with the pSD-O88 FVIII-XTEN variant ing in a further left-shift compared to pSD-O90.

These results clearly demonstrate that: 1) both FVIII-XTEN variant fusion proteins are more resistant to pre-existing anti-FVIII inhibitory antibodies than Refacto; and 2) PSD-O88 is more resistant to anti-FVIII antibodies than 0, which may provide information useful in determining the differences on the XTEN insertion sites in erring with the binding of anti-FVIII dies. Under the conditions of the experiment, the results provide some t for the potential use of FVIII-XTEN compositions for treating hemophilia A patients with factor VIII inhibitors.

Table 47: Anti-FVIII antibod Bethesda titer a ainst FVIII-XTEN ts Anti-FVIII ab. 04-483 05-505 GKl838-2079 F8C-EIA—C ———“ ] Example 53: Half-life tions of FVIII XTEN fusion molecules containing four XTEN insertions in Hemophilia A mice Methods: Eight FVIII-XTEN fusion proteins with four XTEN insertions each at defined locations were tested in FVIII/VWF DKO mice to evaluate the effect of the XTEN insertions on FVIII half-life extension: LSDOO71.00l, contains 403-AG144, l900-AE144, 745(B)-AE144, 2332(CT)-AE288 XTEN insertions (designated as the FVIII amino acid number and the XTEN inserted); LSDOO71.002, containing 144, l900-AE144, -AE144, 2332(CT)-AE288 XTEN insertions; LSDOO72.001, containing 403-AG144, l900-AG144, 745(B)-AE144, 2332(CT)-AE288 XTEN insertions; LSDOO72.002, containing 403-AE144, l900-AG144, 745(B)-AE144, 2332(CT)-AE288 XTEN insertions; pBCO247.004, containing l8-AG144, 403-AE144, l656-AG144, 2332(CT)-AE288 XTEN insertions; pBCO251.002, containing l8-AG144, l656-AG144, l900-AE144, 2332(CT)-AE288 XTEN insertions; pSDO88, containing 26-AG144, 403-AE144, l656)-AG144, E144 XTEN insertions and pSDO90, containing 44, l656-Agl44, l720-AG144, l900-AE144 XTEN insertions. FVIII/VWF DKO mice were treated, as generally described in Example 32, with a single intravenous administration of FVIII-XTEN transfection cell media concentrate of the eight constructs at 100-200 IU/kg, and plasma samples were subsequently collected at 5 min, 8 hrs, 24 hrs, 48 hrs, 72 hrs and 96 hrs post-dosing. Plasma FVIII actiVity was tested using the FVIII genic assay and FVIII- XTEN half-life was ted using the WinNonlin program.

RLults: All of the eight FVIII XTEN fusion molecules containing four XTEN ions ted longer half-life than unmodified FVIII (results in Table 48). Three molecules with XTEN insertions at positions 403, 1900, B domain, and C-terminal achieved half-life up to 16.3 hrs, which is a d improvement in comparison to unmodified BDD FVIII. However, the molecules tested with XTEN insertions at 26/403/1656/1900 8), or at 26/1656/1720/1900 (pSD090) showed ife of 9.1 hrs and 9.5 hrs, respectively, Which, in comparison to BDD FVHI, represents an increase of 36-fold and 38-fold, respectively. pBC247.004 (XTEN insertions at 18/403/1656/CT) and pBC251.002 (XTEN insertions at 18/1900/1656/CT) achieved half-life values of 14.1 hrs and 13 hrs, respectively. The results demonstrate that multiple XTEN ions (in this case, four XTEN insertions for each FVHI molecule) can significantly improve FVHI half-life. It further shows that the effect ofXTEN on FVHI half-life is insertion site dependent, even in the event of multiple XTEN insertions.

Table 48: PK of FVIII-XTEN variants with four XTEN insertions in WF DKO mice ent XTEN Insertions t1/2 (hr) t1/2 Increase (fold) BDD-FVIH None 0.25 NA LSD0071 .001 1900AE/B/CT 16.2 64.8 LSD0071.002 403AE/1900AE/B/CT 16.3 65.2 LSD0072.001 403AG/1900AG/B/CT 11.8 47.2 LSD0072.002 403AE/1900AG/B/CT 16.1 64.4 ch247.004 18/403/1656/CT 14.1 56.4 pBC251.002 18/1900/1656/CT 13.0 52 pSD088 26/403/1656/1900 9.1 36.4 pSD090 26/1656/1720/1900 9.5 38 Table 49: Exem la Biolo icalActivi Exem la Assa s and Preferred Indications Biologically Active Exemplary Activity Protein Biological Activity Assays Preferred Indication: Factor VIII Coagulation factor VIII is a Chromogenix assay Hemophilia A; (Factor VIII; factor essential for (Rosen 8, Scand J ng; Octocog alfa; hemostasis. This gene Haematol (1984) 33 Factor VIII Moroctocog encodes coagulation (Suppl 40):139—45); deficiency; alfa; factor VIII, which participates Chromogenix bleeding es Recombinant in the intrinsic pathway of Coamatic® Factor VIII in patients with Antihemophilic blood coagulation; factor VIII assay; one-stage factor VIII inhibitor; factor; is a cofactor for factor lXa ng assay Surgeay~related Nordiate; which, in the presence of Ca (Lethagen, 8., et al., hemorrhagic o; + 2 and phospholipids, Scandinavian J es Kogenate; converts factor X to the Haematology (1986) Kogenate activated form Xa. This gene 37:448—453.

SF; Helixate; es two alternatively One-stage clotting Recombinate) spliced transcripts. assay and two-stage Transcript variant l encodes clotting assay a large glycoprotein, isoform (Barrowcliffe TW, a, which circulates in plasma Semin Thromb and associates with von Hemost. (2002) rand 28(3):247-256); factor in a noncovalent Development of a complex. This protein simple undergoes multiple chromogenic factor VIII cleavage events. ript assay for t 2 encodes a putative clinical use.

PCT/U82012/046326 Biologically Active Exemplary ty Protein Biological ty Assays red Indication: small protein, isoform b, (Wagenvoord RJ, which consists primarily of Hendrix HH, the olipid binding Hemker HC. domain of factor Vlllc. This Haemostasis binding domain is essential 1989; 19(4): 196-204) for coagulant activity. Bethesda assay Defects in this gene results (Verbruggen B, et al. in hemophilia A, a common Improvements in factor recessive X-linked VIII inhibitor ion: coagulation disorder. From Bethesda to Nijmegen. Semin Thromb . 2009 Nov;35(8):752-759) Table 50: Exemplary CFXTEN comprising FVIII and internal/external XTEN seguences (SEQ ID NOS 1537-1554 res ectivel in order of a earance CFXTEN Amino Acid Sequence Name FVIII BDD2 ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTVHLFNI (Al-K127 — AKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQ AE144- REKEDDKGGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSE V128—N745- GSAPGSEPATSGSETPGSEPATSGSETPGSEPATSGSETPGTSTEPSEGSAPGTSESATPESGPG AE288- SEPATSGSETPGTSTEPSEGSAPGVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDL P1640- VKDLNSGLIGALLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASA Y2332) RAWPKMHTVNGYVNRSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQAS LEISPITFLTAQTLLMDLGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYD DDLTDSEMDVVRFDDDNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSY KSQYLNNGPQRIGRKYKKVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQA SRPYNIYPHGITDVRPLYSRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRY MERDLASGLIGPLLICYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRF LPNPAGVQLEDPEFQASNIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGY TFKHKMVYEDTLTLFPFSGETVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDKNTG YEDISAYLLSKNNAIEPRSFSQNGGTSESATPESGPGSEPATSGSETPGTSESATPES GPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSESATPESGPGSE PATSGSETPGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGTSTEPSEGSAPGTSESATP ESGPGTSESATPESGPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEG TSTEPSEGSAPGTSTEPSEGSAPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGPPVLK RHQREITRTTLQSDQEEIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERL WDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEV EDNIMVTFRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTK DEFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFDETKS WYFTENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLSMG SNENIHSIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHAG MSTLFLVYSNKCQTPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSW IKVDLLAPMIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDS SGIKHNIFNPPIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYF TNMFATWSPSKARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTS MYVKEFLISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVH QIALRMEVLGCEAQDLY FVIII BDD2 ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTVHLFNI (Al-A375- AKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQ AE576- REKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCR K376-N745- EGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVN AE144- RSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLMD P1640- LGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDD 2012/046326 CFXTEN Amino Acid Sequence Name Y2332) DNSPSFIQIRSVAGGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTS TEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPT STEEGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPG TSTEPSEGSAPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSTEP SEGSAPGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGSPAGSPTSTEEGTSESATPESG PGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTST EPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPE SGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGT SESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGTSTEPS EGSAPGKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKYKKVRF MAYTDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPLYSRRL PKGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGLIGPLLI CYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQASNIM HSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGE TVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNA IEPRSFSQNGGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGSPAGSPTSTEEGTSTEPS EGSAPGSEPATSGSETPGSEPATSGSETPGSEPATSGSETPGTSTEPSEGSAPGTSESATPESGP GSEPATSGSETPGTSTEPSEGSAPGPPVLKRHQREITRTTLQSDQEEIDYDDTISVEMKKEDF ENQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEF TDGSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVTFRNQASRPYSFYSSLISYEEDQRQGA EPRKNFVKPNETKTYFWKVQHHMAPTKDEFDCKAWAYFSDVDLEKDVHSGLIGPLLVCH TNTLNPAHGRQVTVQEFALFFTIFDETKSWYFTENMERNCRAPCNIQMEDPTFKENYRFHA INGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYPG VFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLVYSNKCQTPLGMASGHIRDFQITASGQ YGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAPMIIHGIKTQGARQKFSSLYISQFIIMY SLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARYIRLHPTHYSIRSTLRMELM GCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSKARLHLQGRSNAWRPQVNNPK EWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQDGHQWTLFFQNGKVKVFQGN QDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRMEVLGCEAQDLY FVIII BDD2 LGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTVHLFNI (A1-Y1792- AKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQ AF144- REKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCR E1793- EKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVN Y2332- RSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLMD AE864) LGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDD DNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKY KKVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPL YSRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGLI GPLLICYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQA SNIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFP FSGETVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLS PRSFSQNPPVLKRHQREITRTTLQSDQEEIDYDDTISVEMKKEDFDIYDEDENQSPR SFQKKTRHYFIAAVERLWDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRG ELNEHLGLLGPYIRAEVEDNIMVTFRNQASRPYSFYSSLISYGGTSTPESGSASPGTSPSGESS TAPGTSPSGESSTAPGSTSSTAESPGPGSTSESPSGTAPGSTSSTAESPGPGTSPSGESSTAPGT STPESGSASPGSTSSTAESPGPGTSPSGESSTAPGTSPSGESSTAPGTSPSGESSTAPGEEDQRQ GAEPRKNFVKPNETKTYFWKVQHHMAPTKDEFDCKAWAYFSDVDLEKDVHSGLIGPLLV CHTNTLNPAHGRQVTVQEFALFFTIFDETKSWYFTENMERNCRAPCNIQMEDPTFKENYRF HAINGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNL YPGVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLVYSNKCQTPLGMASGHIRDFQITA SGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAPMIIHGIKTQGARQKFSSLYISQFI IMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARYIRLHPTHYSIRSTLRME LMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSKARLHLQGRSNAWRPQVNN PKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQDGHQWTLFFQNGKVKVFQ GNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRMEVLGCEAQDLYGGSPAGSPTSTEE GTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGTSES PGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGS APGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTS TEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSTEPSEGSAPGTSTEPSEGSAPGTSESATP ESGPGTSESATPESGPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPG CFXTEN Amino Acid Sequence Name EGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEP SEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSESATPESG PGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSPAGSPTSTEEGSPA GSPTSTEEGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSEPATSGS ETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGT SESATPESGPGSEPATSGSETPGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGTSTEPS EGSAPGTSESATPESGPGTSESATPESGPGTSESATPESGPGSEPATSGSETPGSEPATSGSETP GSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGSEPATSGSETPGTSESATPESGPGTSTE FVIII BDD2 ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTVHLFNI (A1-Y2043- AKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQ AG144- REKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCR G2044- EGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVN Q2222- RSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLMD AG864- LGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDD V2223- DNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKY Y2332) KKVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPL YSRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGLI GPLLICYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQA SNIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFP FSGETVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLS PRSFSQNPPVLKRHQREITRTTLQSDQEEIDYDDTISVEMKKEDFDIYDEDENQSPR SFQKKTRHYFIAAVERLWDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRG ELNEHLGLLGPYIRAEVEDNIMVTFRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNET KTYFWKVQHHMAPTKDEFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQV TVQEFALFFTIFDETKSWYFTENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLV MAQDQRIRWYLLSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPSKA GIWRVECLIGEHLHAGMSTLFLVYSNKCQTPLGMASGHIRDFQITASGQYGPGSSPSASTGT GPGSSPSASTGTGPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTGSPGT PGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGTPGSG TASSSGGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAPMIIHGIKTQGARQKFSSLYIS QFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARYIRLHPTHYSIRSTLR MELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSKARLHLQGRSNAWRPQG GASPGTSSTGSPGSSPSASTGTGPGSSPSASTGTGPGTPGSGTASSSPGSSTPSGATGSPGSSPS ASTGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGASPGTSST GSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGASPGTSSTGSPGTPGSGTASSSPG SSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGSSTPSGATGSPGSSTPSGATGSPGASPG TSSTGSPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTG SPGASPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGA SPGTSSTGSPGSSTPSGATGSPGSSTPSGATGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSG ATGSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGS PGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGTP GSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSG ATGSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGTPGSGTASSS PGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGSPGSST PSGATGSPGSSPSASTGTGPGASPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGSSTPSGA TGSPGSSTPSGATGSPGASPGTSSTGSPGVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTS MYVKEFLISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVH QIALRMEVLGCEAQDLY FVIII BDD2 ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTVHLFN (A1-G1799- PWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTS AE144- DKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLV A1800- CREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGY F2093- VNRSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTL AE42- LMDLGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVV $2094- RFDDDNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQR V2223- IGRKYKKVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGIT AE42- SRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERD N2224- LASGLIGPLLICYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLE AE42- DPEFQASNIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYE 2012/046326 CFXTEN Amino Acid Sequence Name N2225- DTLTLFPFSGETVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYED G2278— ISAYLLSKNNAIEPRSFSQNPPVLKRHQREITRTTLQSDQEEIDYDDTISVEMKKEDFDIYDE AE42- DENQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTDGS K2279- FTQPLYRGELNEHLGLLGPYIRAEVEDNIMVTFRNQASRPYSFYSSLISYEEDQRQGGGSEP Y2332) ATSGSETPGTSESATPESGPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGSEPATSG SETPGSEPATSGSETPGSEPATSGSETPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETP GTSTEPSEGSAPGAEPRKNFVKPNETKTYFWKVQHHMAPTKDEFDCKAWAYFSDVDLEK DVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFDETKSWYFTENMERNCRAPCNIQ MEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIHSIHFSGHVFTVR MALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLVYSNKCQTPL GMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAPMIIHGIKT QGARQKFGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGSPAGSPGSSLYISQFIIMYS LDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARYIRLHPTHYSIRSTLRMELMG CDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSKARLHLQGRSNAWRPQVGPAGS PTSTEEGTSTEPSEGSAPGTSESATPESGPGSEPATSGGNNPKEWLQVDFQKTMKVTGVTT LTSMYVKEFLISSSQDGHQWTLFFQNGGTEPSEGSAPGSPAGSPTSTEEGTSESAT PESGPGSEPATSGSKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRMEVLG CEAQDLY FVIII BDD2 ATRRYYLGAVELSWDYMQSDLGELPVDARGPGSSPSASTGTGPGSSPSASTGTGPGTPGSG (Al-R28- TASSSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGS AG144-F29- PGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSGFPPRVPKSFPFNTSV G244- VYKKTLFVEFTVHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSY AG288- WKASEGAEYDDQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDL L245- VKDLNSGLIGALLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASA R2090- RAWPKMHTVNGYVNRSLPGGPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSTP AG576- SGATGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGAT Q2091- GSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPG Y2332- SSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPGSSPSA AG864) GASPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGSSTPSGATGSGLIGCHRKSVY WHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLMDLGQFLLFCHISSHQH DGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDDDNSPSFIQIRSVAKK HPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKYKKVRFMAYTDETF KTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPLYSRRLPKGVKHLK DFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGLIGPLLICYKESVDQR GNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQASNIMHSINGYVFDS LQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGETVFMSMENP GLWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNAIEPRSFSQNP PVLKRHQREITRTTLQSDQEEIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAA VERLWDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYI RAEVEDNIMVTFRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHM APTKDEFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFD ETKSWYFTENMERNCRAPCNIQMEDPTFKENYRFHAGINGYIMDTLPGLVMAQDQRIRWY LLSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGE STLFLVYSNKCQTPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWST KEPFSWIKVDLLAPMIIHGIKTQGARGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGS PAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGSEPATS SPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEE GTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSEPA TSGSETPGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGSPAGSPTST EEGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGTS TEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSE GSAPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPG TSTEPSEGSAPGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGSPAGSPTSTEEGTSESA TPESGPGTSTEPSEGSAPGQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSS GIKHNIFNPPIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFT NMFATWSPSKARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSM YVKEFLISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQ IALRMEVLGCEAQDLYGGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGSPAGSPTST EEGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSP AGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSE WO 22617 CFXTEN Amino Acid Sequence Name GSAPGTSTEPSEGSAPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPG TSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGSPAGSPTSTEEGTSESA TPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSA PSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSE SATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEG SAPGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGT GSAPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESAT PESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGP PTSTEEGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGTSES ATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGS APGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAP FVIII ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTDHLFNI (Al-T1651- AKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQ AG576- REKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCR R1652- EGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVN K1808- RSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLMD AG144- LGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDD P1809- DNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKY F2093- KKVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPL AG288- YSRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGLI S2094- GPLLICYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQA Y2332) SNIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFP FSGETVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLS KNNAIEPRSFSQNSRHPSTRQKQFNATTIPENDIEKTDPWFAHRTPMPKIQNVSSSDLLMLLR QSPTPHGLSLSDLQEAKYETFSDDPSPGAIDSNNSLSEMTHFRPQLHHSGDMVFTPESGLQL RLNEKLGTTAATELKKLDFKVSSTSNNLISTIPSDNLAAGTDNTSSLGPPSMPVHYDSQLDT TLFGKKSSPLTESGGPLSLSEENNDSKLLESGLMNSQESSWGKNVSSTESGRLFKGKRAHGP ALLTKDNALFKVSISLLKTNKTSNNSATNRKTHIDGPSLLIENSPSVWQNILESDTEFKKVTP LMDKNATALRLNHMSNKTTSSKNMEMVQQKKEGPIPPDAQNPDMSFFKMLFLPE SARWIQRTHGKNSLNSGQGPSPKQLVSLGPEKSVEGQNFLSEKNKVVVGKGEFTKDVGLK EMVFPSSRNLFLTNLDNLHENNTHNQEKKIQEEIEKKETLIQENVVLPQIHTVTGTKNFMKN LFLLSTRQNVEGSYDGAYAPVLQDFRSLNDSTNRTKKHTAHFSKKGEEENLEGLGNQTKQI VEKYACTTRISPNTSQQNFVTQRSKRALKQFRLPLEETELEKRIIVDDTSTQWSKNMKHLTP STLTQIDYNEKEKGAITQSPLSDCLTRSHSIPQANRSPLPIAKVSSFPSIRPIYLTRVLFQDNSS HLPAASYRKKDSGVQESSHFLQGAKKNNLSLAILTLEMTGDQREVGSLGTSATNSVTYKK VENTVLPKPDLPKTSGKVELLPKVHIYQKDLFPTETSNGSPGHLDLVEGSLLQGTEGAIKWN EANRPGKVPFLRVATESSAKTPSKLLDPLAWDNHYGTQIPKEEWKSQEKSPEKTAFKKKDT ILSLNACESNHAIAAINEGQNKPEIEVTWAKQGRTERLCSQNPPVLKRHQREITGPGTPGSGT ASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGSSTPSGATGSPGSSTPSGATGSP GASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGASPGTSSTGSPGASP GTSSTGSPGASPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGASPGTSSTGSPGASPGTSST GSPGASPGTSSTGSPGSSTPSGATGSPGSSTPSGATGSPGASPGTSSTGSPGTPGSGTASSSPG ATGSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTGSPGASPG TSSTGSPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTG SPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSS TPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGTPGSGT ASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSSGRTTLQSDQEEI DYDDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLRNRA QSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVTFRNQASRPYS FYSSLISYEEDQRQGAEPRKNFVKGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSG ATGSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGTPGSGTASSS PGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGPNETKTYFWKVQHHMAPTKD EFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFDETKSW YFTENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLSMGS NENIHSIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHAGM STLFLVYSNKCQTPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWI KVDLLAPMIIHGIKTQGARQKFGPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSST PSGATGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGA TGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSP GSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPGSSPS CFXTEN Amino Acid Sequence Name ASTGTGPGASPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGSSTPSGATGSGSSLYISQFII MYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARYIRLHPTHYSIRSTLRME LMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSKARLHLQGRSNAWRPQVNN VDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQDGHQWTLFFQNGKVKVFQ GNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRMEVLGCEAQDLY FVIII BDD2 ATRRYYLGAVELSWDYMQSDLGELPVDAGGAPSPSASTGTGPGTPGSGTASSSPGSSTPSG (Al-A28- ATGSPGPSGPGRFPPRVPKSFPFNTSVVYKKTLFVEFTVHLFNIAKPRPPWMGLLGPTIQAEV AG42-F29- YDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQREKEGGPGTPGSGTASSSPG E124- SSTPSGATGSPGSSPSASTGTGPGASPGDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYS AG42- LVKDLNSGLIGALLVCREGSLAKEKTQTLHKFILLFAVFDEGGSPSASTGTGPGAS D125-E124- PGTSSTGSPGTPGSGTASSSPGSSTPSGAGKSWHSETKNSLMQDRDAASARAWPKMHTVN AG42- GYVNSSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQT D125-P333- QFLLFCHISSHQHDGMEAYVKVDSCPEEPGSASTGTGPGASPGTSSTGSPGTPGSG AG42- TASSSPGSSTPSGATGGQLRMKNNEEAEDYDDDLTDSEMDVVRFDDDNSPSFIQIRSVAKK Q334- HPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKYKKVRFMAYTDETF Y2332) KTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPLYSRRLPKGVKHLK DFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGLIGPLLICYKESVDQR GNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQASNIMHSINGYVFDS LQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGETVFMSMENP GLWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNAIEPRSFSQNP PVLKRHQREITRTTLQSDQEEIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAA VERLWDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYI RAEVEDNIMVTFRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHM APTKDEFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFD ETKSWYFTENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYL LSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEH LHAGMSTLFLVYSNKCQTPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTK EPFSWIKVDLLAPMIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFF GNVDSSGIKHNIFNPPIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQIT ASSYFTNMFATWTPSKARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVK SLLTSMYVKEFLISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQ SWVHQIALRMEVLGCEAQDLY FVIII ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTDHLFNI (Al-D345- AKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQ AE144- REKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCR Y346- EGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVN D403- RSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLMD AE144- FCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDGGSEPATSGSETPGTSES R405- ATPESGPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGSEPATSGSETPGSEPATSGSE R1797- TPGSEPATSGSETPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSTEPSEGSAPGYD AE288- DDLTDSEMDVVRFDDDNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDGGT Q1798- SASPGTSPSGESSTAPGTSPSGESSTAPGSTSSTAESPGPGSTSESPSGTAPGSTSSTAE Y2322) SPGPGTSPSGESSTAPGTSTPESGSASPGSTSSTAESPGPGTSPSGESSTAPGTSPSGESSTAPG TSPSGESSTAPGRSYKSQYLNNGPQRIGRKYKKVRFMAYTDETFKTREAIQHESGILGPLLY LLIIFKNQASRPYNIYPHGITDVRPLYSRRLPKGVKHLKDFPILPGEIFKYKWTVTV EDGPTKSDPRCLTRYYSSFVNMERDLASGLIGPLLICYKESVDQRGNQIMSDKRNVILFSVF DENRSWYLTENIQRFLPNPAGVQLEDPEFQASNIMHSINGYVFDSLQLSVCLHEVAYWYILS IGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGETVFMSMENPGLWILGCHNSDFRNRGM TALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNAIEPRSFSQNSRHPSTRQKQFNATTIPEN DIEKTDPWFAHRTPMPKIQNVSSSDLLMLLRQSPTPHGLSLSDLQEAKYETFSDDPSPGAIDS NNSLSEMTHFRPQLHHSGDMVFTPESGLQLRLNEKLGTTAATELKKLDFKVSSTSNNLISTI PSDNLAAGTDNTSSLGPPSMPVHYDSQLDTTLFGKKSSPLTESGGPLSLSEENNDSKLLESG LMNSQESSWGKNVSSTESGRLFKGKRAHGPALLTKDNALFKVSISLLKTNKTSNNSATNRK THIDGPSLLIENSPSVWQNILESDTEFKKVTPLIHDRMLMDKNATALRLNHMSNKTTSSKN MEMVQQKKEGPIPPDAQNPDMSFFKMLFLPESARWIQRTHGKNSLNSGQGPSPKQLVSLGP EKSVEGQNFLSEKNKVVVGKGEFTKDVGLKEMVFPSSRNLFLTNLDNLHENNTHNQEKKI QEEIEKKETLIQENVVLPQIHTVTGTKNFMKNLFLLSTRQNVEGSYDGAYAPVLQDFRSLN DSTNRTKKHTAHFSKKGEEENLEGLGNQTKQIVEKYACTTRISPNTSQQNFVTQRSKRALK QFRLPLEETELEKRIIVDDTSTQWSKNMKHLTPSTLTQIDYNEKEKGAITQSPLSDCLTRSHSI PQANRSPLPIAKVSSFPSIRPIYLTRVLFQDNSSHLPAASYRKKDSGVQESSHFLQGAKKNNL CFXTEN Amino Acid Sequence Name SLAILTLEMTGDQREVGSLGTSATNSVTYKKVENTVLPKPDLPKTSGKVELLPKVHIYQKD LFPTETSNGSPG WDNHYGTQIPKEEWKSQEKSPEKTAFKKKDTILSLNACESNHAIAAINEGQNKPEIEVTWA RLCSQNPPVLKRHQREITRTTLQSDQEEIDYDDTISVEMKKEDFDIYDEDENQSPR SFQKKTRHYFIAAVERLWDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRG ELNEHLGLLGPYIRAEVEDNIMVTFRNQASRPYSFYSSLISYEEDQRGGTSESATPESGPGSE PATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGSPAGSPT STEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEG TSTEPSEGSAPGTSESATPESGPGTSESATPESGPGTSESATPESGPGSEPATSGSETPGSEPAT SGSETPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGSEPATSGSETPGTSESATPESG PGTSTEPSEGSAPGQGAEPRKNFVKPNETKTYFWKVQHHMAPTKDEFDCKAWAYFSDVDL EKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFDETKSWYFTENMERNCRAPCNI QMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIHSIHFSGHVFTVR KKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLVYSNKCQTPLG MASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAPMIIHGIKTQG ARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARYIRL HPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSKARLHL QGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQDGHQW TLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRMEVLGCEAQDLY FVIII (A1- ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTVHLFNI N745)- AKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQ AE864- REKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCR (P1640- EGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVN Y2332) IGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLMD LGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDD DNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKY KKVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPL YSRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGLI GPLLICYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQA SNIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFP FMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLS KNNAIEPRSFSQNGGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGT STEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSP TSTEEGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAP GTSTEPSEGSAPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSTE PSEGSAPGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGSPAGSPTSTEEGTSESATPES GPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTS TEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSESATP ESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPG TSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGTSTEP GTSESATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESG PSEGSAPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSPA EEGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGTSESATPE SGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGS EPATSGSETPGTSESATPESGPGTSTEPSEGSAPGPPVLKRHQREITRTTLQSDQEEIDYDDTIS VEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLRNRAQSGSVPQ FKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVTFRNQASRPYSFYSSLISY EEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKDEFDCKAWAYFSDVDLEKDVHSG LIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFDETKSWYFTENMERNCRAPCNIQMEDPTF KENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIHSIHFSGHVFTVRKKEEYK MALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLVYSNKCQTPLGMASGHI RDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAPMIIHGIKTQGARQKFS SLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARYIRLHPTHYSI RSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSKARLHLQGRSNA WRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQDGHQWTLFFQN GKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRMEVLGCEAQDLY FVIII BDD9 ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTS V V Y KKTLFVEFTVHLFNI (Al- N745)- AKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQ AE288- REKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCR CFXTEN Amino Acid Sequence Name (P1640- EGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVN Y2332) RSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLMD LGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDD DNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKY KKVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPL YSRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGLI YKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQA SNIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFP FMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLS PRSFSQNGGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGT SESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESAT PESGPGSPAGSPTSTEEGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSESATPESGP GTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGTSTE PSEGSAPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGPPVLKRHQREITRTTLQSDQ EEIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLRN RAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVTFRNQASRP YSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKDEFDCKAWAYFSDVD LEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFDETKSWYFTENMERNCRAPC NIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIHSIHFSGHVFT VRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLVYSNKCQTP LGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAPMIIHGIKT QGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARYI RLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSKARL HLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQDGH QWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRMEVLGCEAQ FVIII BDD9 ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTVHLFNI (Al- S743)- AKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQ AE288- REKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCR (Q1638- EGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVN Y2332) RSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLMD LGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDD DNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKY KKVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPL YSRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGLI GPLLICYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQA SNIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFP FSGETVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLS KNNAIEPRSFSGGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSES ATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPES GPGSPAGSPTSTEEGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGTS ESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSE GSAPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGQNPPVLKRHQREITRTTLQSDQE EIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLRNR AQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVTFRNQASRP YSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKDEFDCKAWAYFSDVD LEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFDETKSWYFTENMERNCRAPC NIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIHSIHFSGHVFT YKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLVYSNKCQTP LGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAPMIIHGIKT QGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARYI RLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSKARL NAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQDGH QWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRMEVLGCEAQ FVIII BDD9 ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTVHLFNI (Al- N745)- AKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQ AG288_2- REKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCR (P1640- EGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVN Y2332)- RSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLMD CFXTEN Amino Acid Sequence Name 2 LGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDD DNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKY KKVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPL YSRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGLI YKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQA SNIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFP FSGETVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLS KNNAIEPRSFSQNGPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPG TPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSPSA STGTGPGSSPSASTGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGT GPGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPGSSPSASTGTGPGA SPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGSSTPSGATGSGPPVLKRHQREITRTTLQS DQEEIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVL RNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVTFRNQA SRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKDEFDCKAWAYFS DVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFDETKSWYFTENMERNCR APCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIHSIHFSGH VFTVRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLVYSNKC QTPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAPMIIH GIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPII ARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSK ARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQ DGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRMEVLGC EAQDLYGAGSPGAETAPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATG SPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSS PSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSAST GTGPGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPGSSPSASTGTGP GASPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGSSTPSGATGSGAETAEQKLISEEDLSP FVIII BDD9 ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTVHLFNI (Al- S743)- AKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQ AG288_2- REKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCR (Q1638- EGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVN - RSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLMD AG288_2 LGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDD DNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKY KKVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPL YSRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGLI GPLLICYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQA SNIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFP FMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLS KNNAIEPRSFSGPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTP GSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSPSAST GTGPGSSPSASTGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGP GSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPGSSPSASTGTGPGASP GTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGSSTPSGATGSGQNPPVLKRHQREITRTTLQS DQEEIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVL RNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVTFRNQA SRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKDEFDCKAWAYFS DVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFDETKSWYFTENMERNCR APCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIHSIHFSGH VFTVRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLVYSNKC QTPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAPMIIH GIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPII ARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSK ARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQ DGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRMEVLGC EAQDLYGAGSPGAETAPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATG SPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSS PSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSAST CFXTEN Amino Acid Sequence Name GTGPGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPGSSPSASTGTGP GASPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGSSTPSGATGSGAETAEQKLISEEDLSP FVIII ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTDHLFNI BDD10 AKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQ (Al- N745)- REKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCR AE288- EGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVN (P1640- RSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLMD Y2332)- LGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDD AE288 IQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKY KKVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPL YSRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGLI GPLLICYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQA SNIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFP FSGETVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLS KNNAIEPRSFSQNGGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGT ESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESAT PESGPGSPAGSPTSTEEGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSESATPESGP GTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGTSTE PSEGSAPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGPPVLKRHQAEITRTTLQSDQ EEIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLRN RAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVTFRNQASRP YSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKDEFDCKAWAYFSDVD LEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFDETKSWYFTENMERNCRAPC NIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIHSIHFSGHVFT VRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLVYSNKCQTP LGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAPMIIHGIKT QGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARYI RLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSKARL HLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQDGH QWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRMEVLGCEAQ SESATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGP GTSTEPSEGSAPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSPAG SPTSTEEGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGTSESATPES GPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGSE PATSGSETPGTSESATPESGPGTSTEPSEGSAP FVIII ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTDHLFNI BDD10 AKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQ (Al- S743)- REKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCR AE288- EGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVN (Q1638- RSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLMD Y2332)- LGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDD AE288 DNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKY KKVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPL YSRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGLI YKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQA SNIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFP FSGETVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLS KNNAIEPRSFSGGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSES PGTSTEPSEGSAPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPES GPGSPAGSPTSTEEGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGTS ESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSE GSAPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGQNPPVLKRHQAEITRTTLQSDQE EIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLRNR AQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVTFRNQASRP YSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKDEFDCKAWAYFSDVD LEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFDETKSWYFTENMERNCRAPC NIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIHSIHFSGHVFT YKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLVYSNKCQTP LGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAPMIIHGIKT CFXTEN Amino Acid Sequence Name QGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARYI RLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSKARL HLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQDGH QWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRMEVLGCEAQ DLYGGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGP GTSTEPSEGSAPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSPAG SPTSTEEGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGTSESATPES GPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGSE PATSGSETPGTSESATPESGPGTSTEPSEGSAP FVIII ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTDHLFNI BDD10 AKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQ (Al- N745)- REKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCR AG288_2- EGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVN (P1640- RSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLMD Y2332)- LGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDD AG288_2 DNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKY AYTDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPL YSRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGLI GPLLICYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQA SNIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFP FSGETVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLS KNNAIEPRSFSQNGPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPG ASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSPSA STGTGPGSSPSASTGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGT GPGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPGSSPSASTGTGPGA SPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGSSTPSGATGSPPVLKRHQAEITRTTLQSD QEEIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLR NRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVTFRNQAS SSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKDEFDCKAWAYFSD VDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFDETKSWYFTENMERNCRA PCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIHSIHFSGHVF TVRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLVYSNKCQT PLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAPMIIHGIK TQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARY IRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSKARL NAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQDGH QWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRMEVLGCEAQ DLYGAGSPGAETAPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPG TPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSPSA GSSPSASTGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGT GPGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPGSSPSASTGTGPGA SPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGSSTPSGATGSGAETAEQKLISEEDLSPAT FVIII ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTDHLFNI BDD10 AKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQ (Al- S743)- REKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCR AG288_2- EGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVN (Q1638- RSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLMD - LGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDD AG288_2 DNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKY KKVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPL YSRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGLI GPLLICYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQA SNIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFP FSGETVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLS KNNAIEPRSFSGPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTP GSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSPSAST GTGPGSSPSASTGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGP GSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPGSSPSASTGTGPGASP GTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGSSTPSGATGSQNPPVLKRHQAEITRTTLQSD WO 22617 CFXTEN Amino Acid Sequence Name QEEIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLR NRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVTFRNQAS RPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKDEFDCKAWAYFSD VDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFDETKSWYFTENMERNCRA EDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIHSIHFSGHVF TVRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLVYSNKCQT PLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAPMIIHGIK TQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARY IRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSKARL HLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQDGH QWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRMEVLGCEAQ DLYGAGSPGAETAPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPG TPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSPSA GSSPSASTGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGT GPGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPGSSPSASTGTGPGA SPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGSSTPSGATGSGAETAEQKLISEEDLSPAT ce name reflects N— to C-terminus configuration of the FVIH segments (amino acid spanning numbers relative to mature sequence) and XTEN components Table 51: Exemplary CFXTEN comprising FVIII, cleavage seguences and XTEN ces (SEQ ID NOS 1555-1590 res ectivel in order of a earance CFXTEN Amino Acid Sequence Name SP-AE288- MQIELSTCFFLCLLRFCFSGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETP CS-L- GTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESA (FVIII_1- TPESGPGSPAGSPTSTEEGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSESATPESGP 745)— GTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPS AE288- EGSAPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPQSPRSFQGPEGPSATRRYYLGAVE (FVIII_168 LSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTVHLFNIAKPRPPWMGLLG 6-2332)-L- PTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQREKEDDKVFPGGSH CS-AE288 TYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCREGSLAKEKTQTLHKFI LLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNRSLPGLIGCHRKSVYWH VIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLMDLGQFLLFCHISSHQHDGM EAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDDDNSPSFIQIRSVAKKHPKT WVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKYKKVRFMAYTDETFKTREAI QHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPLYSRRLPKGVKHLKDFPILPGEI VTVEDGPTKSDPRCLTRYYSSFVNMERDLASGLIGPLLICYKESVDQRGNQIMSDK RNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQASNIMHSlNGYVFDSLQLSVCLHEV AYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGETVFMSMENPGLWILGCHNSDF RNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNAIEPRSFSQNGTSESATPESGPGSEP ATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGSPAGSPTST EEGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGTST EPSEGSAPGTSESATPESGPGTSESATPESGPGTSESATPESGPGSEPATSGSETPGSEPATSGSE TPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGSEPATSGSETPGTSESATPESGPGTST EPSEGSAPQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTD GSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVTFRNQASRPYSFYSSLISYEEDQRQGAEPRK NFVKPNETKTYFWKVQHHMAPTKDEFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNP AHGRQVTVQEFALFFTIFDETKSWYFTENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMD TLPGLVMAQDQRIRWYLLSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEML PSKAGIWRVECLIGEHLHAGMSTLFLVYSNKCQTPLGMASGHIRDFQITASGQYGQWAPKLA RLHYSGSlNAWSTKEPFSWIKVDLLAPMIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTY RGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLG MESKAISDAQITASSYFTNMFATWSPSKARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKV CFXTEN Amino Acid Sequence Name TGVTTQGVKSLLTSMYVKEFLISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLL TRYLRIHPQSWVHQIALRMEVLGCEAQDLYGPEGPSQSPRSFQGTSESATPESGPGSEPATSGS ETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTS ESATPESGPGSEPATSGSETPGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGTSTEPSEGS APGTSESATPESGPGTSESATPESGPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPA GSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGSEPATSGSETPGTSESATPESGPGTSTEPSEGS SP-AE576- MQIELSTCFFLCLLRFCFSGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEE CS-L- GTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGS (FVIII_1- PTSTEEGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAP 745)— GTSTEPSEGSAPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSTEPS AE576- EGSAPGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGSPAGSPTSTEEGTSESATPESGPG (FVIII_168 SEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSE 6-2332)-L- GSAPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGS CS-AE288 EPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSESATP ESGPGSPAGSPTSTEEGSPAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPQS PRSFQGPSGPATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFV EFTVHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEY DDQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGA LLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNG YVNRSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLL MDLGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFD FIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKY KKVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPLY SRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGLIGP LLICYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQASNI MHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGE TVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNAIE PRSFSQNGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSA PGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSES PGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSA PGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSTEPSEGSAPGTSTEP SEGSAPGTSESATPESGPGTSESATPESGPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETP GTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPS EGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPG TSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSPAGSP TSTEEGSPAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPQSPRSFQKKTRHY RLWDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLG PYIRAEVEDNIMVTFRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHH MAPTKDEFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFD ETKSWYFTENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLS MGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHA GMSTLFLVYSNKCQTPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSW IKVDLLAPMIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSG IKHNIFNPPIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNM FATWSPSKARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKE FLISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRME QDLYGPEGPSQSPRSFQGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSEPAT SGSETPGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETP GTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSESA TPESGPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAP GTSTEPSEGSAPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAP SP- TCFFLCLLRFCFSATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSV (FVIII_1- VYKKTLFVEFTVHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYW 745)— KASEGAEYDDQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVK AE576- DLNSGLIGALLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAW (FVIII_168 NGYVNRSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPI )-L- TFLTAQTLLMDLGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTD CS-AE576 SEMDVVRFDDDNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNN GPQRIGRKYKKVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPH WO 22617 CFXTEN Amino Acid Sequence Name GITDVRPLYSRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMER IGPLLICYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLED PEFQASNIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTL TLFPFSGETVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYL LSKNNAIEPRSFSQNGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTS TEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTS TEEGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTS TEPSEGSAPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSTEPSEGS APGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGSPAGSPTSTEEGTSESATPESGPGSEP TPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGS APGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGSEP ATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSESATPES GPGSPAGSPTSTEEGSPAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPQSPR SFQKKTRHYFIAAVERLWDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGE LNEHLGLLGPYIRAEVEDNIMVTFRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKT YFWKVQHHMAPTKDEFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQ EFALFFTIFDETKSWYFTENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQD QRIRWYLLSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVE LHAGMSTLFLVYSNKCQTPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINA WSTKEPFSWIKVDLLAPMIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLM VFFGNVDSSGIKHNIFNPPIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQ ITASSYFTNMFATWSPSKARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVK SLLTSMYVKEFLISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQS WVHQIALRMEVLGCEAQDLYGPEGPSQSPRSFQGSPAGSPTSTEEGTSESATPESGPGTSTEPS EGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPG SEPATSGSETPGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSP TSTEEGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPG SEPATSGSETPGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGSPAGSP TSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPG TSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSE GSAPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGT STEPSEGSAPGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGSPAGSPTSTEEGTSESATPE SGPGTSTEPSEGSAP SP-AE576- TCFFLCLLRFCFSGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEE CS-L- GTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGS (FVIII_1- PTSTEEGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAP 745)— GTSTEPSEGSAPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSTEPS AE576- EGSAPGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGSPAGSPTSTEEGTSESATPESGPG (FVIII_168 SEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSE 6-2332) GSAPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGS EPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSESATP ESGPGSPAGSPTSTEEGSPAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPQS PRSFQGPEGPSATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLF VEFTVHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAE YDDQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIG EGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVN GYVNRSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTL LMDLGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRF DDDNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRK YKKVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPL YSRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGLIG PLLICYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQASNI MHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGE TVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNAIE PRSFSQNGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSA PGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSES ATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSA PGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSTEPSEGSAPGTSTEP SEGSAPGTSESATPESGPGTSESATPESGPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETP GTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPS CFXTEN Amino Acid Sequence Name EGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPG TSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSPAGSP TSTEEGSPAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPQSPRSFQKKTRHY FIAAVERLWDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLG PYIRAEVEDNIMVTFRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHH MAPTKDEFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFD ETKSWYFTENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLS MGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHA GMSTLFLVYSNKCQTPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSW IKVDLLAPMIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSG IKHNIFNPPIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNM FATWSPSKARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKE FLISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRME VLGCEAQDLY SP-AE576- MQIELSTCFFLCLLRFCFSGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEE CS-L- GTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGS (FVIII_1- PTSTEEGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAP 743)— GTSTEPSEGSAPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSTEPS AE288- EGSAPGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGSPAGSPTSTEEGTSESATPESGPG _168 SEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSE )-L- GSAPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGS 76 EPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSESATP ESGPGSPAGSPTSTEEGSPAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPIEP RSPSGSPGATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFT VHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDD QTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALL VCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGY VNRSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLM DLGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDD DNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKYK YTDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPLYSR RLPKGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGLIGPLLI CYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQASNIMHS INGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGETVF MSMENPGLWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNAIEPRS SATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTE PSEGSAPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSPAGSPTSTE EGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGTSESATPESGPGSEPA TSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGSEPATSGSETP GTSESATPESGPGTSTEPSEGSAPQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLRNRAQS GSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVTFRNQASRPYSFYS EDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKDEFDCKAWAYFSDVDLEKDV HSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFDETKSWYFTENMERNCRAPCNIQMEDP TFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIHSIHFSGHVFTVRKKEEYK MALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLVYSNKCQTPLGMASGHIRD FQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAPMIIHGIKTQGARQKFSSLYI SQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARYIRLHPTHYSIRSTLR MELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSKARLHLQGRSNAWRPQVN NPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQDGHQWTLFFQNGKVKVFQG NQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRMEVLGCEAQDLYGSPGIEPRSPSGSPAGS PTSTEEGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAP GTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSESATPESGPGTSTEPS EGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPG TSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSTEPSEGSAPGTSTEPSEGSAPGTSESATP ESGPGTSESATPESGPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPGT STEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEG SAPGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSE PATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSPAGSPTSTEEGSPAGSPTS TEEGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAP SP-AG288- MQIELSTCFFLCLLRFCFSPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATG CFXTEN Amino Acid Sequence Name CS-L- SPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSP (FVIII_1- SASTGTGPGSSPSASTGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGT 743)— GPGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPGSSPSASTGTGPGASP AG576- GTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGSSTPSGATGSIEPRSPSGSPGATRRYYLGAVEL (FVIII_168 SWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTVHLFNIAKPRPPWMGLLGP 6-2332)-L- TIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQREKEDDKVFPGGSHT 88 YVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCREGSLAKEKTQTLHKFIL LFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNRSLPGLIGCHRKSVYWHV IGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLMDLGQFLLFCHISSHQHDGME AYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDDDNSPSFIQIRSVAKKHPKTW EEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKYKKVRFMAYTDETFKTREAIQ HESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPLYSRRLPKGVKHLKDFPILPGEIF KYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGLIGPLLICYKESVDQRGNQIMSDKR NVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQASNIMHSINGYVFDSLQLSVCLHEVA YWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGETVFMSMENPGLWILGCHNSDFR NRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNAIEPRSFSPGTPGSGTASSSPGSSTPS GATGSPGSSPSASTGTGPGSSPSASTGTGPGSSTPSGATGSPGSSTPSGATGSPGASPGTSSTGSP GASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGASPGT SSTGSPGSSPSASTGTGPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSP GATGSPGSSTPSGATGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPS GATGSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSP GASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPS GATGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSP GSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSA STGTGPGSSPSASTGTGPGASPGTSSTGSQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLR NRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVTFRNQASRP YSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKDEFDCKAWAYFSDVDL EKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFDETKSWYFTENMERNCRAPCNIQ MEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIHSIHFSGHVFTVRKK EEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLVYSNKCQTPLGMAS GHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAPMIIHGIKTQGARQK FSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARYIRLHPTHYSI RSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSKARLHLQGRSNAW RPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQDGHQWTLFFQNGKV QDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRMEVLGCEAQDLYGSPGQSPRSFQ PGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTP SGATGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTG TSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPG TSSTGSPGASPGTSSTGSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTGSPGSSPSASTGTG PGTPGSGTASSSPGSSTPSGATGS SP-AG576- MQIELSTCFFLCLLRFCFSPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGT CS-L- GPGSSTPSGATGSPGSSTPSGATGSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGTPG (FVIII_1- SGTASSSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGSSPSASTGTGPGTPGSGTASS 745)— GTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPGSSTPSGATGSPGASP AG288- GTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGT (FVIII_168 GPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGASP 6-2332)-L- GTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATG CS-AE576 SPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASP GTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTG SQSPRSFQGSPGATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLF VEFTVHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAE YDDQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIG ALLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVN GYVNRSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTL LMDLGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRF DDDNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRK YKKVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPL YSRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGLIG KESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQASNI MHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGE CFXTEN Amino Acid Sequence Name TVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNAIE PRSFSQNPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASS SPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGSSP SASTGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGT GPGASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTGSPGSSP SASTGTGPGTPGSGTASSSPGSSTPSGATGSQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVL RNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVTFRNQASR PYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKDEFDCKAWAYFSDVD LEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFDETKSWYFTENMERNCRAPCNI QMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIHSIHFSGHVFTVRK KEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLVYSNKCQTPLGMA SGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAPMIIHGIKTQGARQ KFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARYIRLHPTHY SIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSKARLHLQGRSNA WRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQDGHQWTLFFQNG KVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRMEVLGCEAQDLYGSPGQSPR SFQGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTS TEPSEGSAPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSESATPES GPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGTSE SATPESGPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSTEPSEGSAPGTSTEPSEGS APGTSESATPESGPGTSESATPESGPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSE GPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGS APGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSE SATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSPAGSPTST EEGSPAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAP SP- MQIELSTCFFLCLLRFCFSATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSV _1- FVEFTVHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYW 743)— EYDDQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVK AG576- IGALLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAW (FVIII_168 NGYVNRSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPI 6-2332)-L- TFLTAQTLLMDLGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTD CS-AG576 SEMDVVRFDDDNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNN GPQRIGRKYKKVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPH GITDVRPLYSRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMER DLASGLIGPLLICYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLED PEFQASNIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTL TLFPFSGETVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYL LSKNNAIEPRSFSPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGSST PSGATGSPGSSTPSGATGSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASS SPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGASP GTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPGSSTPSGATGSPGASPGTSSTG SPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGASP GTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTG SPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGTPG SGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTG SPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSQSPRS FQKKTRHYFIAAVERLWDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGEL NEHLGLLGPYIRAEVEDNIMVTFRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTY FWKVQHHMAPTKDEFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQE FALFFTIFDETKSWYFTENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQD QRIRWYLLSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVE CLIGEHLHAGMSTLFLVYSNKCQTPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINA WSTKEPFSWIKVDLLAPMIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLM VFFGNVDSSGIKHNIFNPPIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQ ITASSYFTNMFATWSPSKARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVK SLLTSMYVKEFLISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQS WVHQIALRMEVLGCEAQDLYGSPGQSPRSFQPGTPGSGTASSSPGSSTPSGATGSPGSSPSAST GTGPGSSPSASTGTGPGSSTPSGATGSPGSSTPSGATGSPGASPGTSSTGSPGASPGTSSTGSPG ASPGTSSTGSPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGSSPSAS TGTGPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPG CFXTEN Amino Acid Sequence Name ATGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSTPSG ATGSPGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGASPGTSSTGSPG ASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGT ASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPG SSPSASTGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSAS TGTGPGASPGTSSTGS SP-AG288- MQIELSTCFFLCLLRFCFSPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATG CS-L- SPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSP _1- SASTGTGPGSSPSASTGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGT 743)— GPGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPGSSPSASTGTGPGASP AG288- GTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGSSTPSGATGSQSPRSFQGPSGPATRRYYLGAV (FVIII_168 ELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTVHLFNIAKPRPPWMGLL 6-2332)-L- GPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQREKEDDKVFPGGS CS-AE288 HTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCREGSLAKEKTQTLHK VFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNRSLPGLIGCHRKSVYW HVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLMDLGQFLLFCHISSHQHDG MEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDDDNSPSFIQIRSVAKKHPK TWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKYKKVRFMAYTDETFKTREA IQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPLYSRRLPKGVKHLKDFPILPGE TVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGLIGPLLICYKESVDQRGNQIMSDK RNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQASNIMHSINGYVFDSLQLSVCLHEV AYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGETVFMSMENPGLWILGCHNSDF RNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNAIEPRSFSPGASPGTSSTGSPGASPG TSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSS PGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGTPGS GTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGS PGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGSSTP SGATGSQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTDG SFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVTFRNQASRPYSFYSSL1SYEEDQRQGAEPRKN FVKPNETKTYFWKVQHHMAPTKDEFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPA HGRQVTVQEFALFFTIFDETKSWYFTENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTL PGLVMAQDQRIRWYLLSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPS KAGIWRVECLIGEHLHAGMSTLFLVYSNKCQTPLGMASGHIRDFQITASGQYGQWAPKLARL HYSGSINAWSTKEPFSWIKVDLLAPMIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRG NSTGTLMVFFGNVDSSGIKHNIFNPPIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGME SKAISDAQITASSYFTNMFATWSPSKARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTG VTTQGVKSLLTSMYVKEFLISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTR YLRIHPQSWVHQIALRMEVLGCEAQDLYGPSGPQSPRSFQGTSESATPESGPGSEPATSGSETP GTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSESA TPESGPGSEPATSGSETPGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGTSTEPSEGSAP GTSESATPESGPGTSESATPESGPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGS PTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAP SP-AE576- MQIELSTCFFLCLLRFCFSGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEE CS-L- GTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGS (FVIII_1- PTSTEEGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAP 743)— GTSTEPSEGSAPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSTEPS AG576- EGSAPGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGSPAGSPTSTEEGTSESATPESGPG (FVIII_168 SEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSE 6-2332) GSAPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGS EPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSESATP ESGPGSPAGSPTSTEEGSPAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPQS SPGATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVE FTVHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYD DQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGAL SLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGY VNRSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLM DLGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDD DNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKYK KVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPLYSR RLPKGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGLIGPLLI 2012/046326 CFXTEN Amino Acid Sequence Name CYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQASNIMHS INGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGETVF MSMENPGLWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNAIEPRS GSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGSSTPSGATGSPGSS GSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGASPGTSST GSPGASPGTSSTGSPGASPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGASPGTSSTGSPGAS PGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPGSSTPSGATGSPGASPGTSSTGSPGTPGSGTAS SSPGSSTPSGATGSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTGSPGAS PGTSSTGSPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSST GSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSS TPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGTPGSGTAS SSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSQSPRSFQKKTRHYFIA AVERLWDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYI RAEVEDNIMVTFRNQASRPYSFYSSL1SYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAP TKDEFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFDETKS MERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLSMGS NENIHSIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHAGMS TLFLVYSNKCQTPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKV DLLAPMIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKH NIFNPPIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFAT WSPSKARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLI SSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRMEVL GCEAQDLY FVIII ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTVHLFNIA BDDZ KPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQREK S3 67- EDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCREGSL FXIa- AKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNSSLPGL AE42- IGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLMDLGQFLLF F3 68- CHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDDDNSPSKLT Y23 32- RAETGEPSEGSAPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSGFIQIRSVAKKHPKTWVHY FXIa- IAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKYKKVRFMAYTDETFKTREAIQHESG AE864 ILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPLYSRRLPKGVKHLKDFPILPGEIFKYK WTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGLIGPLLICYKESVDQRGNQIMSDKRNVIL FSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQASNIMHSINGYVFDSLQLSVCLHEVAYWY ILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGETVFMSMENPGLWILGCHNSDFRNRG MTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNAIEPRSFSQNPPVLKRHQREITRTTLQSD QEEIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLRNR AQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVTFRNQASRPYS FYSSL1SYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKDEFDCKAWAYFSDVDLEK DVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFDETKSWYFTENMERNCRAPCNIQME NYRFHAINGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIHSIHFSGHVFTVRKKEEY KMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLVYSNKCQTPLGMASGHIR DFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAPMIIHGIKTQGARQKFSSL IMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARYIRLHPTHYSIRSTL RMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWTPSKARLHLQGRSNAWRPQV NNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQDGHQWTLFFQNGKVKVFQ GNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRMEVLGCEAQDLYKLTRAETGGSPAGSP TSTEEGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPG TSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSESATPESGPGTSTEPSE GSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGT STEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPE SGPGTSESATPESGPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTS TEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGS APGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSEP ATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSPAGSPTSTEEGSPAGSPTST EEGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSE SATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSESATPES GPGSEPATSGSETPGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGTSTEPSEGSAPGTSE SATPESGPGTSESATPESGPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTST EEGTSTEPSEGSAPGTSTEPSEGSAPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAP CFXTEN Amino Acid Sequence Name FVIII ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTVHLFNIA BDDZ KPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQREK N745 - EDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCREGSL FIXa- TLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNRSLPGL AGZ88- IGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLMDLGQFLLF FIXa- CHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDDDNSPSFIQI P 1 640- RSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKYKKVRFMAY Y23 32- TDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPLYSRRLPKGVK FIXa- HLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGLIGPLLICYKESVD AG864 QRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQASNIMHSINGYVFD SLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGETVFMSMENPG LWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNAIEPRSFSQNPLGR IVGGPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPG SSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGSSPSAS TGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPG ASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTGSPGSSPSAS TGTGPGTPGSGTASSSPGSSTPSGATGSGPLGRIVGGPPVLKRHQREITRTTLQSDQEEIDYDDT ISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLRNRAQSGSVPQ FKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVTFRNQASRPYSFYSSLISYE EDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKDEFDCKAWAYFSDVDLEKDVHSGLIG PLLVCHTNTLNPAHGRQVTVQEFALFFTIFDETKSWYFTENMERNCRAPCNIQMEDPTFKEN NGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIHSIHFSGHVFTVRKKEEYKMALYN LYPGVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLVYSNKCQTPLGMASGHIRDFQITAS GQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAPMIIHGIKTQGARQKFSSLYISQFIIM KWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARYIRLHPTHYSIRSTLRMELMG CDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSKARLHLQGRSNAWRPQVNNPKEW LQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQDGHQWTLFFQNGKVKVFQGNQDSF TPVVNSLDPPLLTRYLRIHPQSWVHQIALRMEVLGCEAQDLYPLGRIVGGGASPGTSSTGSPG SSPSASTGTGPGSSPSASTGTGPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGASPGTS STGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPG TPGSGTASSSPGSSTPSGATGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSAS TGTGPGSSPSASTGTGPGSSTPSGATGSPGSSTPSGATGSPGASPGTSSTGSPGASPGTSSTGSPG ASPGTSSTGSPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGSSPSAS TGTGPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPG SSTPSGATGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSTPSG ATGSPGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGASPGTSSTGSPG ASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGT ASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPG SSPSASTGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSAS TGTGPGASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTGSPG SSPSASTGTGPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGASPGTSSTGSP FVIII ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTVHLFNIA BDDZ KPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQREK V1 2 8- EDDKVLQVRIVGGGAPSPSASTGTGPGTPGSGTASSSPGSSTPSGATGSPGPSGPGLQVRIVGG FVIIa- FPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCREGSLAKEKTQ AG42- TLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNRSLPGLIGCHRK FVIIa- SVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLMDLGQFLLFCHISSH G2044- AYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDDDNSPSFIQIRSVAK FVIIa- KHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKYKKVRFMAYTDETF AG144- QHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPLYSRRLPKGVKHLKDF Y23 32- PILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGLIGPLLICYKESVDQRGNQ FVIIa- NVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQASNIMHSINGYVFDSLQLSV AG576 CLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGETVFMSMENPGLWILGC HNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNAIEPRSFSQNPPVLKRHQRE ITRTTLQSDQEEIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERLWDYGMS SSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVTF RNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKDEFDCKAWA YFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFDETKSWYFTENMERNC RAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIHSIHFSGHV FTVRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLVYSNKCQTP CFXTEN Amino Acid Sequence Name LGMASGHIRDFQITASGQYGLQVRIVGGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTP SGATGSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGTPGSGTASSS PGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGLQVRIVGGQWAPKLARLHYSGS INAWSTKEPFSWIKVDLLAPMIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGT LMVFFGNVDSSGIKHNIFNPPIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISD AQITASSYFTNMFATWSPSKARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQG VKSLLTSMYVKEFLISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHP QSWVHQIALRMEVLGCEAQDLYLQVRIVGGPGTPGSGTASSSPGSSTPSGATGSPGSSPSAST GTGPGSSPSASTGTGPGSSTPSGATGSPGSSTPSGATGSPGASPGTSSTGSPGASPGTSSTGSPG ASPGTSSTGSPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGSSPSAS TGTGPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPG SSTPSGATGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSTPSG ATGSPGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGASPGTSSTGSPG ASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGT SSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPG SSPSASTGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSAS TGTGPGASPGTSSTGS AE864- GSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPS FVIII- EGSAPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSESATPESGPG Thrombin- TSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGTSESATP AE144 ESGPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSTEPSEGSAPGTSTEPSEGSAPGT SESATPESGPGTSESATPESGPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPE SGPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTS TEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSESATPES GPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSPAGSPTSTEEGSPA GSPTSTEEGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSE TPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSES ATPESGPGSEPATSGSETPGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGTSTEPSEGSA PGTSESATPESGPGTSESATPESGPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAG SPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAP GATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTDHLFNI AKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQRE KEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCREGS LAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNRSLPG LIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLMDLGQFLL FCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDDDNSPSFIQ KHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKYKKVRFMAY TDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPLYSRRLPKGVK HLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGLIGPLLICYKESVD QRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQASNIMHSINGYVFD SLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGETVFMSMENPG LWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNAIEPRSFSQNSRHP FNATTIPENDIEKTDPWFAHRTPMPKIQNVSSSDLLMLLRQSPTPHGLSLSDLQEAKY ETFSDDPSPGAIDSNNSLSEMTHFRPQLHHSGDMVFTPESGLQLRLNEKLGTTAATELKKLDF KVSSTSNNLISTIPSDNLAAGTDNTSSLGPPSMPVHYDSQLDTTLFGKKSSPLTESGGPLSLSEE LESGLMNSQESSWGKNVSSTESGRLFKGKRAHGPALLTKDNALFKVSISLLKTNKT SNNSATNRKTHIDGPSLLIENSPSVWQNILESDTEFKKVTPLIHDRMLMDKNATALRLNHMSN NMEMVQQKKEGPIPPDAQNPDMSFFKMLFLPESARWIQRTHGKNSLNSGQGPSPKQ LVSLGPEKSVEGQNFLSEKNKVVVGKGEFTKDVGLKEMVFPSSRNLFLTNLDNLHENNTHNQ EKKIQEEIEKKETLIQENVVLPQIHTVTGTKNFMKNLFLLSTRQNVEGSYDGAYAPVLQDFRS LNDSTNRTKKHTAHFSKKGEEENLEGLGNQTKQIVEKYACTTRISPNTSQQNFVTQRSKRAL KQFRLPLEETELEKRIIVDDTSTQWSKNMKHLTPSTLTQIDYNEKEKGAITQSPLSDCLTRSHSI PQANRSPLPIAKVSSFPSIRPIYLTRVLFQDNSSHLPAASYRKKDSGVQESSHFLQGAKKNNLS LAILTLEMTGDQREVGSLGTSATNSVTYKKVENTVLPKPDLPKTSGKVELLPKVHIYQKDLFP TETSNGSPG PKEEWKSQEKSPEKTAFKKKDTILSLNACESNHAIAAINEGQNKPEIEVTWAKQGRT ERLCSQNPPVLKRHQREITRTTLQSDQEEIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKKTR HYFIAAVERLWDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGL LGPYIRAEVEDNIMVTFRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQH HMAPTKDEFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIF CFXTEN Amino Acid Sequence Name DETKSWYFTENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYL LSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLH AGMSTLFLVYSNKCQTPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFS WIKVDLLAPMIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDS SGIKHNIFNPPIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTN PSKARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYV KEFLISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALR MEVLGCEAQDLYGLTPRSLLVGGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGSPAGS PTSTEEGTSTEPSEGSAPGSEPATSGSETPGSEPATSGSETPGSEPATSGSETPGTSTEPSEGSAP GTSESATPESGPGSEPATSGSETPGTSTEPSEGSAP FVIII ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTVHLFNIA BDD3 - KPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQREK FXIIa- EDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCREGSL AE144 AKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNRSLPGL IGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLMDLGQFLLF CHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDDDNSPSFIQI RSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKYKKVRFMAY TREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPLYSRRLPKGVK HLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGLIGPLLICYKESVD QRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQASNIMHSINGYVFD SLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGETVFMSMENPG LWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNAIEPRSFSQNPPVL KRHQGEITRTTLQSDQEEIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERL SSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVE FRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKDEF DCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFDETKSWYFT CRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIH SIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLV YSNKCQTPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAP MIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNP PIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPS KARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQD GHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRMEVLGCEA QDLYGTMTRIVGGGGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGSPAGSPTSTEEGTS TEPSEGSAPGSEPATSGSETPGSEPATSGSETPGSEPATSGSETPGTSTEPSEGSAPGTSESATPES GPGSEPATSGSETPGTSTEPSEGSAP FVIII ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTVHLFNIA BDD3 - KPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQREK Elastase- EDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCREGSL AE144 AKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNRSLPGL IGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLMDLGQFLLF CHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDDDNSPSFIQI RSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKYKKVRFMAY TDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPLYSRRLPKGVK HLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGLIGPLLICYKESVD QRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQASNIMHSINGYVFD SLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGETVFMSMENPG LWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNAIEPRSFSQNPPVL KRHQGEITRTTLQSDQEEIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERL WDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVE DNIMVTFRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKDEF DCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFDETKSWYFT ENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIH SIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLV YSNKCQTPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAP MIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNP IRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPS KARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQD GHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRMEVLGCEA QDLYGGGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAP WO 22617 CFXTEN Amino Acid Sequence Name GSEPATSGSETPGSEPATSGSETPGSEPATSGSETPGTSTEPSEGSAPGTSESATPESGPGSEPAT SGSETPGTSTEPSEGSAP FVIII ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTVHLFNIA BDD3 - MGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQREK FXIa- EDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCREGSL AE144 AKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNRSLPGL IGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLMDLGQFLLF CHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDDDNSPSFIQI RSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKYKKVRFMAY TDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPLYSRRLPKGVK HLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGLIGPLLICYKESVD QRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQASNIMHSINGYVFD SLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGETVFMSMENPG LWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNAIEPRSFSQNPPVL KRHQGEITRTTLQSDQEEIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERL WDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVE DNIMVTFRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKDEF DCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFDETKSWYFT ENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIH SIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLV YSNKCQTPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAP MIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNP PIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPS KARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQD GHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRMEVLGCEA LTRAETGGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGSPAGSPTSTEEGTST EPSEGSAPGSEPATSGSETPGSEPATSGSETPGSEPATSGSETPGTSTEPSEGSAPGTSESATPES ATSGSETPGTSTEPSEGSAP FVIII ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTVHLFNIA BDD3 - KPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQREK Thrombin- EDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCREGSL AE144 AKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNRSLPGL IGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLMDLGQFLLF CHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDDDNSPSFIQI RSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKYKKVRFMAY TDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPLYSRRLPKGVK HLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGLIGPLLICYKESVD QRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQASNIMHSINGYVFD SLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGETVFMSMENPG LWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNAIEPRSFSQNPPVL KRHQGEITRTTLQSDQEEIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERL WDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVE DNIMVTFRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKDEF DCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFDETKSWYFT CRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIH SIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLV YSNKCQTPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAP MIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNP PIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPS QGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQD GHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRMEVLGCEA QDLYGLTPRSLLVGGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGSPAGSPTSTEEGTS TEPSEGSAPGSEPATSGSETPGSEPATSGSETPGSEPATSGSETPGTSTEPSEGSAPGTSESATPES GPGSEPATSGSETPGTSTEPSEGSAP AE144- GSEPATSGSETPGTSESATPESGPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGSEPAT FVIII SGSETPGSEPATSGSETPGSEPATSGSETPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETP BDDZ- GTSTEPSEGSAPGATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKT MMP- 1 7- LFVEFTVHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEG AE864 AEYDDQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGL IGALLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHT CFXTEN Amino Acid Sequence Name VNGYVNRSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQ TLLMDLGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVV RFDDDNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIG RKYKKVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVR PLYSRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGL IGPLLICYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQAS NIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFS GETVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNN AIEPRSFSQNPPVLKRHQREITRTTLQSDQEEIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKK TRHYFIAAVERLWDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHL GLLGPYIRAEVEDNIMVTFRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKV QHHMAPTKDEFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFF TIFDETKSWYFTENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRW YLLSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEH LHAGMSTLFLVYSNKCQTPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEP FSWIKVDLLAPMIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNV DSSGIKHNIFNPPIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYF TNMFATWSPSKARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSM YVKEFLISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIA LRMEVLGCEAQDLYGAPLGLRLRGGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGSPA GSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGSEPATSGSE TPGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTST EPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSE TPGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGSPAGSPTSTEEGTSES PGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSA PGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSES PGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSA PGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGTSTEP SEGSAPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGP SEGSAPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSPAGS PTSTEEGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGTSESATPESGP GSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGSEPAT SGSETPGTSESATPESGPGTSTEPSEGSAP AE144- GSEPATSGSETPGTSESATPESGPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGSEPAT FVIII SGSETPGSEPATSGSETPGSEPATSGSETPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETP BDDZ- GTSTEPSEGSAPGATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKT FXIIa- LFVEFTVHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEG AE864 AEYDDQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGL CREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHT VNGYVNRSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQ TLLMDLGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVV RFDDDNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIG RKYKKVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVR PLYSRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGL CYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQAS NIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFS GETVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNN AIEPRSFSQNPPVLKRHQREITRTTLQSDQEEIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKK TRHYFIAAVERLWDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHL GLLGPYIRAEVEDNIMVTFRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKV TKDEFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFF TIFDETKSWYFTENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRW YLLSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEH LHAGMSTLFLVYSNKCQTPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEP FSWIKVDLLAPMIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNV DSSGIKHNIFNPPIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYF TNMFATWSPSKARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSM YVKEFLISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIA LRMEVLGCEAQDLYGTMTRIVGGGGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGSPA GSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGSEPATSGSE CFXTEN Amino Acid Sequence Name TPGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTST EPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSE TPGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGSPAGSPTSTEEGTSES ATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSA PGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSES ATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSA PGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGTSTEP SEGSAPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGP GTSTEPSEGSAPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSPAGS PTSTEEGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGTSESATPESGP GSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGSEPAT SGSETPGTSESATPESGPGTSTEPSEGSAP AG144- SGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGT FVIII GPGSSPSASTGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSP BDDZ- SASTGTGPGASPGATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKT FXIa- LFVEFTVHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEG AG576 TSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGL IGALLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHT VNGYVNRSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQ TLLMDLGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVV SPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIG RKYKKVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVR PLYSRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGL IGPLLICYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQAS NIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFS GETVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNN AIEPRSFSQNPPVLKRHQREITRTTLQSDQEEIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKK TRHYFIAAVERLWDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHL GLLGPYIRAEVEDNIMVTFRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKV QHHMAPTKDEFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFF TIFDETKSWYFTENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRW YLLSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEH TLFLVYSNKCQTPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEP FSWIKVDLLAPMIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNV DSSGIKHNIFNPPIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYF TNMFATWSPSKARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSM YVKEFLISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIA LRMEVLGCEAQDLYGKLTRAETGPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSP GPGSSTPSGATGSPGSSTPSGATGSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTG SPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGSSPSASTGTGPGTPG SGTASSSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPGSSTPSGATG SPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSTPSGATGSPGSSP SASTGTGPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTG SPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSST PSGATGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGT GPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASP GTSSTGS AE144- GSEPATSGSETPGTSESATPESGPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGSEPAT FXIa-FVIII SGSETPGSEPATSGSETPGSEPATSGSETPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETP BDDZ- SEGSAPGKLTRAETGATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNT AE864 TLFVEFTDHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVS YWKASEGAEYDDQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDL VKDLNSGLIGALLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASAR AWPKMHTVNGYVNRSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEI SPITFLTAQTLLMDLGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDL TDSEMDVVRFDDDNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYL NNGPQRIGRKYKKVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIY PHGITDVRPLYSRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNM ERDLASGLIGPLLICYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQL EDPEFQASNIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYED CFXTEN Amino Acid Sequence Name TLTLFPFSGETVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISA YLLSKNNAIEPRSFSQNPPVLKRHQREITRTTLQSDQEEIDYDDTISVEMKKEDFDIYDEDENQ SPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPLY RGELNEHLGLLGPYIRAEVEDNIMVTFRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNE TKTYFWKVQHHMAPTKDEFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQV TVQEFALFFTIFDETKSWYFTENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVM AQDQRIRWYLLSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPSKAGIW RVECLIGEHLHAGMSTLFLVYSNKCQTPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGS KEPFSWIKVDLLAPMIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGT LMVFFGNVDSSGIKHNIFNPPIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISD AQITASSYFTNMFATWSPSKARLHQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQG SMYVKEFLISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHP QSWVHQIALRMEVLGCEAQDLYGGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGSPA GSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGSEPATSGSE TPGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTST EPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSE TPGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGSPAGSPTSTEEGTSES ATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSA PGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSES ATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSA PGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGTSTEP SEGSAPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGP GTSTEPSEGSAPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSPAGS PTSTEEGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGTSESATPESGP GSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGSEPAT SGSETPGTSESATPESGPGTSTEPSEGSAP AE144- GSEPATSGSETPGTSESATPESGPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGSEPAT FVIII SGSETPGSEPATSGSETPGSEPATSGSETPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETP BDDZ- GTSTEPSEGSAPGATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKT Y23 32- LFVEFTVHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEG Thrombin- TSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGL AE864 IGALLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHT RSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQ TLLMDLGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVV RFDDDNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIG RKYKKVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVR PLYSRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGL IGPLLICYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQAS NIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFS SMENPGLWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNN AIEPRSFSQNPPVLKRHQREITRTTLQSDQEEIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKK TRHYFIAAVERLWDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHL IRAEVEDNIMVTFRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKV QHHMAPTKDEFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFF TIFDETKSWYFTENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRW YLLSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEH LHAGMSTLFLVYSNKCQTPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEP FSWIKVDLLAPMIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNV DSSGIKHNIFNPPIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYF TNMFATWSPSKARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSM YVKEFLISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIA LRMEVLGCEAQDLYGLTPRSLLVGGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGSPA GSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGSEPATSGSE TPGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTST EPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSE TPGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGSPAGSPTSTEEGTSES ATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSA PGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSES ATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSA CFXTEN Amino Acid Sequence Name PGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGTSTEP SEGSAPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGP GTSTEPSEGSAPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSPAGS PTSTEEGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGTSESATPESGP SGSETPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGSEPAT SGSETPGTSESATPESGPGTSTEPSEGSAP AE864- GSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPS FVIII- EGSAPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSESATPESGPG MMP TSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGTSESATP AE144 ESGPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSTEPSEGSAPGTSTEPSEGSAPGT SESATPESGPGTSESATPESGPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPE SGPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTS TEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSESATPES GPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSPAGSPTSTEEGSPA GSPTSTEEGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSE SATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSES ATPESGPGSEPATSGSETPGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGTSTEPSEGSA PGTSESATPESGPGTSESATPESGPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAG SPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAP GATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTDHLFNI AKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQRE KEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCREGS QTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNRSLPG LIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLMDLGQFLL FCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDDDNSPSFIQ KHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKYKKVRFMAY TDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPLYSRRLPKGVK HLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGLIGPLLICYKESVD QRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQASNIMHSINGYVFD CLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGETVFMSMENPG LWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNAIEPRSFSQNSRHP STRQKQFNATTIPENDIEKTDPWFAHRTPMPKIQNVSSSDLLMLLRQSPTPHGLSLSDLQEAKY ETFSDDPSPGAIDSNNSLSEMTHFRPQLHHSGDMVFTPESGLQLRLNEKLGTTAATELKKLDF KVSSTSNNLISTIPSDNLAAGTDNTSSLGPPSMPVHYDSQLDTTLFGKKSSPLTESGGPLSLSEE NNDSKLLESGLMNSQESSWGKNVSSTESGRLFKGKRAHGPALLTKDNALFKVSISLLKTNKT SNNSATNRKTHIDGPSLLIENSPSVWQNILESDTEFKKVTPLIHDRMLMDKNATALRLNHMSN KTTSSKNMEMVQQKKEGPIPPDAQNPDMSFFKMLFLPESARWIQRTHGKNSLNSGQGPSPKQ LVSLGPEKSVEGQNFLSEKNKVVVGKGEFTKDVGLKEMVFPSSRNLFLTNLDNLHENNTHNQ EKKIQEEIEKKETLIQENVVLPQIHTVTGTKNFMKNLFLLSTRQNVEGSYDGAYAPVLQDFRS LNDSTNRTKKHTAHFSKKGEEENLEGLGNQTKQIVEKYACTTRISPNTSQQNFVTQRSKRAL KQFRLPLEETELEKRIIVDDTSTQWSKNMKHLTPSTLTQIDYNEKEKGAITQSPLSDCLTRSHSI PQANRSPLPIAKVSSFPSIRPIYLTRVLFQDNSSHLPAASYRKKDSGVQESSHFLQGAKKNNLS LAILTLEMTGDQREVGSLGTSATNSVTYKKVENTVLPKPDLPKTSGKVELLPKVHIYQKDLFP TETSNGSPG HYGTQIPKEEWKSQEKSPEKTAFKKKDTILSLNACESNHAIAAINEGQNKPEIEVTWAKQGRT ERLCSQNPPVLKRHQREITRTTLQSDQEEIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKKTR VERLWDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGL LGPYIRAEVEDNIMVTFRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQH HMAPTKDEFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIF DETKSWYFTENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYL LSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLH AGMSTLFLVYSNKCQTPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFS WIKVDLLAPMIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDS SGIKHNIFNPPIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTN MFATWSPSKARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYV KEFLISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALR MEVLGCEAQDLYGAPLGLRLRGGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGSPAGS PTSTEEGTSTEPSEGSAPGSEPATSGSETPGSEPATSGSETPGSEPATSGSETPGTSTEPSEGSAP GTSESATPESGPGSEPATSGSETPGTSTEPSEGSAP AF144- GTSTPESGSASPGTSPSGESSTAPGTSPSGESSTAPGSTSSTAESPGPGSTSESPSGTAPGSTSSTA CFXTEN Amino Acid Sequence Name FXIIa- ESPGPGTSPSGESSTAPGTSTPESGSASPGSTSSTAESPGPGTSPSGESSTAPGTSPSGESSTAPGT FVIII- SPSGESSTAPGTMTRIVGGATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSV FXIIa- VYKKTLFVEFTDHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYW AF864 KASEGAEYDDQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVK DLNSGLIGALLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAW PKMHTVNGYVNRSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPI TFLTAQTLLMDLGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTD RFDDDNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNN GPQRIGRKYKKVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPH GITDVRPLYSRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMER DLASGLIGPLLICYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLED PEFQASNIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTL TLFPFSGETVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYL IEPRSFSQNSRHPSTRQKQFNATTIPENDIEKTDPWFAHRTPMPKIQNVSSSDLLMLL RQSPTPHGLSLSDLQEAKYETFSDDPSPGAIDSNNSLSEMTHFRPQLHHSGDMVFTPESGLQLR TTAATELKKLDFKVSSTSNNLISTIPSDNLAAGTDNTSSLGPPSMPVHYDSQLDTTLF GKKSSPLTESGGPLSLSEENNDSKLLESGLMNSQESSWGKNVSSTESGRLFKGKRAHGPALLT KDNALFKVSISLLKTNKTSNNSATNRKTHIDGPSLLIENSPSVWQNILESDTEFKKVTPLIHDR MLMDKNATALRLNHMSNKTTSSKNMEMVQQKKEGPIPPDAQNPDMSFFKMLFLPESARWIQ RTHGKNSLNSGQGPSPKQLVSLGPEKSVEGQNFLSEKNKVVVGKGEFTKDVGLKEMVFPSSR NLFLTNLDNLHENNTHNQEKKIQEEIEKKETLIQENVVLPQIHTVTGTKNFMKNLFLLSTRQN VEGSYDGAYAPVLQDFRSLNDSTNRTKKHTAHFSKKGEEENLEGLGNQTKQIVEKYACTTRI SPNTSQQNFVTQRSKRALKQFRLPLEETELEKRIIVDDTSTQWSKNMKHLTPSTLTQIDYNEKE KGAITQSPLSDCLTRSHSIPQANRSPLPIAKVSSFPSIRPIYLTRVLFQDNSSHLPAASYRKKDSG VQESSHFLQGAKKNNLSLAILTLEMTGDQREVGSLGTSATNSVTYKKVENTVLPKPDLPKTS GKVELLPKV SSAKTPSKLLDPLAWDNHYGTQIPKEEWKSQEKSPEKTAFKKKDTILSLNACESNHAIAAINE GQNKPEIEVTWAKQGRTERLCSQNPPVLKRHQREITRTTLQSDQEEIDYDDTISVEMKKEDFD IYDEDENQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTD GSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVTFRNQASRPYSFYSSLISYEEDQRQGAEPRK NFVKPNETKTYFWKVQHHMAPTKDEFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNP AHGRQVTVQEFALFFTIFDETKSWYFTENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMD MAQDQRIRWYLLSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEML PSKAGIWRVECLIGEHLHAGMSTLFLVYSNKCQTPLGMASGHIRDFQITASGQYGQWAPKLA RLHYSGSINAWSTKEPFSWIKVDLLAPMIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTY RGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLG MESKAISDAQITASSYFTNMFATWSPSKARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKV TGVTTQGVKSLLTSMYVKEFLISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLL HPQSWVHQIALRMEVLGCEAQDLYGTMTRIVGGGSTSESPSGTAPGTSPSGESSTAP GSTSESPSGTAPGSTSESPSGTAPGTSTPESGSASPGTSTPESGSASPGSTSESPSGTAPGSTSESP SGTAPGTSPSGESSTAPGSTSESPSGTAPGTSPSGESSTAPGTSPSGESSTAPGSTSSTAESPGPGT SPSGESSTAPGTSPSGESSTAPGSTSSTAESPGPGTSTPESGSASPGTSTPESGSASPGSTSESPSG TAPGSTSESPSGTAPGTSTPESGSASPGSTSSTAESPGPGTSTPESGSASPGSTSESPSGTAPGTSP SGESSTAPGSTSSTAESPGPGTSPSGESSTAPGTSTPESGSASPGSTSSTAESPGPGSTSSTAESPG PGSTSSTAESPGPGSTSSTAESPGPGTSPSGESSTAPGSTSESPSGTAPGSTSESPSGTAPGTSTPE SGPXXXGASASGAPSTXXXXSESPSGTAPGSTSESPSGTAPGSTSESPSGTAPGSTSESPSGTAP GSTSESPSGTAPGSTSESPSGTAPGTSTPESGSASPGTSPSGESSTAPGTSPSGESSTAPGSTSSTA TSPSGESSTAPGTSTPESGSASPGSTSESPSGTAPGSTSESPSGTAPGTSPSGESSTAPGS TSESPSGTAPGTSTPESGSASPGTSTPESGSASPGSTSESPSGTAPGTSTPESGSASPGSTSSTAES PGPGSTSESPSGTAPGSTSESPSGTAPGTSPSGESSTAPGSTSSTAESPGPGTSPSGESSTAPGTST PESGSASPGTSPSGESSTAPGTSPSGESSTAPGTSPSGESSTAPGSTSSTAESPGPGSTSSTAESPG PGTSPSGESSTAPGSSPSASTGTGPGSSTPSGATGSPGSSTPSGATGSP AE864- GSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPS FVIII- EGSAPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSESATPESGPG FXIa- TSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGTSESATP AE144 ESGPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSTEPSEGSAPGTSTEPSEGSAPGT SESATPESGPGTSESATPESGPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPE SGPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTS TEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSESATPES GPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSPAGSPTSTEEGSPA CFXTEN Amino Acid Sequence Name GSPTSTEEGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSE TPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSES PGSEPATSGSETPGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGTSTEPSEGSA PGTSESATPESGPGTSESATPESGPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAG SPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAP GATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTDHLFNI AKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQRE KEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCREGS QTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNRSLPG LIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLMDLGQFLL FCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDDDNSPSFIQ IRSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKYKKVRFMAY TDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPLYSRRLPKGVK HLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGLIGPLLICYKESVD QRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQASNIMHSINGYVFD SLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGETVFMSMENPG LWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNAIEPRSFSQNSRHP STRQKQFNATTIPENDIEKTDPWFAHRTPMPKIQNVSSSDLLMLLRQSPTPHGLSLSDLQEAKY ETFSDDPSPGAIDSNNSLSEMTHFRPQLHHSGDMVFTPESGLQLRLNEKLGTTAATELKKLDF KVSSTSNNLISTIPSDNLAAGTDNTSSLGPPSMPVHYDSQLDTTLFGKKSSPLTESGGPLSLSEE NNDSKLLESGLMNSQESSWGKNVSSTESGRLFKGKRAHGPALLTKDNALFKVSISLLKTNKT NRKTHIDGPSLLIENSPSVWQNILESDTEFKKVTPLIHDRMLMDKNATALRLNHMSN KTTSSKNMEMVQQKKEGPIPPDAQNPDMSFFKMLFLPESARWIQRTHGKNSLNSGQGPSPKQ LVSLGPEKSVEGQNFLSEKNKVVVGKGEFTKDVGLKEMVFPSSRNLFLTNLDNLHENNTHNQ EKKIQEEIEKKETLIQENVVLPQIHTVTGTKNFMKNLFLLSTRQNVEGSYDGAYAPVLQDFRS LNDSTNRTKKHTAHFSKKGEEENLEGLGNQTKQIVEKYACTTRISPNTSQQNFVTQRSKRAL KQFRLPLEETELEKRIIVDDTSTQWSKNMKHLTPSTLTQIDYNEKEKGAITQSPLSDCLTRSHSI PQANRSPLPIAKVSSFPSIRPIYLTRVLFQDNSSHLPAASYRKKDSGVQESSHFLQGAKKNNLS LAILTLEMTGDQREVGSLGTSATNSVTYKKVENTVLPKPDLPKTSGKVELLPKVHIYQKDLFP TETSNGSPG HYGTQIPKEEWKSQEKSPEKTAFKKKDTILSLNACESNHAIAAINEGQNKPEIEVTWAKQGRT ERLCSQNPPVLKRHQREITRTTLQSDQEEIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKKTR HYFIAAVERLWDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGL AEVEDNIMVTFRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQH HMAPTKDEFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIF DETKSWYFTENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYL LSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLH AGMSTLFLVYSNKCQTPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFS WIKVDLLAPMIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDS SGIKHNIFNPPIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTN MFATWSPSKARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYV KEFLISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALR MEVLGCEAQDLYGKLTRAETGGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGSPAGSP TSTEEGTSTEPSEGSAPGSEPATSGSETPGSEPATSGSETPGSEPATSGSETPGTSTEPSEGSAPG PESGPGSEPATSGSETPGTSTEPSEGSAP AE144- GSEPATSGSETPGTSESATPESGPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGSEPAT FXIa-FVIII SGSETPGSEPATSGSETPGSEPATSGSETPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETP BDD9- SEGSAPGKLTRAETGATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNT AE864 SVVYKKTLFVEFTDHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVS YWKASEGAEYDDQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDL VKDLNSGLIGALLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASAR AWPKMHTVNGYVNRSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEI SPITFLTAQTLLMDLGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDL TDSEMDVVRFDDDNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYL NNGPQRIGRKYKKVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIY PHGITDVRPLYSRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNM ERDLASGLIGPLLICYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQL EDPEFQASNIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYED TLTLFPFSGETVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISA YLLSKNNAIEPRSFSQNPPVLKRHQREITRTTLQSDQEEIDYDDTISVEMKKEDFDIYDEDENQ CFXTEN Amino Acid Sequence Name SPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPLY RGELNEHLGLLGPYIRAEVEDNIMVTFRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNE TKTYFWKVQHHMAPTKDEFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQV TVQEFALFFTIFDETKSWYFTENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVM AQDQRIRWYLLSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPSKAGIW RVECLIGEHLHAGMSTLFLVYSNKCQTPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGS INAWSTKEPFSWIKVDLLAPMIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGT LMVFFGNVDSSGIKHNIFNPPIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISD AQITASSYFTNMFATWSPSKARLPEQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQG VKSLLTSMYVKEFLISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHP QSWVHQIALRMEVLGCEAQDLYGGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGSPA GSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGSEPATSGSE TPGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTST EPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSE TPGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGSPAGSPTSTEEGTSES ATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSA PGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSES ATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSA PGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGTSTEP SEGSAPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGP SEGSAPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSPAGS GSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGTSESATPESGP GSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGSEPAT SGSETPGTSESATPESGPGTSTEPSEGSAP AE48— MAEPAGSPTSTEEGTPGSGTASSSPGSSTPSGATGSPGASPGTSSTGSPGKLTRAETGATRRYY FXIa-FVIII LGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTDHLFNIAKPRPPW BDD9- MGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQREKEDDKVF AE864 PGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCREGSLAKEKTQ TLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNRSLPGLIGCHRK SVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLMDLGQFLLFCHISSH QHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDDDNSPSFIQIRSVAK VHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKYKKVRFMAYTDETF KTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPLYSRRLPKGVKHLKDF IFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGLIGPLLICYKESVDQRGNQ IMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQASNIMHSINGYVFDSLQLSV CLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGETVFMSMENPGLWILGC HNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNAIEPRSFSQNPPVLKRHQRE ITRTTLQSDQEEIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERLWDYGMS SSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVTF RNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKDEFDCKAWA YFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFDETKSWYFTENMERNC RAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIHSIHFSGHV FTVRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLVYSNKCQTP LGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAPMIIHGIKTQ GARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARYIRLH PTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSKARLHLQGR SNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQDGHQWTLFFQ NGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRMEVLGCEAQDLYGGSPAG SPTSTEEGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAP GTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSESATPESGPGTSTEPS EGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPG TSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSTEPSEGSAPGTSTEPSEGSAPGTSESATP ESGPGTSESATPESGPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPGT STEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEG SAPGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSE PATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSPAGSPTSTEEGSPAGSPTS AGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTS ESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSESATPES GPGSEPATSGSETPGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGTSTEPSEGSAPGTSE SATPESGPGTSESATPESGPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTST WO 22617 CFXTEN Amino Acid ce Name EEGTSTEPSEGSAPGTSTEPSEGSAPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAP FVIII ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTDHLFNIA BDD9- KPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQREK FXIa- EDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCREGSL AG288_2 AKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNRSLPGL SVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLMDLGQFLLF CHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDDDNSPSFIQI RSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKYKKVRFMAY TDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPLYSRRLPKGVK HLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGLIGPLLICYKESVD QRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQASNIMHSINGYVFD SLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGETVFMSMENPG HNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNAIEPRSFSQNPPVL KRHQREITRTTLQSDQEEIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERL WDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVE DNIMVTFRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKDEF DCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFDETKSWYFT ENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIH SIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLV YSNKCQTPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAP MIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNP PIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPS KARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQD GHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRMEVLGCEA QDLYKLTRAETGPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPG SGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGT GPGSSPSASTGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSP SASTGTGPGASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTG SPGSSPSASTGTGPGTPGSGTASSSPGSSTPSGATGS FVIII ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTDHLFNIA BDD9- MGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQREK FXIa- EDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCREGSL AG864 AKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNRSLPGL IGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLMDLGQFLLF CHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDDDNSPSFIQI RSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKYKKVRFMAY TDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPLYSRRLPKGVK HLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGLIGPLLICYKESVD QRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQASNIMHSINGYVFD SLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGETVFMSMENPG LWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNAIEPRSFSQNPPVL KRHQREITRTTLQSDQEEIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERL WDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVE DNIMVTFRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKDEF DCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFDETKSWYFT ENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIH SIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLV YSNKCQTPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAP MIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNP PIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPS KARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQD GHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRMEVLGCEA QDLYKLTRAETGGASPGTSSTGSPGSSPSASTGTGPGSSPSASTGTGPGTPGSGTASSSPGSSTP SGATGSPGSSPSASTGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSS PGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGASPGTSSTGSPGTPGS GTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGSSTPSGATGSPGSSTPSGATGS PGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGASPGTSSTGSPGASPG TSSTGSPGASPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGS PGASPGTSSTGSPGSSTPSGATGSPGSSTPSGATGSPGASPGTSSTGSPGTPGSGTASSSPGSSTP SGATGSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGS WO 22617 CFXTEN Amino Acid Sequence Name PGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGTPGS GTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGS PGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTP SGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGS PGSSPSASTGTGPGASPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGSSTPSGATGSPGSSTP SGATGSPGASPGTSSTGSP FVIII ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTDHLFNIA BDD9 (1— KPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQREK 745) EDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCREGSL AG288_2- AKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNRSLPGL (1640- IGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLMDLGQFLLF - QHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDDDNSPSFIQI FXIa- RSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKYKKVRFMAY AG864 TDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPLYSRRLPKGVK HLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGLIGPLLICYKESVD QRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQASNIMHSINGYVFD SLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGETVFMSMENPG LWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNAIEPRSFSQNGPG ASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSG ATGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPG ASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTS STGSPGASPGTSSTGSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTGSPGSSPSASTGTGPG TPGSGTASSSPGSSTPSGATGSPPVLKRHQREITRTTLQSDQEEIDYDDTISVEMKKEDFDIYDE DENQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFT QPLYRGELNEHLGLLGPYIRAEVEDNIMVTFRNQASRPYSFYSSLISYEEDQRQGAEPRKNFV KPNETKTYFWKVQHHMAPTKDEFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAH GRQVTVQEFALFFTIFDETKSWYFTENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTLP GLVMAQDQRIRWYLLSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPS KAGIWRVECLIGEHLHAGMSTLFLVYSNKCQTPLGMASGHIRDFQITASGQYGQWAPKLARL HYSGSINAWSTKEPFSWIKVDLLAPMIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRG NSTGTLMVFFGNVDSSGIKHNIFNPPIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGME AQITASSYFTNMFATWSPSKARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTG VTTQGVKSLLTSMYVKEFLISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTR YLRIHPQSWVHQIALRMEVLGCEAQDLYKLTRAETGGASPGTSSTGSPGSSPSASTGTGPGSS PSASTGTGPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTGSPGTPGSGTAS SSPGSSTPSGATGSPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSS TPSGATGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTG TGPGSSTPSGATGSPGSSTPSGATGSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGTP GSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGSSPSASTGTGPGTPGSGTAS SSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPGSSTPSGATGSPGAS PGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTG TGPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGAS PGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGAT GSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGAS PGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSST GSPGASPGTSSTGSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTGSPGSSPSASTGTGPGTP GSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGASPGTSSTGSP FVIII ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTDHLFNIA BDD9 (1— KPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQREK 743) EDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCREGSL AG288_2- AKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNRSLPGL (163 8- IGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLMDLGQFLLF Y2332)- CHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDDDNSPSFIQI FXIa- HPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKYKKVRFMAY AG864 TDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPLYSRRLPKGVK HLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGLIGPLLICYKESVD QRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQASNIMHSINGYVFD SLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGETVFMSMENPG HNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNAIEPRSFSGPGASP GTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATG CFXTEN Amino Acid Sequence Name SPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASP GTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTG GTSSTGSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTGSPGSSPSASTGTGPGTPG SGTASSSPGSSTPSGATGSQNPPVLKRHQREITRTTLQSDQEEIDYDDTISVEMKKEDFDIYDE DENQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFT QPLYRGELNEHLGLLGPYIRAEVEDNIMVTFRNQASRPYSFYSSLISYEEDQRQGAEPRKNFV KPNETKTYFWKVQHHMAPTKDEFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAH GRQVTVQEFALFFTIFDETKSWYFTENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTLP GLVMAQDQRIRWYLLSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPS KAGIWRVECLIGEHLHAGMSTLFLVYSNKCQTPLGMASGHIRDFQITASGQYGQWAPKLARL HYSGSINAWSTKEPFSWIKVDLLAPMIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRG NSTGTLMVFFGNVDSSGIKHNIFNPPIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGME SKAISDAQITASSYFTNMFATWSPSKARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTG VTTQGVKSLLTSMYVKEFLISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTR YLRIHPQSWVHQIALRMEVLGCEAQDLYKLTRAETGGASPGTSSTGSPGSSPSASTGTGPGSS TGPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTGSPGTPGSGTAS SSPGSSTPSGATGSPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSS TPSGATGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTG TGPGSSTPSGATGSPGSSTPSGATGSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGTP GSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGSSPSASTGTGPGTPGSGTAS SSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPGSSTPSGATGSPGAS GSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTG TGPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGAS PGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGAT GSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGAS PGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSST GSPGASPGTSSTGSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTGSPGSSPSASTGTGPGTP GSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGASPGTSSTGSP BDD10 (1— ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTDHLFNIA 745) KPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQREK AG288_2- EDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCREGSL (1640- AKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNRSLPGL Y2332)- IGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLMDLGQFLLF FXIa- CHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDDDNSPSFIQI AG864 RSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKYKKVRFMAY TDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPLYSRRLPKGVK HLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGLIGPLLICYKESVD MSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQASNIMHSINGYVFD SLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGETVFMSMENPG LWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNAIEPRSFSQNGPG ASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSG ATGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPG ASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTS STGSPGASPGTSSTGSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTGSPGSSPSASTGTGPG TPGSGTASSSPGSSTPSGATGSPPVLKRHQAEITRTTLQSDQEEIDYDDTISVEMKKEDFDIYDE DENQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFT QPLYRGELNEHLGLLGPYIRAEVEDNIMVTFRNQASRPYSFYSSLISYEEDQRQGAEPRKNFV KPNETKTYFWKVQHHMAPTKDEFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAH GRQVTVQEFALFFTIFDETKSWYFTENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTLP GLVMAQDQRIRWYLLSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPS KAGIWRVECLIGEHLHAGMSTLFLVYSNKCQTPLGMASGHIRDFQITASGQYGQWAPKLARL HYSGSINAWSTKEPFSWIKVDLLAPMIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRG MVFFGNVDSSGIKHNIFNPPIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGME SKAISDAQITASSYFTNMFATWSPSKARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTG VTTQGVKSLLTSMYVKEFLISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTR YLRIHPQSWVHQIALRMEVLGCEAQDLYKLTRAETGGASPGTSSTGSPGSSPSASTGTGPGSS PSASTGTGPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTGSPGTPGSGTAS SSPGSSTPSGATGSPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSS TPSGATGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTG TGPGSSTPSGATGSPGSSTPSGATGSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGTP CFXTEN Amino Acid Sequence Name GSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGSSPSASTGTGPGTPGSGTAS SSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPGSSTPSGATGSPGAS PGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTG TGPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGAS PGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGAT GSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGAS PGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSST GSPGASPGTSSTGSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTGSPGSSPSASTGTGPGTP GSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGASPGTSSTGSP FVIII ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTDHLFNIA BDD10- KPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQREK FXIa- EDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCREGSL AG288_2 AKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNRSLPGL IGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLMDLGQFLLF CHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDDDNSPSFIQI RSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKYKKVRFMAY TDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPLYSRRLPKGVK HLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGLIGPLLICYKESVD QRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQASNIMHSINGYVFD SLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGETVFMSMENPG LWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNAIEPRSFSQNPPVL KRHQAEITRTTLQSDQEEIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERL WDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVE DNIMVTFRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKDEF DCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFDETKSWYFT ENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIH SIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLV YSNKCQTPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAP MIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNP PIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPS KARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQD FFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRMEVLGCEA TRAETGAGSPGAETAPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSG ATGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPG SSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSAS TGTGPGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGSPGSSPSASTGTGPG ASPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGSSTPSGATGSGAETAEQKLISEEDLSPATG FVIII ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTDHLFNIA BDD 1 0- MGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQREK FXIa- EDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCREGSL AG864 TLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNRSLPGL IGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLMDLGQFLLF CHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDDDNSPSFIQI RSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKYKKVRFMAY TDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPLYSRRLPKGVK HLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGLIGPLLICYKESVD QRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQASNIMHSINGYVFD SLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGETVFMSMENPG LWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNAIEPRSFSQNPPVL KRHQAEITRTTLQSDQEEIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERL WDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVE DNIMVTFRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKDEF DCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFDETKSWYFT ENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIH SIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLV TPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAP MIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNP PIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPS KARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQD GHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRMEVLGCEA CFXTEN Amino Acid Sequence Name QDLYKLTRAETGGASPGTSSTGSPGSSPSASTGTGPGSSPSASTGTGPGTPGSGTASSSPGSSTP SGATGSPGSSPSASTGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSS TSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGASPGTSSTGSPGTPGS GTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGSSTPSGATGSPGSSTPSGATGS PGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGASPGTSSTGSPGASPG TSSTGSPGASPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGS PGASPGTSSTGSPGSSTPSGATGSPGSSTPSGATGSPGASPGTSSTGSPGTPGSGTASSSPGSSTP SGATGSPGSSTPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGS PGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGTPGS GTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGS PGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTP SGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGSPGSSTPSGATGS PGSSPSASTGTGPGASPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGSSTPSGATGSPGSSTP SGATGSPGASPGTSSTGSP FVIII ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTDHLFNIA BDD l 0- KPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQREK FXIa- EDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCREGSL AE864 AKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNRSLPGL IGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLMDLGQFLLF CHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDDDNSPSFIQI HPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKYKKVRFMAY TDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPLYSRRLPKGVK HLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGLIGPLLICYKESVD QRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQASNIMHSINGYVFD SLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGETVFMSMENPG LWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNAIEPRSFSQNPPVL ITRTTLQSDQEEIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERL WDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVE DNIMVTFRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKDEF DCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFDETKSWYFT CRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIH SIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLV YSNKCQTPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAP MIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNP PIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPS KARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQD GHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRMEVLGCEA QDLYKLTRAETGGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSTE PGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTE ATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTE PSEGSAPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSTEPSEGSA PGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGSPAGSPTSTEEGTSESATPESGPGSEPA TSGSETPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAP GTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGSEPAT SGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGP GSPAGSPTSTEEGSPAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGTSESA TPESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAP PTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSPAGSPTSTEEGSPAGS PTSTEEGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGTSESATPESGPGSEPATSGSETP GSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGSEPATSGSETPGTSESA TPESGPGTSTEPSEGSAP Sequence name reflects N— to C-terminus configuration of the FVIII variant and XTEN components: signal peptide (SP); linker (L); cleavage sequence (CS) may be denoted by protease name active on the sequence, and XTEN components by family name and length, With insertion points for components denoted by FVIII amino acid and numbered positions adjacent to the inserted sequence or Al being the N—terminus and Y2332 being the C-terminus of the FVIII.

The term “comprise” and variants of the term such as “comprises” or “comprising” are used herein to denote the inclusion of a stated integer or stated integers but not to exclude any other integer or any other integers, unless in the context or usage an exclusive interpretation of the term is ed.

Any reference to publications cited in this cation is not an admission that the disclosures constitute common general knowledge in Australia. 309a

Claims (49)

What we claim is:

1. A recombinant factor VIII fusion protein comprising a factor VIII polypeptide fused to an extended recombinant polypeptide (XTEN), wherein the factor VIII polypeptide comprises A1 domain, A2 domain, A3 domain, a3 , C1 , C2 domain, and optionally a B domain or a portion thereof, wherein the XTEN is ed within thefactor VIII polypeptide.

2. The inant factor VIII fusion protein of claim 1, wherein the XTEN is inserted into the B domain or the portion thereof.

3. The recombinant factor VIII fusion protein of claim 1, wherein the XTEN is inserted into the A1 domain, the A2 domain, the A3 domain, the a3 domain, or any combination thereof.

4. The recombinant factor VIII fusion n of claim 1 or claim 3, wherein the Al domain ses a permissive loop-1 (Al-1) region and a permissive loop—2 (Al-2) region wherein the XTEN is inserted into AI-l, A1-2, or both.

5. The recombinant factor VIII fusion protein of claim 1 or claim 3, wherein the A2 domain comprises a permissive loop-1 (A2—l) region and a permissive loop-2 (AZ-2) region wherein the at least _ one XTEN is inserted into A2-1, A2-2, or both.

6. The recombinant factor VIII fusion protein of claim 1 or claim 3, wherein the A3 domain comprises a permissive loop-1 (A3-1) region and a permissive loop-2 (A3-2) region wherein the at least one XTEN is ed into A3-1, A3-2, or both.

7. The recombinant factor VIII fusion protein of claim 4, wherein the permissive loop-1 (Al-1) region corresponds to a region in native mature human factor VIII from amino acid 15 to amino acid 45 or from amino acid 18 to amino acid 32 of SEQ ID NO:2, and wherein the XTEN is inserted into Al-l.

8. The recombinant factor VIII fusion protein of claim 4, wherein the permissive loop-2 (Al-2) region corresponds to a region in native mature human factor VIII from amino acid 201 to amino acid 232 or from amino acid 211 to amino acid 224 of SEQ ID NO: 2, and n the XTEN is inserted into Al-2.

9. The recombinant factor VIII fusion protein of claim 5, wherein the permissive loop-1 (AZ-l) region corresponds to a region in native mature human factor VIII from amino acid 395 to amino acid 421 or from amino acid 397 to amino acid 418 of SEQ ID NO: 2, and wherein the XTEN is inserted into A2-1.

10. The recombinant factor VIII fusion protein of claim 5, wherein the permissive loop-2 (A2—2) region corresponds to a region in native mature human factor VIII from amino acid 577 to amino acid 635 or from amino acid 595 to amino acid 607 of SEQ ID NO: 2, and wherein the XTEN is inserted into A2-2.

11. The recombinant factor VIII fusion protein of claim 6, wherein the permissive loop—1 (A3—l) region corresponds to a region in native mature human factor VIII from amino acid 1705 to amino acid 1732 or from amino acid 1711 to amino acid 1725 of SEQ H) NO: 2, and wherein the XTEN is ed into A3—1.

12. The recombinant factor VIII fusion n of claim 6, wherein the permissive loop-2 (A3-2) region corresponds to a region in native mature human factor VIII from amino acid 1884 to amino acid 1917 or from amino acid 1900 to amino acid 1912 of SEQ ID NO: 2, and wherein the XTEN is inserted into A3 -2.

13. The recombinant factor VIII fusion protein of claim 4 or claim 7, wherein the XTEN is ed within Al-l immediately downstream of an amino acid corresponding to amino acid 17 of SEQ ID NO: 2, amino acid 18 of SEQ ID NO: 2, amino acid 22 of SEQ ID NO: 2, amino acid 24 of SEQ ID NO: 2, amino acid 26 of SEQ ID NO: 2, amino acid 28 of SEQ ID NO: 2, amino acid 32 of SEQ ID NO: 2, amino acid 38 of SEQ ID NO: 2, amino acid 40 of SEQ ID NO: 2, or amino acid 41 of SEQ ID NO: 2.

14. The recombinant factor VIII fusion protein of claim 4 or claim 8, wherein the XTEN is inserted within A1-2 immediately downstream of an amino acid corresponding to amino acid 205 of SEQ ID NO: 2, amino acid 210 of SEQ ID NO: 2, amino acid 211 of SEQ ID NO: 2, amino acid 216 of SEQ ID NO: 2, amino acid 220 of SEQ ID NO: 2, amino acid 222 of SEQ ID NO: 2, amino acid 223 of SEQ ID NO: 2, amino acid 224 of SEQ ID NO: 2, or amino acid 230 of SEQ ID NO: 2.

15. The recombinant factor VIII fusion protein of claim 5 or claim 9, wherein the XTEN is ed within A2-1 immediately downstream of an amino acid corresponding to amino acid 399 of SEQ ID NO: 2, amino acid 403 of SEQ ID NO: 2, amino acid 405 of SEQ ID NO: 2, amino acid 409 of SEQ ID NO: 2, or amino acid 416 of SEQ ID NO: 2.

16. The recombinant factor VIII fusion protein of claim 5 or claim 10, wherein the XTEN is ed within A2-2 immediately downstream of an amino acid corresponding to amino acid 598 of SEQ ID NO: 2, amino acid 599 of SEQ ID NO: 2, amino acid 603 of SEQ ID NO: 2, or amino acid 616 of SEQ ID NO: 2.

17. The recombinant factor VIII fusion protein of claim 6 or claim 11, wherein the XTEN is inserted within A3-1 immediately downstream of an amino acid corresponding to amino acid 1711 of SEQ ID NO: 2, amino acid 1713 of SEQ ID NO: 2, amino acid 1720 of SEQ ID NO: 2, amino acid 1724 of SEQ ID NO: 2, amino acid 1725 of SEQ ID NO: 2, or amino acid 1726 of SEQ ID NO: 2.

18. The recombinant factor VIII fusion protein of claim 6 or claim 12, wherein the XTEN is ed within A3-2 immediately downstream of an amino acid corresponding to amino acid 1896 of SEQ ID NO: 2, amino acid 1900 of SEQ ID NO: 2, amino acid 1904 of SEQ ID NO: 2, amino acid 1905 of SEQ ID NO: 2, or amino acid 1910 of SEQ ID NO: 2.

19. The inant factor VIII fusion protein of claim 1, wherein the XTEN is ed within a3 immediately downstream of an amino acid ponding to amino acid 1656 of SEQ ID NO: 2.

20. The recombinant factor VIII fusion protein of claim 1 or claim 2, wherein the at the least one XTEN is inserted immediately downstream of an amino acid corresponding to amino acid 740 or 745 of SEQ ID NO: 2.

21. The recombinant factor VIII fusion protein of claim 1, wherein the XTEN is inserted within the C1 or the C2 domain.

22. The recombinant factor VIII fusion protein of claim 21, wherein the XTEN is inserted immediately downstream of an amino acid corresponding to an amino acid selected from the group consisting of amino acid 2020 of SEQ ID NO: 2, amino acid 2044 of SEQ ID NO: 2, amino acid 2068 of SEQ ID NO: 2, amino acid 2073 of SEQ ID NO: 2, amino acid 2090 of SEQ ID NO: 2, amino acid 2092 of SEQ ID NO: 2, amino acid 2093 of SEQ ID NO: 2, amino acid 2111 of SEQ ID NO: 2, amino acid 2115 of SEQ ID NO: 2, amino acid 2120 of SEQ ID NO: 2, amino acid 2125 of SEQ ID NO: 2, amino acid 2171 of SEQ ID NO: 2, amino acid 2173 of SEQ ID NO: 2, amino acid 2188 of SEQ ID NO: 2, amino acid 2223 of SEQ ID NO: 2, amino acid 2224 of SEQ ID NO: 2, amino acid 2227 of SEQ ID NO: 2, amino acid 2268 of SEQ ID NO: 2, amino acid 2277 of SEQ ID NO: 2, amino acid 2278 of SEQ ID NO: 2, or amino acid 2290 of SEQ ID NO: 2.

23. The recombinant factor VIII protein of claim 1, wherein the XTEN is inserted immediately downstream of an amino acid corresponding to an amino acid selected from the group consisting of amino acid 18 of SEQ ID NO: 2, amino acid 22 of SEQ ID NO: 2, amino acid 26 of SEQ ID NO: 2, amino acid 28 of SEQ ID NO: 2, amino acid 32 of SEQ ID NO: 2, amino acid 40 of SEQ ID NO: 2, amino acid 211 of SEQ ID NO: 2, amino acid 216 of SEQ ID NO: 2, amino acid 220 of SEQ ID NO: 2, amino acid 224 of SEQ ID NO: 2, amino acid 333 of SEQ ID NO: 2, amino acid 336 of SEQ ID NO: 2, amino acid 339 of SEQ ID NO: 2, amino acid 399 of SEQ ID NO: 2, amino acid 403 of SEQ ID NO: 2, amino acid 409 of SEQ ID NO: 2, amino acid 416 of SEQ ID NO: 2, amino acid 599 of SEQ ID NO: 2, amino acid 603 of SEQ ID NO: 2, amino acid 740 of SEQ ID NO: 2, amino acid 745 of SEQ ID NO: 2, amino acid 1656 of SEQ ID NO: 2, amino acid 1711 of SEQ ID NO: 2, amino acid 1720 of SEQ ID NO: 2, amino acid 1796 of SEQ ID NO: 2, amino acid 1802 of SEQ ID NO: 2, amino acid 1900 of SEQ ID NO: 2, amino acid 1904 of SEQ ID NO: 2, amino acid 1905 of SEQ ID NO: 2, amino acid 1910 of SEQ ID NO: 2, amino acid 1656 of SEQ ID NO: 2 amino acid 2068 of SEQ ID NO: 2, amino acid 2171 of SEQ ID NO: 2, amino acid 2227 of SEQ ID NO: 2, or amino acid 2277 of SEQ ID NO: 2.

24. The recombinant factor VIII fusion protein of any one of claims 1 to 23, comprising two XTENs.

25. The recombinant factor VIII fusion protein of claim 24, n the two XTENS are inserted or fused immediately downstream of one or two amino acids corresponding to amino acid 18 of SEQ ID NO: 2, amino acid 26 of SEQ ID NO: 2, amino acid 40 of SEQ ID NO: 2, amino acid 399 of SEQ ID NO: 2, amino acid 403 of SEQ ID NO: 2, amino acid 599 of SEQ ID NO: 2, amino acid 745 of SEQ ID NO: 2, amino acid 1656 of SEQ ID NO: 2, amino acid 1711 of SEQ ID NO: 2, amino acid 1720 of SEQ ID NO: 2, amino acid 1725 of SEQ ID NO: 2, amino acid 1900 of SEQ ID NO: 2, amino acid 1905 of SEQ ID NO: 2, or amino acid 2332 of SEQ ID NO: 2.

26. The recombinant factor VIII fusion protein of claim 24 or claim 25, wherein the two XTENs are inserted or. fused immediately downstream of the amino acids corresponding to: i. amino acids 745 and 2332 of SEQ ID NO: 2; ii. amino acids 1656 and 2332 of SEQ ID NO: 2; iii. amino acids 26 and 403 of SEQ ID NO: 2; iv. amino acids 40 and 403 of SEQ ID NO: 2; v. amino acids 18 and 403 of SEQ ID NO: 2; vi. amino acids 26 and 599 of SEQ ID NO: 2; vii. amino acids 40 and 599 of SEQ ID NO: 2; viii. amino acids 18 and 599 of SEQ ID NO: 2; ix. amino acids 18 and 1656 of SEQ ID NO: 2; x. amino acids 26 and 1656 of SEQ ID NO: 2; xi. amino acids 40 and 1656 of SEQ ID NO: 2; xii. amino acids 403 and 1656 of SEQ ID NO: 2; xiii. amino acids 1656 and 1720 of SEQ ID NO: 2; xiv. amino acids 40 and 399 of SEQ ID NO: 2; xv. amino acids 26 and 1900 of SEQ ID NO: 2; xvi. amino acids 18 and 399 of SEQ ID NO: 2; xvii. amino acids 40 and 399 of SEQ ID NO: 2; or xviii. amino acids 1656 and 1900 of SEQ ID NO: 2.

27. The recombinant factor VIII fusion protein of any one of claims 1 to 26, comprising three XTENs, four XTENs, five XTENs, or six XTENs.

28. The recombinant factor VIII fusion protein of claim 27, wherein i. the three XTENs are inserted or fused immediately downstream of one or more amino acids corresponding to amino acid 18 of SEQ ID NO: 2, amino acid 26 of SEQ ID NO: 2, amino acid 40 of SEQ ID NO: 2, amino acid 399 of SEQ ID NO: 2, amino acid 403 of SEQ ID NO: 2, amino acid 599 of SEQ ID NO: 2, amino acid 745 of SEQ ID NO: 2, amino acid 1656 of SEQ ID NO: 2, amino acid 1711 of SEQ ID NO: 2, amino acid 1720 of SEQ ID NO: 2, amino acid 1725 of SEQ ID NO: 2, amino acid 1900 of SEQ ID NO: 2, amino acid 1905 of SEQ ID NO: 2, amino acid 1910 of SEQ ID NO: 2, or amino acid 2332 of SEQ ID NO: 2; ii. the four XTENs are inserted or fused immediately downstream of one or more amino acids corresponding to amino acid 18 of SEQ ID NO: 2, amino acid 26 of SEQ ID NO: 2, amino acid 40 of SEQ ID NO: 2, amino acid 403 of SEQ ID NO: 2, amino acid 409 of SEQ ID NO: 2, amino acid 745 of SEQ ID NO: 2, amino acid 1656 of SEQ ID NO: 2, amino acid 1720 of SEQ ID NO: 2, amino acid 1900 of SEQ ID NO: 2, amino acid 1905 of SEQ ID NO: 2, amino acid 1910 of SEQ ID NO: 2, or amino acid 2332 of SEQ ID NO: 2; or iii. the five XTENs are inserted or fused immediately downstream of one or more amino acids corresponding to amino acid 18 of SEQ ID NO: 2, amino acid 403 of SEQ ID NO: 2, amino acid 745 of SEQ ID NO: 2, amino acid 1656 of SEQ ID NO: 2, amino acid 1720 of SEQ ID NO: 2, amino acid 1900 of SEQ ID NO: 2, or amino acid 2332 of SEQ ID NO: 2.

29. The recombinant factor VIII fusion protein of any one of claims 1 to 28, wherein the XTEN comprises 36 amino acids, 42 amino acids, 72 amino acids, 96 amino acids, 144 amino acids, or 288 amino acids.

30. The recombinant factor VIII fusion n of claim 29, wherein the XTEN comprises 72 amino acids, 144 amino acids, or 288 amino acids.

31. The recombinant factor VIII fusion protein of any one of claims 1 to 30, wherein the XTEN comprises one or more XTEN sequence motifs, which are selected from the group consisting of SEQ ID N05: 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, and 48.

32. The recombinant factor VIII fusion n of claim 31, wherein the one or more XTEN ce motifs are selected from the group consisting of SEQ ID N05: 23, 24, 25, and 26. 3 14

33. The recombinant factor VIII fusion protein of any one of claims 1 to 32, wherein the XTEN comprises an amino acid sequence having 90%, 96%, 97%, 98%, 99%, or 100% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 49, 50, 51, 52, 57, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 78, and 79.

34. The inant factor VIII fusion protein of any one of claims 1 to 32, wherein the XTEN comprises an amino acid sequence having 90%, 95%, 96%, 97%, 98%, 99%, or 100% ce identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 279, 281, 283, 285, 287, 289, 291, 293, 295, 297, 299, 301, 303, 305, 307, 309, 311, 313, 315, 317, 319, 321, 323, 325, 327, 329, 331, 333, 335, 337, 339, 341, 343, 345, 347, 349, and 351.

35. The recombinant factor VIII fusion protein of any one of claims 1 to 34, wherein the factor VIII polypeptide comprises a native factor VIII polypeptide.

36. The recombinant factor VIII fusion protein of any one of claims 1 to 35, wherein the factor VIII ptide comprises a partially deleted B domain or a fully deleted B domain.

37. The recombinant factor VIII fusion protein of any one of claims 1 to 36, wherein the factor VIII polypeptide comprises a single chain factor VIII ptide.

38. The recombinant factor VIII fusion protein of any one of claims 1 to 37, wherein a heterologous polypeptide is fused to the factor VIII polypeptide.

39. The recombinant factor VIII fusion protein of claim 38, wherein the heterologous polypeptide is an Fc fragment of immunoglobulin or an FcRn g domain.

40. The recombinant factor VIII fusion protein of claim 38, wherein the heterologous polypeptide is ed from the group consisting of albumin or a fragment thereof, a β subunit of C-terminal peptide of human chorionic gonadotropin, a HAP sequence, a transferrin, a PAS polypeptide, a polyglycine linker, a polyserine linker, and a combination f.

41. An isolated nucleic acid encoding the recombinant factor VIII fusion protein of any one of claims 1 to 40.

42. A vector comprising the isolated nucleic acid of claim 41.

43. The vector of claim 42, wherein the vector is a d, a cosmid, a viral particle, or phage.

44. An isolated host cell comprising the vector of claim 42 or claim 43.

45. A pharmaceutical composition comprising the inant factor VIII fusion protein of any one of claims 1 to 40 and a pharmaceutically acceptable carrier.

46. A ceutical ition comprising the isolated nucleic acid of claim 41, the vector of claim 42 or 43, or the host cell of claim 44, and a pharmaceutically acceptable carrier.

47. A method of making a recombinant factor VIII fusion protein comprising culturing the host cell of claim 44 in media under suitable conditions.

48. Use of the pharmaceutical composition of claim 45 or 46 in the manufacture of a ment for the treatment of a coagulopathy in a subject in need thereof.

49. Use of the recombinant factor VIII fusion protein of any of one of claims 1 to 40 in the manufacture of a medicament for the treatment of a coagulopathy. Amunix Operating Inc. Biogen MA Inc. by the patent attorneys for the applicants CULLENS